<SEC-DOCUMENT>0001213900-21-014709.txt : 20210311
<SEC-HEADER>0001213900-21-014709.hdr.sgml : 20210311
<ACCEPTANCE-DATETIME>20210311070101
ACCESSION NUMBER:		0001213900-21-014709
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		75
CONFORMED PERIOD OF REPORT:	20201231
FILED AS OF DATE:		20210311
DATE AS OF CHANGE:		20210311

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Protara Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001359931
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				204580525
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36694
		FILM NUMBER:		21731813

	BUSINESS ADDRESS:	
		STREET 1:		345 PARK AVENUE SOUTH
		STREET 2:		3RD FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10010
		BUSINESS PHONE:		646-844-0337

	MAIL ADDRESS:	
		STREET 1:		345 PARK AVENUE SOUTH
		STREET 2:		3RD FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10010

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ArTara Therapeutics, Inc.
		DATE OF NAME CHANGE:	20200110

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PROTEON THERAPEUTICS INC
		DATE OF NAME CHANGE:	20060420
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>f10k2020_protaratherapeutics.htm
<DESCRIPTION>ANNUAL REPORT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>
<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0pt; margin-bottom: 0pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<P STYLE="font: 16pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>UNITED
STATES</B></FONT></P>

<P STYLE="font: 16pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WASHINGTON,
D.C. 20549</B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Form
10-K</B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Mark
One)</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#9746; <FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</B></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>For
the fiscal year ended December 31, 2020</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Or</B></FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#9744; <FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</B></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>For
the transition period from &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to</B></FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Commission
File Number: 001-36694</B></FONT></P>

<P STYLE="font: 16pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: center"><B>PROTARA THERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; border-bottom: Black 1.5pt solid"><B>(Exact
Name of Registrant as Specified in Its Charter)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-family: Times New Roman, Times, Serif">
<tr style="vertical-align: top">
    <TD STYLE="width: 49%; border-bottom: Black 1.5pt solid; padding-right: 0.8pt; text-align: center; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>Delaware</b></font></td>
    <TD STYLE="width: 2%; padding-right: 0.8pt; text-align: center; font-size: 10pt">&nbsp;</td>
    <TD STYLE="width: 49%; border-bottom: Black 1.5pt solid; padding-right: 0.8pt; text-align: center; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>20-4580525</b></font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: center; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>&nbsp;(State or Other Jurisdiction of</b></font><br>
<font style="font: 10pt Times New Roman, Times, Serif"><b>Incorporation or Organization)</b></font></td>
    <TD STYLE="padding-right: 0.8pt; text-align: center; font-size: 10pt">&nbsp;</td>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.8pt 0 0; text-align: center"><b>(I.R.S. Employer</b></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.8pt 0 0; text-align: center"><b>Identification Number)</b>&nbsp;</P></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>345 Park Avenue South</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>3<SUP>rd</SUP> Floor</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>New York, NY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>(Address of Principal Executive Offices)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>10010</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>(Zip Code)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>(646) 844-0337</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>(Registrant&rsquo;s telephone number, including
area code)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>Securities registered pursuant to Section
12(b) of the Act:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 33%; padding-right: 0.8pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Title of each class</b></font></td>
    <TD STYLE="vertical-align: bottom; width: 2%; padding-right: 0.8pt; text-align: center">&nbsp;</td>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 32%; padding-right: 0.8pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Trading Symbol(s)</b></font></td>
    <TD STYLE="vertical-align: bottom; width: 2%; padding-right: 0.8pt; text-align: center">&nbsp;</td>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 31%; padding-right: 0.8pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name
of each exchange on which registered</B></FONT></td></tr>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-right: 0.8pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common
Stock, par value $0.001 per share</B></FONT></td>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt; text-align: center">&nbsp;</td>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>TARA</b></font></td>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt; text-align: center">&nbsp;</td>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>The Nasdaq Capital Market</b></font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Securities registered pursuant to Section
12(g) of the Act: None</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Indicate by check mark if the registrant is a well-known seasoned
issuer, as defined in Rule 405 of the Securities Act. Yes <FONT STYLE="font-family: Wingdings">o</FONT> No <FONT STYLE="font-family: Wingdings">x</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Indicate by check mark if the registrant is not required to file
reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Yes <FONT STYLE="font-family: Wingdings">o</FONT> No <FONT STYLE="font-family: Wingdings">x</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Indicate by check mark whether the registrant (1) has filed all
reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for
such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements
for the past 90 days. Yes <FONT STYLE="font-family: Wingdings">x</FONT> No <FONT STYLE="font-family: Wingdings">o</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Indicate by check mark whether the registrant has submitted electronically
every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&sect; 232.405 of this chapter) during
the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes <FONT STYLE="font-family: Wingdings">x</FONT> No <FONT STYLE="font-family: Wingdings">o</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Indicate by check mark whether the registrant is a large accelerated
filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions
of &ldquo;large accelerated filer&rdquo;, &ldquo;accelerated filer&rdquo;, &ldquo;smaller reporting company&rdquo; and &ldquo;emerging
growth company&rdquo; in Rule 12b-2 of the Securities Exchange Act of 1934:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 61%; padding-right: 0.8pt"><font style="font: 10pt Times New Roman, Times, Serif">Large accelerated filer <FONT STYLE="font-family: Wingdings">o</FONT></font></td>
    <td style="width: 39%; padding-right: 0.8pt"><font style="font: 10pt Times New Roman, Times, Serif">Accelerated filer <FONT STYLE="font-family: Wingdings">o</FONT></font></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 0.8pt"><font style="font: 10pt Times New Roman, Times, Serif">Non-accelerated filer <FONT STYLE="font-family: Wingdings">x</FONT></font></td>
    <td style="padding-right: 0.8pt"><font style="font: 10pt Times New Roman, Times, Serif">Smaller reporting company <FONT STYLE="font-family: Wingdings">x</FONT></font></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt"><font style="font: 10pt Times New Roman, Times, Serif">Emerging growth company <FONT STYLE="font-family: Wingdings">o</FONT></font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. <FONT STYLE="font-family: Wingdings">o</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Indicate by check mark whether the registrant has filed a report
on and attestation to its management&rsquo;s assessment of the effectiveness of its internal control over financial reporting under
Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its
audit report. <FONT STYLE="font-family: Wingdings">o</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Indicate by check mark whether the registrant is a shell company
(as defined in Rule 12b-2 of the Securities Exchange Act of 1934). Yes <FONT STYLE="font-family: Wingdings">o</FONT> No <FONT STYLE="font-family: Wingdings">x</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">As of June 30, 2020, the last business day of the registrant&rsquo;s
most recently completed second fiscal quarter, the aggregate market value of the registrant&rsquo;s common stock held by non-affiliates
of the registrant was approximately $76.9 million, based on the closing price of the registrant&rsquo;s common stock on the Nasdaq
Capital Market on June 30, 2020 of $29.32 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">As of March 9,
2021, 11,228,606 shares of the registrant&rsquo;s common stock, $0.001 par value,
were outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>DOCUMENTS INCORPORATED BY REFERENCE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Portions of the registrant&rsquo;s definitive Proxy Statement to
be filed with the Securities and Exchange Commission by  April 30, 2021 are incorporated
by reference into Part III of this report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 12pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><PAGE></PAGE></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0pt 0 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>PROTARA THERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>FORM 10-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>For the Year Ended December 31, 2020</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR>
    <TD STYLE="text-align: left; width: 10%; vertical-align: top"><B>&nbsp;</B></td>
    <TD STYLE="vertical-align: bottom; width: 80%">&nbsp;</td>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 10%; text-align: center">Page</td></tr>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; vertical-align: top"><a href="#aph203237a001"><B><U>PART I</U></B></a></td>
    <TD STYLE="vertical-align: bottom">&nbsp;</td>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</td></tr>
<TR STYLE="background-color: White">
    <TD STYLE="text-align: left; vertical-align: top"><a href="#aph203237a002"><U>Item 1.</U></a></td>
    <TD STYLE="vertical-align: bottom"><a href="#aph203237a002"><U>Business</U></a></td>
    <TD STYLE="vertical-align: bottom; text-align: center">3</td></tr>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; vertical-align: top"><a href="#aph203237a003"><U>Item 1A.</U></a></td>
    <TD STYLE="vertical-align: bottom"><a href="#aph203237a003"><U>Risk Factors</U></a></td>
    <TD STYLE="vertical-align: bottom; text-align: center">27</td></tr>
<TR STYLE="background-color: White">
    <TD STYLE="text-align: left; vertical-align: top"><a href="#aph203237a004"><U>Item 1B.</U></a></td>
    <TD STYLE="vertical-align: bottom"><a href="#aph203237a004"><U>Unresolved Staff Comments</U></a></td>
    <TD STYLE="vertical-align: bottom; text-align: center">48</td></tr>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; vertical-align: top"><a href="#aph203237a005"><U>Item 2.</U></a></td>
    <TD STYLE="vertical-align: bottom"><a href="#aph203237a005"><U>Properties</U></a></td>
    <TD STYLE="vertical-align: bottom; text-align: center">48</td></tr>
<TR STYLE="background-color: White">
    <TD STYLE="text-align: left; vertical-align: top"><a href="#aph203237a006"><U>Item 3.</U></a></td>
    <TD STYLE="vertical-align: bottom"><a href="#aph203237a006"><U>Legal Proceedings</U></a></td>
    <TD STYLE="vertical-align: bottom; text-align: center">48</td></tr>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; vertical-align: top"><a href="#aph203237a007"><U>Item 4.</U></a></td>
    <TD STYLE="vertical-align: bottom"><a href="#aph203237a007"><U>Mine Safety Disclosures</U></a></td>
    <TD STYLE="vertical-align: bottom; text-align: center">48</td></tr>
<TR STYLE="background-color: White">
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</td>
    <TD STYLE="vertical-align: bottom">&nbsp;</td>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</td></tr>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; vertical-align: top"><a href="#aph203237a008"><B><U>PART II</U></B></a><B><U> </U></B></td>
    <TD STYLE="vertical-align: bottom">&nbsp;</td>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</td></tr>
<TR STYLE="background-color: White">
    <TD STYLE="text-align: left; vertical-align: top"><a href="#aph203237a009"><U>Item 5.</U></a></td>
    <TD STYLE="vertical-align: bottom"><a href="#aph203237a009"><U>Market for Registrant&rsquo;s Common Equity,
    Related Stockholder Matters and Issuer Purchases of Equity Securities</U></a></td>
    <TD STYLE="vertical-align: bottom; text-align: center">49</td></tr>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; vertical-align: top"><a href="#aph203237a010"><U>Item 6.</U></a></td>
    <TD STYLE="vertical-align: bottom"><a href="#aph203237a010"><U>Selected Financial Data</U></a></td>
    <TD STYLE="vertical-align: bottom; text-align: center">49</td></tr>
<TR STYLE="background-color: White">
    <TD STYLE="text-align: left; vertical-align: top"><a href="#aph203237a011"><U>Item 7.</U></a></td>
    <TD STYLE="vertical-align: bottom"><a href="#aph203237a011"><U>Management&rsquo;s Discussion and Analysis
    of Financial Condition and Results of Operations</U></a></td>
    <TD STYLE="vertical-align: bottom; text-align: center">50</td></tr>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; vertical-align: top"><a href="#aph203237a012"><U>Item 7A.</U></a></td>
    <TD STYLE="vertical-align: bottom"><a href="#aph203237a012"><U>Quantitative and Qualitative Disclosures
    About Market Risk</U></a></td>
    <TD STYLE="vertical-align: bottom; text-align: center">57</td></tr>
<TR STYLE="background-color: White">
    <TD STYLE="text-align: left; vertical-align: top"><a href="#aph203237a013"><U>Item 8.</U></a></td>
    <TD STYLE="vertical-align: bottom"><a href="#aph203237a013"><U>Financial Statements and Supplementary
    Data</U></a></td>
    <TD STYLE="vertical-align: bottom; text-align: center">58</td></tr>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; vertical-align: top"><a href="#aph203237a014"><U>Item 9.</U></a></td>
    <TD STYLE="vertical-align: bottom"><a href="#aph203237a014"><U>Changes in Disagreements With Accountants
    on Accounting and Financial Disclosure</U></a></td>
    <TD STYLE="vertical-align: bottom; text-align: center">58</td></tr>
<TR STYLE="background-color: White">
    <TD STYLE="text-align: left; vertical-align: top"><a href="#aph203237a015"><U>Item 9A.</U></a></td>
    <TD STYLE="vertical-align: bottom"><a href="#aph203237a015"><U>Controls and Procedures</U></a></td>
    <TD STYLE="vertical-align: bottom; text-align: center">58</td></tr>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; vertical-align: top"><a href="#aph203237a016"><U>Item 9B.</U></a></td>
    <TD STYLE="vertical-align: bottom"><a href="#aph203237a016"><U>Other Information</U></a></td>
    <TD STYLE="vertical-align: bottom; text-align: center">58</td></tr>
<TR STYLE="background-color: White">
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</td>
    <TD STYLE="vertical-align: bottom">&nbsp;</td>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</td></tr>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; vertical-align: top"><a href="#aph203237a017"><B><U>PART III</U></B></a></td>
    <TD STYLE="vertical-align: bottom">&nbsp;</td>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</td></tr>
<TR STYLE="background-color: White">
    <TD STYLE="text-align: left; vertical-align: top"><a href="#aph203237a018"><U>Item 10.</U></a></td>
    <TD STYLE="vertical-align: bottom"><a href="#aph203237a018">Directors, Executive Officers and Corporate
    Governance</a></td>
    <TD STYLE="vertical-align: bottom; text-align: center">59</td></tr>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; vertical-align: top"><a href="#aph203237a019"><U>Item 11.</U></a></td>
    <TD STYLE="vertical-align: bottom"><a href="#aph203237a019">Executive Compensation</a></td>
    <TD STYLE="vertical-align: bottom; text-align: center">59</td></tr>
<TR STYLE="background-color: White">
    <TD STYLE="text-align: left; vertical-align: top"><a href="#aph203237a020"><U>Item 12.</U></a></td>
    <TD STYLE="vertical-align: bottom"><a href="#aph203237a020">Security Ownership of Certain Beneficial
    Owners and Management and Related Stockholder Matters</a></td>
    <TD STYLE="vertical-align: bottom; text-align: center">59</td></tr>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; vertical-align: top"><a href="#aph203237a021"><U>Item 13.</U></a></td>
    <TD STYLE="vertical-align: bottom"><a href="#aph203237a021">Certain Relationships and Related Transactions,
    and Director Independence</a></td>
    <TD STYLE="vertical-align: bottom; text-align: center">59</td></tr>
<TR STYLE="background-color: White">
    <TD STYLE="text-align: left; vertical-align: top"><a href="#aph203237a022"><U>Item 14.</U></a></td>
    <TD STYLE="vertical-align: bottom"><a href="#aph203237a022">Principal Accountant Fees and Services</a></td>
    <TD STYLE="vertical-align: bottom; text-align: center">59</td></tr>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</td>
    <TD STYLE="vertical-align: bottom">&nbsp;</td>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</td></tr>
<TR STYLE="background-color: White">
    <TD STYLE="text-align: left; vertical-align: top"><a href="#aph203237a023"><B><U>PART IV</U></B></a></td>
    <TD STYLE="vertical-align: bottom">&nbsp;</td>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</td></tr>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; vertical-align: top"><a href="#aph203237a024"><U>Item 15.</U></a></td>
    <TD STYLE="vertical-align: bottom"><a href="#aph203237a024">Exhibits and Financial Statement Schedules</a></td>
    <TD STYLE="vertical-align: bottom; text-align: center">60</td></tr>
<TR STYLE="background-color: White">
    <TD STYLE="text-align: left; vertical-align: top"><a href="#aph203237a025"><U>Item 16.</U></a></td>
    <TD STYLE="vertical-align: bottom"><a href="#aph203237a025">Form 10-K Summary</a></td>
    <TD STYLE="vertical-align: bottom; text-align: center">63</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="aph203237a001"></A>PART I</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>FORWARD-LOOKING STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">This report and the information
incorporated herein by reference contain forward-looking statements that involve a number of risks and uncertainties, as well as
assumptions that, if they never materialize or prove incorrect, could cause our results to differ materially from those expressed
or implied by such forward-looking statements. Although our forward-looking statements reflect the good faith judgment of our management,
these statements can only be based on facts and factors currently known by us. Consequently, forward-looking statements are inherently
subject to risks and uncertainties, and actual results and outcomes may differ materially from results and outcomes discussed in
the forward-looking statements. In addition, statements that &ldquo;we believe&rdquo; and similar statements reflect our beliefs
and opinions on the relevant subject. These statements are based upon information available to us as of the date of this report,
and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete,
and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially
available relevant information. These statements are inherently uncertain and you are cautioned not to unduly rely upon these statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">The forward-looking statements
are contained principally in the sections entitled &ldquo;<I>Business,</I>&rdquo; &ldquo;<I>Risk Factors,</I>&rdquo; and <I>&ldquo;Management&rsquo;s
Discussion and Analysis of Financial Condition and Results of Operations</I>.&rdquo; All statements, other than statements of historical
facts, contained in this document, including statements regarding our business, operations and financial performance and conditions,
as well as our plans, objectives and expectations for our business operations and financial performance and condition, are forward-looking
statements. These statements relate to future events or to our future financial performance and involve known and unknown risks,
uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from
any future results, performance or achievements expressed or implied by the forward-looking statements. The words &ldquo;anticipate,&rdquo;
&ldquo;believe,&rdquo; &ldquo;continue,&rdquo; &ldquo;could,&rdquo; &ldquo;estimate,&rdquo; &ldquo;expect,&rdquo; &ldquo;intend,&rdquo;
&ldquo;may,&rdquo; &ldquo;might,&rdquo; &ldquo;plan,&rdquo; &ldquo;predict,&rdquo; &ldquo;project,&rdquo; &ldquo;potential,&rdquo;
&ldquo;should,&rdquo; &ldquo;target,&rdquo; &ldquo;will,&rdquo; &ldquo;would,&rdquo; or the negative of those terms and similar
expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying
words.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin: 0pt">These forward-looking statements include, but are not limited
to, statements about:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 12pt">&nbsp;</td>
    <TD STYLE="width: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD STYLE="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">the impact of the novel coronavirus disease (&ldquo;COVID-19&rdquo;) pandemic on our business and operations as well as the business or operations of our manufacturers, research partners, and other third parties with whom we conduct business or regulatory agencies;</font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="font-size: 12pt">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="font-size: 12pt">&nbsp;</td>
    <TD STYLE="font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD STYLE="text-align: left; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">estimates regarding our financial performance, including future revenue, expenses and capital requirements;</font></td></tr>

<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 12pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <TD STYLE="font-size: 12pt">&nbsp;</td>
    <TD STYLE="font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD STYLE="text-align: left; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">our expected cash position and ability to obtain financing in the future on satisfactory terms or at all;</font></td></tr>

<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 12pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <TD STYLE="font-size: 12pt">&nbsp;</td>
    <TD STYLE="font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD STYLE="text-align: left; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">expectations regarding our plans to research, develop and commercialize our current and future product candidates, including TARA-002, and Intravenous (IV) Choline Chloride;</font></td></tr>

<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 12pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <TD STYLE="font-size: 12pt">&nbsp;</td>
    <TD STYLE="font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD STYLE="text-align: left; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">expectations regarding the safety and efficacy of our product candidates;</font></td></tr>

<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 12pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <TD STYLE="font-size: 12pt">&nbsp;</td>
    <TD STYLE="font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD STYLE="text-align: left; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">expectations regarding the timing, costs and outcomes of our planned clinical trials;</font></td></tr>

<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 12pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <TD STYLE="font-size: 12pt">&nbsp;</td>
    <TD STYLE="font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD STYLE="text-align: left; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">expectations regarding potential market size;</font></td></tr>

<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 12pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <TD STYLE="font-size: 12pt">&nbsp;</td>
    <TD STYLE="font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD STYLE="text-align: left; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">expectations regarding the timing of the availability of data from our clinical trials;</font></td></tr>

<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 12pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <TD STYLE="font-size: 12pt">&nbsp;</td>
    <TD STYLE="font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD STYLE="text-align: left; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">expectations regarding the clinical utility, potential benefits and market acceptance of our product candidates;</font></td></tr>

<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 12pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <TD STYLE="font-size: 12pt">&nbsp;</td>
    <TD STYLE="font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD STYLE="text-align: left; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">expectations regarding our commercialization, marketing and manufacturing capabilities and strategy;</font></td></tr>

<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 12pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <TD STYLE="font-size: 12pt">&nbsp;</td>
    <TD STYLE="font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD STYLE="text-align: left; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">the implementation of our business model, strategic plans for our business, product candidates and technology;</font></td></tr>

<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 12pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <TD STYLE="font-size: 12pt">&nbsp;</td>
    <TD STYLE="font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD STYLE="text-align: left; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">expectations regarding our ability to identify additional products or product candidates with significant commercial potential;</font></td></tr>

<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 12pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <TD STYLE="font-size: 12pt">&nbsp;</td>
    <TD STYLE="font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD STYLE="text-align: left; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">developments and projections relating to our competitors and industry;</font></td></tr>

<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 12pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <TD STYLE="font-size: 12pt">&nbsp;</td>
    <TD STYLE="font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD STYLE="text-align: left; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">our ability to remain listed on the Nasdaq Capital Market;</font></td></tr>

<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 12pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <TD STYLE="font-size: 12pt">&nbsp;</td>
    <TD STYLE="font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD STYLE="text-align: left; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">the impact of government laws and regulations;</font></td></tr>

</TABLE>

<P STYLE="margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><PAGE></PAGE></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="font-size: 12pt; width: 0.25in">&nbsp;</td>
    <TD STYLE="font-size: 10pt; width: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD STYLE="text-align: left; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">the timing or likelihood of regulatory filings and approvals; and</font></td></tr>

<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 12pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <TD STYLE="font-size: 12pt">&nbsp;</td>
    <TD STYLE="font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD STYLE="text-align: left; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">our ability to protect our intellectual property position.</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">We may not actually achieve
the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our
forward-looking statements. Forward-looking statements should be regarded solely as our current plans, estimates and beliefs. Actual
results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements
we make. We have included important factors in the cautionary statements included in this document, particularly in the &ldquo;<B><I>Risk
Factors</I></B>&rdquo; section, that we believe could cause actual results or events to differ materially from the forward-looking
statements that we make. Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time
to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business
or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained
in any forward-looking statements we may make. Our forward-looking statements do not reflect the potential impact of any future
acquisitions, mergers, dispositions, joint ventures or investments we may make.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">We undertake no obligation
to revise or publicly release the results of any revision to these forward-looking statements, except as required by law. Given
these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. All forward-looking
statements are qualified in their entirety by this cautionary statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.25in"><B>SUMMARY OF RISKS AFFECTING
OUR BUSINESS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in"><I>Below is a summary of the principal factors
that make an investment in our securities speculative or risky. This summary does not address all of the risks that we face. Additional
discussion of the risks and uncertainties summarized in this risk factor summary, and other risks and uncertainties that we face,
are set forth in Part I, Item 1A, Risk Factors, and should be carefully considered, together with other information in this Report
on Form 10-K and our other filings with the SEC before making investment decisions regarding our securities.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</td>
    <TD STYLE="width: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD STYLE="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">We have a very limited operating history and have never generated any revenues.</font></td></tr>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</td>
    <TD STYLE="width: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD STYLE="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">We expect to incur significant losses for the foreseeable future and may never achieve or maintain profitability.</font></td></tr>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</td>
    <TD STYLE="width: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD STYLE="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">The COVID-19 coronavirus could adversely impact our business, including our clinical development plans.</font></td></tr>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</td>
    <TD STYLE="width: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD STYLE="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">We will need to raise additional financing in the future to fund our operations, which may not be available to us on favorable terms or at all.</font></td></tr>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</td>
    <TD STYLE="width: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD STYLE="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Our business depends on the successful clinical development, regulatory approval and commercialization of TARA-002 and IV Choline Chloride.</font></td></tr>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</td>
    <TD STYLE="width: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD STYLE="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">We have never made an IND, BLA or NDA submission or conducted a clinical trial and may be unable to successfully do so for TARA-002 or IV Choline Chloride.</font></td></tr>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</td>
    <TD STYLE="width: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD STYLE="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">TARA-002 is an immunopotentiator, and the indications for which we plan to pursue are the treatment of lymphatic malformations and non-muscle invasive bladder cancer. There are no FDA-approved therapies for the treatment of lymphatic malformations. It is difficult to predict the timing and costs of clinical development for TARA-002 with respect to lymphatic malformations as well as the corresponding regulatory approval path.</font></td></tr>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</td>
    <TD STYLE="width: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD STYLE="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Even if a product candidate obtains regulatory approval, it may fail to achieve the broad degree of physician and patient adoption and use necessary for commercial success.</font></td></tr>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</td>
    <TD STYLE="width: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD STYLE="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Our product candidates, if approved, will face significant competition, and may face competition sooner than anticipated, and their failure to compete effectively may prevent them from achieving significant market penetration.</font></td></tr>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</td>
    <TD STYLE="width: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD STYLE="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">We currently have limited marketing capabilities and no sales organization. If we are unable to grow our sales and marketing capabilities on our own or through third parties, we will be unable to successfully commercialize our product candidates, if approved, or generate product revenue.</font></td></tr>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</td>
    <TD STYLE="width: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD STYLE="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">We may not be able to obtain, maintain or enforce global patent rights or other intellectual property rights that cover our product candidates and technologies that are of sufficient breadth to prevent third parties from competing against us.</font></td></tr>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</td>
    <TD STYLE="width: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD STYLE="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Certain stockholders have the ability to control or significantly influence certain matters submitted to our stockholders for approval.</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><PAGE></PAGE></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><A NAME="aph203237a002"></A><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Item 1.</B></FONT> <FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Business.</I></B></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">We are a New York City
based clinical-stage biopharmaceutical company committed to identifying and advancing transformative therapies for the treatment
of cancer and rare diseases with significant unmet needs. We prioritize creativity, diverse perspectives, integrity and tenacity
to expedite our goal of bringing life-changing therapies to people with limited treatment options.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 6.5pt; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">Our portfolio includes
two development programs utilizing TARA-002, an investigational cell therapy based on the broad immunopotentiator, OK-432, which
was originally granted marketing approval by the Japanese Ministry of Health and Welfare as an immunopotentiating cancer therapeutic
agent. This cell therapy is currently approved in Japan for lymphatic malformations, or LMs, and multiple oncologic indications.
It has never been approved outside Japan and we have secured worldwide rights to the asset excluding Japan and Taiwan and have
begun to explore its use in rare and oncology indications. We are developing TARA-002 in non-muscle invasive bladder cancer, or
NMIBC, and in LMs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">TARA-002&rsquo;s
lead oncology program is in NMIBC, which is cancer found in the tissue that lines the inner surface of the bladder that has not
spread into the bladder muscle. Bladder cancer is the sixth most common cancer in the United States, with NMIBC representing approximately
80% of bladder cancer diagnoses. Approximately 65,000 patients are diagnosed with NMIBC in the United States each year. Very few
new therapeutics have been approved in NMIBC since the 1990s and the current standard of care for NMIBC includes intravesical
Bacillus Calmette-Guerin, or BCG,. The mechanism of TARA-002 is similar to BCG. Both TARA-002 and BCG are intravesically administered
and elicit a type Th1 type immune response and locally activated generally similar array of cytokines and immune cells.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">In August of 2020,
we announced constructive feedback following a pre-Investigational New Drug (pre-IND) interaction with the Office of Tissues and
Advanced Therapies division of the Center for Biologics Evaluation and Research, or CBER, at the FDA on a development plan for
TARA-002 in NMIBC. Building on existing data from OK-432, and subject to the completion of non-clinical studies as well as acceptance
of the IND application, we plan to commence a Phase 1 clinical trial in late 2021 to assess the safety and tolerability of TARA-002
in patients with high grade NMIBC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">Our most advanced
clinical program is for LMs, which are rare, non-malignant cysts of the lymphatic vascular system that primarily form in the head
and neck region of children before the age of two. In July 2020, the U.S. Food and Drug Administration, or FDA, granted Rare Pediatric
Disease designation for TARA-002 for the treatment of LMs. OK-432, the originator compound to TARA-002, has been the standard of
care in LMs in Japan for over 20 years. In addition to the clinical experience in Japan, we have secured the rights to a dataset
from one of the largest ever conducted Phase 2 studies in lymphatic malformations, in which OK-432 was administered via a compassionate
use program led by the University of Iowa to over 400 pediatric and adult patients. We have updated the initial IND that was submitted
by the University of Iowa and submitted the update and accompanying clarifying questions to the FDA Division of Vaccines and Related
Products Applications, or the Division, in connection with the IND for TARA-002 in LMs. We plan to utilize the robust dataset for
OK-432 in LMs to support the potential filing of a Biological License Application (BLA) for TARA-002 in lymphatic LMs. We are encouraged
by the progress to date and, at the FDA&rsquo;s request, have submitted the full Clinical Study Report (CSR) of the randomized
Phase 2 study of OK-432 in LMs led by the University of Iowa. We continue to prepare for a potential BLA filing in the second half
of 2021, or to initiate additional clinical work as required by FDA.</P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 6.5pt; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">TARA-002 was developed
from the same master cell bank of genetically distinct group A<I> Streptococcus pyogenes</I> as OK-432 (marketed as Picibanil<SUP>&reg;&nbsp;</SUP>in
Japan and Taiwan by Chugai Pharmaceutical Co., Ltd., or Chugai Pharmaceutical). Following a pre-IND interaction with the Office
of Tissues and Advanced Therapies Division of the Center for Biologics Evaluation and Research, or CBER, the FDA agreed that we
have successfully demonstrated initial manufacturing comparability between TARA-002 and OK-432. This initial comparability will
be confirmed by GMP scale batches, which are currently underway using the same release tests that have already been approved by
the FDA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">The third development
program in our portfolio is intravenous, or IV, Choline Chloride, an investigational phospholipid substrate replacement therapy
initially in development for patients receiving parenteral nutrition, or PN, who have intestinal failure associated liver disease,
or IFALD. IV Choline Chloride has been granted Orphan Drug Designation by the FDA for this indication and has also been granted
Fast Track Designation for the treatment of IFALD. Following a positive end of Phase 2 meeting with the FDA, we received feedback
on the design of the studies necessary to complete the registration package for IV Choline Chloride for the treatment of IFALD,
including a Phase 1 pharmacokinetic study followed by Phase 3 trial. Prior to initiating these clinical studies, we are currently
undertaking a prevalence study in partnership with a large home health organization in the United States to enhance understanding
of the PN patient population and we plan to use this information to determine the next steps for the development program. The goal
of the study is to understand the presence/incidence of liver disease in this patient population.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">Our fourth program, vonapanitase,
is a recombinant human elastase. We are reviewing the research and preclinical and clinical data of vonapanitase and have not yet
determined whether to pursue further development of this product candidate in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><PAGE></PAGE></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">We have devoted substantial
efforts to the development of these programs and do not have any approved products and have not generated any revenue from product
sales. TARA-002 is in later stage development for LMs and has not yet been approved for use for treatment of LMs, NMIBC or any
other indications. We do not expect to generate revenues prior to 2022, if ever. To finance our current strategic plans, including
the conduct of ongoing and future clinical trials and further research and development costs, we will need to raise additional
capital.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Our Product Candidate Pipeline</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">The following chart summarizes
the current status of our product candidate pipeline:</P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in; color: Red">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><IMG SRC="image_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">*</TD><TD STYLE="text-align: left">TARA-002 Granted Rare Pediatric Disease Designation for
the treatment of LMs. OK-432 Granted Orphan Drug Designation by the U.S. FDA for the treatment of LMs, which we believe is applicable
under established comparability.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="text-align: left; width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">**</TD><TD STYLE="text-align: left">Granted Orphan Drug and Fast Track Designations by the
U.S. FDA</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="text-align: left; width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><SUP>&dagger;</SUP></TD><TD STYLE="text-align: left">Phase 1 PK study to be conducted prior to commencing Phase
3</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>Our Corporate Strategy:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">We are an oncology and
rare disease company focused on identifying and acquiring or licensing de-risked assets and optimizing and/or accelerating their
development. Leveraging the drug development and commercialization experience of our management team, our goal is to build a leading
biopharmaceutical company focused on bringing life-saving therapies to patients with significant unmet needs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>1. Establish comparability of OK-432
and TARA-002 </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">Utilizing the same genetically
distinct <I>Streptococcus pyogenes</I> strain and proprietary manufacturing process used by Chugai Pharmaceutical to manufacture
OK-432 (marketed as Picibanil&reg; in Japan and Taiwan), we have produced development batches of TARA-002 and conducted comparability
studies using commercial OK-432 manufactured in Japan as a reference. Following a pre-IND interaction with the Office of Tissues
and Advanced Therapies division of the Center for Biologics Evaluation and Research, or CBER, the FDA agreed that we had successfully
demonstrated initial manufacturing comparability between TARA-002 and OK-432. This initial comparability will be confirmed by GMP
scale batches, which are currently underway using the same release tests that have already been accepted by the FDA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>2.</I></B><I> <B>Seek FDA approval for
the use of TARA-002 in Lymphatic Malformations</B></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">We plan to utilize the robust dataset for OK-432 in LMs to support
the potential filing of a Biological License Application (BLA) for TARA-002 in lymphatic LMs. We are encouraged by the progress
to date and, at the FDA&rsquo;s request, have submitted the full Clinical Study Report (CSR) of the randomized Phase 2 study of
OK-432 in LMs led by the University of Iowa. We continue to prepare for a potential BLA filing in the second half of 2021, or to
initiate additional clinical work as required by FDA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>3. Pursue development of TARA-002 for
the treatment of non-muscle invasive bladder cancer (NMIBC). Complete toxicology and MOA characterization&nbsp;&amp; immunogenicity
studies in order to file an IND and initiate P1 study</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">We are developing TARA-002
for the treatment of non-muscle invasive bladder cancer, or NMIBC. Building on existing safety and efficacy data from OK-432, and
subject to the completion of non-clinical studies, including toxicology and MOA characterization&nbsp;&amp; immunogenicity studies,
which are currently underway, as well as acceptance of an Investigational New Drug, or IND, application, we plan to commence a
Phase 1 clinical trial in 2021 to assess the safety and tolerability of TARA-002 in patients with high grade NMIBC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><PAGE></PAGE></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>4. Further characterize the patient population
of IFALD to determine the appropriate strategy/path for IV Choline Chloride as a potential treatment option</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">Following a positive end
of Phase 2 meeting with the FDA, we received feedback on the design of the studies necessary to complete the registration package
for IV Choline Chloride for the treatment of IFALD, including a Phase 1 pharmacokinetic study followed by Phase 3 trial. Prior
to initiating these clinical studies, we are currently undertaking a prevalence study in partnership with a very large home health
organization in the United States to enhance understanding of the PN patient population and plan to use this information to inform
the next steps for the development program.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>5. Explore opportunities to expand our
pipeline </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">The immunological activity
of TARA-002&rsquo;s reference product, OK-432, has been effectively interrogated in patients in a long list of indications. We
plan to carefully evaluate the case reports and the literature and perform initial <I>in vitro</I> characterization studies to
better understand the mechanism of action of TARA-002 and its potential activity in indications beyond LMs and NMIBC. We also plan
to engage with regulatory authorities outside of the US to explore the potential opportunities to bring TARA-002 to other geographies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">In addition, our leadership
team has a strong track record of licensing, acquiring and optimizing product candidates and we intend to leverage this skill to
identify opportunities for potential combination opportunities for TARA-002, particularly in NMIBC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>Our Pipeline</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>TARA-002 / OK-432</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">TARA-002, our lead program,
is an investigational cell therapy developed from the master cell line of the same genetically distinct <I>Streptococcus pyogenes</I>
(group A, type 3) Su strain as OK-432, a the broad immunopotentiator (marketed as Picibanil&reg; in Japan and Taiwan by Chugai
Pharmaceutical Co., Ltd. (Chugai Pharmaceutical)). We expect to utilize the same regulatory starting materials as OK-432 and manufacture
TARA-002 using an updated version of the same proprietary processes used to manufacture OK-432. Functionally, our lead product
is OK-432. We have designated this product as TARA-002 in order to differentiate the regulatory path in the U.S. and other geographies
from that of OK-432 in Japan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">We entered into an agreement
with Chugai Pharmaceutical in June 2019 to support our development of TARA-002. The agreement provides us with exclusive access
to certain materials and documents relating to OK-432 including the master cell bank of <I>Streptococcus pyogenes</I> used in the
manufacture of OK-432. Additionally, the agreement provides technical support during a certain period. We have utilized the materials,
proprietary manufacturing process and technical support provided by Chugai Pharmaceutical to produce TARA-002 at a GMP-compliant
facility in the United States. Under the agreement with Chugai Pharmaceutical, we will have sole responsibility for the development
and commercialization of TARA-002 worldwide, excluding Japan and Taiwan. On July 14, 2020, we entered into an amendment with Chugai
to the Chugai Pharmaceutical agreement. This agreement is exclusive through June 17, 2030 or following any termination of the agreement
by either party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">In Japan, OK-432 is indicated
for: the treatment of lymphangiomas (lymphatic malformations); the prolongation of survival time in patients with gastric cancer
(postoperative cases) or primary lung cancer in combination with chemotherapy; and the reduction of cancerous pleural effusion
or ascites in patients with lung cancer or gastrointestinal cancer respectively, head and neck cancer (maxillary cancer, laryngeal
cancer, pharyngeal cancer, and tongue cancer) and thyroid cancer that are resistant to other drugs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">We plan to pursue development
of TARA-002 for the treatment of lymphatic malformations (LMs) and non-muscle invasive bladder cancer (NMIBC) initially in the
U.S. and plan to also seek approval in Europe and other regions in the future, and may also explore additional indications where
its utility as an immunostimulant has been hypothesized to be of therapeutic benefit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>TARA-002 in NMIBC&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt"><I>Disease Overview:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">Bladder cancer is the
sixth most common cancer in the United States, with NMIBC representing approximately 80% of bladder cancer diagnoses. NMIBC is
cancer found in the tissue that lines the inner surface of the bladder that has not spread into the bladder muscle. There are 3
subtypes of NMIBC: Ta (non-invasive papillary carcinoma), Tis (carcinoma in situ or CIS), and T1 (carcinoma invading the lamina
propria). Among the types of NMIBC, Ta accounts for most NMIBC cases (70%), whereas T1 and CIS account for 20% and 10%, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><PAGE></PAGE></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">Based on currently available
treatment data, we believe that there are approximately 30,000 incident cases of High-Grade NMIBC per year that would be appropriate
for treatment with TARA-002 in the U.S. There are 65,000 incident cases of NMIBC in the U.S. every year, of these, approximately
45% (~30,000) are made up of High-Grade tumor types that are considered higher risk, and therefore candidates for immunotherapies,
such as TARA-002). In addition, NMIBC has one of the highest rates of recurrence with 3-year rate estimated at up to 80%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: left"><I>Treatment: </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">Treatment for NMIBC is
typically targeted to reduce unresectable persistence, recurrence after resection, and to prevent disease progression to muscle-invasive
bladder cancer. The initial treatment for NMIBC includes cystoscopy and complete transurethral resection of the bladder tumor (TURBT)
for papillary Ta or T1, or biopsy for CIS. A single postoperative instillation of intravesical chemotherapy is recommended in patients
with low risk of progression, and for patients with intermediate and high-risk disease, a longer course of intravesical therapy
is administered. The most efficacious intravesical agent is Bacillus Calmette-Guerin (BCG), a live attenuated form of <I>Mycobacterium
bovis</I>. BCG has been the subject of multiple supply shortages in the past decade due to the inability to meet demand to treat
the large population of patients with NMIBC resulting in strategies to conserve the use of the therapy. There has been a significant
increase in bladder cancer recurrence and progression and an escalated number of patients who needed to be treated by cystectomy
have been reported. As such, with the current BCG shortage and limited effective alternate therapies or dosing strategies, there
continues to be a significant unmet need for treatment options for patients with NMIBC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: left"><I>Manufacturing:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">TARA-002 will be manufactured
using an equivalent, but modernized, proprietary manufacturing process as is used to produce OK-432 by Chugai Pharmaceutical, starting
with a master cell line propagated by us but utilizing the same genetically distinct strain of <I>Streptococcus pyogenes</I> (A
group, type 3) Su strain as OK-432. We have contracted a contract development and manufacturing organization (CDMO), to manufacture
TARA-002. TARA-002 has received initial comparability to OK-432 from the FDA. We are currently conducting confirmatory large scale
GMP manufacturing comparability, which are scheduled to be completed in 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>TARA-002 for the Treatment of Lymphatic
Malformations</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><I>Disease Overview:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">We are pursuing regulatory
approval for TARA-002 for the treatment of lymphatic malformations. Lymphatic malformations are rare, non-malignant cystic masses
that primarily form in the head and neck region of children before the age of two. The International Society for the Study of Vascular
Anomalies classifies LMs as either macrocystic, microcystic, or mixed. Macrocystic and microcystic LMs are differentiated by the
size of the fluid-containing portion of the malformation. Macrocystic LMs are characteristically large, fluid-filled cysts with
a thin endothelial lining. Macrocystic LMs are composed of cysts greater than 2 cm3 in size and present as a soft, fluid-filled
swelling beneath normal or slightly discolored skin. Macrocystic LMs are usually located in the antero-lateral cervical region
of the neck; however, it is possible for this type of LM to originate in other areas of the body. In contrast, microcystic LMs
have very limited internal space with a thick irregular endothelial lining. Microcystic LMs are comprised of cysts less than 2
cm3 in size and are often composed of micro-lymphatic channels that integrate and infiltrate normal soft tissue. Microcystic LMs
can involve both superficial and deep aspects including muscle and bone. Microcystic LMs can thicken or swell causing enlargement
of surrounding soft tissue and bones and can be found on any area of the skin or mucous membrane. Mixed LMs are comprised of varying
degrees of both macrocystic and microcystic LMs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">While the exact prevalence
of LMs is not known, in the United States, the condition is thought to be present in approximately one in every 4,000 live births
and we believe there are approximately 1,400-1,800 LM cases per year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><I>Treatment:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">Outside of Japan and Taiwan,
the standard of care is surgical excision, which is associated with high rates of recurrence and complications. There are no approved
pharmacotherapies for LMs, except in Japan and Taiwan where OK-432 is approved. In these countries, OK-432 has been the standard
of care for LMs for over 25 years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">Treatment of LMs varies
depending on the symptoms and complications that present themselves. The standard of care outside Japan and Taiwan for the treatment
of LMs is either a partial or complete surgical excision of the cysts. While surgery is the standard approach to the treatment
of LMs in the head and neck, the region is a difficult area to operate in because of the large number of important anatomical structures
in the area. Major venous and arterial trunks travel through the neck, as do important nerves. Surgery on such malformations frequently
results in high rates of recurrence and complications including life-long chronic conditions, such as damage to nerves and other
important structures of the head and neck.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><PAGE></PAGE></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><I>Clinical Development</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">When OK-432 is administered
locally for LMs, it is hypothesized that innate immune cells within the cyst are activated and produce a strong immune cascade.
Neutrophils and monocytes infiltrate the cyst and various cytokines, including interleukins IL-6, IL-8, IL-12, interferon (IFN)-gamma,
tumor necrosis factor (TNF)-alpha, and vascular endothelial growth factor (VEGF) are secreted by immune cells within the cyst in
response to the presence of OK-432. In concert, these immune activities induce a strong local inflammatory reaction in the cyst
wall, resulting in fluid drainage, shrinkage and fibrotic adhesion of the cyst.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in"><FONT STYLE="font-size: 10pt">A
randomized, phase 2 clinical trial led by the University of Iowa studied the use of OK-432 in patients with LM from 1998 to 2005.
Most eligible subjects were between 6 months and 18 years of age with macrocystic or mixed macrocystic-microcystic LMs (with &ge;
50% macrocytic disease) of the head and/or neck. There were three treatment groups: immediate treatment (ITG), delayed treatment
(DTG), and open label</FONT> <FONT STYLE="font-size: 10pt">treatment group. The immediate treatment group received treatment with
OK-432 upon diagnosis. The delayed treatment group received OK-432 treatment following a six-month observation period; the cross-over
design was intended to investigate spontaneous resolution. The open-label treatment group included infants younger than six months
of age, adults older than 18 years of age, patients with LMs involving sites other than the head and neck (such as the axilla,
thorax, and extremities), and patients treated on an emergent basis. The open label treatment group were treated immediately with
OK-432. Response to therapy was measured by quantitating change in lesion size. Clinical success was defined as a complete (90%
to 100%) or substantial (60% to 89%) response to treatment based on radiographically confirmed shrinkage in lesions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">Results presented in this
report were based on a retrospective analysis of source verified data that included the full dataset of subjects enrolled in the
P2 randomized study between January 1998 and August 2005, including data in the published study (Smith et al. 2009) which included
subjects enrolled between January 1998 and November 2004.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">Overall, 310 subjects
were enrolled with intent to treat: 246 subjects were randomized to the immediate (ITG, N=171) and delayed (DTG, N=75) treatment
groups; 64 subjects were nonrandomized and assigned to the open-label group. Analysis of the primary efficacy endpoint (N=150)
demonstrated clinical success (complete and/or substantial response) in 69% of patients in the ITG 6 months after enrollment, while
7.5% of patients in the DTG experienced spontaneous regression of a LM during this time interval (p &lt; 0.0001)). When the results
were analyzed by lesion type across all treatment groups, a successful outcome was observed in 84% and 60% of patients with macrocystic
and mixed macrocystic-microcystic LM, respectively. None of the patients with microcystic LM demonstrated clinical success to OK-432
therapy. The results of the retrospective analysis were consistent with the results observed in the original analysis (Smith et
al. 2009).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">Figure 1: demonstrates that the primary endpoint
was met showing that 69% of patients in the immediate treatment group had a complete or substantial response to OK-432 while 7.5%
of patients in the delayed treatment group had a complete or substantial response after six months of observation and before treatment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><IMG SRC="image_002.jpg" ALT=""></P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">&#450;</TD><TD STYLE="text-align: left">Clinical Success was defined as complete or substantial
response</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">**</TD><TD STYLE="text-align: left">Results were analyzed by lesion type across all treatment
groups</TD>
</TR></TABLE>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0"></P>


<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><PAGE></PAGE></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Figure 2: illustrates that patients with
radiographically confirmed macrocystic lesions had the greatest likelihood of clinical success and in those patients with mixed
legions, clinical success was also achieved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><IMG SRC="image_003.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&#450;</B></FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Clinical
Success was defined as complete or substantial response</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">*</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Reflects
data prior to dosing with OK-432. After dosing, the clinical success rate was 66%, which was not statistically different from
the Immediate Treatment Group</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">**</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Results
were analyzed by lesion type across all treatment groups</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><I>Safety Profile</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">The most common adverse events with treatment
were local injection site reactions, fever, fatigue, decreased appetite, with resolution within a few days. Treatment emergent
serious adverse events (defined as any SAE occurring or worsening on or after the first dose of study drug and within 35 days after
the last dose of study drug) associated with OK-432 treatment were reported in 4.1% of patients, with the most severe events being
airway obstruction and facial paralysis due to massive swelling post-injection that required tracheostomy and hospitalization.
Both of these events were reported as resolved</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">The safety findings from the Sponsor-conducted
retrospective analysis are consistent with the original analysis reported in Smith et al. 2009, and with safety data in published
studies in approximately 865 patients with LMs after treatment with OK-432.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><I>Preclinical Development:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">A comprehensive preclinical
development program for OK-432, including <I>in vitro</I> and <I>in vivo</I> pharmacology and toxicology studies, was conducted
by Chugai Pharmaceutical to support the filing of a new drug application with the Japan Pharmaceuticals and Medical Devices Agency.
We plan to discuss with the FDA the ability to rely on these studies for the submission of a BLA for TARA-002.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><I>Regulatory Interactions:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">In July 2020, the U.S.
Food and Drug Administration, or FDA, granted Rare Pediatric Disease designation for TARA-002 for the treatment of LMs. The FDA
grants Rare Pediatric Disease designation for serious diseases that primarily affect children ages 18 years or younger and fewer
than 200,000 persons in the United States. Under the FDA&rsquo;s Rare Pediatric Disease Priority Review Voucher program, a sponsor who
receives an approval of a new drug application or biologics license application for a product for the prevention or treatment of
a rare pediatric disease may be eligible for a voucher, which can be redeemed to obtain priority review for any subsequent marketing
application or may be sold or transferred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">We plan to utilize
the robust dataset for OK-432 in LMs to support the potential filing of a Biological License Application (BLA) for TARA-002 in
lymphatic LMs. We are encouraged by the progress to date and, at the FDA&rsquo;s request, have submitted the full Clinical Study
Report (CSR) of the randomized Phase 2 study of OK-432 in LMs led by the University of Iowa. We continue to prepare for a potential
BLA filing in the second half of 2021, or to initiate additional clinical work as required by FDA.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><I>Manufacturing Plans:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">TARA-002 will be manufactured
using an equivalent, but modernized, proprietary manufacturing process as is used to produce OK-432 by Chugai Pharmaceutical.
Starting with a master cell line propagated by us but utilizing the same genetically distinct strain of <I>Streptococcus pyogenes
</I>(A group, type 3) Su strain as OK-432. We have contracted a contract development and manufacturing organization (CDMO), to
manufacture TARA-002. TARA-002 has received initial comparability to OK-432 from the FDA. We are currently conducting confirmatory
large scale GMP manufacturing comparability, which are scheduled to be completed in 2021.</P>


<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><PAGE></PAGE></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>IV Choline Chloride for the treatment of Intestinal
Failure Associated Liver Disease</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>Background:</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">IV Choline Chloride is
an intravenous (IV) substrate replacement therapy initially in development for patients receiving parenteral (typically intravenous)
nutrition (PN) who have intestinal failure associated liver disease (IFALD).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">Choline is a known important
substrate for phospholipids that are critical for healthy liver function. Because patients receiving PN cannot sufficiently absorb
adequate levels of choline and no available PN components contain sufficient amounts of choline to correct this deficit, they often
experience a prolonged progression to hepatic failure and death, with the only known intervention being a dual small bowel / liver
transplant. If approved, IV Choline Chloride would be the first approved therapy for IFALD. It has been granted Orphan Drug Designations
(ODDs) by the FDA for the treatment of IFALD and the prevention of choline deficiency in PN patients. We are currently undertaking
a prevalence study in partnership with a very large home health organization in the United States to enhance understanding of the
PN patient population.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">We have entered into a
license agreement with Dr. Alan Buchman for exclusive rights to the IND, ODDs and other regulatory assets related to IV Choline
Chloride, as well as exclusive rights to the data from previously conducted phase 1 and phase 2 clinical trials led by Dr. Buchman.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">The results of a randomized,
controlled, phase 2 clinical trial demonstrated that treatment with IV Choline Chloride resulted in normalization of plasma-free
choline concentrations, improvement of hepatic steatosis, and a clinically meaningful and statistically significant improvement
in cholestasis in patients dependent on PN.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: left">We had an end of phase 2 meeting with the FDA
in November 2018 and received the FDA&rsquo;s support for the design of studies necessary to complete the registration package
for IV Choline Chloride for the treatment of IFALD, including a Phase 1 pharmacokinetic study followed by Phase 3 trial.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0"><B><I>Disease Overview: </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">Intestinal Failure Associated
Liver Disease or IFALD is a rare hepatic/metabolic disease. IFALD, which occurs in patients dependent upon PN, is characterized
by choline deficiency, hepatic steatosis, cholestasis, and rapid progression of liver disease through to hepatic failure and death,
in the absence of intestine-liver transplant. IFALD carries a relatively poor prognosis, with a 15-34% death rate within one to
four years. When IFALD presents in children, mortality is even higher, with studies reporting death rates of 23-40% within 18 months.
A patient is considered to have IFALD if she/he:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 12pt">&nbsp;</td>
    <TD STYLE="width: 0.25in; padding-right: 0.8pt; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD STYLE="padding-right: 0.8pt; text-align: left; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">is dependent on PN for more than six months (e.g., has chronic intestinal failure);</font></td></tr>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 12pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</td>
    <TD STYLE="padding-right: 0.8pt; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD STYLE="padding-right: 0.8pt; text-align: left; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">has evidence of steatosis, determined by imaging techniques or histologic assessments;</font></td></tr>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</td>
    <TD STYLE="padding-right: 0.8pt; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD STYLE="padding-right: 0.8pt; text-align: left; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">has evidence of cholestasis (e.g., elevated alkaline phosphatase (ALP), elevated bilirubin and/or histology); and</font></td></tr>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</td>
    <TD STYLE="padding-right: 0.8pt; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD STYLE="padding-right: 0.8pt; text-align: left; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">may have evidence of ongoing, progressive liver injury on the basis of multiple abnormal liver function tests, in conjunction with findings of fibrosis, cirrhosis, and/or end-stage liver disease (ESLD).</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">According to recent Medicare diagnosis data, we estimate that
there are about 5,000 IFALD patients in the U.S.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">Many patients receiving
PN are entirely dependent on PN for their nutritional needs. PN delivers nearly all the macro and micro-nutrients necessary for
survival in their patients, with the notable exception of choline. Consequently, patients dependent on PN support have been shown
to be choline deficient. Patients dependent upon PN are unable to synthesize sufficient levels of choline and malabsorption limits
the bioavailability of choline chloride from the PN diet. The American Society for Parenteral and Enteral Nutrition and the Academy
of Nutrition and Dietetics&rsquo; Dietitians in Nutrition Support both recommend that choline be required in PN products; however,
there are currently no FDA-approved choline chloride PN products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">Dependence on PN and resulting
choline deficiency often leads to IFALD, which is the most common adverse outcome in chronic PN adult patients that is associated
with death. Low free choline plasma concentrations are associated with alanine aminotransferase (&ldquo;ALT&rdquo;), aspartate
aminotransferase (&ldquo;AST&rdquo;), and alkaline phosphatase (&ldquo;ALP&rdquo;) elevations as well as steatosis (fatty liver)
and Cholestasis (when bile from the liver stops or slows), all indicators of ongoing liver damage.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><PAGE></PAGE></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>Clinical History:</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">In a Phase 2 randomized,
double-blind, controlled 24-week clinical trial, patients (n=15) receiving nightly PN for &gt; 85% of their nutritional needs (for
at least 12 weeks prior to entry) were randomized to receive via IV infusion (10-12 hours) their usual PN with placebo (n = 8),
or PN to which 2g IV Choline Chloride was added (n = 7).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">In the IV Choline Chloride
group, mean choline levels were within or greater than the estimated normal range (i.e., 6.7 to 26.9 nmol/mL) throughout the 24-week
trial and quickly returned to baseline levels when treatment was discontinued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>Steatosis:</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">Upon conversion of the
quantification of computed tomography (CT) values to magnetic resonance imaging proton density fat fraction (MRI-PDFF), significant
differences in the least square (LS) mean change from baseline in estimated MRI-PDFF were observed in the IV Choline Chloride group
in comparison to placebo group at Week 4 through Week 24, demonstrating a clinically meaningful and statistically significant reduction
in steatosis. When LS mean percent changes from baseline in MRI-PDFF were compared between treatment groups, significant differences
in LS mean changes (range, 31.7% to 53.6%) were observed from Weeks 4 to 24 with p-values of 0.0009 to 0.0297 favoring the IV Choline
Chloride group.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Figure 3. Liver CT Images: Before and After Treatment with
IV Choline Chloride</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><IMG SRC="image_004.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>Alkaline Phosphatase:</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">At baseline, LS mean ALP
concentration was 239.3 &plusmn; 118.93 in the IV Choline Chloride group and 148.1 &plusmn; 100.2 in the placebo group. The MMRM
analyses demonstrated statistically significant decreases in ALP concentrations at Week 12 (p = 0.008), Week 16 (p = 0.005), Week
20 (p = 0.007), and Week 24 (p = 0.005) for the IV Choline Chloride group, demonstrating a reduction in cholestasis. A trend towards
significance was observed at Week 4 (p = 0.076) and Week 6 (p = 0.056). At Week 34, 10 weeks after discontinuation of IV Choline
Chloride treatment, LS mean change from baseline in ALP concentrations still demonstrated statistically significant decreases (p
= 0.002), demonstrating a significant improvement in cholestasis with treatment with IV Choline Chloride (Figure 4).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">In the subgroup of subjects with ALP concentration
&gt; 1.5x upper limit of normal (ULN) at baseline, (n=7), mean values at baseline were comparable between the IV Choline Chloride
and placebo groups (294.20 &plusmn; 87.947 versus 277.00 &plusmn; 128.693, respectively). In the sub-group analysis, improvement
in ALP was consistent and substantial, with 20-30% improvement over 12-24 weeks of treatment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>


<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><PAGE></PAGE></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">Figure 4. Improvement in Cholestasis</FONT><FONT STYLE="font-size: 8pt"><SUP>1</SUP></FONT><FONT STYLE="font-size: 10pt">:
All Patients</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-bottom: 0">&nbsp;<IMG SRC="image_005.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">                                                                                                                                          <TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="text-align: left">1</TD><TD STYLE="text-align: left">Protara Therapeutics re-analysis of patient CRF&rsquo;s, data
on file</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 8pt">*</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">mixed model for repeated
measurement (&ldquo;MMRM&rdquo;) method used for imputation</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#450;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">A
                                         placebo subject was excluded from all analyses due to likely IV contrast-induced imaging
                                         abnormalities, confirmed by independent radiologist in subsequent re-analysis.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>Preclinical Development:</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">Table 1. Preclinical Studies Conducted by us
for IV Choline Chloride</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr>
    <TD STYLE="width: 30%; border-bottom: Black 1.5pt solid; padding-right: 0; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>Study Type&nbsp;</b></font></td>
    <TD STYLE="width: 2%; padding-right: 0; font-size: 10pt">&nbsp;</td>
    <TD STYLE="width: 68%; border-bottom: Black 1.5pt solid; padding-right: 0; text-align: center; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>Brief Description</b></font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-right: 0; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif"><i>In vitro </i>protein binding</font></td>
    <TD STYLE="padding-right: 0; font-size: 10pt">&nbsp;</td>
    <TD STYLE="padding-right: 0; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">Evaluation of Protein Binding by Choline Chloride in Plasma Using Rapid Equilibrium Dialysis</font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-right: 0; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif"><i>In vitro </i>cardiac ion channel study</font></td>
    <TD STYLE="padding-right: 0; font-size: 10pt">&nbsp;</td>
    <TD STYLE="padding-right: 0; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">In Vitro Assessment of the Effect of Choline on Currents Mediated by hERG, Cav1.2, and Peak and Late Nav1.5 Channels Expressed in Human Embryonic Kidney (HEK) Cells</font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-right: 0; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif"><i>In vitro </i>drug-drug interaction</font></td>
    <TD STYLE="padding-right: 0; font-size: 10pt">&nbsp;</td>
    <TD STYLE="padding-right: 0; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">Evaluation of Transporter Inhibition by Choline Chloride in Transporter-Transfected HEK293 Cells</font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-right: 0; font-size: 10pt">&nbsp;</td>
    <TD STYLE="padding-right: 0; font-size: 10pt">&nbsp;</td>
    <TD STYLE="padding-right: 0; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">Evaluation of OCT2, MATE1 and MATE2-K Inhibition by Choline Chloride in Transporter-Transfected HEK293 Cells</font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-right: 0; font-size: 10pt">&nbsp;</td>
    <TD STYLE="padding-right: 0; font-size: 10pt">&nbsp;</td>
    <TD STYLE="padding-right: 0; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">Evaluation of Transporter Inhibition by Choline Chloride in Caco-2 Cells</font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-right: 0; font-size: 10pt">&nbsp;</td>
    <TD STYLE="padding-right: 0; font-size: 10pt">&nbsp;</td>
    <TD STYLE="padding-right: 0; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">Evaluation of Time Dependent Cytochrome P450 Inhibition (IC50 Shift) by Choline Chloride in Human Liver Microsomes</font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-right: 0">&nbsp;</td>
    <TD STYLE="padding-right: 0">&nbsp;</td>
    <TD STYLE="padding-right: 0"><font style="font: 10pt Times New Roman, Times, Serif">Evaluation of Direct Cytochrome P450 Inhibition by Choline Chloride in Human Liver Microsomes</font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-right: 0">&nbsp;</td>
    <TD STYLE="padding-right: 0">&nbsp;</td>
    <TD STYLE="padding-right: 0"><font style="font: 10pt Times New Roman, Times, Serif">Evaluation of Cytochrome P450 Induction by Choline Chloride in Human Hepatocytes</font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-right: 0">&nbsp;</td>
    <TD STYLE="padding-right: 0">&nbsp;</td>
    <TD STYLE="padding-right: 0"><font style="font: 10pt Times New Roman, Times, Serif">Evaluation of Transporter Inhibition by Choline Chloride in Caco-2 Cells</font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-right: 0">&nbsp;</td>
    <TD STYLE="padding-right: 0">&nbsp;</td>
    <TD STYLE="padding-right: 0"><font style="font: 10pt Times New Roman, Times, Serif">Evaluating of Cytochrome P450 2C8, 2C9, and 2C19 mRNA Induction by Choline Chloride in Human Hepatocytes</font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-right: 0"><font style="font: 10pt Times New Roman, Times, Serif"><i>In vitro BSEP inhibition</i></font></td>
    <TD STYLE="padding-right: 0">&nbsp;</td>
    <TD STYLE="padding-right: 0"><font style="font: 10pt Times New Roman, Times, Serif">Assessment of Choline as an Inhibitor of Human BSEP Mediated Transport</font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-right: 0">&nbsp;</td>
    <TD STYLE="padding-right: 0">&nbsp;</td>
    <TD STYLE="padding-right: 0"><font style="font: 10pt Times New Roman, Times, Serif">Assessment of Choline as a Substrate of Human BSEP Mediated Transport</font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-right: 0"><font style="font: 10pt Times New Roman, Times, Serif"><i>Nonclinical pharmacology studies</i></font></td>
    <TD STYLE="padding-right: 0">&nbsp;</td>
    <TD STYLE="padding-right: 0"><font style="font: 10pt Times New Roman, Times, Serif">Non-GLP Pilot Single Dose, Escalating Dose Tolerance Study of Choline by Intravenous Infusion in Male Beagle Dogs</font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-right: 0">&nbsp;</td>
    <TD STYLE="padding-right: 0">&nbsp;</td>
    <TD STYLE="padding-right: 0"><font style="font: 10pt Times New Roman, Times, Serif">GLP Single-dose IV Cardiovascular Study in Surgically Instrumented Male Dogs Monitored by Telemetry</font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-right: 0">&nbsp;</td>
    <TD STYLE="padding-right: 0">&nbsp;</td>
    <TD STYLE="padding-right: 0"><font style="font: 10pt Times New Roman, Times, Serif">GLP Combined Single-dose IV Neurobehavioral and Respiratory Study</font></td></tr>
</table>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><PAGE></PAGE></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>Clinical Development Plan:</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">We have reached
agreement with FDA on a number of key aspects of the overall clinical program necessary for registration, including a Phase 1
pharmacokinetic study and a Phase 3 study. We are currently undertaking a prevalence study in partnership with a large home
health organization in the United States to enhance understanding of the PN patient population, and plans to use this
information to determine the appropriate next steps for the development program.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>Manufacturing Plans:</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">We have manufactured sufficient
amounts of GMP drug substance and drug product to initiate the planned clinical trials. Scale up for commercial demand is ready
and will commence when appropriate. Our end-to-end manufacturing of IV Choline Chloride is conducted in the United States by a
GMP-compliant CDMO.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>Vonapanitase</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">As a result of the Merger,
we acquired the product candidate, vonapanitase, a recombinant human elastase that we previously pursued development for the improvement
of vascular access outcomes in patients with chronic kidney disease, undergoing or preparing for hemodialysis, and as a treatment
for patients with symptomatic peripheral artery disease. We are reviewing the research, preclinical and clinical data of vonapanitase
and has not yet determined whether to pursue any further development of this product candidate in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>Collaborations and License Agreements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>Chugai Agreement</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">On June 17, 2019, we entered
into an agreement (the &ldquo;Chugai Agreement&rdquo;) with Chugai Pharmaceutical, a company organized and existing under the laws
of Japan. Chugai Pharmaceutical has developed and commercialized a therapeutic product, OK-432 (Existing Product), in Japan and
Taiwan (the &ldquo;Chugai Territory&rdquo;), and owns and controls certain materials and documents related to the Existing Product
(the &ldquo;Chugai Materials&rdquo;). Pursuant to the Chugai Agreement, Chugai Pharmaceutical will provide us with certain materials
and documents relating to the Existing Product and will provide certain technical services to us for our development and commercialization
in territories other than the Chugai Territory (the &ldquo;Protara Territory&rdquo;) of a new therapeutic product (the &ldquo;New
Product&rdquo; or &ldquo;TARA-002&rdquo;) comparable to the Existing Product beginning on the effective date of the Chugai Agreement
and ending on June 30, 2020, or any other date to be agreed to by the parties (the &ldquo;Chugai Service Period&rdquo;), Chugai
Pharmaceutical will exclusively provide the Existing Product and Chugai Materials to us and will not provide the Existing Product
or Chugai Materials to any third parties during the Chugai Service Period, other than for medical, compassionate use and/or non-commercial
research purposes. Additionally, beginning on the effective date of the Chugai Agreement and ending on the fifth anniversary of
such date or upon the termination of the Chugai Agreement, whichever comes earlier, Chugai Pharmaceutical shall not provide Chugai
Materials or technical support to any third party for the purpose of development and commercialization in the Protara Territory
of a therapeutic product comparable to the Existing Product. We are responsible, at our sole cost and expense, for the development
and commercialization of the New Product in the Protara Territory.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">On July 14, 2020, we entered
into an amended agreement with Chugai Pharmaceutical (the &ldquo;Amended Chugai Agreement&rdquo;) with an effective date as of
June 30, 2020. The Chugai Amendment extended the date through which Chugai will exclusively provide the Existing Product and materials
to us from June 30, 2020 to June 30, 2021, extended the date through which Chugai will not provide materials or technical support
to any third party for the purpose of development and commercialization in a given area from the fifth anniversary to the eleventh
anniversary of the original effective date (extended to June 17, 2030) and provides that, in addition to the designated fee provided
upon the initial indication approval in the Chugai Pharmaceutical Agreement, we will pay Chugai a designated fee for each additional
indication approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">As consideration for Chugai
Pharmaceutical&rsquo;s performance under the Chugai Agreement, we agreed to pay Chugai Pharmaceutical a payment in the low, single-digit
millions, which payments shall be made in two installments with an initial payment in July 2020, and the remaining majority of
the payment payable upon FDA approval of the New Product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">We granted Chugai Pharmaceutical
a right of first refusal on terms to be negotiated between the parties for a license related to the New Product-relevant information,
data and documentation and inventions to develop and commercialize the New Product in the Chugai Territory. We will be responsible
for manufacturing and supplying or causing our CDMO to manufacture and supply the New Product to Chugai Pharmaceutical.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">The Chugai Agreement shall
remain in full force and effect until the first anniversary of the date of FDA approval of the New Product, unless terminated sooner
(the &ldquo;Chugai Term&rdquo;). Following the Chugai Service Period and during the Chugai Term, Chugai Pharmaceutical may terminate
the Chugai Agreement, in whole or in part, without cause, by providing us 90 days prior written notice. Following such termination,
we would maintain exclusive access to Chugai Materials, subject to the termination clauses outlined below. We may terminate the
Chugai Agreement, in whole only, by providing Chugai Pharmaceutical 90 days prior written notice if (i) we decide to discontinue
the New Product development; (ii) we decide that the FDA&rsquo;s requirements for the New Product are not likely to be met; or
(iii) the FDA identifies a safety issue regarding the New Product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><PAGE></PAGE></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">In addition, either party
may terminate the Chugai Agreement, in whole or in part, in the event that the other party materially breaches the Chugai Agreement
and fails to cure the breach within 30 days of written notice. Either party may terminate the Chugai Agreement in its entirety
immediately upon notice to the other party if such other party: (i) is dissolved or liquidated or takes any corporate action for
such purpose; (ii) becomes insolvent or is generally unable to pay, or fails to pay, its debts as they become due; (iii) files
or has filed against it a petition for voluntary or involuntary bankruptcy or otherwise becomes subject to any proceeding under
any domestic or foreign bankruptcy or insolvency laws; (iv) makes or seeks to make a general assignment for the benefit of creditors;
or (v) applies for or has a receiver, trustee, custodian or similar agent appointed by order of any court to take charge of or
sell any material portion of its property or business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">In the event that we undergo
a change of control, Chugai Pharmaceutical may terminate the Chugai Agreement upon 90 days written notice to us, absent a written
pledge by the new controlling party of its agreement to fulfill and undertake all obligations of ours and to be bound by the Chugai
Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>Sponsored Research and License Agreement</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">On November 28, 2018,
we entered into a sponsored research and license agreement (the &ldquo;Research Agreement&rdquo;) with The University of Iowa (the
&ldquo;University&rdquo;), pursuant to which the University will provide access to certain program data related to Chugai Pharmaceutical&rsquo;s
OK-432 and will assist us in conducting certain clinical studies. As consideration for the University&rsquo;s performance under
the Research Agreement, we will pay the University $30,000 per year in funding for the project, taking into consideration the time
spent by University employees required for the Project. The parties also agree to discuss in good faith potential additional funding
required for completion of the project pursuant to the Research Agreement as applicable and necessary. In addition, within 45 days
of approval of the TARA-002 BLA by the FDA, we will pay a one-time approval milestone to the University, the amount of which depends
on the usefulness of the program data in TARA-002&rsquo;s BLA filing, and the milestone amount will range from $0 to $1 million.
We will also be responsible for certain tiered royalties on annual net sales of products for the indication, which royalty rates
are in the low single digit percentages. These royalty rates are also subject to a reduction in the event that regulatory authorities
determine that the program data is not sufficient for regulatory approval on its own and additional pediatric efficacy and safety
clinical studies are required. In the event that the annual net sales surpass certain dollar amount thresholds, we will need to
make certain additional milestone payments following the close of the calendar quarter in which each milestone is reached, with
the payments ranging from $62,500 to $125,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">We may terminate the Research
Agreement upon 30 days prior written notice to the University. Either party may terminate the project under the Research Agreement
and all commitments and obligations with respect thereto upon 30 days prior written notice to the other party. In the event of
any termination of the project under the Research Agreement by the University, (a) the University agrees to complete certain phases
of the project and (b) we will continue to provide annual funding until the completion of the second phase of the project. Upon
termination of the project by us, the Agreement will terminate and we will reassign to the University the IND.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>Choline License Agreement </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">On September 27, 2017,
we entered into a choline license agreement (the &ldquo;Choline Agreement&rdquo;) with Alan L. Buchman, M.D., pursuant to which
Dr. Buchman granted us an exclusive, worldwide, non-transferable license in and to certain licensed orphan designations, certain
licensed IND, certain existing study data and to certain licensed know-how to develop, make, use, sell, offer for sale and import
the licensed product during the term of the Choline Agreement. We are solely responsible for all fees and expenses related to the
undertaking of the Choline Agreement, including all due diligence obligations, regulatory authority fees, attorney fees and consulting
fees. During the term of the Choline Agreement, Dr. Buchman may not work with any third parties on any product competing with the
licensed product. In consideration for the rights and licenses granted under the Agreement, we made an initial upfront payment
of $50,000 payable to Dr. Buchman.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in"><FONT STYLE="font-size: 10pt">We
will also owe Dr. Buchman certain milestone and royalty payments</FONT>.<FONT STYLE="font-size: 10pt"> Pursuant to the Choline
Agreement, we paid Dr. Buchman $50,000 in October 2019 because we had not received at least $5 million in working capital from
any source or in any manner as of October 15, 2019. Also, we paid Dr. Buchman an additional $550,000 upon the closing of the Private
Placements following the consummation of the Merger because we received at least $5 million in working capital.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">Regardless of whether
development or commercialization is undertaken by us under the Choline Agreement, commencing on November 21, 2022 and during the
term of the Choline Agreement, we shall pay Dr. Buchman a minimum annual royalty that ranges between $25,000 and $75,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><PAGE></PAGE></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">We owe Dr. Buchman sales royalties based on aggregate net sales
of IV Choline Chloride in each calendar quarter, with the royalty rates ranging from 5.0% to 10.5% based on the amount of net sales.
In the event of development or commercialization activity by any sublicensees, we also agreed to pay Dr. Buchman a royalty in the
mid-single digit percentage of (i) net cash receipts after payment of taxes received by us from sublicensees for their sales of
licensed products and (ii) any other consideration received by us from such sublicensees; in each case, including a fair monetary
value for any transaction that is not a bona fide arms-length transaction or that is for consideration other than monetary. Further,
in the event of a sale or transfer of a priority review voucher regarding the license product, regardless of whether any development
or commercialization activity is undertaken by us or our sublicensees, we agreed to pay Dr. Buchman a milestone payment representing
the mid-single digit percentage of (i) net cash receipts after payment of taxes and (ii) any other consideration; in each case,
received by us, our affiliates, or our sublicensees, including a fair monetary value for any transaction that is not a bona fide
arms-length transaction or that is for consideration other than monetary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">We shall also pay Dr.
Buchman up to an aggregate of up to $775,000 in additional milestone payments upon the achievement of various regulatory approval
milestones.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">The Choline Agreement
will remain in full force and effect until the last sale of the licensed product under the Choline Agreement. After we received
the FDA&rsquo;s written minutes regarding its initial FDA meeting concerning the development of the first licensed product for
one or more of the licensed indications, we paid an additional payment of $100,000 to Dr. Buchman and elected not terminate the
Choline Agreement. The Choline Agreement may be terminated by Dr. Buchman if, following regulatory approval of a licensed product,
we have not made our first sale of a licensed product within such country within a specified time period. We may terminate the
Choline Agreement for convenience upon 90 days prior written notice to Dr. Buchman. Dr. Buchman may terminate the Choline Agreement
effective immediately for non-payment of any payment due that has not been cured. Either party may terminate the Choline Agreement
effective immediately if the other party is in material breach and has not cured such breach within 60 days&rsquo; notice. In addition,
Dr. Buchman may terminate the Choline Agreement effective immediately upon 60 days prior written notice if (a) we cease or threaten
to cease to carry on its business; (b) a petition or resolution for the making of an administration order or for the bankruptcy,
winding-up or dissolution of us is presented or passed; (c) we file a voluntary petition in bankruptcy or insolvency; (d) a receiver
or administrator takes possession of our assets or (e) any similar procedure is commenced against us in the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0"><B><I>License Agreement</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">On December 22, 2017,
we entered into a license agreement (the &ldquo;License Agreement&rdquo;) with The Feinstein Institute for Medical Research, a
not-for-profit corporation organized and existing under the laws of New York (the &ldquo;Institute&rdquo;). The Institute owns,
by assignment, a U.S. patent related to the treatment of fatty liver disease in humans. Pursuant to the License Agreement, the
Institute granted us an exclusive, worldwide license, with the right to grant sublicenses to non-affiliate third parties, to develop,
make, have made, use, sell, offer for sale and import certain products for use in the field of fatty liver disease in humans receiving
total parenteral nutrition, by administering, as monotherapy, a pharmaceutical composition comprising intravenous choline, wherein
the fatty liver disease is selected from IFALD, non-alcoholic fatty liver, non-alcoholic steatohepatitis (&ldquo;NASH&rdquo;),
NASH-associated liver fibrosis, or non-alcoholic cirrhosis. Notwithstanding the exclusive rights granted to us, the Institute shall
retain the right to make, use and practice such patents in its own laboratories solely for non-commercial scientific purposes and
for continued non-commercial research.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">As consideration for the
license grant, we agreed to pay the Institute tiered royalties of between 1.0% and 1.5% of all net sales. In addition, we agreed
to pay the Institute a low double digit percentage of net proceeds resulting from agreements entered into within two years from
the effective date of the License Agreement and a mid-single digit percentage of net proceeds resulting from agreements entered
into thereafter. We also agreed to make certain license maintenance payments of $15,000 beginning on the second anniversary of
the effective date of the License Agreement and continuing upon every anniversary thereafter until the first commercial sale of
a licensed product. Beginning on the first anniversary of the effective date of the License Agreement after the first commercial
sale of a licensed product and every anniversary of the effective date of the License Agreement thereafter, we shall pay the Institute
$30,000 as a license maintenance fee. Such license maintenance fees are non-refundable but are creditable against future royalty
payments due to the Institute during the 12-month period following each such anniversary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">We agreed to make certain
one-time milestone payments in the aggregate amount of $375,000 upon the achievement of certain regulatory approval milestones,
of which $100,000 was paid on January 28, 2020 upon us having consummated the Private Placements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">Unless terminated earlier,
the License Agreement will expire upon the expiration of the last to expire patent under the License Agreement. We may terminate
the License Agreement by giving the Institute 60 days prior notice. Either party may terminate the License Agreement in the event
of a default or breach by the other party that has not been cured within 60 days of such notice. If we (i) make an assignment for
the benefit of creditors or if proceedings for a voluntary bankruptcy are instituted on behalf of us; (ii) is declared bankrupt
or insolvent or (iii) is convicted of a felony relating to the manufacture, use or sale of the licensed products or a felony relating
to moral turpitude, the Institute may terminate the License Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><PAGE></PAGE></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>Intellectual Property</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">Our intellectual property
is critical to our business and we strive to protect it, including by obtaining and maintaining patent protection in the U.S. and
internationally for our product candidates, novel biological discoveries, epitopes, new therapeutic approaches and potential indications,
and other inventions that are important to our business. Throughout the development of our product candidates, we will seek to
identify additional means of obtaining patent protection that would potentially enhance commercial success.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">The patent positions of
biotechnology companies like us are generally uncertain and involve complex legal, scientific and factual questions. We recognize
that the ability to obtain patent protection and the degree of such protection depends on a number of factors, including the extent
of the prior art, the novelty and non-obviousness of the invention, and the ability to satisfy the enablement requirement of the
patent laws. In addition, the coverage claimed in a patent application can be significantly reduced before the patent is issued,
and its scope can be reinterpreted after issuance. Consequently, we may not obtain or maintain adequate patent protection for any
of our product candidates. Any patents that we hold may be challenged, circumvented or invalidated by third parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">Our commercial success
will also depend in part on not infringing the proprietary rights of third parties. In addition, we have licensed rights under
proprietary technologies of third parties to develop, manufacture and commercialize specific aspects of our products and services.
It is uncertain whether the issuance of any third-party patent would require us to alter our development or commercial strategies,
alter our processes, obtain licenses or cease certain activities. The expiration of patents or patent applications licensed from
third parties or our breach of any license agreements or failure to obtain a license to proprietary rights that it may require
to develop or commercialize our future technology may have a material adverse impact on it. If third parties prepare and file patent
applications in the United States that also claim technology to which we have rights, we may have to participate in interference
proceedings in the United States Patent and Trademark Office (the &ldquo;USPTO&rdquo;) to determine priority of invention. For
a more comprehensive discussion of the risks related to our intellectual property, please see &ldquo;<I>Risk Factors&mdash;Risks
Related to Our Intellectual Property.</I>&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>TARA-002:</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">TARA-002 is a genetically
distinct Su strain of <I>Streptococcus pyogenes</I> (group A, type 3). TARA-002 is produced through a proprietary manufacturing
process. We believe a significant barrier to entry exists, as it believes only Chugai Pharmaceutical and us have the specific strain
and possess the know-how to manufacture the product. We anticipate that, if approved by the FDA, TARA-002 will be protected by
12 years of biologic exclusivity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>IV Choline Chloride:</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">With respect to IV Choline
Chloride, we have acquired an exclusive, worldwide license to U.S. Patent 8,865,641 B2 from the Feinstein Institute for Medical
Research providing protection in the United States until 2035. The patent applies to a method of treating a fatty liver disease
in a subject. In particular, the method comprises administering to the subject an effective amount of a cholinergic pathway stimulating
agent, wherein the fatty liver disease is selected from non-alcoholic fatty liver (NAFL), alcoholic fatty liver (AFL), non-alcoholic
steatohepatitis (NASH), alcoholic steatohepatitis (ASH), NASH-associated liver fibrosis, ASH-associated liver fibrosis, non-alcoholic
cirrhosis and alcoholic cirrhosis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">The term of individual
patents depends upon the legal term of the patents in the countries in which they are obtained. In most countries in which we may
file, the patent term is 20 years from the earliest date of filing a non-provisional patent application related to the patent.
A U.S. patent also may be accorded a patent term adjustment under certain circumstances to compensate for delays in obtaining the
patent from the USPTO. In some instances, such a patent term adjustment may result in a U.S. patent term extending beyond 20 years
from the earliest date of filing a non-provisional patent application related to the U.S. patent. In addition, in the United States,
the term of a U.S. patent that covers an FDA-approved drug may also be eligible for patent term extension, which permits patent
term restoration as compensation for the patent term lost during the FDA regulatory review process. The Hatch-Waxman Act permits
a patent term extension of up to five years beyond the expiration of the patent. The length of the patent term extension is related
to the length of time the drug is under regulatory review. Patent term extension cannot extend the remaining term of a patent beyond
a total of 14 years from the date of product approval and only one patent applicable to an approved drug may be extended. Similar
provisions are available in Europe and other foreign jurisdictions to extend the term of a patent that covers an approved drug.
In the future, if and when our products receive FDA approval, we expect to apply for patent term extensions on patents covering
certain of those products, when applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">We also rely on trade
secrets relating to product candidates and seek to protect and maintain the confidentiality of proprietary information to protect
aspects of our business that are not amenable to, or that we do not consider appropriate for, patent protection. Although we take
steps to protect our proprietary information and trade secrets, including through contractual means with our employees and consultants,
third parties may independently develop substantially equivalent proprietary information and techniques or otherwise gain access
to our trade secrets, including through breaches of such agreements with our employees and consultants. Thus, we may not be able
to meaningfully protect our trade secrets. It is our policy to require our employees, consultants, outside scientific partners,
sponsored researchers and other advisors to execute confidentiality agreements upon the commencement of employment or consulting
relationships with us. These agreements provide that all confidential information concerning our business or financial affairs
developed or made known to the individual during the course of the individual&rsquo;s relationship with us is to be kept confidential
and not disclosed to third parties except in specific circumstances. Our agreements with employees also provide that all inventions
conceived by the employee in the course of employment with us or from the employee&rsquo;s use of our confidential information
are our exclusive property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><PAGE></PAGE></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>Manufacturing</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">We rely on contract development
and manufacturing organizations (&ldquo;CDMOs&rdquo;) to produce our drug candidates in accordance with current Good Manufacturing
Practices (&ldquo;cGMP&rdquo;), regulations for use in clinical trials and commercial product. The manufacture of pharmaceuticals
is subject to extensive cGMP regulations, which impose various procedural and documentation requirements and govern all areas of
record keeping, production processes and controls, personnel and quality control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">The CDMOs that we partner
with have the capability to produce clinical supply required for clinical trials, as well as support commercial scale up activities
for both products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">Both TARA-002 and Choline
Chloride will be produced in the United States. The starting materials for TARA-002 were provided to us pursuant to an agreement
with Chugai Pharmaceutical. The regulatory starting materials for Choline Chloride are available commercially.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>Sales and Marketing</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">We plan to become a
fully integrated biopharmaceutical company pursuing our mission of supporting and improving the lives of patients suffering
from cancer and rare diseases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">If approved by the FDA,
we plan to commercialize both of our current product candidates in the U.S. first and then move to other geographies. As we advance
TARA-002 and IV Choline Chloride through our respective clinical development programs, we plan to grow our commercial organization
in support of anticipated product launches.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>Competition</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">The process for commercialization
of new drugs is very competitive, and we could potentially face worldwide competition from other pharmaceutical companies, biotechnology
companies and ultimately generic products. Our potential competitors may develop or market therapies that are more clinically effective,
safer or less expensive than any therapeutic products we develop.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>Government Regulation and Product Approval</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">The FDA and other regulatory
authorities at federal, state, and local levels, as well as in foreign countries, extensively regulate, among other things, the
research, development, testing, manufacture, quality control, import, export, safety, effectiveness, labeling, packaging, storage,
distribution, record keeping, approval, advertising, promotion, marketing, post-approval monitoring, and post-approval reporting
of drugs and biologics such as those we are developing. We, along with third-party contractors, will be required to navigate the
various preclinical, clinical and commercial approval requirements of the governing regulatory agencies of the countries in which
we wish to conduct studies or seek approval or licensure of our product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">In the United States,
the FDA regulates drugs under the Federal Food, Drug and Cosmetic Act (&ldquo;FDCA&rdquo;) and biologics additionally under the
Public Health Services Act (&ldquo;PHSA&rdquo;) as well as their respective implementing regulations. The process required by the
FDA before biopharmaceutical product candidates may be marketed in the United States generally involves the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 12pt">&nbsp;</td>
    <TD STYLE="width: 0.25in; padding-right: 0.8pt; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD STYLE="padding-right: 0.8pt; text-align: left; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">completion of preclinical laboratory tests and animal studies performed in accordance with the FDA&rsquo;s current Good Laboratory Practices (&ldquo;GLP&rdquo;) regulations;</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 12pt">&nbsp;</td>
    <TD STYLE="width: 0.25in; padding-right: 0.8pt; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD STYLE="padding-right: 0.8pt; text-align: left; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">submission to the FDA of an IND, which must become effective before clinical trials may begin and must be updated annually or when significant changes are made;</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 12pt">&nbsp;</td>
    <TD STYLE="width: 0.25in; padding-right: 0.8pt; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD STYLE="padding-right: 0.8pt; text-align: left; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">approval by an independent Institutional Review Board (&ldquo;IRB&rdquo;) or ethics committee at each clinical site before the trial is commenced;</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 12pt">&nbsp;</td>
    <TD STYLE="width: 0.25in; padding-right: 0.8pt; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD STYLE="padding-right: 0.8pt; text-align: left; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">performance of adequate and well-controlled human clinical trials to establish the safety and efficacy of a drug product candidate and the safety, purity and potency of the proposed biologic product candidate for its intended purpose;</font></td></tr>
</table>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 12pt">&nbsp;</td>
    <TD STYLE="width: 0.25in; padding-right: 0.8pt; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD STYLE="padding-right: 0.8pt; text-align: left; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">preparation of and submission to the FDA of an NDA or BLA after completion of all pivotal clinical trials that includes substantial evidence of safety, purity and potency or efficacy from results of nonclinical testing and clinical trials;</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 12pt">&nbsp;</td>
    <TD STYLE="width: 0.25in; padding-right: 0.8pt; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD STYLE="padding-right: 0.8pt; text-align: left; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">a determination by the FDA within 60 days of its receipt of an NDA or BLA to file the application for review;</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 12pt">&nbsp;</td>
    <TD STYLE="width: 0.25in; padding-right: 0.8pt; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD STYLE="padding-right: 0.8pt; text-align: left; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">satisfactory completion of an FDA Advisory Committee review, if applicable;</font></td></tr>
</table>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 12pt">&nbsp;</td>
    <TD STYLE="width: 0.25in; padding-right: 0.8pt; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD STYLE="padding-right: 0.8pt; text-align: left; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">satisfactory completion of an FDA pre-approval inspection of the manufacturing facility or facilities at which the proposed product is produced to assess compliance with cGMP, and of selected clinical investigation sites to assess compliance with Good Clinical Practices (&ldquo;GCP&rdquo;); and</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 12pt">&nbsp;</td>
    <TD STYLE="width: 0.25in; padding-right: 0.8pt; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD STYLE="padding-right: 0.8pt; text-align: left; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">FDA review and approval, or licensure, of the NDA or BLA to permit commercial marketing of the product for particular indications for use in the United States.</font></td></tr>
</table>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>


<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><PAGE></PAGE></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>Preclinical and Clinical Development</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">Prior to beginning the
first clinical trial with a product candidate, we must submit an IND to the FDA. An IND is a request for authorization from the
FDA to administer an investigational new drug product to humans. The central focus of an IND submission is on the general investigational
plan and the protocol(s) for clinical trials. The IND also includes results of animal and <I>in vitro</I> studies assessing the
toxicology, pharmacokinetics, pharmacology, and pharmacodynamic characteristics of the product candidate; chemistry, manufacturing,
and controls information; and any available human data or literature to support the use of the investigational product. An IND
must become effective before human clinical trials may begin. The IND automatically becomes effective 30 days after receipt by
the FDA, unless the FDA, within the 30-day time period, raises safety concerns or questions about the proposed clinical trial.
In such a case, the IND may be placed on clinical hold and the IND sponsor and the FDA must resolve any outstanding concerns or
questions before the clinical trial can begin. Submission of an IND therefore may or may not result in FDA authorization to begin
a clinical trial.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">Clinical trials involve
the administration of the investigational product to human subjects under the supervision of qualified investigators in accordance
with GCPs, which include the requirement that all research subjects provide their informed consent for their participation in any
clinical trial. Clinical trials are conducted under protocols detailing, among other things, the objectives of the trial, the parameters
to be used in monitoring safety and the effectiveness criteria to be evaluated. A separate submission to the existing IND must
be made for each successive clinical trial conducted during product development and for any subsequent protocol amendments. Furthermore,
an independent IRB for each site proposing to conduct the clinical trial must review and approve the plan for any clinical trial
and its informed consent form before the clinical trial begins at that site, and must monitor the trial until completed. Regulatory
authorities, the IRB or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the subjects
are being exposed to an unacceptable health risk or that the trial is unlikely to meet its stated objectives. Some studies also
include oversight by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety
monitoring board, which provides authorization for whether or not a trial may move forward at designated check points based on
access to certain data from the trial and may halt the clinical trial if it determines that there is an unacceptable safety risk
for subjects or other grounds, such as no demonstration of efficacy. There are also requirements governing the reporting of ongoing
clinical trials and clinical trial results to public registries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">Human clinical trials
are typically conducted in three sequential phases that may overlap.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 12pt">&nbsp;</td>
    <TD STYLE="width: 0.25in; padding-right: 0.8pt; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD STYLE="padding-right: 0.8pt; text-align: left; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">Phase 1&mdash;The investigational product is initially introduced into healthy human subjects or patients with the target disease or condition. These trials are designed to test the safety, dosage tolerance, absorption, metabolism, distribution and elimination of the investigational product in humans, the side effects associated with increasing doses, and, if possible, to gain early evidence on effectiveness.</font></td></tr>
</table>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 12pt">&nbsp;</td>
    <TD STYLE="width: 0.25in; padding-right: 0.8pt; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD STYLE="padding-right: 0.8pt; text-align: left; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">Phase 2&mdash;The investigational product is administered to a limited patient population with a specified disease or condition to evaluate the preliminary efficacy, optimal dosages and dosing schedule and to identify possible adverse side effects and safety risks. Multiple Phase 2 clinical trials may be conducted to obtain information prior to beginning larger and more expensive Phase 3 clinical trials.</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 12pt">&nbsp;</td>
    <TD STYLE="width: 0.25in; padding-right: 0.8pt; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD STYLE="padding-right: 0.8pt; text-align: left; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">Phase 3&mdash;The investigational product is administered to an expanded patient population to further evaluate dosage, to provide statistically significant evidence of clinical efficacy and to further test for safety, generally at multiple geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk/benefit ratio of the investigational product and to provide an adequate basis for product approval.</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">In some cases, the FDA
may require, or companies may voluntarily pursue, additional clinical trials after a product is approved to gain more information
about the product. These so- called Phase 4 trials may be made a condition to approval of the NDA or BLA. Concurrent with clinical
trials, companies may complete additional animal studies and develop additional information about the biological characteristics
of the product candidate, and must finalize a process for manufacturing the product in commercial quantities in accordance with
cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate
and, among other things, must develop methods for testing the identity, strength, quality and purity of the final product, or for
biologics, the safety, purity and potency. Additionally, appropriate packaging must be selected and tested and stability studies
must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><PAGE></PAGE></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>Application Submission, Review and Approval</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">Assuming successful completion
of all required testing in accordance with all applicable regulatory requirements, the results of product development, nonclinical
studies and clinical trials are submitted to the FDA as part of an NDA or BLA requesting approval to market the product for one
or more indications. The NDA or BLA must include all relevant data available from pertinent preclinical and clinical trials, including
negative or ambiguous results as well as positive findings, together with detailed information relating to the product&rsquo;s
chemistry, manufacturing, controls, and proposed labeling, among other things. The submission of an NDA or BLA requires payment
of a substantial application user fee to FDA, unless a waiver or exemption applies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">Once an NDA or BLA has
been submitted, the FDA&rsquo;s goal is to review standard applications within ten months after it accepts the application for
filing, or, if the application qualifies for priority review, six months after the FDA accepts the application for filing. In both
standard and priority reviews, the review process is often significantly extended by FDA requests for additional information or
clarification. The FDA reviews the application to determine, among other things, whether a product is safe, pure and potent and
the facility in which it is manufactured, processed, packed, or held meets standards designed to assure the product&rsquo;s continued
safety, purity and potency. The FDA may convene an advisory committee to provide clinical insight on application review questions.
Before approving an NDA or BLA, the FDA will typically inspect the facility or facilities where the product is manufactured. The
FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with
cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before
approving an NDA or BLA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP. If the FDA determines
that the application, manufacturing process or manufacturing facilities are not acceptable, it will outline the deficiencies in
the submission and often will request additional testing or information. Notwithstanding the submission of any requested additional
information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">The FDA may issue an approval
letter or a Complete Response letter. An approval letter authorizes commercial marketing of the product with specific prescribing
information for specific indications. A Complete Response letter will describe all of the deficiencies that the FDA has identified
in the NDA or BLA. In issuing the Complete Response letter, the FDA may recommend actions that the applicant might take to place
the application in condition for approval, including requests for additional information or clarification. The FDA may delay or
refuse approval of an application if applicable regulatory criteria are not satisfied, require additional testing or information
and/or require post-marketing testing and surveillance to monitor safety or efficacy of a product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">If regulatory approval
of a product is granted, such approval will be granted for particular indications and may entail limitations on the indicated uses
for which such product may be marketed. For example, the FDA may impose a Risk Evaluation and Mitigation Strategy (REMS), to ensure
the benefits of the product outweigh its risks. A REMS is a safety strategy to manage a known or potential serious risk associated
with a product and to enable patients to have continued access to such medicines by managing their safe use, and could include
medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient
registries and other risk minimization tools. The FDA also may condition approval on, among other things, changes to proposed labeling
or the development of adequate controls and specifications. Once approved, the FDA may withdraw the product approval if compliance
with pre- and post-marketing requirements is not maintained or if problems occur after the product reaches the marketplace. The
FDA may require one or more Phase 4 post-market trials and surveillance to further assess and monitor the product&rsquo;s safety
and effectiveness after commercialization, and may limit further marketing of the product based on the results of these post-marketing
trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>Orphan Drug Designation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">Under the Orphan Drug
Act, the FDA may grant orphan designation to a drug or biologic intended to treat a rare disease or condition, which is a disease
or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals in the United States
for which there is no reasonable expectation that the cost of developing and making available in the United States a drug or biologic
for this type of disease or condition will be recovered from sales in the United States for that drug or biologic. Orphan designation
must be requested before submitting an NDA or BLA. After the FDA grants orphan designation, the generic identity of the therapeutic
agent and its potential orphan use are disclosed publicly by the FDA. The orphan drug designation does not convey any advantage
in, or shorten the duration of, the regulatory review or approval process.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><PAGE></PAGE></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">If a product that has
orphan designation subsequently receives the first FDA approval for the disease for which it has such designation, the product
is entitled to orphan exclusivity, which means that the FDA may not approve any other applications, including a full NDA or BLA,
to market the same product for the same indication for seven years, except in limited circumstances, such as a showing of clinical
superiority to the product with orphan drug exclusivity. Orphan exclusivity does not prevent FDA from approving a different drug
or biologic for the same disease or condition, or the same drug or biologic for a different disease or condition. Among the other
benefits of orphan drug designation are tax credits for certain research and a waiver of the BLA application fee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">A designated orphan product
may not receive orphan exclusivity if it is approved for a use that is broader than the indication for which it received orphan
designation. In addition, exclusive marketing rights in the United States may be lost if the FDA later determines that the request
for designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product to meet
the needs of patients with the rare disease or condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">The FDA incentivizes the
development of drugs and biologics that meet the definition of a &ldquo;rare pediatric disease,&rdquo; defined to mean a serious
or life-threatening disease in which the serious of life-threatening manifestations primarily affect individuals aged from birth
to 18 years and the disease affects fewer than 200,000 individuals in the United States or affects 200,000 or more in the United
States and for which there is no reasonable expectation that the cost of developing and making in the United States a drug for
such disease or condition will be received from sales in the United States of such drug. The sponsor of a product candidate for
a rare pediatric disease may be eligible for a voucher that can be used to obtain a priority review for a subsequent human drug
or biologic application after the date of approval of the rare pediatric disease drug product, referred to as a priority review
voucher, or PRV. A rare pediatric disease designation does not guarantee that a sponsor will receive a PRV upon approval of its
NDA or BLA. If a PRV is received, it may be sold or transferred an unlimited number of times. Congress has extended the PRV program
until September&nbsp;30, 2024, with the potential for PRVs to be granted until September 30, 2026.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>Post-Approval Requirements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">Any products manufactured
or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other
things, requirements relating to quality control and quality assurance, record-keeping, reporting of adverse experiences, periodic
reporting, product sampling and distribution, and advertising and promotion of the product. After approval, most changes to the
approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There
also are continuing user fee requirements, under which FDA assesses an annual program fee for each product identified in an approved
NDA or BLA. Biopharmaceutical manufacturers and their subcontractors are required to register their establishments with the FDA
and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance
with cGMP, which impose certain procedural and documentation requirements upon sponsors and their third-party manufacturers. Changes
to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require prior FDA approval
before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting
requirements upon sponsor and third-party manufacturers. Accordingly, manufacturers must continue to expend time, money and effort
in the area of production and quality control to maintain compliance with cGMP and other aspects of regulatory compliance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">The FDA may withdraw approval
if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market.
Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency,
or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling
to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of
distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 12pt">&nbsp;</td>
    <TD STYLE="width: 0.25in; padding-right: 0.8pt; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD STYLE="padding-right: 0.8pt; text-align: left; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">restrictions on the marketing or manufacturing of a product, mandated modification of promotional materials or issuance of corrective information, issuance by FDA or other regulatory authorities of safety alerts, Dear Healthcare Provider letters, press releases or other communications containing warnings or other safety information about the product, or complete withdrawal of the product from the market or product recalls;</font></td></tr>
</table>
<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 12pt">&nbsp;</td>
    <TD STYLE="width: 0.25in; padding-right: 0.8pt; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD STYLE="padding-right: 0.8pt; text-align: left; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">fines, warning or untitled letters or holds on post-approval clinical trials;</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 12pt">&nbsp;</td>
    <TD STYLE="width: 0.25in; padding-right: 0.8pt; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD STYLE="padding-right: 0.8pt; text-align: left; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of existing product approvals;</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 12pt">&nbsp;</td>
    <TD STYLE="width: 0.25in; padding-right: 0.8pt; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD STYLE="padding-right: 0.8pt; text-align: left; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">product seizure or detention, or refusal of the FDA to permit the import or export of products; or</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 12pt">&nbsp;</td>
    <TD STYLE="width: 0.25in; padding-right: 0.8pt; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD STYLE="padding-right: 0.8pt; text-align: left; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">injunctions, consent decrees or the imposition of civil or criminal penalties.</font></td></tr>
</table>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><PAGE></PAGE></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">The FDA closely regulates
the marketing, labeling, advertising and promotion of biopharmaceuticals. A company can make only those claims relating to safety
and efficacy, purity and potency of a biopharmaceutical that are approved by the FDA and in accordance with the provisions of the
approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses.
Failure to comply with these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising
and potential civil and criminal penalties. Physicians may prescribe legally available products for uses that are not described
in the product&rsquo;s labeling and that differ from those approved by the FDA. Such off-label uses are common across medical specialties.
Physicians may believe that such off-label uses are the best treatment for many patients in varied circumstances. The FDA does
not regulate the behavior of physicians in their choice of treatments. The FDA does, however, restrict manufacturer&rsquo;s communications
on the subject of off-label use of their products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>Biosimilars and Reference Product Exclusivity</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">The Patient Protection
and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (ACA), signed into law in 2010, includes
a subtitle called the Biologics Price Competition and Innovation Act of 2009 (BPCIA), which created an abbreviated approval pathway
for biological products that are biosimilar to or interchangeable with an FDA-approved reference biological product. To date, a
number of biosimilars have been licensed under the BPCIA, and numerous biosimilars have been approved in Europe. The FDA has issued
several guidance documents outlining its approach to the review and approval of biosimilars.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">Biosimilarity, which requires
that there be no clinically meaningful differences between the biological product and the reference product in terms of safety,
purity, and potency, can be shown through analytical studies, animal studies, and a clinical trial or trials. Interchangeability
requires that a product is biosimilar to the reference product and the product must demonstrate that it can be expected to produce
the same clinical results as the reference product in any given patient and, for products that are administered multiple times
to an individual, the biologic and the reference biologic may be alternated or switched after one has been previously administered
without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic. Complexities
associated with the larger, and often more complex, structures of biological products, as well as the processes by which such products
are manufactured, pose significant hurdles to implementation of the abbreviated approval pathway that are still being worked out
by the FDA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">Under the BPCIA, an application
for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first
licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from
the date on which the reference product was first licensed. During this 12-year period of exclusivity, another company may still
market a competing version of the reference product if the FDA approves a full BLA for the competing product containing that applicant&rsquo;s
own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of
its product. The BPCIA also created certain exclusivity periods for biosimilars approved as interchangeable products. At this juncture,
it is unclear whether products deemed &ldquo;interchangeable&rdquo; by the FDA will, in fact, be readily substituted by pharmacies,
which are governed by state pharmacy law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">The BPCIA is complex and
continues to be interpreted and implemented by the FDA. In addition, recent government proposals have sought to reduce the 12-year
reference product exclusivity period. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have
also been the subject of recent litigation. As a result, the ultimate impact, implementation, and impact of the BPCIA is subject
to significant uncertainty.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>Other U.S. Healthcare Laws and Compliance
Requirements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">In the United States,
our current and future operations are subject to regulation by various federal, state and local authorities in addition to the
FDA, including but not limited to, the Centers for Medicare&nbsp;&amp;Medicaid Services (&ldquo;CMS&rdquo;), other divisions of
the U.S. Department of Health and Human Services (&ldquo;HHS&rdquo;) (such as the Office of Inspector General, Office for Civil
Rights and the Health Resources and Service Administration), the U.S. Department of Justice (&ldquo;DOJ&rdquo;) and individual
U.S. Attorney offices within the DOJ, and state and local governments. For example, our clinical research, sales, marketing and
scientific/educational grant programs will need to comply with the anti-fraud and abuse provisions of the Social Security Act,
the false claims laws, the privacy and security provisions of the Health Insurance Portability and Accountability Act (&ldquo;HIPAA&rdquo;),
and similar state laws, each as amended, as applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">The federal Anti-Kickback
Statute prohibits, among other things, any person or entity, from knowingly and willfully offering, paying, soliciting or receiving
any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or in return for purchasing, leasing,
ordering or arranging for the purchase, lease or order of any item or service reimbursable, in whole or in part, under Medicare,
Medicaid or other federal healthcare programs. The term remuneration has been interpreted broadly to include anything of value.
The Anti-Kickback Statute has been interpreted to apply to arrangements between therapeutic product manufacturers on one hand and
prescribers, purchasers, and formulary managers on the other. There are a number of statutory exceptions and regulatory safe harbors
protecting some common activities from prosecution. The exceptions and safe harbors are drawn narrowly and practices that involve
remuneration that may be alleged to be intended to induce prescribing, purchasing or recommending may be subject to scrutiny if
they do not qualify for an exception or safe harbor. Failure to meet all of the requirements of a particular applicable statutory
exception or regulatory safe harbor does not make the conduct per se illegal under the Anti-Kickback Statute. Instead, the legality
of the arrangement will be evaluated on a case-by-case basis based on a cumulative review of all of its facts and circumstances.
Our practices may not in all cases meet all of the criteria for protection under a statutory exception or regulatory safe harbor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><PAGE></PAGE></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">Additionally, the intent
standard under the Anti-Kickback Statute was amended by the Patient Protection and Affordable Care Act, as amended by the Health
Care and Education Reconciliation Act of 2010 (the &ldquo;Affordable Care Act&rdquo;) to a stricter standard such that a person
or entity no longer needs to have actual knowledge of the statute or specific intent to violate it in order to have committed a
violation. In addition, the Affordable Care Act codified case law that a claim including items or services resulting from a violation
of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal False Claims Act (the
&ldquo;FCA&rdquo;) (discussed below).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">The federal false claims,
including the FCA, and civil monetary penalty laws, which imposes significant penalties and can be enforced by private citizens
through civil qui tam actions, prohibit any person or entity from, among other things, knowingly presenting, or causing to be presented,
a false or fraudulent claim for payment to, or approval by, the federal government, including federal healthcare programs, such
as Medicare and Medicaid, knowingly making, using, or causing to be made or used a false record or statement material to a false
or fraudulent claim to the federal government, or knowingly making a false statement to improperly avoid, decrease or conceal an
obligation to pay money to the federal government. A claim includes &ldquo;any request or demand&rdquo; for money or property presented
to the U.S. government. For instance, historically, pharmaceutical and other healthcare companies have been prosecuted under these
laws for allegedly providing free product to customers with the expectation that the customers would bill federal programs for
the product. Other companies have been prosecuted for causing false claims to be submitted because of the companies&rsquo; marketing
of the product for unapproved, off-label, and thus generally non-reimbursable, uses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">HIPAA created additional
federal criminal statutes that prohibit, among other things, knowingly and willfully executing, or attempting to execute, a scheme
to defraud or to obtain, by means of false or fraudulent pretenses, representations or promises, any money or property owned by,
or under the control or custody of, any healthcare benefit program, including private third-party payors, willfully obstructing
a criminal investigation of a healthcare offense, and knowingly and willfully falsifying, concealing or covering up by trick, scheme
or device, a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of
or payment for healthcare benefits, items or services. Like the Anti-Kickback Statute, the Affordable Care Act amended the intent
standard for certain healthcare fraud statutes under HIPAA such that a person or entity no longer needs to have actual knowledge
of the statute or specific intent to violate it in order to have committed a violation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">Also, many states have
similar, and typically more prohibitive, fraud and abuse statutes or regulations that apply to items and services reimbursed under
Medicaid and other state programs, or, in several states, apply regardless of the payor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">We may be subject to data
privacy and security regulations by both the federal government and the states in which it conducts business. HIPAA, as amended
by the Health Information Technology for Economic and Clinical Health Act (HITECH) and its implementing regulations, imposes requirements
on &ldquo;covered entities,&rdquo; including certain healthcare providers, health plans, and healthcare clearinghouses, as well
as their respective &ldquo;business associates&rdquo; that create, receive, maintain or transmit individually identifiable health
information for or on behalf of a covered entity as well as their covered subcontractors relating to the privacy, security and
transmission of individually identifiable health information. Among other things, HITECH makes HIPAA&rsquo;s privacy and security
standards directly applicable to business associates, independent contractors, or agents of covered entities that receive or obtain
protected health information in connection with providing a service on behalf of a covered entity. HITECH also created four new
tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates,
and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce HIPAA
and seek attorneys&rsquo; fees and costs associated with pursuing federal civil actions. In addition, many state laws govern the
privacy and security of health information in specified circumstances, many of which differ from each other in significant ways,
are often not pre-empted by HIPAA, and may have a more prohibitive effect than HIPAA, thus complicating compliance efforts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: left; text-indent: 0.25in">We may develop
products that, once approved, may be administered by a physician. Under currently applicable U.S. law, certain products not usually
self-administered (including injectable drugs) may be eligible for coverage under Medicare through Medicare Part B. Medicare Part
B is part of original Medicare, the federal health care program that provides health care benefits to the aged and disabled, and
covers outpatient services and supplies, including certain biopharmaceutical products, that are medically necessary to treat a
beneficiary&rsquo;s health condition. As a condition of receiving Medicare Part B reimbursement for a manufacturer&rsquo;s eligible
drugs, the manufacturer is required to participate in other government healthcare programs, including the Medicaid Drug Rebate
Program and the 340B Drug Pricing Program. The Medicaid Drug Rebate Program requires pharmaceutical manufacturers to enter into
and have in effect a national rebate agreement with the Secretary of HHS as a condition for states to receive federal matching
funds for the manufacturer&rsquo;s outpatient drugs furnished to Medicaid patients. Under the 340B Drug Pricing Program, the manufacturer
must extend discounts to entities that participate in the program.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">In addition, many pharmaceutical
manufacturers must calculate and report certain price reporting metrics to the government, such as average sales price (&ldquo;ASP&rdquo;)
and best price. Penalties may apply in some cases when such metrics are not submitted accurately and timely. Further, these prices
for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by
any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than
in the United States. It is difficult to predict how Medicare coverage and reimbursement policies will be applied to our products
in the future and coverage and reimbursement under different federal healthcare programs are not always consistent. Medicare reimbursement
rates may also reflect budgetary constraints placed on the Medicare program.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 23 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><PAGE></PAGE></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">Additionally, the federal
Physician Payments Sunshine Act (the &ldquo;Sunshine Act&rdquo;), within the Affordable Care Act, and its implementing regulations,
require that certain manufacturers of drugs, devices, biological and medical supplies for which payment is available under Medicare,
Medicaid or the Children&rsquo;s Health Insurance Program (with certain exceptions) report annually to CMS information related
to certain payments or other transfers of value made or distributed to physicians (defined to include doctors, dentists, optometrists,
podiatrists and chiropractors) and teaching hospitals, or to entities or individuals at the request of, or designated on behalf
of, the physicians and teaching hospitals and to report annually certain ownership and investment interests held by physicians
and their immediate family members. Beginning in 2022, applicable manufacturers also will be required to report such information
regarding its relationships with physician assistants, nurse practitioners, clinical nurse specialists, anesthesiologist assistants,
certified registered nurse anesthetists and certified nurse midwives during the previous year. Failure to report accurately could
result in penalties. In addition, many states also govern the reporting of payments or other transfers of value, many of which
differ from each other in significant ways, are often not pre-empted, and may have a more prohibitive effect than the Sunshine
Act, thus further complicating compliance efforts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">In order to distribute
products commercially, we must comply with state laws that require the registration of manufacturers and wholesale distributors
of drug and biological products in a state, including, in certain states, manufacturers and distributors who ship products into
the state even if such manufacturers or distributors have no place of business within the state. Some states also impose requirements
on manufacturers and distributors to establish the pedigree of product in the chain of distribution, including some states that
require manufacturers and others to adopt new technology capable of tracking and tracing product as it moves through the distribution
chain. Several states and/or localities have enacted legislation requiring pharmaceutical and biotechnology companies to establish
marketing compliance programs, file periodic reports with the state, make periodic public disclosures on sales, marketing, pricing,
clinical trials and other activities, and/or register their sales representatives, as well as to prohibit pharmacies and other
healthcare entities from providing certain physician prescribing data to pharmaceutical and biotechnology companies for use in
sales and marketing, and to prohibit certain other sales and marketing practices. All of our activities are potentially subject
to federal and state consumer protection and unfair competition laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">Ensuring business arrangements
with third parties comply with applicable healthcare laws and regulations is a costly endeavor. If our operations are found to
be in violation of any of the federal and state healthcare laws described above or any other current or future governmental regulations
that apply to it, it may be subject to penalties, including without limitation, significant civil, criminal and/or administrative
penalties, damages, fines, disgorgement, imprisonment, exclusion from participation in government programs, such as Medicare and
Medicaid, injunctions, private &ldquo;qui tam&rdquo; actions brought by individual whistleblowers in the name of the government,
or refusal to allow it to enter into government contracts, contractual damages, reputational harm, administrative burdens, diminished
profits and future earnings, additional reporting obligations and oversight if we become subject to a corporate integrity agreement
or other agreement to resolve allegations of non-compliance with these laws, and the curtailment or restructuring of its operations,
any of which could adversely affect our ability to operate our business and our results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>Coverage, Pricing and Reimbursement</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">Significant uncertainty
exists as to the coverage and reimbursement status of any product candidates for which we may obtain regulatory approval. In the
United States and in foreign markets, sales of any products for which we receive regulatory approval for commercial sale will depend,
in part, on the extent to which third-party payors provide coverage and establish adequate reimbursement levels for such products.
In the United States, third-party payors include federal and state healthcare programs, private managed care providers, health
insurers and other organizations. Adequate coverage and reimbursement from governmental healthcare programs, such as Medicare and
Medicaid in the United States, and commercial payors are critical to new product acceptance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">Our ability to commercialize
any products successfully also will depend in part on the extent to which coverage and reimbursement for these products and related
treatments will be available from government health administration authorities, private health insurers and other organizations.
Government authorities and other third-party payors, such as private health insurers and health maintenance organizations, decide
which therapeutics they will pay for and establish reimbursement levels. Coverage and reimbursement by a third-party payor may
depend upon a number of factors, including the third-party payor&rsquo;s determination that use of a therapeutic is:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 12pt">&nbsp;</td>
    <TD STYLE="width: 0.25in; padding-right: 0.8pt; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD STYLE="padding-right: 0.8pt; text-align: left; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">a covered benefit under its health plan;</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 12pt">&nbsp;</td>
    <TD STYLE="width: 0.25in; padding-right: 0.8pt; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD STYLE="padding-right: 0.8pt; text-align: left; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">safe, effective and medically necessary;</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 12pt">&nbsp;</td>
    <TD STYLE="width: 0.25in; padding-right: 0.8pt; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD STYLE="padding-right: 0.8pt; text-align: left; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">appropriate for the specific patient;</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 12pt">&nbsp;</td>
    <TD STYLE="width: 0.25in; padding-right: 0.8pt; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD STYLE="padding-right: 0.8pt; text-align: left; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">cost-effective; and</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 12pt">&nbsp;</td>
    <TD STYLE="width: 0.25in; padding-right: 0.8pt; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD STYLE="padding-right: 0.8pt; text-align: left; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">neither experimental nor investigational.</font></td></tr>
</table>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><PAGE></PAGE></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">We cannot be sure that
reimbursement will be available for any product that it commercializes and, if coverage and reimbursement are available, what the
level of reimbursement will be. Coverage may also be more limited than the purposes for which the product is approved by the FDA
or comparable foreign regulatory authorities. Reimbursement may impact the demand for, or the price of, any product for which we
obtain regulatory approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">Third-party payors are
increasingly challenging the price, examining the medical necessity, and reviewing the cost-effectiveness of medical products,
therapies and services, in addition to questioning their safety and efficacy. Obtaining reimbursement for our products may be particularly
difficult because of the higher prices often associated with branded drugs and drugs administered under the supervision of a physician.
We may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness
of our products, in addition to the costs required to obtain FDA approvals. Our product candidates may not be considered medically
necessary or cost-effective. Obtaining coverage and reimbursement approval of a product from a government or other third-party
payor is a time-consuming and costly process that could require us to provide to each payor supporting scientific, clinical and
cost-effectiveness data for the use of our product on a payor-by-payor basis, with no assurance that coverage and adequate reimbursement
will be obtained. A payor&rsquo;s decision to provide coverage for a product does not imply that an adequate reimbursement rate
will be approved. Further, one payor&rsquo;s determination to provide coverage for a product does not assure that other payors
will also provide coverage for the product. Adequate third-party reimbursement may not be available to enable us to maintain price
levels sufficient to realize an appropriate return on our investment in product development. If reimbursement is not available
or is available only at limited levels, we may not be able to successfully commercialize any product candidate that it successfully
develops.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">Different pricing and
reimbursement schemes exist in other countries. In the European Union, governments influence the price of biopharmaceutical products
through their pricing and reimbursement rules and control of national health care systems that fund a large part of the cost of
those products to consumers. Some jurisdictions operate positive and negative list systems under which products may only be marketed
once a reimbursement price has been agreed. To obtain reimbursement or pricing approval, some of these countries may require the
completion of clinical trials that compare the cost effectiveness of a particular product candidate to currently available therapies.
Other member states allow companies to fix their own prices for medicines but monitor and control company profits. The downward
pressure on health care costs has become intense. As a result, increasingly high barriers are being erected to the entry of new
products. In addition, in some countries, cross-border imports from low-priced markets exert a commercial pressure on pricing within
a country.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">The marketability of any
product candidates for which we receive regulatory approval for commercial sale may suffer if the government and third-party payors
fail to provide adequate coverage and reimbursement. In addition, emphasis on managed care, the increasing influence of health
maintenance organizations, and additional legislative changes in the United States has increased, and we expect will continue to
increase, the pressure on healthcare pricing. The downward pressure on the rise in healthcare costs in general, particularly prescription
medicines, medical devices and surgical procedures and other treatments, has become very intense. Coverage policies and third-party
reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products
for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>Healthcare Reform</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">In the United States and
some foreign jurisdictions, there have been, and continue to be, several legislative and regulatory changes and proposed changes
regarding the healthcare system that could prevent or delay marketing approval of product candidates, restrict or regulate post-approval
activities, and affect the ability to profitably sell product candidates for which marketing approval is obtained. Among policy
makers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems
with the stated goals of containing healthcare costs, improving quality and/or expanding access. In the United States, the pharmaceutical
industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 25 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><PAGE></PAGE></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">For example, the Affordable
Care Act has substantially changed healthcare financing and delivery by both governmental and private insurers. Among the Affordable
Care Act provisions of importance to the pharmaceutical and biotechnology industries, in addition to those otherwise described
above, are the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 12pt">&nbsp;</td>
    <TD STYLE="width: 0.25in; padding-right: 0.8pt; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD STYLE="padding-right: 0.8pt; text-align: left; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">an annual, nondeductible fee on any entity that manufactures or imports certain specified branded prescription drugs and biologic agents apportioned among these entities according to their market share in some government healthcare programs;</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 12pt">&nbsp;</td>
    <TD STYLE="width: 0.25in; padding-right: 0.8pt; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD STYLE="padding-right: 0.8pt; text-align: left; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program to 23.1% and 13% of the average manufacturer price for most branded and generic drugs, respectively, and capped the total rebate amount for innovator drugs at 100% of the Average Manufacturer Price (the &ldquo;AMP&rdquo;);</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 12pt">&nbsp;</td>
    <TD STYLE="width: 0.25in; padding-right: 0.8pt; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD STYLE="padding-right: 0.8pt; text-align: left; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">a new Medicare Part D coverage gap discount program, in which manufacturers must now agree to offer 70% point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturers&rsquo; outpatient drugs to be covered under Medicare Part D;</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 12pt">&nbsp;</td>
    <TD STYLE="width: 0.25in; padding-right: 0.8pt; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD STYLE="padding-right: 0.8pt; text-align: left; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">extension of manufacturers&rsquo; Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations;</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 12pt">&nbsp;</td>
    <TD STYLE="width: 0.25in; padding-right: 0.8pt; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD STYLE="padding-right: 0.8pt; text-align: left; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional individuals and by adding new mandatory eligibility categories for individuals with income at or below 133% of the federal poverty level, thereby potentially increasing manufacturers&rsquo; Medicaid rebate liability;</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 12pt">&nbsp;</td>
    <TD STYLE="width: 0.25in; padding-right: 0.8pt; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD STYLE="padding-right: 0.8pt; text-align: left; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">expansion of the entities eligible for discounts under the 340B Drug Discount Program;</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 12pt">&nbsp;</td>
    <TD STYLE="width: 0.25in; padding-right: 0.8pt; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD STYLE="padding-right: 0.8pt; text-align: left; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research;</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 12pt">&nbsp;</td>
    <TD STYLE="width: 0.25in; padding-right: 0.8pt; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD STYLE="padding-right: 0.8pt; text-align: left; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">expansion of healthcare fraud and abuse laws, including the FCA and the Anti-Kickback Statute, new government investigative powers, and enhanced penalties for noncompliance;</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 12pt">&nbsp;</td>
    <TD STYLE="width: 0.25in; padding-right: 0.8pt; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD STYLE="padding-right: 0.8pt; text-align: left; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted, or injected;</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 12pt">&nbsp;</td>
    <TD STYLE="width: 0.25in; padding-right: 0.8pt; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD STYLE="padding-right: 0.8pt; text-align: left; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">requirements to report certain financial arrangements with physicians and teaching hospitals;</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 12pt">&nbsp;</td>
    <TD STYLE="width: 0.25in; padding-right: 0.8pt; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD STYLE="padding-right: 0.8pt; text-align: left; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">a requirement to annually report certain information regarding drug samples that manufacturers and distributors provide to physicians;</font></td></tr>
</table>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 12pt">&nbsp;</td>
    <TD STYLE="width: 0.25in; padding-right: 0.8pt; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD STYLE="padding-right: 0.8pt; text-align: left; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">establishment of a Center for Medicare and Medicaid Innovation at CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending; and</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 12pt">&nbsp;</td>
    <TD STYLE="width: 0.25in; padding-right: 0.8pt; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <TD STYLE="padding-right: 0.8pt; text-align: left; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">a licensure framework for follow on biologic products.</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">There remain legal and
political challenges to certain aspects of the Affordable Care Act. Since January 2017, the Trump administration signed several
executive orders and other directives designed to delay, circumvent, or loosen certain requirements mandated by the Affordable
Care Act. In December 2017, Congress repealed the tax penalty for an individual&rsquo;s failure to maintain Affordable Care Act-mandated
health insurance as part of a tax reform bill. Further, the 2020 federal spending package permanently eliminated, effective January
1, 2020, the Affordable Care Act-mandated &ldquo;Cadillac&rdquo; tax on high-cost employer-sponsored health coverage and medical
device tax and, effective January 1, 2021, also eliminated the health insurer tax. On December 14, 2018, a U.S. District Court
Judge in the Northern District of Texas ruled that the individual mandate is a critical and inseverable feature of the Affordable
Care Act, and therefore, because it was repealed as part of the tax reform bill, the remaining provisions of the Affordable Care
Act are invalid as well. Additionally, on December 18, 2019, the U.S. Court of Appeals for the 5th Circuit upheld the District
Court ruling that the individual mandate was unconstitutional and remanded the case back to the District Court to determine whether
the remaining provisions of the Affordable Care Act are invalid as well. The U.S. Supreme Court is currently reviewing this case,
although it is unclear when a decision will be made. Although the U.S. Supreme Court has yet ruled on the constitutionality of
the ACA, on January 28, 2021, President Biden issued an executive order to initiate a special enrollment period from February 15,
2021 through May 15, 2021 for purposes of obtaining health insurance coverage through the Affordable Care Act marketplace. The
executive order also instructs certain governmental agencies to review and reconsider their existing policies and rules that limit
access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work
requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or
the Affordable Care Act. It is unclear how the Supreme Court ruling, other such litigation, and the healthcare reform measures
of the Biden administration will impact the ACA and our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 26 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><PAGE></PAGE></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">We anticipate that the
Affordable Care Act, if substantially maintained in its current form, will continue to result in additional downward pressure on
coverage and the price that we receive for any approved product, and could seriously harm our business. Any reduction in reimbursement
from Medicare and other government programs may result in a similar reduction in payments from private payors. The implementation
of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability,
or commercialize our products. Such reforms could have an adverse effect on anticipated revenue from product candidates that we
may successfully develop and for which we may obtain regulatory approval and may affect our overall financial condition and ability
to develop product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">Further legislation or
regulation could be passed that could harm our business, financial condition and results of operations. Other legislative changes
have been proposed and adopted since the Affordable Care Act was enacted. For example, in August 2011, President Obama signed into
law the Budget Control Act of 2011, which, among other things, created the Joint Select Committee on Deficit Reduction to recommend
to Congress proposals in spending reductions. The Joint Select Committee on Deficit Reduction did not achieve a targeted deficit
reduction of at least $1.2 trillion for fiscal years 2012 through 2021, triggering the legislation&rsquo;s automatic reduction
to several government programs. This includes aggregate reductions to Medicare payments to providers of up to 2% per fiscal year,
which went into effect beginning on April 1, 2013 and will stay in effect through 2030 unless additional Congressional action is
taken. However, COVID-19 pandemic relief legislation has suspended the 2% Medicare sequester from May 1, 2020 through March 31,
2021. In January 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced
Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment centers, and increased
the statute of limitations period for the government to recover overpayments to providers from three to five years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">Additionally, there has
been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices. Specifically,
there have been several recent U.S. Congressional inquiries and proposed federal legislation designed to, among other things, bring
more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing
and manufacturer patient programs, and reform government program reimbursement methodologies for drugs. At the federal level, the
Trump administration&rsquo;s budget proposal for fiscal year 2021 includes a $135 billion allowance to support legislative proposals
seeking to reduce drug prices, increase competition, lower out-of-pocket drug costs for patients, and increase patient access to
lower-cost generic and biosimilar drugs. Further, the Trump administration previously released a &ldquo;Blueprint<B><I>,</I></B>&rdquo;
or plan, to lower drug prices and reduce out of pocket costs of drugs that contains additional proposals to increase drug manufacturer
competition, increase the negotiating power of certain federal healthcare programs, incentivize manufacturers to lower the list
price of their products, and reduce the out of pocket costs of drug products paid by consumers. Several final rules have been recently
promulgated that seek to implement several of the Trump administration&rsquo;s proposals. However, it is unclear whether the Biden
administration will work to reverse these measures or pursue similar policy initiatives. Individual states in the United States
have also become increasingly active in passing legislation and implementing regulations designed to control biopharmaceutical
product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing
cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk
purchasing. Further, it is possible that additional government action is taken in response to the COVID-19 pandemic.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>The Foreign Corrupt Practices Act</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">The Foreign Corrupt Practices
Act (the &ldquo;FCPA&rdquo;), prohibits any U.S. individual or business from paying, offering, or authorizing payment or offering
of anything of value, directly or indirectly, to any foreign official, political party or candidate for the purpose of influencing
any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business. The
FCPA also obligates companies whose securities are listed in the United States to comply with accounting provisions requiring us
to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries,
and to devise and maintain an adequate system of internal accounting controls for international operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>Additional Regulation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">In addition to the foregoing,
state and federal laws regarding environmental protection and hazardous substances, including the Occupational Safety and Health
Act, the Resource Conservancy and Recovery Act and the Toxic Substances Control Act, affect our business. These and other laws
govern our use, handling and disposal of various biological, chemical and radioactive substances used in, and wastes generated
by, our operations. If our operations result in contamination of the environment or expose individuals to hazardous substances,
we could be liable for damages and governmental fines. We believe that we are in material compliance with applicable environmental
laws and that continued compliance therewith will not have a material adverse effect on our business. We cannot predict, however,
how changes in these laws may affect our future operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 27 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><PAGE></PAGE></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>Other Regulations</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">We are also subject to
numerous federal, state and local laws relating to such matters as safe working conditions, manufacturing practices, environmental
protection, fire hazard control, and disposal of hazardous or potentially hazardous substances. We may incur significant costs
to comply with such laws and regulations now or in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>Employees</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">As of March 11, 2021,
we had twenty-nine employees, twenty-seven of whom were full-time employees and two of whom were contract employees. As of March
11, 2021, twelve of our employees were engaged in research and development activities and seventeen of our employees were engaged
in business development, finance, commercial, information systems, facilities, human resources or administrative support. As of
March 11, 2021, all of our employees were located in the U.S. None of our U.S. employees are represented by any collective bargaining
agreements. We believe that we maintain good relations with our employees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>COVID-19</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">The ultimate impact of
the current COVID-19 pandemic or a similar health epidemic is highly uncertain and subject to change. We have experienced delays,
but may experience additional future delays that impact our business, our research and development activities, healthcare systems
and the global economy as a whole. However, we will continue to monitor the COVID-19 situation closely should the effects have
a material impact on our operations, liquidity and capital resources.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">In response to public
health directives and orders, we have implemented work-from-home policies for our employees and temporarily modified our operations
to comply with applicable social distancing recommendations. Similar health directives and orders are affecting third parties with
whom we do business, including the third parties that we have contracted with to conduct studies for TARA-002. The effects of the
orders and our related adjustments in our business are likely to negatively impact productivity, disrupt our business and delay
our timelines, the magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations
on our ability to conduct our business in the ordinary course.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">Severe and/or long-term
disruptions in our operations will negatively impact our business, operating results and financial condition in other ways, as
well. Specifically, we anticipate that the stress of COVID-19 on healthcare systems around the globe will negatively impact our
ability to conduct clinical trials in the near term due primarily to the lack of resources at clinical trial sites and the resulting
inability to enroll patients in the trials. We also anticipate that the global impact of COVID-19 will negatively impact our ability
to conduct nonclinical studies due primarily to laboratory closures and limited availability of personnel. In addition, while the
potential economic impact brought by, and the duration of, COVID-19 may be difficult to assess or predict, it has significantly
disrupted global financial markets, and may limit our ability to access capital, which could in the future negatively affect our
liquidity. A recession or market correction resulting from the spread of COVID-19 could materially affect our business and the
value of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>Corporate Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">On January 9, 2020, Protara
Therapeutics, Inc. (formerly ArTara Therapeutics, Inc., formerly Proteon Therapeutics, Inc. the &ldquo;Company&rdquo; or &ldquo;Protara&rdquo;),
and privately-held ArTara Subsidiary, Inc. (&ldquo;Private ArTara&rdquo;), completed the merger and reorganization, or the Merger,
in accordance with the terms of the Agreement and Plan of Merger and Reorganization, dated September 23, 2019, or the Merger Agreement,
by and among the Company, Private ArTara and REM 1 Acquisition, Inc., a wholly owned subsidiary of the Company (&ldquo;Merger Sub&rdquo;),
whereby Merger Sub merged with and into Private ArTara, with Private ArTara surviving as a wholly owned subsidiary of the Company.
The Merger was structured as a reverse merger and Private ArTara was determined to be the accounting acquirer based on the terms
of the Merger and other factors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">Refer to Note 3, Reverse
Merger with Protara and Recapitalization, to our financial statements appearing elsewhere in this Annual Report on Form 10-K for
additional information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">We were originally incorporated
in Delaware in March 2006, and at that time, acquired Proteon Therapeutics, LLC, the predecessor of Protara, which was formed in
June 2001.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">Our principal executive
offices are located at 345 Park Avenue South, 3<SUP>rd</SUP> Floor, New York, New York 10010, our telephone number is (646) 844-0337
and our website address is www.protaratx.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">Unless the context requires
otherwise, references in this Annual Report to &ldquo;Protara&rdquo;, &ldquo;TARA&rdquo;, &ldquo;we&rdquo;, &ldquo;us&rdquo;, the
&ldquo;Company&rdquo; and &ldquo;our&rdquo; refer to Protara Therapeutics, Inc. (formerly ArTara Therapeutics, Inc., formerly Proteon
Therapeutics, Inc.) and our subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>Available Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">Annual Reports on Form
10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and amendments to reports filed pursuant to Sections 13(a) and
15(d) of the Securities Exchange Act of 1934, as amended, or the Exchange Act, will be made available free of charge on our website
as soon as reasonably practicable after we electronically file such material with, or furnish it to, the Securities and Exchange
Commission, or SEC. The contents of our website are not incorporated into this Annual Report and our reference to the URL for our
website is intended to be an inactive textual reference only. The information contained on, or that can be accessed through, our
website is not a part of this document.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 28 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><PAGE></PAGE></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><A NAME="aph203237a003"></A><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Item 1A.</B></FONT> <FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Risk Factors.</I></B></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in"><I>You should consider
carefully the following information about the risks described below, together with the other information contained in this Annual
Report and in our other public filings, in evaluating our business. If any of the following risks actually occurs, our business,
financial condition, results of operations, and future growth prospects would likely be materially and adversely affected. In these
circumstances, the market price of our common stock would likely decline.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>Risks Related to Our Financial Condition</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>We have a very limited operating history
and have never generated any revenues.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">We are an early-stage
biopharmaceutical company with a very limited operating history that may make it difficult to evaluate the success of our business
to date and to assess our future viability. Our operations, with respect to the entity that operationally survived the Merger,
have been limited to organizing and staffing the company, business planning, raising capital, developing our pipeline assets (TARA-002
and IV Choline Chloride), identifying product candidates, and other research and development. Although our employees have made
regulatory submissions and conducted successful clinical trials in the past across many therapeutic areas while employed at other
companies, we have not yet demonstrated an ability to successfully complete any clinical trials and have never completed the development
of any product candidate, nor have we ever generated any revenue from product sales or otherwise. Consequently, we have no meaningful
operations upon which to evaluate our business, and predictions about our future success or viability may not be as accurate as
they could be if we had a longer operating history or a history of successfully developing and commercializing biopharmaceutical
products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;<B><I>We expect to incur significant losses
for the foreseeable future and may never achieve or maintain profitability.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">Investment in biopharmaceutical
product development is highly speculative because it entails substantial upfront capital and significant risk that a product candidate
will fail to gain regulatory approval or become commercially viable. We have never generated any revenues, and cannot estimate
with precision the extent of our future losses. We expect to incur increasing levels of operating losses for the foreseeable future
as we execute on the plan to continue research and development activities, including the ongoing and planned clinical development
of our product candidates, potentially acquire new products and/or product candidates, seek regulatory approvals of and potentially
commercialize any approved product candidates, hire additional personnel, protect our intellectual property, and incur the additional
costs of operating as a public company. We expect to continue to incur significant and increasing operating losses and negative
cash flows for the foreseeable future. These losses have had and will continue to have an adverse effect on our financial position
and working capital.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">To become and remain profitable,
we must develop or acquire and eventually commercialize a product with significant market potential. This will require us to be
successful in a range of challenging activities, including completing preclinical studies and clinical trials, obtaining marketing
approval, manufacturing, marketing and selling any product candidate for which we obtain marketing approval, and satisfying post-marketing
requirements, if any. We may never succeed in these activities and, even if we succeed in obtaining approval for and commercializing
one or more products, we may never generate revenues that are significant enough to achieve profitability. In addition, as a young
business, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown challenges. Furthermore,
because of the numerous risks and uncertainties associated with biopharmaceutical product development, we are unable to accurately
predict the timing or amount of increased expenses or when, or if, we will be able to achieve profitability. If we achieve profitability,
we may not be able to sustain or increase profitability on a quarterly or annual basis and may continue to incur substantial research
and development and other expenditures to develop and market additional product candidates. Our failure to become and remain profitable
would decrease the value of us and could impair our ability to raise capital, maintain our research and development efforts, expand
the business or continue operations. A decline in the value of us could also cause you to lose all or part of your investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>The COVID-19 coronavirus could adversely
impact our business, including our clinical development plans.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">In December 2019, a novel
coronavirus disease (&ldquo;COVID-19&rdquo;) was reported and in January 2020, the World Health Organization (the &ldquo;WHO&rdquo;)
declared it a Public Health Emergency of International Concern. On February 28, 2020, the WHO raised its assessment of the COVID-19
threat from high to very high at a global level due to the continued increase in the number of cases and affected countries, and
on March 11, 2020, the WHO characterized COVID-19 as a pandemic. As COVID-19 continues to spread in the United States and around
the world, we may experience disruptions that could severely impact our business, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; padding-right: 0pt; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 0.25in; padding-right: 0pt; text-align: left">&#9679;</TD>
    <TD STYLE="padding-right: 0pt; text-align: left">interruption of key manufacturing, research and clinical
    development activities, due to limitations on work and travel imposed or recommended by federal or state governments, employers
    and others;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; padding-right: 0pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; padding-right: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="padding-right: 0pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">delays or difficulties in clinical trial site operations, including difficulties in recruiting clinical site investigators and clinical site staff and difficulties in enrolling patients;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>
<!-- Field: Page; Sequence: 29 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><PAGE></PAGE></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; padding-right: 0pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; padding-right: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="padding-right: 0pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">interruption of key business activities, due to illness and/or quarantine of key individuals and delays associated with recruiting, hiring and training new temporary or permanent replacements for such key individuals, both internally and at our third party service providers;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; padding-right: 0pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; padding-right: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="padding-right: 0pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">delays in research and clinical trial sites receiving the supplies and materials needed to conduct preclinical studies and clinical trials, due to work stoppages, travel and shipping interruptions or restrictions or other reasons;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">delays or difficulties conducting nonclinical studies due to limitations in employee resources or laboratory closures;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; padding-right: 0pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; padding-right: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="padding-right: 0pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">difficulties in raising additional capital needed to pursue the development of our programs due to the slowing of our economy and near term and/or long term negative effects of the pandemic on the financial, banking and capital markets;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; padding-right: 0pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; padding-right: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="padding-right: 0pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">changes in local regulations as part of a response to the COVID-19 coronavirus outbreak which may require us to change the ways in which research, including clinical development, is conducted, which may result in unexpected costs; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; padding-right: 0pt; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 0.25in; padding-right: 0pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="padding-right: 0pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">delays in necessary interactions with regulators, ethics committees and other important agencies and contractors due to limitations in employee resources, travel restrictions or forced furlough of government employees.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">The global outbreak
of COVID- continues to evolve. The extent to which the COVID-19 coronavirus may impact our business will depend on future developments,
which are highly uncertain and cannot be predicted with confidence, such as the ultimate geographic spread of the disease, the
duration of the outbreak, travel restrictions and social distancing in the United States and other countries, business closures
or business disruptions and the effectiveness of actions taken in the United States and other countries to contain and treat the
virus. The duration and extent of the impact from the COVID-19 pandemic depend on future developments that cannot be accurately
predicted at this time, such as the severity and transmission rate of the virus, the extent and effectiveness of containment actions
and the impact of these and other factors on our operations, employees, partners and vendors. If we are not able to respond to
and manage the impact of such events effectively, our business will be harmed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">In addition, while the
potential economic impact brought by, and the duration of, COVID-19 may be difficult to assess or predict, it has significantly
disrupted global financial markets, and may limit our ability to access additional capital, which could in the future negatively
affect our liquidity. A recession or market correction resulting from the spread of COVID-19 could materially affect our business
and the value of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">To the extent the COVID-19
pandemic adversely affects our business and results of operations, it may also have the effect of heightening many of the other
risks and uncertainties described elsewhere in this &ldquo;Risk Factors&rdquo; section.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>We will need to raise additional financing
in the future to fund our operations, which may not be available to us on favorable terms or at all.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">We will require substantial
additional funds to conduct the costly and time-consuming clinical efficacy trials necessary to pursue regulatory approval of each
potential product candidate and to continue the development of TARA-002 and IV Choline Chloride in new indications or uses. Our
future capital requirements will depend upon a number of factors, including: the number and timing of future product candidates
in the pipeline; progress with and results from preclinical testing and clinical trials; the ability to manufacture sufficient
drug supplies to complete preclinical and clinical trials; the costs involved in preparing, filing, acquiring, prosecuting, maintaining
and enforcing patent and other intellectual property claims; and the time and costs involved in obtaining regulatory approvals
and favorable reimbursement or formulary acceptance. Raising additional capital may be costly or difficult to obtain and could
significantly dilute stockholders&rsquo; ownership interests or inhibit our ability to achieve our business objectives. As a result
of economic conditions, general global economic uncertainty, political change, and other factors, including uncertainty associated
with the COVID-19 pandemic, we do not know whether additional capital will be available when needed, or that, if available, we
will be able to obtain additional capital on reasonable terms. Specifically, the COVID-19 pandemic has significantly disrupted
global financial markets, and may limit our ability to access capital, which could in the future negatively affect our liquidity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 30 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><PAGE></PAGE></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">If we raise additional
funds through public or private equity offerings, the terms of these securities may include liquidation or other preferences that
adversely affect the rights of our common stockholders. Further, to the extent that we raise additional capital through the sale
of common stock or securities convertible or exchangeable into common stock, the ownership interests of our common stockholders
will be diluted. In addition, any debt financing may subject us to fixed payment obligations and covenants limiting or restricting
our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If
we raise additional capital through marketing and distribution arrangements or other collaborations, strategic alliances or licensing
arrangements with third parties, we may have to relinquish certain valuable intellectual property or other rights to our product
candidates, technologies, future revenue streams or research programs or grant licenses on terms that may not be favorable to us.
Even if we were to obtain sufficient funding, there can be no assurance that it will be available on terms acceptable to us or
our stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>Clinical drug development is very expensive,
time-consuming and uncertain.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">Clinical development for our product candidates
is very expensive, time-consuming, difficult to design and implement, and the outcomes are inherently uncertain. Most product candidates
that commence clinical trials are never approved by regulatory authorities for commercialization and of those that are approved
many do not cover their costs of development. In addition, we, any partner with which we may in the future collaborate, the FDA,
an institutional review board (IRB), or other regulatory authorities, including state and local agencies and counterpart agencies
in foreign countries, may suspend, delay, require modifications to or terminate our clinical trials at any time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>Risks Related to Drug/Biologics Development</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>Our business depends on the successful
clinical development, regulatory approval and commercialization of TARA-002 and IV Choline Chloride.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">The success of our business,
including our ability to finance our self and generate revenue in the future, primarily depends on the successful development,
regulatory approval and commercialization of TARA-002 and IV Choline Chloride. The clinical and commercial success of TARA-002
and IV Choline Chloride depends on a number of factors, including the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 16.2pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; padding-right: 0pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; padding-right: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="padding-right: 0pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">timely and successful completion of required clinical trials not yet initiated, which may be significantly slower or costlier than we currently anticipate and/or produce results that do not achieve the endpoints of the trials;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; padding-right: 0pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; padding-right: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="padding-right: 0pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">whether we are required by the FDA or similar foreign regulatory agencies to conduct additional studies beyond those planned to support the approval and commercialization of TARA-002 and IV Choline Chloride;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; padding-right: 0pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; padding-right: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="padding-right: 0pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">achieving and maintaining, and, where applicable, ensuring that our third-party contractors achieve and maintain compliance with their contractual obligations and with all regulatory requirements applicable to TARA-002 and IV Choline Chloride;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="padding-right: 0pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">ability to confirm the comparability of TARA-002 and OK-432;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; padding-right: 0pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; padding-right: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="padding-right: 0pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">ability of third parties with whom we contract to manufacture adequate clinical trial and commercial supplies of TARA-002 and IV Choline Chloride, to remain in good standing with regulatory agencies and to develop, validate and maintain commercially viable manufacturing processes that are compliant with current good manufacturing practices (&ldquo;cGMP&rdquo;);</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; padding-right: 0pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; padding-right: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="padding-right: 0pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">a continued acceptable safety profile during clinical development and following approval of TARA-002 and IV Choline Chloride;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; padding-right: 0pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; padding-right: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="padding-right: 0pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">ability to obtain favorable labeling for TARA-002 and IV Choline Chloride through regulators that allows for successful commercialization, given the drugs may be marketed only to the extent approved by these regulatory authorities (unlike with most other industries);</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; padding-right: 0pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; padding-right: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="padding-right: 0pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">ability to successfully commercialize TARA-002 and IV Choline Chloride in the United States and internationally, if approved for marketing, sale and distribution in such countries and territories, whether alone or in collaboration with others;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; padding-right: 0pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; padding-right: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="padding-right: 0pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">acceptance by physicians, insurers and payors, and patients of the quality, benefits, safety and efficacy of TARA-002 and IV Choline Chloride, if either is approved, including relative to alternative and competing treatments;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; padding-right: 0pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; padding-right: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="padding-right: 0pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">existence of a regulatory environment conducive to the success of TARA-002 and IV Choline Chloride;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; padding-right: 0pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; padding-right: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="padding-right: 0pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">ability to price TARA-002 and IV Choline Chloride to recover our development costs and generate a satisfactory profit margin; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; padding-right: 0pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; padding-right: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="padding-right: 0pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">our ability and our partners&rsquo; ability to establish and enforce intellectual property rights in and to TARA-002 and IV Choline Chloride.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">If we do not achieve one
or more of these factors, many of which are beyond our control, in a timely manner or at all, we could experience significant delays
or an inability to obtain regulatory approvals or commercialize TARA-002 and IV Choline Chloride. Even if regulatory approvals
are obtained, we may never be able to successfully commercialize TARA-002 and IV Choline Chloride. Accordingly, we cannot assure
you that we will be able to generate sufficient revenue through the sale of TARA-002 and IV Choline Chloride to continue our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 31 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><PAGE></PAGE></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">The COVID-19 pandemic is impacting our business
and the business of the third-parties with which we contract for key services related to our clinical development plans. If the
crisis persists, it is likely to have a significant delay in our development timelines and result in additional and unexpected
costs. Presently, we anticipate that the stress of COVID-19 on healthcare systems around the globe will negatively impact our ability
to conduct clinical trials in the near term due primarily to the lack of resources at clinical trial sites and the resulting inability
to enroll patients in these trials. In addition, it is possible that the stress of the COVID-19 pandemic on regulatory agencies
may make it more difficult to collaborate with, and receive guidance from, such agencies, which could delay our development timelines
and negatively impact our business.<BR>
<BR>
</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>We have never made an IND, BLA or NDA
submission or conducted a clinical trial and may be unable to successfully do so for TARA-002 or IV Choline Chloride.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">The conduct of a clinical
trials is a long, expensive, complicated and highly regulated process. Although our employees have made regulatory submissions
and conducted successful clinical trials in the past across many therapeutic areas while employed at other companies, we, as a
company, have not submitted an investigational new drug application (IND), conducted any clinical trials, or submitted a BLA or
new drug application (NDA), and as a result may require more time and incur greater costs than we anticipate. Failure to commence
or complete, or delays in, our planned regulatory submissions or clinical trials would prevent us from, or delay us, in obtaining
regulatory approval of and commercializing TARA-002 and IV Choline Chloride, which would adversely impact our financial performance,
as well as subject us to significant contract liabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>TARA-002 is an immunopotentiator, and
one indication for which we plan to pursue is the treatment of lymphatic malformations. There are no FDA-approved therapies for
the treatment of lymphatic malformations. It is difficult to predict the timing and costs of clinical development for TARA-002
with respect to lymphatic malformations as well as the corresponding regulatory approval path.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">To date, there are no
FDA-approved therapies for the treatment of lymphatic malformations. The regulatory approval process for novel product candidates
such as TARA-002 can be more expensive and take longer than for other, better known or extensively studied therapeutic approaches.
In addition, the previous clinical trials conducted on OK-432 for LMs in the United States included a control arm in which treatment
was initially delayed. It is unclear whether this trial design could support FDA approval or whether a placebo-control or other
randomization will be required by the FDA. Delay or failure to obtain, or unexpected costs in obtaining, the regulatory approval
necessary to bring TARA-002 to market could decrease our ability to generate sufficient revenue to maintain our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>The regulatory path to approval of TARA-002
is dependent on FDA acceptance of prior clinical data from OK-432.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">The proposed regulatory
strategy for the TARA-002 program is a combination of demonstrating comparability to a product that is not FDA approved and relying
upon existing data. By demonstrating that TARA-002 is, in fact, OK-432, we believe that the large volume of data published on OK-432
including the data generated by the University of Iowa led study in LMs will then apply to TARA-002. We have been granted initial
comparability by FDA and if comparability is fully demonstrated and accepted by regulatory authorities, we will attempt to rely
on existing OK-432 safety and efficacy data to submit the BLA. There is no example to date of a biologic product that was approved
utilizing this regulatory approach that we are aware of.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>Our product candidates may cause undesirable
side effects or have other unexpected properties that could delay or prevent their regulatory approval, limit the commercial profile
of an approved label, or result in post-approval regulatory action.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">Unforeseen side effects
from TARA-002 or IV Choline Chloride could arise either during clinical development or, if approved, after it has been marketed.
Undesirable side effects could cause us, any partners with which we may collaborate, or regulatory authorities to interrupt, extend,
modify, delay or halt clinical trials and could result in a more restrictive or narrower label or the delay or denial of regulatory
approval by the FDA or comparable foreign authorities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">Results of clinical trials
could reveal a high and unacceptable severity and prevalence of side effects. In such an event, trials could be suspended or terminated,
and the FDA or comparable foreign regulatory authorities could order us to cease further development of or deny approval of a product
candidate for any or all targeted indications. The drug-related side effects could affect patient recruitment or the ability of
enrolled patients to complete the trial or result in product liability claims. Any of these occurrences may harm our business,
financial condition, operating results and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">Additionally, if we or
others identify undesirable side effects, or other previously unknown problems, caused by a product after obtaining U.S. or foreign
regulatory approval, a number of potentially negative consequences could result, which could prevent us or our potential partners
from achieving or maintaining market acceptance of the product and could substantially increase the costs of commercializing such
product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 32 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><PAGE></PAGE></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>A fast track designation by the FDA may not actually lead
to a faster development or regulatory review or approval process for IV Choline Chloride for the treatment of IFALD.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 16.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">The FDA has granted fast
track designation to IV Choline Chloride for the treatment of IFALD. If a drug is intended for the treatment of a serious or life-threatening
condition and the drug demonstrates the potential to address unmet medical needs for this condition, the drug sponsor may apply
for fast track designation. Even though we have received fast track designation for IV Choline Chloride for the treatment of IFALD,
we may not experience a faster development process, review or approval. The FDA may withdraw fast track designation if it believes
that the designation is no longer supported by data from our clinical development program.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 16.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>Although the FDA has granted Rare Pediatric Disease&nbsp;Designation
for TARA-002 for the treatment of LMs, a BLA for TARA-002,&nbsp;if approved, may not meet the eligibility criteria for a priority
review voucher.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 16.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">Rare Pediatric Disease
Designation has been granted for TARA-002 for the treatment of LMs. In 2012, Congress authorized the FDA to award priority review
vouchers to sponsors of certain rare pediatric disease product applications. This provision is designed to encourage development
of new drug and biological products for prevention and treatment of certain rare pediatric diseases. Specifically, under this program,
a sponsor who receives an approval for a drug or biologic for a &ldquo;rare pediatric disease&rdquo; may qualify for a voucher
that can be redeemed to receive a priority review of a subsequent marketing application for a different product. The sponsor of
a rare pediatric disease drug product receiving a priority review voucher may transfer (including by sale) the voucher to another
sponsor. The voucher may be further transferred any number of times before the voucher is used, as long as the sponsor making the
transfer has not yet submitted the application. The FDA may also revoke any priority review voucher if the rare pediatric disease
drug for which the voucher was awarded is not marketed in the U.S. within one year following the date of approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">For the purposes of this
program, a &ldquo;rare pediatric disease&rdquo; is a (a)&nbsp;serious or life-threatening disease in which the serious or life-threatening
manifestations primarily affect individuals aged from birth to 18 years, including age groups often called neonates, infants, children,
and adolescents; and (b)&nbsp;rare disease or conditions within the meaning of the Orphan Drug Act. Congress has only authorized
the Rare Pediatric Disease Priority Review Voucher program until September 30,2024. However, if a drug candidate received Rare
Pediatric Disease Designation before September 30,2024, it is eligible to receive a voucher if it is approved before September
30, 2026.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">However, TARA-002 for
the treatment of LMs may not be approved by that date, or at all, and, therefore, we may not be in a position to obtain a priority
review voucher prior to expiration of the program, unless Congress further reauthorizes the program. Additionally, designation
of a drug for a rare pediatric disease&nbsp;does not guarantee that a BLA will meet the eligibility criteria for a&nbsp;rare pediatric
disease priority review voucher at the time the application is approved. Finally, a&nbsp;Rare Pediatric Disease Designation does
not lead to faster development or regulatory review of the product, or increase the likelihood that it will receive marketing approval.
We may or may not realize any benefit from receiving a voucher.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 16.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;<B><I>Even if a product candidate obtains
regulatory approval, it may fail to achieve the broad degree of physician and patient adoption and use necessary for commercial
success.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">The commercial success
of both TARA-002 and IV Choline Chloride, if approved, will depend significantly on the broad adoption and use of them by physicians
and patients for approved indications, and neither may be commercially successful even though the product is shown to be safe and
effective. The degree and rate of physician and patient adoption of a product, if approved, will depend on a number of factors,
including but not limited to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 16.2pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; padding-right: 0pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; padding-right: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="padding-right: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">patient demand for approved products that treat the indication for which a product is approved;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; padding-right: 0pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; padding-right: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="padding-right: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the effectiveness of the product compared to other available therapies;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; padding-right: 0pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; padding-right: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="padding-right: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the availability of coverage and adequate reimbursement from managed care plans and other healthcare payors;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; padding-right: 0pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; padding-right: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="padding-right: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the cost of treatment in relation to alternative treatments and willingness to pay on the part of patients;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; padding-right: 0pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; padding-right: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="padding-right: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">in the case of TARA-002, overcoming physician or patient biases toward surgery for the treatment of lymphatic malformations;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; padding-right: 0pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; padding-right: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="padding-right: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">insurers&rsquo; willingness to see the applicable indication as a disease worth treating;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; padding-right: 0pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; padding-right: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="padding-right: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">proper administration;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; padding-right: 0pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; padding-right: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="padding-right: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">patient satisfaction with the results, administration and overall treatment experience;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 33 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><PAGE></PAGE></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; padding-right: 0pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; padding-right: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="padding-right: 0pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">limitations or contraindications, warnings, precautions or approved indications for use different than those sought by us that are contained in the final FDA-approved labeling for the applicable product;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; padding-right: 0pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; padding-right: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="padding-right: 0pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">any FDA requirement to undertake a risk evaluation and mitigation strategy;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; padding-right: 0pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; padding-right: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="padding-right: 0pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the effectiveness of our sales, marketing, pricing, reimbursement and access, government affairs, and distribution efforts;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; padding-right: 0pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; padding-right: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="padding-right: 0pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">adverse publicity about a product or favorable publicity about competitive products;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; padding-right: 0pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; padding-right: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="padding-right: 0pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">new government regulations and programs, including price controls and/or limits or prohibitions on ways to commercialize drugs, such as increased scrutiny on direct-to-consumer advertising of pharmaceuticals; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; padding-right: 0pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; padding-right: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="padding-right: 0pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">potential product liability claims or other product-related litigation.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">If either TARA-002 or
IV Choline Chloride is approved for use but fails to achieve the broad degree of physician and patient adoption necessary for commercial
success, our operating results and financial condition will be adversely affected, which may delay, prevent or limit our ability
to generate revenue and continue our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>Any adverse developments that occur in
patients undergoing treatment with OK-432 / Picibanil or in patients participating in clinical trials conducted by third parties
may affect our ability to obtain regulatory approval or commercialize TARA-002.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">Chugai Pharmaceutical
Co., Ltd., over which we have no control, has the rights to commercialize TARA-002 and it is currently marketed in Japan and Taiwan,
under the name Picibanil, for various indications. In addition, clinical trials using Picibanil are currently ongoing in various
countries around the world. If serious adverse events occur with patients using Picibanil or during any clinical trials of Picibanil
conducted by third parties, the FDA may delay, limit or deny approval of TARA-002 or require us to conduct additional clinical
trials as a condition to marketing approval, which would increase our costs. If we receive FDA approval for TARA-002 and a new
and serious safety issue is identified in connection with use of Picibanil or in clinical trials of Picibanil conducted by third
parties, the FDA may withdraw the approval of the product or otherwise restrict our ability to market and sell TARA-002. In addition,
treating physicians may be less willing to administer TARA-002 due to concerns over such adverse events, which would limit our
ability to commercialize TARA-002.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>We may in the future conduct clinical
trials for our product candidates outside the United States, and the FDA and applicable foreign regulatory authorities may not
accept data from such trials.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">We may in the future choose
to conduct one or more of our clinical trials outside of the United States. Although the FDA or applicable foreign regulatory authority
may accept data from clinical trials conducted outside the United States or the applicable jurisdiction, acceptance of such study
data by the FDA or applicable foreign regulatory authority may be subject to certain conditions or exclusion. Where data from foreign
clinical trials are intended to serve as the basis for marketing approval in the United States, the FDA will not approve the application
on the basis of foreign data alone unless such data are applicable to the U.S. population and U.S. medical practice; the studies
were performed by clinical investigators of recognized competence; and the data are considered valid without the need for an on-site
inspection by the FDA or, if the FDA considers such an inspection to be necessary, the FDA is able to validate the data through
an on-site inspection or other appropriate means. Many foreign regulatory bodies have similar requirements. In addition, such foreign
studies would be subject to the applicable local laws of the foreign jurisdictions where the studies are conducted. There can be
no assurance the FDA or applicable foreign regulatory authority will accept data from trials conducted outside of the United States
or the applicable home country. If the FDA or applicable foreign regulatory authority does not accept such data, it would likely
result in the need for additional trials, which would be costly and time-consuming and delay aspects of our business plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>We may choose not to continue developing
or commercializing any of our product candidates at any time during development or after approval, which would reduce or eliminate
the potential return on investment for those product candidates.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">At any time, we may decide
to discontinue the development of any of our product candidates for a variety of reasons, including the appearance of new technologies
that make our product obsolete, competition from a competing product or changes in or failure to comply with applicable regulatory
requirements. For example, we are reviewing the research and preclinical and clinical data of vonapanitase and have not yet determined
whether to pursue further development of this product candidate in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">If we terminate a program
in which we have invested significant resources, we will not receive any return on our investment and we will have missed the opportunity
to have allocated those resources to potentially more productive uses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">&nbsp;</P>


<!-- Field: Page; Sequence: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><PAGE></PAGE></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 16.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>Our or our third party&rsquo;s clinical
trials may fail to demonstrate the safety and efficacy of our product candidates, or serious adverse or unacceptable side effects
may be identified during their development, which could prevent or delay marketing approval and commercialization, increase our
costs or necessitate the abandonment or limitation of the development of the product candidate.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">Before obtaining marketing
approvals for the commercial sale of any product candidate, we must demonstrate through lengthy, complex and expensive preclinical
testing and clinical trials that such product candidate is both safe and effective for use in the applicable indication, and failures
can occur at any stage of testing. Clinical trials often fail to demonstrate safety and are associated with side effects or have
characteristics that are unexpected. Based on the safety profile seen in clinical testing, we may need to abandon development or
limit development to more narrow uses in which the side effects or other characteristics are less prevalent, less severe or more
tolerable from a risk-benefit perspective. The FDA or an IRB may also require that we suspend, discontinue, or limit clinical trials
based on safety information. Such findings could further result in regulatory authorities failing to provide marketing authorization
for the product candidate. Many pharmaceutical candidates that initially showed promise in early stage testing and which were efficacious
have later been found to cause side effects that prevented further development of the drug candidate and, in extreme cases, the
side effects were not seen until after the drug was marketed, causing regulators to remove the drug from the market post-approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">Our regulatory strategy
for TARA-002 requires that we demonstrate that TARA-002 is the same biologic substance as OK-432, which is currently manufactured
in Japan and marketed in Japan and Taiwan by Chugai. The FDA has agreed that we have successfully demonstrated initial manufacturing
comparability between TARA-002 and OK-432; we are on track to conduct three large-scale batch runs to confirm comparability. Good
Manufacturing Practice (GMP) scale up is currently in process and we have initiated GMP comparability runs. There can be no assurances
that our contract manufacturer will be able to produce a sufficiently comparable product or that the FDA will find such substances
comparable or permit us to use any of the data from prior clinical trials as part of the BLA filing for TARA-002.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>Other Risks Related to Our Business</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>Our product candidates, if approved,
will face significant competition and their failure to compete effectively may prevent them from achieving significant market penetration.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">The pharmaceutical industry
is characterized by rapidly advancing technologies, intense competition, less effective patent terms, and a strong emphasis on
developing newer, fast-to-market proprietary therapeutics. Numerous companies are engaged in the development, patenting, manufacturing
and marketing of healthcare products competitive with those that we are developing, including TARA-002 and IV Choline Chloride.
We will face competition from a number of sources, such as pharmaceutical companies, generic drug companies, biotechnology companies
and academic and research institutions, many of which have greater financial resources, marketing capabilities, sales forces, manufacturing
capabilities, research and development capabilities, regulatory expertise, clinical trial expertise, intellectual property portfolios,
more international reach, experience in obtaining patents and regulatory approvals for product candidates and other resources than
we have. Some of the companies that offer competing products also have a broad range of other product offerings, large direct sales
forces and long-term customer relationships with our target physicians, which could inhibit our market penetration efforts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">With respect to our lead
product candidate, TARA-002, for the treatment of LMs and NMIBC, the active ingredient in TARA-002 is a genetically distinct strain
of <I>Streptococcus pyogenes</I> (group A, type 3) Su strain. TARA-002 is produced through a proprietary manufacturing process.
We anticipate that, if approved by the FDA, TARA-002 will be protected by 12 years of biologic exclusivity. In addition, TARA-002
is likely to have seven years of concurrent Orphan Drug Designation exclusivity for the treatment of LMs if deemed comparable to
OK-432 by the FDA based on the prevalence of the disease. There are no approved pharmacotherapies currently available for the treatment
of LMs and the current standard of care is a high-risk surgical procedure. There are a number of drug development companies and
academic researchers exploring oral formulations of various agents including macrolides, phosphodiesterase inhibitors, and calcineurin/
mTOR inhibitors. These are in early development. TARA-002, if approved for the treatment of NMIBC, would be subject to competition
from existing treatment methods of surgery, chemotherapy and immunomodulatory therapy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">There are no treatments
currently available for IFALD. With respect to IV Choline Chloride for the treatment of IFALD, IV Choline Chloride is the only
sterile injectable form of choline chloride that can be combined with parenteral nutrition. Further, if approved, IV Choline Chloride
will be protected by Orphan Drug Designation exclusivity for seven years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">&nbsp;</P>


<!-- Field: Page; Sequence: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><PAGE></PAGE></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>TARA-002 and any future product candidates
for which we intend to seek approval as biologic products may face competition sooner than anticipated.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">The Patient Protection
and Affordable Care Act, or Affordable Care Act, signed into law on March 23, 2010, includes a subtitle called the Biologics Price
Competition and Innovation Act of 2009, or BPCIA, which created an abbreviated approval pathway for biological products that are
biosimilar to or interchangeable with an FDA-licensed reference biological product. Under the BPCIA, an application for a biosimilar
product may not be submitted to the FDA until four years following the date that the reference product was first licensed by the
FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which
the reference product was first licensed. During this 12-year period of exclusivity, another company may still market a competing
version of the reference product if the FDA approves a full BLA for the competing product containing the sponsor&rsquo;s own preclinical
data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of their product.
The law is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate impact, implementation
and meaning are subject to uncertainty. While it is uncertain when such processes are intended to implement BPCIA may be fully
adopted by the FDA, any such processes could have a material adverse effect on the future commercial prospects for our biological
products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 16.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">We believe that any of
our product candidates approved as a biological product under a BLA should qualify for the 12-year period of exclusivity. However,
there is a risk that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider
our product candidates to be reference products for competing products, potentially creating the opportunity for biosimilar competition
sooner than anticipated. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been
the subject of recent litigation. Moreover, the extent to which a biosimilar, once approved, will be substituted for any one of
our reference products in a way that is similar to traditional generic substitution for non-biological products is not yet clear,
and will depend on a number of marketplace and regulatory factors that are still developing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>We rely on third-party CROs and other
third parties to conduct and oversee our clinical trials. If these third parties do not meet our requirements or otherwise conduct
the trials as required, we may not be able to satisfy our contractual obligations or obtain regulatory approval for, or commercialize,
our product candidates.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">We rely on third-party
contract research organizations (CROs) to conduct and oversee our TARA-002 and IV Choline Chloride clinical trials and other aspects
of product development. We also rely on various medical institutions, clinical investigators and contract laboratories to conduct
our trials in accordance with our clinical protocols and all applicable regulatory requirements, including the FDA&rsquo;s regulations
and good clinical practice (GCP) requirements, which are an international standard meant to protect the rights and health of patients
and to define the roles of clinical trial sponsors, administrators and monitors, and state regulations governing the handling,
storage, security and recordkeeping for drug and biologic products. These CROs and other third parties will play a significant
role in the conduct of these trials and the subsequent collection and analysis of data from the clinical trials. We will rely heavily
on these parties for the execution of our clinical trials and preclinical studies and will control only certain aspects of their
activities. We and our CROs and other third-party contractors will be required to comply with GCP and good laboratory practice
(GLP) requirements, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities. Regulatory
authorities enforce these GCP and GLP requirements through periodic inspections of trial sponsors, principal investigators and
trial sites. If we or any of these third parties fail to comply with applicable GCP and GLP requirements, or reveal noncompliance
from an audit or inspection, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or other regulatory
authorities may require us to perform additional clinical trials before approving our or our partners&rsquo; marketing applications.
We cannot assure that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our
clinical or preclinical trials comply with applicable GCP and GLP requirements. In addition, our clinical trials generally must
be conducted with product produced under cGMP regulations. Our failure to comply with these regulations and policies may require
us to repeat clinical trials, which would delay the regulatory approval process.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">If any of our CROs or
clinical trial sites terminate their involvement in one of our clinical trials for any reason, we may not be able to enter into
arrangements with alternative CROs or clinical trial sites or do so on commercially reasonable terms. In addition, if our relationship
with clinical trial sites is terminated, we may experience the loss of follow-up information on patients enrolled in our clinical
trials unless we are able to transfer the care of those patients to another qualified clinical trial site. In addition, principal
investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and could receive
cash or equity compensation in connection with such services. If these relationships and any related compensation result in perceived
or actual conflicts of interest, the integrity of the data generated at the applicable clinical trial site may be questioned by
the FDA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>We currently have limited marketing capabilities
and no sales organization. If we are unable to grow our sales and marketing capabilities on our own or through third parties, we
will be unable to successfully commercialize our product candidates, if approved, or generate product revenue.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">We currently have limited
marketing capabilities and no sales organization. To commercialize our product candidates, if approved, in the United States, Canada,
the European Union, Latin America and other jurisdictions we seek to enter, we must build our marketing, sales, distribution, managerial
and other non-technical capabilities or make arrangements with third parties to perform these services, and we may not be successful
in doing so. Although our employees have experience in the marketing, sale and distribution of pharmaceutical products, and business
development activities involving external alliances, from prior employment at other companies, we, as a company, have no prior
experience in the marketing, sale and distribution of pharmaceutical products, and there are significant risks involved in building
and managing a sales organization, including our ability to hire, retain and incentivize qualified individuals, generate sufficient
sales leads, provide adequate training to sales and marketing personnel, and effectively manage a geographically dispersed sales
and marketing team. Any failure or delay in the development of our internal sales, marketing, distribution and pricing/reimbursement/access
capabilities would impact adversely the commercialization of these products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">&nbsp;</P>


<!-- Field: Page; Sequence: 36 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><PAGE></PAGE></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 16.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>We have only received the exclusive rights
to the materials required to commercialize TARA-002 in territories other than Japan and Taiwan until June 17, 2030, or an earlier
date if Chugai terminates the agreement with us for any number of reasons, following which such rights become nonexclusive.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">Pursuant to an agreement
with Chugai Pharmaceutical Co., Ltd. dated June 17, 2019, as amended on July 14, 2020 (effective June 30, 2020), Chugai agreed
to provide us with exclusive access to the starting material necessary to manufacture TARA-002 as well as technical support necessary
for us to develop and commercialize TARA-002 anywhere in the world other than Japan and Taiwan. However, this agreement does not
prevent Chugai from providing such materials and support to any third party for medical, compassionate use and/or non-commercial
research purposes and this agreement is exclusive through June 17, 2030 or following any termination of the agreement by either
party. Once our rights to the materials and technology necessary to manufacture, develop and commercialize TARA-002 are not exclusive,
third parties, including those with greater expertise and greater resources, could obtain such materials and technology and develop
a competing therapy, which would adversely affect our ability to generate revenue and achieve or maintain profitability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>We currently have no products approved
for sale, and we may never obtain regulatory approval to commercialize any of our product candidates.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">The research, testing,
manufacturing, safety surveillance, efficacy, quality control, recordkeeping, labeling, packaging, storage, approval, sale, marketing,
distribution, import, export and reporting of safety and other post-market information related to our biopharmaceutical products
are subject to extensive regulation by the FDA and other regulatory authorities in the United States and in foreign countries,
and such regulations differ from country to country and frequently are revised.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">Even after we achieve
U.S. regulatory approval for a product candidate, if any, we will be subject to continued regulatory review and compliance obligations.
For example, with respect to our product candidates, the FDA may impose significant restrictions on the approved indicated uses
for which the product may be marketed or on the conditions of approval. A product candidate&rsquo;s approval may contain requirements
for potentially costly post-approval studies and surveillance, including Phase 4 clinical trials, to monitor the safety and efficacy
of the product. We also will be subject to ongoing FDA obligations and continued regulatory review with respect to, among other
things, the manufacturing, processing, labeling, packaging, distribution, pharmacovigilance and adverse event reporting, storage,
advertising, promotion and recordkeeping for our product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">These requirements include
submissions of safety and other post-marketing information and reports, registration, continued compliance with cGMP requirements
and with the FDA&rsquo;s GCP requirements and GLP requirements, which are regulations and guidelines enforced by the FDA for all
of our product candidates in clinical and preclinical development, and for any clinical trials that it conducts post-approval,
as well as continued compliance with the FDA&rsquo;s laws governing commercialization of the approved product, including but not
limited to the FDA&rsquo;s Office of Prescription Drug Promotion (OPDP) regulation of promotional activities, fraud and abuse,
product sampling, scientific speaker engagements and activities, formulary interactions as well as interactions with healthcare
practitioners. To the extent that a product candidate is approved for sale in other countries, we may be subject to similar or
more onerous (i.e., prohibition on direct-to-consumer advertising that does not exist in the United States) restrictions and requirements
imposed by laws and government regulators in those countries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">In addition, manufacturers
of drug and biologic products and their facilities are subject to continual review and periodic inspections by the FDA and other
regulatory authorities for compliance with cGMP regulations. If we or a regulatory agency discovers previously unknown problems
with a product, such as adverse events of unanticipated severity or frequency, or problems with the manufacturing, processing,
distribution or storage facility where, or processes by which, the product is made, a regulatory agency may impose restrictions
on that product or us, including requesting that we initiate a product recall, or requiring notice to physicians or the public,
withdrawal of the product from the market, or suspension of manufacturing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">If we, our product candidates
or the manufacturing facilities for our product candidates fail to comply with applicable regulatory requirements, a regulatory
agency may:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 16.2pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; padding-right: 0pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; padding-right: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="padding-right: 0pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">impose restrictions on the sale, marketing or manufacturing of the product, amend, suspend or withdraw product approvals or revoke necessary licenses;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; padding-right: 0pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; padding-right: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="padding-right: 0pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">mandate modifications to promotional and other product-specific materials or require us to provide corrective information to healthcare practitioners or in our advertising;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 37 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><PAGE></PAGE></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; padding-right: 0pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; padding-right: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="padding-right: 0pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">require us or our partners to enter into a consent decree, which can include imposition of various fines, reimbursements for inspection costs, required due dates for specific actions, penalties for noncompliance and, in extreme cases, require an independent compliance monitor to oversee our activities;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; padding-right: 0pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; padding-right: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="padding-right: 0pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">issue warning letters, bring enforcement actions, initiate surprise inspections, issue show cause notices or untitled letters describing alleged violations, which may be publicly available;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; padding-right: 0pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; padding-right: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="padding-right: 0pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">commence criminal investigations and prosecutions;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; padding-right: 0pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; padding-right: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="padding-right: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">impose injunctions, suspensions or revocations of necessary approvals or other licenses;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; padding-right: 0pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; padding-right: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="padding-right: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">impose other civil or criminal penalties;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; padding-right: 0pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; padding-right: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="padding-right: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">suspend any ongoing clinical trials;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; padding-right: 0pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; padding-right: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="padding-right: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">place restrictions on the kind of promotional activities that can be done;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; padding-right: 0pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; padding-right: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="padding-right: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">delay or refuse to approve pending applications or supplements to approved applications filed by us or our potential partners;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; padding-right: 0pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; padding-right: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="padding-right: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">refuse to permit drugs or precursor chemicals to be imported or exported to or from the United States;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; padding-right: 0pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; padding-right: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="padding-right: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">suspend or impose restrictions on operations, including costly new manufacturing requirements; or</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; padding-right: 0pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; padding-right: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="padding-right: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">seize or detain products or require us or our partners to initiate a product recall.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 16.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">The regulations, policies
or guidance of the FDA and other applicable government agencies may change, and new or additional statutes or government regulations
may be enacted, including at the state and local levels, which can differ by geography and could prevent or delay regulatory approval
of our product candidates or further restrict or regulate post-approval activities. We cannot predict the likelihood, nature or
extent of adverse government regulations that may arise from future legislation or administrative action, either in the United
States or abroad. If we are not able to achieve and maintain regulatory compliance, we may not be permitted to commercialize our
product candidates, which would adversely affect our ability to generate revenue and achieve or maintain profitability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>We may face product liability exposure,
and if successful claims are brought against us, we may incur substantial liability if our insurance coverage for those claims
is inadequate.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">We face an inherent risk
of product liability or similar causes of action as a result of the clinical testing of our product candidates and will face an
even greater risk if we commercialize any products. This risk exists even if a product is approved for commercial sale by the FDA
and manufactured in facilities licensed and regulated by the FDA or an applicable foreign regulatory authority and notwithstanding
that we comply with applicable laws on promotional activity. Our products and product candidates are designed to affect important
bodily functions and processes. Any side effects, manufacturing defects, misuse or abuse associated with our product candidates
could result in injury to a patient or potentially even death. We cannot offer any assurance that we will not face product liability
suits in the future, nor can we assure you that our insurance coverage will be sufficient to cover our liability under any such
cases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">In addition, a liability
claim may be brought against us even if our product candidates merely appear to have caused an injury. Product liability claims
may be brought against us by consumers, healthcare providers, pharmaceutical companies or others selling or otherwise coming into
contact with our product candidates, among others, and under some circumstances even government agencies. If we cannot successfully
defend our self against product liability or similar claims, we will incur substantial liabilities, reputational harm and possibly
injunctions and punitive actions. In addition, regardless of merit or eventual outcome, product liability claims may result in:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 16.2pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; padding-right: 0pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; padding-right: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="padding-right: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">withdrawal or delay of recruitment or decreased enrollment rates of clinical trial participants;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; padding-right: 0pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; padding-right: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="padding-right: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">termination or increased government regulation of clinical trial sites or entire trial programs;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; padding-right: 0pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; padding-right: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="padding-right: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the inability to commercialize our product candidates;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; padding-right: 0pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; padding-right: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="padding-right: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">decreased demand for our product candidates;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; padding-right: 0pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; padding-right: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="padding-right: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">impairment of our business reputation;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 38 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><PAGE></PAGE></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; padding-right: 0pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; padding-right: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="padding-right: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">product recall or withdrawal from the market or labeling, marketing or promotional restrictions;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; padding-right: 0pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; padding-right: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="padding-right: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">substantial costs of any related litigation or similar disputes;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; padding-right: 0pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; padding-right: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="padding-right: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">distraction of management&rsquo;s attention and other resources from our primary business;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; padding-right: 0pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; padding-right: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="padding-right: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">significant delay in product launch;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; padding-right: 0pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; padding-right: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="padding-right: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">substantial monetary awards to patients or other claimants against us that may not be covered by insurance;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; padding-right: 0pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; padding-right: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="padding-right: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">withdrawal of reimbursement or formulary inclusion; or</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; padding-right: 0pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; padding-right: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="padding-right: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">loss of revenue.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">We intend to obtain product
liability insurance coverage for our clinical trials. Large judgments have been awarded in class action or individual lawsuits
based on drugs that had unanticipated side effects. Our insurance coverage may not be sufficient to cover all of our product liability-related
expenses or losses and may not cover us for any expenses or losses we may suffer. Moreover, insurance coverage is becoming increasingly
expensive, restrictive and narrow, and, in the future, we may not be able to maintain adequate insurance coverage at a reasonable
cost, in sufficient amounts or upon adequate terms to protect us against losses due to product liability or other similar legal
actions. We will need to increase our product liability coverage if any of our product candidates receive regulatory approval,
which will be costly, and we may be unable to obtain this increased product liability insurance on commercially reasonable terms
or at all and for all geographies in which we wish to launch. A successful product liability claim or series of claims brought
against us, if judgments exceed our insurance coverage, could decrease our cash and harm our business, financial condition, operating
results and future prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>Our employees, independent contractors,
principal investigators, other clinical trial staff, consultants, vendors, CROs and any partners with whom we may collaborate may
engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">We are exposed to the
risk that our employees, independent contractors, principal investigators, other clinical trial staff, consultants, vendors, CROs
and any partners with which we may collaborate may engage in fraudulent or other illegal activity. Misconduct by these persons
could include intentional, reckless, gross or negligent misconduct or unauthorized activity that violates: laws or regulations,
including those laws requiring the reporting of true, complete and accurate information to the FDA or foreign regulatory authorities;
manufacturing standards; federal, state and foreign healthcare fraud and abuse laws and data privacy; anticorruption laws, anti-kickback
and Medicare/Medicaid rules, or laws that require the true, complete and accurate reporting of financial information or data, books
and records. If any such or similar actions are instituted against us and we are not successful in defending our self or asserting
our rights, those actions could have a significant impact on our business, including the imposition of significant civil, criminal
and administrative and punitive penalties, damages, monetary fines, possible exclusion from participation in Medicare, Medicaid
and other federal healthcare programs, debarments, contractual damages, imprisonment, reputational harm, diminished profits and
future earnings, injunctions, and curtailment or cessation of our operations, any of which could adversely affect our ability to
operate our business and our operating results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>We may be subject to risks related to
off-label use of our product candidates.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">The FDA strictly regulates
the advertising and promotion of drug products, and drug products may only be marketed or promoted for their FDA approved uses,
consistent with the product&rsquo;s approved labeling. Advertising and promotion of any product candidate that obtains approval
in the United States will be heavily scrutinized by the FDA, the Department of Justice, the Office of Inspector General of the
Department of Health and Human Services, state attorneys general, members of Congress and the public. Violations, including promotion
of our products for unapproved or off-label uses, are subject to enforcement letters, inquiries and investigations, and civil,
criminal and/or administrative sanctions by the FDA. Additionally, advertising and promotion of any product candidate that obtains
approval outside of the United States will be heavily scrutinized by relevant foreign regulatory authorities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">Even if we obtain regulatory
approval for our product candidates, the FDA or comparable foreign regulatory authorities may require labeling changes or impose
significant restrictions on a product&rsquo;s indicated uses or marketing or impose ongoing requirements for potentially costly
post-approval studies or post-market surveillance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">In the United States,
engaging in impermissible promotion of our product candidates for off-label uses can also subject us to false claims litigation
under federal and state statutes, which can lead to significant civil, criminal and/or administrative penalties and fines and agreements,
such as a corporate integrity agreement, that materially restrict the manner in which we promote or distribute our product candidates.
If we do not lawfully promote our products once they have received regulatory approval, we may become subject to such litigation
and, if we are not successful in defending against such actions, those actions could have a material adverse effect on our business,
financial condition and operating results and even result in having an independent compliance monitor assigned to audit our ongoing
operations for a lengthy period of time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">&nbsp;</P>


<!-- Field: Page; Sequence: 39 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><PAGE></PAGE></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 16.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>If we or any partners with which we may
collaborate are unable to achieve and maintain coverage and adequate levels of reimbursement for TARA-002 or IV Choline Chloride
following regulatory approval, their commercial success may be hindered severely.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">If TARA-002 and IV Choline
Chloride only becomes available by prescription, successful sales by us or by any partners with which we may collaborate depend
on the availability of coverage and adequate reimbursement from third-party payors. Patients who are prescribed medicine for the
treatment of their conditions generally rely on third-party payors to reimburse most or part of the costs associated with their
prescription drugs. The availability of coverage and adequate reimbursement from governmental healthcare programs, such as Medicare
and Medicaid in the United States, and private third-party payors is often critical to new product acceptance. Coverage decisions
may depend on clinical and economic standards that disfavor new drug products when more established or lower-cost therapeutic alternatives
are already available or subsequently become available, or may be affected by the budgets and demands on the various entities responsible
for providing health insurance to patients who will use TARA-002 and IV Choline Chloride. Even if we obtain coverage for our products,
the resulting reimbursement payment rates might not be adequate or may require co-payments that patients find unacceptably high.
Patients are unlikely to use a product unless coverage is provided, and reimbursement is adequate to cover a significant portion
of the cost.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">In addition, the market
for our products will depend significantly on access to third-party payors&rsquo; drug formularies or lists of medications for
which third-party payors provide coverage and reimbursement. The industry competition to be included in such formularies often
leads to downward pricing pressures on pharmaceutical companies and there may be time limitations on when a new drug may even apply
for formulary inclusion. Also, third-party payors may refuse to include products in their formularies or otherwise restrict patient
access to such products when a less costly generic equivalent or other treatment alternative is available in the discretion of
the formulary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">Third-party payors, whether
foreign or domestic, or governmental or commercial, are developing increasingly sophisticated methods of controlling healthcare
costs. In addition, in the United States, although private third-party payors tend to follow Medicare practices, no uniform or
consistent policy of coverage and reimbursement for drug products exists among third-party payors. Therefore, coverage and reimbursement
for drug products can differ significantly from payor to payor as well as state to state. Consequently, the coverage determination
process is often a time-consuming and costly process that must be played out across many jurisdictions and different entities and
which will require us to provide scientific, clinical and health economics support for the use of our products compared to current
alternatives and do so to each payor separately, with no assurance that coverage and adequate reimbursement will be obtained and
in what time frame.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">Further, we believe that
future coverage and reimbursement likely will be subject to increased restrictions both in the United States and in international
markets. Third-party coverage and reimbursement for our products may not be available or adequate in either the United States or
international markets, which could harm our business, financial condition, operating results and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>Healthcare reform measures could hinder
or prevent the commercial success of our product candidates.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">The Trump administration
and certain members of the U.S. Congress sought to repeal all or part of the Patient Protection and Affordable Care Act, as amended
by the Health Care and Education Reconciliation Act (collectively, &ldquo;Affordable Care Act&rdquo;), and implement a replacement
program. For example, the so-called &ldquo;individual mandate&rdquo; was repealed as part of tax reform legislation adopted in
December 2017, informally titled the Tax Cuts and Jobs Act (the &ldquo;Tax Act&rdquo;), such that the shared responsibility payment
for individuals who fail to maintain minimum essential coverage under section 5000A of the Code was eliminated beginning in 2019.
In addition, litigation may result in the repeal or replacement of prevent some or all of the Affordable Care Act legislation from
taking effect. For example, on December 14, 2018, the U.S. District Court for the Northern District of Texas held that the individual
mandate is a critical and inseverable feature of the Affordable Care Act, and therefore, because it was repealed as part of the
Tax Act, the remaining provisions of the Affordable Care Act are invalid as well. On December 18, 2019, the U.S. Court of Appeals
for the Fifth Circuit upheld the District Court ruling that the individual mandate was unconstitutional and remanded the case back
to the District Court to determine whether the remaining provisions of the ACA are invalid as well. The United States Supreme Court
is currently reviewing this case, although it is unclear when a decision will be made. Although the United States Supreme Court
has yet ruled on the constitutionality of the Affordable Care Act on January 28, 2021, President Biden issued an executive order
to initiate a special enrollment period from February 15, 2021 through May 15, 2021 for purposes of obtaining health insurance
coverage through the Affordable Care Act marketplace. The executive order also instructs certain governmental agencies to review
and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid
demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining
access to health insurance coverage through Medicaid or the Affordable Care Act. It is unclear how the Supreme Court ruling, other
such litigation and the healthcare reform efforts of the Biden administration will impact the Affordable Care Act and our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">&nbsp;</P>


<!-- Field: Page; Sequence: 40 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><PAGE></PAGE></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 16.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">Additionally, there has
been increasing legislative and enforcement interest in the United States with respect to drug pricing practices. For example,
the Trump administration previously released a &ldquo;Blueprint,&rdquo; or plan, to lower drug prices and reduce out of pocket
costs of drugs that contained proposals to increase drug manufacturer competition, increase the negotiating power of certain federal
healthcare programs, incentivize manufacturers to lower the list price of their products, and reduce the out of pocket costs of
drug products paid by consumers, and the Trump administration&rsquo;s budget proposal for fiscal year 2021 includes a $135 billion
allowance to support legislative proposals seeking to reduce drug prices, increase competition, lower out-of-pocket drug costs
for patients, and increase patient access to lower-cost generic and biosimilar drugs. On March 10, 2020, the Trump administration
sent &ldquo;principles&rdquo; for drug pricing to Congress, calling for legislation that would, among other things, cap Medicare
Part D beneficiary out-of-pocket pharmacy expenses, provide an option to cap Medicare Part D beneficiary monthly out-of-pocket
expenses, and place limits on pharmaceutical price increases. Several final rules have been recently promulgated that seek to implement
several of the Trump administration&rsquo;s proposals. However, it is unclear whether the Biden administration will work to reverse
these measures or pursue similar policy initiatives. We expect that additional state and federal healthcare reform measures will
be adopted in the future, particularly in light of the new Presidential administration, any of which could limit the amounts that
federal and state governments will pay for healthcare products and services, which could result in reduced demand for our product
candidates if approved or additional pricing pressures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">There are also calls to
place additional restrictions on or to ban all direct-to-consumer advertising of pharmaceuticals, which would limit our ability
to market our product candidates. The United States is in a minority of jurisdictions that allow this kind of advertising and its
removal could limit the potential reach of a marketing campaign. Further, it is possible that additional government action is taken
in response to the COVID-19 pandemic.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>We may also be subject to stricter healthcare
laws, regulation and enforcement, and our failure to comply with those laws could adversely affect our business, operations and
financial condition.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">Certain federal and state
healthcare laws and regulations pertaining to fraud and abuse and patients&rsquo; rights are and will be applicable to our business.
We are subject to regulation by both the federal government and the states in which we or our partners conduct business. The healthcare
laws and regulations that may affect our ability to operate include but are not limited to: the federal Anti-Kickback Statute;
federal civil and criminal false claims laws and civil monetary penalty laws; the federal Health Insurance Portability and Accountability
Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act; the Prescription Drug Marketing
Act (for sampling of drug product among other things); the federal physician sunshine requirements under the Affordable Care Act;
the Foreign Corrupt Practices Act as it applies to activities outside of the United States; the new federal Right-to-Try legislation;
and state law equivalents of many of the above federal laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">Because of the breadth
of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our business
activities could be subject to challenge under one or more of such laws. In addition, recent healthcare reform legislation has
strengthened these laws. For example, the recently enacted Affordable Care Act, among other things, amended the intent requirement
of the federal Anti-Kickback Statute and certain criminal healthcare fraud statutes. A person or entity no longer needs to have
actual knowledge of the statute or specific intent to violate it. In addition, the Affordable Care Act provided that the government
may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes
a false or fraudulent claim for purposes of the federal civil False Claims Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">Achieving and sustaining
compliance with these laws may prove costly. In addition, any action against us for violation of these laws, even if we successfully
defend against it, could cause us to incur significant legal expenses and divert management&rsquo;s attention from the operation
of our business and result in reputational damage. If our operations are found to be in violation of any of the laws described
above or any other governmental laws or regulations that apply to us, we may be subject to significant penalties, including administrative,
civil and criminal penalties, damages, including punitive damages, fines, disgorgement, the exclusion from participation in federal
and state healthcare programs, imprisonment, additional oversight and reporting obligations, or the curtailment or restructuring
of our operations, and injunctions, any of which could adversely affect our ability to operate our business and financial results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>We intend to in-license and acquire product
candidates and may engage in other strategic transactions, which could impact our liquidity, increase our expenses and present
significant distractions to our management.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">Our strategy is to in-license
and acquire product candidates and we may engage in other strategic transactions. Additional potential transactions that we may
consider include a variety of different business arrangements, including spin-offs, strategic partnerships, joint ventures, restructurings,
divestitures, business combinations and investments. Any such transaction may require us to incur non-recurring or other charges,
may increase our near- and long-term expenditures and may pose significant integration challenges or disrupt our management or
business, which could adversely affect our operations and financial results. Accordingly, there can be no assurance that we will
undertake or successfully complete any transactions of the nature described above, and any transaction that we do complete could
harm our business, financial condition, operating results and prospects. We have no current plan, commitment or obligation to enter
into any transaction described above, and we are not engaged in discussions related to additional partnerships.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">&nbsp;</P>


<!-- Field: Page; Sequence: 41 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><PAGE></PAGE></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>Our failure to successfully in-license,
acquire, develop and market additional product candidates or approved products would impair our ability to grow our business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">We intend to in-license,
acquire, develop and market additional products and product candidates. Because our internal research and development capabilities
are limited, we may be dependent on pharmaceutical companies, academic or government scientists and other researchers to sell or
license products or technology to us. The success of this strategy depends partly on our ability to identify and select promising
pharmaceutical product candidates and products, negotiate licensing or acquisition agreements with their current owners, and finance
these arrangements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">The process of proposing,
negotiating and implementing a license or acquisition of a product candidate or approved product is lengthy and complex. Other
companies, including some with substantially greater financial, marketing, sales and other resources, may compete with us for the
license or acquisition of product candidates and approved products. We have limited resources to identify and execute the acquisition
or in-licensing of third-party products, businesses and technologies and integrate them into our current infrastructure. Moreover,
we may devote resources to potential acquisitions or licensing opportunities that are never completed, or we may fail to realize
the anticipated benefits of such efforts. We may not be able to acquire the rights to additional product candidates on terms that
we find acceptable or at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">Further, any product candidate
that we acquire may require additional development efforts prior to commercial sale, including preclinical or clinical testing
and approval by the FDA and applicable foreign regulatory authorities. All product candidates are prone to risks of failure typical
of pharmaceutical product development, including the possibility that a product candidate will not be shown to be sufficiently
safe and effective for approval by regulatory authorities. In addition, we cannot provide assurance that any approved products
that we acquire will be manufactured or sold profitably or achieve market acceptance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>We expect to rely on collaborations with
third parties for the successful development and commercialization of our product candidates.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">We expect to rely upon
the efforts of third parties for the successful development and commercialization of our current and future product candidates.
The clinical and commercial success of our product candidates may depend upon maintaining successful relationships with third-party
partners which are subject to a number of significant risks, including the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 16.2pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; padding-right: 0pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; padding-right: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="padding-right: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">our partners&rsquo; ability to execute their responsibilities in a timely, cost-efficient and compliant manner;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; padding-right: 0pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; padding-right: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="padding-right: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">reduced control over delivery and manufacturing schedules;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; padding-right: 0pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; padding-right: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="padding-right: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">price increases and product reliability;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; padding-right: 0pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; padding-right: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="padding-right: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">manufacturing deviations from internal or regulatory specifications;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; padding-right: 0pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; padding-right: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="padding-right: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">quality incidents;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; padding-right: 0pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; padding-right: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="padding-right: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the failure of partners to perform their obligations for technical, market or other reasons;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; padding-right: 0pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; padding-right: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="padding-right: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">misappropriation of our current or future product candidates; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; padding-right: 0pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; padding-right: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="padding-right: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">other risks in potentially meeting our current and future product commercialization schedule or satisfying the requirements of our end-users.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">We cannot assure you that
we will be able to establish or maintain third-party relationships in order to successfully develop and commercialize our product
candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">&nbsp;</P>


<!-- Field: Page; Sequence: 42 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><PAGE></PAGE></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>We rely completely on third-party contractors
to supply, manufacture and distribute clinical drug supplies for our product candidates, which may include sole-source suppliers
and manufacturers; we intend to rely on third parties for commercial supply, manufacturing and distribution if any of our product
candidates receive regulatory approval; and we expect to rely on third parties for supply, manufacturing and distribution of preclinical,
clinical and commercial supplies of any future product candidates.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">We do not currently have,
nor do we plan to acquire, the infrastructure or capability to supply, store, manufacture or distribute preclinical, clinical or
commercial quantities of drug substances or products. Additionally, we have not entered into a long-term commercial supply agreement
to provide us with such drug substances or products. As a result, our ability to develop our product candidates is dependent, and
our ability to supply our products commercially will depend, in part, on our ability to obtain the APIs and other substances and
materials used in our product candidates successfully from third parties and to have finished products manufactured by third parties
in accordance with regulatory requirements and in sufficient quantities for preclinical and clinical testing and commercialization.
If we fail to develop and maintain supply and other technical relationships with these third parties, we may be unable to continue
to develop or commercialize our products and product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">We do not have direct
control over whether our contract suppliers and manufacturers will maintain current pricing terms, be willing to continue supplying
us with API and finished products or maintain adequate capacity and capabilities to serve our needs, including quality control,
quality assurance and qualified personnel. We are dependent on our contract suppliers and manufacturers for day-to-day compliance
with applicable laws and cGMPs for production of both APIs and finished products. If the safety or quality of any product or product
candidate or component is compromised due to a failure to adhere to applicable laws or for other reasons, we may not be able to
commercialize or obtain regulatory approval for the affected product or product candidate successfully, and we may be held liable
for injuries sustained as a result.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">In order to conduct larger
or late-stage clinical trials for our product candidates and supply sufficient commercial quantities of the resulting drug product
and its components, if that product candidate is approved for sale, our contract manufacturers and suppliers will need to produce
our drug substances and product candidates in larger quantities, more cost-effectively and, in certain cases, at higher yields
than they currently achieve. If our third-party contractors are unable to scale up the manufacture of any of our product candidates
successfully in sufficient quality and quantity and at commercially reasonable prices, or are shut down or put on clinical hold
by government regulators, and we are unable to find one or more replacement suppliers or manufacturers capable of production at
a substantially equivalent cost in substantially equivalent volumes and quality, and we are unable to transfer the processes successfully
on a timely basis, the development of that product candidate and regulatory approval or commercial launch for any resulting products
may be delayed, or there may be a shortage in supply, either of which could significantly harm our business, financial condition,
operating results and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">We expect to continue
to depend on third-party contract suppliers and manufacturers for the foreseeable future. Our supply and manufacturing agreements,
if any, do not guarantee that a contract supplier or manufacturer will provide services adequate for our needs. Additionally, any
damage to or destruction of our third-party manufacturer&rsquo;s or suppliers&rsquo; facilities or equipment, even by force majeure,
may significantly impair our ability to have our products and product candidates manufactured on a timely basis. Our reliance on
contract manufacturers and suppliers further exposes us to the possibility that they, or third parties with access to their facilities,
will have access to and may misappropriate our trade secrets or other proprietary information. In addition, the manufacturing facilities
of certain of our suppliers may be located outside of the United States. This may give rise to difficulties in importing our products
or product candidates or their components into the United States or other countries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">In addition, we cannot
be certain that any prolonged, intensified or worsened effect from the COVID-19 pandemic would not impact our supply chain.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>The manufacture of biologics is complex
and our third-party manufacturers may encounter difficulties in production. If our CDMO encounters such difficulties, the ability
to provide supply of TARA-002 for clinical trials, our ability to obtain marketing approval, or our ability to obtain commercial
supply of TARA-002, if approved, could be delayed or stopped.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">We have no experience
in biologic manufacturing and do not own or operate, and we do not expect to own or operate, facilities for product manufacturing,
storage and distribution, or testing. We are completely dependent on CDMOs to fulfill our clinical and commercial supply of TARA-002.
The process of manufacturing biologics is complex, highly regulated and subject to multiple risks. Manufacturing biologics is highly
susceptible to product loss due to contamination, equipment failure, improper installation or operation of equipment, vendor or
operator error, inconsistency in yields, variability in product characteristics and difficulties in scaling the production process.
Even minor deviations from normal manufacturing processes could result in reduced production yields, product defects and other
supply disruptions and higher costs. If microbial, viral or other contaminations are discovered at the facilities of our manufacturer,
such facilities may need to be closed for an extended period of time to investigate and remedy the contamination, which could delay
clinical trials, result in higher costs of drug product and adversely harm our business. Moreover, if the FDA determines that our
manufacturer is not in compliance with FDA laws and regulations, including those governing cGMPs, the FDA may deny BLA approval
until the deficiencies are corrected or we replace the manufacturer in our BLA with a manufacturer that is in compliance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">&nbsp;</P>


<!-- Field: Page; Sequence: 43 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><PAGE></PAGE></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">In addition, there are
risks associated with large scale manufacturing for clinical trials or commercial scale including, among others, cost overruns,
potential problems with process scale-up, process reproducibility, stability issues, compliance with cGMPs, lot consistency and
timely availability of raw materials. Even if we obtain regulatory approval for TARA-002 or any future product candidates, there
is no assurance that our manufacturers will be able to manufacture the approved product to specifications acceptable to the FDA
or other regulatory authorities, to produce it in sufficient quantities to meet the requirements for the potential launch of the
product or to meet potential future demand. If our manufacturers are unable to produce sufficient quantities for clinical trials
or for commercialization, commercialization efforts would be impaired, which would have an adverse effect on our business, financial
condition, results of operations and growth prospects. Scaling up a biologic manufacturing process is a difficult and uncertain
task, and any CDMO we contract may not have the necessary capabilities to complete the implementation and development process of
further scaling up production, transferring production to other sites, or managing its production capacity to timely meet product
demand.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>We expect our stock price to be highly
volatile.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">The market price of our
shares could be subject to significant fluctuations. Market prices for securities of biotechnology and other life sciences companies
historically have been particularly volatile subject even to large daily price swings. Some of the factors that may cause the market
price of our shares to fluctuate include, but are not limited to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 16.2pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; padding-right: 0pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; padding-right: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="padding-right: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">our ability to obtain timely regulatory approvals for TARA-002, IV Choline Chloride or future product candidates, and delays or failures to obtain such approvals;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; padding-right: 0pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; padding-right: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="padding-right: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">failure of TARA-002 or IV Choline Chloride, if approved, to achieve commercial success;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; padding-right: 0pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; padding-right: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="padding-right: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">issues in manufacturing TARA-002, IV Choline Chloride or future product candidates;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; padding-right: 0pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; padding-right: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="padding-right: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the results of current and any future clinical trials of TARA-002 or IV Choline Chloride;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; padding-right: 0pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; padding-right: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="padding-right: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">failure of other of our product candidates, if approved, to achieve commercial success;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; padding-right: 0pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; padding-right: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="padding-right: 0pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the entry into, or termination of, or breach by partners of key agreements, including key commercial partner agreements;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; padding-right: 0pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; padding-right: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="padding-right: 0pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the initiation of, material developments in, or conclusion of any litigation to enforce or defend any intellectual property rights or defend against the intellectual property rights of others;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; padding-right: 0pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; padding-right: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="padding-right: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">announcements of any dilutive equity financings;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; padding-right: 0pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; padding-right: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="padding-right: 0pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">announcements by commercial partners or competitors of new commercial products, clinical progress or the lack thereof, significant contracts, commercial relationships or capital commitments;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; padding-right: 0pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; padding-right: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="padding-right: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">failure to elicit meaningful stock analyst coverage and downgrades of our stock by analysts; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; padding-right: 0pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; padding-right: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="padding-right: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the loss of key employees.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">Moreover, the stock markets
in general have experienced substantial volatility in our industry that has often been unrelated to the operating performance of
individual companies or a certain industry segment. These broad market fluctuations may also adversely affect the trading price
of our shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">In the past, following
periods of volatility in the market price of a company&rsquo;s securities, shareholders have often instituted class action securities
litigation against those companies. Such litigation, if instituted, could result in substantial costs and diversion of management
attention and resources, which could significantly harm our profitability and reputation. In addition, such securities litigation
often has ensued after a reverse merger or other merger and acquisition activity. Such litigation if brought could impact negatively
our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>We incur costs and demands upon management
as a result of complying with the laws and regulations affecting public companies.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">As a public company, we
have incurred, and will continue to incur, significant legal, accounting and other expenses that ArTara Subsidiary Inc. did not
incur as a private company, including costs associated with public company reporting and other SEC requirements. We have also incurred,
and will continue to incur, costs associated with corporate governance requirements, including requirements under the Sarbanes-Oxley
Act, as well as rules implemented by the SEC and Nasdaq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">We expect the rules and
regulations applicable to public companies will continue to substantially increase our legal and financial compliance costs and
to make some activities more time-consuming and costly. Our executive officers and other personnel will need to continue to devote
substantial time to gaining expertise regarding operations as a public company and compliance with applicable laws and regulations.
These rules and regulations may also make it expensive for us to operate our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">&nbsp;</P>


<!-- Field: Page; Sequence: 44 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><PAGE></PAGE></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>We are able to take advantage of reduced
disclosure and governance requirements applicable to smaller reporting companies, which could result in our common stock being
less attractive to investors.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">We have a public float
of less than $250 million and therefore qualify as a smaller reporting company under the rules of the SEC. As a smaller reporting
company, we are able to take advantage of reduced disclosure requirements, such as simplified executive compensation disclosures
and reduced financial statement disclosure requirements in our SEC filings. Decreased disclosures in our SEC filings due to our
status as a smaller reporting company may make it harder for our investors to analyze our results of operations and financial prospects.
We cannot predict if investors will find our common stock less attractive due to our reliance on these exemptions. If some investors
find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock
price may be more volatile. We may take advantage of the reporting exemptions applicable to a smaller reporting company until we
are no longer a smaller reporting company, which status would end once we have a public float greater than $250 million. In that
event, we could still be a smaller reporting company if our annual revenues were below $100 million and we have a public float
of less than $700 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>If we fail to attract and retain management
and other key personnel, we may be unable to continue to successfully develop or commercialize our product candidates or otherwise
implement our business plan.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">Our ability to compete
in the highly competitive pharmaceuticals industry depends on our ability to attract and retain highly qualified managerial, scientific,
medical, legal, sales and marketing and other personnel. We are highly dependent on our management and scientific personnel. The
loss of the services of any of these individuals could impede, delay or prevent the successful development of our product pipeline,
completion of our planned clinical trials, commercialization of our product candidates or in-licensing or acquisition of new assets
and could impact negatively our ability to implement successfully our business plan. If we lose the services of any of these individuals,
we might not be able to find suitable replacements on a timely basis or at all, and our business could be harmed as a result. We
might not be able to attract or retain qualified management and other key personnel in the future due to the intense competition
for qualified personnel among biotechnology, pharmaceutical and other businesses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>Our ability to use our net operating
loss carryforwards and certain other tax attributes to offset future taxable income or taxes may be limited. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">Under the Tax Act, as modified by the CARES Act, federal net
operating losses incurred in tax years beginning after December 31, 2017, may be carried forward indefinitely, but the deductibility
of such federal net operating losses in tax years beginning after December 31, 2020. It is uncertain if and to what extent various
states and localities will conform to the Tax Act or the CARES Act. In addition, under Sections 382 and 383 of the Internal Revenue
Code of 1986, as amended, and corresponding provisions of state law, if a corporation undergoes an &ldquo;ownership change,&rdquo;
which is generally defined as a greater than 50% change in its equity ownership value over a three-year period, the corporation&rsquo;s
ability to use its pre-change net operating loss carryforwards and other pre-change tax attributes to offset its post-change income
or taxes may be limited. We have experienced an ownership change in the past and we may also experience additional ownership changes
in the future as a result of subsequent shifts in our stock ownership, some of which may be outside of our control. If an ownership
change occurs and our ability to use our net operating loss carryforwards is materially limited, it would harm our future operating
results by effectively increasing our future tax obligations. In addition, at the state level, there may be periods during which
the use of net operating loss carryforwards is suspended or otherwise limited, which could accelerate or permanently increase state
taxes owed. As a result, if we earn net taxable income, we may be unable to use all or a material portion of our net operating
loss carryforwards and other tax attributes, which could potentially result in increased future tax liability to us and adversely
affect our future cash flows.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>We may be adversely affected by natural
disasters, pandemics and other catastrophic events and by man-made problems such as terrorism that could disrupt our business operations,
and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">Our corporate office is
located in New York, New York. If a disaster, power outage, computer hacking, or other event occurred that prevented us from using
all or a significant portion of an office, that damaged critical infrastructure, such as enterprise financial systems, IT systems,
manufacturing resource planning or enterprise quality systems, or that otherwise disrupted operations, it may be difficult or,
in certain cases, impossible for us to continue our business for a substantial period of time. As an example, New York City has
been significantly impacted by the COVID-19 pandemic and, due to safety considerations for our employees and government restrictions,
we do not know when we will be able to use our office facilities located there. Our contract manufacturer&rsquo;s and suppliers&rsquo;
facilities are located in multiple locations where there are similar stay-at-home orders in place for the current crisis and where
other natural disasters or similar events, such as tornadoes, fires, explosions or large-scale accidents or power outages, or IT
threats, pandemic, acts of terrorism and other geo-political unrest, could severely disrupt our operations and have a material
adverse effect on our business, financial condition, operating results and prospects. All of the aforementioned risks may be further
increased if we do not implement a disaster recovery plan or our partners&rsquo; or manufacturers&rsquo; disaster recovery plans
prove to be inadequate. To the extent that any of the above should result in delays in the regulatory approval, manufacture, distribution
or commercialization of TARA-002 or IV Choline Chloride, our business, financial condition, operating results and prospects would
suffer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">&nbsp;</P>


<!-- Field: Page; Sequence: 45 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><PAGE></PAGE></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>Anti-takeover provisions in our charter
documents and under Delaware law could make an acquisition of us more difficult and may prevent attempts by our stockholders to
replace or remove management.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">Provisions in our certificate
of incorporation and bylaws may delay or prevent an acquisition or a change in management. In addition, because we are incorporated
in Delaware, we are governed by the provisions of Section 203 of the DGCL, which prohibits stockholders owning in excess of 15%
of the outstanding voting stock from merging or combining with us. These provisions may frustrate or prevent any attempts by our
stockholders to replace or remove then current management by making it more difficult for stockholders to replace members of the
board of directors, which is responsible for appointing the members of management.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>The certificate of incorporation of ours
provides that the Court of Chancery of the State of Delaware is the exclusive forum for substantially all disputes between us and
our stockholders, which could limit our stockholders&rsquo; ability to obtain a favorable judicial forum for disputes with us or
our directors, officers or other employees.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">The certificate of incorporation
of ours provides that the Court of Chancery of the State of Delaware is the sole and exclusive forum for any derivative action
or proceeding brought on our behalf, any action asserting a breach of fiduciary duty owed by any of our directors, officers or
other employees to us or our stockholders, any action asserting a claim against us arising pursuant to any provisions of the DGCL,
our certificate of incorporation or our bylaws, or any action asserting a claim against us that is governed by the internal affairs
doctrine. The choice of forum provision may limit a stockholder&rsquo;s ability to bring a claim in a judicial forum that it finds
favorable for disputes with us or our directors, officers or other employees, which may discourage such lawsuits against us and
our directors, officers and other employees. If a court were to find the choice of forum provision contained in the certificate
of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such
action in other jurisdictions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>Certain stockholders have the ability
to control or significantly influence certain matters submitted to our stockholders for approval.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">Certain stockholders have
consent rights over certain significant matters of our business. These include decisions to effect a merger or other similar transaction,
changes to the principal business of ours, and the sale or other transfer of TARA-002 or other assets with an aggregate value of
more than $2,500,000. As a result, these stockholders, have significant influence over certain matters that require approval by
our stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>If we fail to maintain proper and effective
internal controls, our ability to produce accurate financial statements on a timely basis could be impaired.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">We are subject to the
reporting requirements of the Exchange Act, the Sarbanes-Oxley Act and the rules and regulations of Nasdaq. The Sarbanes-Oxley
Act requires, among other things, that we maintain effective disclosure controls and procedures and internal control over financial
reporting. We must perform system and process evaluation and testing of our internal control over financial reporting to allow
management to report on the effectiveness of our internal controls over financial reporting in our Annual Report on Form 10-K filing
for that year, as required by Section 404 of the Sarbanes-Oxley Act. This will require that we incur substantial professional fees
and internal costs to expand our accounting and finance functions and that we expend significant management efforts. We may experience
difficulty in meeting these reporting requirements in a timely manner.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">We may discover weaknesses
in our system of internal financial and accounting controls and procedures that could result in a material misstatement of our
financial statements. Our internal control over financial reporting will not prevent or detect all errors and all fraud. A control
system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&rsquo;s
objectives will be met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute
assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud will be detected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">If we are not able to
comply with the requirements of Section 404 of the Sarbanes-Oxley Act, or if we are unable to maintain proper and effective internal
controls, we may not be able to produce timely and accurate financial statements. If that were to happen, the market price of our
common stock could decline and we could be subject to sanctions or investigations by Nasdaq, the SEC or other regulatory authorities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">&nbsp;</P>


<!-- Field: Page; Sequence: 46 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><PAGE></PAGE></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>Risks Related to Intellectual Property Rights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>We may not be able to obtain, maintain
or enforce global patent rights or other intellectual property rights that cover our product candidates and technologies that are
of sufficient breadth to prevent third parties from competing against us.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">Our success with respect
to our product candidates will depend, in part, on our ability to obtain and maintain patent protection in both the United States
and other countries, to preserve our trade secrets and to prevent third parties from infringing on our proprietary rights. Our
ability to protect our product candidates from unauthorized or infringing use by third parties depends in substantial part on our
ability to obtain and maintain valid and enforceable patents around the world.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">The patent application
process, also known as patent prosecution, is expensive and time-consuming, and we and our current or future licensors and licensees
may not be able to prepare, file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely
manner in all the countries that are desirable. It is also possible that we or our current licensors, or any future licensors or
licensees, will fail to identify patentable aspects of inventions made in the course of development and commercialization activities
before it is too late to obtain patent protection on them. Therefore, these and any of our patents and applications may not be
prosecuted and enforced in a manner consistent with the best interests of our business. Moreover, our competitors independently
may develop equivalent knowledge, methods and know-how or discover workarounds to our patents that would not constitute infringement.
Any of these outcomes could impair our ability to enforce the exclusivity of our patents effectively, which may have an adverse
impact on our business, financial condition and operating results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">Due to legal standards
relating to patentability, validity, enforceability and claim scope of patents covering pharmaceutical inventions, our ability
to obtain, maintain and enforce patents is uncertain and involves complex legal and factual questions especially across countries.
Accordingly, rights under any existing patents or any patents we might obtain or license may not cover our product candidates or
may not provide us with sufficient protection for our product candidates to afford a sustainable commercial advantage against competitive
products or processes, including those from branded, generic and over-the-counter pharmaceutical companies. In addition, we cannot
guarantee that any patents or other intellectual property rights will issue from any pending or future patent or other similar
applications owned by or licensed to us. Even if patents or other intellectual property rights have issued or will issue, we cannot
guarantee that the claims of these patents and other rights are or will be held valid or enforceable by the courts, through injunction
or otherwise, or will provide us with any significant protection against competitive products or otherwise be commercially valuable
to us in every country of commercial significance that we may target.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">Competitors in the field
of immunology and oncology therapeutics have created a substantial amount of prior art, including scientific publications, posters,
presentations, patents and patent applications and other public disclosures including on the Internet. Our ability to obtain and
maintain valid and enforceable patents depends on whether the differences between our technology and the prior art allow our technology
to be patentable over the prior art. We do not have outstanding issued patents covering all of the recent developments in our technology
and are unsure of the patent protection that we will be successful in obtaining, if any. Even if the patents do successfully issue,
third parties may design around or challenge the validity, enforceability or scope of such issued patents or any other issued patents
we own or license, which may result in such patents being narrowed, invalidated or held unenforceable. If the breadth or strength
of protection provided by the patents we hold or pursue with respect to our product candidates is challenged, it could dissuade
companies from collaborating with us to develop or threaten our ability to commercialize or finance our product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">The laws of some foreign
jurisdictions do not provide intellectual property rights to the same extent or duration as in the United States, and many companies
have encountered significant difficulties in acquiring, maintaining, protecting, defending and especially enforcing such rights
in foreign jurisdictions. If we encounter such difficulties in protecting, or are otherwise precluded from effectively protecting,
our intellectual property in foreign jurisdictions, our business prospects could be substantially harmed, especially internationally.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">Proprietary trade secrets
and unpatented know-how are also very important to our business. Although we have taken steps to protect our trade secrets and
unpatented know-how by entering into confidentiality agreements with third parties, and intellectual property protection agreements
with officers, directors, employees, and certain consultants and advisors, there can be no assurance that binding agreements will
not be breached or enforced by courts, that we would have adequate remedies for any breach, including injunctive and other equitable
relief, or that our trade secrets and unpatented know-how will not otherwise become known, inadvertently disclosed by us or our
agents and representatives, or be independently discovered by our competitors. If trade secrets are independently discovered, we
would not be able to prevent their use and if we and our agents or representatives inadvertently disclose trade secrets and/or
unpatented know-how, we may not be allowed to retrieve this and maintain the exclusivity we previously enjoyed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">&nbsp;</P>


<!-- Field: Page; Sequence: 47 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><PAGE></PAGE></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>We may not be able to protect our intellectual
property rights throughout the world.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">Filing, prosecuting and
defending patents on our product candidates does not guarantee exclusivity. The requirements for patentability differ in certain
countries, particularly developing countries. In addition, the laws of some foreign countries do not protect intellectual property
rights to the same extent as laws in the United States, especially when it comes to granting use and other kinds of patents and
what kind of enforcement rights will be allowed, especially injunctive relief in a civil infringement proceeding. Consequently,
we may not be able to prevent third parties from practicing our inventions in all countries outside the United States and even
in launching an identical version of our product notwithstanding we have a valid patent in that country. Competitors may use our
technologies in jurisdictions where we have not obtained patent protection to develop their own products, or produce copy products,
and, further, may export otherwise infringing products to territories where we have patent protection but enforcement on infringing
activities is inadequate or where we have no patents. These products may compete with our products, and our patents or other intellectual
property rights may not be effective or sufficient to prevent them from competing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">Many companies have encountered
significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain
countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection,
particularly those relating to pharmaceuticals, and the judicial and government systems are often corrupt, which could make it
difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights
generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts
and attention from other aspects of our business, could put our global patents at risk of being invalidated or interpreted narrowly
and our global patent applications at risk of not issuing, and could provoke third parties to assert claims against us. We may
not prevail in any lawsuits that we initiate or infringement actions brought against us, and the damages or other remedies awarded,
if any, may not be commercially meaningful when we are the plaintiff. When we are the defendant we may be required to post large
bonds to stay in the market while we defend ourselves from an infringement action.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">In addition, certain countries
in Europe and certain developing countries have compulsory licensing laws under which a patent owner may be compelled to grant
licenses to third parties, especially if the patent owner does not enforce or use its patents over a protracted period of time.
In some cases, the courts will force compulsory licenses on the patent holder even when finding the patent holder&rsquo;s patents
are valid if the court believes it is in the best interests of the country to have widespread access to an essential product covered
by the patent. In these situations, the royalty the court requires to be paid by the license holder receiving the compulsory license
is not calculated at fair market value and can be inconsequential, thereby disaffecting the patent holder&rsquo;s business. In
these countries, we may have limited remedies if our patents are infringed or if we are compelled to grant a license to our patents
to a third party, which could also materially diminish the value of those patents. This would limit our potential revenue opportunities.
Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant
commercial advantage from the intellectual property that we own or license, especially in comparison to what we enjoy from enforcing
our intellectual property rights in the Unites States. Finally, our ability to protect and enforce our intellectual property rights
may be adversely affected by unforeseen changes in both U.S. and foreign intellectual property laws, or changes to the policies
in various government agencies in these countries, including but not limited to the patent office issuing patents and the health
agency issuing pharmaceutical product approvals For example, in Brazil, pharmaceutical patents require initial approval of the
Brazilian health agency (ANVISA). Finally, many countries have large backlogs in patent prosecution, and in some countries in Latin
America it can take years, even decades, just to get a pharmaceutical patent application reviewed notwithstanding the merits of
the application.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>Obtaining and maintaining patent protection
depends on compliance with various procedural, document submission, fee payment, and other requirements imposed by governmental
patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">Periodic maintenance and
annuity fees on any issued patent are due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime
of the patent. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary,
fee payment and other similar provisions during the patent application process. While an inadvertent lapse can, in many cases,
be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance
can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights
in the relevant jurisdiction just for failure to know about and/or timely pay a prosecution fee. Non-compliance events that could
result in abandonment or lapse of a patent or patent application include failure to respond to official actions within prescribed
time limits, non-payment of fees in prescribed time periods, and failure to properly legalize and submit formal documents in the
format and style the country requires. If we or our licensors fail to maintain the patents and patent applications covering our
product candidates for any reason, our competitors might be able to enter the market, which would have an adverse effect on our
business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">&nbsp;</P>


<!-- Field: Page; Sequence: 48 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><PAGE></PAGE></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>If we fail to comply with our obligations
under our intellectual property license agreements, we could lose license rights that are important to our business. Additionally,
these agreements may be subject to disagreement over contract interpretation, which could narrow the scope of our rights to the
relevant intellectual property or technology or increase our financial or other obligations to our licensors.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">We have entered into in-license
arrangements with respect to certain of our product candidates. These license agreements impose various diligence, milestone, royalty,
insurance and other obligations on us. If we fail to comply with these obligations, the respective licensors may have the right
to terminate the license, in which event we may not be able to develop or market the affected product candidate. The loss of such
rights could materially adversely affect our business, financial condition, operating results and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>If we are sued for infringing intellectual
property rights of third parties, such litigation could be costly and time consuming and could prevent or delay us from developing
or commercializing our product candidates.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">Our commercial success
depends on our ability to develop, manufacture, market and sell our product candidates and use our proprietary technologies without
infringing the proprietary rights of third parties. We cannot assure that marketing and selling such candidates and using such
technologies will not infringe existing or future patents. Numerous U.S.- and foreign-issued patents and pending patent applications
owned by third parties exist in the fields relating to our product candidates. As the biotechnology and pharmaceutical industries
expand and more patents are issued, the risk increases that others may assert that our product candidates, technologies or methods
of delivery or use infringe their patent rights. Moreover, it is not always clear to industry participants, including us, which
patents and other intellectual property rights cover various drugs, biologics, drug delivery systems or their methods of use, and
which of these patents may be valid and enforceable. Thus, because of the large number of patents issued and patent applications
filed in our fields across many countries, there may be a risk that third parties may allege they have patent rights encompassing
our product candidates, technologies or methods.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">In addition, there may
be issued patents of third parties that are infringed or are alleged to be infringed by our product candidates or proprietary technologies
notwithstanding patents we may possess. Because some patent applications in the United States may be maintained in secrecy until
the patents are issued, because patent applications in the United States and many foreign jurisdictions are typically not published
until 18 months after filing and because publications in the scientific literature often lag behind actual discoveries, we cannot
be certain that others have not filed patent applications for technology covered by our own and in-licensed issued patents or our
pending applications. Our competitors may have filed, and may in the future file, patent applications covering our product candidates
or technology similar to our technology. Any such patent application may have priority over our own and in-licensed patent applications
or patents, which could further require us to obtain rights to issued patents covering such technologies, which may mean paying
significant licensing fees or the like. If another party has filed a U.S. patent application on inventions similar to those owned
or in-licensed to us, or, in the case of in-licensed technology, the licensor may have to participate, in the United States, in
an interference proceeding to determine priority of invention.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">We may be exposed to,
or threatened with, future litigation by third parties having patent or other intellectual property rights alleging that our product
candidates or proprietary technologies infringe such third parties&rsquo; intellectual property rights, including litigation resulting
from filing under Paragraph IV of the Hatch-Waxman Act or other countries&rsquo; laws similar to the Hatch-Waxman Act. These lawsuits
could claim that there are existing patent rights for such drug, and this type of litigation can be costly and could adversely
affect our operating results and divert the attention of managerial and technical personnel, even if we do not infringe such patents
or the patents asserted against us is ultimately established as invalid. There is a risk that a court would decide that we are
infringing the third party&rsquo;s patents and would order us to stop the activities covered by the patents. In addition, there
is a risk that a court will order us to pay the other party significant damages for having violated the other party&rsquo;s patents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">Because we rely on certain
third-party licensors and partners and will continue to do so in the future, if one of our licensors or partners is sued for infringing
a third party&rsquo;s intellectual property rights, our business, financial condition, operating results and prospects could suffer
in the same manner as if we were sued directly. In addition to facing litigation risks, we have agreed to indemnify certain third-party
licensors and partners against claims of infringement caused by our proprietary technologies, and we have entered or may enter
into cost-sharing agreements with some our licensors and partners that could require us to pay some of the costs of patent litigation
brought against those third parties whether or not the alleged infringement is caused by our proprietary technologies. In certain
instances, these cost-sharing agreements could also require us to assume greater responsibility for infringement damages than would
be assumed just on the basis of our technology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">The occurrence of any
of the foregoing could adversely affect our business, financial condition or operating results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>We may be subject to claims that our
officers, directors, employees, consultants or independent contractors have wrongfully used or disclosed to us alleged trade secrets
of their former employers or their former or current customers.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">As is common in the biotechnology
and pharmaceutical industries, certain of our employees were formerly employed by other biotechnology or pharmaceutical companies,
including our competitors or potential competitors. Moreover, we engage the services of consultants to assist us in the development
of our products and product candidates, many of whom were previously employed at, or may have previously been or are currently
providing consulting services to, other biotechnology or pharmaceutical companies, including our competitors or potential competitors.
We may be subject to claims that these employees and consultants or we have inadvertently or otherwise used or disclosed trade
secrets or other proprietary information of their former employers or their former or current customers. Although we have no knowledge
of any such claims being alleged to date, if such claims were to arise, litigation may be necessary to defend against any such
claims. Even if we are successful in defending against any such claims, any such litigation could be protracted, expensive, a distraction
to our management team, not viewed favorably by investors and other third parties, and may potentially result in an unfavorable
outcome.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">&nbsp;</P>


<!-- Field: Page; Sequence: 49 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><PAGE></PAGE></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>General Risk Factors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>We do not anticipate paying any dividends
in the foreseeable future.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">The current expectation
is that we will retain our future earnings to fund the development and growth of our business. As a result, capital appreciation,
if any, of your shares of us will be your sole source of gain, if any, for the foreseeable future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>Our business and operations would suffer
in the event of system failures, cyber-attacks or a deficiency in our cyber-security.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">Despite the implementation
of security measures, our internal computer systems and those of our current and future CROs and other contractors and consultants
are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and
electrical failures. The risk of a security breach or disruption, particularly through cyber-attacks or cyber-intrusion, including
by computer hackers, foreign governments, and cyber-terrorists, has generally increased as the number, intensity and sophistication
of attempted attacks and intrusions from around the world have increased. If such an event were to occur and cause interruptions
in our operations, it could result in a material disruption of our development programs and our business operations. In the first
quarter of 2020, our email server was compromised in a cyber-attack. We quickly isolated the incident and have, since, implemented
additional risk prevention measures. In addition, since we sponsor clinical trials, any breach that compromises patient data and
identities causing a breach of privacy could generate significant reputational damage and legal liabilities and costs to recover
and repair, including affecting trust in us to recruit for future clinical trials. For example, the loss of clinical trial data
from completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our
costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss of, or damage
to, our data or applications or inappropriate disclosure of confidential or proprietary information, we could incur liability and
the further development and commercialization of our products and product candidates could be delayed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>If equity research analysts do not publish
research or reports, or publish unfavorable research or reports, about us, our business or our market, our stock price and trading
volume could decline.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 16.2pt">The trading market for
our common stock is influenced by the research and reports that equity research analysts publish about us and our business. Equity
research analysts may elect not to provide research coverage of our common stock, and such lack of research coverage may adversely
affect the market price of our common stock. In the event we do have equity research analyst coverage, we will not have any control
over the analysts or the content and opinions included in their reports. The price of our common stock could decline if one or
more equity research analysts downgrade our stock or issue other unfavorable commentary or research. If one or more equity research
analysts ceases coverage of us or fails to publish reports on us regularly, demand for our common stock could decrease, which in
turn could cause our stock price or trading volume to decline.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><A NAME="aph203237a004"></A><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Item 1B.</B></FONT> <FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Unresolved Staff Comments.</I></B></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">This item is not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><A NAME="aph203237a005"></A><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Item 2.</B></FONT> <FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Properties.</I></B></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">As of December 31, 2020, we lease approximately 10,252 square
feet of space for our headquarters in New York, New York under an agreement that expires in March 2028, with monthly rent of $93,122.
This lease has been entered into but the Company will not have access to the premises until the second quarter of 2021. Our previous
headquarters for approximately 700 square feet of space with monthly rent of $15,300 expires in March 2021 and we do not intend
to extend this lease. In addition, we entered into a quarter-to-quarter lease agreement for a development lab, a manufacturing
space and an additional manufacturing space, all located in North Carolina for quarterly rent of $1,309, $19,173 and $10,625, respectively.
The development lab space has been occupied as of May 2019, the manufacturing space has been occupied as of March 2020 and the
additional manufacturing space has been occupied as of December 2020. We believe that our existing facilities are adequate to meet
our current needs, and that suitable additional alternative spaces will be available in the future on commercially reasonable terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><A NAME="aph203237a006"></A><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Item 3.</B></FONT> <FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Legal Proceedings.</I></B></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">From time to time, we
may be subject to various legal proceedings and claims that arise in the ordinary course of our business activities. We are not
currently a party to any legal proceedings that, in the opinion of our management, are likely to have a material adverse effect
on our business. Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion
of management resources and other factors.<BR>
<BR>
</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><A NAME="aph203237a007"></A><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Item 4.</B></FONT> <FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Mine Safety Disclosures.</I></B></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">This item is not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<!-- Field: Page; Sequence: 50 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><PAGE></PAGE></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0"><B><A NAME="aph203237a008"></A>PART
II</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><A NAME="aph203237a009"></A><B>Item 5.
<I>Market for Registrant&rsquo;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</I></B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">Our common stock is traded
on the Nasdaq Capital Market under the symbol &ldquo;<B><I>TARA</I></B>&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>Holders of Our Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">As of March 11, 2021,
there were 11,228,606 shares of common stock outstanding held by approximately 25 stockholders of record. The actual number of
stockholders is greater than this number of record holders, and includes stockholders who are beneficial owners, whose shares
are held in street name by brokers and other nominees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0"><B>Dividend Policy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">We have never declared or
paid cash dividends on our Common Stock, and we do not expect to pay any cash dividends on our Common Stock in the foreseeable
future. Payment of future dividends, if any, on our Common Stock will be at the discretion of our Board of Directors after taking
into account various factors, including our financial condition, operating results, anticipated cash needs, and plans for expansion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>Securities Authorized for Issuance under Equity
Compensation Plans</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">See Item 12 of Part III
of this Annual Report on Form 10-K regarding information about securities authorized for issuance under our equity compensation
plans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>Recent Sales of Unregistered Securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">Other than as previously
disclosed in our past Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, we did not have any sales of unregistered
securities for the period covered by this Annual Report on Form 10-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><A NAME="aph203237a010"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
6. <I>Selected Financial Data.</I></B></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">Information requested by
this Item is not applicable as we are electing scaled disclosure requirements available to Smaller Reporting Companies with respect
to this Item.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 51 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><PAGE></PAGE></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><A NAME="aph203237a011"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
7. <I>Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations.</I></B></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0.25in"><I>You should read the
following discussion and analysis of our financial condition and results of operations together with our financial statements
and related notes appearing elsewhere in this report. Some of the information contained in this discussion and analysis or set
forth elsewhere in this report, including information with respect to our plans and strategy for our business and related financing,
includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors
set forth in the &ldquo;Risk Factors&rdquo; section of this document, our actual results could differ materially from the results
described in, or implied by, the forward-looking statements contained in the following discussion and analysis.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">We are a New York City based
clinical-stage biopharmaceutical company committed to identifying and advancing transformative therapies for the treatment of
cancer and rare diseases with significant unmet needs. We prioritize creativity, diverse perspectives, integrity and tenacity
to expedite our goal of bringing life-changing therapies to people with limited treatment options.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">Our portfolio includes
two development programs utilizing TARA-002, an investigational cell therapy based on the broad immunopotentiator, OK-432, which
was originally granted marketing approval by the Japanese Ministry of Health and Welfare as an immunopotentiating cancer therapeutic
agent. This cell therapy is currently approved in Japan for lymphatic malformations, or LMs, and multiple oncologic indications.
It has never been approved outside Japan and we have secured worldwide rights to the asset excluding Japan and Taiwan and have
begun to explore its use in rare and oncology indications. We are developing TARA-002 in non-muscle invasive bladder cancer, or
NMIBC, and in LMs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">TARA-002&rsquo;s
lead oncology program is in non-muscle invasive bladder cancer or NMIBC, which is cancer found in the tissue that lines the inner
surface of the bladder that has not spread into the bladder muscle. Bladder cancer is the sixth most common cancer in the United
States, with NMIBC representing approximately 80% of bladder cancer diagnoses. Approximately 65,000 patients are diagnosed with
NMIBC in the United States each year. Very few new therapeutics have been approved in NMIBC since the 1990s and the current standard
of care for NMIBC includes intravesical Bacillus Calmette-Guerin, or BCG. The mechanism of TARA-002 is similar to BCG. Both TARA-002
and BCG are intravesically administered and elicit a type Th1 type immune response and locally activated generally similar array
of cytokines and immune cells.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">In August of 2020,
we announced constructive feedback following a pre-Investigational New Drug (pre-IND) interaction with the Office of Tissues and
Advanced Therapies division of the Center for Biologics Evaluation and Research, or CBER, at the FDA on a development plan for
TARA-002 in NMIBC. Building on existing data from OK-432, and subject to the completion of non-clinical studies as well as acceptance
of the IND application, we plan to commence a Phase 1 clinical trial in late 2021 to assess the safety and tolerability of TARA-002
in patients with high grade NMIBC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">The most advanced
clinical program is for LMs, which are rare, non-malignant cysts of the lymphatic vascular system that primarily form in the head
and neck region of children before the age of two. In July 2020, the U.S. Food and Drug Administration, or FDA, granted Rare Pediatric
Disease designation for TARA-002 for the treatment of LMs. OK-432, the originator compound to TARA-002, has been the standard
of care in LMs in Japan for over 20 years. In addition to the clinical experience in Japan, we have secured the rights to a dataset
from one of the largest ever conducted Phase 2 studies in lymphatic malformations, in which OK-432 was administered via a compassionate
use program led by the University of Iowa to over 400 pediatric and adult patients. We have updated the initial IND that was submitted
by the University of Iowa and submitted the update and accompanying clarifying questions to the FDA Division of Vaccines and Related
Products Applications, or the Division, in connection with the IND for TARA-002 in LMs. We plan to utilize the robust dataset
for OK-432 in LMs to support the potential filing of a Biological License Application (BLA) for TARA-002 in lymphatic LMs. We
are encouraged by the progress to date and, at the FDA&rsquo;s request, have submitted the full Clinical Study Report (CSR) of
the randomized Phase 2 study of OK-432 in LMs led by the University of Iowa. We continue to prepare for a potential BLA filing
in the second half of 2021, or to initiate additional clinical work as required by FDA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">TARA-002 was developed from
the same master cell bank of genetically distinct group A Streptococcus pyogenes as OK-432 (marketed as Picibanil&reg; in Japan
and Taiwan by Chugai Pharmaceutical Co., Ltd., or Chugai Pharmaceutical). Following a pre-IND interaction with the Office of Tissues
and Advanced Therapies Division of the Center for Biologics Evaluation and Research, or CBER, the FDA agreed that we have successfully
demonstrated initial manufacturing comparability between TARA-002 and OK-432. This initial comparability will be confirmed by
GMP scale batches, which are currently underway using the same release tests that have already been approved by the FDA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 52 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><PAGE></PAGE></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">The third development program
in our portfolio is intravenous, or IV, Choline Chloride, an investigational phospholipid substrate replacement therapy initially
in development for patients receiving parenteral nutrition, or PN, who have intestinal failure associated liver disease, or IFALD.
IV Choline Chloride has been granted Orphan Drug Designation by the FDA for this indication and has also been granted Fast Track
Designation for the treatment of IFALD. Following a positive end of Phase 2 meeting with the FDA, we received feedback on the
design of the studies necessary to complete the registration package for IV Choline Chloride for the treatment of IFALD, including
a Phase 1 pharmacokinetic study followed by Phase 3 trial. Prior to initiating these clinical studies, we are currently undertaking
a prevalence study in partnership with a large home health organization in the United States to enhance understanding of the PN
patient population and we plan to use this information to determine the next steps for the development program. The goal of the
study is to understand the presence/incidence of liver disease in this patient population.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">Our fourth program, vonapanitase,
is a recombinant human elastase. We are reviewing the research and preclinical and clinical data of vonapanitase and have not
yet determined whether to pursue further development of this product candidate in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">We have devoted substantial
efforts to the development of these programs and do not have any approved products and have not generated any revenue from product
sales. TARA-002 is in later stage development for LMs and has not yet been approved for use for treatment of LMs, NMIBC or any
other indications. We do not expect to generate revenues prior to 2022, if ever. To finance our current strategic plans, including
the conduct of ongoing and future clinical trials and further research and development costs, we will need to raise additional
capital.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">Since inception, we have
incurred significant operating losses. As of December 31, 2020, we had an accumulated deficit of approximately $46.8 million.
We expect to continue to incur significant expenses and increasing operating losses for at least the next few years as we continue
our development of, and seek marketing approvals for, our product candidates, prepare for and begin the commercialization of any
approved products, and add infrastructure and personnel to support our product development efforts and operations as a public
company in the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">As a clinical-stage company,
our expenses and results of operations are likely to fluctuate significantly from quarter to quarter and year to year. We believe
that our period-to-period comparisons of our results of operations should not be relied upon as indicative of our future performance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">As of December 31, 2020,
we had approximately $168.6 million in cash and cash equivalents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>Merger</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">On January 9, 2020, Protara
Therapeutics, Inc. (formerly ArTara Therapeutics, Inc., formerly Proteon Therapeutics, Inc., the &ldquo;Company&rdquo;), completed
its previously announced merger transaction with ArTara Subsidiary, Inc. (formerly ArTara Therapeutics, Inc., &ldquo;Private ArTara&rdquo;)
in accordance with the terms of the Agreement and Plan of Merger and Reorganization, dated as of September 23, 2019, by and among
the Company, REM 1 Acquisition, Inc. (&ldquo;Merger Sub&rdquo;), and Private ArTara (as amended on November, 19, 2019, the &ldquo;Merger
Agreement&rdquo;), pursuant to which Merger Sub merged with and into Private ArTara, with Private ArTara surviving as a wholly
owned subsidiary of the Company (the &ldquo;Merger&rdquo;).The Merger was structured as a reverse merger and Private ArTara was
determined to be the accounting acquirer based on the terms of the Merger and other factors. Following the completion of the Merger,
the Company is focused on advancing Private ArTara&rsquo;s drug development programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">On January 9, 2020, in connection
with, and prior to the completion of, the Merger, the Company effected a 1-for-40 reverse stock split of its common stock (the
&ldquo;Reverse Stock Split&rdquo;), Private ArTara changed its name from &ldquo;ArTara Therapeutics, Inc.&rdquo; to &ldquo;ArTara
Subsidiary, Inc.&rdquo;, and the Company changed its name from &ldquo;Proteon Therapeutics, Inc.&rdquo; to &ldquo;ArTara Therapeutics,
Inc.&rdquo;. On May 11, 2020, the Company changed its name to Protara Therapeutics, Inc. In addition, immediately following the
closing of the Private Placement (defined below), all of the outstanding shares of the Company&rsquo;s Series A Preferred Stock
were converted into shares of the Company&rsquo;s common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">Under the terms of the Merger
Agreement, the Company issued shares of its common stock (&ldquo;Common Stock&rdquo;) to Private ArTara&rsquo;s stockholders,
at an exchange ratio of 0.190756 shares of Common Stock, after taking into account the Reverse Stock Split, for each share of
Private ArTara common stock outstanding immediately prior to the Merger. The Company assumed all of the outstanding and unexercised
stock options of Private ArTara, with such stock options now representing the right to purchase a number of shares of Common Stock
equal to 0.190756 multiplied by the number of shares of Private ArTara common stock previously represented by such Private ArTara
stock options. The Company also assumed all of the unvested Private ArTara restricted stock awards, which were exchanged for a
number of shares of Common Stock equal to 0.190756 multiplied by the number of shares of Private ArTara common stock previously
represented by such Private ArTara restricted stock awards and unvested to the same extent as such Private ArTara restricted stock
awards and subject to the same restrictions as such Private ArTara restricted stock awards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 53 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><PAGE></PAGE></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">The shares of Common Stock
issued to the former stockholders of Private ArTara were registered with the U.S. Securities and Exchange Commission (the &ldquo;SEC&rdquo;)
on a Registration Statement on Form S-4 (Reg. No. 333-234549) (the &ldquo;Registration Statement&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">The shares of Common Stock
listed on The Nasdaq Capital Market, previously trading through the close of business on Thursday, January 9, 2020 under the ticker
symbol &ldquo;PRTO,&rdquo; commenced trading on The Nasdaq Capital Market, on a post-Reverse Stock Split adjusted basis, under
the ticker symbol &ldquo;TARA,&rdquo; on Friday, January 10, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>COVID-19 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">The ultimate impact of the
current COVID-19 pandemic or a similar health epidemic is highly uncertain and subject to change. We have experienced delays,
but may experience additional future delays that impact our business, our research and development activities, healthcare systems
and the global economy as a whole. However, we will continue to monitor the COVID-19 situation closely should the effects have
a material impact on our operations, liquidity and capital resources.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">In response to public health
directives and orders, we have implemented work-from-home policies for our employees and temporarily modified our operations to
comply with applicable social distancing recommendations. Similar health directives and orders are affecting third parties with
whom we do business, including the third parties that we have contracted with to conduct studies for TARA-002. The effects of
the orders and our related adjustments in our business are likely to negatively impact productivity, disrupt our business and
delay our timelines, the magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations
on our ability to conduct our business in the ordinary course.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">Severe and/or long-term
disruptions in our operations will negatively impact our business, operating results and financial condition in other ways, as
well. Specifically, we anticipate that the stress of COVID-19 on healthcare systems around the globe will negatively impact our
ability to conduct clinical trials in the near term due primarily to the lack of resources at clinical trial sites and the resulting
inability to enroll patients in the trials. We also anticipate that the global impact of COVID-19 will negatively impact our ability
to conduct nonclinical studies due primarily to laboratory closures and limited availability of personnel. In addition, while
the potential economic impact brought by, and the duration of, COVID-19 may be difficult to assess or predict, it has significantly
disrupted global financial markets, and may limit our ability to access capital, which could in the future negatively affect our
liquidity. A recession or market correction resulting from the spread of COVID-19 could materially affect our business and the
value of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 54 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><PAGE></PAGE></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>Financial Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>Research and Development Expenses</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">Research and development
expenses consist primarily of costs incurred for the development of TARA-002 and IV Choline Chloride, which include employee-related
expenses, including salaries, benefits, travel and stock-based compensation expense, expenses incurred under agreements with clinical
research organizations (&ldquo;CROs&rdquo;), contract development and manufacturing organizations (&ldquo;CDMOs&rdquo;), the cost
of acquiring, developing and manufacturing clinical trial materials, clinical and non-clinical related costs, costs associated
with regulatory operations and facilities, depreciation and other expenses, which include expenses for rent and maintenance of
facilities and other supplies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>General and Administrative Expenses</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">General and administrative
expenses consist principally of employee-related expenses, including salaries, benefits, travel and stock-based compensation expense,
in executive and other administrative functions. Other general and administrative expenses also include professional fees for
legal, patent review, consulting and accounting services as well as facility related costs, as well as expenses related to audit,
legal, regulatory and tax-related services associated with maintaining compliance with our NASDAQ listing and SEC requirements,
director and officer liability insurance premiums and investor relations costs associated with being a public company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>Interest Income, Net</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="text-indent: 0.25in; text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0">Interest income, net, consists
of interest income earned on our cash, cash equivalents and restricted cash, net of interest expense related to our short-term
debt.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Critical Accounting Policies and Significant Judgments and Estimates</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">Management&rsquo;s discussion
and analysis of our financial position and results of operations is based on our consolidated financial statements, which have
been prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP. The preparation
of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the amounts reported
in the financial statements and accompanying notes. On an ongoing basis, we evaluate estimates, which include estimates related
to clinical trial accruals, valuation of deferred tax assets, fair value of business combinations, fair value of goodwill and
evaluation of impairment, stock stock-based compensation expense, and reported amounts of revenues and expenses during the reported
period. We base our estimates on historical experience and other market-specific or other relevant assumptions that we believe
to be reasonable under the circumstances. Actual results may differ materially from those estimates or assumptions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">While our significant accounting
policies are described in more detail in the notes to our consolidated financial statements and related notes appearing elsewhere
in this Annual Report, we believe the following accounting policies to be most critical to the judgments and estimates used in
the preparation of our financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>Goodwill</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">Goodwill represents the
excess of purchase price over the fair value of identifiable net assets acquired in a business combination. Goodwill and other
intangible assets acquired in a business combination and determined to have an indefinite useful life are not amortized, but instead
tested for impairment at least annually. An entity has the option to first assess qualitative factors to determine whether events
or circumstances lead to a conclusion that is more likely than not that the fair value of a reporting unit is greater than its
carrying amount. If an entity determines that qualitative factors indicate that it is more likely than not that the fair value
of the entity exceeds the carrying amount, the quantitative evaluation is not necessary. Under the quantitative impairment test,
the evaluation of impairment involves comparing the current fair value of each reporting unit to its carrying value, including
goodwill.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">In the event the estimated
fair value of our company is less than the carrying value, we would recognize a goodwill impairment equal to the difference between
the carrying value and its fair value, not to exceed the carrying value of goodwill.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>Income Taxes</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">Deferred tax assets and
liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement
carrying amounts of existing assets and liabilities and their respective tax basis, operating loss and tax credit carryforwards.
Deferred tax assets and liabilities are measured using enacted tax rates in effect for the year in which those temporary differences
are expected to be recovered or settled. The measurement of net deferred tax assets is reduced by the amount of any tax benefit
that, based on available evidence, is not expected to be realized, and a corresponding valuation allowance is established.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 55 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><PAGE></PAGE></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">Tax benefits are recognized
only for tax positions that are more likely than not to be sustained upon examination by tax authorities. The amount recognized
is measured as the largest amount of benefit that is greater than 50 percent likely to be realized upon settlement. A liability
for &ldquo;unrecognized tax benefits&rdquo; is recorded for any tax benefits claimed in our tax returns that do not meet these
recognition and measurement standards. As of December 31, 2020 and 2019, no liability for unrecognized tax benefits was required
to be recorded. The guidance also discusses the classification of related interest and penalties on income taxes. Our policy is
to record interest and penalties on uncertain tax positions as a component of income tax expense. No interest or penalties were
recorded during the years ended December 31, 2020 and 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>Business Combinations</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">For a business combination,
the assets acquired and the liabilities assumed are recognized at the acquisition date, measured at their fair values as of that
date. In a business combination achieved in stages, the identifiable assets and liabilities are recognized at their fair values.
In a bargain purchase in which the total acquisition-date fair value of the identifiable net assets acquired exceeds the fair
value of the consideration transferred plus any non-controlling interest in the acquiree, that excess in fair value is recognized
as a gain.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">Deferred tax liabilities
and assets are recognized for the deferred tax consequences of differences between the tax bases and the recognized values of
assets acquired and liabilities assumed in a business combination in accordance with ASC Topic 740-10 &ldquo;Income Taxes&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>Stock-Based Compensation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">We issue stock-based awards
to employees and non-employees. We account for our stock-based awards in accordance with FASB ASC Topic 718, Compensation&mdash;Stock
Compensation, (&ldquo;ASC 718&rdquo;). ASC 718 requires all stock-based payments to employees, including grants of employee stock
options and modifications to existing stock options, to be recognized in the consolidated statements of operations and comprehensive
loss based on their fair values. We account for stock-based awards to non-employees in accordance with ASC 718, which requires
the fair value of the award to be remeasured at fair value as the award vests.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">Our stock-based awards are
subject to service-based vesting conditions. Compensation expense related to awards to employees and directors with service-based
vesting conditions is recognized on a straight-line basis based on the grant date fair value over the associated service period
of the award, which is generally the vesting term. Compensation expense related to awards to non-employees with service-based
vesting conditions is recognized on the then-current fair value at each financial reporting date prior to the measurement date
over the associated service period of the award, which is generally the vesting term, using the accelerated attribution method.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">Described below is the methodology
we have utilized in measuring stock-based compensation expense. Following the consummation of the Merger, stock option values
have been determined based on the quoted market price of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">We estimate the fair value
of our stock-based awards to employees and non-employees using the Black-Scholes option pricing model, which requires the input
of highly subjective assumptions, including (i) the expected volatility of our stock, (ii) the expected term of the award, (iii)
the risk-free interest rate and (iv) expected dividends. We calculate the expected volatility using the historical volatility
for a pool of peer companies over the most recent period equal to the expected term and evaluate the extent to which available
information indicate that future volatility may differ from historical volatility. For these analyses, we select companies with
comparable characteristics to ours including enterprise value, risk profiles, position within the industry, and with historical
share price information sufficient to meet the expected life of the stock-based awards. We compute the historical volatility data
using the daily closing prices for the selected companies&rsquo; shares during the equivalent period of the calculated expected
term of our stock-based awards. We account for forfeitures as they occur. We estimate the expected life of our employee stock
options using the &ldquo;simplified&rdquo; method, whereby, the expected life equals the average of the vesting term and the original
contractual term of the option. The risk-free interest rates for periods within the expected life of the option were based on
the U.S. Treasury yield curve in effect during the period the options were granted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 56 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><PAGE></PAGE></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>Results of Operations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>Comparison of the Years Ended December
31, 2020 and 2019</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">The following table summarizes
our results of operations for the years ended December 31, 2020 and 2019 (in thousands):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year
    Ended December 31,</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" ROWSPAN="2" STYLE="border-bottom: black 1.5pt solid; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Period-to-Period
    <BR>
    Change</FONT></TD>
    <TD>&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2019</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating expenses:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; padding-left: 0.15in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
    and development</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,982</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,878</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,104</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.15in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General and administrative</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22,462</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,952</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18,510</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total operating expenses</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">34,444</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,830</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">26,614</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.15in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss from operations</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(34,444</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7,830</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(26,614</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other income, net:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.15in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest income,
    net</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(466</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ndash;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(466</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.15in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total other income,
    net</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(466</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ndash;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(466</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net Loss</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 4pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(33,978</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 4pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7,830</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 4pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(26,148</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in"><I>Research and Development
Expenses</I>. During the year ended December 31, 2020, our research and development expenses were approximately $12.0 million
which represented an increase of approximately $8.1 million as compared to the year ended December 31, 2019. This increase was
primarily due to an increase of approximately $3.2 million of non-clinical, clinical, regulatory expenses and outside services
associated with TARA-002, an increase of approximately $2.5 million for manufacturing activities associated with TARA-002, an
increase of approximately $1.5 million in headcount cost due to bonuses earned upon the merger and the hiring of additional employees
and an increase of approximately $0.5 million in stock-based compensation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in"><I>General and Administrative
Expenses</I>. During the year ended December 31, 2020, our general and administrative expenses were approximately $22.5 million
which represented an increase of approximately $18.5 million as compared to the year ended December 31, 2019. The increase, principally
on account of becoming a public company on January 9, 2020, was primarily due to an increase of approximately $8.8 million in
stock-based compensation, an increase of approximately $2.5 million in insurance, an increase of approximately $2.0 million in
public company costs, an increase of approximately $2.8 million in headcount cost due to bonuses earned upon the merger and the
hiring of additional employees, an increase of approximately $1.2 million in recruiting fees, an increase of approximately $0.3
million in board of director fees, and an increase of approximately $0.2 million in franchise and other taxes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in"><I>Interest Income, Net</I>.
During the year ended December 31, 2020, interest income, net was approximately $0.5 million higher as compared to the year ended
December 31, 2019. The increase was primarily due to us earning interest on the funds received in the Private Placements and Underwritten
Offerings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>Liquidity and Capital Resources</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>Overview</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">As of December 31,
2020 and 2019, our cash and cash equivalents was approximately $168.6 million and $0.6 million, respectively. We have not generated
revenues since our inception and have incurred net losses of approximately $34.0 million and $7.8 million for the years ended
December 31, 2020 and 2019, respectively. As of December 31, 2020, we had working capital of approximately $166.5 million and
stockholder&rsquo;s equity of approximately $199.2 million. During the year ended December 31, 2020, cash flows used in operating
activities were approximately $23.4 million, consisting primarily of a net loss of approximately $34.0 million, which includes
non-cash stock-based compensation charges of approximately $9.7 million. Since inception, we have met our liquidity requirements
principally through the sale of our common stock and preferred stock in private placements and underwritten offerings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in"></P>


<!-- Field: Page; Sequence: 57 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><PAGE></PAGE></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>Liquidity</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">In connection with the Merger,
we consummated the Private Placements, raising gross proceeds of approximately $42.5 million. Upon the consummation of the Merger
and the Private Placements, the post-merger combined company was expected to have cash of approximately $39.6 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">Concurrently with the execution
of the Merger Agreement, certain institutional investors (together, the &ldquo;Investors&rdquo;) entered into a subscription agreement
(as amended on November 19, 2019, the &ldquo;Subscription Agreement&rdquo;) with Protara Therapeutics, Inc. and Private ArTara,
pursuant to which (A) Protara Therapeutics, Inc. issued, in a private placement immediately after the Merger (the &ldquo;Proteon
Private Placement&rdquo;), (i) 3,879.356 of shares of Protara Therapeutics, Inc.&rsquo;s Series 1 Convertible Non-Voting Preferred
Stock (&ldquo;Series 1 Preferred Stock&rdquo;) at a purchase price of approximately $7,011.47 per share for gross proceeds of
$27.2 million and proceeds, net of issuance costs, of $25.3 million, (ii) 1,896,888 shares of Protara Therapeutics, Inc.&rsquo;s
Common Stock at a purchase price of approximately $7.01 per share for gross proceeds of $13.3 million and proceeds, net of issuance
costs, of $12.4 million and (B) Private ArTara issued, in a private placement immediately prior to the Merger (the &ldquo;ArTara
Private Placement&rdquo;), 284,875 shares of Private ArTara common stock (post-Exchange Ratio (as defined in the Merger Agreement)
basis) at a purchase price of approximately $7.01 per share (post-Exchange Ratio basis) (together with the Proteon Private Placement,
the &ldquo;Private Placements&rdquo;) for gross proceeds of $2.0 million and proceeds, net of issuance costs, of $1.9 million.
The shares issued in the Proteon Private Placement were registered for resale on a registration statement on Form S-3 filed and
declared effective by the U.S. Securities and Exchange Commission (the &ldquo;SEC&rdquo;) on February 10, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">In connection with the Preferred
Offering on September 22, 2020, we filed a Certificate of Amendment to the Certificate of Designation of Preferences, Rights and
Limitations of Series 1 Convertible Non-Voting Preferred Stock of ours (the &ldquo;Amendment&rdquo;) with the Secretary of State
of the State of Delaware to increase the authorized number of shares of our Series 1 Convertible Preferred Stock that may be issued
from 3,880 to 8,028.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">On September 24, 2020, pursuant
to an underwriting agreement, dated September 22, 2020, we issued and sold in an underwritten public offering (the &ldquo;Common
Offering&rdquo;) an aggregate of 4,600,000 shares of our common stock at an offering price of $16.87 per share, for gross and
net proceeds of approximately $77.6 million and $73.6 million, respectively. The underwriters were granted an option to purchase
up to 690,000 additional shares of common stock at the public offering price, less the underwriting discount. This option was
exercisable for a period of 30 days. On October 6, 2020, the underwriters exercised their overallotment option in full, purchasing
an additional 690,000 shares, resulting in the receipt of gross and net proceeds of approximately $11.6 million and $11.1 million,
respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">On September 24, 2020, pursuant
to an underwriting agreement, dated September 22, 2020, we issued and sold in an underwritten public offering (the &ldquo;Preferred
Offering&rdquo;) an aggregate of 4,148 shares of our Series 1 Preferred Stock at an offering price of $16,873.54 per share, for
gross and net proceeds of approximately $70.0 million and $66.3 million, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">The Common Offering and
the Preferred Offering were made pursuant to our registration statement on Form S-3, declared effective by the Securities and
Exchange Commission on May 26, 2020 (Registration No. 333-238273).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">In December 2020, we filed
a shelf registration statement on Form S-3, or the Shelf Registration Statement, which became effective in December 2020. The
Shelf Registration Statement permits: (i) the offering, issuance and sale by us of up to a maximum aggregate offering price of
$300.0 million of common stock, preferred stock, debt securities and warrants in one or more offerings and in any combination.
No securities have been sold to date under the Shelf Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">We are in the business of
developing biopharmaceuticals and have no current or near term revenues. We have incurred substantial clinical and other costs
in our drug development efforts. We will need to raise additional capital in order to fully realize management&rsquo;s plans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">We believe that our current
financial resources, as of the date of the issuance of these condensed consolidated financial statements, are sufficient to satisfy
our estimated liquidity needs for at least twelve months from the issuance of these condensed consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">As a result of economic
conditions, general global economic uncertainty, political change, global pandemics, and other factors, we do not know whether
additional capital will be available when needed, or that, if available, we will be able to obtain additional capital on reasonable
terms. If we are unable to raise additional capital due to the volatile global financial markets, general economic uncertainty
or other factors, we may need to curtail planned development activities. Specifically, the COVID-19 pandemic has significantly
disrupted global financial markets, and may limit our ability to access capital, which could in the future negatively affect our
liquidity. A recession or market correction resulting from the spread of COVID-19 could materially affect our business and the
value of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 58 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><PAGE></PAGE></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>Cash Flows</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">The following table summarizes
our sources and uses of cash for the years ended December 31, 2020 and 2019 (in thousands):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD><B>&nbsp;</B></TD>
    <TD><B>&nbsp;</B></TD>
    <TD COLSPAN="6" STYLE="border-bottom: black 1.5pt solid; text-align: center"><B>Years Ended December 31,</B></TD>
    <TD><B>&nbsp;</B></TD>
    <TD><B>&nbsp;</B></TD>
    <TD COLSPAN="2" ROWSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1.5pt solid; text-align: center"><B>Period-to-Period<BR>
    Change</B></TD>
    <TD><B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><B>&nbsp;</B></TD>
    <TD><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><B>2020</B></TD>
    <TD><B>&nbsp;</B></TD>
    <TD><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><B>2019</B></TD>
    <TD><B>&nbsp;</B></TD>
    <TD><B>&nbsp;</B></TD>
        <TD><B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: left">Net cash used in operating activities</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(23,407</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(5,011</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(18,396</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Net cash provided by/(used in) investing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,835</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(475</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,310</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Net cash provided by financing activities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">189,401</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">500</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">188,901</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Net increase/(decrease) in cash and cash equivalents, and restricted cash</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">168,829</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(4,986</TD><TD STYLE="padding-bottom: 3pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">173,815</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>Comparison of the Years Ended December
31, 2020 and 2019</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 13.5pt">Net cash used in operating
activities was approximately $23.4 million for the year ended December 31, 2020 compared to approximately $5.0 million for the
year ended December 31, 2019. The increase of approximately $18.4 million in cash used in operating activities was primarily driven
by an increase net loss of approximately $26.1 million and a decrease in accrued expenses of approximately $3.0 million, off-set
by increases of approximately $9.3 million of stock-based compensation and approximately $1.4 million in prepaid expenses and
other current assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 13.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 13.5pt">Net cash provided by investing
activities was approximately $2.8 million for the year ended December 31, 2020 compared to net cash used in investing activities
of approximately $0.5 million in the year ended December 31, 2019. The increase of approximately $3.3 million was primarily due
to the cash and restricted cash acquired in connection with the Merger with Protara Therapeutics, Inc. of approximately $3.7 million,
off-set by an increase in purchases of property and equipment of approximately $0.4 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 13.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 13.5pt">Net cash provided by financing
activities was approximately $189.4 million for the year ended December 31, 2020 compared to approximately $0.5 million for the
year ended December 31, 2019. The increase of approximately $188.9 million was primarily due to proceeds, net of offering costs,
from the Common Offering of approximately $73.6 million, the Preferred Offering of approximately $66.3 million, the issuance of
Series 1 Preferred Stock of approximately $25.3 million, the Proteon Private Placement of approximately $12.4 million, the underwriters
overallotment option of approximately $11.1 million, and the ArTara Private Placement of approximately $1.9 million, offset by
repayments of short-term debt of approximately $1.7 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>Off-Balance Sheet Arrangements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">We did not have, during
the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined under the applicable regulations
of the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>Contractual Obligations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0.25in">Our future contractual
obligations as of December 31, 2020 are (in thousands):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="18" STYLE="border-bottom: Black 1.5pt solid; text-align: center">Payments due by period</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center">Total</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center">Less than <BR>
    1 year</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center">1-3 years</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center">3-5 years</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center">More than <BR>
    5 years</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 33%; text-align: left; padding-left: 5.4pt">Operating Lease Obligations</TD>
    <TD STYLE="width: 9%">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">9,824</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">1,111</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">2,671</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">2,765</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">3,277</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><A NAME="aph203237a012"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
7A. <I>Quantitative and Qualitative Disclosures About Market Risk</I></B></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">No disclosure required.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 59 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><PAGE></PAGE></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><A NAME="aph203237a013"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
8. <I>Financial Statements and Supplementary Data.</I></B></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">The consolidated financial
statements required pursuant to this item are included in Item 15 of this report and are presented beginning on page 60.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><A NAME="aph203237a014"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
9. <I>Changes in and Disagreements With Accountants on Accounting and Financial Disclosure.</I></B></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><A NAME="aph203237a015"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
9A. Controls and Procedures.</B></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><I>Disclosure Controls and Procedures</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">We maintain disclosure controls
and procedures (as defined in Rules 13a-15(e) or 15d-15(e) under the Exchange Act) that are designed to ensure that information
required to be disclosed in the reports that we file or submit under the Exchange Act is (1) recorded, processed, summarized,
and reported within the time periods specified in the SEC&rsquo;s rules and forms and (2) accumulated and communicated to our
management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions
regarding required disclosure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">As of December 31, 2020,
our management, with the participation of our principal executive officer and principal financial officer, evaluated the effectiveness
of our disclosure controls and procedures as of the end of the period covered by this Annual Report on Form 10-K. Our management
recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of
achieving their objectives, and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible
controls and procedures. Our principal executive officer and principal financial officer have concluded based upon the evaluation
described above that, as of December 31, 2020, our disclosure controls and procedures were effective at the reasonable assurance
level.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">We continue to review and
document our disclosure controls and procedures, including our internal controls and procedures for financial reporting, and may
from time to time make changes aimed at enhancing their effectiveness and to ensure that our systems evolve with our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><I>Management&rsquo;s Report on Internal Control
Over Financial Reporting</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">Our management is responsible
for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting
is a process designed under the supervision and with the participation of our management, including our Chief Executive Officer
and Chief Financial Officer, to provide reasonable assurance regarding the reliability of financial reporting and the preparation
of financial statements for external purposes in accordance with accounting principles generally accepted in the United States
of America.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">As of December 31, 2020,
our management assessed the effectiveness of our internal control over financial reporting using the criteria set forth by the
Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control-Integrated Framework (2017). Based
on this assessment, management, under the supervision and with the participation of our Chief Executive Officer and Chief Financial
Officer, concluded that, as of December 31, 2020, our internal control over financial reporting was effective based on those criteria.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><I>Changes in Internal Control Over Financial
Reporting</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">An evaluation was performed
under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial
Officer, of any changes in our internal control over financial reporting that occurred during our last fiscal quarter that has
materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. That evaluation
did not identify any change in our internal control over financial reporting, as such term is defined in Rules 13a-15(f) and 15(d)-15(f)
promulgated under the Securities Exchange Act of 1934, that occurred during our latest fiscal quarter and that has materially
affected, or is reasonably likely to materially affect, our internal control over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><A NAME="aph203237a016"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
9B. <I>Other Information</I></B></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in">None.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 60 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><PAGE></PAGE></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="aph203237a017"></A><B>PART III</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><A NAME="aph203237a018"></A><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Item 10.</B></FONT> <FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Directors, Executive Officers and Corporate Governance.</I></B></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">The information required by this Item and not set forth below
will be set forth in the section headed &ldquo;&mdash;Election of Directors&rdquo; and &ldquo;Information Regarding the Board of
Directors and Corporate Governance&rdquo; in our definitive Proxy Statement for our 2021 Annual Meeting of Stockholders to be filed
with the SEC on or before April 30, 2021 (our &ldquo;<B><I>Proxy Statement</I></B>&rdquo;) and is incorporated in this report by
reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">We have adopted a
code of ethics for directors, officers (including our principal executive officer, principal financial officer and principal accounting
officer) and employees, known as the Code of Business Conduct and Ethics. The Code of Business Conduct and Ethics is available
on our website at <I>http://www.protaratx.com</I> under the Corporate Governance section of our Investors page. We will promptly
disclose on our website (i) the nature of any amendment to the policy that applies to our principal executive officer, principal
financial officer, principal accounting officer or controller, or persons performing similar functions and (ii) the nature of any
waiver, including an implicit waiver, from a provision of the policy that is granted to one of these specified individuals, the
name of such person who is granted the waiver and the date of the waiver. Stockholders may request a free copy of the Code of Business
Conduct and Ethics by emailing the Company at info@protaratx.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt"><A NAME="aph203237a019"></A><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Item 11.</B></FONT> <FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Executive Compensation.</I></B></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">The information required
by this Item will be set forth in the section headed &ldquo;<I>Executive Compensation</I>&rdquo; in our Proxy Statement and is
incorporated in this report by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt"><A NAME="aph203237a020"></A><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Item 12.</B></FONT> <FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.</I></B></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">The information required
by this Item will be set forth in the section headed &ldquo;<I>Security Ownership of Certain Beneficial Owners and Management</I>&rdquo;
in our Proxy Statement and is incorporated in this report by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">Information regarding
our equity compensation plans will be set forth in the section headed &ldquo;<I>Executive Compensation</I>&rdquo; in our Proxy
Statement and is incorporated in this report by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt"><A NAME="aph203237a021"></A><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Item 13.</B></FONT> <FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Certain Relationships and Related Transactions, and Director Independence.</I></B></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">The information required
by this Item will be set forth in the section headed &ldquo;<I>Transactions With Related Persons</I>&rdquo; in our Proxy Statement
and is incorporated in this report by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt"><A NAME="aph203237a022"></A><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Item 14.</B></FONT> <FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Principal Accountant Fees and Services.</I></B></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">The information required
by this Item will be set forth in the section headed <I>&ldquo;&mdash;Ratification of Selection of Independent Registered Public
Accounting Firm&rdquo;</I> in our Proxy Statement and is incorporated in this report by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 61 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><PAGE></PAGE></TD></TR></TABLE></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="aph203237a023"></A><B>PART IV</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt"><A NAME="aph203237a024"></A><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Item 15.</B></FONT> <FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Exhibits and Financial Statement Schedules.</I></B></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><I>(a) Documents filed
as part of this report.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">1. The following financial
statements of Protara Therapeutics, Inc. and Report of Marcum LLP, Independent Registered Public Accounting Firm, are included
in this report:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 91%">&nbsp;</TD>
    <TD STYLE="width: 9%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: black 1.5pt solid"><B>Page&nbsp;Number</B></P>

</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#aph203237b001">Report of Independent Registered Public Accounting Firm</A></TD>
    <TD STYLE="text-align: center">F-2</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#aph203237b002">Consolidated Balance Sheets</A></TD>
    <TD STYLE="text-align: center">F-3</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#aph203237b003">Consolidated Statements of Operations</A></TD>
    <TD STYLE="text-align: center">F-4</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#aph203237b004">Consolidated Statements of Changes in Stockholders&rsquo; Equity (Deficit)</A></TD>
    <TD STYLE="text-align: center">F-5</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#aph203237b005">Consolidated Statements of Cash Flows</A></TD>
    <TD STYLE="text-align: center">F-6</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#aph203237b006">Notes to Consolidated Financial Statements</A></TD>
    <TD STYLE="text-align: center">F-7</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">2. List of financial
statement schedules:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">All schedules have
been omitted because they are not applicable or the required information is shown in the financial statements or notes thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">3. List of Exhibits
required by Item 601 of Regulation S-K. See part (b) below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><I>(b) Exhibits.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; width: 9%; vertical-align: bottom"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 0.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit
                                         No.</FONT></P></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left; width: 1%; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; padding-bottom: 1pt; text-align: left; width: 90%; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
    Description</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1359931/000104746919005409/a2239754zex-2_1.htm">Agreement
    and Plan of Merger and Reorganization, dated September 23, 2019, by and among the Registrant, ArTara Therapeutics, Inc. and
    REM 1 Acquisition, Inc. (filed as Exhibit 2.1 to the Registrant&rsquo;s Current Report on Form 8-K as filed on September 24,
    2019, and incorporated herein by reference).</A></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1359931/000104746919006649/a2240114zex-2_2.htm">Amendment
    No. 1 to Agreement and Plan of Merger and Reorganization, dated November 19, 2019, by and among the Registrant, ArTara Therapeutics,
    Inc. and REM 1 Acquisition, Inc. (filed as Exhibit 2.2 to the Registrant&rsquo;s Registration Statement on Amendment No. 2
    to Form S-4 as filed on December 4, 2019, and incorporated herein by reference).</A></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1359931/000110465914074038/a14-15225_12ex3d1.htm">Sixth
    Amended and Restated Certificate of Incorporation of the Company (incorporated by reference to Exhibit 3.1 to the Company&rsquo;s
    Current Report on Form 8-K filed on October 27, 2014).</A></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1359931/000110465920003115/tm201618d1_ex3-1.htm">Certificate
    of Amendment to the Sixth Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the
    Registrant&rsquo;s Current Report on Form 8-K, filed with the SEC on January 10, 2020).</A></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1359931/000121390020011893/f10q0320ex3-3_artara.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Second Certificate of Amendment to the Sixth Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.3 to the Registrant&rsquo;s Quarterly Report on Form 10-Q, filed with the SEC on May 13, 2020).</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1359931/000110465920003115/tm201618d1_ex3-2.htm">Certificate
    of Designation of Preferences, Rights and Limitations of Series 1 Convertible Preferred Stock (incorporated by reference to
    Exhibit 3.2 to the Registrant&rsquo;s Current Report on Form 8-K, filed with the SEC on January 10, 2020).</A></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.5</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1359931/000121390020027951/ea127215ex3-1_protara.htm">Certificate
    of Amendment to the Certificate of Designation of Preferences, Rights and Limitations of Series 1 Convertible Non-Voting Preferred
    Stock (incorporated by reference to Exhibit 3.1 to the Registrant&rsquo;s Current Report on Form 8-K, filed with the SEC on
    September 23, 2020).</A></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.6</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1359931/000117184317004634/exh_32.htm">Second
    Amended and Restated Bylaws (incorporated by reference to Exhibit 3.2 of Current Report on Form 8-K, filed on August 3, 2017).</A></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1359931/000110465920003115/tm201618d1_ex4-1.htm">Form
    of Common Stock Certificate (incorporated by reference to Exhibit 4.1 to the Registrant&rsquo;s Current Report on Form 8-K,
    filed with the SEC on January 10, 2020).</A></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2+</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="f10k2020ex4-2_protara.htm">Description of securities registered under Section 12 of the Exchange Act of 1934</A></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1359931/000104746919005409/a2239754zex-10_5.htm">Registration
    Rights Agreement, dated as of September 23, 2019, by and among the Registrant and the institutional investors named therein
    (incorporated by reference to Exhibit 10.5 to the Registrant&rsquo;s Current Report on Form 8-K, filed with the SEC on September
    24, 2019).</A></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1&dagger;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1359931/000104746914008146/a2221509zex-10_1.htm">2006
    Equity Incentive Plan, as amended and restated August 21, 2014 (incorporated by reference to Exhibit 10.1 to Amendment No.
    1 to the Company&rsquo;s Registration Statement on Form S-1 filed on October 7, 2014 (File No. 333-198777)).</A></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2&dagger;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1359931/000104746914007662/a2221427zex-10_16.htm">Form
    of Stock Option Grant Notice and Stock Option Agreement under the Company&rsquo;s 2006 Equity Incentive Plan, as amended (incorporated
    by reference to Exhibit 10.16 to the Company&rsquo;s Registration Statement on Form S-1 filed on September 16, 2014).</A></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
<!-- Field: Page; Sequence: 62 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><PAGE></PAGE></TD></TR></TABLE></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="width: 9%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 90%"><A HREF="http://www.sec.gov/Archives/edgar/data/1359931/000104746914007662/a2221427zex-10_11.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assignment of Rights/License Agreement, effective as of February 4, 2002, by and between Johns Hopkins University and F. Nicholas Franano (incorporated by reference to Exhibit 10.11 to the Company&rsquo;s Registration Statement on Form S-1 filed on September 16, 2014).</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1359931/000104746914007662/a2221427zex-10_14.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Letter Agreement, dated January 12, 2009, by and between F. Nicholas Franano and the Company (as successor-in-interest to Proteon Therapeutics, L.L.C.) (incorporated by reference to Exhibit 10.14 to the Company&rsquo;s Registration Statement on Form S-1 filed on September 16, 2014).</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5&dagger;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1359931/000104746914008146/a2221509zex-10_25.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2014 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.25 to Amendment No. 1 to the Company&rsquo;s Registration Statement on Form S-1 filed on October 7, 2014).</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6**</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1359931/000104746919005409/a2239754zex-10_4.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subscription Agreement, dated September 23, 2019, by and among the Registrant and the institutional investors named therein (incorporated by reference to Exhibit 10.4 to the Registrant&rsquo;s Current Report on Form 8-K, filed with the SEC on September 24, 2019).</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7**</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1359931/000104746919006649/a2240114zex-99_12.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">First Amendment to Subscription Agreement, dated November 19, 2019, by and among the Registrant and the institutional investors named therein (incorporated by reference to Exhibit 99.12 to the Registrant&rsquo;s Registration Statement on Form S-4).</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8&dagger;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1359931/000110465920003115/tm201618d1_ex10-1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated 2014 Equity Incentive Plan of the Registrant (incorporated by reference to Exhibit 10.1 to the Registrant&rsquo;s Current Report on Form 8-K, filed on January 10, 2020).</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9&dagger;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1359931/000117184320001860/exh_1025.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forms of Stock Option Agreement, Option Exercise, Restricted Stock Unit Grant and Restricted Stock Unit Agreement under the Amended and Restated 2014 Equity Incentive Plan of the Registrant, as amended (incorporated by reference to Exhibit 10.25 to the Registrant&rsquo;s Annual Report on form 10-K on form 10-K for the fiscal year ended December 31, 2019 filed on March 20, 2020).</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10&dagger;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1359931/000110465920003115/tm201618d1_ex10-11.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2017 Equity Incentive Plan of ArTara Subsidiary, Inc. (incorporated by reference to Exhibit 10.11 to the Registrant&rsquo;s Current Report on Form 8-K, filed with the SEC on January 10, 2020).</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11&dagger;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1359931/000121390020008073/ea120117ex10-1_artaratherap.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inducement Plan of the Registrant (incorporated by reference to Exhibit 10.1 to the Registrant&rsquo;s Current Report on Form 8-K, filed with the SEC on March 30, 2020).</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12&dagger;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1359931/000121390020008073/ea120117ex10-2_artaratherap.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Stock Option Grant Notice and Stock Option Agreement under the Inducement Plan of the Registrant (incorporated by reference to Exhibit 10.2 to the Registrant&rsquo;s Current Report on Form 8-K, filed with the SEC on March 30, 2020).</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.13&dagger;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1359931/000121390020008073/ea120117ex10-3_artaratherap.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forms of Restricted Stock Unit Grant Notice and Restricted Stock Unit Agreement under the Inducement Plan of the Registrant (incorporated by reference to Exhibit 10.3 to the Registrant&rsquo;s Current Report on Form 8-K, filed with the SEC on March 30, 2020).</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.14&dagger;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1359931/000110465920003115/tm201618d1_ex10-2.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive Employment Agreement, dated as of November 5, 2019, as amended on December 4, 2019, by and between ArTara Subsidiary, Inc. and Jesse Shefferman. (incorporated by reference to Exhibit 10.2 to the Registrant&rsquo;s Current Report on Form 8-K, filed with the SEC on January 10, 2020).</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.15&dagger;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1359931/000110465920003115/tm201618d1_ex10-3.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive Employment Agreement, dated as of December 17, 2019, by and between ArTara Subsidiary, Inc. and Jacqueline Zummo, Ph.D., MPH, MBA. (incorporated by reference to Exhibit 10.3 to the Registrant&rsquo;s Current Report on Form 8-K, filed with the SEC on January 10, 2020).</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.16&dagger;^</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1359931/000121390020019642/f10q0620ex10-2_protara.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Separation Agreement and Release, dated as of July 23, 2020, by and between the Registrant and Julio Casoy (incorporated by reference to Exhibit 10.2 to the Registrant&rsquo;s Quarterly Report on Form 10-Q, filed with the SEC on July 31, 2020).</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.17&dagger;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1359931/000117184320001860/exh_1030.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive Employment Agreement, effective as of February 11, 2020 by and between the Registrant and Blaine Davis (incorporated by reference to Exhibit 10.30 to the Registrant&rsquo;s Annual Report on Form 10-K, filed with the SEC on March 19, 2020).</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.18&dagger;&dagger;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1359931/000110465920003115/tm201618d1_ex10-4.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Choline License Agreement, by and between ArTara Subsidiary, Inc. and Alan L. Buchman, M.D. dated as of September 27, 2017. (incorporated by reference to Exhibit 10.4 to the Registrant&rsquo;s Current Report on Form 8-K, filed with the SEC on January 10, 2020).</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.19&dagger;&dagger;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1359931/000110465920003115/tm201618d1_ex10-5.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sponsored Research and License Agreement, by and between ArTara Subsidiary, Inc. and The University of Iowa dated as of November 28, 2018. (incorporated by reference to Exhibit 10.5 to the Registrant&rsquo;s Current Report on Form 8-K, filed with the SEC on January 10, 2020).</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.20&dagger;&dagger;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1359931/000110465920003115/tm201618d1_ex10-6.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">License Agreement, by and between ArTara Subsidiary, Inc. and The Feinstein Institute for Medical Research dated as of December 22, 2017. (incorporated by reference to Exhibit 10.6 to the Registrant&rsquo;s Current Report on Form 8-K, filed with the SEC on January 10, 2020).</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.21&dagger;&dagger;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1359931/000110465920003115/tm201618d1_ex10-7.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agreement, by and between ArTara Subsidiary, Inc. and Chugai Pharmaceutical Co., Ltd. dated as of June 17, 2019. (incorporated by reference to Exhibit 10.7 to the Registrant&rsquo;s Current Report on Form 8-K, filed with the SEC on January 10, 2020).</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.22&dagger;&dagger;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1359931/000121390020036343/f10q0920ex10-1_protara.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment to Agreement, by and between Chugai Pharmaceutical Co., Ltd. and the Registrant, dated as of July 14, 2020 and effective as of June 30, 2020 (incorporated by reference to Exhibit 10.1 to the Registrant&rsquo;s Quarterly Report on Form 10-Q, filed with the SEC on November 12, 2020).</FONT></A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
<!-- Field: Page; Sequence: 63 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><PAGE></PAGE></TD></TR></TABLE></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="width: 9%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.23&dagger;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 90%"><A HREF="http://www.sec.gov/Archives/edgar/data/1359931/000110465920003115/tm201618d1_ex10-8.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Indemnity Agreement between the Registrant and each of its directors and officers. (incorporated by reference to Exhibit 10.8 to the Registrant&rsquo;s Current Report on Form 8-K, filed with the SEC on January 10, 2020).</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.24&dagger;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1359931/000121390020019642/f10q0620ex10-1_protara.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restated Non-Employee Director Compensation Policy (incorporated by reference to Exhibit 10.1 to the Registrant&rsquo;s Quarterly Report on Form 10-Q, filed with the SEC on July 31, 2020).</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.25&dagger;&dagger; **+</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="f10k2020ex10-25_protara.htm">Lease by and between 345 PAS HOLDING LLC, and the Registrant, dated as of December 7, 2020.</A></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.1+</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><A HREF="f10k2020ex21-1_protara.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">List of Subsidiaries.</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1+</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><A HREF="f10k2020ex23-1_protara.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Marcum LLP, independent registered public accounting firm.</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1+</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><A HREF="f10k2020ex31-1_protara.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of Principal Executive Officer Required Under Rule 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended.</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.2+</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><A HREF="f10k2020ex31-2_protara.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of Principal Financial Officer Required Under Rule 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended.</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1+</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><A HREF="f10k2020ex32-1_protara.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal Executive Officer Certification and Principal Financial Officer Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101*</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interactive Data Files Pursuant to Rule 405 of Regulation S-T: (i) the Consolidated
Balance Sheets as of December 31, 2020 and 2019; (ii) the Consolidated Statements of Operations for the years ended December 31,
2020 and 2019; (iii) the Consolidated Statements of Changes in Stockholders&rsquo; Equity (Deficit) for the years ended December
31, 2020 and 2019; (iv) the Consolidated Statements of Cash Flows for the years ended December 31, 2020 and 2019; and (v) the notes
to the Consolidated Financial Statements.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in; text-align: left">+</TD><TD STYLE="text-align: left">Filed herewith.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in; text-align: left">**</TD><TD STYLE="text-align: left">Schedules have been omitted pursuant to Item 601(b)(2)
of Regulation S-K. A copy of any omitted schedules will be furnished to the SEC upon request.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in; text-align: left">&dagger;</TD><TD STYLE="text-align: left">Indicates management contract or compensatory plan
or arrangement.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in; text-align: left">&dagger;&dagger;</TD><TD STYLE="text-align: left">Certain portions of this exhibit (indicated by &ldquo;[***]&rdquo;)
have been omitted as the Registrant has determined (i) the omitted information is not material and (ii) the omitted information
would likely cause harm to the Registrant if publicly disclosed.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in; text-align: left">^</TD><TD STYLE="text-align: left">Certain exhibits and schedules have been omitted pursuant
to Item 601(a)(5) of Regulation S-K. The Registrant hereby undertakes to furnish supplementally a copy of any omitted exhibit
or schedule upon request by the SEC.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>


<!-- Field: Page; Sequence: 64 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><PAGE></PAGE></TD></TR></TABLE></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt"><A NAME="aph203237a025"></A><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Item 16.</B></FONT> <FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Form 10-K Summary</I></B></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 65 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><PAGE></PAGE></TD></TR></TABLE></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">Pursuant to the requirements
of Section 13 or 15(d) of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its
behalf by the undersigned thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; width: 60%">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: bottom; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Protara
    Therapeutics, <FONT STYLE="font-variant: small-caps">Inc.</FONT></B></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: left">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: March 11, 2021</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
<FONT STYLE="font-variant: small-caps">Jesse Shefferman</FONT></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jesse Shefferman</FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President and Chief Executive Officer</FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(on behalf of the registrant and as the registrant&rsquo;s</FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal Executive&nbsp;Officer)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">KNOW ALL PERSONS BY
THESE PRESENTS, that each individual whose signature appears below constitutes and appoints Stephen Davis, his true and lawful
attorney-in-fact and agent with full power of substitution, for him and in his or her name, place and stead, in any and all capacities,
to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto and all documents
in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent, full power
and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully
to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact
and agent, or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">Pursuant to the requirements
of the Securities and Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant
and in the capacities and on the dates indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 35%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: black 1.5pt solid"><B>Signature</B></P>

</TD>
    <TD STYLE="width: 45%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: black 1.5pt solid"><B>Title</B></P>

</TD>
    <TD STYLE="width: 20%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: black 1.5pt solid"><B>Date</B></P>

</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: black 1.5pt solid">/s/ JESSE
        SHEFFERMAN</P>

</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President and Chief
Executive Officer and Director</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 11, 2021</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jesse Shefferman</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Principal Executive Officer)</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="vertical-align: bottom; text-align: center">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: black 1.5pt solid">/s/ BLAINE
        DAVIS</P>

</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 11, 2021</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Blaine Davis</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Principal Financial and Accounting Officer)</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ LUKE BESHAR</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman of the Board of Directors</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 11, 2021</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Luke Beshar</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: black 1.5pt solid">/s/ BARRY
        FLANNELLY, PHARMD</P>

</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 11, 2021</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Barry Flannelly, PharmD</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: black 1.5pt solid">/s/ ROGER
        GARCEAU, M.D.</P>

</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 11, 2021</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Roger Garceau, M.D.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: black 1.5pt solid">/s/ RICHARD
        LEVY, M.D.</P>

</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 11, 2021</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Richard Levy, M.D.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: black 1.5pt solid">/s/ GREGORY
        P. SARGEN</P>

</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 11, 2021</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gregory P. Sargen</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: black 1.5pt solid">/s/ MICHAEL
        SOLOMON, PH.D.</P>

</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 11, 2021</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael Solomon, Ph.D.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ CYNTHIA SMITH</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 11, 2021</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cynthia Smith</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&nbsp;</P>
<!-- Field: Page; Sequence: 66 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><PAGE></PAGE></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Protara Therapeutics, Inc.<BR>
Index to Consolidated Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-bottom: 1pt; width: 90%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Protara Therapeutics, Inc. for the Years
    Ended December 31, 2020 and 2019</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 9%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page&nbsp;No.</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt"><A HREF="#aph233908a001"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Report of Independent Registered Public Accounting Firm</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">F-2</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 10pt"><A HREF="#aph233908a002"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Consolidated Balance Sheets as of December 31, 2020 and 2019</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">F-3</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt"><A HREF="#aph233908a003"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Consolidated Statements of Operations for the Years Ended December 31, 2020 and 2019</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">F-4</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 10pt"><A HREF="#aph233908a004"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Consolidated Statement of Changes in Stockholders&rsquo; (Deficit) Equity for the Years Ended December 31, 2020 and 2019</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">F-5</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt"><A HREF="#aph233908a005"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Consolidated Statements of Cash Flows for the Years Ended December 31, 2020 and 2019</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">F-6</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 10pt"><A HREF="#aph233908a006"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Notes to Consolidated Financial Statements</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">F-7</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
<!-- Field: Page; Sequence: 67; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="aph203237b001"></A><A NAME="aph233908a001"></A>REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To the Shareholders and Board of Directors of</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Protara Therapeutics, Inc.<BR>
 New York, New York</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Opinion on the Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have audited the accompanying consolidated balance
sheets of Protara Therapeutics, Inc. (the &ldquo;Company&rdquo;) as of December 31, 2020 and 2019, the related consolidated statements
of operations, stockholders&rsquo; equity (deficit) and cash flows for each of the years in the period ended December 31, 2020,
and the related notes (collectively referred to as the &ldquo;financial statements&rdquo;). In our opinion, the financial statements
present fairly, in all material respects, the financial position of the Company as of December 31, 2020 and 2019, and the results
of its operations and its cash flows for each of the years in the period ended December 31, 2020, in conformity with accounting
principles generally accepted in the United States of America.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Basis for Opinion</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">These financial statements are the responsibility
of the Company&rsquo;s management. Our responsibility is to express an opinion on the Company&rsquo;s financial statements based on our audits.
We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&ldquo;PCAOB&rdquo;)
and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable
rules and regulations of the Securities and Exchange Commission and the PCAOB.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We conducted our audits in accordance with the standards
of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial
statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged
to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding
of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&rsquo;s
internal control over financial reporting. Accordingly, we express no such opinion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our audits included performing procedures to assess
the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond
to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial
statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as
well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis
for our opinion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Critical Audit Matters</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Critical audit matters are matters arising from the
current period audit of the financial statements that were communicated or required to be communicated to the audit committee and
that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging,
subjective, or complex judgments. We determined that there are no critical audit matters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ Marcum LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have served as the Company&rsquo;s auditor
since 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><BR>
New York, New York</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">March
 11, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 68; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="aph233908a002"></A>PROTARA THERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="aph203237b002"></A>CONSOLIDATED BALANCE SHEETS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(in thousands, except share and per share
data)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid">As of December 31,</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-left: 10pt; text-indent: -10pt">Assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 10pt; text-indent: -10pt">Current assets:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left; padding-left: 0.25in; text-indent: -10pt">Cash and cash equivalents</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">168,598</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">564</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25in; text-indent: -10pt">Restricted cash</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">50</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.25in; text-indent: -10pt">Deferred offering costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">122</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in; text-indent: -10pt">Prepaid expenses and other current assets</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">787</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">78</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 0.375in; text-indent: -10pt">Total current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">169,435</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">764</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; padding-left: 10pt; text-indent: -10pt">Non-current assets:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25in; text-indent: -10pt">Restricted cash, long-term</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">745</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.25in; text-indent: -10pt">Property and equipment, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,240</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">459</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-indent: -10pt">Goodwill</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">29,517</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in; text-indent: -10pt">Other assets</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,220</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 4pt; padding-left: 0.375in; text-indent: -10pt">Total assets</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">203,157</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1,223</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 10pt; text-indent: -10pt">Liabilities and Stockholders&rsquo; Equity
    (Deficit) </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><B>Current liabilities:</B></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25in; text-indent: -10pt">Accounts payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">914</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">716</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.25in; text-indent: -10pt">Accrued expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,913</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,635</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in; text-indent: -10pt">Operating lease liability, current</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">88</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 0.375in; text-indent: -10pt">Total current liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,915</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,351</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; padding-left: 10pt; text-indent: -10pt">Non-current liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in; text-indent: -10pt">Operating lease liability, long-term</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">999</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt; padding-left: 0.375in; text-indent: -10pt">Total liabilities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">3,914</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">3,351</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 10pt; text-indent: -10pt">Commitments and Contingencies (Note 7)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 10pt; text-indent: -10pt">Stockholders&rsquo; Equity (Deficit)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25in; text-indent: -10pt">Preferred Stock, $0.001 par value, authorized 10,000,000 shares: Series 1 Convertible Preferred Stock, 8,028 and 0 shares authorized at December 31, 2020 &nbsp;and 2019, respectively, 8,027 and 0 shares issued and outstanding as of December 31, 2020 and 2019, respectively.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-indent: -10pt">Common Stock, $0.001 par value, authorized 100,000,000 shares:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 30pt; text-indent: -10pt">Common Stock, 11,211,840 and 2,627,533 shares issued and outstanding as of December 31, 2020 and 2019, respectively.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.25in; text-indent: -10pt">Additional Paid in Capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">245,992</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,651</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in; text-indent: -10pt">Accumulated Deficit</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(46,760</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(12,782</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt; text-indent: -10pt">Total Stockholders&rsquo; Equity (Deficit)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">199,243</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(2,128</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 4pt; padding-left: 30pt; text-indent: -10pt">Total Liabilities and Stockholders&rsquo; Equity (Deficit)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">203,157</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1,223</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part of these consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 69; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: -10pt"><B><A NAME="aph233908a003"></A>PROTARA THERAPEUTICS,
INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: -10pt"><A NAME="aph203237b003"></A><B>CONSOLIDATED STATEMENTS
OF OPERATIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: -10pt"><I>(in thousands, except
share and per share data)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: -10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid">For the Years Ended <BR> December 31,</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">Operating expense:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left; padding-left: 20pt; text-indent: -10pt">Research &amp; development</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">11,982</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">3,878</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 20pt; text-indent: -10pt">General &amp; administrative</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">22,462</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">3,952</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 20pt; text-indent: -10pt">Total operating expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">34,444</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">7,830</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 20pt; text-indent: -10pt">Operating loss</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(34,444</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(7,830</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt">Other income, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 20pt; text-indent: -10pt">Interest income, net</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(466</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 20pt; text-indent: -10pt">Total other income, net</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(466</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt; padding-left: 10pt; text-indent: -10pt">Net Loss</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(33,978</TD><TD STYLE="padding-bottom: 2pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(7,830</TD><TD STYLE="padding-bottom: 2pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt; padding-left: 10pt; text-indent: -10pt">Weighted Average Shares Outstanding, basic and diluted</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">7,233,913</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">2,577,493</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt; padding-left: 10pt; text-indent: -10pt">Net loss per share, basic and diluted</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(4.70</TD><TD STYLE="padding-bottom: 2pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(3.04</TD><TD STYLE="padding-bottom: 2pt; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part of these consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
<!-- Field: Page; Sequence: 70; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="aph233908a004"></A>PROTARA THERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="aph203237b004"></A><B>CONSOLIDATED STATEMENTS OF CHANGES IN
STOCKHOLDERS&rsquo; EQUITY (DEFICIT)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FOR THE YEARS ENDED DECEMBER 31, 2020
AND 2019</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(in thousands, except share and per share
data)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Series 1 Convertible Preferred Stock</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Common Stock</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">Additional</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">Total</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Shares</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Amount</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Shares</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Amount</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Paid-in <BR> Capital</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Accumulated <BR> Deficit</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Stockholders&rsquo;<BR> Equity&nbsp;(Deficit)</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 28%; font-weight: bold; text-indent: -10pt; padding-left: 10pt">Balance at January 1, 2019</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 6%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">2,558,419</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 6%; text-align: right">3</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 7%; text-align: right">9,727</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(4,952</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">4,778</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Stock-based compensation - stock options</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">313</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">313</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Stock-based compensation - restricted stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">75</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">75</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Stock-based compensation - restricted stock units</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">36</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">36</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Issuance of common stock in September capital raise</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">69,114</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">500</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">500</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Net loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(7,830</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(7,830</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Balance at December 31, 2019</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,627,533</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">3</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">10,651</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(12,782</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(2,128</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Issuance of Common Stock in ArTara Private Placement, net of offering costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">284,875</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,867</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,867</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Issuance of Common Stock in Proteon Private Placement, net of offering costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,896,888</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,411</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,413</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Issuance of Series 1 Convertible Preferred Stock in Proteon Private Placement, net of offering costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,879</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">25,319</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">25,319</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Reverse business combination</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,033,907</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">34,532</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">34,533</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Issuance of Common Stock in Common Offering, net of offering costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,600,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">73,566</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">73,570</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Issuance of Series 1 Convertible Preferred Stock in Preferred Offering, net of offering costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,148</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">66,284</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">66,284</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Issuance of Common Stock in Common Offering (Underwriters Overallotment Option), net of offering costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">690,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,086</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,087</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Settlement of restricted stock units</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20,870</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt">Exercise of stock options</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">57,767</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">530</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">530</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Stock-based compensation - restricted stock units</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,357</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,357</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Stock-based compensation - stock options</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,389</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,389</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Net loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(33,978</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(33,978</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Balance at December 31, 2020</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">8,027</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">11,211,840</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">11</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">245,992</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(46,760</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">199,243</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part of these consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 71; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="aph233908a005"></A>PROTARA THERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="aph203237b005"></A><B>CONSOLIDATED STATEMENTS OF CASH FLOWS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(in thousands)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid">For the Years Ended <BR> December 31,</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">Cash flows from operating activities:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt">Net loss</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(33,978</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(7,830</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Adjustments to reconcile net loss to net cash used
    in operating activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Stock based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,746</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">424</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Amortization of operating lease right-of-use asset</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">93</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -10pt; padding-left: 20pt">Depreciation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">103</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Changes in operating assets and liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Prepaid expenses and other current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,405</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(37</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Other Assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">58</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Accounts payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">198</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">366</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Accrued expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(966</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,050</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 20pt">Right-of-use liability</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(66</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 30pt">Net cash used in operating activities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(23,407</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(5,011</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Cash flows from investing activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Cash and restricted cash acquired in connection with the reverse merger with ArTara Therapeutics, Inc.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,719</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 20pt">Purchase of property and equipment</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(884</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(475</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 30pt">Net cash provided by/(used in) investing activities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,835</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(475</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Cash flows from financing activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Proceeds from - ArTara Private Placement, net of offering costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,867</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Proceeds from - Common Stock in Proteon Private Placement, net of offering costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,413</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Proceeds from - Series 1 Convertible Preferred Stock in Proteon Private Placement, net of offering costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">25,319</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Proceeds from Common Offering, net of offering costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">73,570</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Proceeds from Preferred Offering, net of offering costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">66,284</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Proceeds from Underwriters Overallotment Option</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,087</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Repayments under short-term debt</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,669</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Proceeds from the exercise of stock options</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">530</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 20pt">Proceeds from private placements</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">500</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 30pt">Net cash provided by financing activities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">189,401</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">500</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Net increase/(decrease) in cash and cash equivalents and restricted cash</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">168,829</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,986</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 20pt">Cash and cash equivalents and restricted cash - beginning of year</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">564</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">5,550</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 20pt">Cash and cash equivalents and restricted cash - end of year</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">169,393</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">564</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Reconciliation of cash and cash equivalents and restricted cash to the consolidated balance sheets:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Cash and cash equivalents</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">168,598</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">564</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Restricted cash</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">50</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 20pt">Restricted cash, long-term</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">745</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Cash and cash equivalents and restricted cash</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">169,393</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">564</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -10pt; padding-left: 10pt">Supplemental cash flow information</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Cash paid for:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt; text-indent: -10pt; padding-left: 20pt">Interest</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">34</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 20pt">Income Taxes</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Non-cash investing and financing activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 20pt">Deferred offering costs recorded in accrued expenses</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">122</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 20pt">Deferred offering costs recognized that were previously recorded in accrued expenses</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">122</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 20pt">Purchase of insurance agreement with notes payable</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1,669</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 20pt">Common stock issued in connection with the reverse merger with ArTara Therapeutics, Inc.</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">34,533</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">The accompanying notes are an integral part of these consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 72; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="aph233908a006"></A>Protara Therapeutics, Inc. and Consolidated
Subsidiaries</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="aph203237b006"></A><B>Notes to Consolidated Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><I>(amounts in thousands, except share and per share data)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 1 &ndash; BUSINESS, LIQUIDITY AND CAPITAL RESOURCES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Overview</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Protara Therapeutics, Inc. and its consolidated subsidiaries
(&ldquo;Protara&rdquo; or the &ldquo;Company&rdquo;) is committed to identifying and advancing transformative therapies for the
treatment of cancer and rare diseases with significant unmet needs. Protara&rsquo;s portfolio includes two development programs
utilizing TARA-002, an investigational cell therapy in development for the treatment of lymphatic malformations (LMs) and non-muscle
invasive bladder cancer (NMIBC). The third program in the portfolio is Intravenous (IV) Choline Chloride, an investigational phospholipid
substrate replacement therapy initially in development for patients receiving parenteral nutrition (PN) who have intestinal failure
associated liver disease (IFALD). The fourth program in the portfolio is Vonapanitase, a recombinant human elastase.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On January 9, 2020, privately-held ArTara Subsidiary, Inc. (&ldquo;Private
ArTara&rdquo;) and Protara Therapeutics, Inc. (formerly ArTara Therapeutics, Inc., formerly Proteon Therapeutics, Inc.) completed
the merger and reorganization (the &ldquo;Merger&rdquo;), in accordance with the terms of the Agreement and Plan of Merger and
Reorganization, dated September 23, 2019, (the &ldquo;Merger Agreement&rdquo;) by and among Protara Therapeutics, Inc., Private
ArTara and REM 1 Acquisition, Inc., a wholly owned subsidiary of Protara Therapeutics, Inc (&ldquo;Merger Sub&rdquo;). Thereupon,
Merger Sub merged with and into Private ArTara, with Private ArTara surviving as a wholly owned subsidiary of Protara Therapeutics,
Inc. The Merger was structured as a reverse merger and Private ArTara was determined to be the accounting acquirer based on the
terms of the Merger and other factors, and the post-merger company retained the name ArTara Therapeutics, Inc., which on May 11,
2020 was changed to Protara Therapeutics, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On January 9, 2020, in connection with and prior to the completion
of the Merger, Protara Therapeutics, Inc. effected a 1-for-40 reverse stock split of its common stock (the &ldquo;Protara Reverse
Stock Split&rdquo;), Private ArTara changed its name from &ldquo;ArTara Therapeutics, Inc.&rdquo; to &ldquo;ArTara Subsidiary,
Inc.&rdquo;, and ArTara Therapeutics, Inc. changed its name from &ldquo;Proteon Therapeutics, Inc.&rdquo; to &ldquo;ArTara Therapeutics,
Inc&rdquo; then subsequently changed its name from &ldquo;ArTara Therapeutics, Inc&rdquo; to &ldquo;Protara Therapeutics, Inc.&rdquo;
All share and per share amounts presented in this annual report on Form 10-K have been adjusted to reflect the Protara Reverse
Stock Split and the Exchange Ratio (defined below). In addition, immediately following the closing of the Private Placements (defined
below), all of the outstanding shares of Protara Therapeutics, Inc.&rsquo;s Series A Preferred Stock were converted into shares
of Protara Therapeutics, Inc.&rsquo;s Common Stock (defined below). Shares of the Company&rsquo;s Common Stock commenced trading
on The Nasdaq Capital Market under the new name and ticker symbol &ldquo;TARA&rdquo; as of market open on January 10, 2020. See
Note 3 for the full discussion regarding the Merger, Exchange Ratio and recapitalization.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Liquidity, Capital Resources
and Management Plans</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of December 31, 2020 and 2019, the Company&rsquo;s cash and
cash equivalents was $168,598 and $564, respectively. The Company has not generated revenues since its inception and has incurred
net losses of $33,978 and $7,830 for the years ended December 31, 2020 and 2019, respectively. As of December 31, 2020, the Company
had working capital of $166,520 and stockholder&rsquo;s equity of $199,243. During the year ended December 31, 2020, cash flows
used in operating activities were $23,407, consisting primarily of a net loss of $33,978, which includes non-cash stock-based compensation
charges of $9,746. Since inception, the Company has met its liquidity requirements principally through the sale of its Common Stock
and Series 1 Convertible Preferred Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In connection with the Merger, the Company consummated the Private
Placements, raising gross proceeds of $42.5 million and proceeds, net of offering costs, of $39.6 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On September 22, 2020, the Company entered into underwriting
agreements with Cowen and Company, LLC and Guggenheim Securities, LLC, as representatives of several underwriters for separate,
concurrent underwritten public offerings of the Company&rsquo;s Common Stock and Series 1 Convertible Preferred Stock. On September
24, 2020, gross and net proceeds from this offering were $147.6 million and $139.9 million, respectively. On October 6, 2020, the
underwriters exercised their overallotment option, resulting in the receipt of gross and net proceeds of $11.6 million and $11.1
million, respectively (See Note 8).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 73; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Protara Therapeutics, Inc. and Consolidated
Subsidiaries</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Notes to Consolidated Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><I>(amounts in thousands, except share and per share data)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 1 &ndash; BUSINESS, LIQUIDITY AND CAPITAL RESOURCES
(Continued)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Liquidity, Capital Resources
and Management Plans (Continued)</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company is in the business of developing biopharmaceuticals
and has no current or near term revenues. The Company has incurred substantial clinical and other costs in its drug development
efforts. The Company will need to raise additional capital in order to fully realize management&rsquo;s plans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company believes that its current financial resources are
sufficient to satisfy the Company&rsquo;s estimated liquidity needs for at least twelve months from the date of issuance of these
consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>Basis of Presentation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5pt 0pt 0">The accompanying financial statements have been prepared
in accordance with accounting principles generally accepted in the United States of America (&ldquo;U.S. GAAP&rdquo;) and pursuant
to the rules and regulations of the Securities and Exchange Commission (&ldquo;SEC&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5pt 0pt 0; text-indent: 0.5in"><B><I>Principles of Consolidation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5pt 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The consolidated financial statements include the accounts of
the Company and its wholly-owned subsidiaries. All inter-company balances and transactions have been eliminated in the accompanying
consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Use of Estimates</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The preparation of financial statements in conformity with U.S.
GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure
of contingent assets and liabilities as of the date of the financial statements, and also that affect the amount of expenses reported
for each period. Actual results could differ from those which result from using such estimates. Management also utilizes various
other estimates, including but not limited to income taxes, the valuation of deferred tax assets, determining the fair value of
business combination considerations, determining the fair value and evaluation for impairment of goodwill, determining the fair
value of the Company&rsquo;s Common Stock, and the valuation of securities and assumptions underlying stock-based compensation.
The results of any changes in accounting estimates are reflected in the financial statements of the period in which the change
becomes evident. Estimates and assumptions are reviewed periodically and the effects of revisions are reflected in the period that
they are determined to be necessary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Cash and cash equivalents</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company considers all highly liquid instruments with an
original maturity of three months or less when acquired to be cash equivalents. Cash and cash equivalents are held in depository
and money market accounts and are reported at fair value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Restricted Cash</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Restricted cash as of December 31, 2020 and 2019 was $795 and
$0, respectively. As of December 31, 2020, restricted cash consists of cash deposits of $795 to collateralize letter of credit
obligations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 74; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Protara Therapeutics, Inc. and Consolidated
Subsidiaries</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Notes to Consolidated Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><I>(amounts in thousands, except share and per share data)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>Property and Equipment</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Property and equipment is recorded at cost. Major property additions,
replacements, and betterments are capitalized, while maintenance and repairs that do not extend the useful lives of an asset or
add new functionality are expensed as incurred. Property and equipment not placed into service is not depreciated until such time
that it is placed into service. Depreciation is recorded using the straight-line method over the respective estimated useful lives
of the Company&rsquo;s assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Goodwill</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Goodwill represents the excess of purchase price over the fair
value of identifiable net assets acquired in a business combination. Goodwill and other intangible assets acquired in a business
combination and determined to have an indefinite useful life are not amortized, but instead tested for impairment at least annually.
An entity has the option to first assess qualitative factors to determine whether events or circumstances lead to a conclusion
that is more likely than not that the fair value of a reporting unit is greater than its carrying amount. If an entity determines
that qualitative factors indicate that it is more likely than not that the fair value of the entity exceeds the carrying amount,
the quantitative evaluation is not necessary. Under the quantitative impairment test, the evaluation of impairment involves comparing
the current fair value of each reporting unit to its carrying value, including goodwill.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In the event the estimated fair value of the Company is less
than the carrying value, the Company would recognize a goodwill impairment equal to the difference between the carrying value and
its fair value, not to exceed the carrying value of goodwill.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On January 9, 2020, in connection with the Merger, the Company
separately valued the assets and liabilities acquired, and then determined goodwill as the residual of the purchase price less
identified net assets. On December 31, 2020, in connection with the finalization of the purchase price allocation, the Company
recorded an adjustment of $150 to goodwill related to prepaid expenses and accrued expenses (See Note 3).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 75; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Protara Therapeutics, Inc. and Consolidated
Subsidiaries</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Notes to Consolidated Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><I>(amounts in thousands, except share and per share data)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>Net Loss per Common Share</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Basic loss per common share is computed by dividing net loss
by the weighted average number of common shares outstanding during the period. Diluted loss per common share is computed by dividing
net loss by the weighted average number of common shares outstanding, plus the impact of common shares, if dilutive, resulting
from the exercise of outstanding stock options.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following securities are excluded from the calculation of
weighted average dilutive common shares because their inclusion would have been anti-dilutive:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid">For the Years Ended<BR> December 31,</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left">Stock options</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">674,039</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">219,592</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Restricted stock units</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">407,325</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,245</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -8.1pt; padding-left: 8.1pt">Conversion of Series 1 Convertible Preferred Stock</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">8,029,039</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: 10pt">Total potentially dilutive shares</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">9,110,403</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">224,837</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Concentrations of Credit Risk</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Financial instruments which potentially subject the Company
to concentrations of credit risk consists principally of cash amounts on deposit with financial institutions. At times, the Company&rsquo;s
cash in banks is in excess of the Federal Deposit Insurance Corporation insurance limit. The Company has not experienced any loss
as a result of these deposits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Stock-Based Compensation</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company accounts for stock-based compensation in accordance
with the Financial Accounting Standards Board (&ldquo;FASB&rdquo;) Accounting Standards Codification, or (&ldquo;ASC&rdquo;), Topic
718, &ldquo;Compensation - Stock Compensation&rdquo; (&ldquo;ASC 718&rdquo;). ASC 718 establishes accounting for stock-based awards
exchanged for employee and consultant services. Under the provisions of ASC 718, stock-based compensation cost is measured at the
grant date, based on the fair value of the award, and is recognized as expense over the employee&rsquo;s requisite service period
(generally the vesting period of the equity grant). The fair value of the Company&rsquo;s stock options are estimated using the
Black Scholes option-pricing model with the following assumptions: fair value of the Company&rsquo;s Common Stock, expected volatility,
dividend rate, risk free interest rate and the expected life. The Company calculates the expected volatility using the historical
volatility for a pool of peer companies over the most recent period equal to the expected term and evaluates the extent to which
available information indicate that future volatility may differ from historical volatility. The expected dividend rate is zero
as the Company does not expect to pay or declare any cash dividends on its Common Stock. The risk-free rates for the expected terms
of the stock options are based on the U.S. Treasury yield curve in effect at the time of the grant. The Company has not experienced
significant exercise activity on stock options. Due to the lack of historical information, the Company determined the expected
term of its stock option awards issued using the simplified method. The simplified method assumes each vesting tranche of the award
has a term equal to the midpoint between when the award vests and when the award expires. Restricted stock awards generally vest
over the requisite service periods (vesting on a straight&ndash;line basis). The fair value of a stock award is equal to the fair
market value of a share of the Company&rsquo;s Common Stock on the grant date. The Company accounts for the forfeiture of equity
awards as they occur.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 76; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Protara Therapeutics, Inc. and Consolidated
Subsidiaries</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Notes to Consolidated Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><I>(amounts
in thousands, except share and per share data)</I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Fair Value Measurements</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The carrying amounts of cash and cash equivalents, prepaid expenses
and accounts payable approximate their fair values due to the short-term nature of these instruments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ASC Topic 820 &ldquo;Fair Value Measurements and Disclosures&rdquo; provides the framework for measuring fair value. That framework
provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives
the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurements) and
the lowest priority to unobservable inputs (level 3 measurements).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Fair value is defined as an exit price, representing the amount
that would be received upon the sale of an asset or payment to transfer a liability in an orderly transaction between market participants.
Fair value is a market-based measurement that is determined based on assumptions that market participants would use in pricing
an asset or liability. A three-tier fair value hierarchy is used to prioritize the inputs in measuring fair value as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 22.5pt"></TD><TD STYLE="width: 13.5pt"><FONT STYLE="font-family: Wingdings">&Oslash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Level 1 Quoted prices in active markets
for identical assets or liabilities.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 22.5pt"></TD><TD STYLE="width: 13.5pt"><FONT STYLE="font-family: Wingdings">&Oslash;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Level 2 Quoted prices for similar assets or liabilities in active
markets, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are
observable, either directly or indirectly.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 22.5pt"></TD><TD STYLE="width: 13.5pt"><FONT STYLE="font-family: Wingdings">&Oslash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Level 3 Significant unobservable inputs
that cannot be corroborated by market data.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>Income Taxes</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Deferred tax assets and liabilities are recognized for the estimated
future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities
and their respective tax basis, operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using
enacted tax rates in effect for the year in which those temporary differences are expected to be recovered or settled. The measurement
of net deferred tax assets is reduced by the amount of any tax benefit that, based on available evidence, is not expected to be
realized, and a corresponding valuation allowance is established.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Tax benefits are recognized only for tax positions that are
more likely than not to be sustained upon examination by tax authorities. The amount recognized is measured as the largest amount
of benefit that is greater than 50 percent likely to be realized upon settlement. A liability for &ldquo;unrecognized tax benefits&rdquo;
is recorded for any tax benefits claimed in the Company&rsquo;s tax returns that do not meet these recognition and measurement
standards. As of December 31, 2020 and 2019, no liability for unrecognized tax benefits was required to be recorded. The guidance
also discusses the classification of related interest and penalties on income taxes. The Company&rsquo;s policy is to record interest
and penalties on uncertain tax positions as a component of income tax expense. No interest or penalties were recorded during the
years ended December 31, 2020 and 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Research and Development Costs</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Research and development costs are expensed as incurred. These
expenses include the costs of our proprietary research and development efforts, as well as costs incurred in connection with certain
licensing arrangements. Before a compound receives regulatory approval, the Company records upfront and milestone payments made
to third parties under licensing arrangements as expense. Upfront payments are recorded when incurred, and milestone payments are
recorded when the specific milestone or progress has been achieved. Once a compound receives regulatory approval, the Company records
any milestone payments in&nbsp;identifiable intangible assets, less accumulated amortization&nbsp;and, unless the asset is determined
to have an indefinite life, the Company amortizes the payments on a straight-line basis over the remaining agreement term or the
expected product life cycle, whichever is shorter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Research and development expenses were $11,982 and $3,878 for
the years ended December 31, 2020 and 2019, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 77; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Protara Therapeutics, Inc. and Consolidated
Subsidiaries</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Notes to Consolidated Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-weight: normal"><I>(amounts
in thousands, except share and per share data)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B><I>Business Combinations</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For a business combination, the assets acquired and the liabilities
assumed are recognized at the acquisition date, measured at their fair values as of that date. In a business combination achieved
in stages, the identifiable assets and liabilities are recognized at their fair values. In a bargain purchase in which the total
acquisition-date fair value of the identifiable net assets acquired exceeds the fair value of the consideration transferred plus
any non-controlling interest in the acquiree, that excess in fair value is recognized as a gain.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Deferred tax liabilities and assets are recognized for the deferred
tax consequences of differences between the tax bases and the recognized values of assets acquired and liabilities assumed in a
business combination in accordance with ASC Topic 740-10 &ldquo;Income Taxes&rdquo;. See Note 3 for the Company&rsquo;s accounting
for the reverse merger.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>Recent Accounting Pronouncements Adopted</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In January 2017, the FASB issued Accounting Standards Update
(&ldquo;ASU&rdquo;) 2017-04 (&ldquo;ASU 2017-04&rdquo;), Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill
Impairment. ASU 2017-04 simplifies the subsequent measurement of goodwill by eliminating the second step of the goodwill impairment
test. The second step measures a goodwill impairment loss by comparing the implied fair value of a reporting unit&rsquo;s goodwill
with the carrying amount of that goodwill. Under ASU 2017-04, a company will record an impairment charge based on the excess of
a reporting unit&rsquo;s carrying amount over its fair value. ASU 2017-04 will be applied prospectively and is effective for annual
or interim goodwill impairment tests in fiscal years beginning after December 15, 2019. On January 1, 2020, the Company adopted
ASU 2017-04. The adoption of this standard did not have a material effect on the Company&rsquo;s financial position, results of
operations, or cash flows.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In August 2018, the FASB issued ASU No. 2018-13, Fair Value
Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement (&ldquo;ASU 2018-13&rdquo;),
which removes, adds and modifies certain disclosure requirements for fair value measurements in Topic 820. The Company will no
longer be required to disclose the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy
as well as the valuation processes of Level 3 fair value measurements. The Company will be required to provide additional disclosure
related to the changes in unrealized gains and losses included in other comprehensive loss for recurring Level 3 fair value measurements
and the range and weighted average of assumptions used to develop significant unobservable inputs for Level 3 fair value measurements.
On January 1, 2020, the Company adopted ASU 2018-13. The adoption of this standard did not have a material effect on the Company&rsquo;s
financial position, results of operations, or cash flows.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>Subsequent Events </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company evaluated subsequent events and transactions that
occurred after the balance sheet date up to the date that the financial statements were available to be issued. The Company did
not identify any subsequent events that would have required adjustment or disclosure in the financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 78; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Protara Therapeutics, Inc. and Consolidated
Subsidiaries</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Notes to Consolidated Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(amounts in thousands, except share and
per share data)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 3 &ndash; REVERSE MERGER WITH PROTARA AND RECAPITALIZATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On January 9, 2020, in connection with, and prior to the completion
of the Merger, Protara Therapeutics, Inc. effected the Protara Reverse Stock Split, which resulted in 557,631 pre-merger shares
of Protara Therapeutics, Inc. outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Under the terms of the Merger Agreement, Protara Therapeutics,
Inc. issued shares of its common stock (&ldquo;Common Stock&rdquo;) to the Company&rsquo;s stockholders, at an exchange ratio of
0.190756 (the &ldquo;Exchange Ratio&rdquo;), after taking into account the Protara Reverse Stock Split, for each share of Private
ArTara common stock outstanding immediately prior to the Merger. Protara Therapeutics, Inc. assumed all of the unvested Private
ArTara restricted stock awards, which were exchanged for a number of shares of Common Stock equal to 0.190756 multiplied by the
number of shares of Private ArTara common stock previously represented by such Private ArTara restricted stock awards and unvested
to the same extent as such Private ArTara restricted stock awards and subject to the same restrictions as such Private ArTara restricted
stock awards. On account of the adjustment required pursuant to the Exchange Ratio, there were 2,627,533 shares of Private ArTara
common stock outstanding immediately prior to the Merger.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Protara Therapeutics, Inc. assumed all of the outstanding and
unexercised stock options of Private ArTara, with such stock options representing the right to purchase a number of shares of Common
Stock equal to 0.190756 multiplied by the number of shares of Private ArTara common stock previously represented by such Private
ArTara stock options. As a result, 219,699 shares were assumed under Private ArTara&rsquo;s 2017 Equity Incentive Plan. No additional
awards will be made under the 2017 Equity Incentive Plan. On January 1, 2020, Protara Therapeutics, Inc. amended its Amended and
Restated 2014 Equity Incentive Plan (the &ldquo;2014 Equity Incentive Plan&rdquo;) to increase the number of shares of stock available
for issuance under the 2014 Equity Incentive Plan to 1,048,300 shares and made conforming changes and updates pursuant to Section
162(m) of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Concurrently with the execution of the Merger Agreement, certain
institutional investors (together, the &ldquo;Investors&rdquo;) entered into a subscription agreement (as amended on November 19,
2019, the &ldquo;Subscription Agreement&rdquo;) with Protara Therapeutics, Inc. and Private ArTara, pursuant to which (A) Protara
Therapeutics, Inc. issued in a private placement immediately after the Merger (the &ldquo;Proteon Private Placement&rdquo;) (i)
3,879.356 of shares of Protara Therapeutics, Inc.&rsquo;s Series 1 Convertible Non-Voting Preferred Stock at a purchase price of
approximately $7,011.47 per share for gross proceeds of $27,200 and proceeds, net of issuance costs, of $25,319, (ii) 1,896,888
shares of Protara Therapeutics, Inc.&rsquo;s Common Stock at a purchase price of approximately $7.01 per share for gross proceeds
of $13,300 and proceeds, net of issuance costs, of $12,413 and (B) Private ArTara issued in a private placement immediately prior
to the Merger (the &ldquo;ArTara Private Placement&rdquo;) 284,875 shares of Private ArTara common stock (post-Exchange Ratio basis)
at a purchase price of approximately $7.01 per share (post-Exchange Ratio basis) (together with the Proteon Private Placement,
the &ldquo;Private Placements&rdquo;) for gross proceeds of $2,000 and proceeds, net of issuance costs, of $1,867. The shares issued
in the Proteon Private Placement were registered for resale on a registration statement on Form S-3 filed and declared effective
by the SEC on January 30, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Immediately following the closing of the Proteon Private Placement,
18,954 shares of Protara Therapeutics, Inc.&rsquo;s Series A Convertible Preferred Stock outstanding were converted into 476,276
shares of Protara Therapeutics, Inc.&rsquo;s Common Stock. These shares, combined with the 557,631 pre-merger shares of Protara
Therapeutics, Inc. outstanding after the Protara Reverse Stock Split, resulted in an aggregate of 1,033,907 shares of Common Stock
issued in connection with the Merger.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Immediately after the consummation of the Merger and prior to
the consummation of the Proteon Private Placement, the former stockholders and option holders of Private ArTara owned, or held
rights to acquire, approximately 75.2% of the fully-diluted Common Stock of Protara, with Protara Therapeutics, Inc.&rsquo;s stockholders
and option holders immediately prior to the Merger owning approximately 24.8% of the fully-diluted Common Stock of Protara.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 79; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Protara Therapeutics, Inc. and Consolidated
Subsidiaries</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Notes to Consolidated Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(amounts in thousands, except share and
per share data)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 3 &ndash; REVERSE MERGER WITH PROTARA AND RECAPITALIZATION
(Continued)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Based
on the terms of the Merger, the transaction was treated as a reverse merger of Protara Therapeutics, Inc. by Private ArTara.</FONT>
<FONT STYLE="font: 10pt Times New Roman, Times, Serif">The Merger was accounted for using acquisition accounting under ASC Topic
805 &ldquo;Business Combinations&rdquo;. Under acquisition accounting, the assets and liabilities (including executory contracts,
commitments and other obligations) of Protara Therapeutics, Inc. as of the effective time of the Merger were recorded at their
respective fair values and added to those of Private ArTara. Any excess of purchase price consideration over the fair values of
the identifiable net assets is recorded as goodwill. During the year ended December 31, 2020, the Company recorded an adjustment
of $150 to goodwill. This adjustment was comprised of a decrease of $78 in prepaid expenses and other current assets, and an increase
of $77 in accrued expenses, resulting in a final purchase price allocation as follows: </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; text-indent: -10pt; padding-left: 10pt">Cash</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">3,669</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Restricted cash</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">50</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Prepaid expenses and other current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,662</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt">Goodwill</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">29,517</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Accrued expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(365</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Total purchase price consideration</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">34,533</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The total fair value of the net assets of Protara Therapeutics
Inc. was determined by the Company to be $34,533 based on the consideration transferred. The total consideration was based on the
enterprise value of Protara Therapeutics Inc. as of January 9, 2020, based upon the number of common shares deemed outstanding,
multiplied by the closing stock price on January 9, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Of the amount of goodwill acquired in the reverse merger, no
portion is deductible for tax purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The primary reasons for the reverse merger: the increased access
to sources of capital and a broader range of investors to support the clinical development of Private ArTara&rsquo;s product candidates,
the potential to provide current stockholders with greater liquidity by owning stock in a public company, the potential for a more
cost-effective means to access capital and the registration of Protara Common Stock issued to Private ArTara&rsquo;s stockholders.
In addition, Protara assumed the existing 2014 Equity Incentive Plan (the &ldquo;2014 Plan&rdquo;), and all outstanding stock options
thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 80; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Protara Therapeutics, Inc. and Consolidated
Subsidiaries</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Notes to Consolidated Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(amounts in thousands, except share and
per share data)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 3 &ndash; REVERSE MERGER WITH PROTARA AND RECAPITALIZATION
(Continued)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following presents the unaudited pro forma combined financial
information as if the reverse merger had occurred as of January 1, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid">For the Years Ended <BR> December 31,</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Net loss</TD><TD STYLE="width: 1%; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="width: 9%; border-bottom: Black 4pt double; text-align: right">(33,754</TD><TD STYLE="width: 1%; padding-bottom: 2pt; text-align: left">)</TD><TD STYLE="width: 1%; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="width: 9%; border-bottom: Black 4pt double; text-align: right">(22,821</TD><TD STYLE="width: 1%; padding-bottom: 2pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Pro forma loss per common share, basic and diluted</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(4.62</TD><TD STYLE="padding-bottom: 2pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(3.94</TD><TD STYLE="padding-bottom: 2pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Pro forma weighted average number of common shares outstanding, basic and diluted</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">7,304,201</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">5,793,024</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The pro forma combined results of operations are not necessarily
indicative of the results of operations that actually would have occurred had the reverse merger been completed as of January 1,
2019, nor are they necessarily indicative of future consolidated results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 81; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Protara Therapeutics, Inc. and Consolidated
Subsidiaries</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Notes to Consolidated Financial Statements</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(amounts in thousands, except share and
per share data)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 4 &ndash; PROPERTY AND EQUIPMENT </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: -1in">Property and
equipment consists of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: -1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: -1in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; text-align: center">As of December 31,</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1.5pt solid">Useful Life <BR> (in years)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center">2019</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: left; padding-left: 10pt; text-indent: -10pt">Computer equipment</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 11%; text-align: center; padding-left: 5.4pt">5</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">34</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt">Furniture, fixtures and other</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 5.4pt">5</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">21</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">21</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt">Laboratory equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 5.4pt">7</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">601</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">446</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt; vertical-align: top">Leasehold improvements</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 5.4pt">Over the shorter of the useful life or the lease term</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">200</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt; padding-bottom: 1.5pt">Property and equipment not yet placed into service</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 5.4pt; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">503</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">8</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25in; text-indent: -10pt">Total property and equipment, gross</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 5.4pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,359</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">475</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt; padding-bottom: 1.5pt">Less: Accumulated depreciation</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: right; padding-left: 5.4pt; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">(119</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">(16</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25in; text-indent: -10pt; padding-bottom: 4pt">Total property and equipment, net</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="text-align: right; padding-left: 5.4pt; padding-bottom: 4pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 4pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 4pt double">1,240</TD><TD STYLE="text-align: left; padding-bottom: 4pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 4pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 4pt double">459</TD><TD STYLE="text-align: left; padding-bottom: 4pt">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: -1in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Depreciation expense was $103 and $16 for the years ended December
31, 2020 and 2019, respectively. During the year ended December 31, 2020, $99 and $4 was included in research and development expense
and general and administrative expense, respectively, within the consolidated statements of operations. For the year ended December
31, 2019, $16 was included in research and development expense within the consolidated statements of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: -1in"><B>NOTE 5 &ndash;
ACCRUED EXPENSES </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: -1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">Included in the Company&rsquo;s
accrued expenses within the consolidated financial statements are:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid">As of December 31,</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">2019</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left">Employee bonus</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">1,530</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Taxes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">159</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Legal fees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">156</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,573</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Research and development costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">37</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,050</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Other expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">31</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">12</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 4pt">Total</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 4pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 4pt double">1,913</TD><TD STYLE="text-align: left; padding-bottom: 4pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 4pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 4pt double">2,635</TD><TD STYLE="text-align: left; padding-bottom: 4pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 6 &ndash; SHORT-TERM DEBT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>Financing Agreement</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On February 19, 2020, the Company entered into a nine month
financing agreement with AFCO Credit Corporation for its directors and officers (&ldquo;D&amp;O&rdquo;) liability insurance in the
amount of $2,225. The Company made a down payment of $556, leaving a principal balance of $1,669. The financing bore interest at
a rate of 4.25% per annum, and was repaid in monthly installments of $189, which included both principal and interest. As of December
31, 2020, the balance under this debt was $0. The Company recorded interest expense of $34 for the year ended December 31, 2020
under this financing agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 82; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Protara Therapeutics, Inc. and Consolidated
Subsidiaries</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Notes to Consolidated Financial Statements</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(amounts in thousands, except share and
per share data)</I></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 7 &ndash; COMMITMENTS AND CONTINGENCIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Lease Agreements</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company has entered into operating leases for office and
laboratory space. On January 1, 2019 (&ldquo;Effective Date&rdquo;), the Company adopted ASC Topic 842, Leases (&ldquo;ASC 842&rdquo;),
which increases transparency and comparability by recognizing a lessee&rsquo;s rights and obligations resulting from leases. ASC
842 requires the recognition of the right-of-use (&ldquo;ROU&rdquo;) assets and related operating lease liabilities on the balance
sheet. The Company adopted the new guidance using the modified retrospective approach on January 1, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The adoption of ASC 842 on January 1, 2019 did not immediately
result in the recognition of ROU assets as the Company did not have any leases at that time with a term of twelve months or more.
However, on January 9, 2020, subsequent to the Merger and Private Placements, it became reasonably certain that the Company would
maintain its quarter-to-quarter lease with its contract development and manufacturing organization for its manufacturing space
for an expected term of approximately eight years, therefore resulting in the recognition of an ROU asset and related operating
lease liability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company elected the package of practical expedients permitted
within the standard, which allow an entity to forgo reassessing (i) whether a contract contains a lease, (ii) classification of
leases, and (iii) whether capitalized costs associated with a lease meet the definition of initial direct costs. Also, the Company
elected the expedient to allow the Company to not have to separate lease and non-lease components. The Company has also elected
the short-term lease accounting policy under which the Company would not recognize a lease liability or ROU asset for any lease
that at the commencement date has a lease term of twelve months or less and does not include a purchase option that the Company
is more than reasonably certain to exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On July 1, 2020 and December 1, 2020, the Company entered into
additional quarter-to-quarter leases for additional contract development and manufacturing space for expected terms of approximately
seven years, therefore resulting in the recognition of additional ROU assets and related operating lease liabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On December 1, 2020, the Company entered into a long-term lease
for office space for a term of seven years. This lease was entered into with a related party of the Company, and its terms were
determined by management to be on an arms-length basis. The lease will not commence until the second quarter of 2021 when the Company
is granted access to the premises. Accordingly, as of December 31, 2020, the Company did not recognize an additional ROU asset
and related operating lease liability for this lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For contracts entered into on or after the Effective Date, at
the inception of a contract, the Company will assess whether the contract is, or contains, a lease. The Company&rsquo;s assessment is
based on: (i) whether the contract involves the use of a distinct identified asset, (ii) whether the Company obtained the right
to substantially all the economic benefit from the use of the asset throughout the period, and (iii) whether the Company has the
right to direct the use of the asset. Leases entered into prior to January 1, 2019, which were accounted for under ASC 840, Leases,
were not reassessed for classification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 83; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Protara Therapeutics, Inc. and Consolidated
Subsidiaries</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Notes to Consolidated Financial Statements</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(amounts in thousands, except share and
per share data)</I></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">NOTE 7 &ndash; COMMITMENTS AND CONTINGENCIES (Continued)</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Lease Agreements (Continued)</I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For operating leases, the lease liability is initially and subsequently
measured at the present value of the unpaid lease payments. The Company generally uses its incremental borrowing rate as the discount
rate for leases, unless an interest rate is implicitly stated in the lease. The present value of the lease payments is calculated
using the incremental borrowing rate for operating leases, which was determined using a rate of interest that the Company would
have to pay to borrow an amount equal to the lease payments on a collateralized basis over a similar term. The lease term for the
Company&rsquo;s lease includes the noncancellable period of the lease plus any additional periods covered by either a Company option
to extend the lease that the Company is reasonably certain to exercise, or an option to extend the lease controlled by the lessor.
ROU assets, once recorded, are reviewed for impairment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Lease expense for operating leases consists of the lease payments
plus any initial direct costs and is recognized on a straight-line basis over the lease term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Balance sheet information related to our leases is presented
below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="text-align: center; border-bottom: Black 1.5pt solid">As of</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-style: italic; border-bottom: Black 1.5pt solid">Operating leases:</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1.5pt solid">Balance Sheet <BR>
Location</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">December 31, <BR>
2020</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">January 9, 2020</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">December 31, <BR>
2019</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 30%; padding-bottom: 4pt; padding-left: 0in">Right-of-use assets</TD><TD STYLE="width: 1%; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="width: 30%; text-align: left; padding-bottom: 4pt">Other assets</TD><TD STYLE="width: 1%; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 4pt double; text-align: right">1,060</TD><TD STYLE="width: 1%; padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 4pt double; text-align: right">403</TD><TD STYLE="width: 1%; padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="width: 1%; padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt; padding-left: 0in">Operating lease liability, current</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 4pt">Operating lease liability, current</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">88</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">9</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt; padding-left: 0in">Operating lease liability, long-term</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 4pt">Operating lease liability, long-term</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">999</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">394</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following provides details of the Company&rsquo;s lease
expense:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt">Lease cost</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">For the Year Ended<BR> December 31, 2020</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 82%; text-align: left; padding-left: 0.125in">Operating lease cost</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 15%; text-align: right">93</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in">Short-term lease cost</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">215</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt">Total</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">308</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 84; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Protara Therapeutics, Inc. and Consolidated
Subsidiaries</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Notes to Consolidated Financial Statements</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(amounts in thousands, except share and
per share data)</I></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">NOTE 7 &ndash; COMMITMENTS AND CONTINGENCIES (Continued)</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Lease Agreements (Continued)</I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.05pt; text-indent: -20.05pt">Other information related
to leases is presented below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.05pt; text-indent: -20.05pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">As of <BR> December 31, 2020</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 0.125in">Other information</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 82%; text-align: left; padding-left: 0.125in">Weighted-average discount rate &ndash; operating lease</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; text-align: right">12.00</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.125in">Weighted-average remaining lease term &ndash; operating lease (in months)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">87</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of December 31, 2020, the expected annual minimum lease payments
of our operating lease liabilities and other short-term leases were as follows (includes long-term lease entered into on December
1, 2020 that does not commence until the second quarter of 2021):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">For Years Ending December 31,</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Operating lease</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 82%; text-align: left">2021</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 15%; text-align: right">1,111</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">2022</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,333</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">2023</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,338</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">2024</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,342</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">2025</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,423</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">Thereafter</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">3,277</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Total future minimum lease payments, undiscounted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,824</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Less: Imputed interest for leases in excess of one year</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">8,676</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Present value of future minimum lease payments</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1,148</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Present value of future minimum lease payments for our operating lease liabilities</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1,087</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Present value of future minimum lease payments, short-term leases</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">61</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Employment Agreements</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Executive Employment Agreements</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company&rsquo;s executive officers have entered into at-will
employment agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 85; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Protara Therapeutics, Inc. and Consolidated
Subsidiaries</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Notes to Consolidated Financial Statements</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(amounts in thousands, except share and
per share data)</I></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">NOTE 7 &ndash; COMMITMENTS AND CONTINGENCIES (Continued)</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Employment Agreements (Continued)</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Temporary Employment Agreement</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On December 6, 2018, the Company entered into a temporary employment
agreement (the &ldquo;Temporary Employment Agreement&rdquo;) with an individual who assisted with certain corporate development
activities. Pursuant to the Temporary Employment Agreement, the individual was entitled to receive an annual base salary of $90.
In addition, the individual would be entitled to a performance-based success fee which would be adjusted based on amounts of funding
achieved and timing of when such funding was received. On January 9, 2020, the Company&rsquo;s capital raise triggered a performance-based
compensation obligation and accordingly this individual was paid $462, which was included in general and administrative expenses
within the Company&rsquo;s consolidated statements of operations for the year ended December 31, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B><I>Collaborations and License Agreements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Choline License Agreement</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On September 27, 2017, the Company entered into a license agreement
(the &ldquo;Choline License Agreement&rdquo;) with Alan L. Buchman (&ldquo;Dr. Buchman&rdquo;). Pursuant to the Choline License
Agreement, the Company received from Dr. Buchman the license rights in and to the &ldquo;Licensed Orphan Designations&rdquo;, the
&ldquo;Licensed IND&rdquo;, &ldquo;Existing Study Data&rdquo; and the &ldquo;Licensed Know-How&rdquo; for one or more of the licensed
indications. In consideration for the rights and licenses granted, Dr. Buchman received a payment of $50 on October 2, 2017, and
license payments of $50 and $50 on December 12, 2018 and January 8, 2019, respectively, upon the Company meeting the criteria for
certain meetings to be held with the Federal Drug Administration (the &ldquo;FDA&rdquo;). Pursuant to the Choline License Agreement,
effective October 2017, the Company incurred a fixed obligation to Dr. Buchman of $400 (the &ldquo;Choline License Fee&rdquo;).
Upon the Company receiving $5,000 in cumulative funding (as defined), Dr. Buchman would be entitled to receive payment of the Choline
License Fee as a lump sum if the funds are received by April 15, 2019 and the Choline License Fee shall be increased to a one-time
payment of $600 if the funds are received by October 15, 2019. On October 2, 2019, the Company made a payment of $50 to Dr. Buchman.
On January 22, 2020, in connection with the closing of the Merger and concurrent financing, Dr. Buchman was paid $550 which was
included in accrued expenses as of December 31, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the years ended December 31, 2020 and 2019, the Company
recorded research and development expense of $0 and $200 (representing the increase in the Choline License Fee obligation), respectively,
for expenditures to Dr. Buchman in connection with obligations under the Choline License Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 86; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Protara Therapeutics, Inc. and Consolidated
Subsidiaries</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Notes to Consolidated Financial Statements</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(amounts in thousands, except share and
per share data)</I></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 7 &ndash; COMMITMENTS AND CONTINGENCIES (Continued)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B><I>Collaborations and License Agreements (Continued)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>License Agreement</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On December 22, 2017, the Company entered into an agreement
(the &ldquo;Feinstein Agreement&rdquo;) with The Feinstein Institute for Medical Research (the &ldquo;Feinstein Institute&rdquo;),
a not-for-profit corporation with 50 research labs and 2,500 clinical research studies. Pursuant to the Feinstein Agreement, the
Company acquired an exclusive license relating to treatment of fatty liver diseases in humans for which Choline may be an effective
therapeutic. In consideration for the rights and license granted, the Feinstein Institute would receive a royalty of one percent
(1%) of the first one hundred million dollars ($100,000) of net sales of IV Choline Chloride and a royalty of one and one-half
percent (1.5%) of all net sales thereafter. In addition, the Company would pay the Feinstein Institute twelve and one-half percent
(12.5%) of net proceeds resulting from agreements entered within 2 years from the effective date, and seven and one-half percent
(7.5%) of net proceeds resulting from agreements entered into thereafter. Pursuant to the Feinstein Agreement additional payments
would be due to the Feinstein Institute for license maintenance payments and for meeting milestone events. On January 9, 2020,
the Company&rsquo;s raising of over $5,000 triggered a financing milestone obligation and accordingly the Feinstein Institute was
paid $100. Pursuant to the Feinstein Agreement, upon the achievement of certain future new drug application milestones, the Company
would be obligated to remit an aggregate of $275.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the years ended December 31, 2020 and 2019, the Company
recorded research and development expense of $115 and $1, respectively, in connection with the Feinstein Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Sponsored Research and License Agreement</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On November 28, 2018, the Company entered into a sponsored research
and license agreement (the &ldquo;Iowa Agreement&rdquo;) with the University of Iowa. Pursuant to the Iowa Agreement, the University
of Iowa, which is engaged in clinical research to improve the diagnosis and treatment of lymphangioma using a pharmaceutical product
(OK-432), would assist the Company in collecting case reports, forms, source data, and safety data available to the University
of Iowa in support of the development of the Company&rsquo;s proprietary <I>Streptococcus Pyogenes</I> investigational product,
TARA-002 for the LMs indication. During the term of the services, the Company would pay the University of Iowa thirty thousand
dollars ($30) per year to fund the project, plus additional amounts upon the realization of certain milestones. More specifically,
upon forty-five (45) days of an approval of TARA-002 by the FDA, the Company would pay up to $1,750 to the University of Iowa for
meeting these milestones. Furthermore, the Company would pay the University of Iowa royalties of up to 1.75% for net sales ranging
from $0 - $25,000, 2.25% for net sales ranging from $25,000 to $50,000, and 2.50% for net sales in excess of $50,000. Pursuant
to the Iowa Agreement, the University of Iowa would be entitled to additional payments for the Company achieving annual net sales
of product according to the milestones. For annual net sales of product up to $25,000; $62; for annual net sales of product of
up to $50,000; $62; and for annual net sales of product of up to $100,000; $125.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the years ended December 31, 2020 and 2019, the Company
recorded research and development expense of $30 and $30 respectively, in connection with the Iowa Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 87; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Protara Therapeutics, Inc. and Consolidated
Subsidiaries</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Notes to Consolidated Financial Statements</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(amounts in thousands, except share and
per share data)</I></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 7 &ndash; COMMITMENTS AND CONTINGENCIES (Continued)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Collaborations and License Agreements<FONT STYLE="font-weight: normal; font-style: normal">
</FONT>(Continued)</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Chugai Agreement</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On June 17, 2019, the Company entered into an agreement (the
&ldquo;Chugai Pharmaceutical Agreement&rdquo;) with Chugai Pharmaceutical Co., LTD (&ldquo;Chugai&rdquo;), a drug manufacturing
firm with offices and operations in Japan. Pursuant to the Chugai Pharmaceutical Agreement, Chugai would help the Company in its
goals to develop and commercialize a therapeutic product (the &ldquo;New Product&rdquo;) which is comparable to the Chugai existing
therapeutic product (the &ldquo;Existing Product&rdquo;). In addition, the Company would be entitled to the use of Chugai materials
and technical support as necessary. On July 14, 2020, the Company and Chugai entered into an amendment (the &ldquo;Chugai Amendment&rdquo;)
to the Chugai Pharmaceutical Agreement. The Chugai Amendment is effective as of June 30, 2020. The Chugai Amendment extended the
date through which Chugai will exclusively provide the Existing Product and materials to the Company from June 30, 2020 to June
30, 2021, extended the date through which Chugai will not provide materials or technical support to any third party for the purpose
of development and commercialization in a given area from the fifth anniversary to the eleventh anniversary of the original effective
date and provides that, in addition to the designated fee provided upon the initial indication approval in the Chugai Pharmaceutical
Agreement, the Company will pay Chugai a designated fee for each additional indication approval. The Company is obligated to Chugai
for certain payments upon the completion of agreed upon milestones. As of December 31, 2019, the Company recorded an obligation
of $500 upon Chugai having completed an agreed upon milestone, which the Company paid on July 27, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the years ended December 31, 2020 and 2019, the Company
recorded research and development expense of $0 and $500, respectively, respectively, in connection with the Chugai Agreement,
as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Johns Hopkins University</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In February 2002, Proteon entered into an agreement to license
certain intellectual property in connection with vonapanitase with Johns Hopkins University. The agreement calls for payments to
be made by the Company upon the commencement of vonapanitase related product sales, in the form of a royalty of 2.5% on net sales
of the product. As of December 31, 2020, the Company has not commenced vonapanitase product sales and therefore has recognized
no royalties on product sales.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 88; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Protara Therapeutics, Inc. and Consolidated
Subsidiaries</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Notes to Consolidated Financial Statements</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(amounts in thousands, except share and
per share data)</I></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 7 &ndash; COMMITMENTS AND CONTINGENCIES (Continued)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>Litigation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">From time to time, Protara may be subject to various legal proceedings
and claims that arise in the ordinary course of its business activities. Management is of the opinion that the ultimate outcome
of these matters would not have a material adverse impact on the financial position of the Company or the results of its operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In the normal course of business, the Company enters into contracts
in which it makes representations and warranties regarding the performance of its services and that its services will not infringe
on third party intellectual rights. There have been no significant events related to such representations and warranties in which
the Company believes the outcome could result in losses or penalties in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 8 &ndash; STOCKHOLDERS&rsquo; EQUITY </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>Authorized Common Stock </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of December 31, 2020, the Company has 100,000,000 shares
of Common Stock authorized for issuance, $0.001 par value per share, of which 11,211,840 and 2,627,533 shares were issued and outstanding
as of December 31, 2020 and 2019, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The holders of the Company&rsquo;s Common Stock are entitled
to one vote per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>Authorized Series 1 Convertible Preferred
Stock</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In connection with the Preferred Offering (defined below) on
September 22, 2020, the Company filed a Certificate of Amendment to the Certificate of Designation of Preferences, Rights and Limitations
of Series 1 Convertible Preferred Stock of the Company (the &ldquo;Amendment&rdquo;) with the State of Delaware to increase the
authorized number of shares of the Company&rsquo;s Series 1 Convertible Preferred Stock that may be issued from 3,880 to 8,028.
The Amendment was approved by a committee of the Company&rsquo;s Board of Directors and the requisite holders of outstanding shares
of Series 1 Convertible Preferred Stock. No approval of the holders of the Company&rsquo;s Common Stock was required to effectuate
the Amendment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of December 31, 2020 and 2019, the Company has 10,000,000
shares of preferred stock authorized for issuance, $0.001 par value per share of which 8,028 shares of Series 1 Convertible Preferred
Stock are authorized for issuance and 8,027 and 0 shares were issued and outstanding, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 89; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Protara Therapeutics, Inc. and Consolidated
Subsidiaries</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Notes to Consolidated Financial Statements</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(amounts in thousands, except share and
per share data)</I></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 8 &ndash; STOCKHOLDERS&rsquo; EQUITY (Continued)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>Description of Series 1 Convertible
Preferred Stock</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Each share of Series 1 Convertible Preferred Stock is convertible
into 1,000 shares of Common Stock, at a conversion price initially equal to approximately $7.01 per common share, subject to adjustment
for any stock splits, stock dividends and similar events, at any time at the option of the holder, provided that any conversion
of Series 1 Convertible Preferred Stock by a holder into shares of Common Stock would be prohibited if, as a result of such conversion,
the holder, together with its affiliates and any other person or entity whose beneficial ownership of the Common Stock would be
aggregated with such holder&rsquo;s for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, would beneficially
own more than 9.99% of the total number of shares Common Stock issued and outstanding after giving effect to such conversion. Upon
written notice to the Company, the holder may from time to time increase or decrease such limitation to any other percentage not
in excess of 19.99% specified in such notice. Each share of Series 1 Convertible Preferred Stock is entitled to a preference of
$10.00 per share upon liquidation of the Company, and thereafter will share ratably in any distributions or payments on an as-converted
basis with the holders of Common Stock. In addition, upon the occurrence of certain transactions that involve the merger or consolidation
of the Company, an exchange or tender offer, a sale of all or substantially all of the assets of the Company or a reclassification
of its Common Stock, each share of Series 1 Convertible Preferred Stock will be convertible into the kind and amount of securities,
cash and/or other property that the holder of a number of shares of Common Stock issuable upon conversion of one share of Series
1 Convertible Preferred Stock would receive in connection with such transaction. The Company&rsquo;s Series 1 Convertible Preferred
Stock are non-voting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The terms of the Series 1 Convertible Preferred Stock provide
that, in the event of a fundamental transaction (as such term is described in the certificate of designation of preferences, rights
and limitations of series 1 convertible non-voting preferred stock), each share of Series 1 Convertible Preferred Stock outstanding
shall thereafter be convertible into the kind and amount of securities, cash and/or other property which a holder of the number
of shares of Common Stock of the Company issuable upon conversion of one share of Series 1 Convertible Preferred Stock immediately
prior to such fundamental transaction would have been entitled to receive pursuant to such fundamental transaction, provided that,
if the value of the aggregate of such securities, cash and/or other property the which the holder of one share of Series 1 Convertible
Preferred Stock would be entitled to upon conversion thereof would be less than the stated value, then each outstanding share of
Series 1 Convertible Preferred Stock shall instead be convertible into such kind of securities, cash and/or other property with
an aggregate value equal to the stated value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>Common Stock</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On September 23, 2019, the Company completed a placement of
69,114 shares of its common stock at a price of $7.23 per share for gross proceeds of $500.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 90; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Protara Therapeutics, Inc. and Consolidated
Subsidiaries</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Notes to Consolidated Financial Statements</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(amounts in thousands, except share and
per share data)</I></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 8 &ndash; STOCKHOLDERS&rsquo; EQUITY (Continued)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>Underwritten Public Offering </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On September 24, 2020, pursuant to an underwriting agreement
dated September 22, 2020, the Company issued and sold in an underwritten public offering (the &ldquo;Common Offering&rdquo;) an
aggregate of 4,600,000 shares of its Common Stock at an offering price of $16.87 per share, for gross and net proceeds of approximately
$77.6 million and $73.6 million, respectively. The underwriters were granted an option to purchase up to 690,000 additional shares
of Common Stock at the public offering price, less the underwriting discount. On October 6, 2020, the underwriters exercised their
overallotment option in full, purchasing an additional 690,000 shares, resulting in the receipt of gross and net proceeds of $11.6
million and $11.1 million, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On September 24, 2020, pursuant to an underwriting agreement
(dated September 22, 2020), the Company issued and sold in an underwritten public offering (the &ldquo;Preferred Offering&rdquo;)
an aggregate of 4,148 shares of its Series 1 Convertible Preferred Stock at an offering price of $16,873.54 per share, for gross
and net proceeds of approximately $70.0 million and $66.3 million, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Common Offering and the Preferred Offering were made pursuant
to the Company&rsquo;s registration statement on Form S-3, declared effective by the Securities and Exchange Commission on May
26, 2020 (Registration No. 333-238273).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In December 2020, the Company filed a shelf registration statement
on Form S-3, declared effective by the Securities and Exchange Commission on December 18, 2020 (Registration No. 333-251224) (the
&ldquo;Shelf Registration Statement&rdquo;). The Shelf Registration Statement permits: (i) the offering, issuance and sale by the
Company of up to a maximum aggregate offering price of $300 million of common stock, preferred stock, debt securities and warrants
in one or more offerings and in any combination. No securities have been sold to date under the Shelf Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 9 &ndash; STOCK-BASED COMPENSATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>2020 Inducement Plan</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On March 26, 2020, the Compensation Committee of the Board of
Directors (the &ldquo;Compensation Committee&rdquo;) approved the ArTara Therapeutics, Inc. Inducement Plan (the &ldquo;2020 Inducement
Plan&rdquo;) in order to award nonstatutory stock options, restricted stock awards, restricted stock unit awards and other stock-based
awards to persons not previously an employee or director of the Company, or following a bona fide period of non-employment, as
an inducement material to such persons entering into employment with the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The 2020 Inducement Plan provides for a total of 600,000 shares
for the issuance of the Company&rsquo;s Common Stock. The Compensation Committee also adopted a form of stock option grant notice
and stock option agreement and forms of restricted stock unit grant notice and restricted stock unit agreement for use with the
Inducement Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of December 31, 2020, 460,650 shares remain available to
be issued under the 2020 Inducement Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>2017 Equity Incentive Plan </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On August 10, 2017, Private ArTara, its Board of Directors and
its shareholders approved the ArTara Therapeutics, Inc. 2017 Equity Incentive Plan (the &ldquo;2017 Equity Incentive Plan&rdquo;)
to enable Private ArTara and its affiliates to recruit and retain highly qualified personnel and to incentivize personnel for productivity
and growth.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The 2017 Equity Incentive Plan provided for the grant of a total
of 2,000,000 shares for the issuance of stock options, stock appreciation rights, restricted stock and restricted stock units to
among others, members of the Board of Directors, employees, consultants and service providers to the Company and its affiliates.
As of January 9, 2020, in connection with the Merger, no additional awards will be made under the 2017 Equity Incentive Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 91; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Protara Therapeutics, Inc. and Consolidated
Subsidiaries</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Notes to Consolidated Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(amounts in thousands, except share and
per share data)</I></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 9 &ndash; STOCK-BASED COMPENSATION (Continued)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B><I>2014 Equity Incentive Plan </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">On October 3, 2014, the stockholders approved
the 2014 Plan. On June 20, 2017, the Company&rsquo;s Board of Directors amended the 2014 Plan (the &ldquo;Amended 2014 Plan&rdquo;).
On July 31, 2017, the stockholders approved this amendment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 18pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Amended 2014 Plan provides for the grant of incentive and
non-statutory stock options, stock appreciation rights, restricted stock and stock unit awards, performance units, stock grants
and qualified performance-based awards. The 2014 Plan provides that the number of shares reserved and available for issuance under
the 2014 Plan will automatically increase each January 1, beginning January 1, 2015 by four percent of the outstanding shares of
Common Stock on the immediately preceding December 31 or such lesser number of shares as determined by the Company&rsquo;s Board
of Directors prior to each such January 1st. The Amended 2014 Plan clarifies that the number of shares for purposes of calculating
the evergreen feature includes the number of shares of Common Stock issuable upon conversion of any security that the Company may
issue that is convertible into or exchangeable for Common Stock, including, but not limited to, preferred stock or warrants. Pursuant
to a special meeting of the Proteon stockholders held on January 9, 2020, the number of shares available for issuance under the
Amended 2014 Plan increased by 900,002 shares from 148,298 shares to 1,048,300 shares on January 1, 2020. As of December 31, 2020,
227,850 shares remain available to be issued under the Amended 2014 Plan. On January 1, 2021, pursuant to the Amended 2014 Plan&rsquo;s
annual evergreen feature, the number of shares authorized under the Amended 2014 Plan was increased by 812,889 shares to 1,861,189
shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 18pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Terms of the stock awards, including vesting requirements, are
determined by the Board of Directors, subject to the provisions of the plans. Certain awards provide for accelerated vesting if
there is a change in control as defined in the plans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>2014 Employee Stock Purchase Plan</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On October 3, 2014, the stockholders approved the 2014 Employee
Stock Purchase Plan (the &ldquo;2014 ESPP&rdquo;). The 2014 ESPP initially authorized the issuance of up to 3,513 shares of Common
Stock. The number of shares increases each January 1, commencing on January 1, 2015 and ending on (and including) January 1, 2024,
by an amount equal to the lesser of one percent of the outstanding shares as of the end of the immediately preceding fiscal year,
7,025 shares or any lower amount determined by the Company&rsquo;s Board of Directors prior to each such January 1st. As of December
31, 2020, the authorized number of shares under the 2014 ESPP is 18,012 and the number of shares available for issuance is 13,340.
During the years ended December 31, 2020 and 2019, no shares were issued under the 2014 ESPP. On January 1, 2021, pursuant to the
increase per the 2014 ESPP, the number of share authorized under the 2014 ESPP was increased by 7,025 shares to 25,037 shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 92; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Protara Therapeutics, Inc. and Consolidated
Subsidiaries</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Notes to Consolidated Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(amounts in thousands, except share and
per share data)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 9 &ndash; STOCK-BASED COMPENSATION (Continued)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>Restricted Stock Units</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Awards to Directors</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following restricted stock units (&ldquo;RSUs&rdquo;) were
granted pursuant to the Amended 2014 Plan. Settlement for the RSUs is deferred until the earliest to occur of (i) the director&rsquo;s
termination of service, (ii) death, (iii) disability or (iv) a change in control of the Company. In the event of a change in control
of the Company, the RSUs will vest in full.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the year ended December 31, 2020, the Board of Directors
granted an aggregate of 316,000 RSUs to directors of the Company. Of these RSUs, 254,000 vest 12.5% on the date of grant and in
twenty-one equal monthly installments thereafter and the remaining 62,000 RSUs vest 50% on the one year anniversary of the grant
date and the remainder vest in 12 equal monthly installments thereafter. The grant date fair value of these RSUs was $9,480.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Awards to Others</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the year ended December 31, 2019, the Board of Directors
granted of 5,245 RSUs to a consultant. The RSUs were granted under the Company&rsquo;s 2017 Equity Incentive Plan. The RSUs vested
in five equal installments of 1,049 units on the 15th and 30th of each month, beginning on October 30, 2019. The grant date fair
value of this RSU was $36.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the year December 31, 2020, Board of Directors granted
an aggregate of 163,325 RSUs to employees of the Company. These RSUs will vest 25% on each of the first, second, third and fourth
year anniversaries of the date of grant. The grant date fair value of these RSUs was $4,887.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Following is a summary of restricted stock unit activities for
the year ended December 31, 2020:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Restricted Stock Units</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Weighted <BR>
Average Grant <BR>
Date Fair Value</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: left; text-indent: -0.9pt">Non-vested 1/1/2020</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 15%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: 8.1pt; text-align: left">Granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">479,325</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">29.97</TD><TD STYLE="text-align: left">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 8.1pt; text-align: left">Forfeited</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(56,375</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">30.00</TD><TD STYLE="text-align: left">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: 8.1pt; text-align: left">Vested</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">(148,334</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">30.00</TD><TD STYLE="text-align: left">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Non-vested 12/31/2020</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 4pt double">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 4pt double">274,616</TD><TD STYLE="text-align: left; padding-bottom: 4pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 4pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 4pt double">29.95</TD><TD STYLE="text-align: left; padding-bottom: 4pt">&nbsp;</TD>
    </TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 93; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Protara Therapeutics, Inc. and Consolidated
Subsidiaries</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Notes to Consolidated Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(amounts in thousands, except share and
per share data)</I></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 9 &ndash; STOCK-BASED COMPENSATION (Continued)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B><I>Restricted Stock Units (Continued)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The fair
value of restricted stock units is amortized on a straight line basis over the requisite service periods of the respective awards.
As of December 31, 2020, the unamortized value of RSUs was $6,299. As of December 31, 2020, the weighted average remaining amortization
period was 1.81 years.</FONT> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">As of December 31, 2020 and 2019, 132,709
and 5,245 RSUs, respectively, have vested that have not yet been settled into shares of the Company&rsquo;s Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the year ended December 31, 2020, the Company issued
20,870 shares of Common Stock from the settlement of RSUs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>Restricted Stock Units Modification</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On July 23, 2020, the Company agreed to accelerate the vesting
of 5,687 RSUs of a former executive. The Company recorded a charge of $152 during the year ended December 31, 2020 to research
and development expense within the Company&rsquo;s consolidated statements of operations in connection with the modification of
this award. <B> </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>Stock Option Grants</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Options to Directors</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the year ended December 31, 2019, the Board of Directors
granted options for the purchase of 47,114 shares of the Company&rsquo;s common stock to members of the board of directors. These
options were granted under the Company&rsquo;s 2017 Equity Incentive Plan, had an exercise price of $9.18 per share and a term
of 10 years. These options vest ratably over approximately four years. The options had a grant date fair value of $317.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the year ended December 31, 2020, the Board of Directors
granted options for the purchase of 80,250 shares of the Company&rsquo;s common stock to members of the board of directors. These
options were granted under the Company&rsquo;s 2014 Equity Incentive Plan, had an exercise price ranging from $26.70 to $35.00
per share and a term of 10 years. These options vest ratably over approximately one year. The options had a grant date fair value
of $1,903.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Options to Employees</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the year ended December 31, 2019, the Board of Directors
granted options for the purchase of 50,549 shares of the Company&rsquo;s common stock to employees of the Company. These options
were granted under the Company&rsquo;s 2017 Equity Incentive Plan, had an exercise price of $9.18 per share and a term of 10 years.
These options vest ratably over approximately four years. The options had a grant date fair value of $322.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the year ended December 31, 2020, the Board of Directors
granted options for the purchase of 484,850 shares of the Company&rsquo;s common stock to employees of the Company. These options
were granted under the Company&rsquo;s 2014 Equity Incentive Plan, had an exercise price ranging from $17.84 to $51.12 per share
and a term of 10 years. These options vest ratably over approximately four years. The options had a grant date fair value of $10,867.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 94; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Protara Therapeutics, Inc. and Consolidated
Subsidiaries</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Notes to Consolidated Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(amounts in thousands, except share and
per share data)</I></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 9 &ndash; STOCK-BASED COMPENSATION (Continued)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>Stock Option Modifications</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Effective July 20, 2020, a former director notified the Company
of his resignation from the Company&rsquo;s Board of Directors. In connection with his resignation, the Compensation Committee
approved the accelerated vesting of all stock options issued to him prior to the Merger, and to extend the post-termination exercise
period of vested options to 12 months from the date of resignation. Due to the modification of his options, the Company recorded
the incremental value of $501 during the year ended December 31, 2020 to general and administrative expense within the Company&rsquo;s
consolidated statements of operations.
</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>Stock Options </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company determined the fair value of stock options granted
based upon the assumptions as provided below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="vertical-align: bottom; border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">For the Years Ended </FONT><BR>
<FONT STYLE="font: 10pt Times New Roman, Times, Serif">December 31,</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; width: 40%; padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 3%; padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 27%; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2020</FONT></TD>
    <TD STYLE="vertical-align: top; width: 4%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 26%; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2019</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Stock price</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$ 17.84 - $ 51.12</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$ 6.81 - $ 8.65</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Exercise price</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$ 17.84 - $ 51.12</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$ 9.18</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Dividend yield</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">0.00%</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">0.00%</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Expected volatility</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">95.00% - 101.00%</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">97.00%</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Risk-free interest rate</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">0.28% - 1.69%</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.71% - 2.37%</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Expected life (in years)</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">5.27 - 6.08</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">5.58 - 6.02</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Following is a summary of stock option activities for the year
ended December 31, 2020:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Options</TD><TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Weighted Average Grant Date Fair Value</TD><TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Weighted Average Exercise Price</TD><TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Weighted Average Remaining Contractual Term (years)</TD><TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Aggregate Intrinsic Value</TD><TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 35%; text-indent: -0.9pt">Outstanding 1/1/2020</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">219,592</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">7.29</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">9.18</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">9.72</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: 8.1pt">Granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">565,100</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">22.61</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">29.23</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 8.1pt">Exercised</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(57,767</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.72</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9.18</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: 8.1pt">Forfeited</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">(52,886</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14.08</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">18.91</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt">Outstanding 12/31/2020</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 4pt double">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 4pt double">674,039</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">20.60</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">25.23</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9.06</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2,311</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt">Exercisable as of 12/31/2020</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 4pt double">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 4pt double">109,117</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">11.44</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">15.63</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8.25</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,201</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The weighted average grant date fair value of the options granted
during the year ended December 31, 2019 was $6.55 per share. The fair value of stock options is amortized on a straight line basis
over the requisite service periods of the respective awards. As of December 31, 2020, the unamortized value of stock options was
$9,973. As of December 31, 2020, the weighted average remaining amortization period was 3.00 years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 95; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Protara Therapeutics, Inc. and Consolidated
Subsidiaries</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Notes to Consolidated Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(amounts in thousands, except share and
per share data)</I></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 9 &ndash; STOCK-BASED COMPENSATION (Continued)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>Summary of Stock-Based Compensation
Expense</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following tables summarize total stock-based compensation
costs recognized:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -4.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid">For the Years Ended <BR>December 31,</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; text-align: left">Restricted stock</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">75</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>RSUs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,357</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">36</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Stock options</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">3,389</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">313</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Total</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">9,746</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">424</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -4.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Stock-based compensation expense was reflected within the statements
of operations as:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid">For the Years Ended <BR>December 31,</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; text-align: left">Research and development</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">741</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">200</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">General and administrative</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">9,005</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">224</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Total</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">9,746</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">424</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 10 &ndash; INCOME TAXES </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Federal and State income tax expense is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid">For the Years Ended <BR>December&nbsp;31,</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>Current</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -27.9pt; padding-left: 0.5in">Federal</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; text-indent: -27.9pt; padding-left: 0.5in">State</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -40.5pt; padding-left: 0.8in">Total current</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 5.4pt">Deferred</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; text-indent: -27.9pt; padding-left: 0.5in">Federal</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">(6,211</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">(1,614</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; text-indent: -27.9pt; padding-left: 0.5in">State</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(2,439</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(930</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -18.9pt; padding-left: 0.5in">Total deferred</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(8,650</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(2,544</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 5.4pt">Change in valuation allowance</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">8,650</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,544</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt; padding-left: 5.4pt">Total income tax expense (benefit)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 96; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Protara Therapeutics, Inc. and Consolidated
Subsidiaries</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Notes to Consolidated Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(amounts in thousands, except share and
per share data)</I></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 10 &ndash; INCOME TAXES (Continued)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Deferred income taxes, if applicable, are provided for the differences
between the basis of assets and liabilities for financial reporting and income tax purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The tax effects of temporary differences that give rise to significant
portions of the deferred tax assets are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid">As of <BR>December&nbsp;31,</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">Deferred tax assets:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; width: 74%; text-align: left">Net operating loss carry forwards</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">19,371</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">3,806</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Organization costs/legal fees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left">Stock option expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">443</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">111</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Research and development credits</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">70</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left">Operating lease liability</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">330</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Restricted stock expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">238</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left">RSU expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,796</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Charitable contributions</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left">Total deferred tax assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">22,020</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,178</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Valuation allowance</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(21,698</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(4,176</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left">Deferred tax assets, net of valuation allowance</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">322</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Deferred tax liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left">Operating right-of-use asset</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(322</TD><TD STYLE="text-align: left">)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">-</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt">Depreciation</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(2</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left">Total deferred tax liabilities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(322</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(2</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Deferred tax assets, net of valuation allowance and deferred tax liabilities</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A reconciliation of the provision for income taxes with the
amounts computed by applying the statutory Federal income tax to income before provision for income taxes is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid">For the Years Ended <BR>December&nbsp;31,</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; text-align: left">U.S. federal statutory rate</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">(21.0</TD><TD STYLE="width: 1%; text-align: left">)%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">(21.0</TD><TD STYLE="width: 1%; text-align: left">)%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">State taxes, net of federal benefit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(9.4</TD><TD STYLE="text-align: left">)%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(12.1</TD><TD STYLE="text-align: left">)%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Option expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.2</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.5</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Other</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.9</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.1</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">True-up to prior years return</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.8</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Change in valuation allowance</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">25.5</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">32.5</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Effective tax rate</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">%</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">%</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 97; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Protara Therapeutics, Inc. and Consolidated
Subsidiaries</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Notes to Consolidated Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(amounts in thousands, except share and
per share data)</I></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 10 &ndash; INCOME TAXES (Continued)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">As of December 31, 2020 for U.S. federal and state income tax
reporting purposes, the Company has approximately $63.7 million of unused net operating losses (&ldquo;NOLs&rdquo;) available for
carry forward to future years. The 2018 - 2020 federal NOLs may be carried forward indefinitely. The Company does not have the
ability to carry any of these losses back. The New York state and city NOLs may be carried forward through the year 2040 and may
be applied against future taxable income. Because United States tax laws limit the time during which NOL carry forwards may be
applied against future taxable income, the Company may be unable to take full advantage of its NOLs for federal and state income
tax purposes when the Company does generate taxable income. Further, the benefit from utilization of NOL carry forwards could be
subject to limitations due to material ownership changes that could occur as the Company continues to issue additional shares of
common stock pursuant to its capital raising plans. Based on such limitations, the Company has significant NOLs for which realization
of tax benefits is uncertain.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On January 9, 2020, the Company completed the Merger. In connection
with the Merger, the Company acquired NOL&rsquo;s from Proteon of $41.6 million. These NOLs were determined to be impaired by $12.4
million, with an annual limitation of $0.5 million on the remaining $29.2 million of NOLs. The general business credits of $3.6
million acquired in the merger were determined to be fully impaired.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As a result of the Merger, the company performed a study to
review the application of IRC &sect;382 to the Company. It was determined there was an ownership change as of January 9, 2020 and
the Company&rsquo;s NOLs generated prior to January 9, 2020 would be limited. The annual limitation of the Company&rsquo;s NOL&rsquo;s
after application of the IRC &sect;382 are $1.4 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company remains subject to examination by tax authorities
for tax years 2018 through 2020. The Company has identified its federal tax return and its state tax return in New York state and
New York City as its &ldquo;major&rdquo; tax jurisdictions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Based on a history of cumulative losses at the Company and the
results of operations for the years ended December 31, 2020 and 2019, the Company determined that it is more likely than not that
it will not realize benefits from the net deferred tax assets. The Company will not record income tax benefits in the financial
statements until it is determined that it is more likely than not that the Company will generate sufficient taxable income to realize
the deferred income tax assets. As a result of the analysis, the Company determined that a full valuation allowance against the
deferred tax assets was required. As of December 31, 2020 and 2019, the Company has recorded a valuation allowance of $21.7 million
and $4.2 million, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of December 31, 2020 and 2019, management does not believe
that the Company has any material uncertain tax positions that would require it to measure and reflect the potential lack of sustainability
of a position on audit in its consolidated financial statements. The Company will continue to evaluate its uncertain tax positions
in future periods to determine if measurement and recognition in its financial statements is necessary. The Company does not believe
there will be any material changes in its unrecognized tax positions over the next year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 98; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Protara Therapeutics, Inc. and Consolidated
Subsidiaries</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Notes to Consolidated Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(amounts in thousands, except share and
per share data)</I></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 11 &ndash; EMPLOYEE BENEFIT PLAN </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company maintains a defined contribution benefit plan under
section 401(k) of the Internal Revenue Code covering substantially all qualified employees of the Company (the &ldquo;401(k) Plan&rdquo;).
Under the 401(k) Plan, the Company matches 100% up to a 4% contribution. The 401(k) Plan was implemented in June of 2020. For the
year ended December 31, 2020, the Company recorded expense of $69 under the 401(k) Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 12 &ndash; COVID-19</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The ultimate impact of the current COVID-19 pandemic or a similar
health epidemic is highly uncertain and subject to change. The Company has experienced minimal delays, but may experience future
delays that impact its business, research and development activities, healthcare systems and the global economy as a whole. However,
the Company will continue to monitor the COVID-19 situation closely should the effects have a material impact on its operations,
liquidity and capital resources.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 18pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In response to public health directives and orders, the Company
has implemented work-from-home policies for its employees and temporarily modified its operations to comply with applicable social
distancing recommendations. Similar health directives and orders are affecting third parties with whom the Company does business,
including the third parties that the Company has contracted with to conduct studies for TARA-002. The effects of the orders and
the Company&rsquo;s related adjustments in its business are likely to negatively impact productivity, disrupt the Company&rsquo;s
business and delay its timelines, the magnitude of which will depend, in part, on the length and severity of the restrictions and
other limitations on the Company&rsquo;s ability to conduct its business in the ordinary course.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 18pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Severe and/or long-term disruptions in the Company&rsquo;s operations
will negatively impact its business, operating results and financial condition in other ways, as well. Specifically, the Company
anticipates that the stress of COVID-19 on healthcare systems around the globe will negatively impact its ability to conduct clinical
trials in the near term due primarily to the lack of resources at clinical trial sites and the resulting inability to enroll patients
in the trials. The Company also anticipates that the global impact of COVID-19 will negatively impact its ability to conduct nonclinical
studies due primarily to laboratory closures and limited availability of personnel. In addition, while the potential economic impact
brought by, and the duration of, COVID-19 may be difficult to assess or predict, it has significantly disrupted global financial
markets, and may limit the Company&rsquo;s ability to access capital, which could in the future negatively affect its liquidity.
A recession or market correction resulting from the spread of COVID-19 could materially affect the Company&rsquo;s business and
the value of its Common Stock.</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-33</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B><I>&nbsp;</I></B></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.2
<SEQUENCE>2
<FILENAME>f10k2020ex4-2_protara.htm
<DESCRIPTION>DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT OF 1934
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 4.2</B></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>DESCRIPTION OF COMMON STOCK </B></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0">The following description summarizes the most important terms
of our common stock. Because it is only a summary, it does not contain all the information that may be important to you. For a
complete description of the matters set forth in this &ldquo;Description of Common Stock,&rdquo; you should refer to our sixth
amended and restated certificate of incorporation, as amended (the &ldquo;certificate of incorporation&rdquo;), and second amended
and restated bylaws (the &ldquo;bylaws&rdquo;), which are included as exhibits to our Annual Report on Form 10-K, and to the applicable
provisions of Delaware law. Our authorized capital stock consists of 100,000,000 shares of common stock, $0.001 par value per share,
8,028 shares of Series 1 Preferred Stock, $0.001 par value per share and 9,991,972 shares of undesignated preferred stock, $0.001
par value per share. Our board of directors is authorized, without stockholder approval, except as required by the listing standards
of The Nasdaq Stock Market LLC, to issue additional shares of our capital stock. In addition, our board of directors may, without
further action by our stockholders, designate the rights, preferences, privileges, and restrictions of our preferred stock in one
or more series.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Voting Rights.</I></B> Each holder of our common stock
is entitled to one vote for each share on all matters submitted to a vote of the stockholders, including the election of directors.
Our stockholders do not have cumulative voting rights in the election of directors. An election of directors by our stockholders
shall be determined by a plurality of votes cast by the stockholders entitled to vote on the election.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Dividends.</I></B> Subject to preferences that may be
applicable to any then outstanding preferred stock, holders of our common stock are entitled to receive dividends, if any, as may
be declared from time to time by the board of directors out of legally available funds.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Liquidation.</I></B> In the event of our liquidation,
dissolution or winding up, holders of our common stock will be entitled to share ratably in the net assets legally available for
distribution to stockholders after the payment of all of our debts and other liabilities and the satisfaction of any liquidation
preference granted to the holders of any then outstanding shares of preferred stock.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Rights and Preferences.</I></B> Holders of common stock
have no preemptive, conversion or subscription rights and there are no redemption or sinking fund provisions applicable to the
common stock. The rights, preferences and privileges of the holders of common stock are subject to, and may be adversely affected
by, the rights of the holders of shares of any series of preferred stock that we may designate in the future.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Delaware Anti-Takeover Law and Provisions of Our Amended
and Restated Certificate of Incorporation, as amended, and Bylaws, as amended</B></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our certificate of incorporation and our bylaws contain certain
provisions that could have the effect of delaying, deterring or preventing another party from acquiring control of us, and therefore
could adversely affect the market price of our common stock. These provisions and certain provisions of Delaware General Corporation
Law (the &ldquo;DGCL&rdquo;), which are summarized below, may also discourage coercive takeover practices and inadequate takeover
bids, and are designed, in part, to encourage persons seeking to acquire control of us to negotiate first with our board of directors.
We believe that the benefits of increased protection of our potential ability to negotiate more favorable terms with an unfriendly
or unsolicited acquirer outweigh the disadvantages of potentially discouraging a proposal to acquire us.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B><I>Delaware Anti-Takeover Law</I></B></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are subject to Section 203 of the DGCL (&ldquo;Section 203&rdquo;).
Section 203 generally prohibits a public Delaware corporation from engaging in a &ldquo;business combination&rdquo; with an &ldquo;interested
stockholder&rdquo; for a period of three years following the time that such stockholder became an interested stockholder, unless:</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -9.6pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 26.4pt"></TD><TD STYLE="width: 9.6pt">&#9679;</TD><TD STYLE="text-align: left">prior to such time the board of directors of the corporation approved either the business combination or the transaction which
resulted in the stockholder becoming an interested stockholder;</TD></TR></TABLE>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -9.6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0 0pt 0.5in; text-indent: -9.6pt"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -9.6pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 26.4pt"></TD><TD STYLE="width: 9.6pt">&#9679;</TD><TD STYLE="text-align: left">upon consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the interested stockholder
owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes
of determining the voting stock outstanding (but not the outstanding voting stock owned by the interested stockholder) those shares
owned (i) by persons who are directors and also officers and (ii) employee stock plans in which employee participants do not have
the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or</TD></TR></TABLE>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -9.6pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 26.4pt"></TD><TD STYLE="width: 9.6pt">&#9679;</TD><TD STYLE="text-align: left">at or subsequent to such time the business combination is approved by the board of directors and authorized at an annual or
special meeting of stockholders, and not by written consent, by the affirmative vote of at least 66 2/3% of the outstanding voting
stock which is not owned by the interested stockholder.</TD></TR></TABLE>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Section 203 defines a business combination to include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 26.4pt"></TD><TD STYLE="width: 9.6pt">&#9679;<FONT STYLE="font-family: Symbol"></FONT></TD><TD>any merger or consolidation involving the corporation and the interested stockholder;</TD></TR></TABLE>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -9.6pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 26.4pt"></TD><TD STYLE="width: 9.6pt">&#9679;</TD><TD STYLE="text-align: left">any sale, transfer, pledge or other disposition involving the interested stockholder of 10% or more of the assets of the corporation;</TD></TR></TABLE>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -9.6pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 26.4pt"></TD><TD STYLE="width: 9.6pt">&#9679;</TD><TD STYLE="text-align: left">subject to exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation
to the interested stockholder;</TD></TR></TABLE>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -9.6pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 26.4pt"></TD><TD STYLE="width: 9.6pt">&#9679;</TD><TD STYLE="text-align: left">subject to exceptions, any transaction involving the corporation that has the effect of increasing the proportionate share
of the stock of any class or series of the corporation beneficially owned by the interested stockholder; and</TD></TR></TABLE>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -9.6pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 26.4pt"></TD><TD STYLE="width: 9.6pt">&#9679;</TD><TD>the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits
provided by or through the corporation.</TD></TR></TABLE>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0">In general, Section 203 defines an interested stockholder as
any entity or person beneficially owning 15% or more of the outstanding voting stock of the corporation and any entity or person
affiliated with or controlling or controlled by the entity or person.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B><I>Certificate of Incorporation and
Bylaws</I></B></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our certificate of incorporation and bylaws contain certain
provisions that are intended to enhance the likelihood of continuity and stability in the composition of the board of directors
and which may have the effect of delaying, deferring or preventing a future takeover or change in control unless such takeover
or change in control is approved by the board of directors. In addition, the authorization of undesignated preferred stock makes
it possible for our board of directors to issue preferred stock with voting or other rights or preferences that could impede the
success of any attempt to change our control. These provisions include:</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Classified board of directors.</I></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our certificate of incorporation provides that the board of
directors is divided into three classes of directors, with the classes as nearly equal in number as possible. Any additional directorships
resulting from an increase in the number of directors will be apportioned by the board of directors among the three classes. The
classification of directors will have the effect of making it more difficult for stockholders to change the composition of the
board of directors.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our certificate of incorporation provides that, subject to any
rights of holders of preferred stock to elect additional directors under specified circumstances, the number of directors will
be fixed exclusively pursuant to a resolution adopted by the board of directors. Any additional directorships resulting from an
increase in the number of directors will be distributed among the three classes so that, as nearly as possible, each class shall
consist of one third of the board of directors.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.5in"><I></I></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Action by Written Consent; Special Meetings
of Stockholders.</I></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our certificate of incorporation provides that stockholder action
can be taken only at an annual or special meeting of stockholders and cannot be taken by written consent in lieu of a meeting.
Our certificate of incorporation and bylaws also provide that, except as otherwise required by law, special meetings of the stockholders
can be called only by or at the direction of the board of directors pursuant to a resolution adopted by a majority of the total
number of directors. Except as described above, stockholders will not be permitted to call a special meeting or to require the
board of directors to call a special meeting.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Removal of Directors.</I></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our certificate of incorporation provides that our directors
may be removed only for cause by the affirmative vote of at least 75% of the voting power of our outstanding shares of capital
stock, voting together as a single class and entitled to vote in the election of directors. This requirement of a supermajority
vote to remove directors could enable a minority of our stockholders to prevent a change in the composition of the board of directors.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Advance Notice Procedures.</I></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our bylaws include an advance notice procedure for stockholder
proposals to be brought before an annual meeting of our stockholders, including proposed nominations of persons for election to
the board of directors. Stockholders at an annual meeting will only be able to consider proposals or nominations specified in the
notice of meeting or brought before the meeting by or at the direction of the board of directors or by a stockholder who was a
stockholder of record on the record date for the meeting, who is entitled to vote at the meeting and who has given our Secretary
timely written notice, in proper form, of the stockholder&rsquo;s intention to bring that business before the meeting. Although the bylaws
do not give the board of directors the power to approve or disapprove stockholder nominations of candidates or proposals regarding
other business to be conducted at a special or annual meeting, the bylaws may have the effect of precluding the conduct of certain
business at a meeting if the proper procedures are not followed or may discourage or deter a potential acquirer from conducting
a solicitation of proxies to elect its own slate of directors or otherwise attempting to obtain control of us.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Super Majority Approval Requirements.</I></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Delaware General Corporation Law generally provides that
the affirmative vote of a majority of the shares entitled to vote on any matter is required to amend a corporation&rsquo;s certificate
of incorporation or bylaws, unless either a corporation&rsquo;s certificate of incorporation or bylaws requires a greater percentage.
Our certificate of incorporation and bylaws provide that the affirmative vote of holders of at least 75% of the outstanding shares
of capital stock, voting together as a single class and entitled to vote in the election of directors will be required to amend,
alter, change or repeal the bylaws and the certificate of incorporation. This requirement of a supermajority vote to approve amendments
to our bylaws could enable a minority of our stockholders to exercise veto power over any such amendments.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Authorized but Unissued Shares.</I></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our authorized but unissued shares of common stock will be available
for future issuance without stockholder approval. These additional shares may be utilized for a variety of corporate purposes,
including future public offerings to raise additional capital, corporate acquisitions and employee benefit plans. The existence
of authorized but unissued shares of common stock could render more difficult or discourage an attempt to obtain control of a majority
of our common stock by means of a proxy contest, tender offer, merger or otherwise.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Exclusive Forum.</I></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our certificate of incorporation provides that, subject to limited
exceptions, the state or federal courts located in the State of Delaware will be the sole and exclusive forum for (i) any derivative
action or proceeding brought on our behalf, (ii) any action asserting a claim of breach of a fiduciary duty owed by any of our
directors, officers or other employees to us or our stockholders, (iii) any action asserting a claim against us arising pursuant
to any provision of the Delaware General Corporation Law, our certificate of incorporation or our bylaws, or (iv) any other action
asserting a claim against our that is governed by the internal affairs doctrine; provided, that these provisions will not apply
to actions or proceedings brought to enforce a duty or liability created by the Securities Act of 1933, as amended, the Securities
Exchange Act of 1934, as amended, or any other claim for which the federal courts have exclusive jurisdiction. Any person or entity
purchasing or otherwise acquiring any interest in shares of our capital stock shall be deemed to have notice of and to have consented
to the provisions of our certificate of incorporation described above. Although we believes these provisions benefit us by providing
increased consistency in the application of Delaware law for the specified types of actions and proceedings, the provisions may
have the effect of discouraging lawsuits against our directors and officers. The enforceability of similar choice of forum provisions
in other companies&rsquo; certificates of incorporation has been challenged in legal proceedings, and it is possible that, in connection
with one or more actions or proceedings described above, a court could find the choice of forum provisions contained in our certificate
of incorporation to be inapplicable or unenforceable.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt"><B><I>&nbsp;</I></B></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt"><B><I>Transfer Agent and Registrar
</I></B></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The transfer agent and registrar for our common stock is Computershare
Trust Company, N.A.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Listing</I></B></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our common stock is listed on The Nasdaq Capital Market under
the symbol &ldquo;TARA.&rdquo;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">4</P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.25
<SEQUENCE>3
<FILENAME>f10k2020ex10-25_protara.htm
<DESCRIPTION>LEASE BY AND BETWEEN 345 PAS HOLDING LLC, AND THE REGISTRANT, DATED AS OF DECEMBER 7, 2020
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0pt"><B>Exhibit 10.25</B></P>

<P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase"><FONT STYLE="text-transform: none">&ldquo;CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND
(II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.&rdquo;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase"><FONT STYLE="text-transform: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0in"><B><I>Execution Version</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B></B></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">345 PAS HOLDING LLC,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">Landlord,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">TO</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">PROTARA THERAPEUTICS INC.,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">Tenant</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-weight: normal">LEASE</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-weight: normal"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">Premises at:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">345 Park Avenue South</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">New York, New York</P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B><U>TABLE OF CONTENTS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in; padding-bottom: 1.5pt; width: 10%; text-align: right; text-indent: 0in"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 80%; text-align: right; text-indent: 0in"><B>&nbsp;</B></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 10%; text-align: center; text-indent: 0in"><FONT STYLE="text-decoration: none"><B>PAGE</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">ARTICLE 1 BASIC LEASE PROVISIONS AND ENUMERATION OF EXHIBITS</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">1</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">1.1</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">INTRODUCTION</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">1</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">1.2</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">BASIC DATA</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">1</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">1.3</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">ENUMERATION OF EXHIBITS</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">3</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">1.4</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">OTHER DEFINITIONS</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">4</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2" STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">ARTICLE 2 PREMISES</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">7</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">2.1</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">DEMISE &ndash; PREMISES</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in">7</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">2.2</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">APPURTENANT RIGHTS AND RESERVATIONS</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in">7</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">ARTICLE 3 LEASE TERM</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">8</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">3.1</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">COMMENCEMENT DATE</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in">8</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">3.2</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">EXPIRATION DATE</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">9</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">3.3</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">COMMENCEMENT DATE AGREEMENT</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in">9</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">ARTICLE 4 COMPLETION OF THE PREMISES</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">11</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">4.1</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">PERFORMANCE OF WORK</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">11</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">4.2</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">QUALITY AND PERFORMANCE OF WORK</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">11</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2" STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">ARTICLE 5 ANNUAL FIXED RENT AND ADDITIONAL RENT</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">12</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">5.1</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">FIXED RENT</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">12</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">5.2</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">ADVANCE PAYMENT OF ONE MONTH&rsquo;S RENT</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">12</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">5.3</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">ADDITIONAL RENT</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">12</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">5.4</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">LATE PAYMENT</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">13</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">5.5</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">RENT CONCESSION</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">13</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2" STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">ARTICLE 6 TAXES, IMPOSITIONS, PILOT AND OPERATING EXPENSES</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">14</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">6.1</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">TAXES, IMPOSITIONS AND PILOT</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">14</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">6.2</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">OPERATING EXPENSE ESCALATION</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">19</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">ARTICLE 7 REPAIRS AND SERVICES</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">26</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">7.1</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">LANDLORD&rsquo;S OBLIGATION TO REPAIR</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">26</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">7.2</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">TENANT&rsquo;S REPAIRS AND MAINTENANCE</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">27</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">7.3</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">SERVICES</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">28</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">7.4</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">LAB COSTS</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in">28</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2" STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">ARTICLE 8 ALTERATIONS</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">29</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">8.1</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">TENANT&rsquo;S RIGHTS</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">29</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">8.2</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">CONFORMITY WITH LAW</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">31</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">8.3</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">PERFORMANCE OF WORK, GOVERNMENTAL APPROVALS, INSURANCE</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">31</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">8.4</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">LIENS</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">32</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">8.5</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">VIOLATIONS; DISRUPTION</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">32</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">8.6</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">TENANT&rsquo;S PROPERTY</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">33</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">8.7</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">SURVIVAL</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">33</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2" STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">ARTICLE 9 LAWS, ORDINANCES, REQUIREMENTS OF PUBLIC AUTHORITIES</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">34</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">9.1</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">CERTIFICATE OF OCCUPANCY</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">34</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">9.2</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">TENANT&rsquo;S OBLIGATIONS</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">34</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">9.3</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">TENANT&rsquo;S RIGHT TO CONTEST</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">34</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">9.4</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">WINDOW CLEANING</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">35</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">ARTICLE 10 USE</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">35</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in; width: 10%">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in; width: 80%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in; width: 10%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">10.1</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">PERMITTED USE</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">35</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">10.2</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">ADDITIONAL PERMITTED USES</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">35</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">10.3</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">RESTRICTIONS</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">36</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">10.4</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">PROHIBITED USES</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">36</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">10.5</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">LICENSES AND PERMITS</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">38</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">10.6</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">HAZARDOUS SUBSTANCES</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">38</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">10.7</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">OPERATIONS AND MAINTENANCE PROGRAMS</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">39</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">10.8</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">FITNESS CENTER</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">39</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">10.9</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">PANTRIES</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">40</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">10.10</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">WET INSTALLATIONS</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">40</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2" STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">ARTICLE 11 TENANT&rsquo;S INDEMNITY AND INSURANCE</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">40</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">11.1</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">TENANT&rsquo;S INDEMNITY</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">40</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">11.2</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">TENANT&rsquo;S RISK</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">42</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">11.3</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">TENANT&rsquo;S COMMERCIAL GENERAL LIABILITY INSURANCE</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">42</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">11.4</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">TENANT&rsquo;S PROPERTY INSURANCE</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">43</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">11.5</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">TENANT&rsquo;S OTHER INSURANCE</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">43</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">11.6</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">REQUIREMENTS FOR INSURANCE</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">44</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">11.7</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">ADDITIONAL INSUREDS</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">44</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">11.8</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">CERTIFICATES OF INSURANCE</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">45</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">11.9</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">SUBTENANTS AND OTHER OCCUPANTS</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">45</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">11.10</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">NO VIOLATION OF BUILDING POLICIES</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">45</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">11.11</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">TENANT TO PAY PREMIUM INCREASES</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">45</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">11.12</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">WAIVER OF SUBROGATION</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">46</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">11.13</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">ALTERATIONS</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">46</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">11.14</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">LANDLORD INDEMNITY</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">46</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">ARTICLE 12 FIRE, CASUALTY OR TAKING</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">47</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">12.1</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">RIGHT TO TERMINATE LEASE</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">47</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">12.2</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">RESTORATION OF THE PREMISES</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">48</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">12.3</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">PAYMENT OF RENT FOLLOWING CASUALTY</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in">48</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">12.4</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">UNINSURED CASUALTY</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">49</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">12.5</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">LANDLORD NOT TO INSURE LEASEHOLD IMPROVEMENTS OR TENANT&rsquo;S PROPERTY</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">49</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">12.6</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">EMINENT DOMAIN &ndash; COMPLETE OR SUBSTANTIAL TAKING</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">49</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">12.7</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">EMINENT DOMAIN &ndash; PARTIAL TAKING</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">50</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">12.8</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">LANDLORD TO RECEIVE ENTIRE AWARD</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">50</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2" STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">ARTICLE 13 ASSIGNMENT, SUBLETTING, MORTGAGING</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">51</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">13.1</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">LANDLORD&rsquo;S CONSENT REQUIRED</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">51</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">13.2</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">OFFER NOTICE</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">53</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">13.3</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">LANDLORD&rsquo;S RIGHT TO UNDERLET</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">54</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">13.4</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">LANDLORD&rsquo;S RIGHT TO TERMINATE</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">56</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">13.5</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">ADDITIONAL CONDITIONS</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">56</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">13.6</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">LANDLORD MAY COLLECT RENT FROM SUBTENANT OR ASSIGNEE</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">58</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">13.7</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">ASSUMPTION OF LEASE</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in">59</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">13.8</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">TENANT&rsquo;S INDEMNIFICATION</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">59</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">13.9</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">TIME LIMITATION; AMENDMENTS</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">59</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">13.10</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">ADDITIONAL RENT DUE UPON ASSIGNMENT OR SUBLETTING</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">59</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">13.11</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">LIABILITY NOT DISCHARGED</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">60</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">13.12</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">EFFECT OF LISTING OF NAMES</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">60</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">13.13</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">GOOD REPUTATION</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">60</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2" STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">ARTICLE 14 NO LIABILITY OR REPRESENTATIONS BY LANDLORD; FORCE MAJEURE</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">61</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">14.1</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">NO LIABILITY</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">61</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; width: 10%; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">14.2</FONT></TD>
    <TD STYLE="width: 80%; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">NO REPRESENTATIONS BY LANDLORD</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 10%; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">62</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">14.3</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">FORCE MAJEURE</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">62</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2" STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">ARTICLE 15 ENTRY, RIGHT TO CHANGE PUBLIC PORTIONS OF THE BUILDING</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">62</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">15.1</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">LANDLORD&rsquo;S RIGHT OF ENTRY</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">62</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">15.2</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">LANDLORD&rsquo;S RIGHT TO CHANGE ENTRIES, ETC.</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">64</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">15.3</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">EXCAVATION</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">64</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2" STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">ARTICLE 16 ELECTRICITY</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">64</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">16.1</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">TENANT TO PURCHASE ELECTRICITY</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">64</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">16.2</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">LANDLORD NOT LIABLE</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">65</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">16.3</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">TENANT NOT TO OVERLOAD CIRCUITS</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">65</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">16.4</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">TENANT NOT TO EXCEED CAPACITY; LIGHT BULBS</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">65</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">ARTICLE 17 SUBORDINATION; ASSIGNMENT OF RENTS</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">65</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">17.1</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">SUBORDINATION TO MORTGAGES, ETC.</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">65</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">17.2</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">RIGHTS OF MORTGAGEES, ETC.</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in">67</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">17.3</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">MODIFICATIONS REQUIRED BY LENDERS</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">67</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">17.4</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">ASSIGNMENT OF LEASE TO MORTGAGEE, ETC.</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">67</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">17.5</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">SUBORDINATION OF MORTGAGE, ETC., TO LEASE</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">68</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">ARTICLE 18 CERTAIN ADDITIONAL TENANT COVENANTS</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">68</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">ARTICLE 19 TENANT&rsquo;S DEFAULT; LANDLORD&rsquo;S REMEDIES</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">69</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">19.1</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">TENANT&rsquo;S DEFAULT</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">69</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">19.2</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">TERMINATION</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">72</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">19.3</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">RE-ENTRY; CONTINUED LIABILITY; RELETTING</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">73</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">19.4</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">LIQUIDATED DAMAGES</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">74</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">19.5</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">RIGHTS IN THE EVENT OF TENANT&rsquo;S BANKRUPTCY</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">74</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">19.6</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">WAIVER OF REDEMPTION, ETC.</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">74</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">19.7</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">ADDITIONAL RIGHTS OF LANDLORD</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">75</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">19.8</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">LANDLORD&rsquo;S DEFAULT</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">75</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">19.9</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">FEES AND EXPENSES</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">76</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">ARTICLE 20 MISCELLANEOUS</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">76</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">20.1</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">WAIVER</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">76</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">20.2</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">CONSENTS</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">77</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">20.3</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">QUIET ENJOYMENT</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">77</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">20.4</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">SURRENDER</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">78</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">20.5</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">BROKER</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">78</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">20.6</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">INVALIDITY OF PARTICULAR PROVISIONS</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">79</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">20.7</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">PROVISIONS BINDING, ETC</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">79</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">20.8</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">NO RECORDING</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">79</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">20.9</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">NOTICES</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">79</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">20.10</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">WHEN LEASE BECOMES BINDING</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">80</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">20.11</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">HEADINGS</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">80</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">20.12</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">SUSPENSION OF SERVICES</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">80</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">20.13</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">RULES AND REGULATIONS</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">81</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">20.14</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">DEVELOPMENT RIGHTS</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">82</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">20.15</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">ESTOPPEL CERTIFICATES</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">82</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">20.16</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">SELF-HELP</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">83</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">20.17</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">HOLDING OVER</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">83</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">20.18</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">RENT CONTROL</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">83</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">20.19</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">COUNTERPARTS</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">84</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">20.20</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">ENTIRE AGREEMENT</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">84</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">20.21</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">NO PARTNERSHIP</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">84</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; width: 10%; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">20.22</FONT></TD>
    <TD STYLE="width: 80%; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">SECURITY DEPOSIT</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 10%; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">84</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">20.23</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">FINANCIAL STATEMENTS</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in">86</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">20.24</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">GOVERNING LAW, ETC.</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">86</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">20.25</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">CONDOMINIUM CONVERSION</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">87</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">20.26</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">CONFIDENTIALITY OF LEASE</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">87</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">20.27</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">OFAC</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">88</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">20.28</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">ELECTRONIC SIGNATURES</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">88</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">20.29</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">BUILDING NAME AND SIGNAGE</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">89</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">20.30</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">IDA PILOT PROGRAM</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">89</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">20.31</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">EMISSIONS</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">89</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">20.32</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">REGULATORY REQUIREMENTS.</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">90</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">20.33</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">LAB AREA AND LAB REQUIREMENTS</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">90</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">20.34</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">RIGHT OF FIRST OFFER.</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">92</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iv<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">THIS INSTRUMENT IS AN
INDENTURE OF LEASE in which the Landlord and the Tenant are the parties hereinafter named, and which relates to space in the building
(the &ldquo;Building&rdquo;) known as, and with an address at, 345 Park Avenue South, New York, New York 10010.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">The parties to this
instrument hereby agree with each other as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase"><U>ARTICLE
1</U></FONT><BR>
<BR>
<U>B<FONT STYLE="text-transform: uppercase">ASIC LEASE PROVISIONS AND ENUMERATION OF EXHIBITS</FONT></U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">1.1 <U>INTRODUCTION</U>.
The following sets forth the basic data and identifying Exhibits, elsewhere hereinafter referred to in this Lease, and, where appropriate,
constitutes definitions of the terms hereinafter listed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">1.2 <U>BASIC DATA</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: left">&nbsp;</TD>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; width: 2.25in; text-align: left">Date:</TD>
    <TD STYLE="width: 0.1in; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">December 1, 2020</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Landlord:</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">345 PAS HOLDING LLC,</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">a Delaware limited liability
        company</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Present Mailing Address of Landlord:</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">c/o Deerfield Management
        Company, L.P.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">780 Third Avenue</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">New York, New York 10017</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">Attn.: Karen Noy</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">with a copy to:</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">Vinson &amp; Elkins LLP</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">The Grace Building</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">1114 Avenue of the Americas,
        32<SUP>nd</SUP> Floor</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">New York, New York 10036</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">Attn: Adam M. Endick,
        Esq.</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Landlord&rsquo;s Construction Representative:</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">MLP Ventures</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">201 King of Prussia Road,
        Suite 501</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">Radnor, PA 19087</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">Attn: Joseph Kelly</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">with a copy to:</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">Campbell Rocco Law<BR>
2701 Renaissance Boulevard,
        4<SUP>th</SUP> Floor</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">King of Prussia, Pennsylvania
        19406</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">Attn: Joseph Rocco,
Esq.</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; width: 0.5in">&nbsp;</TD>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left; width: 2.25in"><FONT STYLE="font-size: 10pt">Tenant:</FONT></TD>
    <TD STYLE="text-align: left; width: 0.1in">&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">ProTara Therapeutics Inc.,</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">a Delaware corporation</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-size: 10pt">Present Mailing Address of Tenant:</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">1 Little West 12<SUP>th</SUP>
        Street</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">New York, New York 10014</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">Attn.: Blaine Davis, CFO</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">with a copy to:</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">Cooley LLP</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">55 Hudson Yards</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">New York, New York 10001</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">Attn: Daniel A. Goldberger,
        Esq.</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-size: 10pt">Commencement Date:</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">As defined in Section 3.1 hereof.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-size: 10pt">Rent Commencement Date:</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">The date which is one (1) month after the Commencement Date.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-size: 10pt">Rent Concession Period:</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">As defined in Section 5.5 hereof.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-size: 10pt">Initial Expiration Date:</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">As defined in Section 3.2 hereof.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-size: 10pt">Expiration Date:</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">As defined in Section 3.2 hereof.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-size: 10pt">Lease Term:</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">As defined in Section 3.1 hereof.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-size: 10pt">Lease Year:</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">A period of twelve (12) consecutive calendar months commencing on the Commencement Date and ending on the day preceding the first (1st) anniversary of the Commencement Date, and each succeeding period of twelve (12) consecutive calendar months thereafter during the Lease Term commencing on each anniversary of the Commencement Date and ending on the day preceding the next anniversary of the Commencement Date, except that the last Lease Year shall end on the Expiration Date or such earlier date upon which the Lease Term may expire or be terminated pursuant to any of the conditions of limitation or other provisions of this Lease or pursuant to law.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-size: 10pt">Building:</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">The building and other improvements erected on the Land known as and by the street number 345 Park Avenue South, New York, New York.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: left">&nbsp;</TD>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; width: 2.25in; text-align: left"><FONT STYLE="font-size: 10pt">Premises:</FONT></TD>
    <TD STYLE="width: 0.1in; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">That portion of the Building depicted in Exhibit B hereto.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-size: 10pt">Annual Fixed Rent:</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">From the Rent Commencement Date through the day preceding the fourth (4<SUP>th</SUP>) anniversary of the Rent Commencement Date, the sum of One Million One Hundred Seventeen Thousand Four Hundred Sixty-Eight and 00/100 Dollars ($1,117,468.00);</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">and from the fourth (4<SUP>th</SUP>) anniversary of the Rent Commencement Date through the Expiration Date, the sum of One Million Two Hundred Nineteen Thousand Nine Hundred Eighty-Eight and 00/100 Dollars ($1,219,988.00).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-size: 10pt">Additional Rent:</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">All charges and other sums payable by Tenant as set forth in this Lease, other than and in addition to Annual Fixed Rent.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-size: 10pt">Tenant&rsquo;s Share:</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">[***]%.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-size: 10pt">GAAP:</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">United States generally accepted accounting principles consistently applied.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-size: 10pt">Security Deposit:</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">At all times, an amount equal to $[***] (subject to reduction as provided in Section 20.22).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-size: 10pt">Brokers:</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">CBRE, Inc.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-size: 10pt">Guarantor:</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">None.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">1.3 <U>ENUMERATION
OF EXHIBITS</U>. The following Exhibits are a part of this Lease, are incorporated herein by reference, attached hereto, and are
to be treated as a part of this Lease for all purposes. Undertakings contained in such Exhibits are agreements on the part of Landlord
and Tenant, as the case may be, to perform the obligations stated therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 1in; text-align: left; text-indent: 0in">Exhibit A</TD>
    <TD STYLE="width: 0.2in; text-align: center">--</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Description of the Land.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Exhibit B</TD>
    <TD STYLE="text-align: center">--</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Floor Plans of Premises.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Exhibit C</TD>
    <TD STYLE="text-align: center">--</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Work Letter.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Schedule C-1</TD>
    <TD STYLE="text-align: center">--</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Base Work.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Schedule C-2</TD>
    <TD STYLE="text-align: center">--</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Scheduled Tenant Changes</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Schedule C-3</TD>
    <TD STYLE="text-align: center">--</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Test Fit</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Exhibit D</TD>
    <TD STYLE="text-align: center">--</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Landlord&rsquo;s Services.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 1in; text-align: left; text-indent: 0in">Exhibit E</TD>
    <TD STYLE="width: 0.2in; text-align: center">--</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Rules and Regulations.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Exhibit F</TD>
    <TD STYLE="text-align: center">--</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Form of Letter of Credit.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Exhibit G</TD>
    <TD STYLE="text-align: center">--</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Form of Commencement Date Agreement.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Exhibit H</TD>
    <TD STYLE="text-align: center">--</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Rider to Tenant Lease Agreement.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Exhibit I</TD>
    <TD STYLE="text-align: center">--</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Form of Living Wage Agreement.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Exhibit J</TD>
    <TD STYLE="text-align: center">--</TD>
    <TD STYLE="text-align: left; text-indent: 0in">HireNYC Requirements.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Schedule 6.1.4(c)</TD>
    <TD STYLE="text-align: center">--</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Agency Lease PILOT Payment Schedule.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">1.4 <U>OTHER DEFINITIONS</U>.
The following additional terms, wherever used in this Lease (unless the context requires otherwise), shall have the respective
meanings specified in the Sections of this Lease set forth below after such Terms:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 93%; border-collapse: collapse; margin-left: 0.5in">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 80%; text-align: left">&ldquo;AAA&rdquo;</TD>
    <TD STYLE="width: 20%; text-align: left">Section 3.4.3(b)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&ldquo;Additional Insureds&rdquo;</TD>
    <TD STYLE="text-align: left">Section 11.7</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&ldquo;Additional Tenant Changes&rdquo;</TD>
    <TD STYLE="text-align: left">Exhibit C</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&ldquo;Affiliate&rdquo;</TD>
    <TD STYLE="text-align: left">Section 13.1</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&ldquo;Agency Lease&rdquo;</TD>
    <TD STYLE="text-align: left">Section 6.1</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&ldquo;Alterations&rdquo;</TD>
    <TD STYLE="text-align: left">Section 8.1</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&ldquo;Anticipated Delivery Date&rdquo;&rdquo;</TD>
    <TD STYLE="text-align: left">Section 3.1</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&ldquo;available for leasing&rdquo;</TD>
    <TD STYLE="text-align: left">Section 20.34(f)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&ldquo;Base Taxes&rdquo;</TD>
    <TD STYLE="text-align: left">Section 6.1</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&ldquo;Base Work&rdquo;</TD>
    <TD STYLE="text-align: left">Exhibit C</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&ldquo;BID Surcharge&rdquo;</TD>
    <TD STYLE="text-align: left">Section 6.1</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&ldquo;Burn Down Amount&rdquo;</TD>
    <TD STYLE="text-align: left">Section 20.22</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&ldquo;Burn Down Conditions&rdquo;</TD>
    <TD STYLE="text-align: left">Section 20.22</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&ldquo;Burn Down Date&rdquo;</TD>
    <TD STYLE="text-align: left">Section 20.22</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&ldquo;Cash Deposit&rdquo;</TD>
    <TD STYLE="text-align: left">Section 20.22</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&ldquo;Conversion&rdquo;</TD>
    <TD STYLE="text-align: left">Section 20.25</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&ldquo;Change Cost&rdquo;</TD>
    <TD STYLE="text-align: left">Exhibit C</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&ldquo;Date of the taking&rdquo;</TD>
    <TD STYLE="text-align: left">Section 12.6</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&ldquo;Due date&rdquo;</TD>
    <TD STYLE="text-align: left">Section 5.4</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&ldquo;Electronic signature&rdquo;</TD>
    <TD STYLE="text-align: left">Section 20.28</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&ldquo;Event of Default&rdquo;</TD>
    <TD STYLE="text-align: left">Section 19.1</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&ldquo;Excess Operating Expenses&rdquo;</TD>
    <TD STYLE="text-align: left">Section 6.2</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&ldquo;Fair Market Rent&rdquo;</TD>
    <TD STYLE="text-align: left">Section 3.4.3(a)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&ldquo;Fair Market Rent Proposal&rdquo;</TD>
    <TD STYLE="text-align: left">Section 3.4.3(b)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&ldquo;Fitness Center&rdquo;</TD>
    <TD STYLE="text-align: left">Section 10.8</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&ldquo;Force Majeure&rdquo;</TD>
    <TD STYLE="text-align: left">Section 14.3</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&ldquo;Hazardous Substance&rdquo;</TD>
    <TD STYLE="text-align: left">Section 10.6</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&ldquo;Impositions&rdquo;</TD>
    <TD STYLE="text-align: left">Section 6.1</TD></TR>
</TABLE>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 93%; border-collapse: collapse; margin-left: 0.5in">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 80%; text-align: left; text-indent: 0in">&ldquo;Incoming Deliveries&rdquo;</TD>
    <TD STYLE="width: 20%; text-align: left; text-indent: 0in">Schedule D-2</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&ldquo;Initiating Party&rdquo;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Section 3.4.3(b)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&ldquo;ISO&rdquo;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Section 11.3</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&ldquo;Lab Area&rdquo;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Section 7.4</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&ldquo;Lab Costs&rdquo;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Section 7.4</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&ldquo;Lab Rules and Regulations&rdquo;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Section 20.13</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&ldquo;Lab Systems&rdquo;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Section 20.33</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&ldquo;Land&rdquo;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Section 2.1</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&ldquo;Landlord Parties&rdquo;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Section 11.1</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&ldquo;Landlord&rsquo;s Statement&rdquo;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Section 6.2.2</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&ldquo;Latent Defect&rdquo;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Section 7.1</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&ldquo;Lease Interest Rate&rdquo;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Section 5.4</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&ldquo;Leasehold Improvements&rdquo;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Section 8.1</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&ldquo;Letter&rdquo;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Section 20.22</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&ldquo;Letter of Credit&rdquo;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Section 20.22</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&ldquo;Lien&rdquo;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Section 8.4</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&ldquo;LW Agreement&rdquo;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Section 20.30</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&ldquo;Non-Common Expenses&rdquo;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Section 6.2</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&ldquo;Non-Common Services&rdquo;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Section 6.2</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&ldquo;Non-Qualified Use&rdquo;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Section 10.1</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&ldquo;notice&rdquo;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Section 20.9; Exhibit C</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&ldquo;Messenger Center&rdquo;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Schedule D-2</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&ldquo;Messenger Center Operating Hours&rdquo;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Schedule D-2</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&ldquo;Mortgagee&rdquo;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Section 17.1</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&ldquo;OFAC&rdquo;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Section 20.27</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&ldquo;Offer Notice&rdquo;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Section 13.2</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&ldquo;Offered Space&rdquo;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Section 20.34</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&ldquo;Operating Days&rdquo;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Exhibit D</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&ldquo;Operating Expense Statement Date&rdquo;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Section 6.2</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&ldquo;Operating Expenses&rdquo;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Section 6.2</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&ldquo;Operating Hours&rdquo;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Exhibit D</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&ldquo;Operating Year&rdquo;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Section 6.2</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&ldquo;Original Tenant&rdquo;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Section 13.1</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&ldquo;Outside Date&rdquo;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Section 3.1</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&ldquo;Outgoing Deliveries&rdquo;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Schedule D-2</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&ldquo;Overlandlord&rdquo;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Section 17.1</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&ldquo;Overtime Service&rdquo;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Exhibit D</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&ldquo;Permitted Capital Expenditures&rdquo;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Section 6.2</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&ldquo;PILOT&rdquo;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Section 6.1</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&ldquo;PILOT Commencement Date&rdquo;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Section 6.1</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&ldquo;PILOT Percentage&rdquo;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Section 6.1</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&ldquo;PILOT Program&rdquo;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Section 6.1</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&ldquo;PILOT Term&rdquo;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Section 6.1</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&ldquo;Plans and Specifications&rdquo;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Exhibit C</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&ldquo;Prohibited Person&rdquo;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Section 20.27</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&ldquo;Projected Annual Savings&rdquo;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Section 6.2</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 93%; border-collapse: collapse; margin-left: 0.5in">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 80%; text-align: left; text-indent: 0in">&ldquo;Property&rdquo;</TD>
    <TD STYLE="width: 20%; text-align: left; text-indent: 0in">Section 6.2</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&ldquo;Punchlist Items&rdquo;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Exhibit C</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&ldquo;Qualified Arbitrator&rdquo;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Section 3.4.3(b)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&ldquo;Qualified Life Science Uses&rdquo;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Section 10.1</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&ldquo;Regulated Medical Waste&rdquo;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Section 20.33</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&ldquo;REIT&rdquo;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Section 7.3</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&ldquo;Renewal Notice&rdquo;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Section 3.4.1</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&ldquo;Renewal Term&rdquo;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Section 3.4.1</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&ldquo;Renewal Term Commencement Date&rdquo;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Section 3.4.1</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&ldquo;Renewal Term Expiration Date&rdquo;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Section 3.4.1</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&ldquo;Renewal Option&rdquo;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Section 3.4.1</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&ldquo;rent&rdquo;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Section 5.3</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&ldquo;Replacement Letter&rdquo;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Section 20.22</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&ldquo;Rider&rdquo;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Section 20.30</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&ldquo;ROFO Conditions&rdquo;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Section 20.34</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&ldquo;ROFO Election Notice&rdquo;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Section 20.34</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&ldquo;ROFO Delivery Date&rdquo;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Section 20.34</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&ldquo;ROFO Notice&rdquo;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Section 20.34</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&ldquo;ROFO Offer&rdquo;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Section 20.34</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&ldquo;ROFO Option&rdquo;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Section 20.34</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&ldquo;Rules and Regulations&rdquo;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Section 20.13</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&ldquo;Service Provider&rdquo;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Section 7.3</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&ldquo;Scheduled Tenant Changes&rdquo;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Exhibit C</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&ldquo;Space Occupant&rdquo;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Section 13.1(e)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&ldquo;Specialty Alterations&rdquo;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Section 8.1</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&ldquo;Substantial Completion&rdquo;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Exhibit C</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&ldquo;Taxes&rdquo;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Section 6.1</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&ldquo;Tax Expenses&rdquo;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Section 6.1</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&ldquo;Tax Year&rdquo;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Section 6.1</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&ldquo;Tenant Changes&rdquo;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Exhibit C</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&ldquo;Tenant Delay&rdquo;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Exhibit C</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&ldquo;Tenant Parties&rdquo;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Section 11.1</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&ldquo;Tenant Advertisement&rdquo;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Exhibit E</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&ldquo;Tenant&rsquo;s Architect&rdquo;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Exhibit C</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&ldquo;Tenant&rsquo;s Costs&rdquo;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Exhibit C</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&ldquo;Tenant&rsquo;s Property&rdquo;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Section 8.6</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&ldquo;Tenant&rsquo;s Share of BID&rdquo;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Section 6.1</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&ldquo;Tenant&rsquo;s Share of Impositions&rdquo;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Section 6.1</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&ldquo;Tenant&rsquo;s Share of PILOT&rdquo;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Section 6.1</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&ldquo;Tenant&rsquo;s Share of Taxes&rdquo;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Section 6.1</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&ldquo;Tenant&rsquo;s Tax Payment&rdquo;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Section 6.1</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&ldquo;Tenant&rsquo;s Termination Notice&rdquo;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Section 3.1</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&ldquo;Tenant&rsquo;s Work&rdquo;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Exhibit C</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&ldquo;Test Fit&rdquo;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Exhibit C</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&ldquo;Underlying Lease&rdquo;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Section 17.1</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&ldquo;Untenantable&rdquo;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Section 20.12</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="width: 80%; text-align: left; text-indent: 0in">&ldquo;Wet Installations&rdquo;</TD>
    <TD STYLE="width: 20%; text-align: left; text-indent: 0in">Section 10.10</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&ldquo;Work&rdquo;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Exhibit C</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&ldquo;Work Letter&rdquo;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Exhibit C</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase"><U>ARTICLE
2</U></FONT><BR>
<BR>
<U>P<FONT STYLE="text-transform: uppercase">REMISES</FONT></U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">2.1 <U>DEMISE &ndash;
PREMISES</U>. Landlord hereby demises and leases to Tenant, and Tenant hereby takes and hires from Landlord, a portion of the Building
erected on the land (the &ldquo;Land&rdquo;) more particularly described in Exhibit A hereto, which portion of the Building (the
&ldquo;Premises&rdquo;) is depicted in the floor plan(s) annexed hereto as Exhibit B, for the term hereinafter stated, for the
rent hereinafter reserved and upon and subject to the covenants, agreements, terms, conditions, limitations, exceptions and reservations
contained in this Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">2.2 <U>APPURTENANT
RIGHTS AND RESERVATIONS</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(a) Tenant shall have,
as appurtenant to the Premises, the non-exclusive right to use in common with others, subject to reasonable rules of general applicability
to tenants of the Building from time to time made by Landlord of which Tenant is given notice: (i) the common lobbies, corridors,
stairways and elevators of the Building, and (ii) if the Premises includes less than the entire rentable floor area of any floor,
the common toilets, corridors and elevator lobby of such floor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(b) Landlord reserves
the right from time to time: (i) to install, use, maintain, repair, replace and relocate, for service to the Premises and/or other
parts of the Building, shafts, pipes, ducts, conduits, wires, risers and other facilities and appurtenant fixtures, in the Premises
or in other parts of the Building, and (ii) to alter or relocate other common facilities, whether located in the Premises or in
other parts of the Building; provided that, with respect to clauses (i) and (ii): (A) any replacements, substitutions or alterations
are, in the reasonable opinion of Landlord, substantially equivalent to or better than then existing facilities, (B) installations,
replacements and relocations shall be located so far as practicable in the central core area of the Building, above ceiling surfaces
(if available and practicable), below floor surfaces, within perimeter walls of the Premises or otherwise in boxed enclosures,
and (C) all such work within the Premises shall be performed at such times and in such manner, as to create the least practicable
interference with Tenant&rsquo;s use of the Premises (it being understood that the foregoing shall in no event obligate Landlord
to do such work on an &ldquo;overtime&rdquo; basis). Tenant acknowledges that the Building is located in a residential district
and certain construction work on weekends and on weekdays is prohibited between the hours of 6:00 p.m. and 7:00 p.m. Except in
the case of emergencies, Landlord agrees to give Tenant reasonable advance notice of any of the foregoing activities which require
work in the Premises.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase"></FONT></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase"><U>ARTICLE
3</U></FONT><BR>
<BR>
<U>L<FONT STYLE="text-transform: uppercase">EASE TERM</FONT></U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">3.1 <U>COMMENCEMENT
DATE</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(a) The term of this
Lease and the estate hereby granted (the &ldquo;Lease Term&rdquo;) shall commence on the date that Landlord makes possession of
the Premises available to Tenant with the Base Work Substantially Complete pursuant to the Work Letter. Such date of commencement
is hereinafter called the &ldquo;Commencement Date&rdquo;. If Landlord fails to cause the Commencement Date to occur on or before
the date that is <FONT STYLE="font-size: 10pt">[***]</FONT> following the later to occur of (x) the date hereof and (y) the date
on which the Plans and Specifications are finalized and approved by Landlord and Tenant in accordance with the terms of the Work
Letter (as such date shall be extended on a day for day basis for Force Majeure and Tenant Delay, the &ldquo;Anticipated Delivery
Date&rdquo;), then the Rent Commencement Date shall be postponed by (i) <FONT STYLE="font-size: 10pt">[***]</FONT> for each day
that occurs during the period commencing on the day immediately following the Anticipated Delivery Date to but not including the
earlier to occur of (A) <FONT STYLE="font-size: 10pt">[***]</FONT> and (B) the date that is <FONT STYLE="font-size: 10pt">[***]</FONT>
after the Anticipated Delivery Date, and (ii) <FONT STYLE="font-size: 10pt">[***]</FONT> for each day that occurs during the period
commencing on the <FONT STYLE="font-size: 10pt">[***]</FONT> after the Anticipated Delivery Date to but not including the Commencement
Date, and any delay in such date shall be Tenant&rsquo;s sole remedy at law or in equity (Tenant hereby waiving any right to rescind
this Lease and/or to recover any damages on account of such delay other than as expressly set forth in Section 3.1(b) below). Landlord
hereby agrees to use commercially reasonable efforts to cause the Commencement Date to occur prior to the Anticipated Delivery
Date and Landlord shall keep Tenant reasonably apprised of any anticipated delay in the Substantial Completion of the Base Work.
The foregoing is intended to be &ldquo;an express provision to the contrary&rdquo; under Section 223&not;a of the New York Real
Property Law or any successor statute of similar import. If Tenant occupies all or any portion of the Premises prior to the Commencement
Date specified above for the normal operation of its business therein (and not for the purpose of installing Tenant&rsquo;s furniture,
fixtures or equipment prior to the Commencement Date, if the same is permitted hereunder), the Commencement Date shall be treated
as having occurred on such date of occupancy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(b) If the Commencement
Date does not occur on or before the date that is twelve (12) months following the later to occur of (i) the date hereof and (ii)
the date on which the Plans and Specifications are finalized and approved by Landlord and Tenant in accordance with the terms of
the Base Work Letter (as such date shall be extended on a day-for-day basis for Force Majeure (but in no event shall such Force
Majeure extension exceed ninety (90) days in the aggregate) and Tenant Delay, the &ldquo;Outside Date&rdquo;), then Tenant, in
Tenant&rsquo;s sole discretion, shall have the right to terminate this Lease upon written notice (&ldquo;Tenant&rsquo;s Termination
Notice&rdquo;) delivered to Landlord within ten (10) days after the Outside Date, time being of the essence. If Tenant does not
deliver Tenant&rsquo;s Termination Notice within the aforesaid ten (10) day period, then Tenant shall be deemed to waived such
termination right. If Tenant exercises such termination right and Landlord does not deliver the Premises to Tenant within thirty
(30) days after the giving of Tenant&rsquo;s Termination Notice (time being of the essence and Force Majeure notwithstanding),
then this Lease shall cease and come to an end without further liability or obligation on the part of either party; <U>provided</U>,
<U>however</U>, if Landlord shall cause the Commencement Date to occur within thirty (30) days after receipt of Tenant&rsquo;s
Termination Notice, this Lease shall not be so terminated and Tenant&rsquo;s termination right under this <U>Section 3.1(b)</U>
shall be void and of no further force or effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">3.2 <U>EXPIRATION
DATE</U>. The Lease Term shall end on the day immediately preceding the seventh (7<SUP>th</SUP>) anniversary of the Rent Commencement
Date, which ending date is hereinafter called the &ldquo;Initial Expiration Date&rdquo;, or shall end on such earlier date upon
which the Lease Term may expire or be terminated pursuant to any of the conditions of limitation or other provisions of this Lease
or pursuant to law. Notwithstanding the foregoing, if the Rent Commencement Date is other than the first day of a month, the Initial
Expiration Date shall be the last day of the calendar month in which the seventh (7<SUP>th</SUP>) anniversary of the Rent Commencement
Date occurs. The Initial Expiration Date, as the same may be extended to the Renewal Term Expiration Date, is referred to herein
as the &ldquo;Expiration Date&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">3.3 <U>COMMENCEMENT
DATE AGREEMENT</U>. As soon as may be convenient after the Commencement Date has been determined, Landlord and Tenant agree to
join with each other in the execution of a written agreement, in the form of Exhibit G hereto, in which the Commencement Date,
the Rent Commencement Date and the Expiration Date shall be stated, but the failure by either party to so execute or deliver such
agreement shall not in any way reduce the respective obligations or rights of Landlord or Tenant under this Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">3.3.1 <U>RENEWAL OPTION</U>.
If on the date on which Tenant delivers the Renewal Notice to Landlord (a) this Lease is in full force and effect, (b) no Event
of Default (or any state of facts that, with the giving of notice or the passage of time, would constitute an Event of Default)
shall have occurred and then be continuing, and (c) Tenant actually occupies one hundred percent (100%) of the Premises, then Original
Tenant shall have the right, at its option (the &ldquo;Renewal Option&rdquo;), to renew the initial Term of this Lease with respect
to the entire Premises for one (1) additional period of five (5) years (the &ldquo;Renewal Term&rdquo;) commencing on the day immediately
succeeding the Initial Expiration Date (the &ldquo;Renewal Term Commencement Date&rdquo;) and expiring on the fifth (5th) anniversary
of the Renewal Term Commencement Date or such earlier date upon which the Lease Term may expire or be terminated pursuant to any
of the conditions of limitation or other provisions of this Lease or pursuant to law (the &ldquo;Renewal Term Expiration Date&rdquo;).
Tenant shall exercise the Renewal Option by delivering a written notice (the &ldquo;Renewal Notice&rdquo;) to Landlord no later
than twelve (12) months prior to the Expiration Date, time being of the essence. If Tenant timely exercises the Renewal Option,
then the Lease Term shall be extended for the Renewal Term without the requirement of any further instrument, upon all of the same
terms, provisions and conditions set forth in this Lease, except as otherwise set forth in this Section 3.4. If Tenant fails to
timely give the Renewal Notice, Tenant shall have no further rights under this Section 3.4, and Landlord shall be under no further
obligation to offer to renew or extend the Term. There shall be no further right to extend the Lease Term beyond the Renewal Term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">3.3.2 <U>RENEWAL TERM
RENT</U>. Annual Fixed Rent for the Renewal Term shall be the Fair Market Rent for the Premises as of the commencement of the Renewal
Term; provided, however, in no event shall the Annual Fixed Rent for the Renewal Term be less than the Annual Fixed Rent on a per
rentable square foot basis in effect for the twelve (12) month period immediately preceding the Renewal Term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">3.3.3 <U>RENEWAL TERM
RENT DETERMINATION</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(a) The term &ldquo;Fair
Market Rent&rdquo; shall mean the fair market rental value per annum for the Renewal Term as of the date that is one hundred eighty
(180) days prior to the Renewal Term Commencement Date, taking into account all relevant factors. A determination of the Fair Market
Rent payable for the Renewal Term shall be made in the manner described in Section 3.4.3(b) below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(b) If Tenant shall have
exercised the Renewal Option, then no later than six (6) months prior to the then Expiration Date, Landlord, in a notice given
to Tenant, shall specify its initial determination of the Fair Market Rent. Within twenty (20) Operating Days after delivery by
Landlord to Tenant of Landlord&rsquo;s notice, Tenant shall specify its initial determination of the Fair Market Rent (it being
agreed that if Tenant fails to send to Landlord a written notice specifying Tenant&rsquo;s initial determination of the Fair Market
Rent for the Renewal Term within such twenty (20) Operating Day period, then Fair Market Rent shall be deemed to be Landlord&rsquo;s
initial determination thereof; and if Tenant does not send Landlord a written notice specifying Tenant&rsquo;s initial determination
of the Fair Market Rent within such five (5) Operating Day period, then Fair Market Rent for the Renewal Term shall be deemed to
be Landlord&rsquo;s initial determination thereof). If, within sixty (60) days after delivery by Tenant to Landlord of Tenant&rsquo;s
notice, Landlord and Tenant fail to reach agreement on the determination of the Fair Market Rent, then either Landlord or Tenant
(the &ldquo;Initiating Party&rdquo;) may initiate arbitration proceedings for such determination by notice to the other, and Fair
Market Rent shall be determined pursuant to such arbitration proceedings. Such arbitration proceedings, including the selection
of a commercial real estate broker unaffiliated with either Landlord or Tenant and who shall have at least fifteen (15) years&rsquo;
experience in the leasing of office space in first class office and/or laboratory buildings in the vicinity of the Building (the
&ldquo;Qualified Arbitrator&rdquo;), shall be conducted pursuant to the rules, regulations and procedures from time to time in
effect as promulgated by the American Arbitration Association (the &ldquo;AAA&rdquo;) by a single Qualified Arbitrator in the City,
County and State of New York and otherwise in accordance with the Commercial Arbitration Rules of the AAA, as then in effect, with
hearings conducted as expeditiously as practicable and with no undue delay, and in no event later than thirty (30) days after the
date on which the Initiating Party gives such notice to the other party of its desire to initiate such arbitration proceedings.
Prior written notice of application by either party for arbitration shall be given to the other at least ten (10) days before submission
of the application to the AAA&rsquo;s office in the City, County and State of New York. The Qualified Arbitrator, forthwith upon
his or her appointment, shall (i) hear the parties to this Lease and their respective witnesses, and each of the parties shall
upon the conclusion of their presentation be required to submit a complete statement (the &ldquo;Fair Market Rent Proposal&rdquo;)
setting forth in detail all of the relevant economic terms of the party&rsquo;s proposed determination of the Fair Market Rent
(which terms shall not differ from the economic terms initially proposed by such party), (ii) examine the records relating to the
Building and such other documents and records as may, in his or her judgment, be necessary and (iii) select as the Fair Market
Rent either Landlord's Fair Market Rent Proposal or Tenant's Fair Market Rent Proposal, whichever the Qualified Arbitrator determines
to be closest to the Fair Market Rent. The Qualified Arbitrator shall have no power to vary or modify the provisions of this Lease
or to determine any matter other than the Fair Market Rent for the Renewal Term. The determination of the Qualified Arbitrator
shall be final and binding on Landlord and Tenant and may be enforced in any court of competent jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(c) Any determination
of Fair Market Rent pursuant to this Section 3.4 shall be made taking into consideration (i) the fair market rental value of space
of similar size and comparable condition in any first class office and/or laboratory building (including the Building) available
for leasing for a comparable term, by a ready, willing and able tenant from a ready, willing and able landlord, neither of whom
is under compulsion to enter into a lease, (ii) Tenant&rsquo;s payment with respect to Taxes, Impositions, PILOT and Operating
Expenses as provided in Article 6 of this Lease (provided that base years for determining Base Operating Expenses shall be updated
in connection with determining the Fair Market Rent, and accordingly, during the applicable Renewal Term, Tenant shall calculate
its payments under Article 6 hereof using such updated Base Operating Expenses) and (iii) all other relevant factors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(d) The cost of the arbitration
shall be shared equally by Landlord and Tenant. Each of Landlord and Tenant shall pay the legal fees and expenses of their respective
counsel and witnesses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">3.3.4 (a) If, pursuant
to Section 3.4.3 above, Fair Market Rent has not been determined as of the date the same is to become effective, Tenant shall pay
on account of Annual Fixed Rent Landlord&rsquo;s Fair Market Rent Proposal until such determination is made. If, based upon the
final determination of such Fair Market Rent as provided herein, such payments made by Tenant on account of Annual Fixed Rent for
the Renewal Term are greater than the Fair Market Rent as finally determined in accordance with the provisions hereof, Landlord
shall either pay such excess to Tenant within thirty (30) days after final determination of the Fair Market Rent, or credit the
amount of such excess against the next installments of rent due under this Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(b) If Tenant shall validly
exercise the Renewal Option, Landlord and Tenant shall promptly after such election and determination of the Fair Market Rent enter
into an amendment to this Lease incorporating the terms of such leasing, but failure to do so shall have no effect on Tenant&rsquo;s
agreement to extend the Lease Term as set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase"><U>ARTICLE
4</U></FONT><BR>
<BR>
<U>C<FONT STYLE="text-transform: uppercase">OMPLETION OF THE PREMISES</FONT></U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">4.1 <U>PERFORMANCE
OF WORK</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(a) Tenant has inspected
the Premises, and, subject to completion of the Work and Landlord&rsquo;s repair and maintenance obligations under this Lease,
the Premises are being leased in &ldquo;AS IS&rdquo; condition, without representation or warranty by Landlord except as expressly
set forth herein, and Landlord has no obligation to perform any other work, construct any other improvements or make any contribution
available to prepare the Premises for Tenant&rsquo;s occupancy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(b) Prior to the Commencement
Date, Landlord, at Landlord&rsquo;s sole cost and expense, shall Substantially Complete the Base Work. The Base Work shall be performed
using building standard materials (or such above building standard materials as are indicated in the Test Fit, if any).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">4.2 <U>QUALITY AND
PERFORMANCE OF WORK</U>. All construction work required or permitted by this Lease shall be done in a good and workmanlike manner
and in compliance with all applicable laws and requirements of public authorities and insurance bodies related to, or arising out
of the performance of, such construction work. Each party may inspect the work of the other at reasonable times, and the Construction
Representative of each party shall promptly give notice of any approvals and other actions on the party&rsquo;s behalf required
to be given in connection with design and construction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase"><U>ARTICLE
5</U></FONT><BR>
<BR>
<U>A<FONT STYLE="text-transform: uppercase">NNUAL FIXED RENT AND ADDITIONAL RENT</FONT></U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">5.1 <U>FIXED RENT</U>.
Tenant agrees to pay to Landlord on the Commencement Date (but subject to the provisions of Section 5.2) and thereafter monthly,
in advance, on the first day of each and every calendar month during the Lease Term, a sum equal to one twelfth of the Annual Fixed
Rent specified in Section 1.2 hereof in lawful money of the United States, without any set-off or deduction whatsoever. Until notice
of some other designation is given, Annual Fixed Rent and all other charges for which provision is herein made shall be paid by
remittance to or to the order of &ldquo;345 PAS HOLDING LLC&rdquo; at the following address: Deerfield Management Company, L.P.,
345 Park Avenue South, New York, NY 10010. All remittances by Tenant shall be drawn on a member bank of The Clearing House Association,
or, at Tenant&rsquo;s election, by wire transfer of immediately available funds or ACH electronic transfer to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse; margin-left: 1in">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%; text-align: left; text-indent: 0in">Bank Name:</TD>
    <TD STYLE="width: 60%; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">[***]</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">[***]</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">[***]</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">[***]</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">Bank Routing #:</TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">[***]</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">Account #:</TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">[***]</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">Account Name:</TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">[***]</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">Reference:</TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">[***]</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">Contact Person:</TD>
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">[***]</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">5.2 <U>ADVANCE PAYMENT
OF ONE MONTH&rsquo;S RENT</U>. Tenant shall, simultaneously with the execution and delivery of this Lease, pay to Landlord an amount
equal to one twelfth of the Annual Fixed Rent, to be applied to the monthly installment of Annual Fixed Rent due on the first (1st)
day of the month next following the Rent Commencement Date. Landlord shall hold the amount paid by Tenant under this Section 5.2
in trust until the same is applied pursuant to this Section or any other provision of this Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">5.3 <U>ADDITIONAL RENT</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(a) All amounts over
and above, or in addition to, the Annual Fixed Rent which are payable by Tenant to Landlord under the terms of this Lease or otherwise
in connection with the use and occupancy of the Premises including, without limitation, sums payable under work orders issued
by the managing agent for the Building, shall be deemed Additional Rent hereunder and shall be paid by Tenant in lawful money
of the United States, without any set-off or deduction whatsoever and otherwise in the same manner as an installment of the Annual
Fixed Rent as elsewhere provided in this Lease; and Landlord shall have all the rights and remedies in the event of the non-payment
thereof as it would have had in the event of the non-payment of any installment of the Annual Fixed Rent. Tenant&rsquo;s obligation
to pay any Annual Fixed Rent or any Additional Rent which shall have theretofore become due and payable shall survive the expiration
or earlier termination of this Lease. (The Annual Fixed Rent and Additional Rent are sometimes collectively referred to in this
Lease as &ldquo;rent.&rdquo;) Rent for any partial months during the Lease Term shall be prorated on a per diem basis. Except
as otherwise expressly set forth in this Lease, to the extent that Tenant shall fail to dispute any invoice for Additional Rent
within ninety (90) days after receipt thereof, such invoice shall be conclusive and binding upon Tenant and Tenant shall be deemed
to have waived any right to dispute the same.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(b) Any Additional Rent
for which no due date is specified in this Lease shall be due and payable within thirty (30) days after the date of invoice. Whenever
pursuant to this Lease either Landlord or Tenant, as applicable, requests reimbursement for its out-of-pocket costs (as opposed
to specified costs), (i) such reimbursement shall be limited to those out-of-pocket expenses actually paid to unaffiliated third
parties and (ii) such party shall deliver to the reimbursing party reasonable supporting documentation evidencing such costs promptly
after delivery to such party of a written request therefor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">5.4 <U>LATE PAYMENT</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(a) If Landlord shall
not have received any payment or installment of rent on or before the date that is five (5) days after the date (the &ldquo;due
date&rdquo;) on which the same first becomes payable under this Lease, the amount of such payment or installment shall bear interest
from the due date through and including the date such payment or installment is received by Landlord, at a rate (the &ldquo;Lease
Interest Rate&rdquo;) equal to the lesser of (i) the rate announced by Citibank, N.A. or its successor from time to time as its
prime or base rate (the &ldquo;Base Rate&rdquo;), plus <FONT STYLE="font-size: 10pt">[***]</FONT>, or (ii) the maximum applicable
legal rate, if any. Such interest shall be deemed Additional Rent and shall be paid by Tenant to Landlord upon demand; provided,
however, that the foregoing five (5) day grace period set forth above shall not apply in the event Tenant has failed to pay any
installment of rent when due more than once in any twelve (12) month period, in which event such grace period shall not apply again
until Tenant shall have timely paid all installments of rent for twelve (12) consecutive months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(b) In addition to the
interest set forth in Section 5.4(a) above, if any installment of rent or any other sum due from Tenant shall not be received by
Landlord on or before its due date, then Tenant shall pay to Landlord a late charge equal to <FONT STYLE="font-size: 10pt">[***]</FONT>
of the overdue amount. The late charge shall be deemed Additional Rent and shall be paid by Tenant to Landlord upon demand. The
late charge shall be in addition to all of Landlord&rsquo;s other rights and remedies hereunder or at law and shall not be construed
as liquidated damages or as limiting Landlord&rsquo;s remedies in any manner.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">5.5 RENT CONCESSION.
Anything contained in this Article to the contrary notwithstanding, provided no Event of Default exists, Landlord hereby waives
payment of Annual Fixed Rent for the period (the &ldquo;Rent Concession Period&rdquo;) from and including the Commencement Date
through and including the date that is one (1) day prior to Rent Commencement Date, and payment of Annual Fixed Rent shall commence
on the Rent Commencement Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase"><U>ARTICLE
6</U></FONT><BR>
<BR>
<U>T<FONT STYLE="text-transform: uppercase">AXES, IMPOSITIONS, PILOT AND OPERATING EXPENSES</FONT></U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">6.1 TAXES, IMPOSITIONS
AND PILOT.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">6.1.1 <U>DEFINITIONS</U>.
For the purposes of this Section 6.1, the following terms shall have the respective meanings set forth below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">(a) &ldquo;Agency Lease&rdquo;
shall mean that certain Agency Lease Agreement, dated as of September 1, 2019, by and between the New York City Industrial Development
Agency (the &ldquo;IDA&rdquo;), as lessor, and Landlord, as lessee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">(b) &ldquo;Annual Administrative
Fee&rdquo; shall having the meaning set forth in the Agency Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">(c) &ldquo;BID Surcharge&rdquo;
shall mean any payments due and owing by Landlord to any Business Improvement District (&ldquo;BID&rdquo;) organization that has
jurisdiction over any area that includes the Building.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">(d) &ldquo;Impositions&rdquo;
shall mean the aggregate amount of all real estate and personal property taxes and any general or special assessments (exclusive
of penalties thereon but inclusive of interest on assessments payable in installments) assessed or imposed upon or with respect
to the Building and the Land, if any, during the PILOT Term, and including, without limitation, (i) taxes or assessments made upon
or with respect to any development rights now or hereafter appurtenant to or used in connection with the construction of the Building,
(ii) any fee, tax or charge imposed by any governmental authority for, on or in respect of any vaults, vault space or other space
within or outside the boundaries of the Land, (iii) any assessments for public improvement or benefit to the Building, the Land,
or the locality in which the Land is situated, and (iv) any tax, assessment or charge imposed on or with respect to any fixtures,
equipment or personal property serving or used in connection with the Building or the Land. There shall be excluded from Impositions
all amounts included in the definition of &ldquo;PILOT&rdquo; or &ldquo;Bid Surcharge&rdquo; and all income, estate, succession,
inheritance, transfer and franchise taxes imposed upon Landlord; provided, however, that if at any time during the Lease Term the
method of taxation of real estate shall be changed and as a result any other tax or assessment, however denominated and including,
without limitation, any franchise, income, profit, use, occupancy, gross receipts or rental tax, shall be imposed upon Landlord
or the owner of the Building and the Land, or the rents or income therefrom, in substitution for or in addition to, in whole or
in part, any of the taxes or assessments listed in the preceding sentence, such other tax or assessment shall be included in and
deemed part of Impositions, but only to the extent that the same would be payable if the Building, the Land and all appurtenances
thereto (including development rights) were the only property of Landlord. The amount of any special assessments for public improvements
or benefits to be included in Impositions for any year, in the case where the same may, at the option of the taxpayer, be paid
in installments, shall be limited to the amount of the installment due in respect of such year, together with any interest payable
in connection therewith (other than interest payable by reason of the delinquent payment of such installment).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">(e) &ldquo;PILOT&rdquo;
shall mean (i) the payment in lieu of taxes to be paid by Landlord pursuant to Section 5.1 of the Agency Lease, and (ii) the Annual
Administrative Fee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">(f) &ldquo;PILOT Commencement
Date&rdquo; shall have the meaning set forth in the Agency Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">(g) &ldquo;PILOT Percentage&rdquo;
shall mean, as reasonably determined by Landlord from time to time, a fraction, expressed as a percentage, the numerator of which
is the rentable square footage of the portion of the Premises, if any, in respect of which PILOT is payable under the Agency Lease,
and the denominator of which is the aggregate rentable square footage of all space in the Building in respect of which PILOT is
payable at such time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">(h) &ldquo;PILOT Program&rdquo;
shall mean the payment of PILOT in an amount less than actual Taxes pursuant to the Agency Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">(i) &ldquo;PILOT Term&rdquo;
shall have the meaning set forth in the Agency Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">(j) &ldquo;Taxes&rdquo;
shall mean the aggregate amount of all real estate and personal property taxes and any general or special assessments (exclusive
of penalties thereon but inclusive of interest on assessments payable in installments) assessed or imposed upon or with respect
to the Building and the Land and including, without limitation, (i) taxes or assessments made upon or with respect to any development
rights now or hereafter appurtenant to or used in connection with the construction of the Building, (ii) any fee, tax or charge
imposed by any governmental authority for, on or in respect of any vaults, vault space or other space within or outside the boundaries
of the Land, (iii) any assessments for public improvement or benefit to the Building, the Land, or the locality in which the Land
is situated, and (iv) any tax, assessment or charge imposed on or with respect to any fixtures, equipment or personal property
serving or used in connection with the Building or the Land. There shall be excluded from Taxes all income, estate, succession,
inheritance, transfer and franchise taxes imposed upon Landlord; provided, however, that if at any time during the Lease Term the
method of taxation of real estate shall be changed and as a result any other tax or assessment, however denominated and including,
without limitation, any franchise, income, profit, use, occupancy, gross receipts or rental tax, shall be imposed upon Landlord
or the owner of the Building and the Land, or the rents or income therefrom, in substitution for or in addition to, in whole or
in part, any of the taxes or assessments listed in the preceding sentence, such other tax or assessment shall be included in and
deemed part of Taxes, but only to the extent that the same would be payable if the Building, the Land and all appurtenances thereto
(including development rights) were the only property of Landlord. The amount of any special assessments for public improvements
or benefits to be included in Taxes for any year, in the case where the same may, at the option of the taxpayer, be paid in installments,
shall be limited to the amount of the installment due in respect of such year, together with any interest payable in connection
therewith (other than interest payable by reason of the delinquent payment of such installment).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">(k) &ldquo;Tenant&rsquo;s
Tax Payment&rdquo; shall mean, collectively, Tenant&rsquo;s Share of Impositions, Tenant&rsquo;s Share of Taxes, Tenant&rsquo;s
Share of PILOT and Tenant&rsquo;s Share of BID.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">(l) &ldquo;Tax Year&rdquo;
shall mean each period from July 1 through June 30 (or such other fiscal period as may hereafter be adopted by the City of New
York as the fiscal year for any tax, levy or charge included in Taxes), any part or all of which occurs during the Lease Term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">(m) &ldquo;Tax Expenses&rdquo;
shall mean all expenses, including, without limitation, attorney&rsquo;s fees and disbursements and experts&rsquo; and other witnesses&rsquo;
fees, incurred by Landlord in seeking to reduce the amount of any assessed valuation of the Land and/or Building, in contesting
the amount or validity of any Taxes or Impositions, or in seeking a refund of Taxes or Impositions, or in contesting, negotiating
or otherwise reporting to the IDA in connection with the PILOT.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">6.1.2 <U>TENANT&rsquo;S
SHARE OF TAXES, IMPOSITIONS, PILOT AND BID</U>. Tenant shall pay, as Additional Rent for each Tax Year, all or any portion of which
shall be within the Term:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(i)</TD><TD STYLE="text-align: left">during the period commencing on the Rent Commencement
Date through and including the day immediately preceding the PILOT Commencement Date, an amount (&ldquo;Tenant&rsquo;s Share of
Taxes&rdquo;) equal to Tenant&rsquo;s Share of the Taxes applicable to each Tax Year (or portion thereof) occurring during such
period;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(ii)</TD><TD STYLE="text-align: left">during the period commencing on the PILOT Commencement
Date through and including the earlier to occur of (x) the Expiration Date or (y) the expiration of the PILOT Term, (A) an amount
(&ldquo;Tenant&rsquo;s Share of PILOT&rdquo;) equal to the product of (1) the PILOT Percentage times (2) the PILOT applicable
to each Tax Year (or portion thereof) occurring during such period, and (B) an amount (&ldquo;Tenant&rsquo;s Share of Impositions&rdquo;)
equal to Tenant&rsquo;s Share of the Impositions applicable to each Tax Year (or portion thereof) occurring during such period;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(iii)</TD><TD STYLE="text-align: left">during the period commencing on the day after the PILOT
Term expires or if ever Section 6.1.4(a) hereof becomes applicable, then for the period during which such Section becomes applicable,
and in each case until the Expiration Date, Tenant&rsquo;s Share of Taxes applicable to such period, subject to Section 6.1.4(b)
hereof; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(iv)</TD><TD STYLE="text-align: left">during the period commencing on the Commencement Date
and thereafter throughout the Term, an amount (&ldquo;Tenant&rsquo;s Share of BID&rdquo;) equal to the BID Surcharge applicable
to each Tax Year occurring during such period times Tenant&rsquo;s Share.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">From and after the Rent
Commencement Date, Tenant shall also pay to Landlord, as Additional Rent, Tenant&rsquo;s Share of Tax Expenses. Tenant&rsquo;s
Tax Payment for each Tax Year shall be payable in monthly installments as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">(a) Estimated
payments by Tenant on account of PILOT, Impositions, Taxes, BID Surcharge and Tax Expenses shall be made on the first day of
each and every calendar month during the Lease Term, and otherwise in the same fashion herein provided for the payment of
Annual Fixed Rent. The monthly amount so to be paid to Landlord shall be sufficient to provide Landlord by the time PILOT,
Impositions, Taxes, BID Surcharge and Tax Expenses are due a sum equal to Tenant&rsquo;s required payments, as estimated by
Landlord from time to time, on account of PILOT, Impositions, Taxes, BID Surcharge and Tax Expenses for the then current Tax
Year. Promptly after receipt by Landlord of bills for such PILOT, Impositions, Taxes, BID Surcharge and Tax Expenses,
Landlord shall advise Tenant of the amount thereof and the computation of Tenant&rsquo;s payment on account thereof. If
estimated payments theretofore made by Tenant for the Tax Year covered by such bills exceed the required payments on account
thereof for such Tax Year, Landlord shall credit the amount of overpayment against subsequent obligations of Tenant on
account of PILOT, Impositions, Taxes, BID Surcharge and Tax Expenses (or refund such overpayment if the Lease Term has ended
and Tenant has no further obligation to Landlord); but if the required payments on account thereof for such Tax Year are
greater than estimated payments theretofore made on account thereof for such Tax Year, Tenant shall make payment to Landlord
within thirty (30) days after being so advised by Landlord. Tenant&rsquo;s Tax Payment for each Tax Year shall, at
Landlord&rsquo;s option, be payable on a monthly basis as provided above, or at such other time as Landlord shall render a
statement therefor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">(b) It is understood
that the provisions of this Section 6.1 are based upon the method of payment (i) with respect to PILOT, set forth in the Agency
Lease, to wit, in semi-annual installments in advance on the first days of July and January of each Tax Year, and (ii) with respect
to Taxes, Impositions, Tax Expenses and the BID Surcharge, of New York City real property taxes in effect at the date of this Lease,
to wit, in semi-annual installments in advance on the first days of July and January of each Tax Year; provided, however, that
the amounts payable by Tenant in respect thereof shall be payable monthly in advance as described in Section 6.1.2(a) hereof. If
such method of payment is hereafter changed, Landlord shall have the right to change the method by which Tenant pays Tenant&rsquo;s
Share of PILOT or Tenant&rsquo;s Share of Impositions, Tenant&rsquo;s Share of Taxes, Tenant&rsquo;s Share of Tax Expenses, and
Tenant&rsquo;s Share of BID, as applicable, to a method of periodic payments that provides Landlord with the full amount of Tenant&rsquo;s
Tax Payment in respect of any installment of PILOT, Impositions, Taxes, BID Surcharge or Tax Expenses by the date on which such
installment becomes due.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">6.1.3 <U>TAX REDUCTION
PROCEEDINGS</U>. Only Landlord shall have the right to institute tax reduction or other proceedings to reduce the assessed valuation
of the Land and Building. Should Landlord be successful in any such reduction proceedings and obtain a refund for any Tax Year
or Years in respect of which Tenant shall have made a payment to Landlord, pursuant to this Section 6.1, Landlord shall credit
Tenant&rsquo;s Share (applicable to Taxes) of such refund (or, in the case of a refund of Taxes for a Tax Year, only a fraction
of which is included in the Lease Term, such fraction thereof) against the monthly installment or installments of Annual Fixed
Rent next falling due under this Lease, or if the Lease Term has then expired and Tenant has no further obligations to Landlord,
such amount shall be refunded by Landlord to Tenant. In calculating the amount of any such credit or payment, Landlord shall have
the right to deduct from such refund all Tax Expenses incurred by Landlord in obtaining the same. The provisions of this subsection
6.1.3 shall survive the expiration of the Lease Term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">6.1.4 <U>PILOT PROGRAM
TERMINATION</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">(a) In the event that
the Agency Lease is terminated or the Property otherwise ceases to be exempt from the payment of Taxes and becomes subject to the
payment of Taxes on substantially the same basis as other privately owned office buildings in Manhattan, then, from and after the
date (the &ldquo;PILOT Early Termination Date&rdquo;) on which Taxes first becomes payable, (i) Tenant&rsquo;s Share of PILOT and
Tenant&rsquo;s Share of Impositions shall cease to be payable hereunder with respect to any period occurring after the PILOT Early
Termination Date, and (ii) Tenant shall commence to make the payments of Tenant&rsquo;s Share of Taxes pursuant to this Section
6.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">(b) If the Property
shall cease to be exempt from the payment of Taxes and becomes subject to the payment of Taxes on substantially the same basis
as other privately owned office buildings in Manhattan prior to the expiration of the PILOT Term as a result of Landlord&rsquo;s
breach of the terms of the Agency Lease, then, until the earlier to occur of (x) the expiration of the PILOT Term or (y) the end
of the initial Term of this Lease (i.e., prior to the commencement of any renewal term), in lieu of Tenant&rsquo;s Share of Taxes,
Tenant shall pay an amount equal to the amount of the applicable Tenant&rsquo;s Tax Payment that Tenant would have been paying
if the Pilot Program were still in effect. If the Property or the Premises shall cease to be exempt from the payment of Taxes and
becomes subject to the payment of Taxes on substantially the same basis as other privately owned office buildings in Manhattan
prior to the expiration of the PILOT Term as a result of any act or omission of Tenant (including, without limitation, Tenant or
any other Tenant&rsquo;s Party&rsquo;s use of the Premises for a Non-Qualified Use), then Tenant shall indemnify, defend and hold
Landlord harmless from and against all costs, losses, claims or expenses incurred by Landlord in connection therewith, including,
without limitation, any incremental amounts that Landlord is required to repay under the Agency Lease as a result thereof. If the
Property or the Premises shall cease to be exempt from the payment of Taxes and becomes subject to the payment of Taxes on substantially
the same basis as other privately owned office buildings in Manhattan prior to the expiration of the PILOT Term as a result of
any act or omission of any other tenant in the Building, then any net amounts recovered on account of Taxes by Landlord from other
tenants in the Building shall be passed on to Tenant such that the same are applied to Tenant&rsquo;s tax payments due pursuant
Section 6.1.2(iii); provided, however, that in no event shall any such net amounts to be applied in accordance with the foregoing
exceed the amount due from Tenant pursuant to Section 6.1.2(iii).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">(c) Landlord hereby
represents and warrants to Tenant that (i) the Agency Lease provides that the term &ldquo;PILOT Abatement&rdquo; means, with respect
to any semi-annual period, an amount equal to the product of (y) 100% less the Non-Qualified Use Percentage (as defined in the
Agency Lease), and (z) the Full PILOT Amount (as defined in the Agency Lease) with respect to the Facility Realty (as defined in
the Agency Lease) (without duplication of any Additional Improvements PILOT (as defined in the Agency Lease)) and (ii) pursuant
to Section 5.1(c) of the Agency Lease, Landlord is obligated to pay PILOT with respect to the Facility Realty as described on Schedule
6.1.4(c) attached hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">6.2 <U>OPERATING EXPENSE
ESCALATION</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">6.2.1 <U>DEFINITIONS</U>.
For the purposes of this Section 6.2, the following terms shall have the respective meanings set forth below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">(a) &ldquo;Base Operating
Expenses&rdquo; shall mean the actual Operating Expenses for the Operating Year commencing on January 1, 2021 and ending on December
31, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">(b) &ldquo;Operating
Expenses&rdquo; shall mean the aggregate of all costs and expenses (including taxes, if any, thereon) paid or incurred by or on
behalf of Landlord (whether directly or through independent contractors) in connection with the operation and maintenance of the
Property, including all expenses incurred by Landlord as a result of its compliance with any of its obligations under Sections
7.1 and 7.3 hereof, but excluding those items set forth as excluded from Operating Expenses at the end of this subsection 6.2.1(b).
Operating Expenses shall be calculated on the accrual basis of accounting (but subject to the further provisions of this Section
6.2) and shall include, without limitation, the following expenses:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">(i) salaries, wages,
medical, surgical and general welfare benefits (including group life insurance), pension and welfare payments or contributions
and all other fringe benefits paid to, for or with respect to all persons (whether they be employees of Landlord or its managing
agent) for their services in the operation (including, without limitation, security services), maintenance, repair, or cleaning
of the Property, and payroll taxes, workers&rsquo; compensation, uniforms and dry cleaning costs for such persons;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">(ii) payments under service
contracts with independent contractors for operating (including, without limitation, providing security services), maintaining,
repairing, replacing or cleaning of the Property or any portion thereof or any fixtures or equipment therein;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">(iii) all costs or charges
for steam, hot water, heat, ventilation, air conditioning and water (including sewer rents) furnished to the Property and/or used
in the operation of the Property and all costs or charges for electricity furnished to the public and service areas of the Property
and/or used in the operation of the service facilities of the Property, including any taxes on any such utilities;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">(iv) ordinary repairs
that are appropriate to the continued operation of the Property as a first-class Manhattan office building and, where applicable,
a first-class laboratory and research building;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">(v) costs of lobby decoration,
painting and decoration of non-tenant areas;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">(vi) cost of snow removal
and landscaping in and about the Property;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">(vii) cost of building
and cleaning supplies and equipment, cost of replacements for tools and equipment used in the operation, maintenance and repair
of the Property and charges for telephone service for the Property;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">(viii) financial expenses,
including software charges, incurred in connection with the operation of the Property, such as insurance premiums (including, without
limitation, liability insurance, fire and casualty insurance, rent insurance and any other insurance that is then generally carried
by owners of major first-class office, laboratory and research buildings in Manhattan or may be required by the holder of any mortgage
on the Property), attorneys&rsquo; fees and disbursements (exclusive of any such fees and disbursements incurred in applying for
any reduction of Taxes or in connection with the leasing of space in the Property), auditing and other professional fees and expenses,
Landlord&rsquo;s reasonable home office accounting charges, association dues and any other ordinary and customary financial expenses
incurred in connection with the operation of the Property;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">(ix) management fees
payable to a management company which is unrelated to Landlord or, if to a management company which is owned or controlled by Landlord
or Landlord&rsquo;s principals, then for all purposes of this Lease at a rate of three percent (3%) of actual gross rentals of
the Property per annum;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">(x) the cost of capital
improvements (&ldquo;Permitted Capital Expenditures&rdquo;) made by Landlord either (1) to reduce Operating Expenses, or (2) pursuant
to a requirement of law, ordinance, order, rule or regulation of any public authority having jurisdiction or the requirement of
any insurance carrier or insurance rating organization or underwriting board now or hereafter in effect, whether or not such requirement
is valid or mandatory, in either case (x) that is first enacted or first enforced after the date hereof and (y) calculated as follows:
the cost of any such capital improvement shall be included in Operating Expenses for the Operating Year in which such improvement
was made, provided that such cost shall be amortized on a straight-line basis over the useful life thereof determined reasonably
by Landlord in accordance with GAAP and practices in effect at the time of the capital improvement, and the annual amortization
of such capital improvement, together with interest on the unamortized balance of such cost at the Base Rate, shall be included
in Operating Expenses; provided, however, if Landlord reasonably concludes on the basis of engineering estimates that a particular
capital expenditure will effect savings in other Operating Expenses, including, without limitation, energy related costs, and that
such projected savings will, on an annual basis (&ldquo;Projected Annual Savings&rdquo;), exceed the annual amortization therefor,
then and in such event the amount of amortization for such capital expenditure shall be increased to an amount equal to the Projected
Annual Savings, and in such circumstance, the increased depreciation (in the amount of the Projected Annual Savings) shall be made
for such period of time as it would take to fully amortize the cost of the item in question, together with interest thereon at
the Lease Interest Rate in equal monthly payments, each in the amount of one-twelfth (1/12th) of the Projected Annual Savings,
with such payment to be applied first to interest and the balance to principal;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">(xi) rental payments
made for equipment used in the operation and maintenance of the Property;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">(xii) the cost of governmental
licenses and permits, or renewals thereof, necessary for the operation of the Property;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">(xiii) all costs of reporting
for the Building or any part thereof to maintain certification under the U.S. EPA&rsquo;s Energy Star&reg; rating system, the U.S.
Green Building Council&rsquo;s Leadership in Energy and Environmental Design (LEED) rating system or a similar system or standard
(but excluding costs of seeking, applying for and obtaining any initial certification);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">(xiv) the costs of any
operations and maintenance program pursuant to Section 10.7 hereof;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">(xv) subject to clause
(x) above, all costs incurred by Landlord to comply with applicable laws and requirements of public authorities (including, without
limitation, New York City Local Law 11); and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">(xvi) all other reasonable
and necessary expenses paid in connection with the operation, maintenance, repair and cleaning of the Property which are properly
chargeable against income.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">Any cost or expenses
of the nature described above shall be included in Operating Expenses for any Operating Year no more than once, notwithstanding
that such cost or expenses may fall under more than one of the categories listed above. Subject to the limitation set forth in
subdivision (ix) above, Landlord may use related or affiliated entities to provide services or furnish materials for the Property
provided that the rates or fees charged by such entities are competitive with those charged by unrelated or unaffiliated entities
in the Borough of Manhattan for the same services or materials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The following costs
and expenses shall be excluded from Operating Expenses:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2.5in">(1) Impositions, Taxes,
Tax Expenses, PILOT and BID Surcharge, and any net income, capital stock, succession, transfer, franchise, gift, estate, inheritance
or mortgage taxes imposed upon Landlord;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2.5in">(2) franchise and income
taxes imposed upon Landlord;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2.5in">(3) principal and interest
payments and other costs incurred in connection with any financing or refinancing of the Property or any portions thereof;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2.5in">(4) leasing costs (including
leasing and brokerage commissions and similar fees, lease marketing and advertising, lease takeover or rental assumption obligations
and legal fees in connection with lease negotiations) and the cost of tenant improvements or tenant allowances or inducements made
for tenants of the Building (including permit, license and inspection fees and any other contribution by Landlord to the cost of
tenant improvements);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2.5in">(5) capital improvements
to the Property other than those provided in clause (x) above or to rentable spaces at the Property (even if not leased);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2.5in">(6) the cost of electrical
energy furnished directly to tenants of the Property;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2.5in">(7) the cost of tenant
installations and decorations incurred in connection with preparing space for any tenant;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2.5in">(8) salaries or fringe
benefits of personnel above the grade of senior property manager;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2.5in">(9) rent payable under
any Underlying Lease;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2.5in">(10) the cost of any
items to the extent to which such cost is reimbursed to Landlord by tenants of the Property (other than pursuant to this Section
6.2), insurance or condemnation proceeds or third parties;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2.5in">(11) depreciation of
the building, amortization (except as provided in clause (x) above) and other non-cash charges;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2.5in">(12) management fees
payable to a management company owned or controlled by Landlord or Landlord&rsquo;s principals, in excess of three percent (3%)
of actual gross rentals of the Property per annum, and all amounts paid by Landlord to any other Affiliates of Landlord for services
to the extent the same exceeds the costs of such services as rendered by unaffiliated third party service providers in other first
class office buildings in the vicinity of the Building on a competitive basis;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2.5in">(13) salaries, wages,
fringe benefits and other compensation (including judgments, settlements or arbitration awards relating to the same) of Landlord&rsquo;s
employees above the grade of property manager;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2.5in">(14) any costs of acquiring
or leasing sculptures, paintings or other objects of fine art and insuring such artwork to the extent such insurance cost is in
excess of similar costs incurred in first class office buildings in the vicinity of the Building;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2.5in">(15) any compensation
paid to clerks, attendants or other Persons in commercial concessions operated by Landlord for a profit;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2.5in">(16) any interest,
fine, penalty or other late charges payable by Landlord, incurred as a result of late payments, except to the extent the same was
with respect to a payment, part or all of which was (i) the responsibility of Tenant hereunder and with respect to which Tenant
did not make in a timely fashion or did not make at all or (ii) related to a dispute by Landlord in good faith with respect to
costs otherwise includable in Operating Expenses;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2.5in">(17) any contributions
to charitable organizations, except to the extent the same are customarily included as operating expenses in office leases of first
class office buildings in the vicinity of the Building;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2.5in">(18) costs and expenses
incurred in connection with specialty improvements to the Building (including private cafeterias, lodging or private dining facilities
or private athletic or recreational clubs) with respect to which Tenant is not given access in common with other tenants or occupants
of the Building and other tenants or occupants of the Building are given exclusive access to use and occupy;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2.5in">(19) costs and expenses
in connection with any judgment, settlement or arbitration award resulting from the gross negligence or willful misconduct of Landlord
giving rise to tort liability;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2.5in">(20) costs relating
to withdrawal liability or unfunded pension liability under the Multi-Employer Pension Plan Act;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2.5in">(21) any costs incurred
in connection the remedying of any violations of applicable legal requirements existing as of the date hereof (excluding, for the
avoidance of doubt, any costs in connection with Section 20.31 hereof);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2.5in">(22) expenses and disbursements
relating to disputes with Tenant and other tenants or other occupants of the Building;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2.5in">(23) Non-Common Expenses;
and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2.5in">(24) Lab Costs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">Operating Expenses shall
be net of rebates, credits and similar items of which Landlord receives the benefit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">If Landlord is not furnishing
any particular work or service (the cost of which if performed by Landlord would constitute an Operating Expense (including with
respect to the determination of Base Operating Expenses)) to a tenant who has undertaken to perform such work or service in lieu
of the performance thereof by Landlord, Operating Expenses for any Operating Year (including the year based on which Base Operating
Expenses are determined) during all or any part of which such work or service is not so furnished by Landlord shall be increased
by an amount equal to the additional Operating Expenses which reasonably would have been incurred during such period by Landlord
if it had at its own expense furnished such work or service to such tenant. Notwithstanding anything to the contrary contained
herein, Base Operating Expenses shall not include (I) increases due to extraordinary circumstances, including but not limited to,
Force Majeure, boycotts, strikes, conservation surcharges, security concerns, embargoes or shortages (provided that in the event
that any of the extraordinary circumstances contemplated by this clause (I) shall also be applicable in the Operating Year so compared,
then Base Operating Expenses shall be deemed to include the costs and expenses associated with such event, solely with respect
to such Operating Year in which the extraordinary circumstances continues or otherwise applies) or (II) Permitted Capital Expenditures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">In determining the amount
of Operating Expenses for any Operating Year (including the determination of Base Operating Expenses), if less than one hundred
percent (100%) of the rentable area of the Building shall have been occupied by tenant(s) at any time during such Operating Year,
Operating Expenses shall be determined for such Operating Year to be an amount equal to the Operating Expenses which would normally
be expected to have been incurred had such occupancy been one hundred percent (100%) throughout such Operating Year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">(c) &ldquo;Operating
Year&rdquo; shall mean the calendar year within which the Commencement Date occurs and each subsequent calendar year, any part
or all of which falls within the Lease Term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">(d) &ldquo;Property&rdquo;
shall mean the Land, the Building, and any other land contiguous to the Land, and any improvements constructed on such land, whether
above or below ground, which Landlord may operate or maintain or may contribute to the cost of the operation or maintenance thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">(e) &ldquo;Non-Common
Expenses&rdquo; shall mean all expenses relating to (i) services or other benefits (&ldquo;Non-Common Services&rdquo;) that are
not provided to office tenants of the Building generally without a separate charge (including, without limitation, any incremental
services that Tenant requires in order to operate a laboratory within the Premises), and/or (ii) all charges that Tenant is required
to pay directly to Landlord pursuant to a separate meter or by other means.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">6.2.2 <U>TENANT&rsquo;S
SHARE OF OPERATING EXPENSES</U>. If the Operating Expenses for any full Operating Year falling within the Lease Term shall exceed
the Base Operating Expenses or if, in the case of an Operating Year only a fraction of which is included in the Lease Term, the
amount of the Operating Expenses for such Operating Year multiplied by such fraction exceeds the Base Operating Expenses multiplied
by such fraction (the amount of such excess in either case being hereafter referred to as the &ldquo;Excess Operating Expenses&rdquo;),
then Tenant shall pay to Landlord, as Additional Rent, Tenant&rsquo;s Share of the Excess Operating Expenses for such Operating
Year or portion thereof. Tenant&rsquo;s Share of the Excess Operating Expenses for each Operating Year shall be payable in monthly
installments as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">(a) Estimated payments
by Tenant on account of Operating Expenses shall be made on the first day of each and every calendar month during the Lease Term,
and otherwise in the same fashion herein provided for the payment of Annual Fixed Rent. The monthly amount so to be paid to Landlord
shall be sufficient to provide Landlord by the end of each Operating Year with a sum equal to Tenant&rsquo;s required payments,
as estimated by Landlord from time to time, on account of Operating Expenses for such Operating Year. After the end of each Operating
Year, Landlord shall submit to Tenant a reasonably detailed statement (a &ldquo;Landlord&rsquo;s Statement&rdquo;) of Operating
Expenses for such Operating Year. If estimated payments theretofore made for such Year by Tenant exceed Tenant&rsquo;s required
payment on account therefor for such Operating Year, according to such statement, Landlord shall credit the amount of overpayment
against subsequent obligations of Tenant with respect to Operating Expenses (or refund such overpayment if the Lease Term has
ended and Tenant has no further obligation to Landlord); but, if the required payments on account thereof for such Operating Year
are greater than the estimated payments (if any) theretofore made on account thereof for such Operating Year, Tenant shall make
payment to Landlord within thirty (30) days after being so advised by Landlord. Except as otherwise provided herein, Landlord&rsquo;s
failure to render a Landlord&rsquo;s Statement with respect to any applicable payment period as provided herein shall not prejudice
Landlord&rsquo;s right to thereafter render a Landlord&rsquo;s Statement with respect thereto or with respect to any subsequent
payment period, nor shall the rendering of a Landlord&rsquo;s Statement prejudice Landlord&rsquo;s right (subject to the terms
hereof) to thereafter render a corrected Landlord&rsquo;s Statement for that payment period. Subject to the terms hereof, nothing
herein contained shall restrict Landlord from issuing a Landlord&rsquo;s Statement at any time there is an increase in Operating
Expenses during any payment period or any time thereafter. Notwithstanding the foregoing provisions of this Section 6.2.2, Landlord
shall not be entitled to issue a Landlord's Statement with respect to Operating Expenses for any Operating Year after the date
that is three (3) years after the applicable Operating Year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">(b) If the Operating
Expenses for any Operating Year (as adjusted, if applicable, pursuant to the last two (2) paragraphs of subsection 6.2.1(b)) shall
equal or be less than the Base Operating Expenses, Tenant shall not be obligated to make any payments to Landlord pursuant to this
Section 6.2 in respect of such Operating Year, but in no event shall Tenant be entitled to any refund or reduction in the Annual
Fixed Rent by reason of such fact.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">6.2.3 <U>AUDIT RIGHT</U>.
Subject to the provisions of this Section and provided that no Event of Default exists, Tenant shall have the right to examine
the correctness of the Landlord&rsquo;s Operating Expense statement or any item contained therein. Any request for examination
in respect of any Operating Year may be made by notice from Tenant to Landlord no more than one hundred eighty (180) days after
the date (the &ldquo;Operating Expense Statement Date&rdquo;) Landlord provides Tenant a statement of the actual amount of the
Operating Expenses in respect of such Operating Year and only if Tenant shall have fully paid such amount. Such notice shall set
forth in reasonable detail the matters questioned. Any examination must be completed and the results communicated to Landlord
no more than two hundred ten (210) days after the Operating Expense Statement Date. Tenant hereby acknowledges and agrees that
Tenant&rsquo;s sole right to contest the Operating Expense statement shall be as expressly set forth in this Section. Tenant hereby
waives any and all other rights pursuant to applicable law to inspect Landlord&rsquo;s books and records and/or to contest the
Operating Expense statement. If Tenant shall fail to timely exercise Tenant&rsquo;s right to inspect Landlord&rsquo;s books and
records as provided in this Section, or if Tenant shall fail to timely communicate to Landlord the results of Tenant&rsquo;s examination
as provided in this Section, with respect to any Operating Year, Landlord&rsquo;s statement of Operating Expenses shall be conclusive
and binding on Tenant. So much of Landlord&rsquo;s books and records pertaining to the Operating Expenses for the specific matters
questioned by Tenant for the Operating Year included in Landlord&rsquo;s statement shall be made available to Tenant within a
reasonable time after Landlord timely receives the notice from Tenant to make such examination pursuant to this Section during
normal business hours at the offices in New York, New York where Landlord keeps such books and records. Tenant shall have the
right to make such examination no more than once in respect of any Operating Year in which Landlord has given Tenant a statement
of the Operating Expenses. Such examination may be made only by a qualified employee of Tenant or a qualified independent certified
public accounting firm approved by Landlord, and in no event shall such examination be performed by BDO Seidman, LLP or its successors.
No examination shall be conducted by an examiner who is to be compensated, in whole or in part, on a contingent fee basis. As
a condition to performing any such examination, Tenant and its examiners shall be required to execute and deliver to Landlord
an agreement, in form acceptable to Landlord, agreeing to keep confidential any information which it discovers about Landlord
or the Building in connection with such examination. No subtenant shall have any right to conduct any such examination and no
assignee may conduct any such examination with respect to any period during which the assignee was not in possession of the Premises.
All costs and expenses of any such examination shall be paid by Tenant. If as a result of such examination Landlord and Tenant
agree that the amounts paid by Tenant to Landlord on account of the Operating Expenses exceeded the amounts to which Landlord
was entitled hereunder, or that Tenant is entitled to a credit with respect to the Operating Expenses, Landlord, at its option,
shall refund to Tenant the amount of such excess or apply the amount of such credit, as the case may be, within thirty (30) days
after the date of such agreement. Similarly, if Landlord and Tenant agree that the amounts paid by Tenant to Landlord on account
of Operating Expenses were less than the amounts to which Landlord was entitled hereunder, then Tenant shall pay to Landlord,
as additional rent hereunder, the amount of such deficiency within thirty (30) days after the date of such agreement. All costs
and expenses of any such examination made pursuant to this Section 6.2.3 shall be paid by Tenant except insofar as Landlord and
Tenant agree as a result of such examination that Landlord overstated Operating Expenses by more than seven percent (7%), in which
case Landlord shall pay any reasonable out-of-pocket fees and expenses charged by Tenant&rsquo;s public accounting firm, but in
no case more than the amount overpaid by Tenant for such Operating Year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">6.2.4 <U>GENERAL APPLICABILITY</U>.
The imposition on Landlord by any portion of this Lease of an obligation to perform any work, repairs or other acts with respect
to the Property shall not be construed as preventing Landlord from including the cost of such work, repairs or other acts in Operating
Expenses, to the extent the same is otherwise properly includible therein pursuant to this Section 6.2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase"><U>ARTICLE
7</U></FONT><BR>
<BR>
<U>R<FONT STYLE="text-transform: uppercase">EPAIRS AND SERVICES</FONT></U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">7.1 <U>LANDLORD&rsquo;S
OBLIGATION TO REPAIR</U>. Except as otherwise provided in this Lease, Landlord shall, throughout the Lease Term, keep and maintain
in good order, condition and repair:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(a) the roof, the exterior
and load bearing walls (including exterior windows), the foundation, the structural floor slabs and other structural elements of
the Building; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(b) the common facilities
of the Building, including HVAC, plumbing and other Building systems and equipment servicing the Premises (other than any supplementary
or accessory HVAC, and telecommunication/computer systems and/or any item of such equipment exclusively serving the Premises) up
to the point of connection to the Premises and electricity servicing Common Areas.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">Landlord shall not
be responsible to make any improvements or repairs to the Building or the Premises other than as expressly provided in this
Section 7.1, unless expressly otherwise provided in this Lease. Tenant shall promptly give Landlord notice of any damage to
the Premises or the Building (whether or not caused by Tenant) or of any Latent Defects in any portion thereof or in any
fixtures or equipment therein promptly after Tenant first learns thereof. In making any repairs, alterations, additions or
improvements in the Premises, Landlord shall, use reasonable efforts to minimize interference with Tenant&rsquo;s use and
occupancy of the Premises; provided, however, that Landlord shall have no obligation to employ contractors or labor at
so-called overtime or other premium pay rates or to incur any other overtime costs or expenses whatsoever. Subject to the
foregoing, Landlord will correct any such Latent Defects promptly after receipt of such notice from Tenant; provided,
however, if Tenant does not notify Landlord of any Latent Defect within twelve (12) months after the Commencement Date, then
Landlord shall have no obligation to repair or correct such Latent Defect. &ldquo;Latent Defects&rdquo; shall mean defects in
the Work that adversely affect Tenant&rsquo;s use of the Premises for the Permitted Use in any material respect, which
defects, despite the exercise of commercially reasonable efforts by Tenant, are not susceptible of being detected (and are
not detected) as of the Commencement Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">7.2 <U>TENANT&rsquo;S
REPAIRS AND MAINTENANCE</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(a) Tenant covenants
and agrees that, from and after the date that possession of the Premises is delivered to Tenant and until the end of the Lease
Term, Tenant, at its expense, will keep neat and clean and maintain in good order, condition and repair the Premises, Alterations
and all fixtures or facilities contained in the Premises which do not constitute part of the common areas or the Building systems,
including, without limitation, any distribution conduits for the HVAC system serving the Premises, any supplemental air conditioning
units installed by or on behalf of Tenant or any other Tenant Party, any private lavatory and any public lavatories located on
floors leased entirely to Tenant, shower, toilet, washbasin and kitchen facilities, and all plumbing serving or connected to such
systems or facilities, and will make all required repairs thereto and/or replacements of portions thereof, excepting only for those
repairs or replacements for which Landlord is responsible under the terms of Section 7.1 or Article 12 of this Lease. Tenant shall
not permit or commit any waste, and, notwithstanding anything to the contrary set forth in Section 7.1, Tenant shall be responsible
for the cost of all repairs and replacements to the Premises, the Building and the facilities of the Building, whether ordinary
or extraordinary, structural or, non-structural, when necessitated by Tenant&rsquo;s, or its subtenant&rsquo;s or assignee&rsquo;s,
moving property in or out of the Building or installation or removal of furniture, fixtures or other property or by the performance
by Tenant, or its subtenant or assignee, of any alterations or other work in the Premises, or when necessitated by the acts, omission,
misuse, neglect or improper conduct of Tenant, its assignee or subtenant, or its or their agents, employees, contractors or invitees
or the use or occupancy or manner of use or occupancy of the Premises other than in accordance with the terms of this Lease. All
of said repairs and any restorations or replacements required in connection therewith shall be of a quality and class at least
equal to the original work or installations and shall be done in a good and workmanlike manner to the satisfaction of Landlord.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(b) If repairs or replacements
are required to be made by Tenant pursuant to the terms hereof, Landlord may demand that Tenant make the same forthwith, and (except
in cases of emergency, where no notice or demand shall be required) if Tenant refuses or neglects to commence such repairs or
replacements within thirty (30) days after such demand or to complete the same with reasonable diligence thereafter, Landlord
may (but shall not be required to do so) make or cause such repairs or replacements to be made and shall not be responsible to
Tenant for any loss or damage that may accrue to Tenant&rsquo;s stock or business by reason thereof. If Landlord makes or causes
such repairs or replacements to be made, Tenant agrees that Tenant will forthwith, on demand, pay to Landlord as Additional Rent
the cost thereof, together with interest thereon at the Lease Interest Rate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">7.3 <U>SERVICES</U>.
Subject to the provisions of Sections 14.3 and 20.12, Landlord agrees to provide the services set forth in Exhibit D annexed hereto
to the Building and the Premises during Operating Hours (as defined in Exhibit D). In the event that Tenant purchases any utility
service directly from the provider, Tenant shall promptly provide to Landlord copies of the utility bills for Tenant&rsquo;s usage
of such services in a format reasonably acceptable to Landlord. Notwithstanding anything in this Lease to the contrary, if Landlord
or any affiliate of Landlord has elected to qualify as a real estate investment trust (&ldquo;REIT&rdquo;), any service required
or permitted to be performed by Landlord pursuant to this Lease, the charge or cost of which may be treated as impermissible tenant
service income under the laws governing a REIT, may be performed by a taxable REIT subsidiary that is affiliated with either Landlord
or Landlord&rsquo;s property manager, an independent contractor of Landlord or Landlord&rsquo;s property manager (the &ldquo;Service
Provider&rdquo;). If Tenant is subject to a charge under this Lease for any such service, then, at Landlord&rsquo;s direction,
Tenant will pay such charge either to Landlord for further payment to the Service Provider or directly to the Service Provider,
and, in either case, (i) Landlord will credit such payment against Additional Rent due from Tenant under this Lease for such service,
and (ii) such payment to the Service Provider will not relieve Landlord from any obligation under the Lease concerning the provisions
of such service. Landlord shall not be obligated to provide any services to the Premises other than as set forth on Exhibit D annexed
hereto; provided, however, Landlord shall be obligated to provide any Non-Common Services reasonably requested by Tenant and approved
by Landlord (such approval not to be unreasonably withheld, conditioned or delayed). The consumption of any such Non-Common Services
required by Tenant and provided by Landlord may be measured by one or more submeters installed by Landlord at Tenant&rsquo;s sole
cost and expense. Tenant shall pay the charges for such services within thirty (30) days after rendition of bills therefor, which
bills shall be rendered by or on behalf of Landlord separately for any such charge and shall be delivered no less frequently than
monthly. Landlord&rsquo;s failure to render or delay in rendering a bill with respect to any month shall not prejudice Landlord&rsquo;s
right to thereafter render a bill with respect to any such month, nor shall the rendering of a bill for any month prejudice Landlord&rsquo;s
right to thereafter render a corrected bill for such month.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">7.4 <U>LAB COSTS</U>.
Solely in the event that Tenant operates a laboratory in the Premises, Tenant shall pay to Landlord, as Additional Rent, the Lab
Costs for each Operating Year or, in the case of an Operating Year only a fraction of which is included in the Lease Term, the
applicable portion thereof. Lab Costs for each Operating Year shall be payable in monthly installments as follows: estimated payments
by Tenant on account of Lab Costs shall be made on the first day of each and every calendar month during the Lease Term, and otherwise
in the same fashion herein provided for the payment of Annual Fixed Rent. The monthly amount so to be paid to Landlord shall be
sufficient to provide Landlord by the end of each Operating Year with a sum equal to Tenant&rsquo;s required payments, as estimated
by Landlord from time to time, on account of Lab Costs for such Operating Year. Landlord shall deliver to Tenant an annual estimate
of Lab Costs for each calendar year during the term, which may be revised by Landlord from time to time during such calendar year,
including, without limitation, to increase such estimate as a result of any item of expense or cost reimbursable by Tenant that
relates to a repair, replacement or service benefiting the Lab Area or a portion of the Building that includes the Lab Area or
that varies with occupancy or use. After the end of each Operating Year, Landlord shall submit to Tenant a reasonably detailed
statement of Lab Costs for such Operating Year. If estimated payments theretofore made for such Operating Year by Tenant exceed
Tenant&rsquo;s required payment on account therefor for such Operating Year, according to such statement, Landlord shall credit
the amount of overpayment against subsequent obligations of Tenant with respect to Lab Costs (or refund such overpayment if the
Lease Term has ended and Tenant has no further obligation to Landlord); but, if the required payments on account thereof for such
Operating Year are greater than the estimated payments (if any) theretofore made on account thereof for such Operating Year, Tenant
shall make payment to Landlord within thirty (30) days after being so advised by Landlord. Lab Costs shall be calculated on the
accrual basis of accounting. As used herein, the term (i) &ldquo;Lab Costs&rdquo; shall mean the aggregate of all costs and expenses
(including taxes, if any, thereon) paid or incurred by or on behalf of Landlord (whether directly or through independent contractors)
in connection with the operation and maintenance of the Lab Area and the Lab Systems, including all expenses incurred by Landlord
as a result of its compliance with any of its obligations under Sections 20.31, but excluding Operating Expenses, and (ii) &ldquo;Lab
Area&rdquo; shall mean the portion of the Premises dedicated solely to laboratory uses (and not office uses) qualifying as Qualified
Life Sciences Uses. Landlord acknowledges and agrees that Tenant&rsquo;s initial use of the Premises will be for office space
for a life sciences company; accordingly, so long as Tenant does not operate any laboratory in the Premises, then Tenant will
not be obligated to pay any Lab Costs under this Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase"></FONT></P>

<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase"><U>ARTICLE
8</U></FONT><BR>
<BR>
<U>A<FONT STYLE="text-transform: uppercase">LTERATIONS</FONT></U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">8.1 <U>TENANT&rsquo;S
RIGHTS</U>. Tenant may from time to time during the Lease Term, at its expense, make such alterations, additions, installations,
substitutions, improvements and decorations (collectively, with Tenant&rsquo;s Work, referred to as &ldquo;Alterations&rdquo;)
in and to the Premises as Tenant may consider necessary or desirable for the conduct of its business in the Premises, subject to
the following conditions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(a) the outside appearance
or the strength of the Building or any of its structural parts shall not be affected;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(b) no part of the Building
outside of the Premises shall be physically affected;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(c) no other tenant or
occupant of the Building, and no common area of the Building, shall be affected;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(d) the proper and economical
functioning of the Building systems or facilities of the Building or any portion thereof shall not be affected;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(e) before proceeding
with any Alterations, Tenant shall obtain Landlord&rsquo;s written consent and submit to Landlord for approval plans and specifications
for the work to be performed; it being agreed that Landlord shall not unreasonably withhold, condition or delay its consent if
the proposed Alteration is not a Material Alteration. For purposes of this <U>Article 8</U>, the term &ldquo;Material Alteration&rdquo;
means any Alteration that (i) affects the outside appearance of the Building or the structure of the Building, including the structural
elements of the walls, floors, ceiling or columns of the Building, (ii) would physically affect any components of the exterior
of the Building, (iii) would affect the Building systems or services, (iv) would adversely affect the provision of services to
other Building occupants, (v) would involve excessive noise or fumes (including, but not limited to any Alterations(s) involving
(A) demolition, (B) cutting, trenching, chopping and drilling of floor slabs, (C) shooting fasteners into slab, floor or overhead,
(D) spraying of paint or other coatings, (E) disconnects or shutdowns affecting other tenants or other parts of the Building,
(F) burning or welding of steel which causes fumes to be transmitted to other parts of the Building or (G) the use of air-hammers
or concrete saws) or (vi) would include work that requires the removal of a portion of the floor slab in any portion of the Premises,
or access to, or penetration of the floor slab adjacent to, any space occupied by any other tenant or occupant of the Building
(other than Tenant&rsquo;s subtenants). Landlord&rsquo;s prior written consent shall not be required for any Alterations that
are purely decorative or cosmetic Alterations (and that are not otherwise Material Alterations) such as painting, wall coverings
and floor coverings and that do not cost in excess of Fifty Thousand and 00/100 Dollars ($50,000.00). Landlord may as a condition
of its consent require Tenant (i) to perform all such work at such times and in such manner as to create the least practicable
interference with the use of the Building by the other tenants and occupants thereof, including, but without limitation, on an
&ldquo;overtime&rdquo; basis, (ii) to make revisions in and to its plans and specifications, and/or (iii) to agree to remove,
at or prior to the Expiration Date, any item of work shown on such plans of an unusual nature, such as, but not limited to, internal
stairways, pantries, lavatories, vaults, special flooring for computer areas and the like (&ldquo;Specialty Alterations&rdquo;),
and to restore the affected portion of the Premises;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(f) before proceeding
with any Alterations, any required consent from any Mortgagee and/or Overlandlord shall have been obtained; provided, however,
with respect to any future Mortgagee or Overlandlord, the provisions of the mortgage or Underlying Lease, as applicable, requiring
such future Mortgagee or Overlandlord&rsquo;s consent shall be commercially reasonable; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(g) in performing the
work involved in such Alterations, Tenant shall perform, observe and comply with all of the conditions and covenants set forth
in the provisions of this Article 8.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Landlord&rsquo;s review
and approval of Tenant&rsquo;s plans and specifications and consent to the performance of the work described therein shall not
be deemed an agreement by Landlord that such plans, specifications and work conform with applicable law and insurance requirements,
nor shall it be deemed a waiver by Landlord of compliance by Tenant with any provisions of this Lease, nor shall it impose upon
Landlord any liability or obligation with respect to such work or the performance thereof. All Alterations together with the Work
and other non-base Building improvements in the Premises are collectively referred to herein as the &ldquo;Leasehold Improvements&rdquo;.
If Landlord fails to respond within ten (10) Business Days after Tenant&rsquo;s submittal of Tenant&rsquo;s plans and specifications,
Tenant may provide Landlord with an additional notice which shall set forth in bold capital letters the following statement: &ldquo;<B>IF
LANDLORD FAILS TO RESPOND WITHIN FIVE (5) BUSINESS DAYS AFTER RECEIPT OF THIS NOTICE, THEN TENANT SHALL BE ENTITLED TO COMMENCE
CONSTRUCTION IN ACCORDANCE WITH THE PLANS AND SPECIFICATIONS SUBMITTED TO LANDLORD WITH THIS REQUEST</B>&rdquo;. If Landlord fails
to respond to such notice within five (5) Business Days after receipt by Landlord, then Tenant&rsquo;s plans and specifications
for which the request is submitted shall be deemed to be approved by Landlord and Tenant shall be entitled to perform the Alterations
to which such plans and specifications relate, provided that, as to commencing such Alterations, such plans and specifications
have been appropriately filed in accordance with all applicable law and insurance requirements, all permits and approvals required
to be issued by any governmental authority with respect to such phase of construction work shall have been duly issued, and Tenant
shall otherwise have complied with all provisions of this Lease relating to such Alterations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">8.2 <U>CONFORMITY WITH
LAW</U>. Tenant covenants and agrees that any Alterations made by it to or upon the Premises shall be done in a good and workmanlike
manner and in conformity and compliance with all applicable laws, ordinances, regulations and requirements of all public authorities
having jurisdiction, and with all applicable requirements of insurers and insurance rating or underwriting organizations, that
new materials and equipment of at least equal quality and class to the original installations in the Building shall be employed
therein, that the structure of the Building shall not be endangered or impaired thereby and that the Premises shall not be diminished
in value thereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">8.3 <U>PERFORMANCE
OF WORK, GOVERNMENTAL APPROVALS, INSURANCE</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(a) All Alterations and
installation of furnishings by Tenant (i) shall be coordinated with any work being performed by Landlord and in such manner as
to maintain harmonious labor relations and not to damage the Building or interfere with or delay Building construction or operation
or increase the cost thereof, (ii) shall not interfere with the use or occupancy of any other tenant or occupant of the Building
(iii) to the extent connected to or involving any portion of the HVAC, plumbing, electrical, life safety, proprietary or other
systems of the Building, shall be performed by a contractor designated by Landlord in its sole and absolute discretion, and (iv)
with respect to all Alterations and installations which are not the subject of the foregoing clause (iii), shall be performed by
contractors and subcontractors first approved by Landlord (which approval shall not be unreasonably withheld, delayed or conditioned).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(b) Tenant shall (i)
procure all necessary governmental permits, licenses and certificates, (ii) make all required filings of plans with governmental
authorities before making any Alterations, (iii) obtain all required governmental approvals upon the completion thereof, and (iv)
deliver copies of the items set forth in subsections (i) through (iii) above to Landlord for inspection by Landlord, and, if applicable,
for Landlord&rsquo;s approval. Upon completion of any Alterations, Tenant shall deliver to Landlord (i) an architect&rsquo;s certificate
from Tenant&rsquo;s architect certifying that the Alterations have been completed in accordance with the approved plans and specifications
and (ii) three (3) complete &ldquo;as built&rdquo; sets of Tenant&rsquo;s plans and specifications prepared on an AutoCAD Computer
Assisted Drafting and Design System (or such other system or medium reasonably approved by Landlord and generally used in the
industry) using naming conventions issued by the American Institute of Architects in June, 1990 (or such other naming conventions
as Landlord may reasonably accept) and digital files of such record drawings and specifications, translated into in a format compatible
with AutoCAD Release 2000 or later or another format reasonably acceptable to Landlord. Tenant shall use an expediter designated
by Landlord in connection with making such filings and obtaining such permits, licenses, certificates and approvals. At any and
all times during the period of construction of any Alterations, Landlord shall be entitled to have a representative or representatives
on the site to inspect such Alterations, and such representative or representatives shall have free and unrestricted access to
any and every part of the Premises. Tenant shall keep full and accurate records of the cost of any Alterations in and to the Premises
and shall, if requested by Landlord, make the same available to Landlord for use in connection with any proceeding to review the
assessed valuation of the Building or any proceedings to acquire the Land and Building for public or quasi-public use.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(c) Tenant agrees to
save harmless and indemnify Landlord and all other Landlord Parties from and against any and all injury, loss, claims, damage and
expense (including attorneys&rsquo; fees and disbursements) to any person or property occasioned by or arising out of the performance
of any Alterations pursuant to the provisions of Section 11.1 hereof. In addition, Tenant shall carry or cause each contractor
to carry the insurance required pursuant to Section 11.13 hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(d) In connection with
the making of any Alterations, Tenant shall (i) make all arrangements for, and shall pay all expenses incurred in connection with,
use of the freight elevator(s) serving the Premises, (ii) comply with Landlord&rsquo;s alteration rules and regulations for the
Building and (iii) pay to Landlord its actual out-of-pocket costs for reviewing Tenant&rsquo;s plans and specifications and to
reimburse Landlord for its actual out-of-pocket costs of other services performed or other actual out-of-pocket costs reasonably
incurred by Landlord in connection with such Alterations. Notwithstanding anything to the contrary contained herein or in Exhibit
D attached hereto, Landlord shall waive all charges for Tenant&rsquo;s use of the freight elevator(s) during non-Operating Hours
for the first thirty (30) hours of aggregate usage by Tenant in connection with Tenant&rsquo;s initial move in to the Premises
or Tenant&rsquo;s surrender of the Premises in accordance with Section 20.4.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">8.4 <U>LIENS</U>. Tenant
shall promptly pay and discharge all costs and expenses of any work done in or on the Premises by Tenant or its subtenants, and
its and their agents, employees or contractors, and shall not do or fail to do any act which shall or may render the Building or
any part thereof, or the Premises or any part thereof subject to any mechanic&rsquo;s lien or other lien or security agreement
or charge or chattel mortgage or conditional bill of sale or title retention agreement (hereinafter collectively called &ldquo;Lien&rdquo;),
and if any Lien be filed against the Building, the Premises, any Alterations, or any portion of any of the foregoing, Tenant shall,
at Tenant&rsquo;s own cost and expense, cause the same to be removed of record by bonding or otherwise within twenty (20) days
after the filing of any such Lien; and, in default thereof, Landlord may, in addition to any other rights and remedies it may have
by reason of Tenant&rsquo;s default, cause any such Lien to be removed of record by payment or bond or otherwise, as Landlord may
elect, and Tenant shall reimburse Landlord as Additional Rent for all costs and expenses incidental to the removal of any such
Lien incurred by Landlord, together with interest thereon at the Lease Interest Rate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">8.5 <U>VIOLATIONS;
DISRUPTION</U>. Tenant, at its expense, and with diligence and dispatch, shall cause to be discharged or cancelled all notices
of violation arising from any Alterations which are issued by the Department of Buildings of The City of New York or any other
public or quasi-public authority having jurisdiction. Nothing contained in this Section 8.5 shall prevent Tenant from contesting,
in good faith and at its own expense, any such notices of violation, provided that Tenant shall comply with the provisions of
Section 9.3 hereof. In addition, Tenant shall not exercise any of its rights under this Article 8 or any other provision of this
Lease, or use or occupy the Premises, in such manner as would create any work stoppage, picketing, labor disruption or dispute
or a violation of any of Landlord&rsquo;s union contracts affecting the Land or Building, or which would unreasonably interfere
with the business of Landlord or of any tenant or occupant of Building. In the event of the Tenant&rsquo;s failure to comply with
the preceding sentence, Tenant shall, immediately upon notice from Landlord, cease all manner of exercise of such rights which
give rise to such failure to comply. If Tenant shall fail to cease such manner of exercise of its rights as aforesaid, Landlord,
in addition to any other rights available to it under this Lease and pursuant to law, shall have the right to seek an injunction
without notice to the Tenant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">8.6 <U>TENANT&rsquo;S
PROPERTY</U>. Except as otherwise provided in this Section 8.6, all work, construction, repairs, Alterations, other improvements
or installations made to or upon the Premises (including, but not limited to, the construction performed by Landlord or Tenant
under Article 4 and Exhibit C), whether or not at the expense of Tenant, shall become part of the Premises and shall become the
property of Landlord and remain upon and be surrendered with the Premises as a part thereof upon the Expiration Date or earlier
termination of the Lease Term:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(a) Tenant&rsquo;s movable
business equipment and movable partitions, telephone and other communications equipment, laboratory equipment, computer systems,
furniture, trade fixtures, furnishings, goods, supplies, wares, merchandise and other items of personal property (excluding Lab
Systems, property which is built into the Premises and custom-fitted furniture or cabinetry) and personal property of third parties
in the Premises in Tenant&rsquo;s care, custody, use or control, including but not limited to leased or rented property, in each
case paid for without any contribution to the cost thereof from Landlord, which are removable without damage to the Premises or
Building (collectively, &ldquo;Tenant&rsquo;s Property&rdquo;) shall remain the property of Tenant (or such third parties) and
may be removed by Tenant or any person claiming under Tenant at any time or times during the Lease Term and shall be removed by
Tenant at the expiration or earlier termination of the Lease Term. Tenant shall repair any damage to the Premises occasioned by
the removal by Tenant or any person claiming under Tenant of any Tenant&rsquo;s Property from the Premises.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(b) At the Expiration
Date or earlier termination of the Lease Term, unless otherwise specified in writing by Landlord, Tenant shall remove from the
Premises any Specialty Alterations made to the Premises for which such removal was made a condition of such consent under Section
8.1 or Exhibit C. Upon such removal Tenant shall restore the Premises to their condition prior to installation of such Specialty
Alterations and repair any damage occasioned by such removal and restoration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(c) Any items of Tenant&rsquo;s
Property which remain on the Premises after the Expiration Date or earlier termination of the Lease Term may, at the option of
Landlord, be deemed to have been abandoned and in such case may either be retained by Landlord as its property or may be disposed
of without accountability, at Tenant&rsquo;s expense, in such manner as Landlord may see fit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">8.7 <U>SURVIVAL</U>.
The provisions of this Article 8 shall survive the expiration or sooner termination of this Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase"><U>ARTICLE
9</U></FONT><BR>
<BR>
<U>L<FONT STYLE="text-transform: uppercase">AWS, ORDINANCES, REQUIREMENTS OF PUBLIC AUTHORITIES</FONT></U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">9.1 <U>CERTIFICATE
OF OCCUPANCY</U>. Landlord covenants and agrees that throughout the Lease Term, Landlord will not amend the certificate of occupancy
issued for the Building so as to prohibit Tenant from using the Premises for the Permitted Use.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">9.2 <U>TENANT&rsquo;S
OBLIGATIONS</U>. Except as otherwise set forth herein, Tenant shall, at its expense, comply with all laws and requirements of public
authorities, all licenses and permits required for the proper and lawful conduct of Tenant&rsquo;s business in the Premises (including
all applicable environmental laws) and all requirements of insurance bodies now or hereafter in effect which shall, with respect
to the Premises or the occupancy, use or manner of use of the Premises or to any abatement of nuisance, impose any violation, order
or duty upon Landlord or Tenant, including without limitation, any violation, order or duty arising from (i) Tenant&rsquo;s use
of the Premises, (ii) the manner of conduct of Tenant&rsquo;s business in the Premises or the operation by Tenant of its installations,
equipment or other property thereon, (iii) any cause or condition created by or at the instance of Tenant, (iv) the making or performance
of any Alterations, installations or other work by Tenant in or on the Premises, including, without limitation, any Tenant&rsquo;s
Work, or (v) the breach by Tenant of any of its obligations under this Lease; and Tenant shall make all repairs or Alterations
required thereby, whether structural (in which event all such repairs or Alterations shall be performed by Landlord and the reasonable
cost thereof shall be paid by Tenant) or nonstructural, ordinary or extraordinary; provided, however, Tenant shall only be required
to make any such structural Alterations to the extent the need for the same arises as a result of (A) Tenant&rsquo;s particular
manner of use of the Premises or the manner of conduct of Tenant&rsquo;s business in the Premises or the operation by Tenant of
its installations, equipment or other property thereon, where such manner of use, conduct or operation shall be reasonably distinguishable
from the ordinary use, conduct or operation of a business using the Premises for ordinary office purposes or (B) any of the circumstances
described in clauses (iii) through (v) above. In addition to the foregoing, Tenant agrees to participate in all fire and other
safety compliance procedures instituted by Landlord and/or public authorities for the Building.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">9.3 <U>TENANT&rsquo;S
RIGHT TO CONTEST</U>. If Tenant receives notice of any violation of any law or requirement of public authority or requirement
of insurance bodies applicable to the Premises, it shall give prompt notice thereof to Landlord. Tenant may, at its expense, contest
the validity or applicability of any such law or requirement of public authority or requirement of insurance bodies by appropriate
proceedings prosecuted diligently and in good faith, and may defer compliance therewith, provided that (i) no Landlord Party is
thereby subjected to criminal prosecution or criminal or civil penalty of any nature, (ii) no unsafe or hazardous condition remains
unremedied, (iii) the Premises, or any part thereof, shall not be subject to being condemned or vacated by reason of such non-compliance
or such contest, (iv) no insurance policy carried in respect of the Property by Landlord is cancelled and no premium for any such
policy is increased by reason of such non-compliance or such contest, (v) Landlord shall not be prevented from obtaining or maintaining
any permits or licenses in connection with the operation of the Building or the Property or any portion thereof, nor shall the
certificate of occupancy be suspended or threatened by reason of such non-compliance or such contest, (vi) such non-compliance
or contest shall not constitute or result in any violation of any Underlying Lease or any mortgage on the Building or on an Underlying
Lease thereof, and Tenant complies with all requirements of all such Underlying Leases or mortgages including those, if any, relating
to the furnishing of security, and (vii) if Landlord so requires, Tenant furnishes to Landlord the bond of a surety company, in
form and substance satisfactory to Landlord, in an amount at least equal to <FONT STYLE="font-size: 10pt">[***]</FONT> of the
cost of such compliance (as estimated by Landlord), or such other security reasonably satisfactory in all respects to Landlord.
Tenant hereby agrees to indemnify and save the Landlord Parties harmless from and against any loss, liability, damage and expense
arising out of any such deferral of compliance or contest, including, without limitation, attorneys&rsquo; fees and disbursements
and other expenses reasonably incurred by Landlord, and Tenant shall keep Landlord advised as to all settlements of such contest.
Landlord agrees to execute any document reasonably required by Tenant in order to permit Tenant effectively to carry on any such
contest, provided Landlord is not thereby subjected to any cost or expense or exposed to any liability or obligation on account
thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">9.4 <U>WINDOW CLEANING</U>.
Tenant will not clean, nor require, permit, suffer or allow any window in the Premises to be cleaned, from the outside in violation
of Section 202 of the New York Labor Law or of the rules of the New York City Board of Standards and Appeals or of any other board
or body having or asserting jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase"><U>ARTICLE
10</U></FONT><BR>
<BR>
<U>U<FONT STYLE="text-transform: uppercase">SE</FONT></U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">10.1 <U>PERMITTED USE</U>.
Tenant shall use and occupy the Premises only for one or more of the following uses: (i) &ldquo;turnkey&rdquo; floor space outfitted
in a manner consistent with wet laboratory space dedicated to life sciences research and development where chemicals, drugs, or
other material or biological matter are tested and analyzed requiring water, direct ventilation, and specialized piped utilities,
and including laboratory support and ancillary office space, (ii) life sciences research and development space where chemicals,
drugs, or other material or biological matter are tested and analyzed requiring water, direct ventilation and specialized piped
utilities, and including wet or dry laboratory space, laboratory support and ancillary office space required in connection with
such research and development use or (ii) life sciences, applied science, physical science, medical technology, digital health,
and bioinformatics spaces in the form of offices and/or dry laboratories (collectively, &ldquo;Qualified Life Science Uses&rdquo;).
Subject to the other provisions of this Lease (including all exhibits) and such regulations and procedures as may from time to
time be in effect, Tenant shall have access to the Premises twenty-four (24) hours per day, seven (7) days per week. In no event
shall Tenant use or permit to be used any portion of the Premises for a Non-Qualified Use (as defined in the Agency Lease) during
the PILOT Term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">10.2 <U>ADDITIONAL
PERMITTED USES</U>. Tenant may, in addition to using the Premises for the purposes permitted by Section 10.1 but subject to Tenant&rsquo;s
compliance in respect thereof with the provisions of Section 9.2, also use portions of the Premises for the installation, maintenance
and operation in the Premises of (i) electronic data processing equipment, word processing equipment and business machines, (ii)
duplicating equipment, (iii) one Fitness Center (subject to Section 10.8), (iv) file rooms, pantries (subject to Section 10.9),
meeting, training and conference centers and rooms, and (v) a private bathroom and shower (subject to Section 10.10), in each
case used for purposes incidental to the business of Tenant with electrical loads and floor loads not to exceed the respective
load capacities set forth in Exhibit D.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">10.3 <U>RESTRICTIONS</U>.
Tenant shall not suffer or permit the Premises or any part thereof to be used in any manner, or anything to be done therein, or
suffer or permit anything to be brought into or kept in the Premises, which would in any way (i) violate any law or requirement
of public authorities or requirement of insurance bodies, (ii) cause structural injury to the Building or any part thereof, (iii)
interfere with the normal operation of the HVAC, plumbing, electrical or other mechanical or electrical systems of the Building
or the elevators installed therein, (iv) constitute a public or private nuisance, (v) alter the appearance of the exterior of the
Building, (vi) affect in any adverse way any portion of the interior of the Building other than the Premises, (vii) unreasonably
interfere with the use or occupancy of any other tenant or occupant of the Building, (viii) create any offensive odors or noise
or (ix) result in the leakage of fluid or the growth of mold or the creation of any other condition which causes, or in Landlord&rsquo;s
reasonable opinion would be likely to cause, an internal air quality problem in the Premises or the Building. Tenant shall not
solicit other occupants of the Building to use wireless internet service that emanates from the Premises. Tenant shall use reasonable
efforts to prevent the signals of Tenant&rsquo;s wireless internet service (if any) from emanating beyond the Premises or otherwise
interfering in any material respect with any Building systems. Tenant shall not, nor permit any Tenant Party to, photograph, broadcast,
record or otherwise make, use or transmit images of the Premises or the Building for any reason including, without limitation,
for use in movies, television, the internet, newspapers, magazines or other publications or media; provided that the foregoing
shall not prohibit (A) the making or use of images of the Premises or the Building by Tenant and its permitted assignees and subtenants
solely in connection with advertising approved by Landlord for marketing the Premises or a portion thereof for assignment or subletting
(subject to the provisions of Article 13 hereof) or (B) the photographing and transmission of images of the Premises by Tenant
for advertising its own business; provided, further, that in no event shall Tenant use any such images in a manner disparaging
to the Premises, the Building, Landlord or any Landlord Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">10.4 <U>PROHIBITED
USES</U>. Without limiting the restriction on use set forth in Section 10.1, Tenant shall not under any circumstance use or permit
the use of the Premises or any part thereof for any of the following which are expressly prohibited:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(a) sale at retail of
any products or materials whatsoever;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(b) the conduct of a
public auction of any kind;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(c) the conduct of a
commercial bank, trust company, savings bank, safe deposit or savings and loan association or any branches of any of the foregoing
or a loan company business (except for the conduct of a credit union or benefit plan for Tenant&rsquo;s employees);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(d) the issuance and
sale of traveler&rsquo;s checks, foreign drafts, letters of credit, foreign exchange or domestic money orders or the receipt of
money for transmission;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(e) an employment agency;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 41; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(f) offices or agencies
of a foreign government or political subdivisions thereof;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(g) offices of any governmental
bureau or agency of the United States or any state or political subdivision thereof;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(h) offices of any charitable,
religious, union or other not-for-profit or any tax exempt entity within the meaning of Section 168(j)(4)(A) of the Internal Revenue
Code of 1986, as amended, or any successor statute, or rule or regulation applicable thereto (provided, however, that this Section
10.4(h) shall not prohibit use of the Premises by a not-for-profit or tax exempt entity (such as a university research group) for
Qualified Life Sciences Uses);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(i) offices of any public
utility company, other than corporate, executive or legal staff offices;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(j) data processing services
rendered primarily to others than Tenant and which are not strictly ancillary to Tenant&rsquo;s business;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(k) health care professionals
seeing patients on an off-the-street basis;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(l) schools or other
training or educational uses (other than those which are strictly ancillary to the Tenant&rsquo;s business, such as training of
Tenant&rsquo;s personnel to be employed in the Building);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(m) a clerical support
business rendering clerical support services primarily to others than Tenant or performing functions other than those which are
strictly ancillary to Tenant&rsquo;s business;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(n) reservation centers
for airlines or for travel agencies;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(o) broadcasting centers
for communications firms, such as radio and television stations;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(p) any pornographic
or obscene purposes, any commercial sex establishment, any pornographic, obscene, nude or semi-nude performances, modeling, materials,
activities or sexual conduct or any other use that has or could reasonably be expected to have a material adverse effect on Landlord&rsquo;s
financial condition, the value of the Building or the income therefrom;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(q) a showroom;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(r) except as expressly
set forth herein, gyms and exercise facilities and equipment including, without limitation, cardiovascular and weight/resistance
machines, free weights, exercise and physical training rooms;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 42; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(s) any other use or
purpose which, in the reasonable judgment of Landlord, is not in keeping with the character and dignity of the Building or which
is prohibited under the Rules and Regulations; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(t) any other use or
purpose that, in the reasonable judgment of Landlord, is prohibited under, or inconsistent with, the Lab Rules and Regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">10.5 <U>LICENSES AND
PERMITS</U>. If any governmental license or permit (other than the Building certificate of occupancy which permits general office
use and the Qualified Life Sciences Uses) shall be required for the proper and lawful conduct of Tenant&rsquo;s business in the
Premises, or any part thereof, including, specifically, but without limitation, any place of assembly permit or any amendment to
the Building certificate of occupancy, Tenant, at its expense, shall duly apply for, procure and thereafter maintain such license
or permit and submit the same to Landlord for inspection by Landlord. Tenant&rsquo;s application for and procurement of any such
license, permit or amendment shall be subject to Landlord&rsquo;s review and approval, which shall not be unreasonably withheld
or delayed. Tenant shall at all times comply with each such license and permit and shall not at any time use or occupy, or suffer
or permit anyone to use or occupy, the Premises, or do or permit anything to be done in the Premises, in violation of the certificate
of occupancy for the Building.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">10.6 <U>HAZARDOUS
SUBSTANCES</U>. No Tenant Party shall store, place, generate, manufacture, refine, handle, or locate on, in, under or around
the Premises, the Building or Property any &ldquo;Hazardous Substance&rdquo; (as defined below), except for storage, handling
and use of reasonable quantities and types of biologics, pharmaceuticals, cleaning fluids and office supplies in the Premises
in the ordinary course and the prudent conduct of Tenant&rsquo;s business in the Premises. Tenant agrees that (a) the
storage, handling, use and disposal of such permitted Hazardous Substances must at all times conform to all applicable laws
and requirements of public authorities and to applicable fire, safety and insurance requirements; and (b) the types and
quantities of permitted Hazardous Substances which are stored in the Premises must be reasonable and appropriate to the
nature and size of Tenant&rsquo;s operation in the Premises and reasonable and appropriate for similar first-class office,
laboratory and research buildings in the midtown south area of Manhattan. Tenant shall furnish to Landlord evidence
reasonably acceptable to Landlord of Tenant&rsquo;s compliance with this Section 10.6 from time to time upon Landlord&rsquo;s
request. Tenant shall indemnify, defend and hold harmless Landlord Parties from and against any and all claims, damages,
losses, actions, causes of actions, proceedings, liens, fines, penalties, costs, expenses and liabilities arising out of any
breach of any provision of this paragraph, which expenses shall also include laboratory testing fees, personal injury claims,
clean-up costs and environmental consultants&rsquo; fees and attorneys&rsquo; fees, and such indemnity shall survive the
expiration or earlier termination of this Lease. Tenant agrees that Landlord may be irreparably harmed by Tenant&rsquo;s
breach of this paragraph and that an injunction and/or specific performance action may appropriately be brought by Landlord;
provided that, Landlord&rsquo;s election to bring or not bring any such injunction and/or specific performance action shall
in no way limit, waive, impair or hinder Landlord&rsquo;s other remedies against Tenant. If Hazardous Materials are present
in the Premises or on any floor containing a portion of the Premises and such presence is not caused by a Landlord Party, a
Tenant Party or anyone claiming by, through or under a Tenant Party, Landlord shall, at Landlord&rsquo;s sole cost and
expense, use commercially reasonable efforts to enforce all of its rights and remedies (including, without limitation, the
exercise of any self-help rights) against the party that caused such presence (provided that the foregoing shall not require
Landlord to evict any Tenant or commence or prosecute any litigation). As used in this Lease, the term &ldquo;Hazardous
Substance&rdquo; shall mean and include any chemical, material, element, compound, solution, mixture, substance or other
matter of any kind whatsoever which is now or later designated, classified, listed or regulated under any law, statute,
ordinance, rule, regulation, order or ruling of any agency of the State of New York, the United States Government or any
local governmental authority, including, without limitation, asbestos, petroleum, petroleum hydrocarbons and petroleum based
products, urea formaldehyde foam insulation, biologics and pharmaceuticals, polychlorinated biphenyls and freon and other
chlorofluorocarbons. Landlord covenants that, as of the Commencement Date, the Premises shall be free of Hazardous Materials
that violate applicable laws or requirements of public authorities. Landlord shall be responsible, at its sole cost and
expense, to remove or remediate any Hazardous Substances found in the Premises during the Lease Term to the extent due to a
breach of the foregoing covenants by Landlord or introduced into the Premises by Landlord by a Landlord Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 43; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">10.7 <U>OPERATIONS
AND MAINTENANCE PROGRAMS</U>. Tenant shall implement and comply with any reasonable operations and maintenance program with respect
to the Premises, which program (i) shall address any asbestos-containing material, lead-based paint, mold and/or other applicable
conditions that may now or in the future be detected at or on the Premises, and (ii) shall be subject to Landlord&rsquo;s approval.
Without limiting the generality of the preceding sentence, with respect to such operations and maintenance program, Landlord may
require (a) periodic notices or reports to Landlord in form, substance and at such intervals as Landlord may reasonably specify,
(b) an amendment to such operations and maintenance program to address changing circumstances or laws and (c) at Tenant&rsquo;s
sole cost and expense, supplemental examination of the Premises by consultants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">10.8 <U>FITNESS
CENTER</U>. Any fitness center facility permitted to be operated in the Premises (the &quot;Fitness Center&quot;) shall only
be located in a location designated by Tenant and acceptable to Landlord. There shall only be one (1) Fitness Center. The
Fitness Center may only be used by personnel of Tenant and any permitted subtenants and licensees ordinarily working in the
Building (and with respect to employees of Tenant or a permitted subtenant subleasing all or substantially all of the
Premises, visiting the Premises from another location and short-term invitees of Tenant; provided, however, in no event shall
the Fitness Center be held open for use by the general public. Tenant specifically agrees to perform or have performed on its
behalf and its own expense all prudent and necessary analysis and work to ensure that the Fitness Center (including, without
limitation, any and all weight machines, treadmills and other equipment) is designed and constructed (1) such that the use,
operation and maintenance thereof does not result in any noise that can be heard outside the Premises or any vibrations that
can be felt outside the Premises, (2) to be properly integrated into and not have any adverse impact upon the structure of
the Building and its harmonics, and (3) not to have any adverse impact upon any area of the Building outside the Premises,
including, without limitation, the Lab Areas, common areas or facilities, space demised to any other tenant or occupant and
space controlled by Landlord. Notwithstanding Tenant's compliance with the foregoing and with the other provisions of this
Lease, Landlord shall have the right, if Landlord has received a complaint by any other tenant or occupant of the Building of
interference or material adverse impact caused by such exercise facilities and Landlord reasonably believes such complaint
arises from a condition violative of the immediately preceding sentence, to require Tenant to immediately discontinue use of
the Fitness Center upon notice from Landlord, and Tenant shall discontinue such use, until such time as Tenant rectifies the
cause of and eliminates such interference or material adverse impact to the reasonable satisfaction of Landlord.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 44; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">10.9 <U>PANTRIES</U>.
Incidental to the primary use of the Premises for executive, administrative and general offices as provided in this <U>Article
10</U>, subject to the provisions of this Lease (including the provisions of <U>Article 8</U>), applicable laws and requirements
of public authorities, the Rules and Regulations or the Lab Rules and Regulations, one or more portions of the Premises may be
used as pantries and/or warming kitchens, which may contain reheating (but not cooking) equipment, such as microwaves, coffee makers,
sinks, ice makers, soda machines, vending machines, tables and chairs, dishwashers, hot water heaters and refrigerators; provided
that: (i) no cooking of food (other than the reheating of food by microwave or warming ovens that do not require venting) shall
be done in any such pantry, (ii) no food or beverages will be kept or served in the Premises in a manner or under any conditions
which result in fumes or odors being emitted from, or detectable outside of, the Premises such that same may unreasonably affect
other tenants or occupants of the Building, and (iii) such portion or portions of the Premises shall be at all times maintained
by Tenant in a clean and sanitary condition and free of refuse, insects and rodents (including required use of extermination services).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">10.10 <U>WET INSTALLATIONS</U>.
Ancillary to the use of the Premises for executive, administrative and general office use pursuant to Section 10.1 hereof, Tenant
may install, or cause to be installed, one (1) private bathroom and one (1) shower (collectively, the &ldquo;Wet Installations&rdquo;),
at its sole cost and expense; provided, however, that (i) Tenant install, or cause to be installed, in connection therewith a membrane
waterproofing system throughout all areas of the Premises containing such Wet Installations, which shall be maintained by Tenant
throughout the Term in good working order, (ii) Tenant shall be solely responsible at its expense throughout the Term for (1) preserving
the watertight integrity of the Wet Installations and (2) all leaks from the Wet Installations to all areas of the Building beneath
the Premises and any damage caused thereby, (iii) Tenant shall promptly cease the use of any Wet Installation in the event of any
water leaks occurring from such the Wet Installation, and shall promptly inform Landlord of the same and diligently perform, at
Tenant&rsquo;s sole cost and expense, any work or alteration reasonably requested by Landlord to remedy such problem and (iv) the
indemnity in Section 11.1 shall apply with respect to any and all claims arising out of any such leak.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase"><U>ARTICLE
11</U></FONT><BR>
<BR>
<U>T<FONT STYLE="text-transform: uppercase">ENANT&rsquo;S INDEMNITY AND INSURANCE</FONT></U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">11.1 <U>TENANT&rsquo;S
INDEMNITY</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(a) <U>Indemnity</U>.
To the fullest extent permitted by law, Tenant waives any right to contribution against the Landlord Parties (as hereinafter defined)
and agrees to indemnify and save harmless the Landlord Parties from and against all claims of whatever nature arising from or
claimed to have arisen from (i) any act, omission or negligence of the Tenant Parties (as hereinafter defined); (ii) any accident,
injury or damage whatsoever caused to any person, or to the property of any person, occurring in or about the Premises from the
earlier of (A) the date on which any Tenant Party first enters the Premises for any reason or (B) the Commencement Date, and thereafter
throughout and until the end of the Lease Term and after the end of the Lease Term for as long after the Lease Term as any of
Tenant&rsquo;s Property remains on the Premises, or Tenant or anyone acting by, through or under Tenant may use, be in occupancy
of any part of, or have access to the Premises or any portion thereof; (iii) any accident, injury or damage whatsoever occurring
outside the Premises but within the Building, or on common areas or the Property, where such accident, injury or damage results,
or is claimed to have resulted, from any act, omission or negligence on the part of any of the Tenant Parties; or (iv) any breach
of this Lease by Tenant; except, in each case, to the extent that any such claim results from the gross negligence or willful
misconduct of Landlord or any other Landlord Party. Tenant shall pay such indemnified amounts as they are incurred by the Landlord
Parties. This indemnification shall not be construed to deny or reduce any other rights or obligations of indemnity that a Landlord
Parties may have under this Lease or the common law. Notwithstanding anything to the contrary herein, in no event shall Tenant
be liable for any loss of business or any other consequential, special or punitive damages under this <U>Section 11.1(a)</U> unless
a Landlord Party shall be required to pay the same to a third party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 45; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(b) <U>Breach</U>. In
the event that Tenant breaches any of its indemnity obligations hereunder or under any other contractual or common law indemnity:
(i) Tenant shall pay to the Landlord Parties all liabilities, losses, costs and expenses (including attorney&rsquo;s fees) incurred
as a result of said breach; and (ii) the Landlord Parties may deduct and offset from any amounts due to Tenant under this Lease
any amounts owed by Tenant pursuant to this Section.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(c) <U>No limitation</U>.
The indemnification obligations under this Section shall not be limited in any way by any limitation on the amount or type of damages,
compensation or benefits payable by or for Tenant or any subtenant or other occupant of the Premises under workers&rsquo; compensation
acts, disability benefit acts, or other employee benefit acts. Tenant waives any immunity from or limitation on its indemnity or
contribution liability to the Landlord Parties based upon such acts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(d) <U>Subtenants and
other occupants</U>. Tenant shall require its subtenants and other occupants of the Premises to provide similar indemnities to
the Landlord Parties in a form acceptable to Landlord.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(e) <U>Survival</U>.
The terms of this Section shall survive any termination or expiration of this Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(f) <U>Costs</U>. The
foregoing indemnity and hold harmless agreement shall include indemnity for all costs, expenses and liabilities (including, without
limitation, attorneys&rsquo; fees and disbursements) incurred by the Landlord Parties in connection with any such claim or any
action or proceeding brought thereon, and the defense thereof. In addition, in the event that any action or proceeding shall be
brought against one or more Landlord Parties by reason of any such claim, Tenant, upon request from the Landlord Party, shall resist
and defend such action or proceeding on behalf of the Landlord Party by counsel appointed by Tenant&rsquo;s insurer (if such claim
is covered by insurance without reservation) or otherwise by counsel reasonably satisfactory to the Landlord Party. The Landlord
Parties shall not be bound by any compromise or settlement of any such claim, action or proceeding without the prior written consent
of such Landlord Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 46; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(g) <U>Landlord Parties
and Tenant Parties</U>. The term &ldquo;Landlord Party&rdquo; or &ldquo;Landlord Parties&rdquo; shall mean Landlord, any affiliate
of Landlord, Landlord&rsquo;s managing agents and leasing agents for the Building, Landlord&rsquo;s asset manager for the Building,
each Overlandlord, each Mortgagee, and each of their respective direct or indirect partners, officers, shareholders, directors,
members, trustees, beneficiaries, servants, employees, principals, contractors, licensees, agents or representatives. For the purposes
of this Lease, the term &ldquo;Tenant Party&rdquo; or &ldquo;Tenant Parties&rdquo; shall mean Tenant, any affiliate of Tenant,
any permitted subtenant or any other permitted occupant of the Premises, and each of their respective direct or indirect partners,
officers, shareholders, directors, members, trustees, beneficiaries, servants, employees, principals, contractors, licensees, agents,
invitees or representatives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">11.2 <U>TENANT&rsquo;S
RISK</U>. Tenant agrees to use and occupy the Premises, and to use such other portions of the Building and the Property as Tenant
is given the right to use by this Lease at Tenant&rsquo;s own risk, subject to Landlord&rsquo;s obligations under this Lease. Except
to the extent arising out of the gross negligence or willful misconduct of Landlord or any other Landlord Party, the Landlord Parties
shall not be liable to the Tenant Parties for any damage, injury, loss, compensation, or claim (including, but not limited to,
claims for the interruption of or loss to a Tenant Party&rsquo;s business) based on, arising out of or resulting from any cause
whatsoever, including, but not limited to, repairs to any portion of the Premises or the Building or the Property, any fire, robbery,
theft, mysterious disappearance, or any other crime or casualty, the actions of any other tenants of the Building or of any other
person or persons, or any leakage in any part or portion of the Premises or the Building or the Property, or from water, rain or
snow that may leak into, or flow from any part of the Premises or the Building or the Property, or from drains, pipes or plumbing
fixtures in the Building or the Property, or from any electrical failure in the Building or the Property. Any goods, property or
personal effects stored or placed in or about the Premises shall be at the sole risk of the Tenant Party, and neither the Landlord
Parties nor their insurers shall in any manner be held responsible therefor. The Landlord Parties shall not be responsible or liable
to a Tenant Party, or to those claiming by, through or under a Tenant Party, for any loss or damage that may be occasioned by or
through the acts or omissions of persons occupying adjoining premises or any part of the premises adjacent to or connecting with
the Premises or any part of the Building or otherwise. The provisions of this Section shall be applicable to the fullest extent
permitted by law, and until the expiration or earlier termination of the Lease Term, and during such further period as any of Tenant&rsquo;s
Property remains on the Premises, or Tenant or anyone acting by, through or under Tenant may use, be in occupancy of any part of,
or have access to the Premises or of the Building. None of the foregoing shall be deemed to excuse Landlord from its maintenance,
repair, restoration or other obligations under this Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">11.3 <U>TENANT&rsquo;S
COMMERCIAL GENERAL LIABILITY INSURANCE</U>. Tenant agrees to maintain in full force on or before the earlier of (i) the date on
which any Tenant Party first enters the Premises for any reason or (ii) the Commencement Date and thereafter throughout and until
the end of the Lease Term of this Lease and after the end of the Lease Term for as long after the Lease Term as any of Tenant&rsquo;s
Property remains on the Premises, or Tenant or anyone acting by, through or under Tenant may use, be in occupancy of any part
of, or have access to the Premises or any portion thereof, a policy of commercial general liability insurance, on an occurrence
basis, issued on a form at least as broad as Insurance Services Office (&ldquo;ISO&rdquo;) Commercial General Liability Coverage
&ldquo;occurrence&rdquo; form CG 00 01 10 01 or another ISO Commercial General Liability &ldquo;occurrence&rdquo; form providing
equivalent coverage. Such insurance shall include contractual liability coverage, specifically covering but not limited to the
indemnification obligations undertaken by Tenant in this Lease. The minimum limit of liability of such insurance shall be $<FONT STYLE="font-size: 10pt">[***]
</FONT>per occurrence, which may be satisfied through a combination of primary and excess/umbrella insurance. In addition, in
the event Tenant hosts a function in the Premises, Tenant agrees to obtain, and cause any persons or parties providing services
for such function to obtain, the appropriate insurance coverages as determined by Landlord (including liquor liability coverage,
if applicable) and provide Landlord with evidence of the same.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 47; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">11.4 <U>TENANT&rsquo;S
PROPERTY INSURANCE</U>. Tenant shall maintain at all times during the Term of the Lease, and during such earlier or later time
as Tenant may be performing work in or to the Premises or have property, fixtures, furniture, equipment, machinery, goods, supplies,
wares or merchandise on the Premises, and continuing thereafter so long as any of Tenant&rsquo;s Property remains on the Premises,
or Tenant or anyone acting by, through or under Tenant may use, be in occupancy of or have access to, any part of the Premises,
business interruption insurance and insurance against loss or damage covered by the so-called &ldquo;all risk&rdquo; type insurance
coverage with respect to Tenant&rsquo;s Property and all Leasehold Improvements in the Premises (subject to a deductible not to
exceed <FONT STYLE="font-size: 10pt">[***]</FONT>). The business interruption insurance required by this Section shall be in minimum
amounts typically carried by prudent tenants engaged in similar operations, but in no event shall be in an amount less than the
Annual Fixed Rent then in effect during any Lease Year, plus any Additional Rent due and payable for the immediately preceding
Lease Year. The &ldquo;all risk&rdquo; insurance required by this Section shall be in the amount of the full replacement cost of
Tenant&rsquo;s Property and all Leasehold Improvements in the Premises, and other property of Tenant located at the Premises. In
addition, during such time as Tenant is performing any Alterations in or to the Premises, Tenant, at Tenant&rsquo;s expense, shall
also maintain, or shall cause its contractor(s) to maintain, builder&rsquo;s risk insurance for the full insurable value of such
Alterations. Landlord and such additional persons or entities as Landlord may reasonably request shall be named as loss payees,
as their interests may appear, on the policy or policies required by this Section. In the event of loss or damage covered by the
&ldquo;all risk&rdquo; insurance required by this Section, the responsibilities for repairing or restoring the loss or damage shall
be determined in accordance with Section 12.2. To the extent that Landlord is obligated to pay for the repair or restoration of
the loss or damage covered by the policy, Landlord shall be paid the proceeds of the &ldquo;all risk&rdquo; insurance covering
the loss or damage. To the extent Tenant is obligated to pay for the repair or restoration of the loss or damage, covered by the
policy, Tenant shall be paid the proceeds of the &ldquo;all risk&rdquo; insurance covering the loss or damage. If both Landlord
and Tenant are obligated to pay for the repair or restoration of the loss or damage covered by the policy, the insurance proceeds
shall be paid to each of them in the pro rata proportion of their obligations to repair or restore the loss or damage. If the loss
or damage is not repaired or restored (for example, if the Lease is terminated pursuant to Article 12), the insurance proceeds
shall be paid to Landlord and Tenant in the pro rata proportion of their relative contributions to the cost of the Leasehold Improvements
covered by the policy, and this provision shall survive the expiration or earlier termination of this Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">11.5 <U>TENANT&rsquo;S
OTHER INSURANCE</U>. Tenant agrees to maintain in full force on or before the earlier of (i) the date on which any Tenant
Party first enters the Premises for any reason or (ii) the Commencement Date and thereafter throughout and until the end of
the Lease Term of this Lease and after the end of the Lease Term for as long after the Lease Term as any of Tenant&rsquo;s
Property remains on the Premises or as Tenant or anyone acting by, through or under Tenant may use, be in occupancy of, or
have access to the Premises or any portion thereof, (1) intentionally omitted; (2) worker&rsquo;s compensation insurance; and
(3) employer&rsquo;s liability insurance. Such worker&rsquo;s compensation insurance shall carry minimum limits as defined by
the law of the jurisdiction in which the Premises are located (as the same may be amended from time to time). Such
employer&rsquo;s liability insurance shall be in an amount not less than <FONT STYLE="font-size: 10pt">[***]</FONT> for each
accident, <FONT STYLE="font-size: 10pt">[***] </FONT>disease-policy limit, and <FONT STYLE="font-size: 10pt">[***]</FONT>
disease-each employee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 48; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">11.6 <U>REQUIREMENTS
FOR INSURANCE</U>. All insurance required to be maintained by Tenant pursuant to this Lease shall be maintained with responsible
companies that are admitted to do business, and are in good standing, in the jurisdiction in which the Premises are located and
that have a rating of at least &ldquo;A-&rdquo; and are within a financial size category of not less than &ldquo;Class VIII&rdquo;
in the most current Best&rsquo;s Key Rating Guide or such similar rating as may be reasonably selected by Landlord. All such insurance
shall: (1) [intentionally omitted]; (2) be primary and noncontributory (including all primary and excess/umbrella policies); and
(3) provided that Tenant&rsquo;s insurer then regularly provides the same to landlords of tenants, contain an endorsement prohibiting
cancellation, failure to renew, reduction of amount of insurance, or change in coverage without the insurer first giving Landlord
thirty (30) days&rsquo; prior written notice (by certified or registered mail, return receipt requested, or by fax or email) of
such proposed action. No such policy shall contain any self-insured retention greater than $<FONT STYLE="font-size: 10pt">[***]</FONT>
for property insurance and $<FONT STYLE="font-size: 10pt">[***]</FONT> for commercial general liability insurance. Any deductibles
and such self-insured retentions shall be deemed to be &ldquo;insurance&rdquo; for purposes of the waiver in Section 11.12 below.
Landlord reserves the right from time to time to require Tenant to obtain higher minimum amounts of insurance based on such limits
as are customarily carried with respect to similar properties in the area in which the Premises are located. The minimum amounts
of insurance required by this Lease shall not be reduced by the payment of claims or for any other reason. In the event Tenant
shall fail to obtain or maintain any insurance meeting the requirements of this Article, or to deliver such policies or certificates
as required by this Article, Landlord may, at its option, on five (5) days&rsquo; notice to Tenant, procure such policies for the
account of Tenant, and the cost thereof shall be paid to Landlord within five (5) days after delivery to Tenant of bills therefor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">11.7 <U>ADDITIONAL
INSUREDS</U>. To the fullest extent permitted by law, the commercial general liability and auto insurance carried by Tenant pursuant
to this Lease, and any additional liability insurance carried by Tenant pursuant to Section 11.5 of this Lease or any other provision
of this Lease, shall name Landlord, Landlord&rsquo;s managing agent, each Mortgagee and Overlandlord and such other persons as
Landlord may reasonably request from time to time as additional insureds with respect to liability arising out of or related to
this Lease or the operations of Tenant (collectively &ldquo;Additional Insureds&rdquo;). Such insurance shall provide primary coverage
without contribution from any other insurance carried by or for the benefit of Landlord or the Additional Insureds. Such insurance
shall also waive any right of subrogation against each Additional Insured. For the avoidance of doubt, each primary policy and
each excess/umbrella policy through which Tenant satisfies its obligations under this Section must provide coverage to the Additional
Insureds that is primary and non-contributory.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 49; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">11.8 <U>CERTIFICATES
OF INSURANCE</U>. On or before the earlier of (i) the date on which any Tenant Party first enters the Premises for any reason
or (ii) the Commencement Date, Tenant shall furnish Landlord with certificates evidencing the insurance coverage required by
this Lease, and renewal certificates shall be furnished to Landlord at least annually thereafter, and at least ten (10)
Operating Days prior to the expiration date of each policy for which a certificate was furnished. (Acceptable forms of such
certificates for liability and property insurance are ACORD 25 and ACORD 27, respectively, as of the date hereof, however
other forms of certificates may satisfy the requirements of this Section.) In jurisdictions requiring mandatory participation
in a monopolistic state workers&rsquo; compensation fund, the insurance certificate requirements for the coverage required
for workers&rsquo; compensation will be satisfied by a letter from the appropriate state agency confirming participation in
accordance with statutory requirements. Such current participation letters required by this Section shall be provided every
six (6) months for the duration of this Lease. Failure by the Tenant to provide the certificates or letters required by this
Section shall not be deemed to be a waiver of the requirements in this Section. Upon request by Landlord, a true and complete
copy of any insurance policy required by this Lease shall be delivered to Landlord within ten (10) days following
Landlord&rsquo;s request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">11.9 <U>SUBTENANTS
AND OTHER OCCUPANTS</U>. Tenant shall require its subtenants and other occupants of the Premises to provide written documentation
evidencing the obligation of such subtenant or other occupant to indemnify the Landlord Parties to the same extent that Tenant
is required to indemnify the Landlord Parties pursuant to Section 11.1 above, and to maintain insurance that meets the requirements
of this Article, and otherwise to comply with the requirements of this Article, provided that the terms of this Section 11.9 shall
not relieve Tenant of any of its obligations to comply with the requirements of this Article. Tenant shall require all such subtenants
and occupants to supply certificates of insurance evidencing that the insurance requirements of this Article have been met and
shall forward such certificates to Landlord on or before the earlier of (i) the date on which the subtenant or other occupant or
any of their respective direct or indirect partners, officers, shareholders, directors, members, trustees, beneficiaries, servants,
employees, principals, contractors, licensees, agents, invitees or representatives first enters the Premises or (ii) the commencement
of the sublease. Tenant shall be responsible for identifying and remedying any deficiencies in such certificates or policy provisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">11.10 <U>NO VIOLATION
OF BUILDING POLICIES</U>. Tenant shall not commit or permit any violation of the policies of fire, boiler, sprinkler, water damage
or other insurance covering the Property and/or the fixtures, equipment and property therein carried by Landlord, or do or permit
anything to be done, or keep or permit anything to be kept, in the Premises, which in case of any of the foregoing (i) would result
in termination of any such policies, (ii) would adversely affect Landlord&rsquo;s right of recovery under any of such policies,
or (iii) would result in reputable and independent insurance companies refusing to insure the Property or the property of Landlord
in amounts reasonably satisfactory to Landlord.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">11.11 <U>TENANT TO
PAY PREMIUM INCREASES</U>. If, because of anything done, caused or permitted to be done, or omitted by Tenant (or its subtenant
or other occupants of the Premises) not in keeping with the primary use of the Premises for general, executive and administrative
offices, the rates for liability, fire, boiler, sprinkler, water damage or other insurance on the Property or on the property
and equipment of Landlord or any other tenant or subtenant in the Building shall be higher than they otherwise would be, Tenant
shall reimburse Landlord and/or the other tenants and subtenants in the Building for the additional insurance premiums thereafter
paid by Landlord or by any of the other tenants and subtenants in the Building which shall have been charged because of the aforesaid
reasons, such reimbursement to be made from time to time on Landlord&rsquo;s demand.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 50; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">11.12 <U>WAIVER OF
SUBROGATION</U>. To the fullest extent permitted by law, the parties hereto waive and release any and all rights of recovery against
the other, and agree not to seek to recover from the other or to make any claim against the other, and in the case of Landlord,
against all Tenant Parties, and in the case of Tenant, against all Landlord Parties, for any loss or damage incurred by the waiving/releasing
party to the extent such loss or damage is insured under any insurance policy required by this Lease or which would have been so
insured had the party carried the insurance it was required to carry hereunder. Tenant shall obtain from its subtenants and other
occupants of the Premises a similar waiver and release of claims against any or all of the Tenant Parties and the Landlord Parties.
In addition, the parties hereto (and in the case of Tenant, its subtenants and other occupants of the Premises) shall procure an
appropriate clause in, or endorsement on, any insurance policy required by this Lease pursuant to which the insurance company waives
subrogation. The insurance policies required by this Lease shall contain no provision that would invalidate or restrict the parties&rsquo;
waiver and release of the rights of recovery in this section. The parties hereto covenant that no insurer shall hold any right
of subrogation against the parties hereto by virtue of such insurance policy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">11.13 <U>ALTERATIONS</U>.
During such times as Tenant is performing Alterations or having work or services performed in or to the Premises, Tenant shall
require its contractors, and their subcontractors of all tiers, to obtain and maintain commercial general liability, workers compensation,
employer&rsquo;s liability, builder&rsquo;s risk, and equipment/property insurance in such amounts and on such terms as are customarily
required of such contractors and subcontractors on similar projects. The amounts and terms of all such insurance are subject to
Landlord&rsquo;s written approval, which approval shall not be unreasonably withheld. The commercial general liability carried
by Tenant&rsquo;s contractors and their subcontractors of all tiers pursuant to this section shall name Landlord and the Additional
Insureds as additional insureds with respect to liability arising out of or related to their work or services. Such insurance shall
provide primary coverage without contribution from any other insurance carried by or for the benefit of Landlord or the Additional
Insureds. Such insurance shall also waive any right of subrogation against each Additional Insured. Tenant shall obtain and submit
to Landlord, prior to the earlier of (i) the entry onto the Premises by such contractors or subcontractors or (ii) commencement
of the work or services, certificates of insurance evidencing compliance with the requirements of this Section.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">11.14 <U>LANDLORD
INDEMNITY</U>. Subject to Section 11.12 hereof, to the maximum extent permitted by law, Landlord shall indemnify, defend and hold
harmless the Tenant Parties from and against any and all Claims against any of such parties arising from (i) the performance by
Landlord or any of its employees, agents or contractors of any alterations, improvements, repairs or other work in the Building
or the Premises and (ii) any negligent or otherwise wrongful act or omission of Landlord or any of its employees, agents or contractors
whether resulting in injury or death to persons or damage to property or otherwise, except, in each case, to the extent that any
such Claim results from the negligence or otherwise wrongful act or omission of any Tenant Party. Notwithstanding anything to
the contrary contained herein, in no event shall Landlord be liable for any loss of business or other consequential or punitive
damages under this Lease. The foregoing indemnity and hold harmless agreement shall include all reasonable out-of-pocket costs,
expenses and liabilities (including, without limitation, reasonable attorneys' fees and disbursements) actually incurred by the
Tenant Parties in connection with any such Claim or any action or proceeding brought thereon, and the defense thereof. In case
any action or proceeding shall be brought against the Tenant Parties by reason of any such Claim, Tenant shall notify Landlord
of any such action or proceeding and Landlord, upon notice from Tenant, shall resist and defend such action or proceeding on behalf
of the applicable Tenant Parties by counsel for the insurer (if such Claim is covered by insurance) or otherwise by counsel reasonably
satisfactory to Tenant. In no event shall Landlord be obligated' to indemnify or save harmless the Tenant Parties from or in respect
of any Claim to the extent the same results from the negligence or otherwise wrongful act or omission of the Tenant Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 51; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase"><U>ARTICLE
12</U></FONT><BR>
<BR>
<U>F<FONT STYLE="text-transform: uppercase">IRE, CASUALTY OR TAKING</FONT></U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">12.1 <U>RIGHT TO TERMINATE
LEASE</U>. Tenant shall give immediate notice to Landlord in case of fire or other casualty in the Premises. If (a) so much of
the Building is damaged or rendered untenantable (whether or not the Premises or a portion thereof shall be damaged) by fire or
other cause that Landlord shall determine not to restore the same or to demolish the remainder thereof; or (b) if the Premises
shall suffer damage or be rendered untenantable by fire or other casualty and Landlord shall determine (i) that such portion of
the Premises cannot be reasonably expected to be restored or rendered tenantable under a normal working schedule within a period
of eighteen (18) months after the occurrence of such damage or destruction or (ii) that each Overlandlord and Mortgagee will not
permit Landlord to apply the net proceeds of Landlord&rsquo;s insurance to the restoration of the Building or the Premises, then
and in any such event Landlord shall have the right to terminate this Lease by notice to Tenant given within ninety (90) days
of the occurrence of such fire or other casualty. If either (y) the Premises shall be totally or substantially damaged or rendered
wholly or substantially untenantable (whether or not any other portions of the Building shall be damaged) or (z) the Building
shall be substantially damaged, so that Tenant&rsquo;s access to and use and enjoyment of the Premises shall be rendered substantially
impossible, whether or not the Premises shall be damaged, and in case of either (y) or (z) Landlord determines that the same cannot
reasonably be expected to be restored or rendered tenantable under a normal working schedule within a period of eighteen (18)
months after the occurrence of such damage or destruction, then Landlord shall promptly notify Tenant of such fact, and within
thirty (30) days thereafter either Landlord or Tenant may terminate this Lease by notice to the other party. If during the last
year of the Lease Term the Building or the Premises shall be damaged by fire or casualty, and if such fire or casualty damage,
whether to the Premises or the Building, cannot reasonably be expected to be repaired or restored within one hundred eighty (180)
days from the time that repair or restoration work would commence or prior to the Expiration Date, whichever first occurs, then
Landlord or Tenant shall have the right, by giving notice to the other not later than thirty (30) days after the occurrence of
such damage, to terminate this Lease. If either Landlord or Tenant shall give notice of termination pursuant to this Section,
the Lease Term shall expire by lapse of time upon the date which is thirty (30) days after such notice is given and Tenant shall
vacate the Premises and surrender the same to Landlord. Upon the termination of this Lease under the conditions provided for in
this Section, Tenant&rsquo;s liability for rent shall cease as of the date of such termination, subject, however, to abatement
thereof between the date of such casualty and the date of such termination pursuant to Section 12.3 below. Tenant hereby expressly
waives the provisions of Section 227 of the Real Property Law or any like law which may hereafter be enacted and agrees that the
foregoing provisions of this Article shall govern and control in lieu thereof, this Article being an express agreement governing
any case of damage or destruction of the Premises by fire or other casualty.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 52; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">12.2 <U>RESTORATION
OF THE PREMISES</U>. If the Building or any portion thereof is damaged by fire or other casualty and this Lease is not terminated
pursuant to Section 12.1, then (a) Landlord, promptly after such damage and the determination of the net amount of insurance proceeds
available, shall use due diligence to repair and restore the Premises (other than the Leasehold Improvements and Tenant&rsquo;s
Property) and the Building as nearly as possible to their condition prior to such fire or other casualty, and (b) Tenant, promptly
after the substantial completion of Landlord&rsquo;s restoration work, shall use due diligence to repair and restore the Leasehold
Improvements and Tenant&rsquo;s Property as nearly as possible to their condition prior to such fire or other casualty. Notwithstanding
the foregoing, Landlord shall not be obligated to expend for such repairs and restoration any amount in excess of the net insurance
proceeds made available to Landlord after deduction therefrom of Landlord&rsquo;s expenses in obtaining such proceeds and any amounts
applied by any Overlandlord or Mortgagee to obligations other than restoration of the Building. If Landlord is not obligated to
and elects not to complete such restoration pursuant to the previous sentence, Landlord shall promptly notify Tenant of such fact,
and within thirty (30) days thereafter, Tenant may terminate this Lease by notice to Landlord and the Lease shall terminate as
of a date specified by Tenant in such notice to Landlord, which date shall not be earlier than thirty (30) and not later than ninety
(90) days after the date of Tenant&rsquo;s notice, with the same force and effect as if such date were the date originally established
as the Expiration Date hereof. In no event shall Landlord be obligated to repair or restore the Leasehold Improvements or Tenant&rsquo;s
Property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Where Landlord is obligated
or otherwise elects to effect the repair and restoration of the Premises (other than the Leasehold Improvements and Tenant&rsquo;s
Property), unless such repair and restoration is completed within eighteen (18) months from the date of the casualty, Tenant shall
have the right to terminate this Lease at any time after the expiration of such 18-month period but prior to the time that the
repair and restoration is substantially completed, such termination to take effect as of the thirtieth (30<SUP>th</SUP>) day after
such notice is given, with the same force and effect as if such date were the date originally established as the Expiration Date
hereof unless, within such thirty (30) day period such restoration is substantially completed, in which case Tenant&rsquo;s notice
of termination shall be of no force and effect and this Lease and the Lease Term shall continue in full force and effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">12.3 <U>PAYMENT OF
RENT FOLLOWING CASUALTY</U>. Until this Lease is terminated pursuant to Section 12.1 or, if this Lease is not so terminated, until
Landlord notifies Tenant that Landlord&rsquo;s repair and restoration work has been substantially completed pursuant to Section
12.2, the Annual Fixed Rent, Tenant&rsquo;s Tax Payment and Tenant&rsquo;s Share of Operating Expenses shall be abated on a pro
rata basis according to the part of the Premises that is usable by Tenant. No damages, compensation or claims shall be payable
by Landlord for inconvenience, loss of business or annoyance arising from any repair or restoration of any portion of the Premises
or of the Building. If rent abates in respect of all or any portion of the Premises and Tenant reoccupies the Premises or such
portion thereof, or any part thereof, for the conduct of Tenant&rsquo;s business operations during the period in which Landlord&rsquo;s
restoration work is taking place and prior to the date that the same is made completely tenantable, the Annual Fixed Rent, Tenant&rsquo;s
Tax Payment and Tenant&rsquo;s Share of Operating Expenses allocable to the space so reoccupied shall be payable from the date
of such reoccupancy. Notwithstanding anything in this Section to the contrary, if Landlord shall be unable to collect all of the
insurance proceeds (including rent insurance proceeds) payable by reason of any damage to the Building or the Premises under Landlord&rsquo;s
insurance policies by reason of the failure by Tenant to comply with any of the provisions of this Lease (including, without limitation,
Sections 9.2 and 11.10 hereof) or Tenant&rsquo;s negligence or willful misconduct, then without prejudice to any other remedy
which may be available against Tenant, the abatement of rent provided for in this Section 12.3 shall not be effective to the extent
of the uncollected insurance proceeds, and the amount of any abatement theretofore taken by Tenant shall be immediately payable
to Landlord on demand.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 53; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">12.4 <U>UNINSURED CASUALTY</U>.
Notwithstanding anything to the contrary contained in this Lease, if the Building or the Premises shall be substantially damaged
by fire or casualty as the result of a risk not covered by the forms of casualty insurance at the time maintained by Landlord and
such fire or casualty damage cannot, in the ordinary course, reasonably be expected to be repaired within thirty (30) days from
the time that repair work would commence, either Landlord or Tenant may terminate the Lease Term by giving notice to the other
not later than thirty (30) days after the occurrence of such damage, to terminate this Lease. If Tenant shall give notice of termination
pursuant to this Section, the Lease Term shall expire by lapse of time upon the date which is thirty (30) days after such notice
is given and Tenant shall vacate the Premises and surrender the same to Landlord. If Landlord shall give such notice, then this
Lease shall terminate as of the date of such notice with the same force and effect as if such date were the date originally established
as the Expiration Date hereof. Upon the termination of this Lease under the conditions provided for in this Section, Tenant&rsquo;s
liability for rent shall cease as of the date of such termination, subject, however, to abatement thereof between the date of such
casualty and the date of such termination pursuant to Section 12.3 below. Tenant hereby expressly waives the provisions of Section
227 of the Real Property Law or any like law which may hereafter be enacted and agrees that the foregoing provisions of this Article
shall govern and control in lieu thereof, this Article being an express agreement governing any case of damage or destruction of
the Premises by fire or other casualty.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">12.5 <U>LANDLORD NOT
TO INSURE LEASEHOLD IMPROVEMENTS OR TENANT&rsquo;S PROPERTY</U>. Landlord is not required to carry insurance of any kind on the
Leasehold Improvements or Tenant&rsquo;s Property or any telephone, computer or communications systems, cabinet work or special
decorative effects and shall not be obligated to repair any damage thereto or to replace the same.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">12.6 <U>EMINENT DOMAIN
&ndash; COMPLETE OR SUBSTANTIAL TAKING</U>. If all or substantially all of the Building or of the Premises shall be taken by condemnation
or in any other manner for any public or quasi-public use or purpose (other than for temporary use or occupancy), the Lease Term
shall forthwith cease and terminate as of the date of vesting of title by reason of such taking (which date is hereinafter referred
to as the &ldquo;date of the taking&rdquo;), and the rent shall be apportioned as of such date. If such portion of the Building
shall be so taken so that substantial structural alterations or reconstruction of the Building shall be necessary as a result
of such taking (whether or not the Premises be affected), which alterations or reconstruction Landlord determines will take at
least 180 days to complete, Landlord may, at its option, terminate this Lease and the Lease Term and estate hereby granted as
of the date of such vesting of title by notifying Tenant in writing of such termination within sixty (60) days following the date
of the taking.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 54; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">12.7 <U>EMINENT DOMAIN
&ndash; PARTIAL TAKING</U>. If any part, but less than all or substantially all, of the Premises shall be so taken and this Lease
shall not be terminated pursuant to Section 12.6, then the part so taken shall no longer constitute part of the Premises but this
Lease shall otherwise remain unaffected by such taking; provided, however, that Tenant may elect to terminate the Lease Term in
the event of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">(i) a taking of more
than twenty-five percent (25%) of the total rentable area of the Premises, or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">(ii) a taking that
has a material adverse effect on Tenant&rsquo;s access to the Building or the Premises, if Landlord determines that it will be
unable to provide or in fact fails to provide adequate alternative access to the Premises within one hundred eighty (180) days
thereafter,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">by giving notice of such
election to Landlord not later than sixty (60) days after Tenant&rsquo;s receipt from Landlord of notice of such taking or the
date of such taking, whichever first occurs, or not later than thirty (30) days after such one hundred eightieth (180<SUP>th</SUP>)
day, as the case may be. If notice of termination of this Lease shall be given pursuant to this Section, then upon such date as
may be specified by Tenant by notice to Landlord, which date shall be not earlier than thirty (30) and not later than sixty (60)
days after the date of Tenant&rsquo;s notice, the Lease Term shall terminate as of the date specified in such notice and the rent
shall be apportioned as of such date of termination. Upon a partial taking and this Lease continuing in force as to any part of
the Premises,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(a) the Annual Fixed
Rent, Tenant&rsquo;s Tax Payment and Tenant&rsquo;s Share of Operating Expenses shall be appropriately reduced to reflect the part
that no longer constitutes part of the Premises for the remainder of the Lease Term; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(b) Landlord shall, at
its expense, restore with reasonable diligence the remaining portions of the Premises as nearly as practicable to the same condition
as it was in prior to such condemnation or taking; provided, however, that Landlord shall not be obligated to expend for such restoration
and for restoration of the remainder of the Building any amount in excess of the net condemnation proceeds actually received by
Landlord. Tenant, promptly after the substantial completion of Landlord&rsquo;s restoration work, shall use due diligence to repair
and restore the Leasehold Improvements and Tenant&rsquo;s Property as nearly as possible to their condition prior to such fire
or other casualty. Proceeds of any award applied by the holder of any mortgage to reduction of the indebtedness secured thereby
or retained by any Overlandlord as compensation for the taking shall not be deemed to have been received by Landlord.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">12.8 <U>LANDLORD TO
RECEIVE ENTIRE AWARD</U>. In the event of any condemnation or taking hereinabove mentioned of all or a part of the Building (whether
or not the Premises be affected) Landlord shall be entitled to receive the entire award in the condemnation proceeding, including
any award made for the value of the estate vested by this Lease in Tenant, and Tenant hereby expressly assigns to Landlord any
and all right, title and interest of Tenant now or hereafter arising in or to any such award or any part thereof, and Tenant shall
be entitled to receive no part of such award. The foregoing, however, shall not be deemed to preclude Tenant from recovering a
separate award for Tenant&rsquo;s moving expenses and Tenant&rsquo;s Property, but only provided that such award does not reduce
and is not payable out of the amount for the Land and the Building.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase"></FONT></P>

<!-- Field: Page; Sequence: 55; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase"><U>ARTICLE
13</U></FONT><BR>
<BR>
<U>A<FONT STYLE="text-transform: uppercase">SSIGNMENT, SUBLETTING, MORTGAGING </FONT></U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">13.1 <U>LANDLORD&rsquo;S
CONSENT REQUIRED</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(a) Except as specifically
permitted by this Article, Tenant shall not, by operation of law or otherwise, assign, mortgage or encumber this Lease, or sublet
or permit the Premises or any part thereof to be used by others. If and so long as Tenant is a corporation with fewer than five
hundred (500) shareholders or a limited liability company or a partnership, an assignment, within the meaning of this Article 13,
shall be deemed to include one or more sales or transfers of stock or membership or partnership interests, by operation of law
or otherwise, or the issuance of new stock or membership or partnership interests, by which an aggregate of more than fifty percent
(50%) of Tenant&rsquo;s stock or membership or partnership interests shall be vested in a party or parties who are not stockholders
or members or partners as of the date hereof (a &ldquo;Change in Control&rdquo;); provided, however, the transfer of the outstanding
capital stock of Tenant for purposes of this Section 13.1 shall not be deemed to include the sale of such stock by persons or parties
through the &ldquo;over-the-counter market&rdquo; or through any recognized stock exchange, other than by those deemed to be a
&ldquo;control person&rdquo;&lsquo; within the meaning of the Securities Exchange Act of 1934, as amended. For the purpose of this
Section 13.1, ownership of stock or membership or partnership interests shall be determined in accordance with the principles set
forth in Section 544 of the Internal Revenue Code of 1986, as amended from time to time, or the corresponding provisions of any
subsequent law. In addition, the merger or consolidation of Tenant into or with any other entity, or the sale of all or substantially
all of its assets, shall be deemed to be an assignment within the meaning of this Article 13. The limitations set forth in this
Section 13.1(a) shall be deemed to apply to subtenant(s), assignee(s) and guarantor(s) of this Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(b) Anything in the
foregoing Section 13.1(a) to the contrary notwithstanding, an assignment of this Lease or a subletting of the Premises to an entity
which controls or is controlled by Tenant or is under common control with Tenant (an &ldquo;Affiliate&rdquo;) which does not result
in a physical demise of separate space, shall not require Landlord&rsquo;s consent under this Article 13; provided that: (i) a
copy of any applicable instrument of assignment or sublease shall have been delivered to Landlord at least ten (10) days prior
to the effective date of any such transaction, (ii) in case of an assignment the successor to Tenant agrees directly with Landlord,
by written instrument in form reasonably satisfactory to Landlord, to be bound by all the obligations of Tenant hereunder, (iii)
in no event shall Tenant be released from its obligations under this Lease, (iv) any such transfer or transaction is for a legitimate,
regular business purpose of Tenant including, without limitation, for the purposes of transferring Tenant&rsquo;s interest in
this Lease to a special purpose entity (as long as Tenant remains obligated under this Lease), (v) the Affiliate of Tenant shall
be of good reputation and engaged in a business or activity which is in keeping with the standards of the Building and (vi) the
provisions of Section 13.5(b), (c), (h), (i), (k), (l), (m) and (n) and Section 13.7 hereof shall be satisfied. If any Affiliate
to whom Tenant shall have assigned this Lease or sublet all or any portion of the Premises shall thereafter cease to be an Affiliate
of Tenant, then the continuation of such entity&rsquo;s tenancy or occupancy shall be subject to Landlord&rsquo;s consent pursuant
to this Article 13. For the avoidance of doubt, the terms and conditions of Section 13.3, 13.4 and 13.10 shall not apply to an
assignment of this Lease or a subletting of the Premises permitted without Landlord&rsquo;s consent under this Section 13.1(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 56; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(c) Anything in the foregoing
Section 13.1(a) to the contrary notwithstanding, (i) transactions with an entity into or with which Tenant is merged or consolidated,
(ii) transactions with an entity to which all or substantially all of Tenant&rsquo;s assets (including this Lease) or stock are
transferred as a going concern or (iii) transfers resulting in a Change in Control shall not require Landlord&rsquo;s consent under
this Article 13; provided that: (A) the successor to Tenant has a tangible net worth computed in accordance with GAAP at least
equal to the tangible net worth of Tenant immediately prior to such merger, consolidation or transfer, (B) the creditworthiness,
earnings and earnings forecast of the successor to Tenant shall be comparable to that of Tenant immediately prior to the date of
such merger, consolidation or sale of Tenant&rsquo;s stock or assets, as the case may be and (C) proof satisfactory to Landlord
of such tangible net worth, creditworthiness and earnings shall have been delivered to Landlord at least ten (10) days prior to
the effective date of any such transaction, (D) a copy of any applicable instrument of assignment or sublease shall have been delivered
to Landlord at least ten (10) days prior to the effective date of any such transaction (or, where such pre-transfer notice is prohibited
by contradictory restrictions, Tenant shall provide such notice within five (5) days thereafter), (E) the successor to Tenant agrees
directly with Landlord, by written instrument in form reasonably satisfactory to Landlord, to be bound by all the obligations of
Tenant hereunder, (F) in no event shall Tenant be released from its obligations under this Lease, (G) any such transfer or transaction
is for a legitimate, regular business purpose of Tenant other than a transfer of Tenant&rsquo;s interest in this Lease, (H) the
successor to Tenant shall be of good reputation and engaged in a business or activity which is in keeping with the standards of
comparable first-class office, laboratory and research buildings and (I) the provisions of Section 13.5(b), (c), (h), (i), (k),
(l), (m) and (n) and Section 13.7 hereof shall be satisfied. Notwithstanding the foregoing, a sale of all or substantially all
of Tenant&rsquo;s assets that does not include this Lease or Tenant&rsquo;s operations in the Premises, or an assignment of all
of Tenant&rsquo;s leases other than this Lease, shall be an assignment for purposes of this Article 13 (it being intended that
a transaction that would result in Tenant&rsquo;s only substantial asset or lease being this Lease or Tenant&rsquo;s operation
in the Premises would not be permitted hereunder). For the avoidance of doubt, the terms and conditions of Section 13.3, 13.4 and
13.10 shall not apply to transfers that are permitted without Landlord&rsquo;s consent under this Section 13.1(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(d) The Tenant originally
named in this Lease together with any permitted successors and assigns under Section 13.1(c) is sometimes referred to herein as
&ldquo;Original Tenant&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 57; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(e) Anything in the
foregoing Section 13.1(a) to the contrary notwithstanding, Landlord&rsquo;s consent shall not be required for the occupancy of
offices within the Premises by any individual or business entity who or which is a client, service provider or otherwise has a
bona fide material business relationship with Tenant (a &ldquo;Space Occupant&rdquo;), provided that (i) each Space Occupant shall
be of good reputation, and engaged in a business or activity which is in keeping with the standards of the Building and which
is a permitted use in accordance with the provisions of Article 10 hereof, (ii) the Space Occupants shall not occupy, in the aggregate,
more than twenty percent (20%) of the rentable area of the Premises, (iii) the portions of the Premises occupied by the Space
Occupants shall be physically part of, and not separately demised from, the remainder of the Premises occupied by Tenant, (iv)
no Space Occupant shall have a separate entrance, (v) no Space Occupant shall have any signage outside of the Premises, nor any
listing on the Building&rsquo;s lobby directory, (vi) the proposed Space Occupant shall not then be a tenant, subtenant or occupant
of any space in the Building, nor an affiliate of any tenant, subtenant or occupant of any space in the Building, (vii) the proposed
Space Occupant shall not then be a person or entity, nor an affiliate of a person or entity, with whom Landlord is then actively
negotiating to lease space in the Building, (viii) the consideration paid by the Space Occupant to Tenant shall not exceed the
rent allocable to such space for the period of such occupancy under this Lease and (ix) Tenant shall give Landlord a Space Occupant
Notice (as hereinafter defined) with respect to each such Space Occupant at least thirty (30) days prior to the commencement of
such Space Occupant&rsquo;s occupancy in the Premises. Each such occupancy shall be subject and subordinate to this Lease and
to the matters to which this Lease is or shall be subordinate, shall be terminable on not more than thirty (30) days&rsquo; notice,
and in the event of the termination of this Lease, such occupancy shall immediately terminate. Occupancy by a Space Occupant shall
not be deemed to vest in such Space Occupant any right or interest in this Lease nor shall it relieve, release, impair or discharge
any of Tenant&rsquo;s obligations hereunder. Each &ldquo;Space Occupant Notice&rdquo; given by Tenant to Landlord pursuant to
this Section 13.1 shall include (A) the name and the nature of the business or occupation of such Space Occupant, (B) a description
of the relationship between Tenant and such Space Occupant and (C) the material terms of such Space Occupant&rsquo;s occupancy.
For the avoidance of doubt, the terms and conditions of Section 13.3, 13.4 and 13.10 shall not apply with respect to the occupancy
of Space Occupants permitted without Landlord&rsquo;s consent under this Section 13.1(e).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">13.2 <U>OFFER NOTICE</U>.
If Tenant shall have received and negotiated a bona fide written offer from an independent third party which it desires to accept
to sublet all or any part of the Premises or to assign this Lease, Tenant shall submit to Landlord a notice (any such notice being
hereinafter called an &ldquo;Offer Notice&rdquo;) containing the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">(i) the name and address
of the proposed subtenant or assignee and a brief description of such person&rsquo;s or entity&rsquo;s business, current financial
information in respect of such person or entity (including, without limitation, its most recent balance sheet and income statements
certified by its chief financial officer or a certified public accountant), the identity of any broker entitled to a commission
in respect of such subletting or assignment and the commission, if any, payable to such broker, and any other information reasonably
requested by Landlord; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">(ii) a duplicate
original of the offer setting forth the material economic terms of the proposed assignment or sublease, together with an
executed copy of the proposed instrument of assignment or sublease (both containing, in the case of an assignment, a
provision for assumption by the assignee of all of the terms, covenants, conditions and agreements herein contained on the
Tenant&rsquo;s part to be performed for the Lease Term), the effective date of which shall be at least thirty (30) days but
not more than ninety (90) Operating Days after the date of the giving of such notice, which shall be conditioned on
Landlord&rsquo;s consent thereto and which shall comply with the provisions of Section 13.5 (provided, however, that in the
event Landlord shall have consented to the assignment or sublease proposed in the Offer Notice and Landlord shall not have
exercised its rights under Section 13.3 or 13.4 hereof, the effective date of any such assignment or sublease may occur on
the date of consent; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 58; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">(iii) executed copies
of all other agreements, if any, relating to the proposed assignment or sublease and, if not fully disclosed by such agreements,
a statement of all consideration to be received by Tenant for or in connection with such assignment or sublease (including, without
limitation, any payment to be made for Tenant&rsquo;s Property or Leasehold Improvements) and the terms of payment therefor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">13.3 <U>LANDLORD&rsquo;S
RIGHT TO UNDERLET</U>. Upon receipt of any Offer Notice in which Tenant proposes to sublet all or any part of the Premises, Landlord
shall have the option with respect to each such Offer Notice, exercisable by Landlord in writing within thirty (30) days after
receipt of such Offer Notice, to underlet from Tenant the space which Tenant so desires to sublet, for the term for which Tenant
desires to sublet it and for a rent equal to the lower of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">(i) the net effective
rent for which Tenant proposes to sublet such space taking into consideration all economic terms and transaction costs set forth
in the Offer Notice and otherwise in connection with such proposed sublease such as, but not limited to, free rent, work allowances
and brokerage commissions; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">(ii) the rent which
Tenant by the terms of this Lease is required to pay for the rentable area of the space so to be sublet,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">such underlease to be
upon the covenants, agreements, terms, provisions and conditions contained in this Lease except as hereinafter provided and except
for such thereof which are irrelevant or inapplicable and, without limiting the generality of the foregoing, it is hereby expressly
agreed that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: left; text-indent: 0in">(a) such underlease
to Landlord shall give the undertenant the unqualified and unrestricted right, without Tenant&rsquo;s permission, (x) to assign
such underlease or any interest therein and/or to underlet from time to time the space covered by such underlease or any parts
of such space for any purpose, or purposes that the undertenant, in the undertenant&rsquo;s uncontrolled discretion, shall deem
suitable or appropriate, except that Landlord agrees that any such underlease will not be assigned except simultaneously with an
assignment of Landlord&rsquo;s interest under this Lease so that at all times the Landlord under this Lease and the undertenant
under said underlease shall be the same person, corporation or other entity, and each assignor of such underlease shall thereafter
be released of all obligations under such underlease, and (y) to make any and all changes, alterations and improvements in the
space covered by such underlease deemed desirable by the undertenant;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: left; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 59; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: left; text-indent: 0in">(b) such
underlease shall provide that (x) any assignee or subtenant of the undertenant may, at the election of the undertenant, be
permitted to make alterations, decorations and installations in such space or any part thereof, and (y) any such alterations,
decorations and installations therein made by any assignee or subtenant of the undertenant may be removed, or left, in whole
or in part, by such assignee or subtenant, at its option, prior to or upon the expiration or other termination of such
underlease provided that such assignee or subtenant, at its expense, shall repair the damage and injury to such space so
underlet caused by such removal;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: left; text-indent: 0in">(c) such underlease
shall also provide that the parties to such underlease expressly negate any intention that any estate created under such underlease
be merged with any other estate held by either of said parties;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: left; text-indent: 0in">(d) Tenant
shall and will at all times at its expense provide and permit an appropriate and lawful means of ingress and egress from such space
so underlet by Tenant to Landlord, such means of ingress or egress to be specified by Tenant in the Offer Notice with respect to
such space;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: left; text-indent: 0in">(e) Landlord,
at Tenant&rsquo;s expense, may make such Alterations as may be required or deemed necessary by Landlord physically to separate
the underleased space from the balance of the Premises and to comply with all laws and requirements of public authorities relating
to such separation; provided, however, that any such Alterations shall be undertaken at Landlord&rsquo;s expense in the event that
the Offer Notice provided that the proposed subtenant would be obligated to pay such expenses;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: left; text-indent: 0in">(f) the occupant
or occupants of all or any part or parts of such space shall, in common with Tenant, have the use of toilet and other common facilities
on the floor on which such space is located;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: left; text-indent: 0in">(g) at the
expiration of such underlease, Tenant shall accept the space covered thereby in its then existing condition provided that Landlord
shall have performed Landlord&rsquo;s obligations to keep and maintain such space in good order and condition except for ordinary
wear and tear (and further provided that in the event of Landlord&rsquo;s failure to perform any of such obligations Tenant shall
have no right to terminate this Lease either in whole or as to such part of the space covered by the underlease); and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: left; text-indent: 0in">(h) no default
by Landlord under such underlease or by anyone claiming through such underlease shall be deemed to constitute a default under this
Lease, nor shall Tenant be liable for any default under this Lease or be deemed to be in default hereunder if such default is occasioned
or arises from any act or omission by anyone claiming through such underlease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">If Landlord fails to respond
within thirty (30) days after Tenant&rsquo;s submittal of Tenant&rsquo;s Offer Notice, Tenant may provide Landlord with an additional
notice which shall set forth in bold capital letters the following statement: &ldquo;<B>IF LANDLORD FAILS TO RESPOND WITHIN FIVE
(5) BUSINESS DAYS AFTER RECEIPT OF THIS NOTICE, THEN TENANT SHALL BE ENTITLED TO SUBLET THE PREMISES OR ASSIGN THE LEASE IN ACCORDANCE
WITH THE TERMS OF THAT CERTAIN OFFER SUBMITTED TO LANDLORD ON [ENTER DATE]</B><FONT STYLE="font-style: normal; font-weight: normal">&rdquo;.
If Landlord fails to respond to such notice within five (5) Business Days after receipt by Landlord, then Landlord shall be deemed
to have waived its rights under this Section 13.3 with respect to such Offer Notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 60; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">13.4 <U>LANDLORD&rsquo;S
RIGHT TO TERMINATE</U>. Upon receipt of any Offer Notice in which Tenant proposes to assign this Lease (which shall include, for
purposes of this Section 13.4, a proposed subletting of all or substantially all of the Premises for the entire or substantially
the entire remaining Lease Term), or in which Tenant proposes to sublet less than substantially all of the Premises for the entire
or substantially the entire remaining Lease Term, then and in such event Landlord shall have the right, exercisable by notice to
Tenant given within thirty (30) days after Landlord receives Tenant&rsquo;s Offer Notice, and in addition to the other rights granted
Landlord under this Article 13, (i) in the case of an assignment, to terminate this Lease, in which event this Lease shall terminate
on the date fixed in Landlord&rsquo;s notice, which shall not be less than thirty (30) nor more than ninety (90) days after the
giving of such notice, with the same force and effect as if the termination date fixed in Landlord&rsquo;s notice were the date
originally fixed in this Lease as the Expiration Date, or (ii) in the case of a subletting of less than substantially all of the
Premises, to terminate this Lease with respect to the space proposed by Tenant to be sublet, in which event on the date fixed in
Landlord&rsquo;s notice, which shall not be less than thirty (30) nor more than ninety (90) days after the giving of such notice,
such space shall no longer be part of the Premises or covered by this Lease and the rentable area of the Premises, the Annual Fixed
Rent, Tenant&rsquo;s Tax Payment and Tenant&rsquo;s Share of Operating Expenses shall be appropriately reduced. If Landlord fails
to respond within thirty (30) days after Tenant&rsquo;s submittal of Tenant&rsquo;s Offer Notice, Tenant may provide Landlord with
an additional notice which shall set forth in bold capital letters the following statement: &ldquo;<B>IF LANDLORD FAILS TO RESPOND
WITHIN FIVE (5) BUSINESS DAYS AFTER RECEIPT OF THIS NOTICE, THEN TENANT SHALL BE ENTITLED TO SUBLET THE PREMISES OR ASSIGN THE
LEASE IN ACCORDANCE WITH THE TERMS OF THAT CERTAIN OFFER SUBMITTED TO LANDLORD ON [ENTER DATE]</B>&rdquo;. If Landlord fails to
respond to such notice within five (5) Business Days after receipt by Landlord, then Landlord shall be deemed to have waived its
rights under this Section 13.4 with respect to such Offer Notice. For the avoidance of doubt, the time periods in which Landlord
may exercise its rights under Section 13.3 or this Section 13.4 shall run concurrently with respect to any Offer Notice delivered
to Landlord.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">13.5 <U>ADDITIONAL
CONDITIONS</U>. If Landlord does not exercise any option granted to Landlord by Sections 13.3 and 13.4 with respect to a proposed
sublease or assignment which is the subject of an Offer Notice, Landlord agrees that, after Landlord&rsquo;s receipt of an executed
copy of the proposed instrument of sublease or assignment and all other agreements, if any, related to the proposed sublease or
assignment, and any other information reasonably requested by Landlord, Landlord will not unreasonably withhold, condition or delay
its consent to such proposed sublease or assignment provided that the terms of the instrument of sublease or assignment conform
to the Offer Notice and the following further conditions shall be satisfied:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">(a) the Premises or
any part thereof shall not, without Landlord&rsquo;s prior consent, have been listed or otherwise publicly advertised for subletting
at a rental rate less than the rental rate being sought by Landlord for space in the Building provided that Landlord shall, within
ten (10) days after Tenant so requests, have informed Tenant of the rental rate being sought by Landlord for such space, and all
advertisements of the Premises or any portion thereof for subletting shall have been approved by Landlord. The foregoing, however,
shall not be deemed to prohibit Tenant from negotiating or consummating a sublease at a lower rental rate;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 61; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">(b) Tenant shall not
then be in default under this Lease with respect to any monetary obligations and shall not otherwise be in default under this Lease
beyond the time herein provided, if any, to cure such default;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">(c) the proposed subtenant
or assignee is engaged in a business or activity, and the Premises, or the relevant part thereof, will be used in a manner, which
(A) is in keeping with the then standards of the Building, (B) is limited to the Permitted Use and such incidental ancillary uses
reasonably approved by Landlord in connection therewith and (C) is not prohibited under Section 10.4;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">(d) the proposed subtenant
or assignee shall not then be a tenant, subtenant or occupant of any space in the Building, nor an affiliate of any tenant, subtenant
or occupant of any space in the Building, and Landlord then has (or reasonably expects to have) comparable space in the Building
available for leasing;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">(e) the proposed subtenant
or assignee shall not then be a person or entity, nor an affiliate of a person or entity, with whom Landlord is then actively negotiating
to lease comparable space in the Building;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">(f) the proposed subtenant
or assignee is of good reputation with sufficient financial worth considering the responsibility involved, and Landlord has been
furnished with reasonable evidence of such financial worth and any sublease shall provide that, upon Landlord&rsquo;s request from
time to time, subtenant shall deliver to Landlord a copy of subtenant&rsquo;s most recent financial statements certified by an
officer of subtenant (provided, with respect to such financial statements, that Landlord has executed a non-disclosure agreement
provided by such proposed subtenant or assignee on a customary form reasonably acceptable to Landlord);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">(g) the character of
the business to be conducted or the proposed use of the Premises by the proposed subtenant or assignee shall not (i) be likely
to increase Landlord&rsquo;s operating expenses beyond that which Landlord now incurs for use by Tenant; (ii) increase the burden
on elevators or other Building systems over the burden prior to such proposed subletting; or (iii) violate or be likely to violate
any provisions or restrictions contained herein relating to the use or occupancy of the Premises;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">(h) any proposed sublease
shall state that it is expressly subject to all of the obligations of Tenant under this Lease and shall contain the further condition
and restriction that the sublease shall not be assigned, encumbered or otherwise transferred or the subleased premises further
sublet by the sublessee in whole or in part, or any part thereof suffered or permitted by the sublessee to be used or occupied
by others, without the prior written consent of Landlord in each instance;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 62; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">(i) any proposed sublease
shall provide that it is subject and subordinate to this Lease and to the matters to which this Lease is or shall be subordinate,
and that in the event of the termination of this Lease, or the re-entry or dispossession of Tenant by Landlord under this Lease,
such subtenant shall, at Landlord&rsquo;s option, attorn to Landlord as its sublessor pursuant to the then applicable terms of
such sublease for the remaining term thereof, except that such subtenant shall have no right to use any portion of the Premises
(or other space in the Building occupied or controlled by Tenant) which is not part of the subleased premises, and Landlord shall
not be (i) liable for any previous act or omission of Tenant; (ii) subject to any offset or defense which theretofore accrued to
such subtenant (including, without limitation, any rights under 11 U.S.C. &sect;365(h)); (iii) bound by any rent or other sums
paid by such subtenant more than one month in advance; (iv) liable for any security deposit not actually received by Landlord;
(v) liable for any work or payments on account of improvements to the subleased premises or (vi) bound by any amendment of such
sublease not consented to in writing by Landlord;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">(j) no subletting shall
be for a term of less than two (2) years (provided, however, that if less than two (2) years remains in the Lease Term, such sublease
may be for a term of no less than one (1) year);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">(k) in no event shall
there be more than one (1) occupant (including Tenant) in the Premises and all Alterations made to create a separately demised
unit on any floor of the Premises shall be deemed Specialty Alterations;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">(l) Tenant shall reimburse
Landlord on demand for any reasonable, out-of-pocket costs that may be incurred by Landlord in connection with said sublease or
assignment, including, without limitation, the costs of making investigations as to the acceptability of the proposed subtenant
or assignee and reasonable legal costs incurred in connection with the granting of any consent;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">(m) no part of the
rent payable under the proposed assignment or sublease shall be based in whole or in part on the income or profits derived from
the Premises nor shall any proposed assignment or sublease potentially have any adverse effect on the REIT qualification requirements
applicable to Landlord and its affiliates; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">(n) any proposed sublease
shall comply with the requirements of Section 11.9 hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">Tenant agrees to furnish
Landlord such information in addition to the information set forth in the Offer Notice as Landlord may reasonably request in connection
with the proposed sublease or assignment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">13.6 <U>LANDLORD MAY
COLLECT RENT FROM SUBTENANT OR ASSIGNEE</U>. If this Lease shall be assigned, or if the Premises or any part thereof be sublet
or occupied by any person or persons other than Tenant, Landlord may, after default by Tenant, collect rent from the assignee,
subtenant or occupant and apply the net amount collected to the rent herein reserved, but no such assignment, subletting, occupancy
or collection of rent shall be deemed a waiver of the covenants in this Article, nor shall it be deemed acceptance by Landlord
of the assignee, subtenant or occupant as a tenant, or a release of Tenant from the full performance by Tenant of all the terms,
conditions and covenants of this Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 63; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">13.7 <U>ASSUMPTION
OF LEASE</U>. Each permitted assignee or transferee shall assume and be deemed to have assumed the obligations of Tenant under
this Lease to be performed, or arising or accruing, on and after the effective date of such assignment or transfer and shall be
and remain liable jointly and severally with Tenant for the payment of Annual Fixed Rent and Additional Rent, and for the due performance
of all the terms, covenants, conditions and agreements herein contained on Tenant&rsquo;s part to be performed for the Lease Term.
No assignment shall be binding on Landlord unless such assignee or Tenant shall deliver to Landlord a duplicate original of the
instrument of assignment which contains a covenant of assumption by the assignee of all of the obligations aforesaid and shall
obtain from Landlord the aforesaid written consent, prior thereto. No assignment in whole or in part of this Lease shall release
Tenant or any assignee of Tenant of its continuing liability under this Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">13.8 <U>TENANT&rsquo;S
INDEMNIFICATION</U>. If Landlord shall fail or refuse to give its consent to any proposed assignment or sublease, or if Landlord
shall exercise any of its options set forth in Sections 13.3 and 13.4, Tenant shall indemnify and hold harmless Landlord from and
against any and all loss, liability, costs and expenses (including, without limitation, reasonable attorneys&rsquo; fees) asserted
against, imposed upon or incurred by Landlord by reason of any claims made against Landlord by the proposed assignee or sublessee
or by any brokers, finders or other persons for commissions or other compensation in connection with the proposed assignment or
sublease. Notwithstanding the foregoing, if, after Landlord exercises any of its options under Section 13.3 with respect to a particular
proposed assignment or sublease, Landlord subsequently leases the Premises (or a portion thereof) to Tenant&rsquo;s proposed assignee
or subtenant (if same was previously identified by Tenant to Landlord), the indemnity in the immediately preceding sentence shall
not apply to any claim made against Landlord by (i) such proposed assignee or subtenant or (ii) any broker finders or other persons
that represented such proposed assignee or subtenant, in each case in connection with Tenant&rsquo;s proposed assignment or sublease
or such proposed assignee&rsquo;s or subtenant&rsquo;s lease from Landlord.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">13.9 <U>TIME LIMITATION;
AMENDMENTS</U>. If Landlord grants its consent to an assignment or sublease and such assignment or sublease does not become effective
for any reason within one hundred fifty (150) days after the granting of such consent, or if such assignment or sublease is modified
or amended prior to its becoming effective, then and in either such event Landlord&rsquo;s consent shall be deemed to have been
withdrawn and Tenant shall not have the right to assign this Lease or to sublease all or any portion of the Premises without once
again complying with all of the provisions and conditions of Sections 13.1, 13.2, 13.3, 13.4, 13.5 and 13.6. In no event shall
Tenant agree to modify or amend any sublease to which Landlord has consented without Landlord&rsquo;s prior written consent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">13.10 <U>ADDITIONAL
RENT DUE UPON ASSIGNMENT OR SUBLETTING</U>. If Landlord shall not exercise any of its options set forth in Sections 13.3 and 13.4
and shall give its consent to any assignment of this Lease or to any sublease, Tenant shall, as consideration therefor, pay to
Landlord as Additional Rent the following amounts:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">(a) in the case of
any assignment, an amount equal to fifty percent (50%) of all sums and other considerations paid to or for the benefit of Tenant
by the assignee for or by reason of such assignment (including, but not limited to, sums paid for the sale of any of Tenant&rsquo;s
Property, fixtures or Leasehold Improvements); or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 64; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">(b) in the case of
a sublease, fifty percent (50%) of the excess, if any, of (i) any rents, additional charges or other consideration payable under
the sublease or any agreement relating thereto to or for the benefit of Tenant by the subtenant (including, but not limited to,
sums paid for the sale of any of Tenant&rsquo;s Property, fixtures or Leasehold Improvements) over (ii) the rents accruing during
the term of the sublease in respect of and allocable to the subleased space pursuant to the terms of this Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Amounts due to Landlord
pursuant to this Section 13.10 shall be paid to Landlord as Additional Rent at the time such payments are payable by the assignee
or subtenant to Tenant and whether or not such payments are made. Reasonable attorneys&rsquo; fees and brokerage or leasing commissions
to an independent third-party broker actually incurred by Tenant in connection with the assignment or subletting, which amounts,
in the case of a sublease, shall be amortized on a straight line basis over the term of the sublease without interest, may be deducted
from the rents, charges and other consideration payable by the assignee or subtenant to Tenant in connection with the assignment
or subletting prior to the computation of amounts due to Landlord pursuant to subsection (a) or (b) above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">13.11 <U>LIABILITY
NOT DISCHARGED</U>. The joint and several liability of Tenant and any assignee or successor of Tenant under this Lease, or any
guarantor of Tenant&rsquo;s obligations under this Lease, shall not be discharged, released or impaired in any respect by any agreement
or stipulation made by Landlord modifying any of the obligations contained in this Lease, or by any waiver or failure by Landlord
to enforce any of the obligations of this Lease, but in no event shall Tenant&rsquo;s continued liability exceed what its continuing
liability would have been had the Lease not been modified except for those modifications, if any, which were consented to by Tenant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">13.12 <U>EFFECT OF
LISTING OF NAMES</U>. The listing of any name other than Tenant on the door of the Premises, on the Building directory or otherwise
shall not operate to vest any right or interest in this Lease or in the Premises in any other person or entity, nor shall such
listing be deemed to be the consent of Landlord to any assignment or transfer of this Lease or to any sublease of the Premises
or any portion thereof or to the use or occupancy of the Premises or any portion thereof by others.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">13.13 <U>GOOD REPUTATION</U>.
For purposes of this Article 13, &ldquo;good reputation&rdquo; shall refer to the business reputation of Tenant or any assignee,
subtenant or Space Occupant, and not to how any particular laboratory or life science testing is performed within the Premises.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase"></FONT></P>

<!-- Field: Page; Sequence: 65; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase"><U>ARTICLE
14</U></FONT><BR>
<BR>
<U>N<FONT STYLE="text-transform: uppercase">O LIABILITY OR REPRESENTATIONS BY LANDLORD; FORCE MAJEURE </FONT></U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">14.1 <U>NO LIABILITY</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(a) Neither Landlord
nor any other Landlord Parties shall be liable for (i) any damage to property of Tenant or of others entrusted to employees of
the Building, nor for the loss of or damage to any property of Tenant by theft; (ii) any injury or damage to persons or property
resulting from fire, explosion, falling plaster, steam, gas, electricity, water, rain or snow or leaks in or from any part of the
Building or the Property or from the pipes, vents, risers, appliances or plumbing or from the roof, street or subsurface or from
any other place or by dampness or by any other cause of whatsoever nature; nor shall Landlord and its agents or employees be liable
for any such damage caused by other tenants or persons in the Building or caused by operations in construction of any private,
public or quasi-public work; (iii) any latent defect in the Premises, the Building or other improvements on the Property (except
as expressly set forth in Section 7.1); or (iv) any injury or damages for which Tenant is reimbursed under its insurance policies;
except, in each case, to the extent that any such claim results from the gross negligence or willful misconduct of Landlord or
any other Landlord Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(b) If at any time any
windows of the Premises are temporarily or permanently closed, darkened or bricked up as a result of causes beyond Landlord&rsquo;s
control, or are temporarily closed or darkened by Landlord, Landlord shall not be liable for any damage Tenant may sustain thereby
and Tenant shall not be entitled to any compensation therefor nor abatement of rent nor shall the same release Tenant from its
obligations hereunder nor constitute an eviction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(c) Landlord shall have
no responsibility or liability for the ventilating conditions and/or temperature of the Premises during the hours or days Landlord
is not required to furnish heat, ventilation or air-conditioning pursuant to Exhibit D or pursuant to Sections 14.3 or 20.12, Landlord
having informed Tenant that the windows of the Premises and the Building may be sealed, and that the Premises may become uninhabitable
and the air therein may become unbreathable during such times. Insofar as air temperature and ventilation are concerned, any use
or occupancy of the Premises during the hours or days Landlord is not so required to, or pursuant to Section 14.3 or 20.12 does
not furnish heat, ventilation or air-conditioning to the Premises shall be at the sole risk, responsibility and hazard of Tenant.
Such condition of the Premises shall not constitute nor be deemed to be a breach or a violation of this Lease or of any provision
hereof, nor shall it be deemed an eviction, nor shall Tenant claim or be entitled to claim any abatement of rent nor make any claim
for any damages or compensation by reason of such condition of the Premises.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(d) Tenant shall neither
assert nor seek to enforce any claim against any of Landlord&rsquo;s assets other than Landlord&rsquo;s interest in the Land and
the Building, and Tenant agrees to look solely to such interest for the satisfaction of any liability of Landlord under this Lease,
it being specifically agreed that neither Landlord, nor any successor holder of Landlord&rsquo;s interest hereunder, nor any general
or limited partner of Landlord or any such successor (if Landlord or such successor is a partnership) nor any shareholder of Landlord
or any such successor (if Landlord or such successor is a corporation) shall ever be personally liable for any such claim or liability.
Landlord shall in no event be liable for any loss of business or any indirect or consequential damages under this Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 66; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">14.2 <U>NO REPRESENTATIONS
BY LANDLORD</U>. Tenant expressly acknowledges and agrees that Landlord has not made and is not making, and Tenant, in executing
and delivering this Lease, is not relying upon, any warranties, representations, promises or statements, except for those expressly
set forth in this Lease and the Exhibits annexed hereto or in any other written agreement which may be made between the parties
hereto concurrently with the execution and delivery of this Lease and which shall expressly refer to this Lease. No rights, easements
or licenses are acquired by Tenant by implication or otherwise except as expressly set forth in the provisions of this Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">14.3 <U>FORCE MAJEURE</U>.
This Lease and the obligation of Tenant to pay rent hereunder and perform and comply with all of the other covenants and agreements
hereunder on the part of Tenant to be performed and complied with shall in no way be affected, impaired or excused because of Landlord&rsquo;s
delay or failure to perform or comply with any of the covenants or provisions hereunder on the part of Landlord to be performed
or complied with, or because Landlord is unable to fulfill any of its obligations under this Lease or is unable to supply or is
delayed in supplying any service expressly or impliedly to be supplied or is unable to make or is delayed in making any repair,
additions, alterations or decorations or is unable to supply or is delayed in supplying any equipment or fixtures, if Landlord
is prevented or delayed from so doing by reason of Force Majeure. Except as expressly provided herein to the contrary, this Lease
and the obligation of Landlord to perform and comply with all of the other covenants on the part of Landlord to be performed and
complied with shall in no way be affected, impaired or excused because of Tenant&rsquo;s delay or failure to perform or comply
with any of the covenants or provisions hereunder on the part of Tenant to be performed or complied with (other than Tenant&rsquo;s
obligation to pay rent hereunder), or because Tenant is unable to fulfill any of its obligations under this Lease (other than Tenant&rsquo;s
obligation to pay rent hereunder) or is unable to make or is delayed in making any repair, additions, alterations or decorations,
if Tenant is prevented or delayed from so doing by reason of Force Majeure. For purposes hereof, the term &ldquo;<U>Force Majeure</U>&rdquo;
shall mean, collectively, (i) strikes or labor troubles, (ii) governmental preemption in connection with a national emergency,
(iii) any rule, order or regulation of any government agency or any department or subdivision thereof, whether in connection with
a drought, energy shortage or other like event or otherwise, (iv) any fact, condition or circumstance related to war, terrorism,
virus, global pandemic or other emergency, (v) except as otherwise set forth in Article 12, fire, casualty or other acts of God
(including the time necessary to repair any damage caused thereby) or (vi) any other cause (other than causes delaying the payment
of money due and payable hereunder) whatsoever beyond Landlord&rsquo;s or Tenant&rsquo;s reasonable control. Landlord and Tenant
shall, in each instance, exercise reasonable diligence to effect performance when and as soon as possible or practicable. For the
avoidance of doubt, Tenant&rsquo;s obligation to pay Annual Fixed Rent and Additional Rent hereunder shall not be affected hereby
unless specifically provided for in this Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase"><U>ARTICLE
15</U></FONT><BR>
<BR>
<U>E<FONT STYLE="text-transform: uppercase">NTRY, RIGHT TO CHANGE PUBLIC PORTIONS OF THE BUILDING</FONT></U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">15.1 <U>LANDLORD&rsquo;S
RIGHT OF ENTRY</U>. Landlord shall have the right, without being deemed thereby to evict Tenant from the Premises or any part thereof
or otherwise to violate any of the terms of this Lease or any of Tenant&rsquo;s rights hereunder,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(a) to enter and pass
through the Premises or any part or parts thereof,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">(i) to examine the
Premises and to show them to the fee owners, Overlandlord or Mortgagee (both as hereafter defined) and to prospective purchasers,
mortgagees or lessees of the Building as an entirety;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 67; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">(ii) for the purpose
of performing such maintenance and making such repairs or changes in or to the Premises or in or to the Building or its facilities
as may be provided for or permitted by this Lease or as may be mutually agreed upon by the parties or as Landlord may be required
to make by laws and requirements of public authorities; provided, however, that any such maintenance, repairs or changes in or
to the Premises shall not cause a reduction of the usable floor space of the Premises (other than to a de minimis extent);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">(iii) at such times
as such entry shall be required by circumstances of emergency affecting the Premises or the Building, provided that in such event,
if practicable, Landlord or its agents shall be accompanied by a designated representative of Tenant or a member of the police,
fire, water or other municipal department concerned or of a recognized protection company or of a public utility which is concerned;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">(iv) to exhibit the
Premises or any portion thereof to prospective tenants or occupants (A) during the last twelve (12) months of the Lease Term, (B)
at any time during the Lease Term while there exists a default of Tenant hereunder beyond the expiration of all applicable notice
and cure periods or (C) during any period in which Landlord may exercise a right to underlease the space in question or to terminate
this Lease (provided, however, that in the case of the foregoing clause (A), Landlord shall provide Tenant reasonable prior notice
and the opportunity to designate a representative of Tenant to be present at such exhibiting of the Premises); and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">(v) for the purpose
of photographing the Premises for use by Landlord and/or Landlord&rsquo;s affiliates in connection with promotional and marketing
materials (provided, however, that (A) Landlord shall provide Tenant reasonable prior notice and the opportunity to designate a
representative of Tenant to be present during such photographing of the Premises and (B) Landlord shall in no event photograph
and transmit images disclosing any proprietary information of Tenant).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(b) to take all materials
into and upon the Premises that may be required for any repairs, changes or maintenance and to store the same therein for a reasonable
time as reasonably required in connection with the completion of such repairs, changes or maintenance; provided, however, that
Landlord shall use reasonable efforts (but not including the use of overtime or premium labor) to perform such work in such a manner
so as to minimize interference that might be occasioned to Tenant&rsquo;s business operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">Landlord&rsquo;s rights
under this Section shall be exercised in such manner as to create the least practicable interference with Tenant&rsquo;s use of
the Premises; provided, however, that the foregoing shall not obligate Landlord to perform any work outside of Operating Hours
(as defined in Exhibit D). Except in the case of an emergency which makes notice to Tenant impractical, any entry on the Premises
by Landlord pursuant to this Section 15.1 shall be made after reasonable notice to Tenant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 68; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">15.2 <U>LANDLORD&rsquo;S
RIGHT TO CHANGE ENTRIES, ETC</U>. Landlord shall have the right at any time without thereby creating any actual or constructive
eviction or incurring any liability to Tenant therefor, and without abatement in rent, to change the arrangement or location of
lobbies, entrances, passageways, doors, doorways, stairways, elevators, corridors and other like portions of the Building outside
of the Premises, provided that such change does not interfere with Tenant&rsquo;s access to the Premises.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">15.3 <U>EXCAVATION</U>.
In the event that an excavation or any construction should be made for building or other purposes upon land adjacent to the Building,
or should be authorized to be made, Tenant shall, if necessary, afford to the person or persons causing or authorized to cause
such excavation or construction, license to enter upon the Premises for the purpose of doing such work as shall reasonably be necessary
to protect or preserve the wall or walls of the Building, or the Building, from injury or damage and to support them by proper
foundations, pinning and/or underpinning, or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase"><U>ARTICLE
16</U></FONT><BR>
<BR>
<U>E<FONT STYLE="text-transform: uppercase">LECTRICITY </FONT></U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">16.1 <U>TENANT TO PURCHASE
ELECTRICITY</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(a) Landlord shall make
electricity available to the Premises at the service level set forth in Exhibit D attached hereto, and otherwise subject to and
in accordance with the provisions of this Article.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(b) Tenant acknowledges
that electricity shall be furnished to the Premises on a &ldquo;submetering&rdquo; basis, which may be effectuated by Landlord
through one (1) or more submeters installed by Landlord at Landlord&rsquo;s sole cost and expense. In the event more than one (1)
submeter measures the electric service to Tenant in the Premises, the electric service rendered through each submeter shall be
computed and billed as if one (1) submeter measured such electric service.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(c) In the event that
there is located in the Premises a data center containing high density computing equipment, as defined in the U.S. EPA&rsquo;s
Energy Star&reg; rating system, Landlord may require the installation in accordance with Energy Star of separate metering or sub-metering
equipment (Tenant being responsible for the costs of any such meter or sub-meter and the installation and connectivity thereof).
Tenant shall pay to Landlord, as Additional Rent, an amount equal to (i) the Average Rate (as hereinafter defined) multiplied
by the number of kilowatt-hours of electricity used in the Premises during the period for which such payment is being made plus
five percent (5%) within thirty (30) days after being billed thereof by Landlord; in either case in addition to other electric
charges payable by Tenant under the Lease. For purposes hereof, the term &ldquo;Average Rate&rdquo; shall mean the average cost
to Landlord of supplying one (1) kilowatt-hour of electricity to the Building, and such rate shall be determined by dividing (A)
the electric bill for the Building for the period(s) covered by Tenant&rsquo;s payment by (B) the number of kilowatt-hours of
electricity supplied to the Building during such period. In addition, electrical consumption for any common areas on the floor
on which the Premises is located shall be determined by a meter(s) installed by Landlord at Landlord&rsquo;s expense and, Tenant
shall pay to Landlord, as Additional Rent, for electricity supplied to such common areas, including electricity supplied to the
Building HVAC System serving the Premises, an amount equal to Tenant&rsquo;s pro rata share (based upon the ratio of the rentable
square feet of the Premises to the rentable square feet of the entire floor and adjusted equitably according to estimated usage)
of the actual cost of the entire supply of electric current to the common area of such floor, based upon the bill received by
Landlord from the utility company for electricity rendered through the meter for such floor. Tenant&rsquo;s payments shall be
made within thirty (30) days after receipt of a statement setting forth the actual cost of electricity and the computation of
Tenant&rsquo;s payment shall be adjusted from time to time in accordance with the provisions of this Section 16.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 69; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">16.2 <U>LANDLORD NOT
LIABLE</U>. Subject to Section 20.12, Landlord shall not in any way be liable or responsible to Tenant for any loss or damage or
expense which Tenant may sustain or incur if either the quantity or character of electric service is changed or interrupted or
is no longer available or suitable for Tenant&rsquo;s requirements unless due to the negligence of Landlord, its agents, employees
or contractors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">16.3 <U>TENANT NOT
TO OVERLOAD CIRCUITS</U>. In no event shall Tenant use or install any fixtures, equipment or machines the use of which in conjunction
with other fixtures, equipment and machines in the Premises would result in an overload of the electrical circuits servicing the
Premises.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">16.4 <U>TENANT NOT
TO EXCEED CAPACITY; LIGHT BULBS</U>. Tenant covenants and agrees that at all times its use of electric current shall never exceed
the capacity of the then existing feeders to the Building or the risers or wiring installation. Landlord shall furnish, install
and replace, as required, all lighting tubes, lamps, bulbs and ballasts required in the Premises at Tenant&rsquo;s sole cost and
expense. All lighting tubes, lamps, bulbs and ballasts so installed shall become Landlord&rsquo;s property upon the expiration
or sooner termination of this Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase"><U>ARTICLE
17</U></FONT><BR>
<BR>
<U>S<FONT STYLE="text-transform: uppercase">UBORDINATION; ASSIGNMENT OF RENTS </FONT></U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">17.1 <U>SUBORDINATION
TO MORTGAGES, ETC</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(a) This Lease is and
shall be subject and subordinate to any ground or underlying lease (collectively called &ldquo;Underlying Lease&rdquo;) which
may now or hereafter affect the Building and/or the Land and to any amendment, modification, renewal or extension of any such
Underlying Lease. This Lease also is and shall be subject and subordinate to all mortgages which may now or hereafter affect any
Underlying Lease, the Land and/or the Building, to each and every advance made thereunder and to all renewals, modifications,
amendments, consolidations, replacements or extensions thereof. The landlord or lessor under any Underlying Lease is referred
to herein as a &ldquo;Overlandlord&rdquo; and the secured party under any such mortgage is referred to herein as a &ldquo;Mortgagee&rdquo;.
This clause shall be self-operative and no further instrument of subordination shall be required by any Overlandlord or Mortgagee.
In confirmation of such subordination, Tenant, without cost or charge to Landlord, shall execute promptly any certificate or instrument
of subordination that Landlord may reasonably request, provided that the same shall not increase Tenant&rsquo;s obligations or
decrease Tenant&rsquo;s rights under this Lease (other than to a <I>de minimis </I>extent). Tenant hereby, irrevocably constitutes
and appoints Landlord as Tenant&rsquo;s attorney-in-fact, coupled with an interest, to execute any such certificate or certificates
or any such instrument or instruments for and on behalf of Tenant if Tenant shall fail or refuse to execute the same for ten (10)
days after demand.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 70; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(b) Tenant agrees that
if any Overlandlord or Mortgagee shall succeed to interest of Landlord under this Lease by foreclosure or otherwise, and the Overlandlord
or Mortgagee elects in its sole discretion not to cause this Lease to be terminated in connection therewith, this Lease shall not
be terminated or affected thereby but shall continue in full force and effect as a direct lease between Overlandlord or Mortgagee
and Tenant upon all of the terms, covenants and conditions set forth in this Lease (it being understood that Tenant shall, if requested,
enter into a new lease on terms identical to those in this Lease) and, in such event, Tenant shall attorn to Overlandlord or Mortgagee
provided, however, that the provisions of such Underlying Lease or such mortgage shall govern with respect to the disposition of
any casualty insurance proceeds or condemnation awards and Overlandlord or Mortgagee shall not be (i) bound by any prepayment of
rent which Tenant might have paid for more than the current month to any prior landlord (including Landlord), (ii) bound by any
waiver or forbearance under, or any amendment, modification, cancellation or surrender (in whole or in part) of this Lease made
without the consent of such Overlandlord or Mortgagee, (iii) liable for any act, omission or default of any prior landlord (including
Landlord) under this Lease (it being understood that the foregoing is not intended to relieve any such Overlandlord or Mortgagee
of any liability arising by reason of its acts or omissions (x) from and after the date it succeeds to the interests of Landlord
or (y) prior to the date it succeeds to the interests of Landlord if such default is continuing after such date of succession but
then only to the extent such default occurred after the date of succession), (iv) bound by or subject to any (A) credits, offsets
or abatements the rights to which first accrued prior to the date upon which Successor Landlord succeeded to the interest of Landlord
under the Lease or (B) defenses or claims (except defenses or claims against Successor Landlord based on acts, omissions or other
matters first occurring after Successor Landlord succeeded to the interest of Landlord under the Lease) that Tenant might have
against any prior Landlord (including, without limitation, the then defaulting Landlord), (v) liable for performance of any work
or installations or payment of any sums which are required to be made by Landlord under this Lease, or (vi) liable for any security
deposit, in whatever form, provided by Tenant, unless such security deposit shall have been received in hand by such Overlandlord
or Mortgagee. The provisions of this Section 17.1(b) shall be self-operative and no further instrument shall be required to give
effect to these provisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(c) Tenant shall not
do nor suffer nor permit any action which would constitute a default under any Underlying Lease or any mortgage which may now or
hereafter affect any Underlying Lease, the Land and/or the Building, or cause any Underlying Lease to be terminated or forfeited
by virtue of any right of termination or forfeiture granted to the Overlandlord by such Underlying Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(d) In the event that
(i) any Overlandlord or Mortgagee shall succeed to the interest of Landlord under this Lease by foreclosure or otherwise, (ii)
as of the date of such succession, Landlord has not Substantially Completed the Base Work and (iii) such Overlandlord or Mortgagee
succeeding to Landlord&rsquo;s interest does not agree to Substantially Complete the Base Work, then Tenant, in Tenant&rsquo;s
sole discretion, shall have the right to terminate this Lease upon written notice delivered to Landlord and such Overlandlord
and Mortgagee within thirty (30) days after such succession, time being of the essence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 71; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">17.2 <U>RIGHTS OF MORTGAGEES,
ETC</U>. In the event of any act or omission by Landlord which would or may give Tenant the right to terminate this Lease or to
claim a partial or total eviction (other than under Article 12 or with respect to Tenant&rsquo;s termination rights if the Commencement
Date does not occur by the outside date set forth herein), Tenant will not exercise any such right until:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(a) it has given written
notice of any such act or omission to Landlord, and to any Overlandlord or Mortgagee whose names and addresses have previously
been furnished to Tenant, and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(b) a reasonable period
of time for remedying such act or omission shall have elapsed following such giving of notice during which the parties to whom
such notice has been given, or any of them, have not commenced with reasonable diligence the remedying of such act or omission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">17.3 <U>MODIFICATIONS
REQUIRED BY LENDERS</U>. If, in connection with obtaining temporary or permanent financing for the Land and/or Building, or any
Underlying Lease, any lender shall request reasonable modifications of this Lease as a condition to such financing, Tenant will
not unreasonably withhold, delay or defer the execution of an agreement of modification of this Lease provided such modifications
do not increase the monetary obligations of Tenant hereunder, or materially adversely affect the leasehold interest hereby created,
or Tenant&rsquo;s rights hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">17.4 <U>ASSIGNMENT
OF LEASE TO MORTGAGEE, ETC</U>. With reference to any assignment by Landlord of Landlord&rsquo;s interest in this Lease, or the
rents payable hereunder, conditional in nature or otherwise, which assignment is made to an Overlandlord or Mortgagee, Tenant agrees:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(a) that the execution
thereof by Landlord, and the acceptance thereof by such Overlandlord or Mortgagee, shall never be treated as an assumption by such
Overlandlord or Mortgagee of any of the obligations of Landlord hereunder, unless such Overlandlord or Mortgagee shall, by notice
sent to Tenant, specifically otherwise elect; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(b) that, except as
aforesaid, such Overlandlord, or Mortgagee shall be treated as having assumed Landlord&rsquo;s obligations hereunder only, in
the case of a Mortgagee, upon foreclosure by such Mortgagee and the taking of possession of the Premises, or, in the case of an
Underlying Lease, the assumption of Landlord&rsquo;s position hereunder by such Overlandlord, any such assumption in each such
case to be limited as set forth in Section 14.1(d). In no event shall the acquisition of title to the Building and/or the Land
by a purchaser which, simultaneously therewith, leases the entire Building and/or the Land back to the seller thereof be treated
as an assumption, by operation of law or otherwise, of Landlord&rsquo;s obligations hereunder, but Tenant shall look solely to
such seller-lessee, and its successors from time to time in title, for performance of Landlord&rsquo;s obligations hereunder.
For all purposes, such seller-lessee, and its successors in title, shall be the landlord hereunder unless and until Landlord&rsquo;s
position shall have been assumed by such purchaser-lessor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 72; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">17.5 <U>SUBORDINATION
OF MORTGAGE, ETC., TO LEASE</U>. Notwithstanding anything to the contrary set forth in this Article 17, if any Overlandlord or
Mortgagee shall file in the office of the Register of the City of New York, New York County, an instrument in which such Overlandlord
or Mortgagee shall subordinate its Underlying Lease or mortgage to this Lease, then and in such event such Underlying Lease or
mortgage shall be subordinate to this Lease and the provisions of this Article 17, insofar as they would subordinate this Lease
to that particular Underlying Lease or mortgage, shall be of no further force or effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase"><U>ARTICLE
18</U></FONT><BR>
<BR>
<U>C<FONT STYLE="text-transform: uppercase">ERTAIN ADDITIONAL TENANT COVENANTS </FONT></U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">In addition to the
covenants contained elsewhere in this Lease, Tenant covenants, during the Lease Term and for such further time as Tenant occupies
any part of the Premises:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(a) to pay when due
all Annual Fixed Rent and Additional Rent and all charges for utility services rendered to the Premises and service inspections
therefor and, as further Additional Rent, all charges for additional and special services rendered pursuant to Exhibit D;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(b) to keep the Premises
equipped with all safety appliances (including without limitation fire extinguishers) required by law or ordinance or any other
regulation of any public authority, to procure all licenses and permits so required because of any use made of the Premises or
any portion thereof by Tenant, and, if requested by Landlord, to do any work so required because of such use, it being understood
that the foregoing provisions shall not be construed to broaden in any way the uses to which Tenant is permitted to make of the
Premises under the terms of this Lease;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(c) not to place a
load upon any floor in the Premises exceeding the floor load per square foot of area which such floor was designed to carry and
which is allowed by law; and not to move any safe, vault or other heavy equipment in, about or out of the Premises except in such
manner and at such time as Landlord shall in each instance expressly authorize. Tenant&rsquo;s business machines and mechanical
equipment shall be placed and maintained by Tenant at Tenant&rsquo;s expense in settings sufficient to absorb and prevent vibration
or noise that may be transmitted to the Building structure or to any other space in the Building;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(d) to pay promptly
when due all taxes which may be imposed upon personal property (including, without limitation, fixtures and equipment) in the Premises
by whomever assessed;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 73; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(e) to pay on demand
as Additional Rent, regardless of whether any default or Event of Default has occurred or whether any proceeding to enforce the
Lease has been commenced, all costs and expenses, attorneys&rsquo; fees and disbursements and other fees incurred by Landlord
in connection with (i) the enforcement by Landlord of any obligation of Tenant under this Lease; (ii) the preservation and enforcement
of Landlord&rsquo;s rights and remedies in connection with the Lease; (iii) any unsuccessful attempt by Tenant to enforce any
obligation or purported obligation of Landlord under this Lease; (iv) any unsuccessful action or proceeding brought by Tenant
against Landlord related to this Lease; and (v) any voluntary or involuntary bankruptcy case, proceeding or action by or on behalf
of Tenant, including, without limiting the generality of the foregoing, any and all expenses and attorneys&rsquo; fees incurred
by Landlord related to (A) the assumption or rejection of this Lease, including attempts by Tenant to extend any deadlines related
to such assumptions or rejections; (B) the filing of proof(s) of claim by Landlord, and any defense of such proof(s) of claim;
(C) the assignment of this Lease; and (D) the reorganization or liquidation of Tenant. This provision shall survive the termination
of this Lease;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(f) to observe and
comply with, and to cause its servants, employees, agents, visitors, licensees and sublessees to comply with, the Rules and Regulations
set forth in Exhibit E and the Lab Rules and Regulations (as each of such rules and regulations may, from time to time, be adopted
or amended in accordance with Section 20.13 hereof);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(g) to cause all of
the windows in the Premises to be kept closed; to keep entirely unobstructed at all times all of the vents, intakes, outlets and
grills; and to comply with and observe all reasonable regulations and requirements prescribed by Landlord for the proper functioning
of the heating, ventilating and air-conditioning system;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(h) not to, either
directly or indirectly (i) conduct business in the Premises in such a manner that would or may create or (ii) use any contractors
and/or labor and/or materials if the use thereof, would or may create, any difficulty with other contractors and/or labor and/or
materials engaged or used by Tenant or Landlord or others in the construction, maintenance and/or operation of the Building or
any part thereof. Without limiting any other provision of this Lease, all contractors, vendors and service providers requiring
access to the Premises or the Building shall be subject to Landlord&rsquo;s prior and continuing review and approval with respect
to insurance, security and operational matters. This provision shall apply prior to, as well as during, the Lease Term; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(i) to comply with
all the terms covenants, covenants and conditions of the HireNYC requirements set forth on Exhibit J hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase"><U>ARTICLE
19</U></FONT><BR>
<BR>
<U>T<FONT STYLE="text-transform: uppercase">ENANT&rsquo;S DEFAULT; LANDLORD&rsquo;S REMEDIES</FONT></U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">19.1 <U>TENANT&rsquo;S
DEFAULT</U>. This Lease and the Lease Term are subject to the limitation that Tenant shall be in default if, at any time during
the Lease Term, any one or more of the following events (herein called an &ldquo;Event of Default&rdquo;) shall occur:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">(a) if Tenant shall
fail to pay any installment of the Annual Fixed Rent, or any Additional Rent, or any other charges for which provision is herein
made, or any part thereof, when the same shall become due and payable and such failure shall continue for five (5) days after
notice thereof from Landlord to Tenant (provided that if Tenant shall have failed to pay any such installment or other charge
or portion thereof when the same becomes due and payable two (2) times during any Lease Year and Landlord shall in each case have
given Tenant notice of such failure, then after such second time it shall be an Event of Default in the event Tenant thereafter
during such Lease Year fails to pay any such installment or other charge or portion thereof on the date the same becomes due and
payable, without notice (or, in the case of other charges which are payable on or subsequent to demand, further notice) from Landlord);
or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 74; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">(b) if the Premises
shall become abandoned and such abandonment continues for more than thirty (30) days after notice from Landlord; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">(c) if an assignment
or subletting shall occur or if Tenant&rsquo;s interest in this Lease shall devolve upon or pass to any person or entity, whether
by operation of law or otherwise, and whether directly or indirectly, except as expressly permitted by Article 13 hereof, or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">(d) if Tenant fails
to maintain any of the insurance required to be maintained by Tenant hereunder or to deliver certificates thereof when required
hereunder and Tenant fails to remedy such default within five (5) days after notice by Landlord to Tenant specifying such default;
or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">(e) Tenant shall fail
to perform or observe some term or condition of this Lease which, because of its character, would immediately jeopardize Landlord&rsquo;s
interest in the Property, the health or safety of any person, the operation of the Building or any Building system, or the business
operations of any occupant (including, without limitation, Tenant&rsquo;s failure to perform any Alterations during non-Operating
Hours when required to do so by the terms of this Lease), and such failure continues for two (2) days after notice from Landlord
to Tenant specifying such default; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">(f) if Tenant shall
fail to perform or observe any other term, covenant, or condition of this Lease on the part of Tenant to be performed or observed
and such failure shall continue for thirty (30) days after notice thereof from Landlord to Tenant, or, if said default is curable
but shall reasonably require longer than thirty (30) days to cure, if Tenant shall fail to commence to cure said default within
thirty (30) days after receipt of notice thereof and/or fail continuously to prosecute the curing of the same to completion with
due diligence, and in any event within such period of time as will prevent Landlord from being subjected to the risk of criminal
liability or termination of any Underlying Lease or foreclosure of any mortgage; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">(g) if the estate hereby
created shall be taken on execution or by other process of law; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">(h) (i) if Tenant shall
generally not, or shall be unable to, or shall admit in writing its inability to, pay its debts as they become due; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">(ii) if Tenant shall
commence or institute any case, proceeding or other action (x) seeking relief on its behalf as debtor, or to adjudicate it a bankrupt
or insolvent, or seeking reorganization, arrangement, adjustment, winding-up, liquidation, dissolution, composition or other relief
with respect to it or its debts under any existing or future law of any jurisdiction, domestic or foreign, relating to bankruptcy,
insolvency, reorganization or relief of debtors, or (y) seeking appointment of a receiver, trustee, custodian or other similar
official for it or for all or any substantial part of its property; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 75; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">(iii) if Tenant shall
make a general assignment for the benefit of creditors; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">(iv) if any case, proceeding
or other action shall be commenced or instituted against Tenant (x) seeking to have an order for relief entered against it as debtor
or to adjudicate it a bankrupt or insolvent, or seeking reorganization, arrangement, adjustment, winding-up, liquidation, dissolution,
composition or other relief with respect to it or its debts under any existing or future law of any jurisdiction, domestic or foreign,
relating to bankruptcy, insolvency, reorganization or relief of debtors, or (y) seeking appointment of a receiver, trustee, custodian
or other similar official for it or for all or any substantial part of its property, which either (1) results in any such entry
of an order for relief, adjudication of bankruptcy or insolvency or such an appointment or the issuance or entry of any other order
having a similar effect or (2) remains undismissed for a period of sixty (60) days; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">(v) if any case, proceeding
or other action shall be commenced or instituted against Tenant seeking issuance of a warrant of attachment, execution, distraint
or similar process against all or any substantial part of its property which results in the entry of an order for any such relief
which shall not have been vacated, discharged, or stayed or bonded pending appeal within sixty (60) days from the entry thereof;
or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">(vi) if Tenant shall
take any action in furtherance of, or indicating its consent to, approval of, or acquiescence in, any of the acts set forth in
clauses (ii), (iii), (iv) or (v) above; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">(vii) if a trustee, receiver
or other custodian is appointed for any substantial part of the assets of Tenant which appointment is not vacated or effectively
stayed within seven (7) Operating Days; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">(i) if Tenant fails
to (A) deliver any Security Deposit, Letter of Credit, pre-paid rent, financial information, guaranty or other item required but
not delivered upon the execution and delivery of this Lease within three (3) days after notice from Landlord to Tenant demanding
same, <U>provided</U>, <U>however</U>, that Tenant&rsquo;s failure to timely provide the initial Letter of Credit as replacement
for the Cash Deposit pursuant to Section 20.22 shall constitute an immediate Event of Default hereunder for which Tenant shall
not be entitled to such three (3) day notice and cure period or (B) timely deliver a Replacement Letter in accordance with the
terms of Section 20.22(a), 20.22(b) or 20.22(d) hereof or (C) timely restore the Letter to the face amount then required under
Section 20.22(b) hereof after Landlord has drawn upon the Letter; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">(j) if any representation
or warranty made by Tenant herein or in any report, certificate, financial statement or other instrument, agreement or document
furnished to Landlord shall have been materially false or misleading as of the date the representation or warranty was made.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 76; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">19.2 <U>TERMINATION</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">(a) (i) If an Event
of Default described in Section 19.1(h) hereof shall occur, or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">(ii) if an Event of Default
described in Sections 19.1(a),(b),(c),(d), (e), (f), (g), (i) or (j) shall occur and Landlord, at any time thereafter, at its option
gives written notice to Tenant stating that this Lease and the Lease Term shall expire and terminate on the date specified in such
notice, which date shall not be less than three (3) days after the giving of such notice, then this Lease and the Lease Term and
all rights of Tenant under this Lease shall expire and terminate, as if the date on which the Event of Default described in clause
(i) above occurred, or the date specified in the notice given pursuant to this clause (ii) above, as the case may be, were the
date herein definitely fixed for the expiration of the Lease Term (except that Tenant shall continue liable as hereinafter provided)
and Tenant immediately shall quit and surrender the Premises.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">(b) Anything contained
herein to the contrary notwithstanding, if such termination shall be stayed by order of any court having jurisdiction over any
proceeding described in Section 19.1(h) hereof, or by federal or state statute, then, following the expiration of any such stay,
or if Tenant, or Tenant as debtor-in-possession or the trustee appointed in any such proceeding (being collectively referred to
as &ldquo;Tenant&rdquo; only for the purposes of paragraph (b) of this Section 19.2) shall fail to assume Tenant&rsquo;s obligations
under this Lease within the period prescribed therefor by law or within one hundred twenty (120) days after entry of the order
for relief or as may be allowed by the court, or, if Tenant shall fail to provide adequate protection of Landlord&rsquo;s right,
title and interest in and to the Premises or adequate assurance of the complete and continuous future performance of Tenant&rsquo;s
obligations under this Lease, Landlord, to the extent permitted by law or by leave of the court having jurisdiction over such proceeding,
shall have the right, at its election, to terminate this Lease on three (3) days&rsquo; notice to Tenant and upon the expiration
of said three (3) day period this Lease shall cease and expire as aforesaid and Tenant shall immediately quit and surrender the
Premises as aforesaid. Upon the termination of this Lease provided above, Landlord, without notice, may re-enter and repossess
the Premises using such force for that purpose as may be necessary without being liable to indictment, prosecution or damages therefor
and may dispossess Tenant by summary proceedings or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">(c) If, at any time,
(i) Tenant shall comprise two (2) or more persons, or (ii) Tenant&rsquo;s obligations under this Lease shall have been guaranteed
by any person other than Tenant, or (iii) Tenant&rsquo;s interest in this Lease shall have been assigned, the word &ldquo;Tenant&rdquo;,
as used in clause (h) of Section 19.1, shall be deemed to mean any one or more of the persons primarily or secondarily liable for
Tenant&rsquo;s obligations under the Lease. Any monies received by Landlord from or on behalf of Tenant during the pendency of
any proceeding of the types referred to in said clause (h) shall be deemed paid as compensation for the use and occupation of the
Premises and the acceptance of any such compensation by Landlord shall not be deemed an acceptance of rent or a waiver on the part
of Landlord of any rights under this Section.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">(d) The provisions
of subdivisions (b) and (c) of this Section 19.2 apply only in respect of the circumstances described in subsection 19.1(h) and
as such are not intended to constitute modifications of any of the provisions of Article 13 except in such circumstances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 77; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">19.3 <U>RE-ENTRY; CONTINUED
LIABILITY; RELETTING</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">(a) If Tenant shall
default in the payment of any installment of Annual Fixed Rent or any Additional Rent on any date on which the same becomes due
and payable, and if such default shall continue for five (5) days after Landlord shall have given Tenant notice of such default,
or if this Lease shall be terminated pursuant to or as provided in Section 19.2, Landlord and Landlord&rsquo;s agents and employees
may immediately or at any time thereafter re-enter the Premises, or any part thereof in the name of the whole, either by summary
dispossess proceedings or by any suitable action or proceeding at law or otherwise, without being liable to indictment, prosecution
or damages therefor, and may repossess the same, and may remove any persons therefrom, to the end that Landlord may have, hold,
possess and enjoy the Premises again.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">(b) If this Lease is
terminated or if Landlord shall re-enter the Premises as aforesaid, or in the event of the termination of this Lease, or of re-entry,
by or under any proceeding or action or any provision of law by reason of an Event of Default hereunder on the part of Tenant,
Tenant covenants and agrees forthwith that,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">(i) the Annual Fixed
Rent (including, without limitation, an amount equal to the amount of Annual Fixed Rent which would have been payable during the
Rent Concession Period) and Additional Rent shall become due thereupon and be paid by Tenant up to the time of such re-entry, dispossession
and/or termination, together with such expenses as Landlord may incur for legal expenses, attorneys&rsquo; fees and disbursements,
brokerage, and/or putting the Premises in good order, or for preparing the same for reletting;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">(ii) Landlord may relet
the Premises or any part or parts thereof, either in the name of Landlord or otherwise (but shall have no obligation to do so),
for a term or terms, which may at Landlord&rsquo;s option be less than or exceed the period which would otherwise have constituted
the balance of the Term of this Lease and may grant concessions or free rent;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">(iii) Tenant or the legal
representatives of Tenant shall also pay Landlord, as liquidated damages for the failure of Tenant to observe and perform Tenant&rsquo;s
covenants herein contained, amounts equal to the Annual Fixed Rent and Additional Rent which would have been payable by Tenant
had this Lease not been so terminated, or had Landlord not so reentered the Premises, such payments to be made upon the due dates
therefor specified herein following such termination or re-entry and continuing until the Expiration Date; provided, however, that
if Landlord shall relet the Premises, Landlord shall credit Tenant, up to the amount due from Tenant, with the net rent received
by Landlord for such reletting after deducting from the first installments of such rent received the expenses incurred or paid
by Landlord in terminating this Lease or in re-entering the Premises and in securing possession thereof, as well as the expenses
of reletting, including legal expenses, attorneys&rsquo; fees and disbursements, brokerage commissions, alteration costs and other
expenses incurred for keeping the Premises in good order or for preparing the same for reletting. Any suit brought to collect the
amount of the aforesaid damages for any month or months shall not prejudice in any way the rights of Landlord to collect the damages
for any subsequent month or months by a similar proceeding. Nothing contained herein shall be deemed to require Landlord to postpone
suit until the date when the Lease Term would have expired if it had not been so terminated under or pursuant to Section 19.2,
or under any provision of law, or had Landlord not re-entered the Premises.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 78; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">(c) The terms &ldquo;re-enter&rdquo;
and &ldquo;re-entry,&rdquo; as used herein, are not limited to their technical legal meanings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">19.4 <U>LIQUIDATED
DAMAGES</U>. Landlord may elect, as an alternative to the damages and charges provided for in Section 19.3(b)(iii), and in lieu
of all other such damages thereafter accruing, to have Tenant pay the liquidated damages provided for below, which election may
be made by notice given to Tenant at any time after the termination of this Lease under or pursuant to Section 19.2, above, and
whether or not Landlord shall have collected any damages as hereinabove provided in Section 19.3. Upon such notice, Tenant shall
promptly pay to Landlord, as liquidated damages, in addition to any damages collected or due from Tenant from any period prior
to such notice, such a sum as at the time of such notice represents the amount of the excess, if any, of (i) the discounted present
value, at a discount rate of <FONT STYLE="font-size: 10pt">[***]</FONT>, of the Annual Fixed Rent, Additional Rent and other charges
which would have been payable by Tenant under this Lease for the remainder of the Lease Term if Tenant had fulfilled all of its
obligations hereunder, over and above (ii) the discounted present value, at a discount rate of <FONT STYLE="font-size: 10pt">[***]</FONT>,
of the Annual Fixed Rent, Additional Rent and other charges that would be received by Landlord (after deducting all reasonably
estimated costs of reletting, including, without limitation, brokerage fees, advertising, required tenant improvements and concessions
and attorneys&rsquo; fees) if the Premises were relet at the time of such notice for the remainder of the Lease Term at the fair
rental value thereof at the time of such notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">For the purposes of
this Article, if Landlord elects to require Tenant to pay liquidated damages in accordance with this Section 19.4, (a) the total
rent shall be computed by assuming Tenant&rsquo;s Tax Payment and Tenant&rsquo;s Share of Operating Expenses under Article 6 to
be the same as were payable for the twelve (12) calendar months (or if fewer than twelve calendar months shall have elapsed since
the date hereof, for the partial year, but annualized) immediately preceding such termination or re-entry, and (b) if the Premises
or any part thereof shall have been relet by Landlord for the unexpired portion of the Lease Term, or any part thereof, before
presentation of proof of such damages to any court, commission or tribunal, the amount of rent received upon such reletting shall
be prima facie evidence of the fair rental value of the Premises, or part thereof, so relet during the term of such reletting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">19.5 <U>RIGHTS IN THE
EVENT OF TENANT&rsquo;S BANKRUPTCY</U>. Nothing contained in this Lease shall limit or prejudice the right of Landlord to prove
for and obtain, in proceedings for the termination of this Lease by reason of bankruptcy or insolvency, an amount equal to the
maximum allowed by any statute or rule of law in effect at the time when, and governing the proceedings in which, the damages are
to be proved, whether or not the amount be greater, equal to, or less than the amount of the loss or damages referred to above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">19.6 <U>WAIVER OF REDEMPTION,
ETC</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">(a) Tenant, for itself
and any and all persons claiming through or under Tenant, including its creditors, upon the termination of this Lease or expiration
of the Lease Term in accordance with the terms hereof, or in the event of entry of judgment for the recovery of the possession
of the Premises in any action or proceeding, or if Landlord shall reenter the Premises by process of law or otherwise, hereby
waives any right of redemption provided or permitted by any statute, law or decision now or hereafter in force, and does hereby
waive, surrender and give up all rights or privileges which it or they may or might have under and by reason of any present or
future law or decision, to redeem the Premises or for a continuation of this Lease for the Term of this Lease after having been
dispossessed or ejected therefrom by process of law, or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 79; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">(b) If Tenant is in
arrears in the payment of Annual Fixed Rent or Additional Rent, Tenant waives its right, if any, to designate the item against
which any payments made by Tenant are to be credited and Tenant agrees that Landlord may apply any payment made by Tenant to any
items as Landlord may see fit, irrespective of and notwithstanding any designation or request by Tenant as to the items against
which any such payment shall be credited.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">(c) Landlord, Tenant
and all of Tenant&rsquo;s successors, subtenants, and assignees (Tenant and all of Tenant&rsquo;s successors, subtenants, and assignees
are collectively for the purposes of this Section 19.6(c) referred to as &ldquo;Tenant&rdquo;), each hereby waive trial by jury
in any action, proceeding or counterclaim brought by either against the other on any matter whatsoever arising out of or in any
way connected with the Lease, the relationship of Landlord and Tenant and Tenant&rsquo;s use or occupancy of the Premises or any
other claim (other than claim for personal injuries or property damage). It is further mutually agreed that if Landlord commences
any summary proceedings for non-payment of rent, Tenant will not interpose and does hereby waive the right to interpose any counterclaim
of whatever nature or description in such proceeding (unless failure to impose such counterclaim would preclude or otherwise prejudice
Tenant from asserting in a separate action the claim that is the subject of such counterclaim).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">19.7 <U>ADDITIONAL
RIGHTS OF LANDLORD</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">(a) In the event of
a breach or threatened breach by Tenant of any of its obligations under this Lease, Landlord shall also have the right to obtain
an injunction. The remedies to which Landlord may resort under this Lease are cumulative and are not intended to be exclusive of
any other remedies to which Landlord may be lawfully entitled at any time and Landlord may invoke any remedies allowed at law or
in equity as if specific remedies were not provided for herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">(b) If this Lease shall
terminate under or pursuant to Section 19.2, or if Landlord shall re-enter the Premises under the provisions of this Article, or
in the event of the termination of this Lease, or of re-entry by or under any summary dispossess or other proceeding or action
or any provision of law by reason of Tenant&rsquo;s default hereunder, Landlord shall be entitled to retain all moneys, if any,
paid by Tenant to Landlord, whether as advance rent, security or otherwise, but such moneys shall be credited by Landlord against
any Annual Fixed Rent or Additional Rent due from Tenant at the time of such termination or re-entry or, at Landlord&rsquo;s option,
against any damages payable by Tenant under this Article or pursuant to law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">19.8 <U>LANDLORD&rsquo;S
DEFAULT</U>. Landlord shall in no event be in default in the performance of any of Landlord&rsquo;s obligations hereunder unless
and until (i) Landlord shall have failed to perform such obligations within thirty (30) days (or, if an obligation is such that
it cannot be performed within thirty (30) days, Landlord shall have failed to commence with reasonable diligence performance of
the same within such thirty (30) day period) after notice by Tenant to Landlord properly specifying wherein Landlord has failed
to perform any such obligation, and (ii) Tenant has given notice to all parties as required under Section 17.2 hereof and such
parties have not commenced the performance of such obligations within the time provided in Section 17.2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 80; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">19.9 <U>FEES AND EXPENSES</U>.
If for any reason, any suit is initiated between Landlord and Tenant to interpret or enforce any provision of this Lease, the prevailing
party in such suit shall be entitled to recover from the other party its legal costs, expert witness expenses, and reasonable attorneys&rsquo;
fees, as fixed by the court. Subject to the immediately preceding sentence, Landlord shall be entitled to recover all reasonable
costs and expenses, attorneys&rsquo; fees and disbursements and other fees incurred by Landlord in connection with (i) the enforcement
by Landlord of any obligation of Tenant under this Lease; (ii) the preservation and enforcement of Landlord&rsquo;s rights and
remedies in connection with this Lease; (iii) any unsuccessful attempt by Tenant to enforce any obligation or purported obligation
of Landlord under this Lease; (iv) any unsuccessful action or proceeding brought by Tenant against Landlord related to this Lease;
and (v) any voluntary or involuntary bankruptcy case, proceeding or action by or on behalf of Tenant, including, without limiting
the generality of the foregoing, any and all expenses and attorneys&rsquo; fees incurred by Landlord related to (A) the assumption
or rejection of this Lease, including attempts by Tenant to extend any deadlines related to such assumptions or rejections; (B)
the filing of proof(s) of claim by Landlord, and any defense of such proof(s) of claim; (C) the assignment of this Lease; and (D)
the reorganization or liquidation of Tenant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase"><U>ARTICLE
20</U></FONT><BR>
<BR>
<U>M<FONT STYLE="text-transform: uppercase">ISCELLANEOUS</FONT></U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">20.1 <U>WAIVER</U>.
Failure on the part of Landlord or Tenant to complain of any action or non-action on the part of the other, no matter how long
the same may continue, shall never be a waiver by Tenant or Landlord, respectively, of any of the other&rsquo;s rights hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">No waiver by Landlord
of any condition precedent to the execution or effectiveness of this Lease, nor any failure by Tenant to deliver any security deposit,
letter of credit, pre-paid rent, financial information, guaranty or other item required upon the execution and delivery of this
Lease, shall be construed as excusing satisfaction of any such condition or the delivery of any such item by Tenant, and Landlord
reserves the right to declare the failure of Tenant to satisfy any such condition or deliver any such item a default under this
Lease. Without limiting the foregoing, in no event shall Tenant be permitted to move into the Premises for the conduct of its business
unless Tenant has delivered any security deposit, letter of credit, pre-paid rent, and/or guaranty required under this Lease. Further,
no waiver at any time of any of the provisions hereof by Landlord or Tenant shall be construed as a waiver of any of the other
provisions hereof, and a waiver at any time of any of the provisions hereof shall not be construed as a waiver at any subsequent
time of the same provisions. The consent or approval of Landlord or Tenant to or of any action by the other requiring such consent
or approval shall not be construed to waive or render unnecessary Landlord&rsquo;s or Tenant&rsquo;s consent or approval to or
of any subsequent similar act by the other.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 81; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">No payment by Tenant,
or acceptance by Landlord, of a lesser amount than shall be due from Tenant to Landlord shall be treated otherwise than as a payment
on account. The acceptance by Landlord of a check for a lesser amount with an endorsement or statement thereon, or upon any letter
accompanying such check, that such lesser amount is payment in full, shall be given no effect, and Landlord may accept such check
without prejudice to any other rights or remedies which Landlord may have against Tenant. Further, the acceptance by Landlord
of Annual Fixed Rent, Additional Rent or any other charges paid by Tenant under this Lease shall not be or be deemed to be a waiver
by Landlord of any default by Tenant, whether or not Landlord knows of such default, except for such defaults as to which such
payment relates and then only to the extent of the amount of such payment. If Landlord and Tenant shall now or hereafter enter
into any agreement for the renewal of this Lease at the expiration of the Lease Term, the execution of such renewal agreement
between Landlord and Tenant prior to the expiration of the Lease Term shall not be considered a vested right in Tenant to such
further term so as to prevent Landlord from terminating this Lease and any such extension or renewal thereof if Landlord became
entitled so to do during the remainder of the original Lease Term; and if Landlord shall so terminate this Lease, any such renewal
or extension previously entered into between Landlord and Tenant or the right of Tenant to any such renewal or extension shall
also be terminated thereby. Any right herein contained on the part of Landlord to terminate this Lease shall continue during any
extension or renewal hereof and any default or Event of Default which occurs and is not cured prior to the commencement of a renewal
term or extension of the Lease Term shall continue as such in and during such renewal term or extension of the Lease Term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">20.2 <U>CONSENTS</U>.
Wherever in this Lease Landlord&rsquo;s consent or approval is required and Landlord has expressly agreed in writing that such
consent or approval shall not be unreasonably withheld, if Landlord shall refuse such consent or approval Tenant in no event shall
be entitled to and shall not make any claim, and Tenant hereby waives any claim, for money damages (nor shall Tenant claim any
money damages by way of set-off, counterclaim or defense) based upon any assertion by Tenant that Landlord unreasonably withheld
or unreasonably delayed its consent or approval. Tenant&rsquo;s sole remedy in such circumstance shall be an action or proceeding
to enforce any such provision by way of specific performance, injunction or declaratory judgment. Where Landlord has not so expressly
agreed in writing, it is the express intent of the parties that any such consent shall be given or required only in the sole, absolute
and unfettered discretion of Landlord, and may be withheld for any reason whatsoever.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">20.3 <U>QUIET ENJOYMENT</U>.
Landlord agrees that, upon Tenant&rsquo;s paying the Annual Fixed Rent, Additional Rent and other charges herein reserved, and
performing and observing the covenants, conditions and agreements hereof upon the part of Tenant to be performed and observed,
Tenant shall and may peaceably hold and enjoy the Premises during the term of this Lease, without interruption or disturbance from
Landlord or persons claiming through or under Landlord, subject, however, to the terms of this Lease and to the terms and conditions
of all Underlying Leases and all mortgages which now or hereafter affect the Premises. This covenant shall be construed as running
with the Land to and against subsequent owners and successors in interest, and is not, nor shall it operate or be construed as,
a personal covenant of Landlord, except to the extent of Landlord&rsquo;s interest in the Land and Building, and this covenant
and any and all other covenants of Landlord contained in this Lease shall be binding upon Landlord and upon such subsequent owners
and successors in interest of Landlord&rsquo;s interest under this Lease, to the extent of their respective interests in the Land
and Building, as and when they shall acquire same and then only for so long as they shall retain such interest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 82; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">20.4 <U>SURRENDER</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">(a) No act or thing
done by Landlord during the Lease Term shall be deemed an acceptance of a surrender of the Premises, and no agreement to accept
such surrender shall be valid, unless in writing signed by Landlord. No employee of Landlord or of Landlord&rsquo;s agents shall
have any power to accept the keys of the Premises prior to the termination of this Lease; provided, however, that the foregoing
shall not apply to the delivery of keys to Landlord or its agents in its (or their) capacity as managing agent or for purpose of
emergency access. In any event, however, the delivery of keys to any employee of Landlord or of Landlord&rsquo;s agents shall not
operate as a termination of this Lease or a surrender of the Premises.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">(b) Upon the expiration
or earlier termination of the Lease Term, or upon any re-entry by Landlord of the Premises, Tenant shall quit and surrender the
Premises to Landlord vacant, broom clean and in good order, condition and repair, except for ordinary wear and tear, damage by
fire or other casualty, if any, and other conditions requiring repair, if any, which are not the obligation of Tenant to repair
under the terms of this Lease, and Tenant shall remove all of Tenant&rsquo;s Property therefrom and shall restore the Premises
to the extent required under any of the other provisions of this Lease. Tenant shall repair any damage to the Premises occasioned
by the removal by Tenant or any person claiming under Tenant of any of Tenant&rsquo;s Property and any Specialty Alterations required
to be removed pursuant to this Lease. At Landlord&rsquo;s option, Tenant shall also remove all wiring and cabling located in the
Premises including, without limitation, those located in the ceiling plenums. Tenant&rsquo;s obligations pursuant to this paragraph
shall survive the expiration or sooner termination of the Lease Term. Tenant expressly waives, for itself and for anyone claiming
through or under Tenant, any rights which Tenant may have under the provisions of Section 2201 of the New York Civil Practice Law
and Rules and of any successor law of like import then in force in connection with any holdover summary proceedings which Landlord
may institute to enforce the foregoing provisions of this paragraph.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">20.5 <U>BROKER</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">(a) Tenant warrants
and represents that Tenant has not dealt with any broker in connection with the consummation of this Lease other than the brokers,
persons or firms designated in Section 1.2 hereof. In the event any claim is made against Landlord by any other broker or agent
alleging dealings with Tenant, Tenant shall defend Landlord against such claim, using counsel approved by Landlord, such approval
not to be unreasonably withheld, and save harmless and indemnify Landlord on account of any loss, cost, damage and expense (including,
without limitation, reasonable attorneys&rsquo; fees and disbursements) which may be suffered or incurred by Landlord by reason
of such claim. Landlord agrees that it shall be solely responsible for the payment of brokerage commissions to the brokers, persons
or firms designated in Section 1.2 hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">(b) Landlord warrants
and represents that Landlord has not dealt with any broker in connection with the consummation of this Lease other than the brokers,
persons or firms designated in Section 1.2 hereof. In the event any claim is made against Tenant by any broker or agent alleging
dealings with Landlord, Landlord shall defend Tenant against such claim, using counsel approved by Tenant, such approval not to
be unreasonably withheld, and save harmless and indemnify Tenant on account of any loss, cost, damage and expense (including,
without limitation, reasonable attorneys&rsquo; fees and disbursements) which may be suffered or incurred by Landlord by reason
of such claim.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 83; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">20.6 <U>INVALIDITY
OF PARTICULAR PROVISIONS</U>. If any term or provision of this Lease, or the application thereof to any person or circumstance,
shall to any extent be invalid or unenforceable, the remainder of this Lease, or the application of such term or provision to persons
or circumstances other than those as to which it is held invalid or unenforceable, shall not be affected thereby, and each term
and provision of this Lease shall be valid and be enforced to the fullest extent permitted by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">20.7 <U>PROVISIONS
BINDING, ETC</U>. The obligations of this Lease shall run with the Land, and except as herein otherwise provided, the terms hereof
shall be binding upon and shall inure to the benefit of the successors and assigns, respectively, of Landlord and Tenant and, if
Tenant shall be an individual, upon and to his heirs, executors, administrators, successors and assigns. The reference contained
herein to successors and assigns of Tenant is not intended to constitute a consent to assignment by Tenant, but has reference only
to those instances in which Landlord may hereafter give consent to a particular assignment as required by the provisions of Article
13 hereof. This Lease shall be construed as though the covenants herein between Landlord and Tenant are independent and not dependent
and Tenant hereby expressly waives the benefit of any law to the contrary. Except as otherwise set forth in this Lease, the obligations
of Landlord and Tenant under this Lease shall not survive the expiration or sooner termination of this Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">20.8 <U>NO RECORDING</U>.
Tenant agrees not to record this Lease (whether directly or indirectly), or a memorandum or short form of this Lease or any other
document related thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">20.9 <U>NOTICES</U>.
Whenever, by the terms of this Lease, any notice, demand, request, approval, consent or other communication (each of which shall
be referred to as a &ldquo;notice&rdquo;) shall or may be given either to Landlord or to Tenant, such notice shall be in writing
and shall be deemed sufficiently given or rendered if (i) hand delivered, or (ii) sent by certified or registered United States
mail, postage prepaid, return receipt requested, or (iii) sent by reputable overnight delivery service, such as UPS or FedEx, as
follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">(i) If intended for Landlord,
addressed to Landlord at the Present Mailing Address of Landlord set forth on the first page of this Lease (or to such other address
or addresses as may from time to time hereafter be designated by Landlord by like notice), Attention: Karen Noy, with a copy to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: left; text-indent: 0in">Vinson &amp;
Elkins LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: left; text-indent: 0in">The Grace Building</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: left; text-indent: 0in">1114 Avenue
of the Americas</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: left; text-indent: 0in">New York, New
York 10036</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: left; text-indent: 0in">Attention:
Adam M. Endick, Esq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in"></P>

<!-- Field: Page; Sequence: 84; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">(ii) If intended for
Tenant, addressed to Tenant at the Present Mailing Address of Tenant set forth on the first page of this Lease until the date that
Tenant occupies the Premises for the conduct of its business, and thereafter at the Premises, Attention: Blaine Davis, CFO, with
a copy to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: left; text-indent: 0in">Cooley LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: left; text-indent: 0in">55 Hudson Yards</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: left; text-indent: 0in">New York, New
York 10001</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: left; text-indent: 0in">Attention:
Daniel A. Goldberger, Esq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">In no event shall the
validity of any notice actually given to Landlord or Tenant be affected by any failure to deliver copies of such notices to counsel
as hereinabove provided. Any notice to be given by any party may be given by such party&rsquo;s attorney. Notwithstanding anything
to the contrary contained herein, rent bills and statements regarding Taxes and Operating Expenses shall be deemed sufficiently
given or rendered if sent by regular United States mail.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">20.10 <U>WHEN LEASE
BECOMES BINDING</U>. Employees or agents of Landlord have no authority to make or agree to make a lease or any other agreement
or undertaking in connection herewith. The submission of this document for examination and negotiation does not constitute an offer
to lease, or a reservation of, or option for, the Premises, and this document shall become effective and binding only upon the
execution and delivery hereof by both Landlord and Tenant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">20.11 <U>HEADINGS</U>.
The Article and Section headings throughout this Lease and the Table of Contents hereof are for convenience and reference only,
and the words contained therein shall in no way be held to explain, modify, amplify or aid in the interpretation, construction
or meaning of the provisions of this Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">20.12 <U>SUSPENSION
OF SERVICES</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">(a) Landlord reserves
the right to interrupt, curtail or suspend the services required to be furnished by Landlord under Section 7.3 and Exhibit D when
the necessity therefor arises by reason of accident, repairs, emergency, mechanical breakdown or governmental preemption or restriction,
or when required by any law, order or regulation of any Federal, State, County or municipal authority, or as the result of the
making by Landlord of any additions, improvements or installations in the Building or for any cause beyond the reasonable control
of Landlord. Landlord shall use reasonable diligence to complete all required repairs or other necessary work as quickly as reasonably
possible so that Tenant&rsquo;s inconvenience resulting therefrom may be for as short a period of time as circumstances will reasonably
permit. No diminution or abatement of rent or other compensation shall or will be claimed by Tenant as a result of, nor shall this
Lease or any of the obligations of Tenant be affected or reduced by reason of, any such interruption, curtailment or suspension.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">(b) Provided no Event
of Default exists, if for any reason other than (i) the negligence, willful misconduct, breach of the provisions of this Lease
or violation of law by Tenant Parties or (ii) on account of Force Majeure, Landlord shall fail to supply services, perform repairs
or maintenance, provide access or comply with Laws, in any case which Landlord is obligated under the terms of this Lease to supply,
perform, provide or comply with, for more than ten (10) consecutive Operating Days after written notice thereof is delivered by
Tenant to Landlord, and as a result of such failure the Premises is rendered Untenantable, then, as Tenant&rsquo;s sole and exclusive
remedy, Tenant&rsquo;s obligation to pay Annual Fixed Rent shall be abated on a pro rata basis, from and after the eleventh (11th)
Operating Day after such notice to Landlord until such until such condition is cured or Tenant recommences use or occupancy of
such portion of the Premises. &ldquo;Untenantable&rdquo; means that Tenant shall be unable to occupy and use the Premises (including
due to lack of access) for the ordinary conduct of Tenant&rsquo;s business, and that Tenant shall actually not be occupying or
using the Premises or the applicable portion thereof for any use (other than emergency access).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 85; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">20.13 <U>RULES AND
REGULATIONS</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">(a) Landlord shall
have the right, from time to time during the term of this Lease, to make reasonable and non-discriminatory changes in, and reasonable
and non-discriminatory additions to, the rules and regulations set forth in Exhibit E, provided that such changes or additions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 1.5in">(i) shall
be similar to rules and regulations of comparable first-class office, laboratory and research buildings,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 1.5in">(ii) shall
not apply to matters other than matters similar to those covered in the rules and regulations set forth in Exhibit E, and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 1.5in">(iii) do
not unreasonably interfere with the use of the Premises by Tenant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">Said rules and regulations,
as the same may be modified in accordance with this Section from time to time, are hereinafter called the &ldquo;Rules and Regulations&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">(b) Landlord shall
have the right, from time to time during the term of this Lease, to promulgate reasonable and non-discriminatory rules and regulations
with respect to the use and operation of the laboratories in the Building, provided that such rules and regulations shall be similar
to laboratory rules and regulations of comparable first-class office, laboratory and research buildings, and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">Said rules and regulations,
as the same may be modified from time to time, are hereinafter called the &ldquo;Lab Rules and Regulations&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">(c) The right to dispute
the reasonableness of any change in the Rules and Regulations or the Lab Rules and Regulations upon Tenant&rsquo;s part, or the
non-discriminatory nature of any such change in the Rules and Regulations or the Lab Rules and Regulations or their enforcement,
shall be deemed waived unless the same is asserted by service of a notice upon Landlord within thirty (30) days after notice is
given to Tenant of the adoption of any such change.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">(d) Nothing in this
Lease shall be construed to impose upon Landlord any duty or obligation to enforce the Rules and Regulations or the Lab Rules and
Regulations or terms, covenants or conditions in any other lease against any other tenant. Landlord shall not be liable to Tenant
for violation of the Rules and Regulations or the Lab Rules and Regulations or of any other lease by other tenants or occupants
of the Building, or their servants, agents, visitors or licensees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 86; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">(e) If any inconsistencies
between this Lease and any Rules and Regulations (now existing or hereafter adopted) or Lab Rules and Regulations (now existing
or hereafter adopted) shall be determined to exist, the provisions of this Lease shall prevail.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">20.14 <U>DEVELOPMENT
RIGHTS</U>. Tenant hereby expressly and irrevocably waives any and all right(s) it may have in connection with any zoning lot merger
or transfer of development rights with respect to the Premises including, without limitation, any rights it may have to be a party
to, to contest, or to execute, any Declaration of Restrictions (as such term is defined in Section 12-10 of the Zoning Resolution
of the City of New York effective December 15, 1961 and as subsequently amended) with respect to the Premises, which would cause
the Premises to be merged with or unmerged from any other zoning lot pursuant to such Zoning Resolution or to any document of a
similar nature and purpose, and Tenant agrees that this Lease shall be subject and subordinate to any Declaration of Restrictions
or any other document of similar nature and purpose now or hereafter affecting the Property. In confirmation of such subordination
and waiver, Tenant shall execute and deliver promptly any certificate or instrument that Landlord reasonably may request and, in
connection therewith, Tenant hereby irrevocably constitutes and appoints Landlord as Tenant&rsquo;s attorney-in-fact to execute
any such certificate or instrument for and on behalf of Tenant, such power of attorney being coupled with an interest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">20.15 <U>ESTOPPEL
CERTIFICATES</U>. Each party agrees, at any time and from time to time, as reasonably requested by the other party, upon not less
than ten (10) days&rsquo; prior notice, to execute and deliver to the other a written certified statement executed and acknowledged
by an appropriate individual representing such party (a) stating that this Lease is then in full force and effect and has not
been modified (or if modified, setting forth all modifications), (b) setting forth the then Annual Fixed Rent and Additional Rent,
(c) setting forth the date to which the Annual Fixed Rent, Additional Rent and other charges, if any, have been paid, (d) stating
whether or not, to the best knowledge of the signatory, the other party is in default under this Lease, and if so, setting forth
the specific nature of all such defaults, (e) stating the amount of the security deposit, if any, held by Landlord under this
Lease, (f) stating whether there are any subleases affecting the Premises, (g) stating the address of the person to which all
notices and communication under this Lease shall be sent, (h) stating the Commencement Date, the Rent Commencement Date and the
Expiration Date, (i) if applicable, stating whether or not there are any amounts of contribution by Landlord towards the cost
of Tenant&rsquo;s work not yet advanced to Tenant, (j) stating what portion of the Premises Tenant is in possession and occupancy
of pursuant to this Lease, (k) if applicable, all work required to be completed by Landlord in connection with preparing the Premises
for Tenant&rsquo;s initial occupancy has been completed by Landlord, and (l) as to any other matters reasonably requested by the
party requesting such certificate. The parties acknowledge that any statement delivered pursuant to this Section 20.15 may be
relied upon by others with whom the party requesting such certificate may be dealing, which may, for Landlord, include, without
limitation, any purchaser or owner of the Land or the Building, or of Landlord&rsquo;s interest (directly or indirectly) in the
Land or the Building or any Underlying Lease, or by any Mortgagee or Overlandlord, or by any purchaser of the interest of any
Mortgagee or Overlandlord (directly or indirectly) in the Land or the Building, or by any prospective or actual sublessee of the
Premises or assignee of this Lease, or permitted transferee of or successor to Tenant. Together with its response to each such
request hereunder, Tenant shall provide to Landlord a similar written statement certified to Landlord with respect to each sublease
or other occupancy agreement from every subtenant and other occupant of the Premises.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 87; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">20.16 <U>SELF-HELP</U>.
Landlord may, but shall not be obligated to, cure, at any time, upon reasonable notice given to Tenant (except in any emergency
where no such notice shall be required), any default by Tenant under this Lease without waiving or releasing Tenant from any obligations
of Tenant in this Lease contained. All costs and expenses incurred by Landlord in curing a default, including, without limitation,
attorneys&rsquo; fees, together with interest on the amount of costs and expenses so incurred at the Lease Interest Rate, shall
be paid by Tenant to Landlord on demand, and shall be recoverable as Additional Rent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">20.17 <U>HOLDING OVER</U>.
If Tenant remains in possession of the Premises after the expiration or other termination of the Lease Term, then, at Landlord&rsquo;s
option, Tenant shall be deemed to be occupying the Premises as a month-to-month tenant only, at a monthly rental equal to (i) for
the first thirty (30) days of such holding over, the greater of (a) one hundred fifty percent (150%) of the Annual Fixed Rent and
any Additional Rent payable hereunder during the last month of the Lease Term and (b) one hundred fifty percent (150%) of the then
current market rent for the Premises and (ii) thereafter, the greater of (a) two hundred percent (200%) of the Annual Fixed Rent
and any Additional Rent payable hereunder during the last month of the Lease Term and (b) two hundred percent (200%) of the then
current market rent for the Premises, and otherwise on the terms and conditions set forth in this Lease, as far as applicable.
Tenant shall also pay all Additional Rent payable under the terms of this Lease, prorated for each month during which Tenant remains
in possession. Such month-to-month tenancy may be terminated by Landlord effective as of the last day of any calendar month by
delivery to Tenant of notice of such termination prior to the first day of such calendar month. Landlord waives no rights against
Tenant by reason of accepting any holding over by Tenant and Tenant shall defend, indemnify and hold Landlord harmless from and
against any and all claims, losses and liabilities for damages resulting from failure to surrender possession within forty-five
(45) days after the Expiration Date, including, without limitation, any claims made by any succeeding tenant and any lost profits,
and such obligations shall survive the expiration or sooner termination of this Lease. The provisions of this Section 20.17 shall
not in any way be deemed to (i) permit Tenant to remain in possession of the Premises after the Expiration Date or sooner termination
of this Lease, or (ii) imply any right of Tenant to use or occupy the Premises upon expiration or termination of this Lease and
the Lease Term, and no acceptance by Landlord of payments from Tenant after the Expiration Date or sooner termination of the Lease
Term shall be deemed to be other than on account of the amount to be paid by Tenant in accordance with the provisions of this Section
20.17. Tenant&rsquo;s obligations under this Section 20.17 shall survive the expiration or earlier termination of this Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">20.18 <U>RENT CONTROL</U>.
If any of the Annual Fixed Rent or Additional Rent payable under the terms and provisions of this Lease shall be or become uncollectible,
reduced or required to be refunded because of the laws and requirements of any public authorities, Tenant shall enter into such
agreement(s) and take such other steps (without additional expense to Tenant) as Landlord may request and as may be legally permissible
to permit Landlord to collect the maximum rents which from time to time during the continuance of such legal rent restriction
may be legally permissible (and not in excess of the amounts reserved therefor under this Lease). Upon the termination of such
legal rent restriction, (a) the rent shall become and thereafter be payable in accordance with the amounts reserved herein for
the periods following such termination and (b) Tenant shall pay to Landlord, to the maximum extent legally permissible, an amount
equal to (i) the rent which would have been paid pursuant to this Lease but for such legal rent restriction, less (ii) the rent
actually paid by Tenant during the period such legal rent restriction was in effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 88; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">20.19 <U>COUNTERPARTS</U>.
This Lease may be executed in several counterparts, each of which shall be deemed an original, and such counterparts together shall
constitute but one and the same instrument.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">20.20 <U>ENTIRE AGREEMENT</U>.
This Lease (including the Exhibits attached hereto and all supplementary agreements provided for herein) constitutes the entire
agreement between the parties hereto and supersedes all prior dealings between them, and all negotiations, considerations, representations
and understandings between Landlord and Tenant are merged herein. There are no verbal or collateral understandings, agreements,
representations or warranties not expressly set forth in this Lease. No act or omission of any employee or agent of Landlord shall
alter, change or modify any of the provisions hereof, and no subsequent alteration, amendment, change or addition to this Lease
shall be binding upon Landlord or Tenant, unless reduced to writing and signed by the party or parties to be charged therewith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">20.21 <U>NO PARTNERSHIP</U>.
The relationship of the parties hereto is that of landlord and tenant and no partnership, joint venture or participation is hereby
created.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">20.22 <U>SECURITY DEPOSIT</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(a) Upon execution
by Tenant of this Lease, Tenant shall deposit (the &ldquo;Cash Deposit&rdquo;) with Landlord, in cash, an amount equal to the
Security Deposit as security for the performance by Tenant of all obligations on the part of Tenant hereunder. Within <FONT STYLE="font-size: 10pt">[***] </FONT>days
after the date hereof, Tenant shall furnish to Landlord, at Tenant&rsquo;s sole cost and expense, a clean, irrevocable and
unconditional letter of credit (the &ldquo;Letter of Credit&rdquo;) drawn in favor of Landlord substantially in the form
attached hereto as Exhibit F, and Landlord, within <FONT STYLE="font-size: 10pt">[***]</FONT> Operating Days after receipt of
the Letter of Credit, shall return to Tenant any portion of the Cash Deposit then held by Landlord. The Letter of Credit
shall have a face amount equal to the amount of the Security Deposit and shall be assignable, upon request, to any
Overlandlord, Mortgagee or successor to Landlord at no additional charge to Landlord. Any Letter of Credit which replaces the
initial Letter of Credit delivered hereunder is referred to as a &ldquo;Replacement Letter&rdquo;. Any Replacement Letter
shall be in a face amount at least equal to the Security Deposit then required hereunder. The initial Letter of Credit and
any Replacement Letter are herein sometimes referred to simply as a &ldquo;Letter&rdquo;. Each Letter shall be issued by and
drawn on a commercial bank acceptable to Landlord in its reasonable discretion and at a minimum having a long-term issuer
credit rating from Standard &amp; Poor&rsquo;s Professional Rating Service of A or a comparable rating from Moody&rsquo;s
Professional Rating Service. If the issuer&rsquo;s credit rating is reduced below A, or if the financial condition of such
issuer changes in any other materially adverse way, then Landlord shall have the right to require that Tenant obtain from a
different issuer a Replacement Letter that complies in all respects with the requirements of this Section within <FONT STYLE="font-size: 10pt">[***]</FONT>
days following Landlord&rsquo;s written demand. If the issuer of any Letter held by Landlord is placed into receivership or
conservatorship by the Federal Deposit Insurance Corporation or any successor or similar entity then, effective as of the
date such receivership or conservatorship occurs, said Letter shall be deemed not to meet the requirements of this Section,
and Tenant shall obtain from a different issuer a Replacement Letter that complies in all respects with the requirements of
this Section within <FONT STYLE="font-size: 10pt">[***]</FONT> days following the date such receivership or conservatorship
occurs. In any event, Tenant shall, not later than <FONT STYLE="font-size: 10pt">[***] </FONT>days prior to the expiration of
the term of the initial Letter of Credit or any Replacement Letter, deliver to Landlord a Replacement Letter such that a
Letter shall be in effect at all times after the date of this Lease until <FONT STYLE="font-size: 10pt">[***] </FONT>days
beyond the end of the Lease Term, and any extensions or renewals thereof, and thereafter so long as Tenant is in occupancy of
any part of the Premises. If Tenant fails to deliver to Landlord a Replacement Letter within the time limits set forth in
this Section, Landlord may, without limiting Landlord&rsquo;s other rights or remedies on account of such failure, draw down
the full amount of the existing Letter without notice or demand and retain and apply the proceeds thereof as substitute
security subject to the provisions of this Section. Tenant shall be responsible for the payment of any and all costs incurred
with the review of any Replacement Letter (including without limitation Landlord&rsquo;s reasonable attorneys&rsquo; fees).
Any and all fees or costs charged by the issuer in connection with the issuance, maintenance or transfer of the Letter shall
be paid by Tenant. If a Letter is lost, mutilated, stolen, or destroyed, Tenant shall cooperate with Landlord to have the
Letter replaced. The Security Deposit (whether a Letter, cash or other collateral) will not operate as a limitation on any
recovery to which Landlord may be entitled.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 89; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(b) Landlord shall hold
the Cash Deposit or Letter as security for the performance by Tenant of all obligations on the part of Tenant hereunder. If Tenant
defaults in respect of any of Tenant&rsquo;s obligations hereunder, including but not limited to payment of Annual Fixed Rent or
Additional Rent, or if Tenant remains in occupancy of any part of the Premises beyond the expiration of the Lease Term, Landlord
shall have the right from time to time, without notice and without prejudice to any other remedy Landlord may have on account thereof,
and upon presentation of a certificate of demand, to draw upon the Cash Deposit or any Letter and apply any funds so drawn to Landlord&rsquo;s
damages arising from, or to cure, any default by Tenant, whether such damages accrue before or after summary proceedings or other
reentry by Landlord. If Landlord shall so apply any funds, Tenant shall, within <FONT STYLE="font-size: 10pt">[***]</FONT> days
following Landlord&rsquo;s written demand, restore the Cash Deposit or Letter to the face amount required hereunder or obtain a
Replacement Letter. Landlord shall have the right to hold and draw upon the Cash Deposit or Letter pursuant hereto until <FONT STYLE="font-size: 10pt">[***]</FONT>
days after (i) the expiration of the Lease Term (or the applicable extension or renewal period, if any) or (ii) the date Tenant
has vacated the Premises, whichever is later. If there then exists no default by Tenant in any of the terms or conditions hereof,
Landlord shall return the Letter, or, if applicable, the remaining proceeds thereof, to Tenant. If Landlord conveys Landlord&rsquo;s
interest under this Lease, the Cash Deposit, any Letter or, if applicable, the proceeds thereof, shall be turned over and assigned
by Landlord to Landlord&rsquo;s grantee (or, at Landlord&rsquo;s election, with respect to any Letter, Tenant shall furnish Landlord&rsquo;s
successor with a new Replacement Letter showing such successor as payee, provided that the original Letter then outstanding shall
be simultaneously returned to Tenant). From and after any such transfer, assignment or return, Tenant agrees to look solely to
such grantee for proper application of the funds in accordance with the terms of this Section and the return thereof in accordance
herewith. No Overlandlord or Mortgagee shall be responsible to Tenant for the return or application of the Cash Deposit, any Letter,
or, if applicable, the proceeds thereof, whether or not it succeeds to the position of Landlord hereunder, unless such Cash Deposit
or Letter shall have been received in hand by, and assigned to, such Overlandlord or Mortgagee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(c) On the <FONT STYLE="font-size: 10pt">[***]</FONT>
anniversary of the Rent Commencement Date (the &ldquo;Burn Down Date&rdquo;), provided (i) no Event of Default shall then exist
and (ii) Tenant shall then have liquid assets and a tangible net worth, determined in accordance with GAAP, no less than Tenant&rsquo;s
liquid assets and tangible net worth so determined as of the date hereof (the foregoing conditions set forth in clauses (i) and
(ii) being herein referred to as the &ldquo;Burn Down Conditions&rdquo;), Tenant shall have the right to reduce the amount of the
Security Deposit (by delivery of a Replacement Letter or an amendment to the existing Letter) to an amount (the &ldquo;Burn Down
Amount&rdquo;) equal to <FONT STYLE="font-size: 10pt">[***]</FONT> monthly installments of the then current Annual Fixed Rent (it
being acknowledged and agreed that the foregoing amounts described apply with respect to the Premises prior to the exercise of
the Expansion Option and shall be adjusted as applicable after any exercise of the same). Landlord shall cooperate reasonably with
Tenant to effect such reductions of the amount of the Letter of Credit. If on any Burn Down Date Tenant shall not have the right
to reduce the Security Deposit due to the Burn Down Conditions not being satisfied, if the Burn Down Conditions subsequently become
satisfied, then upon such satisfaction (and provided no Event of Default shall then exist), Tenant shall have the right to reduce
the Security Deposit to the Burn Down Amount.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 90; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">20.23 <U>FINANCIAL STATEMENTS</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(a) Tenant represents
and warrants to Landlord that (i) the financial statements of Tenant heretofore delivered to Landlord are true and correct and
fairly reflect the financial condition and results of operation of Tenant and (ii) as of the date of this Lease, there has been
no material adverse change in the condition, financial or otherwise, of Tenant from the date of such financial statements which
could affect Tenant&rsquo;s ability to perform its obligations hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(b) During the Lease
Term, within ninety (90) days following the end of Tenant&rsquo;s fiscal year and, from time to time, within ten (10) days after
request from Landlord, Tenant shall deliver to Landlord a copy of Tenant&rsquo;s financial statements for Tenant&rsquo;s fiscal
year just ended, certified by an independent certified public accountant as presenting fairly, in all material respects, the financial
condition of Tenant and the results of its operations in accordance with GAAP; provided, however, that the foregoing shall be deemed
satisfied if Tenant instead delivers to Landlord, annually, at the time the same is sent to Tenant's stockholders, a copy of Tenant's
Annual Report to Stockholders in the form filed with the Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(c) Any financial statements
delivered by Tenant to Landlord, whether before or after the date of this Lease, may be delivered to and relied upon by any Overlandlord
or Mortgagee or by other parties with whom Landlord may be dealing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">20.24 <U>GOVERNING
LAW, ETC</U>. This Lease shall be governed by the laws of the State of New York applicable to agreements made and to be wholly
performed within the State, as the same may from time to time exist. Landlord and Tenant agree that any claim or action relating
to this Lease shall be brought and maintained exclusively in a state or federal court located in the Borough of Manhattan, State
of New York, United States of America, and Tenant hereby submits to the jurisdiction of all such state and federal courts and
waives any right to assert that such courts constitute an inconvenient forum. Tenant represents that it is not entitled to immunity
from judicial proceedings and agrees that, in the event Landlord brings any suit, action or proceeding in New York or any other
jurisdiction to enforce any obligation or liability of Tenant arising, directly or indirectly, out of or relating to this Lease,
no immunity from such suit, action or proceedings will be claimed by or on behalf of Tenant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 91; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">20.25 <U>CONDOMINIUM
CONVERSION</U>. Landlord may elect, at any time during the Term, to convert the Building to condominium ownership (a &ldquo;Conversion&rdquo;),
and Tenant, at Landlord&rsquo;s expense, shall cooperate with Landlord as reasonably requested by Landlord in connection with a
Conversion, provided that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(a) no Conversion shall
have the effect of increasing any charges payable by Tenant under this Lease (including, without limitation, Tenant&rsquo;s payments
with respect to Taxes or PILOT), in each case above the amounts as could reasonably have been anticipated to have been payable
in the absence of such Conversion and if any such increase shall result from such Conversion, then the amount of such increase
shall be borne by Landlord and not by Tenant;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(b) the obligations of
Landlord under this Lease shall, at Landlord&rsquo;s option, either (i) continue to be performed and observed by Landlord as set
forth herein, or (ii) shall have been assumed in writing by (A) the successor landlord with respect to obligations hereunder to
be performed within the Premises, and (B) the board of managers or equivalent governing body of the condominium association, with
respect to obligations hereunder affecting the Building and the Building systems outside of the Premises;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(c) no Conversion shall
in any other manner have the effect of (i) increasing Tenant&rsquo;s obligations or decreasing Tenant&rsquo;s rights, or (ii) decreasing
Landlord&rsquo;s obligations (subject to Section 25.25(b) hereof) or increasing Landlord&rsquo;s rights;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(d) the condominium declaration
shall, if permitted by law, expressly provide that this Lease is superior thereto in all respects (or if not so permitted, Tenant
shall be given a non-disturbance agreement reasonably satisfactory to Tenant); and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(e) no Conversion shall
have any effect on the payment of brokerage commissions in connection with this Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">20.26 <U>CONFIDENTIALITY
OF LEASE</U>. Tenant agrees that this Lease and the terms contained herein will be treated as strictly confidential and except
as required by law or the requirements of any securities, bond or commodities exchange applicable to Tenant, Tenant shall not disclose
the same to any third party except for Tenant&rsquo;s partners, lenders, accountants and attorneys who have been advised of the
confidentiality provisions contained herein and agree to be bound by the same. Except as regularly required by any securities,
bond or commodities exchange applicable to Tenant, in the event Tenant is required by law to provide this Lease or disclose any
of its terms, Tenant shall give Landlord prompt notice of such requirement prior to making disclosure so that Landlord may seek
an appropriate protective order. If failing the entry of a protective order Tenant is compelled to make disclosure, Tenant shall
only disclose portions of the Lease which Tenant is required to disclose and will exercise reasonable efforts to obtain assurance
that confidential treatment will be accorded to the information so disclosed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 92; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">20.27 <U>OFAC</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(a) As an inducement
to Landlord to enter into this Lease, Tenant hereby represents and warrants that: (i) Tenant is not, nor is it owned or controlled
directly or indirectly by, any person, group, entity or nation named on the Specially Designated Nationals and Blocked Persons
List maintained by the Office of Foreign Assets Control of the United States Treasury (&ldquo;OFAC&rdquo;) (any such person, group,
entity or nation being hereinafter referred to as a &ldquo;Prohibited Person&rdquo;); (ii) Tenant is not (nor is it owned or controlled,
directly or indirectly, by any person, group, entity or nation which is) acting directly or indirectly for or on behalf of any
Prohibited Person; and (iii) Tenant (and any person, group, or entity which Tenant controls, directly or indirectly) has not conducted
nor will conduct business nor has engaged nor will engage in any transaction or dealing with any Prohibited Person that either
may cause or causes Landlord to be in violation of any OFAC rule or regulation, including without limitation any assignment of
this Lease or any subletting of all or any portion of the Premises. In connection with the foregoing, it is expressly understood
and agreed that (x) any breach by Tenant of the foregoing representations and warranties shall be deemed a default by Tenant under
Section 19.1(e) of this Lease and shall be covered by the indemnity provisions of Section 11.1 above, and (y) the representations
and warranties contained in this subsection shall be continuing in nature and shall survive the expiration or earlier termination
of this Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(b) As an inducement
to Tenant to enter into this Lease, Landlord hereby represents and warrants that: (i) Landlord is not, nor is it owned or controlled
directly or indirectly by, any person, group, entity or nation named on the Specially Designated Nationals and Blocked Persons
List maintained by OFAC; (ii) Landlord is not (nor is it owned or controlled, directly or indirectly, by any person, group, entity
or nation which is) acting directly or indirectly for or on behalf of any Prohibited Person; and (iii) Landlord (and any person,
group, or entity which Landlord controls, directly or indirectly) has not conducted nor will conduct business nor has engaged nor
will engage in any transaction or dealing with any Prohibited Person that either may cause or causes Landlord to be in violation
of any OFAC rule or regulation, including without limitation any assignment of this Lease or any subletting of all or any portion
of the Premises. In connection with the foregoing, it is expressly understood and agreed that (x) any breach by Landlord of the
foregoing representations and warranties shall be deemed a default by Landlord under Section 19.1(e) of this Lease and shall be
covered by the indemnity provisions of Section 11.1 above, and (y) the representations and warranties contained in this subsection
shall be continuing in nature and shall survive the expiration or earlier termination of this Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">20.28 <U>ELECTRONIC
SIGNATURES</U>. The parties acknowledge and agree that, subject to the terms of this paragraph, this Lease may be executed by electronic
signature, which shall be considered as an original signature for all purposes and shall have the same force and effect as an original
signature. &ldquo;Electronic signature&rdquo; shall mean faxed versions of an original signature or electronically scanned and
transmitted versions (i.e., email of a pdf) of an original signature and, absent contrary written instructions by the transmitting
party, the transmission of such an electronic signature by fax or email by one party hereto to the other party(ies) hereto shall
constitute execution and delivery of this Lease by the transmitting party. Any party hereto executing this Lease by electronic
signature shall promptly thereafter deliver such transmitting party&rsquo;s original signature to this Lease to the recipient party(ies),
but the failure to do so shall not affect the validity of this Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 93; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">20.29 <U>BUILDING NAME
AND SIGNAGE</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(a) The Building may
be designated and known by any name Landlord may choose and such designated name may be changed from time to time in Landlord&rsquo;s
sole discretion. Tenant shall have no right to require Landlord to change the name of the Building, whether in connection with
an assignment of this Lease or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(b) Tenant shall have
the right, at Tenant&rsquo;s sole cost and expense and in accordance with the provisions of Article 8 hereof, to install Building
standard signage on the entry doors to the Premises identifying the name of Tenant. Landlord shall provide directional signage
identifying Tenant in the elevator vestibule on the floor on which the Premises are located.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">20.30 <U>IDA PILOT
PROGRAM</U>. Tenant acknowledges that each of Landlord and Tenant derive substantial benefit from the Agency Lease. As a material
inducement to Landlord&rsquo;s entering into this Lease, Tenant hereby agrees to the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(a) On the date of this
Lease, Tenant shall deliver to Landlord the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: left; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(i)</TD><TD STYLE="text-align: left">A counterpart to the Rider to Tenant Lease Agreement
(the &ldquo;Rider&rdquo;) in the form attached hereto as Exhibit H; and,</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: left; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(ii)</TD><TD STYLE="text-align: left">A counterpart to the Living Wage Agreement (the &ldquo;LW
Agreement&rdquo;) in the form attached hereto as Exhibit I.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(b) Tenant shall indemnify,
defend and hold harmless Landlord Parties from and against any and all claims, damages, losses, actions, causes of actions, proceedings,
liens, fines, penalties, costs, expenses and liabilities, including, without limitation, additional tax liabilities, arising out
of (i) any &ldquo;Event of Default&rdquo; under the Agency Lease or any (ii) any claims made against Landlord by the IDA, the New
York City Economic Development Corporation, any successor thereof or any other agency of New York City, occasioned by or arising
out of any act or omission of Tenant including, without limitation, any act or omission resulting in a breach of any terms or conditions
of the Rider, the LW Agreement or this Lease (including, without limitation, Sections 10.1 or 18(i) hereof).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">20.31 <U>EMISSIONS</U>.
Tenant shall be responsible for its allocable share of the payment, within thirty (30) days after demand as Additional Rent, of
any portion of the fines, penalties and/or excess emissions charges incurred by Landlord in connection with applicable laws and
requirements of public authorities (including, without limitation, Local Law 97) attributable to the consumption of utilities serving
the Building in excess of the carbon or other emissions limit allocable to the Building (including, without limitation, Local Law
97), based on the Building&rsquo;s emissions limit in the aggregate for such calendar year in question. In addition to the foregoing,
in the event Landlord performs improvements to the Building required or designed to reduce emissions, the costs of such improvements
shall be included in Operating Expenses, notwithstanding anything contained in Article 6 above to the contrary, as amortized over
the useful life thereof in accordance with Section 6.2.1(x) hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 94; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">20.32 <U>REGULATORY
REQUIREMENTS</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(a) Tenant acknowledges
that Landlord&rsquo;s affiliate, <FONT STYLE="font-size: 10pt">[***] [***]</FONT>, is subject to certain securities industry rules
and regulations, including, but not limited to, regulatory obligations applicable to an investment adviser registered with the
U.S. Securities and Exchange Commission. For the term of this Agreement, Tenant will comply with all rules, policies and procedures
reasonably required, and will reasonably cooperate with the Landlord and its affiliates as Landlord and its affiliates deem necessary,
to fulfill their regulatory obligations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(b) Tenant acknowledges
that <FONT STYLE="font-size: 10pt">[***]</FONT> is subject to U.S. securities laws that make it unlawful for any person to (i)
purchase or sell the securities of a company as to which such person possesses material nonpublic information of the company (&ldquo;<U>MNPI</U>&rdquo;)
or (ii) disclose MNPI to another person under circumstances in which it is reasonably foreseeable that another person may purchase
or sell securities of a company on the basis of such MNPI. Tenant agrees to not convey any MNPI about an issuer to Landlord and
its affiliates absent a non-disclosure agreement with Landlord and/or its affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">20.33 <U>LAB AREA AND
LAB REQUIREMENTS</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(a) Tenant shall have
the right, subject to and in accordance with the terms of this Lease, to use certain of Landlord&rsquo;s furniture, fixtures, personal
property and systems designated by Landlord (collectively, the &ldquo;<U>Lab Systems</U>&rdquo;), from time to time located in
the Lab Area; provided, however, that Tenant shall use the Lab Systems in a manner that will not interfere with the rights of any
tenants or occupants in the Building or the providers of the services associated with the Lab Systems.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(b) Landlord&rsquo;s
sole obligation for providing the Lab Systems shall be (i) to provide the Lab Systems determined by Landlord in the exercise of
its sole and absolute discretion, and (ii) to contract with one or more third parties to maintain the Lab Systems that are deemed
by Landlord in the exercise of its sole and absolute discretion to need periodic maintenance in accordance with the manufacturer&rsquo;s
or supplier&rsquo;s standard guidelines or otherwise. During any period of replacement, repair or maintenance of the Lab Systems
when they are not operational (including, but not limited to, any delays thereto due to the inability to obtain parts or replacements),
Landlord shall have no obligation to provide Tenant with alternative, supplemental, temporary or back-up Lab Systems. Tenant acknowledges
and agrees that Landlord, in its sole and absolute discretion, may (i) reduce the Lab Area or Lab Systems from time to time in
response to a lack of usage by Tenant or obsolescence or similar reasons, (ii) increase, replace or otherwise modify the Lab Area
or Lab Systems and/or resources therein from time to time in response to the needs of Tenant or (iii) reconfigure, relocate or
otherwise modify the Lab Area and/or Lab Systems. Landlord shall have no liability for any such reduction, increase, replacement,
reconfiguration, relocation or modification of the Lab Area or Lab Systems, and none of the foregoing shall reduce the Annual Fixed
Rent payable by Tenant hereunder. Tenant acknowledges and agrees that any such increases, replacements, reconfigurations, relocations
or modifications may result in an increase in Lab Costs, and Tenant agrees to pay for any increases in Lab Costs resulting from
the same. The terms and provisions of this paragraph shall survive the expiration or earlier termination of this Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 95; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(c) Landlord makes no
representations or warranties of any kind, express or implied, with respect to the Lab Area or Lab Systems, and Landlord disclaims
any such representations or warranties. Without limiting the foregoing, Tenant expressly acknowledges and agrees that Landlord
does not guaranty or warrant that the Lab Systems will be operational at all times, will be of sufficient capacity to accommodate
Tenant&rsquo;s use thereof, will be free of Hazardous Substances, or will function or perform adequately, and Landlord shall not
be liable for any damages resulting from any failure of the Lab Systems.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(d) Landlord, for itself
and its employees, agents and contractors, reserves the right to refuse to perform any repairs or services in any portion of the
Premises which, pursuant to Tenant&rsquo;s routine safety guidelines, practices or custom, or prudent industry practices, require
any form of protective clothing or equipment other than safety glasses. In any such case, Tenant shall contract with parties who
are reasonably acceptable to Landlord for all such repairs and services, and Landlord shall, to the extent required, equitably
adjust Lab Costs in respect of such repairs or services to reflect that Landlord is not providing such repairs or services to Tenant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(e) If Tenant or any
Tenant Party uses the Lab Area or the Lab Systems, Tenant shall comply with (or cause to be complied with) all applicable federal,
state and local laws concerning any Regulated Medical Waste that Tenant or any subtenant or occupant of the Premises produces,
brings on, keeps, uses, stores, disposes or treats in or about the Premises or transported from the Premises. Tenant shall also
comply with all applicable federal, state and local laws related to the health and safety of its employees. &ldquo;Regulated Medical
Waste&rdquo; means any substance, gas, material or chemical, or any part thereof, which is defined or included in the definition
of &ldquo;regulated medical waste&rdquo; or words of similar import under any applicable laws and requirements of public authorities,
including, but not limited to, Section 27-1502 of the New York Environmental Conservation Law, 42 U.S.C. Section 6901 et seq.,
the Medical Waste Tracking Act of 1988 and Track XIII of the New York State Public Health Law and the regulations promulgated thereunder.
The terms and provisions of this paragraph shall survive the expiration or earlier termination of this Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(f) If Tenant or any
Tenant Party uses the Lab Area or the Lab Systems and Tenant defaults in its obligations under this Section 20.33 or Section 20.13(b)
hereof, Landlord shall have the right, in addition to any other rights and remedies available to Landlord pursuant to the terms
and conditions of this Lease, to terminate this Lease, in which event this Lease shall terminate on the date fixed in Landlord&rsquo;s
notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 96; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">20.34 <U>RIGHT OF FIRST
OFFER</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(a) Provided that at
the time of such exercise and on the date the space is delivered to Tenant (1) there exists no Event of Default that has occurred
and is then continuing, (2) this Lease is in full force and effect, and (3) Original Tenant is in actual occupancy of one hundred
percent (100%) of the rentable square feet of the Premises (collectively, the &quot;ROFO Conditions&quot;), then if at any time
balance of the 3rd floor of the Building becomes &quot;available for leasing&quot; or is anticipated to become &quot;available
for leasing&quot;, and Landlord desires to lease such space, Landlord shall (i) so notify Tenant (a &quot;ROFO Notice&quot;),
(ii) identify the space available (the &quot;Offered Space&quot;), (iii) set forth the date (the &quot;ROFO Delivery Date&quot;)
on which Landlord anticipates that the Offered Space can be leased pursuant to the exercise by Tenant of its rights under this
Section 20.34, which date shall be no sooner than thirty (30) days after the delivery of such ROFO Notice and (iv) set forth the
Fair Market Rent for the Offered Space determined by Landlord as of the date of the ROFO Notice (the &quot;ROFO Offer&quot;).
Original Tenant shall, within thirty (30) days after receipt of the ROFO Notice, by written notice (the &quot;ROFO Election Notice&quot;),
either (I) accept the ROFO Offer (and state in Tenant&rsquo;s notice whether Tenant accepts the Fair Market Rent specified by
Landlord in the ROFO Offer for the Offered Space or, if Tenant does not accept such Fair Market Rent, specify Tenant&rsquo;s determination
of the Fair Market Rent of the Offered Space), or (II) reject the ROFO Offer, it being understood that Tenant&rsquo;s failure
to respond to the ROFO Offer as aforesaid shall be deemed a rejection thereof. Any election by Tenant to accept or reject the
ROFO Offer shall be irrevocable. If Tenant fails to timely elect to exercise any option to lease any such Offered Space in accordance
with this <U>Section 20.34(a)</U>, then Tenant shall no longer be entitled to exercise the ROFO Option. Original Tenant's option
to lease Offered Space under this <U>Section 20.34</U> shall be referred to herein as the &quot;ROFO Option&quot;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(b) If Tenant accepts
a ROFO Offer, Tenant shall, within thirty (30) days, subject to the terms of clause (d) below, after such election enter into an
amendment to this Lease adding the Offered Space to the Premises and otherwise incorporating the terms contained in the ROFO Notice
(or if Tenant does not accept the Fair Market Rent specified by Landlord in the ROFO Offer, then such amendment shall be entered
into by Tenant within thirty (30) days after the date of the determination of the Fair Market Rent for the Offered Space as provided
in this <U>Section 20.34</U>); <U>provided</U>, <U>however</U>, that Landlord shall have no obligation to enter into such amendment
of this Lease, or make any such ROFO Offer, if at the time of entering into such amendment of this Lease, or making of such ROFO
Offer, the ROFO Conditions are not then met. If Tenant shall fail to enter into such an amendment to this Lease within such thirty
(30) day period and Landlord is willing to enter into such an amendment, then Tenant shall have no further rights under this <U>Section
20.34</U> with respect to the Offered Space (it being agreed that time is of the essence with respect to the giving of such notice
and the execution of such amendment), and Landlord shall be free to lease any or all of the Offered Space to a third party or parties
from time to time on such terms and conditions as it may deem appropriate. If Tenant accepts the ROFO Offer, the Offered Space
shall be delivered broom clean in its then &ldquo;AS IS&rdquo; condition (but free of any furniture and other personal property
of the prior tenant) without representation or warranty by Landlord. Landlord shall have no obligation to remove improvements made
to the Offered Space prior to delivery to Tenant, whether or not made by Landlord, nor shall Landlord have any obligation to prepare
the Offered Space for Tenant&rsquo;s occupancy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(c) If, within sixty
(60) days after receipt of the ROFO Notice, Landlord and Tenant fail to reach agreement on the determination of the Fair Market
Rent to be paid by Tenant for the Offered Space, then either Landlord or Tenant shall initiate the arbitration proceedings for
such determination by notice to the other, and by designating in such notice the name and address of a Qualified Arbitrator. Fair
Market Rent for any Offered Space shall be determined in the same fashion as FMV for the Premises during a Renewal Term is determined
pursuant to <U>Section 3.4.3</U> and the provisions of the <U>Section 3.4.3</U> for determining Fair Market Rent for the Premises
during a Renewal Term shall apply, <I>mutatis mutandis</I>, in respect of a determination of Fair Market Rent for the Offered Space.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 97; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(d) Notwithstanding
anything to the contrary contained herein, Annual Fixed Rent with respect to any Offered Space shall be equal to 100% of the
Fair Market Rent for the Offered Space. If, pursuant to the preceding provisions of this <U>Section 20.34</U>, the Fair
Market Rent for the Offered Space has not been determined as of the actual ROFO Delivery Date thereof, Tenant shall pay on
account of Annual Fixed Rent for the Offered Space Landlord's determination thereof until such final determination is made,
with necessary adjustments between Landlord and Tenant to be made retroactively, by credit against the next installment(s) of
Annual Fixed Rent becoming due with respect to the Offered Space, after a final determination of the Fair Market Rent for the
Offered Space as provided in this <U>Section 20.34</U>. Annual Fixed Rent with respect to the Offered Space shall commence to
be payable on the actual ROFO Delivery Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(e) Notwithstanding anything
to the contrary contained herein, Tenant may only exercise the ROFO Option if (A) Landlord then intends to market the Offered Space
after the initial lease-up thereof, (B) Tenant exercises its option to lease all of the Offered Space under this <U>Section 20.34</U>
that Landlord so intends to market (unless Landlord specifies in the ROFO Notice that Landlord is marketing portions the Offered
Space in separate segments) and (C) the Offered Space is contiguous to the Premises. The term of the leasing of the Offered Space
shall be coterminous with the then current Term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(f) In the event Landlord
fails or is unable to deliver the entire Offered Space to Tenant on the estimated ROFO Delivery Date thereof as a result of the
holding over of the prior tenant or for any other reason (other than Landlord&rsquo;s willful refusal to deliver possession thereof
to Tenant after such space has been vacated by the prior tenant thereof), Landlord shall not be subject to any liability whatsoever
for such failure or inability to deliver possession, and the exercise of the ROFO Option shall remain effective, but the Annual
Fixed Rent and Additional Rent shall not commence with respect to the Offered Space until the date on which the same is actually
delivered to Tenant. The foregoing is intended to be &ldquo;an express provision to the contrary&rdquo; under Section 223-a of
the New York Real Property Law or any successor statute of similar import.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(g) As used in this <U>Sections
20.34</U>, the term &quot;<U>available for leasing</U>&quot; shall mean that Landlord reasonably anticipates that such space shall
be available for Tenant to lease in accordance with the terms of this <U>Section 20.34</U> after the expiration or earlier termination
of the initial lease with respect to such space. Notwithstanding the foregoing, Tenant's rights under this <U>Sections 20.34</U>
shall be subject and subordinate to (A) any option or commitment hereafter held by any existing or future tenant with respect to
the Offered Space or any portion thereof and (B) the renewal or extension of an expiring lease with any such tenant with respect
to the Offered Space.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(h) Notwithstanding anything
to the contrary contained herein, Tenant shall not have any ROFO Option during the final five (5) years of the Term unless, simultaneously
with the exercise of the ROFO Option, Tenant also exercises the Renewal Option, if then available.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">Signatures on next page.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 98; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">EXECUTED in one or
more counterparts by persons or officers hereunto duly authorized on the date set forth in Section 1.2 above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: left; text-indent: 0in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left; text-indent: 0in">LANDLORD:</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left; text-indent: 0in"><B>345 PAS HOLDING LLC,</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left; text-indent: 0in">a Delaware limited liability company</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%; text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="width: 5%; text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="width: 35%; text-align: left; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; text-indent: 0in"><I>/s/ Karen Noy</I></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Name:&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Karen Noy</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Title:</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Authorized Signatory</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left; text-indent: 0in">TENANT:</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left; text-indent: 0in"><B>PROTARA THERAPEUTICS INC.</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Name:</TD>
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Title:</TD>
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 99; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">EXECUTED in one or
more counterparts by persons or officers hereunto duly authorized on the date set forth in Section 1.2 above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: left; text-indent: 0in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left; text-indent: 0in">LANDLORD:</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left; text-indent: 0in"><B>345 PAS HOLDING LLC,</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left; text-indent: 0in">a Delaware limited liability company</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%; text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="width: 5%; text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="width: 35%; text-align: left; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Name:</TD>
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Title:</TD>
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left; text-indent: 0in">TENANT:</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left; text-indent: 0in"><B>PROTARA THERAPEUTICS INC.</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; text-indent: 0in"><I>/s/ Blaine Davis</I></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Name:</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Blaine Davis</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Title:</TD>
    <TD STYLE="text-align: left; text-indent: 0in">CFO</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: left; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 100; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: left; text-indent: 0in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><U>EXHIBIT A</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><U>LAND</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">ALL that certain plot,
piece or parcel of land. situate, lying and being in the Borough of Manhattan. City. County and State of New York. bounded and
described as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">BEGINNING at the corner
formed by the intersection of the easterly side of 4th Avenue with the southerly side of 26th Street:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">RUNNING THENCE easterly
along the southerly side of 26th Street. 120 feet:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">THENCE southerly parallel
with 4th Avenue. 98 feet 9 inches to the center line of the block between 25th and 26th Streets;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">THENCE westerly along
the said center line of the block. 30 feet:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">THENCE southerly and
parallel with the easterly side of 4th Avenue. 98 feet 9 inches to the northerly side of 25th Street:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">THENCE westerly along
the northerly side of 25th Street, 90 feet to the easterly side of 4th Avenue:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">THENCE northerly along
the easterly side of 4th Avenue, 197 feet 6 inches to the southerly side of 26th Street. at the point or place of BEGINNING.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 101; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><U>EXHIBIT B</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><U>PREMISES</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">The portion of the Building
demised to Tenant pursuant to the Lease (the &ldquo;Premises&rdquo;) shall mean a portion of the rentable area on the third (3rd)
floor of the Building substantially as shown on the floor plan(s) annexed to this Exhibit B and forming a part hereof within the
outside walls of the Building, excluding the area occupied by Building stairs, fire towers, elevator shafts, flues, vents, stacks,
pipe shafts and vertical ducts, with their enclosing walls (but including the area occupied by the shafts and machinery for any
private elevators, pneumatic tubes, conveyors, mail chutes and the like installed by Tenant, and the interior walls and partitions
enclosing such shafts and machinery).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 102; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><U>EXHIBIT C</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><U>WORK LETTER</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 103; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">C-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><U>SCHEDULE C-1</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><U>Base Work</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">[see attached]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 104; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Sch. C-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><U>SCHEDULE C-2</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><U>Scheduled Tenant Changes</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">[***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 105; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Sch. C-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><U>SCHEDULE C-3</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><U>Test Fit</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">[see attached]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 106; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Sch. C-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><U>EXHIBIT D</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><U>LANDLORD&rsquo;S SERVICES</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">[***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 107; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">D-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><U>SCHEDULE 1 TO EXHIBIT
D</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><U>CLEANING SPECIFICATIONS</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: center; text-indent: -0.5in">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> [***]</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 108; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">Sch. D-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><U>EXHIBIT E</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><U>RULES AND REGULATIONS</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">1. Tenant shall not
obstruct or encumber the sidewalks, entrances, passages, courts, elevators, vestibules, or corridors and halls outside of the Premises,
nor shall such areas be used for any purpose other than ingress and egress to and from the Premises and for delivery of merchandise
and equipment which delivery shall be completed in a prompt and efficient manner using elevators and passageways designated for
such delivery by Landlord.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">2. No awnings, air-conditioning
units, fans or other projections shall be attached to or project through the outside walls or windows of the Building. Tenant shall
not attach, hang or use any curtains, blinds, shades or screens, other than either mylar shades or other curtains, blinds, shades
or screens that conform to Building standards or are otherwise approved by Landlord, which approval shall not be unreasonably withheld,
conditioned or delayed. Notwithstanding the foregoing (but subject to the provisions of the Lease, including, but not limited to,
Article 8 thereof), Tenant, at its sole cost and expense, shall be permitted to install so called &ldquo;black-out&rdquo; shades
in its conference rooms; provided, however, if any of such shades are visible from the outside of the Building, then Landlord shall
have the right to approve the same, which approval may be granted or withheld in Landlord&rsquo;s reasonable discretion. Tenant
may not, under any circumstances apply mylar or other like films directly to Building glass. All electrical fixtures hung in offices
or spaces along the perimeter of the Premises must be of a quality, type, design and bulb color approved by Landlord, such approval
not to be unreasonably withheld, conditioned or delayed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">3. Except for signage
required by applicable laws and requirements of public authorities or as otherwise provided in the Lease, Tenant shall not exhibit,
inscribe, paint or affix any sign, advertisement, notice or other lettering (collectively, &ldquo;Tenant Advertisement&rdquo;)
on any part of the inside of the Premises if the same can be seen from the outside of the Premises. Except as otherwise expressly
provided in the Lease, Tenant Advertisement may not be exhibited, inscribed, painted or affixed to any part of the outside of the
Premises or the Building.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">4. Tenant shall not
permanently cover or obstruct the exterior windows that reflect or admit light into the Premises except as may be required by applicable
laws and requirements of public authorities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">5. Tenant shall not,
without Landlord&rsquo;s prior written consent, place any showcases or other articles in front of or affix such articles to any
part of the exterior of the Building, nor place such articles in the halls, corridors or vestibules (other than within the Premises
but in all events Tenant shall comply with applicable laws and requirements of public authorities), nor shall any article obstruct
any air-conditioning supply or exhaust.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">6. The water and wash
closets and other plumbing fixtures shall not be used for any purposes other than those for which they were constructed, and no
sweepings, rubbish, rags, acids or other substances shall be deposited therein. All damages resulting from any misuse of such
fixtures in the Premises (or in the core bathrooms on the full floors of the Premises) shall be borne by Tenant unless caused
by a Landlord Party.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 109; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">7. Except as otherwise
approved by Landlord or as otherwise permitted in accordance with the provisions of the Lease, Tenant shall not mark, paint, drill
into, or in any way deface any part of the Premises or the Building, and no boring, cutting or stringing of wires shall be permitted,
except with the prior written consent of Landlord, which consent shall not be unreasonably withheld, conditioned or delayed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">8. Tenant, or any of
Tenant&rsquo;s servants, employees, agents, sublessees, visitors or licensees, shall not at any time bring or keep upon the Premises
any inflammable, combustible or explosive fluid, chemical or substance except such as are incidental to usual office occupancy
and are properly safeguarded.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">9. Tenant shall not
install any additional locks or bolts of any kind upon any of the doors or windows, nor shall Tenant change existing locks or the
mechanism thereof, unless Tenant promptly provides Landlord with the key or combination thereto. Tenant must, upon the termination
of its tenancy, return to Landlord all keys to offices and toilet rooms and in the event of the loss of any keys furnished at Landlord&rsquo;s
expense, pay the cost thereof. Notwithstanding the foregoing, subject to the applicable provisions of the Lease, Tenant, at its
sole cost and expense, shall have the right to install a card key or other electronic or other entry system for the Premises; provided
that at all times Tenant has provided Landlord with such master card keys or other &ldquo;master&rdquo; access rights for such
card key or other electronic or other entry system.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">10. Tenant shall not
bring into or store any bicycles, vehicles or animals of any kind (except for animals to assist the handicapped) in or about the
Premises or the Building; provided, however, (i) Tenant may bring bicycles into the Premises via the loading dock and freight elevator
during Operating Hours in accordance with applicable laws and requirements of public authorities, including, without limitation,
the New York City Bicycle Access to Office Buildings Law, and (ii) nothing set forth herein shall modify the rights of Tenant to
bring bicycles into the Building or the Premises to the extent provided by applicable laws and requirements of public authorities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">11. Tenant shall remove
and bring any safes, freight, furniture or bulky matter of any description into or out of the Premises in the manner and during
the hours (which must be scheduled in advance) which are agreed to by Landlord and Tenant. Landlord reserves the right to inspect
all safes, freight or other bulky articles to be brought into the Building and to exclude from the Building all safes, freight
or other bulky articles which violate any of these Rules and Regulations or the Lease. Landlord shall have the right to prescribe
the weight and position of safes and other objects of excessive weight, and no safe or other object whose weight exceeds the lawful
load for the area, as the same may be reinforced as permitted under the Lease, upon which it would stand, shall be brought into
or kept upon the Premises. If, in the reasonable judgment of Landlord, it is necessary to distribute the concentrated weight of
any heavy object, Landlord shall so advise Tenant. Tenant shall be responsible for the payment of any and all costs incurred by
Landlord as a result of any structural analysis, design or construction undertaken in response to Tenant&rsquo;s request to bring
and keep any such safes, freight, furniture or other bulky matter in the Premises.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">12. Landlord reserves
the right to exclude from the Building all persons who do not present a pass signed or approved by Landlord or Tenant or who otherwise
do not comply with Building security procedures. Landlord may require any person leaving the Building with any package or other
object taken from the Premises to exhibit a pass from Tenant. Tenant shall comply with the security procedures implemented following
the mutual agreement of Landlord and Tenant including provisions for approving companies delivering food and the manner of delivery.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 110; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">13. No delivery persons
or messengers shall be permitted to use the Building passenger elevators.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">14. Tenant shall, at
its expense, provide reasonable quantities of artificial light for the Landlord&rsquo;s employees doing janitor service or other
cleaning, and making repairs or alterations in the Premises during such times as such parties are permitted to do so under the
terms of the Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">15. Tenant&rsquo;s
requirements for above standard services will be addressed only upon written notice delivered to Landlord&rsquo;s office at the
Building. Building employees shall not perform any work or do anything outside of the regular duties unless under special instruction
from the Landlord&rsquo;s office.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">16. Canvassing, soliciting
and peddling in the Building are prohibited and Tenant shall cooperate to prevent the same.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">17. Tenant shall use
commercially reasonable efforts to prevent the use in any space, or in the public halls of the Building, either by Tenant or by
jobbers or others in the delivery or receipt of merchandise, of any hand trucks except those equipped with rubber tires and side
guards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">18. Tenant shall control
access to the Premises in accordance with reasonable security procedures implemented upon the mutual agreement of Landlord and
Tenant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">19. Any person whose
presence in the Building at any time shall, in the judgment of the Landlord, be prejudicial to the safety of the Building or of
its tenants may be denied access to the Building or may be ejected therefrom. In case of invasion, riot, dangerous public excitement
or other dangerous commotion, the Landlord may prevent all access to the Building during the continuance of the same, by closing
the doors or otherwise, for the safety of the tenants and protection or property in the Building.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">20. Smoking is prohibited
at all times throughout any portion of the Building, including, but not limited to, the entrances thereto and the roof garden.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">21. Tenant shall not
make, or permit to be made within the Building, any unseemly or disturbing noises or unreasonably disturb or interfere with occupants
of the Building (in any instance by more than a de minimis extent) by the use of any equipment, machinery, musical instrument,
radio, television or in any other way.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">22. Landlord shall
have the right to prohibit any advertising which refers to the Building which, in Landlord&rsquo;s reasonable judgment, tends to
impair the reputation of the Building and upon notice from Landlord, Tenant shall discontinue such advertising. The use of the
Building address in the ordinary course of Tenant&rsquo;s business shall not constitute an advertisement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">23. Prior to Tenant&rsquo;s
storing, placing, generating, manufacturing, refining, handling, or otherwise bringing on, in, under or around the Premises, the
Building or Property any Hazardous Substances, Tenant shall notify Landlord of Tenant&rsquo;s intention to do any of the foregoing
and shall register with Landlord any such Hazardous Substances, including, without limitation, the quantity, storage and use of
the same.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">In the event of any
inconsistencies between the provisions of the Lease and the provisions of this Exhibit E (as opposed to additional detail or information
in this Exhibit E that shall not be considered inconsistencies for purposes of this sentence), the provisions of the Lease shall
prevail.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 111; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><U>EXHIBIT F</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><U>FORM OF LETTER OF CREDIT</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">[***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 112; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><U>EXHIBIT G</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><U>FORM OF COMMENCEMENT
DATE AGREEMENT</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Agreement made this
___ day of ________, 20__, between _______________, a __________________ having an office c/o Deerfield Management Company, L.P.,
780 Third Avenue, 37<SUP>th</SUP> Floor, New York, NY 10017, Attention: Jonathan Isler, hereinafter referred to as &ldquo;Landlord,&rdquo;
and _______________ _______________ a _______________ having an office at _____________________________________________ hereinafter
referred to as &ldquo;Tenant.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><U>W
I T N E S E T H:</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">1. The parties have
heretofore entered into a written Indenture of Lease, dated as of _______________, 20__, (hereinafter referred to as the &ldquo;Lease&rdquo;)
for the leasing by Landlord to Tenant of certain space on the ____ ( ) floor(s) in the building known as 345 Park Avenue South,
New York, New York, all as in the Lease more particularly described.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">2. Pursuant to Article
3 of the Lease, Landlord and Tenant agree that the Commencement Date of the term of the Lease is _______________; the Rent Commencement
Date is _______________; and that the Expiration Date is _______________.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">IN WITNESS WHEREOF,
Landlord and Tenant have respectively signed this Commencement Date Agreement as of the day and year first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: left; text-indent: 0in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left; text-indent: 0in">LANDLORD:</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left; text-indent: 0in">345 PAS HOLDING LLC,</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left; text-indent: 0in">a Delaware limited liability company</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left; text-indent: 0in">LANDLORD:</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left; text-indent: 0in"><B>345 PAS HOLDING LLC,</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left; text-indent: 0in">a Delaware limited liability company</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%; text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="width: 5%; text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="width: 35%; text-align: left; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; text-indent: 0in"><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</I></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Name:</TD>
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Title:</TD>
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left; text-indent: 0in">TENANT:</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: left; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; text-indent: 0in">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: left; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 113; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">G-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">EXHIBIT H</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">RIDER TO TENANT LEASE
AGREEMENT DATED DECEMBER 1, 2020</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>RIDER TO TENANT LEASE
AGREEMENT DATED DECEMBER 1, 2020</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 5.4pt; width: 32%; border: Black 1pt solid; text-align: left; text-indent: 0in">LANDLORD:</TD>
    <TD STYLE="padding: 5.4pt; width: 68%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; text-indent: 0in">345 PAS Holding LLC</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left; text-indent: 0in">TENANT:</TD>
    <TD STYLE="padding: 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; text-indent: 0in">PROTARA THERAPEUTICS INC.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left; text-indent: 0in">FLOOR(S)/ UNIT(S):</TD>
    <TD STYLE="padding: 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; text-indent: 0in">Suite located on the 3<SUP>rd</SUP> Floor</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left; text-indent: 0in">TENANT&rsquo;S EIN #:</TD>
    <TD STYLE="padding: 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; text-indent: 0in">20-4580525</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left; text-indent: 0in">PREMISES:</TD>
    <TD STYLE="padding: 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; text-indent: 0in">10,252 rentable square feet on the 3rd floor of the Building</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left; text-indent: 0in">AGENCY:</TD>
    <TD STYLE="padding: 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; text-indent: 0in">New York City Industrial Development Agency</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left; text-indent: 0in">COMPANY LEASE:</TD>
    <TD STYLE="padding: 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; text-indent: 0in">Company Lease Agreement, dated as of August 1, 2019, between 345 PAS Holding LLC and the Agency</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left; text-indent: 0in">AGENCY LEASE:</TD>
    <TD STYLE="padding: 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; text-indent: 0in">Agency Lease Agreement, dated as of September 1, 2019, between the Agency and 345 PAS Holding LLC</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left; text-indent: 0in">LEASE AGREEMENT</TD>
    <TD STYLE="padding: 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; text-indent: 0in">Lease Agreement, dated December 1, 2020, between 345 PAS Holding LLC, as Landlord, and ProTara Therapeutics, Inc., as Tenant</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">1. <U>Acknowledgment
and Release</U>. Tenant acknowledges that pursuant to the Company Lease, the Agency holds a leasehold estate in the entire Premises,
and Tenant releases the Agency from any past, present or future claims that Tenant has or may have against the Agency.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">2. <U>Representation
Regarding Relocation</U>. Tenant represents that as a result of entering into the Lease Agreement and this Rider, and upon completion
of the construction occupying the Premises, it has not and will not have relocated or abandoned any plant or facility from outside
of New York City (but within the State of New York).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 114; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">H-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">3. <U>Representation
Regarding Conduct</U>. None of the Tenant, the Principals of the Tenant, or any Person that is an Affiliate of the Tenant:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">a.</TD><TD STYLE="text-align: left">is in default or in breach, beyond any applicable grace
period, of its obligations under any written agreement with the Agency, NYCEDC or the City, unless such default or breach has
been waived in writing by the Agency, NYCEDC or the City, as the case may be;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">b.</TD><TD STYLE="text-align: left">has been convicted of a misdemeanor related to truthfulness
and/or business conduct in the past five (5) years;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">c.</TD><TD STYLE="text-align: left">has been convicted of a felony in the past ten (10) years;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">d.</TD><TD STYLE="text-align: left">has received formal written notice from a federal, state
or local governmental agency or body that such Person is currently under investigation for a felony criminal offense; or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">e.</TD><TD STYLE="text-align: left">has received written notice of default in the payment
to the City of any taxes, sewer rents or water charges, which have not been paid, unless such default is currently being contested
with due diligence in proceedings in a court or other appropriate forum.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">Capitalized terms used
in this section have the meanings set forth below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><B>Affiliate</B> means,
with respect to a given Person, any other Person that directly or indirectly through one or more intermediaries Controls, is Controlled
by, or is under common Control with such given Person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><B>City</B> shall mean
The City of New York.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><B>Control</B> or <B>Controls</B>,
including the related terms &ldquo;controlled by&rdquo; and &ldquo;under common control with&rdquo;, shall mean the power to direct
the management and policies of a Person (x) through the ownership, directly or indirectly, of not less than a majority of its voting
securities, (y) through the right to designate or elect not less than a majority of the members of its board of directors or trustees
or other Governing Body, or (z) by contract or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><B>Entity</B> shall mean
any of a corporation, general partnership, limited liability company, limited liability partnership, joint stock company, trust,
estate, unincorporated organization, business association, tribe, firm, joint venture, governmental authority or governmental instrumentality,
but shall not include an individual.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><B>Governing Body</B>
shall mean, when used with respect to any Person, its board of directors, board of trustees or individual or group of individuals
by, or under the authority of which, the powers of such Person are exercised.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><B>NYCEDC</B> shall mean
New York City Economic Development Corporation, and any successor thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><B>Person</B> shall mean
an individual or any Entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><B>Principals</B> shall
mean, with respect to any Entity, the most senior three officers of such Entity, any Person with a ten percent (10%) or greater
ownership interest in such Entity, and any Person as shall have the power to Control such Entity, and &ldquo;principal&rdquo; shall
mean any of such Persons.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">4. <U>Subordination</U>.
Tenant acknowledges and agrees that the Lease, as modified by this Rider, is subject and subordinate to the Agency Lease, and that
any conflict between the terms of the Agency Lease and the terms of the Lease, as modified by this Rider, shall be resolved in
favor of the Agency Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 115; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">H-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">5. <U>Indemnity</U>.
Tenant agrees to defend, indemnify and hold harmless the Agency, its officers, directors, employees and agents from and against
any and all losses, claims, suits, damages, costs, expenses and liabilities arising from or attributable to any act or omission
of Tenant, its employees or agents in the use or occupancy of the Premises.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">6. <U>Insurance</U>.
Notwithstanding anything to the contrary contained in the Lease, as modified by this Rider, Tenant agrees to obtain and maintain
Commercial General Liability insurance (&ldquo;<U>CGL</U>&rdquo;) on a per occurrence basis in the following amounts: minimum $<FONT STYLE="font-size: 10pt">[***]</FONT>
per occurrence and minimum $<FONT STYLE="font-size: 10pt">[***]</FONT> in the aggregate per location. Tenant additionally agrees
that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">(a) the CGL
policy shall contain coverage for contractual liability, premises operations, and products and completed operations; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">(b) the CGL
policy shall be written on Form CG-0001; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">(c) the CGL
policy shall name the Agency as an additional insured; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">(d) Tenant
shall provide to Landlord at least thirty (30) days before expiration of the CGL policy (and to the Agency upon the Agency&rsquo;s
request), an ACORD certificate evidencing that Tenant has obtained CGL coverage as required herein; and that such ACORD certificate
shall indicate the Agency as an additional insured as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">&ldquo;New
York City Industrial Development Agency is an additional insured on a primary and non-contributory basis for Commercial General
Liability which is written on Form CG-0001 without modification to the contractual liability or waiver-of-subrogation provisions
therein, and covering the following premises: 345 Park Avenue South, New York, New York 10010.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">7. <U>Employment Information</U>.
Tenant acknowledges that pursuant to the Agency Lease, Landlord is obligated to provide to the Agency employment information pertinent
to all occupants of the building in which the Premises are located. Accordingly, Tenant agrees to provide to Landlord and, if requested
by the Agency, to the Agency, information regarding Tenant&rsquo;s employment at the Premises, including, but not limited to, the
then-current New York State Department of Labor&rsquo;s Form NYS-45, and the Agency&rsquo;s employment and benefits report form
for Tenants (or any successor form as may be required by the Agency as a result of a change in law or as required by New York State
agencies).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">8. <U>Living Wage</U>.
Tenant agrees to comply with all of the terms, covenants and provisions of the Living Wage requirements set forth in Appendix A
hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">9. <U>HireNYC</U>.
Tenant agrees to comply with all of the terms, covenants and provisions of the HireNYC requirements set forth in Appendix B hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">10. <U>Intentionally
Omitted</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 116; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">H-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">11. <U>Use of Premises</U>.
Tenant shall occupy 10,252 RSF of the Premises for use by Tenant in its operations as general and administrative use for a pharmaceutical
development organization.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">12. <U>Non-discrimination</U>.
Tenant hall not discriminate nor permit any of its Affiliates (as defined in Section 3 above) to discriminate against any employee
or applicant for employment because of race, color, creed, age, sex or national origin. Tenant shall ensure that employees and
applicants for employment with Tenant are treated without regard to their race, color, creed, age, sex or national origin. As used
herein, the term &ldquo;treated&rdquo; shall mean and include the following: recruited, whether by advertising or other means;
compensated, whether in the form of rates of pay or other forms of compensation; selected for training, including apprenticeship;
promoted; upgraded; downgraded; demoted; transferred; laid off; and terminated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">13. <U>Incorporation
in Sublease Agreement; Third-Party Beneficiary</U>. Tenant agrees and acknowledges that this Rider is a part of and is incorporated
into the Lease; and that the Agency is a third-party beneficiary of the foregoing provisions of this Rider. Except where modified
by this Rider, the terms and conditions of the Lease, as modified by this Rider, remain unmodified and in full force and effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 117; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">H-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">IN WITNESS WHEREOF, Landlord
and Tenant have executed this Rider as of the day and year first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: left; text-indent: 0in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: left; text-indent: 0in">345 PAS HOLDING LLC,</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: left; text-indent: 0in">(Landlord)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: left; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">By:</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: left; text-indent: 0in"><I>&nbsp;</I></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%; text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="width: 4%; text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="width: 5%; text-align: left; text-indent: 0in">Name:</TD>
    <TD STYLE="width: 31%; text-align: left; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Title:</TD>
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: left; text-indent: 0in">PROTARA THERAPEUTICS INC.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: left; text-indent: 0in">(Tenant)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">By:</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: left; text-indent: 0in"><I>&nbsp;</I></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Name:</TD>
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Title:</TD>
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in; text-align: left; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 118; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">H-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><U>EXHIBIT I</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><U>FORM OF LIVING WAGE
AGREEMENT</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">[***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 119; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">I-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><U>EXHIBIT J</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><U>HireNYC</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: center; text-indent: -1.5in">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> [***]</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 120; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">J-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><U>SCHEDULE 6.1.4(c)</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><U>Agency Lease PILOT
Payment Schedule</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">[***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">J-2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>4
<FILENAME>f10k2020ex21-1_protara.htm
<DESCRIPTION>LIST OF SUBSIDIARIES
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 21.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>List of Subsidiaries</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: center; border-bottom: Black 1.5pt solid; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name of Subsidiary</FONT></TD>
    <TD STYLE="text-align: center; padding-bottom: 1.5pt; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; border-bottom: Black 1.5pt solid; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jurisdiction</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proteon Securities Corp.</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Massachusetts</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proteon International Holdings, Inc.</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delaware</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proteon Bermuda Limited</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bermuda</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proteon Ireland Limited </FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ireland</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ArTara Subsidiary, Inc.</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delaware</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">All subsidiaries are 100% owned.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>5
<FILENAME>f10k2020ex23-1_protara.htm
<DESCRIPTION>CONSENT OF MARCUM LLP, INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY>


    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 23.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><U>Independent
Registered Public Accounting Firm&rsquo;s Consent</U></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">We consent to the incorporation by reference
in the Registration Statements of Protara Therapeutics, Inc. on Form S-3 (File No. 333-251224) and Form S-8 (File Nos. 333-237497,
333-235918, 333-229123, 333-222415 and 333-200587) of our report dated March 11, 2021, with respect to our audits of the consolidated
financial statements of Protara Therapeutics, Inc. as of December 31, 2020 and 2019 and for the years ended December 31, 2020 and
2019, which report is included in this Annual Report on Form 10-K of Protara Therapeutics, Inc. for the year ended December 31,
2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ Marcum <FONT STYLE="font-variant: small-caps">llp</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Marcum <FONT STYLE="font-variant: small-caps">llp</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">New York, NY</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">March 11, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>f10k2020ex31-1_protara.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 31.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Certification of the Principal Executive
Officer<BR>
Pursuant to<BR>
&sect;240.13a&minus;14 or &sect;240.15d&minus;14 of the Securities Exchange Act of 1934, as amended</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I, Jesse Shefferman, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">1. I have reviewed
this annual report on Form 10&minus;K of Protara Therapeutics, Inc.;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">2. Based on my
knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period
covered by this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">3. Based on my
knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects
the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">4. The registrant&rsquo;s
other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined
in Exchange Act Rules 13a&minus;15(e) and 15d&minus;15(e)) and internal control over financial reporting (as defined in Exchange
Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: left; text-indent: 0.25in">(a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by
others within those entities, particularly during the period in which this report is being prepared;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: left; text-indent: 0.25in">(b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed
under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of
financial statements for external purposes in accordance with generally accepted accounting principles;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: left; text-indent: 0.25in">(c)
Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions
about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on
such evaluation; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: left; text-indent: 0.25in">(d)
Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the
registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that
has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting;
and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">5. The registrant&rsquo;s
other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting,
to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing
the equivalent functions):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: left; text-indent: 0.25in">(a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which
are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information;
and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: left; text-indent: 0.25in">(b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
internal control over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    March 11, 2021</FONT></TD>
    <TD STYLE="width: 40%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Jesse Shefferman</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jesse Shefferman</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Executive Officer)</FONT></TD></TR>
</TABLE>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>f10k2020ex31-2_protara.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY>


    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 31.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Certification of the Principal Financial
Officer<BR>
Pursuant to<BR>
&sect;240.13a&minus;14 or &sect;240.15d&minus;14 of the Securities Exchange Act of 1934, as amended</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I, Blaine Davis, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">1. I have
reviewed this annual report on Form 10&minus;K of Protara Therapeutics, Inc.;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">2. Based on my
knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period
covered by this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">3. Based on my
knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects
the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">4. The registrant&rsquo;s
other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined
in Exchange Act Rules 13a&minus;15(e) and 15d&minus;15(e)) and internal control over financial reporting (as defined in Exchange
Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: left; text-indent: 0.25in">(a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by
others within those entities, particularly during the period in which this report is being prepared;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: left; text-indent: 0.25in">(b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed
under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of
financial statements for external purposes in accordance with generally accepted accounting principles;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: left; text-indent: 0.25in">(c)
Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions
about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on
such evaluation; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: left; text-indent: 0.25in">(d)
Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the
registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that
has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting;
and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">5. The registrant&rsquo;s
other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting,
to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing
the equivalent functions):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: left; text-indent: 0.25in">(a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which
are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information;
and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: left; text-indent: 0.25in">(b) Any
fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
internal control over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    March 11, 2021</FONT></TD>
    <TD STYLE="width: 40%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Blaine Davis</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Blaine Davis</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial
    Officer</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Financial
    and Accounting Officer)</FONT></TD></TR>
</TABLE>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>f10k2020ex32-1_protara.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 32.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Certification Pursuant to 18 U.S.C.
Section 1350<BR>
(as adopted pursuant to Section 906 of the Sarbanes&minus;Oxley Act of 2002)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">In connection
with this annual report of Protara Therapeutics, Inc. (the &ldquo;Company&rdquo;) on Form 10&minus;K for the year ending December
31, 2020, as filed with the Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), we, Jesse Shefferman,
Chief Executive Officer of the Company, and Blaine Davis, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C.
&sect; 1350, as adopted pursuant to Section 906 of the Sarbanes&minus;Oxley Act of 2002, that, to our knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">1. The Report
fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">2. The information
contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: March 11, 2021</FONT></TD>
    <TD STYLE="text-align: left; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Jesse Shefferman</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jesse Shefferman</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: March 11, 2021</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Blaine Davis</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Blaine Davis</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin: 0pt 0; text-align: left">This certification accompanies the
Form 10-K to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by
reference into any filing of Protara Therapeutics, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange
Act of 1934, as amended (whether made before or after the date of the Form 10-K), irrespective of any general incorporation language
contained in such filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.25in; text-align: justify">&nbsp;</P>





</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $5 L0# 2(  A$! Q$!_\0
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M ,TE'_#U_P#:Z_Y_/AA_X0=Q_P#-)7YL44!?T^X_2?\ X>O_ +77_/Y\,/\
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MI'#55AYU8T85\.ZG]K2KUH1PZ^J0I_5I5HQKN;3K0R?BY^TW_P %K?@-X?\
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M\^GM'<MVGQW^.G[!GP6^&/[+'@;]BRS\+^+?VBO@W\8? 'Q)\2?MI^ O@_\
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M?C;\5/B]::)X?^&EOX?G\9>,-1U^^\/17.B?%76-031+K66U V":I>:!H_\
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M ,&UI_\ *VC_ (9R^'O_ #]>*?\ P;6G_P K:]]\OW_3_P"O1Y?O^G_UZ /
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M\"/"ANA?'Q#X_-\&WB^;Q0YO0_EB'>MV;0W"OY($.\2!O) ASY8"U[;Y?O\
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MU30[3PUH^A_!GQE\:X8;O7M-N/%-YX7\-:5<7VCZA<^!?^$EMO&.E>&_%EY
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M3-E2;K2C1JXC%J$8OZU[."E"E*NY0E]45*,YJ-:FYU,17H5(.E/XP'P_\)$
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MIZ* T\_P_P B#!]#^1HP?0_D:GHH#3S_  _R(,'T/Y&C!]#^1J>B@-//\/\
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MEUC7?B%\4[SP ^I_$6"Z\+>#O@YI0\.:=\._'7Q!L= \?>'O$.K?#_6]2O\
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MXT_Z)/B'_P -6)_^2#_6OA?_ **+)?\ PXT/\CRC!]#^1HP?0_D:]7_X6?\
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M1?S9@^A_(T8/H?R-?H>?V:?A@I(:S\2*1U!UZ<$?4&VR*3_AFKX7?\^OB/\
M\'\W_P C5\X>T?GC@^A_(T8/H?R-?H=_PS5\+O\ GU\1_P#@_F_^1J/^&:OA
M=_SZ^(__  ?S?_(U 'YXX/H?R-&#Z'\C7Z'?\,U?"[_GU\1_^#^;_P"1J/\
MAFKX7?\ /KXC_P#!_-_\C4 ?GC@^A_(T8/H?R-?H=_PS5\+O^?7Q'_X/YO\
MY&H_X9J^%W_/KXC_ /!_-_\ (U 'YXX/H?R-&#Z'\C7Z'?\ #-7PN_Y]?$?_
M (/YO_D:C_AFKX7?\^OB/_P?S?\ R-0!^>.#Z'\C1@^A_(U^AW_#-7PN_P"?
M7Q'_ .#^;_Y&H_X9J^%W_/KXC_\ !_-_\C4 ?GC@^A_(T8/H?R-?H=_PS5\+
MO^?7Q'_X/YO_ )&H_P"&:OA=_P ^OB/_ ,'\W_R-0!^>.#Z'\C1@^A_(U^AW
M_#-7PN_Y]?$?_@_F_P#D:C_AFKX7?\^OB/\ \'\W_P C4 <M^SV"/A_R,?\
M$\U+K_USM**^G?A[\*?!_AOP\-.TR#5%MOMMS<8N=3EGD\R41!SO,2G;A%P,
M<<\\T4 ?Y]UP[1P3R(0'CAD=21D!E1F4D'@C(&0>M?1_C;X-VLOQ5^*G@;P
M\D<O@CP;I_C+P_X7N6N]5UCQ5!9>#_"GB3Q7I&C76XRSZW9V&JZYXFL[&2.1
M[W3=(O-/LP)XH _SNT+.K(T3E74JPVMRK @C@9Y!(XYKW;P[\?\ Q_I/Q#\(
M?$[5C9Z[XK\!ROJ7AK58=&T#PQJR>(;+PVWA_P ,:OK>O>&]!L-9\1Q^'?*T
MRZ%AK%Y<KJ<>F)8W5S'%=74LG^O>94\TO&OEKA*=+!XV*H5:CA"KBY2P5;!\
M\94Y0G3D\/7PE:?/2JX>CC:F(HN=2C&E4_R*R^>66=',?:1A4Q>"E*O2IJ<Z
M6%C'&4L9R252,X5(K$4,71AR5:6(K8*GAZRA3K2J4_0K+]E.&>73-+O?C#X5
MTWQ/K&L_$;P[::,_ACQ%>Z?;:Q\(_!.A^-?B'#JWB*SFDM;.UT9=6O?#=C=6
MMEJ4FK>(M$NHDM;33[B&_3F-0^ OAG1/!#?$WQ!\8+/2O 5Z?A\WAF_7X>Z_
M?>(_$,'Q!TOQ=J4,S>&H=8CM]'/AP^!]?AUZ*Z\07!D2*UGT9M4>Z6V7R/2_
MB!X]T6+1XM.\2:I;C0;CQE>:4WEVTLEI>?$33(M&\<W8DGM97EG\3Z;#':ZD
M\[2X53):BVF9I#Z!H7Q_^(?A[X<O\/+*>"XMH];\&WNG7FKZ3H.OV>G:!X(T
M[Q;;:+X87P[K^A:IH]W!:ZGXOOM<LM5NXY-3L+Q#'!(T=PQC\JKA.*J;INGF
M='%1EBJ"K0C0PF$DL(ZE9UY4:D\#B(TIJ$<.H^TCBY0C*LDJM1QG3]2GB^%Z
MD:BJ996PLHX6LZ,W7Q>*B\4J='V$:U.&.P\JL'.6(<O9RPL9RC1O*E34HS]5
MU_\ 9?TS2K'X=>$;GQEIFD_%GQ-KOQBT.&TBL=<UO0?&4G@P:3K'A"\BU ?8
MH?!VEZYH%_';V5U<6-]J$NIW\2:UI6GQ6<]VGG<WP&TRTLO&UGJ7Q1TS3_'7
MP\^%^F_%;Q7X,3P=K=\EOHNHQ>%;Z31M'\31W\6FZOXETG2/&6B:GJ=K-:Z7
MI#,]U8:;K>H7%LS'SU_BK\3I=:T'Q'/XPUVZU_PQK/B3Q%H6L7I@O;^PUSQ?
M<_;/$VIB>ZMIFNKG6;D"6Y^V_:8HR%2UCMXE6,7_ /A<WQ5_X174O!?_  E5
MT?#VL^$[/P'K4)T;P^VJZSX)TV:UN-,\*:OXG;1CXIU+0M+EL;$Z;87FM316
M"65E#:B*&TMHXG2P/%-*-*,LUPU9RJ*KB).E&'+4GCJ=2K&A[3!5V\&L"J]*
MEA9N->.)JT90QE+#T'1DJN-X8J2JRCE>)HQ5/V>'C[6<^:$,#4ITI5_9XVA%
M8QX[V%6IBHJ5"6'I5HSP=3$8CVL/H_XP?LV>"?#,OCS7/#GB--"^&G@;QQXG
MTK4O$VI:;X@U?Q9%!:6/PQT[0_"UMX6.M26&K3WWB7QK+_9VL?VMI3&V.I3Z
M]>6UM9:3:S>9_!'X4_#CQU\1/'/AKQ#XR.H^"=*^&?B'5=!\=Z5;ZCH$%MXM
MU>?PWX:^'NHZMIFJ1I=6^G6'C7Q5I=EXJTRX>>U^R0ZD]K?WMO%;7<W!'XW?
M%V2YO;JY\87]^=3N?$%UJUIJ>E:%JNDZS+XJ@T&W\0#6=$U'2+K1]6AU*/PM
MX<=K;4+&YM[6YT6PO;"*UO8?M#<SJ/CSQOJUWXNOM0UR]GNO'FEVFA^+72UL
M;6/5]%T^]TC4=/TC[-9V5O:Z=IUA=Z!HLEE9Z1#I\-JFF6MO"B6R-"TX7*^)
M(9?7P6)S=2K3P]*E0Q]*;=:C-2R[VE>2J8)5:N*7U?&S55UH8:I'$0P\L'3Y
MJ]=UB<RX=ECZ&-PV4N-&&(JUJ^ JQM1K0<<Q]G0BX8UTZ6%?M\%!THT9XBE+
M#U,1'&5.6A07TM:_LQ6UQ\)/"U[J-]+X6^*4'C;Q=J'Q6;6FO)M(^'_PFTSP
M)XG\4:-<3Z%9P27]]X@:+X<>--<-K: WFI6>I>'+&(6\4[7*=I\$OV9/A/XK
MT_PMXKU[QQ>>,_!OC/7_  W::;-I6@:YX5UO0QIWC>\\.>+] \0:/)K#Q37&
MLK'90V>H:1KMW%IUA,U_:78U!FM[?Y<G^.7QFNO$&J>*[GX@>);CQ'KFO:#X
MFUC5YFM9;K4]<\,^'K_PEHE[>J]FUO<):>%]4U+P_+8/"=-U'2+ZYLM4L[V*
M5A6E)^T-\;F@T2TA\<7NGZ?X:6!/#VE:/H'A;0](T-+;5)=<ACTO2='T"QTV
MSC&LSSZHZ16H6>]GFFG$K2OGDQ.5<85L/6HPSG#T9XBO5KRJT9U8?5HUZ<YS
MPN'E/ 5,5[*ABG1A@9QJTE1P5&I#$4L17Q4ITNS#9IPA1Q%&M/)\17AAZ%*A
M&E6A2G]9E0J4Z<,3B(PQ]+#>TQ&%5:>.A*E5=7&UJ<\/5P]##1A5Z73O@%!X
MGOM+TO1_'&BV7C+Q3X0LOBIHO@,^'=?2TM/AMK6HI-87,GB>[U748XO$-MX4
MG7Q<?#%RVH?\2B$Z;-XNN?$K&RD[)_V4-&;5%T*S^//A&^U6[\7_ !?\%Z5)
M'X(\70Z%J&I? W0K/7_'VI2:Q-()['P^(+BYL/#M_)I,U[K>IV3(VE6%A<0Z
MA7@VG?%KXFZ3H&G>&=-\37EII6D06=EIK1Z9HS:Q9Z38:S%XAL_#\/B632W\
M2CPQ!KL$6J+X8;5V\/M<I^\TUX6:)JL?Q.^(T-U:WT7B?5$N[+5?'FMVLX@L
MM\&K?%"S&G_$"^0&R*F7Q39*+?4%96BB09L8[-_FKNJ8'BF4ZGLLWP]&E%35
M&/U:A6E*7-B?9SJ2J8)R5+D^HQ5#FJ58NGC95<76EB:,L/P4\;PQ&%/VN4XB
MM4DX.M)8FO2C&/+A_:1I1IXSE=7G^O2]M:G2DJF"C3PE&.&K*OZ'JGP-T70/
M#=E\0?$/Q.MM*^&>O6O@Z3PCXH'@?6+W6]>O/&%AKNI?8KKP=!JRRZ''X<LO
M#.LSZ_>RZY?HPBLH]$AUBXO3#;>TI^RQX=TZRUWPO%KMKXS^)WA_XG_&+P0=
MEKK^A>$/$&G>#?@]I?C'0+C2=0&K07UG=MJVJVNIV#:GH]M%=RW,>DZ^L6FV
MEPT_S!H_Q=^)N@V=IIFG^))GTJPT?0M!LM'U71/#WB#1[73?"]_J>I^&Q#I/
MB#1M4TY+_0;_ %K5[C2M9^S?VU:?VG>P1ZA]FG>&IM1^,_Q<U;4-=U;4O&^N
MWFJ>)]7\5>(/$&H2QV0N]4UOQQX=A\)^+=4N)H[%&6[UWPY;0:5=O 81'#$L
MUHMM=YN#G7R_BJL^6.;8>G"%24X2C%0]K&->7U>%:G2P5.KIA9-8WEQ4:>+Q
M')+#PP4:2YM*&8<,4H\TLJKU)SIQA.,I<_LY2H1^L3HU*N-J4E?%13P7-A95
M,)AU.&(GC957R^J:-^S';>(-9UO2M&^+OANYM? VO^*/"OQ,UR\\)^)K&R\(
MZSX6\%>,?&<T^FVP:YO_ !=H6J+X \6Z%I^H65OIFHKJNFP2W6A0:?J-G<R8
MLO[/:W'@S6/'OA[Q]9^(]!MOA[9_$;0-/M?"VH6WC#6]%_X2#Q-X6\1S7_A1
MM5N+G0]*\%:YX6N+7Q/XAL[OQ+I^GP:SX>U.>.#2[V^O=+XF_P#C9\6]3=);
MOQ??>:$UT7,MII.@Z=)JMSXF\/7'A/Q!JGB"33='M'\2:[JOAJ\N]&NO$&OG
M4M;%I=W9AU"*>ZN)I,K3OBA\1=)T!?#&G>(;BVT6+P[J/A*UMQI6BS7>G^&]
M8O-:OM9TC2=7N-+FUG2+;6)O$>O)JSZ7J%I<:C9ZM>:=>33:>Z6J:QP?%2Y9
MRS/"-JKAKTG0I.$J,>26,YZL,#3FZM6I&HJ#I0IJCA*L*'+4Q-*6+J92Q?"[
MYHQRW%J+IXFU55ZJFJTN=8/DI3QU2"I4:<J?MU4G4=;%4YU^:GAJL<)3]:^
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M<9X3%X>M4H-XF-O9QGAY4[RA_MU.GCE2E4]O X89P,]<#/U[TM/\N3_GF_\
MWRW^%'ER?\\W_P"^6_PKZNS[/[G_ )'R]UW7WK_,97])?_!"S_DC?[:'_7#X
M:?\ IM^)U?S;^7)_SS?_ +Y;_"OZ2O\ @A8I'P>_;/4@AC!\,_E((.#IWQ/
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MGW^KUWTL7A5OB<.M.M>CY?\ 3PX9X?$>]^XK/?:E4?Y09S$O?_=/]:RY>_\
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M8HD_A/5(FFB2>-7:RRT,@8)(-MVWRL5;&>1CD \5Z%+,\M6^8X!:/?&X7O\
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M"_Q68\>!=:/(_P"?$=!CO>5WTLZR9;YOE2TZYE@5V_ZBSEJ97F;O;+<P>G3
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M.-Q;7,MSH%_'.4<K\,TJN&QCP_!>#P594\-4P3J8O-\95_?5J?/3Q%&GQ/\
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M9\R#7..NVP@;_P!OA7C]_P!'^I_D*X#5?NO_ )[U]!A>$,FK6YUC->V+:_\
M<#/$K\29G3ORRPW7?#I[?]Q4?1$WQ^\"P;M]OXB^7D[=,MC[]]0%9,W[2_PZ
M@SOMO%!QG.W2;4]/KJ8_+K[5\F:GUE^G]#7 :A_RT_WFKZ/#>'O#E6W/',->
MV/DNG_8,SQ<3QIG=)OD>"T[X-/K_ -?T?;D_[6/POMR0]IXO./[NBVA'_IV%
M9,W[97PB@SYEGXWXZ[=!L3^6=;!_3/M7Y]ZE_%^->?ZE_%^-?0X;PJX2JM<\
M,UUMMF<UO_W*,\:OX@\14[\LLO\ G@(OK_V$H_2Z;]N3X+09\RR\>\==OAVP
M.?I_Q/?UK,D_;[^!<6=VG_$0X]/#>G'OCOKXK\I-2_B_&N(O.C?1OYU]#A_!
M;@BJESPSK7MF\U_[HL\BMXG\4P;49Y9H^N6Q?6W_ $%G[$_\/!?@/_T#OB1_
MX3&F_P#S04?\/!?@/_T#OB1_X3&F_P#S05^,-%=G_$$.!/\ GWG?_AZJ?_,!
MQ?\ $5N+?YLJ_P##9'_YK/Z'_A5\>?A?\9K8OX(\1QRZI$A>[\,:LBZ7XGLU
M!(,DFDRR.UU!W^U:=+>VP!&Z53P/8:_F'L[N[T^\MM1T^[NM/U"RE6>SO[&X
MFM+VTF0Y66VNK=XYX)%/1XI%;MG'%?I+^S1^U]\7]<US3O /B3PAK/Q?B<Q1
M#6_#]M#%XNT:V)5/MFMW#_9]%U&QA7YY;K5)]+O"JM_IUQ)A#^:<9^"N)RJC
MB<TX;QT,9E]"$Z]? YG7P^%QF%HP3E*5+'5IX;!8RG!+2.(G@<2](J5:<HQG
M]UPOXI4,QJT,OSO"2PV-K2C2I8O T:V(PN(J2:454PM.-?%8:<GNZ4<506K:
MI14G']4FZ'Z'^5=1XJ_X^]-_[ 6F?^@S5SA0;<_,,KG!(R,C.#C(R.AP2,@X
M)')Z?Q2@-WIW7C0]-'Y+-[5^#GZZ<I14NP>I_3_"C8/4_I_A0!%14NP>I_3_
M  HV#U/Z?X4 145+L'J?T_PHV#U/Z?X4 145+L'J?T_PHV#U/Z?X4 145+L'
MJ?T_PHV#U/Z?X4 145+L'J?T_P *-@]3^G^% $5%2[!ZG]/\*-@]3^G^% $5
M%2[!ZG]/\*-@]3^G^% $5%2[!ZG]/\*-@]3^G^% $5%2[!ZG]/\ "C8/4_I_
MA0!%14NP>I_3_"C8/4_I_A0!%14NP>I_3_"C8/4_I_A0!%14NP>I_3_"C8/4
M_I_A0!%14NP>I_3_  HV#U/Z?X4 145+L'J?T_PHV#U/Z?X4 145+L'J?T_P
MHV#U/Z?X4 145+L'J?T_PHV#U/Z?X4 145+L'J?T_P *-@]3^G^% $5%2[!Z
MG]/\*-@]3^G^% $5%2[!ZG]/\*-@]3^G^% $5%2[!ZG]/\*-@]3^G^% $5%2
M[!ZG]/\ "C8/4_I_A0!%14NP>I_3_"C8/4_I_A0!V_A[_D'+_P!=I?YK13M
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M_P [SQ"BO;_^&G?^"1O_ $)W_!17_P 'G[-7_P I*/\ AIW_ ()&_P#0G?\
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M;<N&RIV_FP^)?Y8Q'#5X(RBK?FKY@K_RUJ'ZX9GQE??LV?&:8D1^$X&![_\
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M_-,_^2* />Z*\$_X:)\,?]"WXA_[^:9_\D4?\-$^&/\ H6_$/_?S3/\ Y(H
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M%'_#1/AC_H6_$/\ W\TS_P"2* />Z*\$_P"&B?#'_0M^(?\ OYIG_P D4?\
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MD_XT>4??_OD_XT 97E?[/Z__ %Z/*_V?U_\ KUJ^4??_ +Y/^-'E'W_[Y/\
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M?_KUJ^4??_OD_P"-'E'W_P"^3_C0!E>5_L_K_P#7H\K_ &?U_P#KUJ^4??\
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M_C0!E>5_L_K_ /7H\K_9_7_Z]:OE'W_[Y/\ C1Y1]_\ OD_XT 97E?[/Z_\
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MQJ/R#_=_]"K;FA'FR]/]8_<_WC4?DCV_,U_7Q^TW\F9'D'^[_P"A4>0?[O\
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M?[O_ *%6OY(]OS-'DCV_,T!?R9D>0?[O_H5'D'^[_P"A5K^2/;\S1Y(]OS-
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MNM8T&^TG1KS5;ZUTK4-"U:]UJ\\17&H'5M075IKJZFO=2\QKII([P?:1K?\
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M],E\^]:)A<V<=P)M@$#;HLR+LDR"W.5&*!_)?<CY<\H^_P#WR?\ &CRC[_\
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M%_IH_P#X,F_^1J/^%/>+_31__!DW_P C4!;R7W(\>\H^_P#WR?\ &CRC[_\
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M1]_^^3_C1Y1]_P#OD_XU[#_PI[Q?Z:/_ .#)O_D:C_A3WB_TT?\ \&3?_(U
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MT:=IFFZ<)8?#S3#3M/L[ 3%#XM"&46D,(E*!F"&3<4#,%P&.?SXK]$_V+/\
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MB:+TQ>&Z_P#,OPK[^9SRXES=-VKT=+_\PM'MZGTNWQ^T$?\ ,O:WGT\_3O\
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MXN<<JULPP/\ X9\!_F9RXXXB25L3AO\ P@PW^9]VG]KWP@#@^#/%7_@9HO\
M\?I/^&O_  ?_ -"9XJ_\#-%_^/U\$/U'T_J:94?\1>XZ_P"AA@/_  S9?_F9
M_P"O/$?_ $%X?_P@PI]]?\-?^#_^A,\5?^!FB_\ Q^C_ (:_\'_]"9XJ_P#
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M3WH;G[48/H?R-&#Z'\C7R5\!/BM\6?%TD&GZWX9E\3^'XR(9?&S>7I$MD%&
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MC_B%?B=_T;GCK_Q$>(/_ )UA:/\ S]PO_A?EO_ST//Z*] _X0S0?^BH_"_\
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MA@#2AU'_ "$?7_MWJN?A)XO(/&D=#_S$3_\ (U>Z_P#"9^%_^@Q!_P!^;O\
M^1Z/^$S\+_\ 08@_[\W?_P CUD^!\CEO]?\ EC+?^ZS(?#V7/=XC_P *%_\
M*CP%_@_XR;.!H_3'.I'W_P"G:JS_  :\:G@+HWKG^U#SQ_UZU]#_ /"9^%_^
M@Q!_WYN__D>C_A,_"_\ T&(/^_-W_P#(]9/@'('N\P_\+5Z?] I#X;RQ]<3O
M?_>%_P#*CYN;X*>-R" -$Y_ZBC>O_7K59O@?XZ.<+H?.>NJGC/\ VZ5]-?\
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M)/V8?BFQR$\+]3_S'\=?^W&JS?LN?%8YPGA;G/\ S,'K_P!N%?>'_"9^%_\
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M/4_I_A1L'J?T_P *N[&]/U'^-&QO3]1_C0%GY??$H.@V-R?NMZ>A]J]#^(R
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M;!ZG]/\ "C8/4_I_A5W8WI^H_P :-C>GZC_&@+/R^^)2V#U/Z?X4;!ZG]/\
M"KNQO3]1_C1L;T_4?XT!9^7WQ*6P>I_3_"C8/4_I_A5W8WI^H_QHV-Z?J/\
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MHK_D89):+Q$E##\TOJ=H_6)-1HW?OM_8U9\4_P##-7QU_P"B6^-O_"9UO_Y
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MH^SR_P#/.7_OU)_A7U#10'(_[O\ 7R/E[[/+_P \Y?\ OU)_A1]GE_YYR_\
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MD?\ =_KY'R]]GE_YYR_]^I/\*/L\O_/.7_OU)_A7U#10'(_[O]?(^7OL\O\
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MM14YR]GYI>>+/%-Y@7WB#6)WAN;:Z#3W4JSQ75DL:V<IEPDZFT2.+[,C/Y4
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M9>2LO(****8@K] /V. 3H/C\ $DKH  '))9O%  'N20 .Y(%?G_7Z"?L9?\
M('\<?]=O"_\ Z5>(Z^,\0?\ DDLT_P 6 _\ 4^@?9^'W_)6Y7_@S#_U7USZD
M=E!)+ #)Y) [^]1&>$=9HA]9$']:BN?N_E_,UA3=#]!_.OYRA14[7DU=]$NU
MS^C*E=PVBGZM^?\ D;YO+0=;JW'UFC_^*J,ZA8#K>6H^L\0_FU<-<=#]3_,5
MB77?\?\ V:N^GEL)M7JS5^T8>7GYG#5S*I3VI0?K*:_)'J!U;2UZZC8CZW4
M_F],.M:..NJZ</K>VX_G)7BMQU/T'\ZQ;D#:W XW8X]Q7=3R.C.]\155NT*?
MZLX:F>5H7_V>B[?WZO\ EY'T"=>T-?O:SI:_6_M1_P"U::?$7AX==>T<8]=1
MM?\ X[7S)< $G(!X/7Z"L&Z ^;@=^P_VJ[*?#.'G_P Q==>E*B^E^K.*?$^(
MC>V$H/UJ5OT1]:GQ1X:'7Q#HH^NIV@_G+3#XL\*KU\2Z"/KJMD/YS5\8W('/
M _(?[-8=T!\W []A_M5W4^#<-.U\?B5?M1P_ZR."IQGBJ=TL#AG_ -QL0O\
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M\)CQ!_\ *ROV<HH_XBQF?_0GRW_PHQX?\0GRS_H<9E_X3X _&/\ X4W\4/\
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MW1]CG_N-_P!^YO\ XW7744 <C]CG_N-_W[F_^-T?8Y_[C?\ ?N;_ .-UUU%
M'(_8Y_[C?]^YO_C=6[RVED>(JK$"VA4_NY3R <CB,C/J#R.X%='10!R/V.?^
MXW_?N;_XW1]CG_N-_P!^YO\ XW7744 <C]CG_N-_W[F_^-T?8Y_[C?\ ?N;_
M .-UUU% '(_8Y_[C?]^YO_C='V.?^XW_ '[F_P#C===10!R/V.?^XW_?N;_X
MW1]CG_N-_P!^YO\ XW7744 <C]CG_N-_W[F_^-T?8Y_[C?\ ?N;_ .-UUU%
M'(_8Y_[C?]^YO_C='V.?^XW_ '[F_P#C===10!R/V.?^XW_?N;_XW1]CG_N-
M_P!^YO\ XW7744 <C]CG_N-_W[F_^-T?8Y_[C?\ ?N;_ .-UUU% '(_8Y_[C
M?]^YO_C='V.?^XW_ '[F_P#C===10!R/V.?^XW_?N;_XW1]CG_N-_P!^YO\
MXW7744 <C]CG_N-_W[F_^-T?8Y_[C?\ ?N;_ .-UUU% '(_8Y_[C?]^YO_C=
M'V.?^XW_ '[F_P#C===10!R/V.?^XW_?N;_XW1]CG_N-_P!^YO\ XW7744 <
MC]CG_N-_W[F_^-T?8Y_[C?\ ?N;_ .-UUU% '(_8Y_[C?]^YO_C='V.?^XW_
M '[F_P#C===10!R/V.?^XW_?N;_XW1]CG_N-_P!^YO\ XW7744 <C]CG_N-_
MW[F_^-T?8Y_[C?\ ?N;_ .-UUU% '(_8Y_[C?]^YO_C='V.?^XW_ '[F_P#C
M===10!R/V.?^XW_?N;_XW1]CG_N-_P!^YO\ XW7744 <C]CG_N-_W[F_^-T?
M8Y_[C?\ ?N;_ .-UUU% '(_8Y_[C?]^YO_C='V.?^XW_ '[F_P#C===10!R/
MV.?^XW_?N;_XW1]CG_N-_P!^YO\ XW7744 <C]CG_N-_W[F_^-T?8Y_[C?\
M?N;_ .-UUU% '$7]I<N;;RX)9 EML8I'(0&%Q<-M/R@@X8'! ."#T(HKMZ*"
M'!-MW>OH%%%%!84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
)44 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %= D4# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^W7XL?%CQ
M%X$\166D:19:+<VUSHMMJ3OJ5M?33B>:^U*U9$:UU*SC$0CLXBJF)G#M(3(5
M*JOF'_#1OC?_ *!7A7_P!U?_ .7E'[1O_([Z5_V*MC_Z=]<KP&OS#.,XS3#Y
MICZ-''XBE2I8B4*=.$H*,(J%%J,4Z,G:\I/63W>I\?C\?C*6,Q-.GB:L(0JN
M,8Q<;17+!V5X-VNWU>Y[]_PT;XW_ .@5X5_\ =7_ /EY1_PT;XW_ .@5X5_\
M =7_ /EY7@-%>9_;V<_]#+%?^!4__E!R?VEC_P#H+K??'_Y6>_?\-&^-_P#H
M%>%?_ '5_P#Y>4?\-&^-_P#H%>%?_ '5_P#Y>5X#11_;V<_]#+%?^!4__E ?
MVEC_ /H+K??'_P"5GOW_  T;XW_Z!7A7_P  =7_^7E'_  T;XW_Z!7A7_P
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M_EY7@-%']O9S_P!#+%?^!4__ )0']I8__H+K??'_ .5GOW_#1OC?_H%>%?\
MP!U?_P"7E'_#1OC?_H%>%?\ P!U?_P"7E> T4?V]G/\ T,L5_P"!4_\ Y0']
MI8__ *"ZWWQ_^5GOW_#1OC?_ *!7A7_P!U?_ .7E'_#1OC?_ *!7A7_P!U?_
M .7E> T4?V]G/_0RQ7_@5/\ ^4!_:6/_ .@NM]\?_E9[]_PT;XW_ .@5X5_\
M =7_ /EY1_PT;XW_ .@5X5_\ =7_ /EY7@-%']O9S_T,L5_X%3_^4!_:6/\
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MK??'_P"5GOW_  T;XW_Z!7A7_P  =7_^7E'_  T;XW_Z!7A7_P  =7_^7E>
MT4?V]G/_ $,L5_X%3_\ E ?VEC_^@NM]\?\ Y6>_?\-&^-_^@5X5_P# '5__
M )>4?\-&^-_^@5X5_P# '5__ )>5X#11_;V<_P#0RQ7_ (%3_P#E ?VEC_\
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M_P" .K__ "\H_P"&C?&__0*\*_\ @#J__P O*\!HH_M[.?\ H98K_P "I_\
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MI_\ R@/[2Q__ $%UOOC_ /*SW[_AHWQO_P! KPK_ . .K_\ R\H_X:-\;_\
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M (:-\;_] KPK_P" .K__ "\H_P"&C?&__0*\*_\ @#J__P O*\!HH_M[.?\
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M3HA#8Z9I6G6Z6ME9VT>21'#!&B[G9Y9&!DE>25W=ORK_ ."A'QE^-WB+XS_
M_P#8<_9[\3R^ /%_QPTVY\1>,O'5G-+;ZMI/@F.XUR)X],OK4)J&F06UCX1\
M6ZWK-SI-Q::Q>V^E6FE65[;07E^EUZ9_P3$_X2'_ (4]\1_L_P#PG'_"DO\
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MK2BTUKL]EL7A:52B\-"K"4)K-I2Y96O:6%J2B]&]&FFM=NQV>H_M,:]\6_\
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M"8+K_P#PCUW_ &&FB7<D#3);3Z=:VD7BR-/[8CD\/Q^(+KP\=5:(M:EO4/\
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MM-0UBWO[/[7\0==TBZTW[5=R13_9].CFMYMGFS.LBJI_5C]HW]MO3OA)X4^
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M=3'R;-)+#Q;X=T?Q,S/:Q"QUK0]7O)VMO#Y1?T9_X)__ /)_W_!2'_L?)/\
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M)]&T3PW-JNDZ+8@W&HB0:/X*\%ZG?+;VB2R,OASQMX@U%8XVDCAN60HWT/\
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M.L/*-)T(4J53GDZB=!*5&4Z3E[*-YNHYN#YK3>LMC\"?@3^PY\)OVSOVL_\
M@H6/BAXA^(F@_P#"M_VAO$7]A_\ " ZMX:TO[7_PF'Q)^,/]I_VM_P )#X2\
M4^?Y'_"+:?\ 8?L?V'RO.O/M'VKS(/L_T[_P5C\/V7A+PS^PSX5TZ6ZGT_PS
M\6=(\/V$UZ\4E[-9:-I_A;3;66[D@AMH)+J2"VC>X>&WMXGE+M'#$A$:_K#\
M,_V?/A#\'O%OQ3\=?#GPC_PCOBKXU>(E\5_$W5/[?\3ZO_PDNOIJ7B'5UO\
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ME16'^J63?\^\5_X5U/\ Y49?V)@/Y:W_ (/E_P#('Q;_ ,,Y>-_^@KX5_P#
M[5__ )1T?\,Y>-_^@KX5_P# [5__ )1U]I44?ZI9-_S[Q7_A74_^5!_8F _E
MK?\ @^7_ ,@?%O\ PSEXW_Z"OA7_ ,#M7_\ E'1_PSEXW_Z"OA7_ ,#M7_\
ME'7VE11_JEDW_/O%?^%=3_Y4']B8#^6M_P"#Y?\ R!\6_P##.7C?_H*^%?\
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MV)@/Y:W_ (/E_P#('Q;_ ,,Y>-_^@KX5_P# [5__ )1T?\,Y>-_^@KX5_P#
M[5__ )1U]I44?ZI9-_S[Q7_A74_^5!_8F _EK?\ @^7_ ,@?%O\ PSEXW_Z"
MOA7_ ,#M7_\ E'1_PSEXW_Z"OA7_ ,#M7_\ E'7VE11_JEDW_/O%?^%=3_Y4
M']B8#^6M_P"#Y?\ R!\6_P##.7C?_H*^%?\ P.U?_P"4='_#.7C?_H*^%?\
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M@KX5_P# [5__ )1U]I44?ZI9-_S[Q7_A74_^5!_8F _EK?\ @^7_ ,@?%O\
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MPSEXW_Z"OA7_ ,#M7_\ E'7VE11_JEDW_/O%?^%=3_Y4']B8#^6M_P"#Y?\
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M-!?>"]+BL;S5$UC2XK2XU".XT:YFEMY[7XRT#XM_\%)KC_@H)K7[(6K?'O\
M8>N?!GA?]G3X=?M0ZGXHT[]AKX]:=XGUCPQXT^-GQ$^&%Y\,K$7/_!1K5=*T
M;7K/2OA])J-M\1[BQUO3VU#64$OPW:VTQH=1]<_X*-_\C)_P3?\ ^TEWP._]
M53\?*YO0_P#E-U\4/^T5OP'_ /6M_P!HZ@#@_!GQ=_X*47O_  4&\5?L?>)/
MCW^P[?\ @[X>_LX? W]J/7_%6A_L,_'K0_$WB?PS\5?C9\;OA?JOPRT>._\
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MX(\1_&?]I[XC?#R_\1?#SX,_#SP3X?\ $6J^*=&TGXC^(]!\4?&O4O#E_P"
M/@[X>\=^*TU#3-/ /5_BK_P4@\'? W]NK4_V=?BAKGAFT^%>H_L?_"GXY?#*
M+P3X*^(_Q5^/WQ6^*GC_ .,WQ>\$7_@WX7?#?X5IXW\:?%VQL? 7PZ@\:_\
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M#PUXFTBR^(^G^'KOP/<ZYX8\2Z%%K[:QX>UFQLOPP^$'P,UKPUH7_!!KP/\
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M9\,_$'@KQ'\)? MAXFU;XG:_X:\;WOC_ ,$>';7XZ:!\&-'O=:EUC6M TR^
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MCSX7?%GX2_&#]GGXR^%;#Q#81:CX:\3:Q\%_V@O ?PP^*UMX&\4P-=0>%/B
M?!S>"/%&IZ-XET70/$&HZQX5\26.E?-F@?\ !7G_ ()\^++.UUOPG\;O$/BS
MP4+C1[+Q1\5O"WP"_:0\2?!#X3ZCKFJ'2;72OV@/CKHOPBOO@[^SCK%G(]GJ
MFOZ/\>O''PYU3PMX7U?P_P",?$UII'A+Q'H6M:CX[H'Q<^%7[9__  4A_9G^
M+W['GC#PK\9_AI^S3\$?VGO"G[0G[3OPC\0VGB[X,7Y^+W_"C[CP'^R[I_Q5
M\'2ZIX(^)'Q ?7M"TWXW>)O FGZ[J;_"C1?"/AK7/%":#J?Q'\&VWB#QW]BW
MP/X/T#_@WYU;0](\-:-8Z/XF_9"_:Q\0>(M-CL('L]=UGQK;_&#6/%FH:O!*
MDB:C<:]J&HWLVHF[$JSI.;8J+6.*% #ZX_:Q_P""AFG_ +,_[6_[(/[/$_@S
MXI:[H?QQU/XE?\+(U?PG^R9^UC\8YK+1]#^&?B3Q%X)7X<>+O@Y\.O$O@S6?
M$'_"7Z+ /B%H-D/&>M^"_ \DGBCQ7H_@[P]/;^*EYGP5_P %0?AUHGC[]L'P
M+\=)-;DUOX ?M1^*/A5X.\'_ +.W[/O[1G[1'Q'B^#FA_!KX,>/+3XF?%/P'
M\!O!WQK\7>&]'NO%GCOQCX?3XCZKX<\%?#R_DT2T\/6&?$&G:F][Y#87]YJO
MQ'_X( ZIJ-Q)=ZAJ7PZ^*%_?74I!EN;R\_8&U"XNKB0J%4R33R/(Y  W,< #
MBO:O^"<'AK0=/^,__!63Q19Z7:6_B'Q'_P %)_$5CKFL(A-]J5CX>_92_93&
MB6=Q,S,QM-+.K:I)9VZ;(89M2OIU3SKN=Y #Z?\ 'W[<'[,/P\^'?P>^*=[\
M1KWQSX1_:$DME^!2_ OX>?$_]I'Q;\8(+CPEJ7CQ]1^&WPZ_9\\%_$[XA^,M
M$T[P9I&H>)M=U[0?"U]HOAW1K<WVO7^FPRPM)] _#[Q_X*^*_@7P=\3OAMXG
MT;QM\/OB#X9T3QGX)\7^';V+4="\3^%O$FG6^K:%KND7T),5UI^J:;=V]Y:S
M*?GBE4D*V5'\R_@OQ'^S9X:_8?\ V>_'/Q:_;;\,?L _'[X0?M@?\%</%'[(
M_P =/&=[X9T_X=1S>$/VWOVH/ASXM^%/C/PKXWBL_AW\3? FO^"/$7AG3;[X
M-Q:UX9^*7B33M#AUGX.:]H7B'P;?>(-'_H&_8[^+'Q)^.W[*G[._QF^,7P\E
M^$_Q5^*'P=\ >-_B%\.9;#6])_X1'Q;XB\.6&I:WI,.C^)HXO$VBVD=]/-+9
M:+XFC3Q)H]G+!INOJ-7M;R@#Y9_X*B_MZ>,_V%OA)X$U;X-?".3]H3X]_$;Q
MS)_PB/P4L+A(M9U[X2?"+1+[XQ_M1>,K!'U71$%QX(^ WA#Q:GAN:74A%+\3
M?$?PYT=-*\47FLV?A+7O9/VF?VS?!?P;_8+^*/[<OPY%S\6_!FA_LZ:M\=_A
M5/X-\(^/_'^E^/[+4_ C^+?AKJ4]A\.?#OB#Q18> /$+7FA7WB;QM+IEIH'@
MCP;=:EXT\7:MX>\,Z+J^LZ?^>/PI^$'CS_@HA^UQ\</V^/"'[3WQU_9P^'/P
M@O?&W[#O[(.O? W2?V7_ !?9_$;X>?#[Q? ?VF/C+&/VC_V</VC-"BTWXD_M
M!>&KCP#X6\2?#\^'9?$?@?X':'J=W>ZMHVMZ=M\!@TN?]CS]AC_@K1_P2J\7
M^-=0\5_\* _8=_:@^/'[)?B'Q/:>$M(\3^//V./C%\)/B6QMKO3?!'ASP;X.
M_M?X%?'>/XA?##6[#P9X2\,^&/#7@C4O@S#I?AS0-+US2=,B /H/7O\ @JEX
M_P#A#^SS^Q/\1/B5I_C#XD>-?VEOV@_A_P"#?&5]X&_X)>?\%%OA9HFB_"WQ
M')?IXHL/#/POUY/B]X[M?B=I\L=E#\/GU?Q3JLWQET];_P 4_#3X:^(M M[B
M:S_2_P"+?[:W[/?P3F\ :5XWUKXCWOC3XG>&I?&G@[X2_#7]G[]H3XV?'B[\
M%VD=E_:?C/6/V?\ X,?"WQ]\;/"7A#0;W4]*T+Q-XH\7> ="T'PQXJU?1_"'
MB'4-,\4:MIVD7/Q-^U5_R0C_ ()0?]GI?L*?^HCXBKY@^-\6D_ '_@I7^U;\
M2/VBO^"AGQA_X)X>"/VBOAQ^SE<? ?XQP6'[$?AGX">.O#/PH\(Z_P"&/%?P
M*U'XT?M=_LN?&[3] ^*_@7X@7_C#XK:=\,H_'W@Z3Q9X3^+M[XH\(^$_$3>%
MO'NK:, ?K]9?ML?LP:C\"/\ AI6R^*EI/\'8/&7AOX<:OKZ^&?&RZ_X3^)'B
MGXD>'OA!8_#CQY\.9/#2?$OX??$+2OB;XIT3P7XS\#>-_"'A_P 5?#W6[BYM
M_'ND^&TTO59++T;X(?'SX3_M'^#[WXA?!7Q3)XY\!6WBKQ)X0L?&MKX=\4Z1
MX3\5:AX4OVTO5]8^'OB'Q#HFD:3\3/ KZA'-:Z+\3/A[=^)OASXHDM;W_A&?
M%6KK97;0_P X?QU^&GP7^)'[ 7[?'Q/\/?%C]IO]K#X?_M0_M;?\$]_"GC+X
MQ_M,>#OV>_"7PS_:1TOP3^T9^R?\,[SX@? 31_@#\%?@)I7C;X3ZOX0FL/A+
M<_%K6_ 46G?%6'X966I_#G7_ !A\,K/PKXS\1_U$Z'HNC>&]%TCP[X=TG3-
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**\&_:B_:.^&G[(?[/'QC_::^,.I/I?PW^"G@+7?'GB>6W\EM0OX-(MB;#P_
MHL-Q+!#=^(O%&KR:?X;\-Z>\\(U'7M6TZQ$J-<!A^!/_  ;6_P#!1'4/V^/A
MA^U'\0?C!^V);?%C]HWXD_M ^//C3>?L@7+:A;C]C7X0:KJZ^%?!'@7X>R^*
M- T[7O%?P_N++3=(OVU3PMXA\5^ ?#::KX5L-2B\/?%?7_B-<>*0#^F^BO\
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M!1_P]E^#W_1!?VIO_"*^&7_SX*_1+_A6'@'_ *%31?\ P MO_C='_"L/ /\
MT*FB_P#@!;?_ !N@#\[?^'LOP>_Z(+^U-_X17PR_^?!1_P /9?@]_P!$%_:F
M_P#"*^&7_P ^"OT2_P"%8> ?^A4T7_P MO\ XW1_PK#P#_T*FB_^ %M_\;H
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?G)_P4\_:^^)7[%?
MP$\(_%/X6:'X&U_Q!K_Q>T#P!>6?C_3=?U71HM&U7P9X_P#$5Q<VUOX=\3>%
M;U-32]\*Z?%#-+J$UJMK->H]E)-)!/;_ *-U^'7_  7Z_P"3.OAK_P!G+^#O
M_56_&6OO/"_+<!G/B'P?E6:X2CC\NQ^=4</C,'B%*5#$T)87,YRI58PJ49N#
MG1I2:C5@[PC[VZ?P7BEF>89-X=\8YKE6+K8#,L!DE;$8+&X=QC7PU>.*RR$:
MM*4Z=:"FH5JL4Y4JBM4E[NS7YH_\/^OVQ?\ HFO[-'_A'?%+_P"?+1_P_P"O
MVQ?^B:_LT?\ A'?%+_Y\M?AU17^@?_$'?"W_ *(3A_\ \$8S_P">Y_GO_P 1
MD\5/^B\XA_\ !^#_ /G0?N+_ ,/^OVQ?^B:_LT?^$=\4O_GRT?\ #_K]L7_H
MFO[-'_A'?%+_ .?+7X=44?\ $'?"W_HA.'__  1C/_GN'_$9/%3_ *+SB'_P
M?@__ )T'[B_\/^OVQ?\ HFO[-'_A'?%+_P"?+1_P_P"OVQ?^B:_LT?\ A'?%
M+_Y\M?AU11_Q!WPM_P"B$X?_ /!&,_\ GN'_ !&3Q4_Z+SB'_P 'X/\ ^=!^
MXO\ P_Z_;%_Z)K^S1_X1WQ2_^?+1_P /^OVQ?^B:_LT?^$=\4O\ Y\M?AU11
M_P 0=\+?^B$X?_\ !&,_^>X?\1D\5/\ HO.(?_!^#_\ G0?N+_P_Z_;%_P"B
M:_LT?^$=\4O_ )\M'_#_ *_;%_Z)K^S1_P"$=\4O_GRU^'5%'_$'?"W_ *(3
MA_\ \$8S_P">X?\ $9/%3_HO.(?_  ?@_P#YT'[B_P##_K]L7_HFO[-'_A'?
M%+_Y\M'_  _Z_;%_Z)K^S1_X1WQ2_P#GRU^'5%'_ !!WPM_Z(3A__P $8S_Y
M[A_Q&3Q4_P"B\XA_\'X/_P"=!^XO_#_K]L7_ *)K^S1_X1WQ2_\ GRT?\/\
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M +*#/_\ U>YV?Z[\.?\ ).<._P#9/9!_ZHLD"BBBO&/9"BBB@ HHHH ****
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M^WW_ ,%A/AS^P9X7\-_ #X<_$S_@CW\--=^*WPQ^"?AS3_"/P]T;6?$?Q^^
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M "47$/\ V4&?_P#J]SL_UWX<_P"2<X=_[)[(/_5%D@4445XQ[(4444 %%%%
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M+QM_PU%_PLC_ (6M_P -&_VA_8UU_P *X_X4'_PC'_%L_L7_  D/V+_A-O\
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M^Q5X-_X)[7WPMTK]BZ/]A&?X*?MS_"CQU\0?"'[-WP]TSQ+K.M:'\;_V2/\
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MN!/^R@H?^H>;GYIXR?\ )J^//^R>K_\ J9E!_(91117^GQ_ET%%%% !1110
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M;95EV-Q.!K8?'RJX6JZ-25*E0E3<E&G)N#EB(2<;5(ZN,7=/3:_[&45^.?\
MPU3\>O\ H>__ "U_!G_S.T?\-4_'K_H>_P#RU_!G_P SM>9_Q&[A7_H S_\
M\)<!_P#/$Y/^(AY+_P! V9_^"<-_\U'[&45^.?\ PU3\>O\ H>__ "U_!G_S
M.T?\-4_'K_H>_P#RU_!G_P SM'_$;N%?^@#/_P#PEP'_ ,\0_P"(AY+_ - V
M9_\ @G#?_-1^QE%?CG_PU3\>O^A[_P#+7\&?_,[1_P -4_'K_H>__+7\&?\
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M;2M4DA4I#)J.G6=Z\2,=S)&US#*R*S?,54@$\D9H U:*YG_A"O!O_0I>&?\
MP0Z5_P#(E'_"%>#?^A2\,_\ @ATK_P"1* .FHKF?^$*\&_\ 0I>&?_!#I7_R
M)1_PA7@W_H4O#/\ X(=*_P#D2@#IJ*YG_A"O!O\ T*7AG_P0Z5_\B4?\(5X-
M_P"A2\,_^"'2O_D2@#IJ*YG_ (0KP;_T*7AG_P $.E?_ ")1_P (5X-_Z%+P
MS_X(=*_^1* .FK\.O^"_7_)G7PU_[.7\'?\ JK?C+7[/_P#"%>#?^A2\,_\
M@ATK_P"1*/\ A"O!O_0I>&?_  0Z5_\ (E?2\'<0_P"J?%.1<2_5/K_]BYA3
MQWU+V_U;ZSR4<72]E]8]E7]C?ZUS<_L:EO9VY7S7C\SQEP[_ *V\*Y]PS];^
MH?VWE]3 ?7?8?6?JW/6P=;VOU?VM#VUOJO+R>VIW]I?F7+:7^;;17^DE_P (
M5X-_Z%+PS_X(=*_^1*/^$*\&_P#0I>&?_!#I7_R)7]/_ /$V/_5!_P#FR_\
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M7_"%>#?^A2\,_P#@ATK_ .1*/^$*\&_]"EX9_P#!#I7_ ,B4?\38_P#5!_\
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M .FHKF?^$*\&_P#0I>&?_!#I7_R)1_PA7@W_ *%+PS_X(=*_^1* .FHKF?\
MA"O!O_0I>&?_  0Z5_\ (E'_  A7@W_H4O#/_@ATK_Y$H _-S]MW_DJOA[_L
MGVE_^I'XKKXXK]ZO^$*\&_\ 0I>&?_!#I7_R)1_PA7@W_H4O#/\ X(=*_P#D
M2OQ3B'P>_M[/,TSG_6'ZK_:6+GBOJ_\ 9?MO8\U/#T^3VOU^E[2WL+\WLX7Y
MK<NEW^?9IP)_:68XS'_VI['ZW7E6]E]3]I[.\:4>7G^LPYK>SO?ECO:VFOX*
MT5^]7_"%>#?^A2\,_P#@ATK_ .1*/^$*\&_]"EX9_P#!#I7_ ,B5XW_$"/\
MJJ/_ ##?_A(X/^(;_P#4X_\ +#_[[/P5HK]ZO^$*\&_]"EX9_P#!#I7_ ,B4
M?\(5X-_Z%+PS_P""'2O_ )$H_P"($?\ 54?^8;_\)!_Q#?\ ZG'_ )8?_?9^
M"M%?O5_PA7@W_H4O#/\ X(=*_P#D2C_A"O!O_0I>&?\ P0Z5_P#(E'_$"/\
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M72(B1(D<:+''&JI'&BA$1$ 5$15 5550%55 "@   "@!U%%% !1110 4444
M<SXC\:>#O!TOAN'Q=XL\,^%9O&7B:Q\%^$(O$>O:7H<OBKQCJEIJ%_IGA/PW
M'J=U:MKGB;4;'2=4O;'0=+%UJEW::;J%S;VLD-G</'TU?FC_ ,%&_P#D9/\
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M^UM^U7\,_P!CO6?CE^UMXR\$_%CX>?\ !<KXY_LT:MJG[.'P^_9TT7X?K/\
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MGQNT7X&?'GPSX4\?^#8?$/ASQ=8>&O&5J--?PI_PMCPA\18O!%POA2#2;.S
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M9OAIX8T#7_ACXXUWQ_JNL?L_?$SQ6_A.'X=^$+#6-/\ $6N:W\2)P#]>:*_
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MU/Q%IEC<):7NHZ%8>//$^@76KV%G=2);75WI\5Q;V]PZ0RR)(P4^E?"KXO\
MPF^.W@;2/B=\$/BA\._C)\-=?DU*'0?B'\*O&WAKXA^!M;FT;4[O1=8BTCQ9
MX1U/6- U*32M8L+_ $G4H[/4)FL=3LKNPNA%=6TT2?"NI_\ *8KP3_VC3^)_
M_K47PCKYZ_;*\9> /V"/VQ_#_P"UGX \/2V-Y\3_ -DC]MSXD_M9?"[P#9VV
MFO\ M >&_P!C;X4^&/BOX&^+/B33+*TEMKOXE_#J^NX_@WI?Q+N[&36;S0?C
M)X>\$>(-5U+3M(\"Z/8 '[9UYAX)^,OPV^(OC;XR?#GP;XD_MCQE^S_XP\.>
M ?B[HW]CZ]I__")>+?%OPT\$_&#P]I/]H:KI=CI6O?VA\.OB+X.\1?;_  S?
M:UIEI_;']D7UY;:[I^JZ98_SS:)^W5^U=X8^$O@7]H^3XK?\%!/CI\>[F+PM
MX]^*'[$6G_\ !%W]K?PK^RGKWASQ#=0:AXW^#/[/OQ%@_8.T;XY>%_&OA+PQ
MJ#:9\*OC'\6/VJ_B3X$\5>,O#XUSQQX/MO"'C*/2_!/INH?'+XG?"7]JW_@H
M_P" ?@E?^&/#7QA_:K_X*F?L?_LS^ /B)XW\,W?C7P=\*;KQ!_P2B_9L^*'B
MWXBZWX,LM?\ "<GBV]T3X<?"?QI:^"?#EQXGT/2]6^(^I>#;/6[JXT634-.O
M@#^ANBOQ6^.#_MK_ +(O[0/[ NEV/[<OCW]H'X'_ +2G[7_A_P"!?Q8\._'W
MX3?LM:=\4].#? O]H;XD:;;?#WQK\!?@9\"/#,'@;Q"_@&-O'&B:K\/=>^)$
M6M^'O!FK>#/B5X7\*)\1/#'BOTW6OVJ_C+\-/A-^T9\$-:UZQ\7?MJ^!OB_;
M_!?X!:EKNA:%8VWQ+LOVG_$6O77[&_Q@U[PQX8M-%TBX\)>#_"<NLZ/\<=3T
MG2?#ECJOB']F+]H36]!T#1M(M],T^, _5RBOYNM+_;3^-'Q=\=?M%Z;JO[5/
M_!0;X%Z1^SS\7_'?[+_P?@_9R_X)+_%']J+PY\7/$O[/-Y<_#GXC_'C]I#XH
M^'?V"_CO\/?',GQ)^,FA^(Y;+X5_LP^+?V<+/P3\/M)32;C78O&'B1-3\%?4
M.B?MA?M2_M$^$/V!?@QIEAK?['WQX_:ST;]HOQ3\;/'_ (F^!OBOP_XM^'_@
M#]D/Q)X9\!?$G5?@?\%OVE-"L=5\%>,?CWXF\<^!?&/P&F_:'\">/+7P1\(-
M;U'Q'XS^&?Q'U33[>SN #]5_$/QC^''A7XJ?#7X*:]XC^P?$WXO^'_B-XI^'
M?AG^R->NO^$AT'X2GP:/B#?_ -LV6EW'A_2?^$?/Q \(_P"BZYJNF7FJ_P!K
M_P#$DM]2^P:G]B\V^-O[:/['7[,^O:1X5_:/_:Q_9I_9_P#$^OZ1_P )!H/A
MSXV_';X7?"G7M;T'[9<Z=_;>D:/X[\5:#J&I:1_:%G=V']I6=O-9_;+6YM?.
M\^"5%_,O4? 'QU^%G_!6C_@G[X3^*'[0^L_M*>"M0_9L_P""@NL^ ?&7Q,\&
M_"KP?\<-%U>WO/V0[;QMH7C&Y^!W@GX2?"?Q=X0D2\\+W?@6]\.?!WP=X@\.
M2+XCT[QGK/C!M2\.WUC](?\ !7[_ ),F;_L\#_@FA_Z\J_9)H ^^OA;\6?A7
M\<O FA_%+X*?$OX?_&#X9>)_[3_X1KXB_"WQEX<^('@3Q#_8FL:AX>UG^P_%
MWA/4M7\/ZM_9'B#2=5T/4_L&H7'V#6-,U#3+KRKVRN8(_0*_)KQOXA_:N^*'
M_!5_5?@!X(_:DUSX(_LQ_"']CC]F7]HWQEX!\%?"WX,>)/&_Q*^(7COX]_M;
M^!+SPV?B#\4/A_X]F\+?#KQ5X<^%_AZV^(5GI.DMXOD_X1GPV?AEXM^&5_?^
M--6\2_G#\._^"A_[17[0_P %]1_:T\*_';]NCX8_$7QK/XD\?_L]?LF>$O\
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M_8T_8)^*'[5?Q.^(OBSX??M1?'']D+X?:!\.O!?AGX!_MA_##]GK0/'GB/\
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M\7^%[+5[?XYS3ZS%J5_I/AZ]T, ^R-+_ &>_!>D?M->.OVK+;4_$[_$/X@?
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M^%O".K>!?@3X]U'5=?TC]HOX1Z#JMEI?POG_ .$]\2>"?".I_$?0HM:^!?\
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M!I][_:5Q??K[10!XW\$_AAXV^%7AO4]#\=?M%_&3]I;5+_7)=6M?&7QLT/\
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MQOM<??5% '\V_P#P5@_8%_;=^(OP[_X*-_M(>#OC3\*?B[J7Q"_8R^)G[/\
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H+[56\0>'X=,\16>GZM:>HT %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>image_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %M DL# 2(  A$! Q$!_\0
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MP_UDS3^?#_\ A-#_ .6'TW_PNCPM_P ^&O\ _@+IW_RUH_X71X6_Y\-?_P#
M73O_ ):U\R44?ZMY7_)B/_"F?_RL/]9,T_GP_P#X30_^6'TW_P +H\+?\^&O
M_P#@+IW_ ,M:/^%T>%O^?#7_ /P%T[_Y:U\R44?ZMY7_ "8C_P *9_\ RL/]
M9,T_GP__ (30_P#EA]-_\+H\+?\ /AK_ /X"Z=_\M:/^%T>%O^?#7_\ P%T[
M_P"6M?,E%'^K>5_R8C_PIG_\K#_63-/Y\/\ ^$T/_EA]-_\ "Z/"W_/AK_\
MX"Z=_P#+6C_A='A;_GPU_P#\!=._^6M?,E%'^K>5_P F(_\ "F?_ ,K#_63-
M/Y\/_P"$T/\ Y8?3?_"Z/"W_ #X:_P#^ NG?_+6C_A='A;_GPU__ ,!=._\
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MT>%O^?#7_P#P%T[_ .6M'_"Z/"W_ #X:_P#^ NG?_+6OF2BC_5O*_P"3$?\
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M\-?_ / 73O\ Y:T?\+H\+?\ /AK_ /X"Z=_\M:^9**/]6\K_ ),1_P"%,_\
MY6'^LF:?SX?_ ,)H?_+#Z;_X71X6_P"?#7__  %T[_Y:T?\ "Z/"W_/AK_\
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M  3C_P"%5?\ #5'Q6_X8Q_X65_PQC_PHCPS_ ,)%_P )=_PFO_"+_P##2/\
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M:1V+W\^AQ>*=.N9[F75-'C6QNK+38OKWX1^./C1_P44_9M_:*\+?&7X$7?P
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MV>G0VVGVDU_.DEW+;6-O!9P/*T5M#%"B(O\ *-^V5^V%:?M/>#=9^$7QH_9
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M9&UZ&-'<A9Y+B_U[1-5:ZOM.FLX_$NB/XBTO0=(ATWWO_@L-_P E5_X)U_\
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M!OAQX>,YT#X?^#_#/@G0S=,KW)TCPKHMEH6FFX=$1'G^Q6$/FLB(K2;BJJ"
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M#_\ 09B/_!5#_,^)O^$4\4_]"UK_ /X)]1_^1J/^$4\4_P#0M:__ ."?4?\
MY&K[9HH_UKQ'_0'A_P#P;7_R#_53#_\ 09B/_!5#_,^)O^$4\4_]"UK_ /X)
M]1_^1J/^$4\4_P#0M:__ ."?4?\ Y&K[9HH_UKQ'_0'A_P#P;7_R#_53#_\
M09B/_!5#_,^)O^$4\4_]"UK_ /X)]1_^1J/^$4\4_P#0M:__ ."?4?\ Y&K[
M9HH_UKQ'_0'A_P#P;7_R#_53#_\ 09B/_!5#_,^)O^$4\4_]"UK_ /X)]1_^
M1J/^$4\4_P#0M:__ ."?4?\ Y&K[9HH_UKQ'_0'A_P#P;7_R#_53#_\ 09B/
M_!5#_,^)O^$4\4_]"UK_ /X)]1_^1J/^$4\4_P#0M:__ ."?4?\ Y&K[9HH_
MUKQ'_0'A_P#P;7_R#_53#_\ 09B/_!5#_,^)O^$4\4_]"UK_ /X)]1_^1J/^
M$4\4_P#0M:__ ."?4?\ Y&K[9HH_UKQ'_0'A_P#P;7_R#_53#_\ 09B/_!5#
M_,^)O^$4\4_]"UK_ /X)]1_^1J/^$4\4_P#0M:__ ."?4?\ Y&K[9HH_UKQ'
M_0'A_P#P;7_R#_53#_\ 09B/_!5#_,^)O^$4\4_]"UK_ /X)]1_^1J/^$4\4
M_P#0M:__ ."?4?\ Y&K[9HH_UKQ'_0'A_P#P;7_R#_53#_\ 09B/_!5#_,^)
MO^$4\4_]"UK_ /X)]1_^1J/^$4\4_P#0M:__ ."?4?\ Y&K[9HH_UKQ'_0'A
M_P#P;7_R#_53#_\ 09B/_!5#_,^)O^$4\4_]"UK_ /X)]1_^1J/^$4\4_P#0
MM:__ ."?4?\ Y&K[9HH_UKQ'_0'A_P#P;7_R#_53#_\ 09B/_!5#_,^)O^$4
M\4_]"UK_ /X)]1_^1J/^$4\4_P#0M:__ ."?4?\ Y&K[9HH_UKQ'_0'A_P#P
M;7_R#_53#_\ 09B/_!5#_,^)O^$4\4_]"UK_ /X)]1_^1J/^$4\4_P#0M:__
M ."?4?\ Y&K[9HH_UKQ'_0'A_P#P;7_R#_53#_\ 09B/_!5#_,^)O^$4\4_]
M"UK_ /X)]1_^1J/^$4\4_P#0M:__ ."?4?\ Y&K[9HH_UKQ'_0'A_P#P;7_R
M#_53#_\ 09B/_!5#_,^)O^$4\4_]"UK_ /X)]1_^1J/^$4\4_P#0M:__ ."?
M4?\ Y&K[9HH_UKQ'_0'A_P#P;7_R#_53#_\ 09B/_!5#_,^)O^$4\4_]"UK_
M /X)]1_^1J/^$4\4_P#0M:__ ."?4?\ Y&K[9HH_UKQ'_0'A_P#P;7_R#_53
M#_\ 09B/_!5#_,^)O^$4\4_]"UK_ /X)]1_^1J/^$4\4_P#0M:__ ."?4?\
MY&K[9HH_UKQ'_0'A_P#P;7_R#_53#_\ 09B/_!5#_,^)O^$4\4_]"UK_ /X)
M]1_^1J/^$4\4_P#0M:__ ."?4?\ Y&K[9HH_UKQ'_0'A_P#P;7_R#_53#_\
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MX+\*>#/#NN:'I=GX4B\-6OC/Q'KFIWGB*7Q+8^'+'3=+UFE=^/?B]\:/V/\
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M?XVU1;SQ%>_8OQY^#'_"[=!^'^B?\))_PC/_  @OQP^"OQE^U?V/_;7]J_\
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MH/C_ $SP]:6=[X2T:_\ B+XX\5Z5KD&H:9JVK>,-3\3>-?&S>+VOM"TW1X_
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M1X7\1?"PV^A:]X-\00:[H+7VI?:7PX_9[^'OPW^&GB_X2V\.H>+?!/COQ/\
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MXD71?&/AW4W\)76BZ/J-YH8YCQ-^RJ^O_MB?#:/3+[XO>!]"^$'[&?ASPO\
M#CXZ>"Y(=/UCP[XN\.?$XZ8-$N-=U/PSK'PU\4:AKO@J6['B7P!XR\*^(O#.
MLZ==+K4WA%;O2]"U+2?KGX??LV^&_!6M>._&GB#QM\0_BW\4/B+H%KX0U[XI
M_$V^\*3^*K+P3I]O+'IO@GPEI'@CP?X'^'G@?PO;7EQ=ZY>:;X0\#Z+_ ,)+
MXDNI/$/B^7Q#JT5I=VP!^6/P:^&7B_P5_P $IO!W[2&F?&GXOZ=\8_A?^RC;
M_&/X?7&C_$KQOIGPOT+1_ACX*/C7PO\ #J_^!^EZ[I7PD\7Z#K?A[0!X;\:Z
MKXZ\'^*?%NIW'B3Q!J=EXDM&L?"$7AKTSXC?M3_$+X<?%3]MSXD:'J&K:GIG
M@_\ 8]_9:\<_#[P+XCU[5+OP)X1\7_$C7/B3I,GB:YT19_[.M+2SGNM%U3QK
M=Z9;Z?>:UHOAPP3WT AMKBU_0'3OV9? >F?LJO\ LA0:MXN?X:R?!'4_@(VN
M37^C-XY'@_5?!UWX(N-2&I)H$>@?\)*FE7DMQ#>'PR=+74%CE?1I+8-:-3TC
M]E+X5Z;XN^)GBO4$UOQ3%\6_@MX%^ GC?PKXGGTB_P#"6I_#_P !V'BK2K2U
M.G6VB6-ZUYK^G>,-7L_$KW.IW-A>P&W2RT[30L_V@ \[D_9"\4V&@Z3K7AC]
MJ?\ :(L?CYIMX-;O?BUXE^(OC/QIX"\3:W>B]37[37_V7=0\5V?[/=MX)U2W
MU*[LM.\*^#O!?A"[\)00:-?>%/$>D>(=(AUV7F)=.\0_M)?M2_';X>^+OB%\
M1_"/PE_9SLOA=I&C?#_X5_$#QM\'M6\;^,OB-X)?QIJ'C[Q=\0/AGXB\*_$.
M_P!"TC3]3@\+^&_">G^)-.\*3:MI>N:KKFG:QJ=AIDFG]4W[$'A:^T#3/AQX
ME^.'[1?C#X#:-=!M/^ 'B'QMX3/@DZ/9M=2^'_".L>/M'\ Z1^T1XL\(>&+B
M>TDTS0?&/QN\06M_!H^D:5XG/B'1+,Z9+Z-\1_V9_#OC;XB6/QA\)>/OB5\#
M_BW#H</A35_B!\)+WP8M]XQ\'VK:A-8>%_&_A;XE>"/B1\._%-CI%]J5QJ.A
M:IJG@R;Q1X?N2\6AZ_IUA=7]G> 'Y ?M):7XZ\ :9_P5?^$FJ_&KXE?%#X<>
M'?V-_AAXJ^&WAOXA^-]6\9WGPYL?%FI?%7^T/#MQJ.J3RWFLZE#<:8([?Q7X
MC?5/'FM>$8_"EMXR\3^*=4TPZW>?3OC?P[\3->^+W_!22\^#&KZ[I7Q9\$G]
MC_XE> (="UG6M(;Q/KWP\\"7/BT^ =7@T=V37] ^(NFZ7J'@;5O#VKV.J:/?
MV_B#S+BP:YMK.ZM?<%_X)Q_!^:T_:9&M_$7XY^*O$'[7'@31? OQH\9>)_&7
MAS5?$FIKHDNNM;>(O#X?P5%H'A74S::Z-(M= T30K7X=>'M#T;0M&\(^!O#N
MG6#6\_U#H7PM\)_#GQ_\:OC5:7?BF\UKXK67@N]\8:<L']N6EI!\+_#%YH>D
MIX2T'0="?Q'=7E[ILTTEWIRRZ_J&J:B(8='M87D2SE /D_PA\=1^UE\>O@''
M\)O%NNV/P=\!?!W2_P!ICXGS>&=7U2SM_$OBKXK:1<>'/@M\)/%NH:)=Z=%/
M9Z1IL_Q!\?>*_"=_=:C976M^&O!T.M^'R+9)8-G_ (*!6]CK'A7]F_P;XL>,
M_";Q_P#M>?!KP?\ &BPO5)T/7O MY:>+]2T;PSXHW,EJWAKQ+\4]*^'&AZO:
M:@XT_5(+\:/=QW$6H&UGL_\ !/3X'?\ "H_@CJOBW5_ @^'/CO\ :$^(/BWX
M\^,O!EQIUUI^J>"4\=7[7/@[X=W]OJ5U>ZK8-X$\%1:'HT^A7MRJ:%K7]N6E
MO9:=OEM4^O\ X@_#[P5\5O!7B7X<_$;PUI7C#P1XPTJXT7Q)X;UJW^TZ?JFG
MW.TM'(H9)8+B"5(KNQOK26"_TV_@MM0T^YM;ZUM[B( [&O@GXQ6LEI\6OV9/
MV/?AK<W7P,^$WC7P_P#%GX@>,9/A+#;?#?4M2\*?">7P8+?X1_#[Q!X<ALKC
MP(OBS7/'\>L^,]6\#IH/C>S\+:-?)X3\3^&M2U:;6K3N/^&4/$'V+_A&A^U_
M^U\/A[_;'VS_ (0;_A./AE]M_P"$?_M_^W/^$*'QL/P@/[3W]C_9_P#BGO\
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MGQB_["'PD_\ 5V?#BOI__A3_ (:_X7>/CY]NUW_A,1\*C\(/[-^TV'_"-?\
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M_P $J/C5^Q.FA_M_>'_AS<?';P%^V[HOQ>-W\.OB/\)_#^I>%_!WBWX1ZO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M .:FC_AL_P#;#_Z.O_:5_P##Z_%'_P":FOFJBO6_U=X>_P"B>R#_ ,,.1_\
MSE/(_P!8^(O^BAX@_P##_GO_ ,^SZ5_X;/\ VP_^CK_VE?\ P^OQ1_\ FIH_
MX;/_ &P_^CK_ -I7_P /K\4?_FIKYJHH_P!7>'O^B>R#_P ,.1__ #E#_6/B
M+_HH>(/_  _Y[_\ /L^E?^&S_P!L/_HZ_P#:5_\ #Z_%'_YJ:/\ AL_]L/\
MZ.O_ &E?_#Z_%'_YJ:^:J*/]7>'O^B>R#_PPY'_\Y0_UCXB_Z*'B#_P_Y[_\
M^SZ5_P"&S_VP_P#HZ_\ :5_\/K\4?_FIH_X;/_;#_P"CK_VE?_#Z_%'_ .:F
MOFJBC_5WA[_HGL@_\,.1_P#SE#_6/B+_ **'B#_P_P">_P#S[/I7_AL_]L/_
M *.O_:5_\/K\4?\ YJ:/^&S_ -L/_HZ_]I7_ ,/K\4?_ )J:^:J*/]7>'O\
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M[_V?_P @4?\ "M="_P"?O5O^_P#9_P#R!1_Q,GX6_P#09Q!_XC>,_P#F\/\
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MCJ%WX>UV.QN)WTG7+6PU/3;VXTF_%O?P6FH6-S+;K#=V[R;E !1110 4444
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MF^$EU;5M89$D\%>,1X%TVV\)VMI,=:^'_CF>]CCL>XT_XR_MG>.O@;<?M1^
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M_;FS^WD_LS?J%3XM_L>_\+2G_;%G_P"%B?V%_P -9? GX??!3;_PB/\ :?\
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M_+XSU_-#7]+W_!N[]S]KW_>^ ?\ +XSU^.^/O_)IN*O7)?\ U?Y8?LGT?_\
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ML=2R^DL+2P&8X:;C6JT:\95/:XFDE34$W%RES)1:?Y!45[=_PK70O^?O5O\
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M(**** "BBB@ HHHH **** "BBB@#^@;_ ((6?<_:C_WO@G_+XM5_0%7\_O\
MP0L^Y^U'_O?!/^7Q:K^@*@QG\3^7Y!11102%%%% !1110 4444 %?Q[?\%1O
M^3Z_CG_O_#G_ -5+X#K^PFOX]O\ @J-_R?7\<_\ ?^'/_JI? =!<-WZ?JCX
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M  <^#O\ YI*/^'</[;7_ $0#Q-_X.?!W_P TE 77=?>CXCHK[<_X=P_MM?\
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M_P#!SX._^:2C_AW#^VU_T0#Q-_X.?!W_ ,TE 77=?>CXCHK[<_X=P_MM?]$
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MX17C+_Y0T?\ "6Z5_P ^GB;_ ,(KQE_\H: .FHKF?^$MTK_GT\3?^$5XR_\
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M]KB3X6?L_>&OVZ/!ND> _B+\$?#W[%OAKX(_V;;_ /!,W2?V8])ETL>.[?\
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MATS2=1F,NE0Z1!/&LTOT10 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% 'Y>?&7P9X@^+'[4'[1NH^ EB?Q_\ OV7/V?=1^&C7$$3N_Q?G^+?Q8^
M,.DZ3;S.DWV73M?M?AOX/\+>)9U"S3Z!XLU*P>UO;*>X@G\A_:0\5Z/^UU\
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MZ5HFC6MEIFGP275Q/<R16EK#&\\TTS*9)'9NCH **** "BBB@ HHHH ****
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MT4NLV/@S2/!VE>';'4O%_CC5]*O=%FUC4;'6?T9^&7POM/!/AWX?_P#"2?\
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MHUC5=*\(^&=+U:>/1['6=9O;?5DTKY.\,?M7_#7XT?&[X+^._B]^SKJ_PO\
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MV?Q!?7S7VH:K#I^DV-Q='3M(TVSM?S_LOV=[CX"_!?\ 8T_9%U35SXI^(?Q
M_:T\*^/M?LIO'WQ \>^'F\(_!3QEJ_Q_\3:IH1^(LTY\/>'].T;PCX1T;5M(
MTG2_#^DZGXQ\3([V>H:MXCO=2U( _9+K1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
K 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>image_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #, JP# 2(  A$! Q$!_\0
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MM6?Q#L+S2;__ (7?X,8^$]*\57=_X0UC2-*UCPVS:I^='_!7G]O?XC_M=_\
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MO$0^&7BKX>6.LGP;?#4/%GAV[ED\8Z"=-U@>&-0LM)'_ !-=-.IZCK_L(_\
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MXC0/^"87_1'OVR__  W_ ,)__GR5_E^44 ?Z@?\ Q&@?\$PO^B/?ME_^&_\
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MP5_;/_X!\.?A?U_\/%_7%?E#X]_X-3_B+H\EU_9OC#P?-!'%Y7F:AKWV'O\
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M\$PO^B/?ME_^&_\ A/\ _/DH_P"(T#_@F%_T1[]LO_PW_P )_P#Y\E?Y?E%
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M;6^O+#XX66I6VG:_X@\+W<NE^$O'M_Y7B#PSI=WK'B#2O]$\+,1>Z?8V5RS
M')8=2237^-9J?Q;^(%DFHQV?C#Q!9VESK_\ PD<MG!=W-OYVL6EU_HFODG O
M-;R;0DD@ \GV7PO^U=^T5X%U%]6\'_&3Q_X;U>\UG4=9NM0T[7KF#S=0UBU^
MQZM=-S_IE]J0!_M6_/)(&!6GL_/\/^"9\]^GX_\  /\ 6U^)W_!P9_P2,^#6
MJ:/HGQ'_ &M]+\/ZGKFA6/B2PLS\-/C-JTXT:^VFUN+H:-\.]2^PWA()_LZ_
M*:EG!\OBO.?^(G#_ ((C?]'KZ9_X9O\ :"_^=57^13XT\;^+?B!KVH^)?&?B
M'4_$FO:A+YM_JFJW7GWLYSWS^O3CKUKD)).(PG3RP"/3KG_Z^?Y5F:'^P+_Q
M$X?\$1O^CU],_P##-_M!?_.JH_XB</\ @B-_T>OIG_AF_P!H+_YU5?X_)+_=
MWR,_(P/\2<X_^N/:GH?F'SAOWG\?0_7)_/M0!_L!?\1-O_!$3_H]C2__  SO
MQ[_^=;1_Q$V_\$1/^CV-+_\ #._'O_YUM?Y S6[/YCI-&4C_ -9_Q]>_8@YZ
M>H]:GBL]Z(K-L?RKB65_;L#_ )]?Q /]>_\ XB</^"(W_1ZVF?\ AG?CW_\
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M:FCT>;,,+I))-)$91Y?_ "QS_GG ZT ?Z\__ !$V_P#!$3_H]C2__#._'O\
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MIG_AF_V@O_G54?\ $3A_P1&_Z/7TS_PS?[07_P ZJO\ 'U\Q_P"\:/,?^\:
M/]@K_B)P_P""(W_1Z^F?^&;_ &@O_G54?\1.'_!$;_H]?3/_  S?[07_ ,ZJ
MO\?7S'_O&E\U_7]3_C0!_L$+_P '-O\ P1*;_F]G2Q_W2#X\_P#SJ^OM7=:'
M_P '#/\ P2!\36(U+2/VO](N[02O;^<?A?\ &E,R($D8!7\"(V )4Z@\Y&<
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MY?EZ?XHT'5)_SO<#O^?I7^6QK'Q;\5:HWG77B2]N;G[4/,DN)3.>GV.Z/O\
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M *Z#+]UY?B??/CS_ (-S_P!N?POX?N=8TSX>R:W86\7FQ2>&-4TOQ5_R]?\
M3E??V@?7/]F_2OR/^+?[('QD^"&M:CHGC?P9K>FZEIX_>V]W9W-M?0@_].EV
M!GN,GN*_;7]E/_@Y _;)^!=Q9Z5XR\2>'_BCX2_U5UI?BS1K6QO9K<=K3Q!H
MI_T+_CUN_P#D(]QCU%?O!\,_^"KO_!*W_@H_I=GX/_:]^&FE_#3QEJG_ !*Q
MX@UR6UAL/M'_ !YFZM?%=EG4++_N(_H :"#_ #SK_0+F)D0))O\ +N)1'/\
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MD-SX,^&'@_1]+M[K5+RXN]-TK^V-8%MF[NO]+*F^ON,'GOSG.*_E4_X*<?\
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M>S_Z"VE?GQ_6O[\O^"6?_!9_]EC]MOP[X7^%W[0W]@>"?C9+%_9\J^*!I?\
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MDR_Z+>6]T?(F_P!&_3]/2O3OB!^SWXMCC35;.P^WPV]K;GS(XO\ 7'M=VO\
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MRI9+BU^W0?:/^7OVYSS^7- 'M+^ _!^H>$TAL+S3TO[S[/8:7'_I5A?P\?\
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MO>W5QJDL?FW4\\V>O^3CB@#\RO#?PSMK6SL[!/$-Q<VUO^ZM;:.*U_X]\?\
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M3U__ %>PQ_%G[+]M?W?ANY\;/X@T2P\016^LZ7<?Z^#^S[RZ_P"/K_0OZ5]
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M)HXYM^E6[_\ ;7.?\]_Y\U_)'^U5^T+\(M ^-G[;WPQ^+L/CBPTKXP:]X?\
MLNL?#^PTO5;[3;CPW=?;/]+L]9OM-_Y"/\[P>V0#\W_@%\/X?$GQDTWPJESI
M_B2'_A([>U^V:/?W5]8WA_M3[&+JTNSG_/Z?ZIG[(?P7\#?!_P#9[^%WA3PE
MHEOIJ)X'\/\ V_\ Y;SWFHWFEVGVO[7=_P"?3Z_Y>?[&/B#PQI_[0&@ZK87-
MQ-H.EZ]I]_8_VI%Y%]_9_P#:G_'U=VED/]"ONA^G2O\ 4V_9Q\46'B;X3^$K
MRV>-_L^@Z?Y7[W_EW-K9FT[_ %'\J /B']HB.QTWQI>:;;7/V6:.+S8HY/\
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M_7DUSG4?R4^,KBPFO)KFSL+V"&2UN,6]Q=>?Y/\ 3CJ?RKB;9=22Q_LVYO\
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MGI]A;VIO-8L+KR/]#_T+\SG\:ZIO$VI6]P?/FU2:3RO-BDT^UM8(+RX_3/\
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M]4N=.DE2:/4-G_/S92^?YP_3G]/:@#2M]#LK.2V1[F\N4N(O-EMO]1Y']/\
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MIS]E//\ IV.PP!P.!Q7^([X/\6S^&]2AO+.:Y2;SO-BDCEQ]C^Q\?:NP]O\
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MA/\ ;XLV&=3N[,$8LC>9"V&0-Q!(."*_2VWM8+:"*WAAAA@@C$<4$<0BAB
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M))?W_P!G]?KG_&O9?VK/VX/A=^SWX#UNVTO5;-[;PWHUQ%?W%G)^XA^QVO\
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M-?DUK'_!.C]HCX)_$?3;/Q%X,U#4M!L]4MY9=8T.7[=I7V?_ $0?:O\ 0O\
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M]G_TB3_7S?;;K\KW^7X&M/9^?X?\$Q]II:E_P?\ @FEK6MS:Q<S/<OYWF_\
M'U]H^U>1#]L_S_\ 7ZUS$MQ-')LN?L^R24>;))_U]8Z_AGOZ4S5/.94^?R4C
MB_>^7%_I'/\ RZCG\ZALX[R.%$F3>GF_]^?R_+]>M:$G0QEY)/\ 1G_U<7^K
MMXO;_ET_KS^7?TGPCON)+--EQ^\_U4G^O_Z?;NZ_T+\/RX[BO1_V-_ >A?$+
M]HSX.>$O$FFV>J^&_$'Q0\#Z-K6ER?:H(+S3[S5+.SN[7G_EQ_KCU)/Z<?\
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M_K?]?_I'_/T?Y<^U7]+O/L=YO^TQPIS+]HDXX'_'H?\ W'_^ ')&:_MIM?\
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M&S=/)FC'[JWM_P!_/]H_Y];L7O\ G\>0 <WI>FV%QYSS/;O-YOE2_O;KCO\
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M/?\ VJUDMY?L_P#R]?\ 'K=^G_+YSG\J\M\06]S'<3(_F0P\Q^D'UZ^EI_\
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M9]5N_P#13_Q*_">D_P#+G_U_],8X/2OYN/BY^T1XJ\?7-_;6U_J$6E7]_/\
M;]0O);J?7=>QTNM5N_;T_3- 'N_[9'[9'B[XV^)=1EEUB\U*&YU"XDU._$V;
M>;DC[)9_\^=CI_8C.?3I7YW_ &Z:XV(DV[]Z;J62XBM?^7SU_3_Z^:K7C/<;
M\3?:?M'_ #\?Z_[3_G_/2J'F22Q[.-B#GW_Z=>,_Y-!SFLDIBC?:Z>29!:W6
M1Y\ !%Y:9M!C."N,>H(/( -:GEW,DL,+I\DD7'[KK_HO_'U_GMV[5RL<+?\
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MNC:'^S=0XS_T#*_*+QA^S7\9O@WK$&G>// OBSP9>6TMS%=6?BCPYKWAR?\
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M:?A=^R#\>/CAJB:#\-/A=XX\>:E<77E16_A/PYKVN#BUXM;N[LK'^S\>OO\
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M7[74VN.GP9^(OPG\>6%Y]GNK6SURUNM*OH;<=_M>BC^S_P!?TKW+X;_LZ_\
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M?PYI'BF^T[5=;L;(VMEM@N[^([+AE/1QUYK\>=+F>.1$A\M(X[NW'^M_U/\
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M\N6,'K7L>G_\$P_^"1'[2HF?]DC_ (*66?P]\121?:K7P/\ M&:+:Z'Y&/\
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M]X<OH<7?VRTN_P#B2WW_ %Z?IQZ_L-\#_P#@X5_X*%?"M+/2W^.NL?$O0?\
M1H3X?^,&@Z5\1K&?V-W>V.FZAQD_\Q/K9D#-+V?G^'_!-_:4^_X_\ AA_P""
MOG[?^AVD.FO\=?'$$=O^Z^SW%T#/#]B_Y^[3]/U(YKFM6_X+*?MJWEO]EU7X
MG:IJ7F17'E7&J1'S\_\ /KZ\=J_0S3?^"^'[-/QPL;>P_; _X)R_L[_%W[9%
MY6O>*/ \5KX.\1S?;/\ EZS>V'-_J-]_U$^?7BN8U[XH?\&]GQLEGFO?@/\
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MIDCF\R7RMXF\_K]L_P#)'C%>L>#[=X]3L_\ 6/"\7E?NP/(@_P"?2U[]Z/\
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M]$Q_I7]GZ#=6/DP?^!WOWI_BC_@XBN_$"VU@FB>%[/$?V2ZU"\M=>/G =?\
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M3PE^Q9;VNCZ=IL>F^+?V4X+/5M(GL;>;2Q/%X8O FKV=H4"VNM#J=01BY/\
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M3PYH_C?Q'\0/#]KJEC\.=2UGP?KW^E^%_!%W_P @^]L?$6A_\2_5O[._Z?\
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M_GX/V/\ >?\ CHK'/@K3+=6ECNM1+^9<<O):/_RZS?WK+_IJ_P"8QC%;>_\
MW?Q*YWY?C_F>86ADM_D=[A(9#_SR/[X9[#_MT/!K8CN+F..2&.:1TCBMXHA'
M=>1Z#_P.'_(0]*[]_#>GS8W&1<P6[?)'9+S]K'_3H?K]:UW\+V4C3[[J^;:T
M#IE[3Y3%:G9M_P!#[8YSG-'O_P!W\0YWV7X_YGG<FJ7EG##L2XW_ .JBN/\
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MCVG^F>$_"]W_ *!QXX\.Y/\ :P__ %U^&W[8GBSX8^//BYXDU7X/^&]/\,>
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MX^_MM]_UZ?7VYQZ1I?[*G@.\DD\[Q%XXQ]K\S"7GAA1NP3_T*9X]JFE_92\
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JU]O?"+]F;P./"9_XGGC DW[$EKGPX3DZ?IW<^&>E9U.GS-,/M\O\C__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>image_005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" &A G@# 2(  A$! Q$!_\0
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M_P"3.^_X6AXY_P"@Y_Y3-'_^5]'_  M#QS_T'/\ RF:/_P#*^N!HH_L[ ?\
M0#A/_">E_P#(!_:./_Z#L7_X45?_ ),[[_A:'CG_ *#G_E,T?_Y7T?\ "T/'
M/_0<_P#*9H__ ,KZX&BC^SL!_P! .$_\)Z7_ ,@']HX__H.Q?_A15_\ DSOO
M^%H>.?\ H.?^4S1__E?1_P +0\<_]!S_ ,IFC_\ ROK@:*/[.P'_ $ X3_PG
MI?\ R ?VCC_^@[%_^%%7_P"3.^_X6AXY_P"@Y_Y3-'_^5]'_  M#QS_T'/\
MRF:/_P#*^N!HH_L[ ?\ 0#A/_">E_P#(!_:./_Z#L7_X45?_ ),[[_A:'CG_
M *#G_E,T?_Y7T?\ "T/'/_0<_P#*9H__ ,KZX&BC^SL!_P! .$_\)Z7_ ,@'
M]HX__H.Q?_A15_\ DSOO^%H>.?\ H.?^4S1__E?1_P +0\<_]!S_ ,IFC_\
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M_P"3.^_X6AXY_P"@Y_Y3-'_^5]'_  M#QS_T'/\ RF:/_P#*^N!HH_L[ ?\
M0#A/_">E_P#(!_:./_Z#L7_X45?_ ),[[_A:'CG_ *#G_E,T?_Y7T?\ "T/'
M/_0<_P#*9H__ ,KZX&BC^SL!_P! .$_\)Z7_ ,@']HX__H.Q?_A15_\ DSOO
M^%H>.?\ H.?^4S1__E?1_P +0\<_]!S_ ,IFC_\ ROK@:*/[.P'_ $ X3_PG
MI?\ R ?VCC_^@[%_^%%7_P"3.^_X6AXY_P"@Y_Y3-'_^5]'_  M#QS_T'/\
MRF:/_P#*^N!HH_L[ ?\ 0#A/_">E_P#(!_:./_Z#L7_X45?_ ),[[_A:'CG_
M *#G_E,T?_Y7T?\ "T/'/_0<_P#*9H__ ,KZX&BC^SL!_P! .$_\)Z7_ ,@'
M]HX__H.Q?_A15_\ DSOO^%H>.?\ H.?^4S1__E?1_P +0\<_]!S_ ,IFC_\
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M_P"3.^_X6AXY_P"@Y_Y3-'_^5]'_  M#QS_T'/\ RF:/_P#*^N!HH_L[ ?\
M0#A/_">E_P#(!_:./_Z#L7_X45?_ ),[[_A:'CG_ *#G_E,T?_Y7T?\ "T/'
M/_0<_P#*9H__ ,KZX&BC^SL!_P! .$_\)Z7_ ,@']HX__H.Q?_A15_\ DSOO
M^%H>.?\ H.?^4S1__E?1_P +0\<_]!S_ ,IFC_\ ROK@:*/[.P'_ $ X3_PG
MI?\ R ?VCC_^@[%_^%%7_P"3.^_X6AXY_P"@Y_Y3-'_^5]'_  M#QS_T'/\
MRF:/_P#*^N!HH_L[ ?\ 0#A/_">E_P#(!_:./_Z#L7_X45?_ ),[[_A:'CG_
M *#G_E,T?_Y7T?\ "T/'/_0<_P#*9H__ ,KZX&BC^SL!_P! .$_\)Z7_ ,@'
M]HX__H.Q?_A15_\ DSOO^%H>.?\ H.?^4S1__E?1_P +0\<_]!S_ ,IFC_\
MROK@:*/[.P'_ $ X3_PGI?\ R ?VCC_^@[%_^%%7_P"3.^_X6AXY_P"@Y_Y3
M-'_^5]'_  M#QS_T'/\ RF:/_P#*^N!HH_L[ ?\ 0#A/_">E_P#(!_:./_Z#
ML7_X45?_ ),[[_A:'CG_ *#G_E,T?_Y7T?\ "T/'/_0<_P#*9H__ ,KZX&BC
M^SL!_P! .$_\)Z7_ ,@']HX__H.Q?_A15_\ DSOO^%H>.?\ H.?^4S1__E?1
M_P +0\<_]!S_ ,IFC_\ ROK@:*/[.P'_ $ X3_PGI?\ R ?VCC_^@[%_^%%7
M_P"3.^_X6AXY_P"@Y_Y3-'_^5]'_  M#QS_T'/\ RF:/_P#*^N!HH_L[ ?\
M0#A/_">E_P#(!_:./_Z#L7_X45?_ ),[[_A:'CG_ *#G_E,T?_Y7T?\ "T/'
M/_0<_P#*9H__ ,KZX&BC^SL!_P! .$_\)Z7_ ,@']HX__H.Q?_A15_\ DSOO
M^%H>.?\ H.?^4S1__E?1_P +0\<_]!S_ ,IFC_\ ROK@:*/[.P'_ $ X3_PG
MI?\ R ?VCC_^@[%_^%%7_P"3.^_X6AXY_P"@Y_Y3-'_^5]'_  M#QS_T'/\
MRF:/_P#*^N!HH_L[ ?\ 0#A/_">E_P#(!_:./_Z#L7_X45?_ ),[[_A:'CG_
M *#G_E,T?_Y7T?\ "T/'/_0<_P#*9H__ ,KZX&BC^SL!_P! .$_\)Z7_ ,@'
M]HX__H.Q?_A15_\ DSOO^%H>.?\ H.?^4S1__E?1_P +0\<_]!S_ ,IFC_\
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M3<91JSIPJ5N=<E2M&C-P4:4X1]Q5)Q<O=_=*BOR(^%O_ "F?_:5_[-,\(?\
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M6KUI2I)5(TJ,J,%4ITH5I^TC6G65.BY3I-SA4YXPA!R?['45^&OQ3^%^C_\
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M3ZYXM.J6OBA_!OQ&\"1VMQKDD5C+I*W\6I/-'IE^;>2U6.99_2/V^O%/Q?\
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MI=];W5CJ5G=&PO8Y88;@1_\ !.[]D[X%:;^V5^V_>Z)X+_LO5OV;/BKHN@_
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M_P"H](_1\@_Y%.%]:_\ Z?J&!\:/^1IL/^P!:_\ IQU6O(J]=^-'_(TV'_8
MM?\ TXZK7D5?;9/_ ,BO _\ 8/'_ -+K'Q6<?\C3'?\ 81+_ -(HA1117I'F
MA1110 4444 %%%% !1110 4444 %?DYH7['W[7'[*GC7QW+^PQ\2/@;>?!?X
ME>(-6\87?P5_:3T_Q[_8_P -/$NH_P!EF:X\!:[\.H[C6-3M+P6]W9);:I+H
M\.F:+;:197\'BO5H&\1Q?K'16%;#TZ[A*3J0J4G)TZM&I*E5ASI1FE.*E>,X
MI*<)0G&5D[*48R6]'$5*"G&*ISIU5%5*5:G&K2GRMR@W"3C:4)-N$XSA*-VN
M9QE*+_,_4OV6?VM?'O[,?[2_P^^,W[0'A'XC?%7]H/3;AM&T&+0[KPW\'OA!
M?&WT_3K?P]X+UFVT>]\9W'A=]/TVU-_)J.@L]Q?6\.K)HT?B;4O&GB;QGROQ
MW_87^+7Q/_8"^!/[*N@>(OAU9_$+X8#X1_V_K.L:OXEM_!EY_P (#H=YIFL?
MV/J-EX1U#6[C[3/<(^F_;?#NG^="':Z^QN!&WZM45C++\/.,X2]M)5,.\+.4
MJTY3E2E6=>5YRYI<[J-OGZ)\L81BDH[1S#$0E"<?8Q=/$+%0C&C",(U8T50C
M:$>6/(J:2Y.K7-*<I-RE\!?M1_LA>-O'_P 5/ /[47[-WQ!T;X5?M,?#/3+G
MP];W7BG2)-6^'7Q0\&7GVM;CP3\1K6QAGU.VL]FH7RVOB#3K+5-1L()V6SL8
M=8L_#7B'POYC9?LB?M._M"_&#X:?$K]NGQ[\%+OP;\#M4L_$WPZ^"'[/>E>,
M7\"^(_'$5S/=#QE\0=4^)$":[<7&F^5IEG;Z!$=6T>^L[8QVW_"/)=>)X?&'
MZET4YX'#SJ2G+VEIU(U:E&-6<</5JPY7&I4HI<LI7A!R]Z,9N$'4A4<4VH8[
M$0IQA'V=X4Y4J=:5*$L12I3YE*G3K-\T8M3FE[LI04YJG.FI-+\HOB3^S%^V
MGX=_;9^)'[5W[-6K_LO2V?C_ .&'AOX:/HWQRO\ XKO<VUEI<?ABYU&[33O
M.@010W3ZGX9MA93GQ'>0M833B>PCN)(VM\[QE^S%^W3X=_;#\:?M7? G5_V3
M9=1\?_!_P;\--=T;XMW_ ,87LK:YTNR\*7/B*[TC3O!V@03PP/K_ (90:+/>
M>([R1M'F<7UA'>R!K?\ 6ZBH>74&Y6J8F-\2\6N2NXJG7?/S3I?NI<G-SRYE
M[Z:MM;6UF-=<MZ>&E;#+"/GH*3J4%R<L*O[V//R\D>5^XT[[WT_/3XM_"_\
M;_\ $$WP7^(GPW^+'P&M/'.@>"-9\)?&CX%^,M/\;O\ LR^,M1\2VTK:KXIT
MFYTG2[CXEZC=V-S!I=GHVF^)+D16=C:/+87ND1ZEXPTKQKY?\.?^"??C?X;_
M /!/7XM?LIV7C+PAJWQ1^+L?BGQ!JFL-'J>B?#C1/%WBR+0()]'T8V>CWNL1
M>%-(MM!M[:UO$\.P75[*9KT:#I:7*Z=:?JW15O 4)3G4FZTY3I5*+YZTY*,:
MU.%*M*$6K0G5A"/.X^[S)RC3A*4G*%CZ\80IP5&$85:=9<E&$7*5&I.K1C.2
M=YPI3G+D4O>Y6HRJ3C&*C^5OQ@_8M^._Q#_8D_9W_8^T+Q?\.M#L_#EM\*O#
MW[0&O2ZWXKCCU;PAX"M].DU+3OA^MMX1EDU>XO-9LK;5;1?$EOX;@D.DV,-P
MUO\ :YI+/A?CO_P1]^ K^!(]4_9#\(Z/\&OC_P"%_%/A/Q7X$\:>(OB%\6]7
MT&&ZT#7;.^NK/5(]6UWQP+.-K9)+VROK'PY>7T>K6&GPA[>SN+R5?V,HJ)Y9
M@ZO-[2E[1NC2H1G-\TZ5.C!0I^PFX\U&2LIN</>E42F]4DKAF6,I<OLZOLXJ
MM5KRA!<L*M2M-SJ>W@I<M:+NX*$_=C3;@M&V_P L?VD_V=OV^?B/>^/H_AW\
M6?@+KO@'XX?!.Q^&OQ#^#_QJM/%-UX,^%WB%-.O(K[Q%\&+[PIX,>?5K_P#M
M37==U"R\1^.M'75)S#H$7B73O$=GX=\)6/A'-UC_ ()Y>,M$L?\ @G3X6\!^
M./#6M^'?V-/'MYXH\<ZUXP;6-!UOQ;9ZAKOAS7[Z7PGHNE:9XILX;B2]T_5A
M9:/J^OVEOI]I)IMF=;O2D]TOZP44Y9?AY3G.;K3E/DUG6G+D4:]+$\M.Z]R,
MJU&$YQ3DG9Q@J4&XBCF&(C"$(*C",.?2%&$>=RH5<-S5+/WY1HUIPA)J+5U*
M;JS2D?C5^T7^P_\ MN?',_$WX,ZI\?\ X1>-/V:OBE\3O#GCY/$?Q0\.ZY>_
M'3X466FWNGSW&@?#;3?#VAV/@2*SL;73X[&!(]2\/_VW;SZJIE\-'Q)XD;4_
MUZ\,Z!9^%/#?A_POITMU/I_AO1-)T"QFOI5N+Z:ST>PM].M9;R=(X4FNI(+9
M'N)4AB628NZQH&"C;HK6CA:5"I5JP=24ZJC&4JM6=5QA&52<:<'/6,(RJ3:B
MW-KFMS\JC&.5;%5:].G2FJ<84G*48TJ4*2<Y1A"52:AI*<HTX)R2@GRWY.9R
ME+\,/AC_ ,$R/COX:^#/[)OP;\7^+?A+?Z#\&OVL)OV@OBE:Z7X@\:7>G>(]
M L)](.AZ-X>MKSP'IW]J:Q+9_P#"26%^-8&A6MA!J*BSU"\^UW(M_;_!?_!.
M74?"_P#P4<\5?M>3Z[X6N?A3>1^)/&OA7P9]HU2X\3Z;\7_&>A:5H'B?5KK2
M)M!@\-V^EW;2>(]>BUFTURXUL:F=#@FL'^S-J-O^L%%<\,KP<%22A-^QJ4*E
M-RJ2DU+#4I4J2;<5>*C)N47I*:C)V:1O/-,9-U6YP7MJ>(IU%&G&*<<35C5J
MM+F=I.44HR6L8.45=-GXBWW_  39^.S_ +#7QK_9-L/%7PECU7Q9^T7>?$WX
M9:E-K_C%/#ND_#N;5_#6IV^A^(YT\!3:I9^(8)-)U.9H=/T_6]/>2_AA_M4)
M$TQ_9OPII5QH7A;PUHEV\,EWHV@:-I5U);,[V\EQI^G6UI,\#RQPR-"TD+-$
MTD43LA4O&C$J-^BM\/@Z&&=Z2FG[&G0]Z;DE3I3JS@DFEJG6FK]8\L;6BF\:
M^,K8E6JN#7MJE?W8*+=2K"E";;3>C5&#M_-S2O>3M^#_ (5_X);?'3P3\%_
M,OA7QI\)=(_:?^#W[3_B+XV_#CQ?%JWBR7P3=>"_$\/AB'5_!GBC4#X$CU]C
M>2>'8+J>QB\/:CIC1QSZ<;DV^MW\UO\ 9WQ]_9'^*NO?%[PI^UQ^S1XZ\)?"
MC]IO1_".G>#?&?ASQ;#JWB'X.?%KPO\ ;M-N;WPEXTU'2M/T_P 30V=@D$BV
MOB/3_#S:KJ<>C>&XX+'POJ%A8:YH_P"B5%90RW"TX.G"-2,7[%IJK)2A4P_.
MJ5:$DDX5HQFXNHOC@HQG"45:6L\RQ52:J3E3E)>V33I1<9T\1R.K1G%MJ=&4
MH*2IOX)N4H3C)IQ_,+P;^R+^T;\7_CUX!^/?[<OC_P"$^NQ_!&Z.K?!KX,?
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MG[0GQ:U_XE?"RVM[_P 2WEMIBW5QXMO=&M/B!#+H&C2V3+=:UIJZG!X=O-:
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M<$Y2IX>HJE.[;=Y\T4YS:;FM)+5M_C!9?L'_ +9/Q#^)?[.4?[2GQO\ @_\
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MMYI_)A__  IA_P#*SYDHKZ;_ .%+^%O^?_7_ /P*T[_Y54?\*7\+?\_^O_\
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M=_\ *JC_ %DRO^?$?^$T_P#Y8'^K>:?R8?\ \*8?_*SYDHKZ;_X4OX6_Y_\
M7_\ P*T[_P"55'_"E_"W_/\ Z_\ ^!6G?_*JC_63*_Y\1_X33_\ E@?ZMYI_
M)A__  IA_P#*SYDHKZ;_ .%+^%O^?_7_ /P*T[_Y54?\*7\+?\_^O_\ @5IW
M_P JJ/\ 63*_Y\1_X33_ /E@?ZMYI_)A_P#PIA_\K/F2BOIO_A2_A;_G_P!?
M_P# K3O_ )54?\*7\+?\_P#K_P#X%:=_\JJ/]9,K_GQ'_A-/_P"6!_JWFG\F
M'_\ "F'_ ,K/F2BOIO\ X4OX6_Y_]?\ _ K3O_E51_PI?PM_S_Z__P"!6G?_
M "JH_P!9,K_GQ'_A-/\ ^6!_JWFG\F'_ /"F'_RL^9**^F_^%+^%O^?_ %__
M ,"M._\ E51_PI?PM_S_ .O_ /@5IW_RJH_UDRO^?$?^$T__ )8'^K>:?R8?
M_P *8?\ RL^9**^F_P#A2_A;_G_U_P#\"M._^55'_"E_"W_/_K__ (%:=_\
M*JC_ %DRO^?$?^$T_P#Y8'^K>:?R8?\ \*8?_*SYDHKZ;_X4OX6_Y_\ 7_\
MP*T[_P"55'_"E_"W_/\ Z_\ ^!6G?_*JC_63*_Y\1_X33_\ E@?ZMYI_)A__
M  IA_P#*SYDHKZ;_ .%+^%O^?_7_ /P*T[_Y54?\*7\+?\_^O_\ @5IW_P J
MJ/\ 63*_Y\1_X33_ /E@?ZMYI_)A_P#PIA_\K/F2BOIO_A2_A;_G_P!?_P#
MK3O_ )54?\*7\+?\_P#K_P#X%:=_\JJ/]9,K_GQ'_A-/_P"6!_JWFG\F'_\
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M_P#*SYDHKZ;_ .%+^%O^?_7_ /P*T[_Y54?\*7\+?\_^O_\ @5IW_P JJ/\
M63*_Y\1_X33_ /E@?ZMYI_)A_P#PIA_\K/F2BOIO_A2_A;_G_P!?_P# K3O_
M )54?\*7\+?\_P#K_P#X%:=_\JJ/]9,K_GQ'_A-/_P"6!_JWFG\F'_\ "F'_
M ,K/F2BOIO\ X4OX6_Y_]?\ _ K3O_E51_PI?PM_S_Z__P"!6G?_ "JH_P!9
M,K_GQ'_A-/\ ^6!_JWFG\F'_ /"F'_RL^9**^F_^%+^%O^?_ %__ ,"M._\
ME51_PI?PM_S_ .O_ /@5IW_RJH_UDRO^?$?^$T__ )8'^K>:?R8?_P *8?\
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MY^A'^- 7UM_7Y6_$=13=P_R1Q]>:0N/0]^Z]AG^]^ ]Z.MNMK_+\OQOY!?\
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M'X_^*/A?XN^$FB_#'X<?&W6/A5X!'C']G[XS6?BW4=#T30M(U5]:\3:;XO\
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M'3/B!X>CL8(=,;QE<VFJZUH$]E(+[PG>Z?<>#]:L]2U*_GOH6(\.'[8_[=3
M$?L5?M)$'H1^S=^S8>AP0<?\%=S@@@JRG#*P*L P("_\-C?MU_\ 1E/[2?\
MXC;^S;_]-VK]>X5(B0!]P50N6=IFRORD-*'!D(((+L [$$O\Y:I=K?WA^3?_
M !R@#\?_ /AL;]NO_HRG]I/_ ,1M_9M_^F[4?\-C?MU_]&4_M)_^(V_LV_\
MTW:OV VM_>'Y-_\ '*-K?WA^3?\ QR@#\?\ _AL;]NO_ *,I_:3_ /$;?V;?
M_INU;?PH_:]_:<\??''PI\ O&GPE\9?L_>,?B#X&^(_Q'\(:O\;?V:O \'A3
MQ'I/PFU/X;:3XKL[74/A%_P46^,NJV>M:<WQ-\(A5UC2=.T_4$>Y>RNI?LTJ
M']9=K?WA^3?_ !RO@/XOQK_P\>_8<4D,1^S3^WRH\Q6D#,?%O[$<A4EI,@[4
M9EW;Q\@&1@ @'T'_ ,(]^T[_ -%5^!/_ (87XB__ $2]'_"/?M._]%5^!/\
MX87XB_\ T2]>^44 >!_\(]^T[_T57X$_^&%^(O\ ]$O1_P (]^T[_P!%5^!/
M_AA?B+_]$O7OE% '@?\ PCW[3O\ T57X$_\ AA?B+_\ 1+T?\(]^T[_T57X$
M_P#AA?B+_P#1+U[Y10!X'_PCW[3O_15?@3_X87XB_P#T2]'_  CW[3O_ $57
MX$_^&%^(O_T2]>^44 >!_P#"/?M._P#15?@3_P"&%^(O_P!$O1_PCW[3O_15
M?@3_ .&%^(O_ -$O7OE% '@?_"/?M._]%5^!/_AA?B+_ /1+T?\ "/?M._\
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MCW[3O_15?@3_ .&%^(O_ -$O7OE% '@?_"/?M._]%5^!/_AA?B+_ /1+T?\
M"/?M._\ 15?@3_X87XB__1+U[Y10!X'_ ,(]^T[_ -%5^!/_ (87XB__ $2]
M'_"/?M._]%5^!/\ X87XB_\ T2]>^44 >!_\(]^T[_T57X$_^&%^(O\ ]$O1
M_P (]^T[_P!%5^!/_AA?B+_]$O7OE% '@?\ PCW[3O\ T57X$_\ AA?B+_\
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M(O\ ]$O1_P (]^T[_P!%5^!/_AA?B+_]$O7OE% '@?\ PCW[3O\ T57X$_\
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M7X$_^&%^(O\ ]$O1_P (]^T[_P!%5^!/_AA?B+_]$O7OE% '@?\ PCW[3O\
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M7\62>&=6\4:SKVAV_B5])\2VVE3:WINFZK;Z5?76G016ET]BLR11NSK7J?\
MPAG_  5(_P"BW_L@?^&B^)/_ ,UE?HK10!^=7_"&?\%2/^BW_L@?^&B^)/\
M\UE'_"&?\%2/^BW_ +('_AHOB3_\UE?HK10!^=7_  AG_!4C_HM_[('_ (:+
MXD__ #64?\(9_P %2/\ HM_[('_AHOB3_P#-97Z*T4 ?G5_PAG_!4C_HM_[(
M'_AHOB3_ /-91_PAG_!4C_HM_P"R!_X:+XD__-97Z*T4 ?G5_P (9_P5(_Z+
M?^R!_P"&B^)/_P UE'_"&?\ !4C_ *+?^R!_X:+XD_\ S65^BM% 'YU?\(9_
MP5(_Z+?^R!_X:+XD_P#S64?\(9_P5(_Z+?\ L@?^&B^)/_S65^BM% 'YU?\
M"&?\%2/^BW_L@?\ AHOB3_\ -957X<_LX_M;:I^T_P#"S]H+]HWXM_!?Q-I?
MPF^$7QS^&OA_PA\*_A_XD\-37^I?&OQ!\%-<N_$&IZGX@UC42L>E0_!V*T6R
MB39,VO7;,P,:"OT?HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#E] \#^"O"F
MJ^,==\+>#_"_AK6_B'K]OXL^(&L:!X?TG1]5\<^*;3P]H?A&T\2^,=0TZTMK
MOQ-K]KX3\,^&_#%OK.M37NHP^'O#VAZ+'<KINDV%M;]1110 4444 %%%% $<
MT,-Q#+;W$4<\$\;PSP3(LL,T,JE)(I8W#))'(C,CHZE74E6!!(JAHNBZ-X;T
M;2?#OAW2=,T#P_H.FV.BZ%H6BV%KI6C:+H^EVL5CIFDZ3IEC%!9:=ING64$%
MG8V%G!#:VEK#%;V\4<4:(-.B@ KE/ W@/P/\,/"'AWX>_#3P;X4^'G@'PAI=
MMH?A/P/X&\.Z1X2\(>%]%LD\NST?P[X:T"ST_1=$TNT3Y+;3]-LK:T@3Y8H4
M'%=710 4444 <QX/\$>"_A[HA\-> ?"/ACP/X<.L^)O$1T#P?H&E>&=$/B#Q
MKXEU;QGXRUTZ5HMI96)UGQ;XPU_7?%?B;4_(^VZ]XEUK5M=U6>[U34KRZFZ>
MBB@ HHHH **** "BBB@ KSSXN_\ ))_B?_V3SQK_ .HWJ=>AUYY\7?\ DD_Q
M/_[)YXU_]1O4Z /"/V O^3(/V2O^S>?A+_ZA6CT4?L!?\F0?LE?]F\_"7_U"
MM'HH ^NJ@N5W0., @[<@L$&W>NXEB1M 7)W [AC*?/MJ>H+E2T$@!VD -SC!
MV,'VOE),QOMV2 *6,;,%*L0PRK?P:G^"7Y#6Z]5^9^(/QX\&?L-_M'_MI:U\
M)OB1X>_:9^'7Q$T;2OL/B;XS> ?'_P 5O@O\"_B-XET;PK8^,-1^%VM^*?#/
MB72_"VN>.="^'=QI>O7MVECIVLMH5S%I8UZ26P%C:?KS\,? W@7X=>#] \'_
M  VTRSTGP9HNEVD.B6=G>WVHJ;"6%)K6\GU+4I[O4=9O+V)UGN=8U.]O+^_9
M_M-W>75P[2G\5/VT/@=_P1[UWXC_ !S^('Q7@_9S\1?M86.I:=K/BCPW\4/V
ME_B'\,]9O?%%AX7\*Q:+:7ND^&_&<CZ5--X7MO#MOI M/!MXMU(;>*2"2"XE
MQ^W'P]^S3>#O!US9V1L;:?P?X=GM[1[AKA[&VGTFQ>WLDN)$BENEACV1F1H;
M9/D#_9XYI'0:497P<6F[>QC#1IQ<U&<K73MS<KOR[[NPZK7M/2*WWW\];?TB
MUX_U+Q%I'@O7M3\)6WA^[\1V-C)<Z5#XLU*\TCPRDT3!Y;O7=2TZSU#4;32]
M/M1<:A=RZ?87E^(K5A9VL]P8XF_,;1/^"DJ/\--&^(_B#PAX,O-"\*?!?X>_
M&SXY:SX+\93^)/#>B^%?B=\6O%GPP\,:G\+[\:9!>>+K+4K;X>?$#Q=<VFOV
M>@ZYI-EI5MH.MZ;8>)[R_P!*L/T[\<Z'K7B'PW+IGA[Q-JG@[63?Z1?6/B'2
M+'3-2O+.32]6M-3>TDLM6BEM+C2]<BM'T#78E^SW<NA:IJ4=CJ.DW;PZK9?)
M[_L)_!)+9+"TTS6[?2=8FGMOB+I4$MI#8_$VRNOC5XB_:$U5?%5C'9VUFL%_
M\5_&GCW5;J"PB@MI] \>>,]"T^VC@U>R:R4?AC_A7Y(A=?\ $_S*WP+_ &S-
M$^)/B.+1_&6GZ#X$L?$?PD?X\>"=;GUQXM.N/AA'\1M0^',-UXIO=9ATVUTK
M79;Y-&OU@CEFM6MM:AA2X::%@W*_L$ZOI.N^-OV[M4T/5=,UK3+O]L;QA+:Z
MEI%_::GI]S&?!7@A=T%Y8S3VTH#*RMLE8JRE6 8$5ZCX9_8L^!FC6?B+1/$?
M@K2OB;X8\1>$T^'(\'_$_0=#\;^#=.^&\'B^_P#'<7@K_A'-<M;C1M3TM/%.
MHG45.H6DZF+3O#\,5O%-HTDUWXG_ ,$Z? W@?X;>(/VXO!/PX\$>#?AWX-T'
M]L'QA:Z-X3\ >&-'\'^%=,A;P;X+E9-/\/Z%IFDZ98NS/F[^S6FR>Y$EPLTJ
MRJ10S],:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "O//B[_R2?XG_P#9//&O_J-ZG7H=>>?%W_DD_P 3_P#LGGC7_P!1
MO4Z /"/V O\ DR#]DK_LWGX2_P#J%:/11^P%_P F0?LE?]F\_"7_ -0K1Z*
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M=-?-];^6FG5+LP0,$D !!DDX]3W] "3[#-#21K]YT7YE3YF ^=BH5>3]YBZ
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%>>?%W_DD_Q/_P"R>>-?_4;U.O0Z\\^+O_))_B?_ -D\\:_^HWJ= 'A'[ 7_
M "9!^R5_V;S\)?\ U"M'HJI^P@S+^PK^R>58AA^SQ\(AN'!P?!VBAOID$@^Q
MHK*=50:5F]+[V_K8RG54&E9O2^]C[%J&X7=#*NW<61@%RHR2.!EU=,9ZAD=2
M,AD<$J9JK7JEK6= SJ70H"A"L2Y"A=YBG6-6)VO*T3+$A:1L!2PN7PR_PO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%)D>H_.EH **** "O//B[_ ,DG^)__ &3SQK_ZC>IUZ'7GGQ=_Y)/\3_\
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MS=7GP=UGPII6GQ?V%>8L+UM3M]:LKM6C$'ENA?M>_M@0?%6+1EU_7/''P?\
M#WC;]G7P_P"(O%VG:=X;M_%NEQ?%7XQZ)X3U7Q VB+HUM%\2O"LFJ:KJ?PNU
M_3?#!T/Q#\-8-/T_QQJ":_:Q:U#:_OM:Z3X?2YBN;/3=&^U:;)>P6UQ:V=@)
MM.?5)&O=4@M9HT>6"6^GF-WJ%N'0W+SB1U<MO>"#PMX=M9-(^S>'M$@?1+B]
MGT1[30=*A.B3:E$ZZA=Z0PAW:1)?QO+%?R0A9;S?*DFY7--IIV:::W3336SU
M32>S3VV:>S5P\!_8Z\:>+O'7PJ\7ZCXV\17GBK6-!_:4_:[^'UGK&H'2/MDO
MA3X9?M1_%WX>^!;6<:)I^F6/F6'@KPUX?LF?[''/.8#<3O.\QGD^JZQM"T/1
M?#]DUCH>DZ3HUH]Q+<RVFC:9;:3:-=3!/-N&L[6..-9Y56,RR%2\NU78G(QL
MT@"BBB@#XH_;,^+GQ&^%%C\((OAOXK\(>#M0^(?Q.E\#ZEJGC#PC-XTMYK>X
M\ ^,M9TFTT?2HO$OA1/[8F\2:+H]O"L^J&*ZMKBYTZ"W%]J%O=6U[X(:E^UQ
MXAM_ASX@^+$'P\T'1=:\)^&=4\7>&K'PIJ6B^(]*U2\\,V$^HZ6HO_%-U/I]
MQ;:\]U]HT^[TF.YTR,#3)C+-:O<2?3'B;P5X8\6WOAN_\0:+9ZM>^#M?M_%'
MAB:\:XW:3XBM;::UM-3M1&0BRQVUU=Q9(D0ASN4L3MZU=J( @;:,XR7)Y8YR
MSY;KG&3TQCC%#;7PVUT=^W_#@?B?\/=2_:QTSQ+^TE!%<>.Q\1=>^#_QTT7P
MX^NKK=_X2L?VC?\ A9_[1&K_  9'@R/Q%,_A71K(> =$T&]'EB/1)?"4OP_U
M*_$%OJME=ZQ\TV%I^V%_PFWB*/PU??&RV^&SW'@ _LP76JZQXT>/_A,X]/\
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M_0[BX?!#_!'\@^U/_'_[; ]N;^'_ 'A_6OS[_8>_Y*+^WO\ ]GE>,?\ U"?
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MH_M,_LZ?!0R#XP?'KX+?"L(K"1?B+\4/!?@NZ4C9MVVNNZMI<SLY=0463?\
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M?6E_X;.^)7_1@'[;7_@J_9@]\?\ -T_^[^1]3D_U0XF_Z!L)_P"'#)?_ *)
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M&>N!FEKRT[I/ND_OU&M@HHHI@%>>?%W_ ))/\3_^R>>-?_4;U.O0Z\\^+O\
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MG]F5_C5\;_AMXTM?A[H/@_Q?\-;KPCJ.D_M8:+XFETGXD+X*_P"$MU-_B=\
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M'XW6SD@ D;9%&<$@@E:^[@Q)P1C'"$D'?TR#C&, ]#V.*?AO[B_D/\:_-/\
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M=Q4GTXXR,\_0'\,_C\8_MFS3V_@?X4$AHR?VEO@8JR1NZE%'C*!\JR,I#L5
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M//3)/.3C)SSG)J00Q(\DJ(@DD93(X10S%1M3>V,OL VKDG:O P.*D##;UY[
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M9E4$LP49 W$_Q<8'H??\<]Z 'T4@Y .0<@<CH?<>U+0 4444 %%%% !1110
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M[6UMK(7-Y)'&KW5PEE9V5FD\[22K:6EK;JP@MX8TO@*   % 4!0H  4  +C
M&,8QC QT':L</'ZK15)Z^UQ->>UK.M.<TK7Z*7ZZ'H9QF*S7-<5F"7+[7ZE-
M7DI>[A,ER[*96DE%6J/+E-I*VJ4N:4;D_&.@QVX]:,#T'Y"A>@^@_E2UL>>D
MK+1;+HO+R(C!$<@HN#U'.#WY&>?QKA/$_P +/AAXOBE'B[X<> _%:LD@D7Q-
MX1\/Z\KJRE7#C5=/NPX=25<-PRDAC@FO0*1N01ST/0@'\SP/K4N$&K.$7'?E
MY8M:=DXM7[.R?F=-#&8S"R<\+B\7AIN+BYX;%XG"S<7O%U,-B,//E?5.;77E
M=D?*&J_L??LOZQ"4C^"O@WP\S*5,G@2RN?AVX4@@^6_@6\\.O&XSE)4=)(WV
MNDBLBL.9M_V(?A+HRR_\(7XH^-G@EYGWF;P_\:/'FIO _4"&/QMJWBRWAV,
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MJ"E)1NUS-4XIM)-\L+M\L;28 Z "FE%88*@CZ4ZBD0-"*O10/I2E5/4 \YY
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M&O\ ZC>IUZ'7GGQ=_P"23_$__LGGC7_U&]3H ^?/V$?^3%/V3_\ LWGX1?\
MJ'Z)11^PC_R8I^R?_P!F\_"+_P!0_1**Y:_QK_"OS9RU_C7^%?FS[&JO=AC
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M?A)X9ADDW>;-<> _!.JZ?X#U^2)]LB6WB+PCJ5IOX=)4.V.A'\(_VM?!C$^
M/VF[+QW8QR,_V#]H7X5^'?$5[<0,=RV5IXD^"]Y\$9]-= 1$E[JOAOQ/<Q+^
M\O#J<P:1OMMU!?D=<<X!X'KD9]>GO[TYADD(1G'0';^1 ]L]>>?2N9X'"7E^
M[KI/I2J5:=*.[M&%*I3@E=MVY+7W36A]#'C//^14\=B,+G5-OW89[AL)FDFK
M0C:5?&87ZZVXP4.9YI.:BWRSA)N;^)F^,/[5W@64_P#"ROV78/&^G9D0:E^S
MI\5= \87SP 1@7^H^'?B_IWP/;2TB#,QL]$U[Q=>'[H>XE:-:_&W6_\ @K]X
M(N/^"I7PV\$3?!WX@Z-HFB>&_%/[-5_J_B$IIWBRR\1?$[Q+\.?&+ZW<^"H=
M/O9DL-"O/!%EI!ECO[HWEEJ$^KV331+917_]+\^ -[*C-'C.0Q(SZ8PS$8YX
MXXSQS7Y4>,_V3_V?-1_X*=_#?XH7_P )O!USXWU']GSXF_$>_P!:?2P);_QY
MX.^(7P7\+^%_%EVLB-8-XCT/1O$>HZ?9ZJ\1U*.*[AECG1]-MV3YKB'"<2.6
M3O)<QPM+!TLQ@L4J]*,YQP\>92IQG:4G-4O:0<I24FVDY1:1^U>#/&'@IAZO
MB+'Q3\-,5FM?%>&7%F'X8J<%<0X[)H8'B*M@U&EC\?E.+K8G"U*=5U%3IRP6
M-;I5*'NX'$0FXQ_6&VD,L$<C(4+KN*'<2NXDA6W '< 0&'(#9 9@ QGJ&W&(
M8P&+ +U)4D<GY25+*63[K88\@\FIJ^QBFDE)J4DDI22LI-+5I=$WK\S^;I6Y
MGRWY;OEO=NUW:[:3;M:]TGIJD[A1113$%%%% !7GGQ=_Y)/\3_\ LGGC7_U&
M]3KT.O//B[_R2?XG_P#9//&O_J-ZG0!\^?L(_P#)BG[)_P#V;S\(O_4/T2BG
M?L'JS_L+?LG*H)9OV>OA" !SR?!^B>GIWHKFK)N:LF_=6R;ZOLCFK1E*2LF_
M=6R\V>Z5LZ)_Q\S_ #[!]F.20I!'VBVRC!PPVR#,;8&_:Q\O$FTUC5N^'@#>
M2@@$&U?(/3_705TG2?G'\:?^">?Q*^,GQ&^)7CO3_P#@H?\ MH?"CPQ\0]6M
M;VW^#WPYU[X?V'PLT:RMO#FDZ!J&B66C:Y\/M8\0IIFMS:3=7VM11ZU US)J
M=W/#*CSM/7Z/Z!IT7AOPWH>@PS273Z#H&EZ-]JCB GF72M/AM5FDBB1_)D=+
M9)S&R!'!98X9?EC;K/*B^?Y%_>'+\?>.,9/X<4IC0G)1<^N #U![>X!^H![4
M6U;ZNUWU=KVN_*[MVN^X=+=-[=+][;'RA\4?BMXF^S?'CP$WPW^,'A#3_"/P
M?\6>*M'^/<EUX&T+X;ZW?'P6=3CT;P;KVD?$*3XCQ^*M"O+J9YKG4? /A6SM
M'\/:I/#K,\45G/JWYYWGQ"^+GBGX7?\ !,[QCHWQ@TWQKK5I\,/V>_&7Q4^!
M^G_&CXA^ /CM\6=0^(.A^ -#/Q32^\&?%#1H?B7X6\(:C/XBU/Q=X$^)7@7Q
M+X)^(;76HW-SK>A7VGVVK6_[<S007$;Q3PQ3Q2 K)%*BR1NK+M971P5967*L
MI!#*2I!!(K-A\/Z#;W%K>0:)I$-W8VD6GV5U#IME'<6=A!GR+*UG2%9;>TAR
M?*MH62&/)V(N32225DDDMDE9+T2]7][ _'#]G7X^?M5ZMXBFD\.Z'-\9_%]]
M\ /B#XY\:?#?Q[\0=:\!^&]"^-6F?M+ZEX.\->"YO%LGA#QT/AA'9_#@7B6>
MBV?@N=?$FE:1:^(YK2\+_P!KW/L7_!-+6OB!X@U/]M[5_BAX%T;X;>.+O]L+
MQB=>\&^'_'J?$S2-'O(_!O@J,QV'C!?#'@MM3MY8UCEC,WA?29X]S":%F.ZO
MTWAL+&T:5[2SM;5[J17N7M[>*%[AQNPT[QHK3,-[8:0L1N;GYCGX'_8?);XB
M_M[$G)_X;(\7KG_97P1X&"C\!P*8'Z"T444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #616^\ >W/3
MGKQ[]Z-B?W1TQ^ & /H!3J*=WM=_>*RNW97:Y6[:N-[\K[J^MMK]! H'08I:
M**0]M%HEHEV78**** # ]*0*!R!2T4":3U:3:VND[?@5I<9.  WS<X!_NC/(
M[C.?7H>U?+GB3X?^(KW]L+X<_$>+2XY?!FC?L\?%KP5JFJ^>JRQ>*O$/Q+^"
MWB'0K);;<'D232?"?B*\>ZP%B>U@A+!I4!^HFQYF#W9Q_P".9Q5>3R'N<,@,
MF&C#XR0@ D8#ZG'_ -8=5.C[2*A&*MRU).R2UG&47*UM7=MMVO?5.YU8+,9Y
M=/&58;U,+B<!O):9A0P]",4XM/2=G%.Z4I2=DW<N6ZA(8T!)"J%!)).!P 2>
M21T+')8@G)SFIJ9&044C &, #H . .IZ8I]*$7&,8O>*47ZI6_0YVVVV]VVW
MZMMO\;A1115""BBB@ KSSXN_\DG^)_\ V3SQK_ZC>IUZ'7GGQ=_Y)/\ $_\
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MYT_\-8?MA_\ 2-WXI?\ A]?@E_\ +"C_ (:P_;#_ .D;OQ2_\/K\$O\ Y84
M?HM17YT_\-8?MA_](W?BE_X?7X)?_+"C_AK#]L/_ *1N_%+_ ,/K\$O_ )84
M ?HM17Y0^!_^"@O[1_Q"\1?%WPIX:_X)U?&&YU?X(_$2Q^%WQ!CG^,GP=MH]
M-\7ZE\,?A]\7;:QL)WO@FI0'P5\4_!.I&[MR85DU62VW^9931#T<?M8_MAD
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MQ2_\/K\$O_EA1_PUA^V'_P!(W?BE_P"'U^"7_P L* /T6HK\Z?\ AK#]L/\
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M2@ 1\.K 6:IV:R*)1(6),K.H(0;1(S2;,I@2%"Q!E"JIX0%VC:1[E !1110
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MTG0=*TB74KC3[);6XU>_34M2E!.^[O8=*TW0X9Y IV#RM)TC3;")$542"RA
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MBBB@ HHHH *9Y:=U#?,SC=EL,V<D;B<=3@#  X  I]% $7D0X<>4F)0PD&T
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M^(7P7\97.L?%#]I[Q!X]\!^/?!WC[Q-X.G\'?'C]K&W_ &P? \_A:WT7Q5X
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M1110 4444 %9]Q_Q_P!E_P!<;O\ ]&V5%% %+1O^01I?_8.TC^E5S_QYW/\
MUPU[_P!+YJ** +.F];;_ *];7_TA@JW:_P"HLO\ <A_]%3444 !_X\[;_KV/
M_I(]84__ "#[7_>TC_T0]%% '5'_ %;_ .Z?_0!40ZW/_77_ -M8J** ,S3/
M]=<?]@_2?_1%Q31]W2O^N=Y_Z)-%% &ZO0?0?RI:** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
%** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>14
<FILENAME>tara-20201231.xml
<DESCRIPTION>XBRL INSTANCE FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoXBRL; Version: 5.6b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Source; Value: tara%2D20201231.xfr; Date: 2021%2D03%2D10T22:42:15Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<xbrli:xbrl xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:us-roles="http://fasb.org/us-roles/2020-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:TARA="http://artaratx.com/20201231">
    <link:schemaRef xlink:href="tara-20201231.xsd" xlink:type="simple" />
    <xbrli:context id="From2020-01-01to2020-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_custom_Series1ConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">TARA:Series1ConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-12-31_custom_Series1ConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">TARA:Series1ConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_Series1ConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">TARA:Series1ConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_Series1ConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">TARA:Series1ConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_custom_Series1ConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">TARA:Series1ConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-03to2020-01-09">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-03</xbrli:startDate>
        <xbrli:endDate>2020-01-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-01-09">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-01-09</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-03to2020-01-09_custom_EquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">TARA:EquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-03</xbrli:startDate>
        <xbrli:endDate>2020-01-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_us-gaap_PrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_SeriesAConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">TARA:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-02-02to2020-02-19">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-02-02</xbrli:startDate>
        <xbrli:endDate>2020-02-19</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_RightOffUseAssetsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">TARA:RightOffUseAssetsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_RightOfUseLiabilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">TARA:RightOfUseLiabilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_RightOfUseLeaseLiabilityLongTermMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">TARA:RightOfUseLeaseLiabilityLongTermMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-01-09_custom_RightOffUseAssetsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">TARA:RightOffUseAssetsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-01-09</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-01-09_custom_RightOfUseLiabilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">TARA:RightOfUseLiabilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-01-09</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-01-09_custom_RightOfUseLeaseLiabilityLongTermMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">TARA:RightOfUseLeaseLiabilityLongTermMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-01-09</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_RightOffUseAssetsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">TARA:RightOffUseAssetsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_RightOfUseLiabilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">TARA:RightOfUseLiabilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_RightOfUseLeaseLiabilityLongTermMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">TARA:RightOfUseLeaseLiabilityLongTermMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-09-03to2017-09-27_custom_ClinicalServicesAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">TARA:ClinicalServicesAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-09-03</xbrli:startDate>
        <xbrli:endDate>2017-09-27</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-12-02to2017-12-22">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-12-02</xbrli:startDate>
        <xbrli:endDate>2017-12-22</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_custom_FeinsteinAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">TARA:FeinsteinAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-12-31_custom_FeinsteinAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">TARA:FeinsteinAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-11-03to2018-11-28_custom_IowaAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">TARA:IowaAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-11-03</xbrli:startDate>
        <xbrli:endDate>2018-11-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_custom_IowaAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">TARA:IowaAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-12-31_custom_IowaAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">TARA:IowaAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_ChugaiPharmaceuticalAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">TARA:ChugaiPharmaceuticalAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_custom_ChugaiPharmaceuticalAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">TARA:ChugaiPharmaceuticalAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-12-31_custom_ChugaiPharmaceuticalAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">TARA:ChugaiPharmaceuticalAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_us-gaap_EmployeeStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_EmployeeStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_EmployeeStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-12-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-12-31_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_custom_TwentyTwentyInducementPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">TARA:TwentyTwentyInducementPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-10-01to2014-10-03_custom_TwentyFourteenEmployeeStockPurchasePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">TARA:TwentyFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-10-01</xbrli:startDate>
        <xbrli:endDate>2014-10-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-10-03_custom_TwentyFourteenEmployeeStockPurchasePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">TARA:TwentyFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-10-03</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_TwentyFourteenEmployeeStockPurchasePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">TARA:TwentyFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-03to2020-01-09_custom_MergerAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">TARA:MergerAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-03</xbrli:startDate>
        <xbrli:endDate>2020-01-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-01-09_custom_EquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">TARA:EquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-01-09</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-01-02_custom_EquityIncentivePlanOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">TARA:EquityIncentivePlanOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-01-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_TwentyTwentyInducementPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">TARA:TwentyTwentyInducementPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-08-10_custom_TwentySeventeenEquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">TARA:TwentySeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-08-10</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_TwentyFourteenEquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">TARA:TwentyFourteenEquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_custom_ClinicalServicesAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">TARA:ClinicalServicesAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-12-31_custom_ClinicalServicesAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">TARA:ClinicalServicesAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2002-02-28">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2002-02-28</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_ClinicalServicesAgreementsMember_custom_DrBuchmanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">TARA:ClinicalServicesAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TARA:DrBuchmanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_Series1PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">TARA:Series1PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_Series1PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">TARA:Series1PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_custom_Series1PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">TARA:Series1PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-12-02to2018-12-06_custom_TemporaryEmploymentAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">TARA:TemporaryEmploymentAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-12-02</xbrli:startDate>
        <xbrli:endDate>2018-12-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-01-09_custom_TemporaryEmploymentAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">TARA:TemporaryEmploymentAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-01-09</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-09-25to2020-10-02_custom_ClinicalServicesAgreementsMember_custom_DrBuchmanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">TARA:ClinicalServicesAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TARA:DrBuchmanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-09-25</xbrli:startDate>
        <xbrli:endDate>2020-10-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-09-01to2020-09-24">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-09-01</xbrli:startDate>
        <xbrli:endDate>2020-09-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-03to2020-10-06_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-03</xbrli:startDate>
        <xbrli:endDate>2020-10-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_us-gaap_StockCompensationPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-12-31_us-gaap_StockCompensationPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_us-gaap_ConvertibleDebtSecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-12-31_us-gaap_ConvertibleDebtSecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-22_custom_Series1PreferredStockMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">TARA:Series1PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-22</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-22_custom_Series1PreferredStockMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">TARA:Series1PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-22</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-24_custom_UnderwrittenPublicOfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">TARA:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-09-05to2020-09-24_custom_UnderwrittenPublicOfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">TARA:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-09-05</xbrli:startDate>
        <xbrli:endDate>2020-09-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-03to2020-10-06_us-gaap_OverAllotmentOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-03</xbrli:startDate>
        <xbrli:endDate>2020-10-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-09-05to2020-09-24_custom_UnderwrittenPublicOfferingMember_custom_Series1PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">TARA:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">TARA:Series1PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-09-05</xbrli:startDate>
        <xbrli:endDate>2020-09-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-24_custom_UnderwrittenPublicOfferingMember_custom_Series1PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">TARA:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">TARA:Series1PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-12-31_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-12-31_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-07-23_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-07-23</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_ComputerEquipmentAndSoftwareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">TARA:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_ComputerEquipmentAndSoftwareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">TARA:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_FurnitureAndFixturesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_FurnitureAndFixturesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_LaboratoryEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">TARA:LaboratoryEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_LaboratoryEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">TARA:LaboratoryEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_us-gaap_FurnitureAndFixturesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_custom_LaboratoryEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">TARA:LaboratoryEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-23">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-23</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-09-01to2019-09-23">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-09-01</xbrli:startDate>
        <xbrli:endDate>2019-09-23</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-01-01_custom_TwentyFourteenEmployeeStockPurchasePlanMember_us-gaap_SubsequentEventMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">TARA:TwentyFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-01-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-01-01_custom_TwentyFourteenEmployeeStockPurchasePlanMember_us-gaap_SubsequentEventMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">TARA:TwentyFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-01-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-01-01_custom_TwentyFourteenEquityIncentivePlanMember_us-gaap_SubsequentEventMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">TARA:TwentyFourteenEquityIncentivePlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-01-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-01-01_custom_TwentyFourteenEquityIncentivePlanMember_us-gaap_SubsequentEventMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">TARA:TwentyFourteenEquityIncentivePlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-01-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-01-09_custom_TwentyFourteenEquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">TARA:TwentyFourteenEquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-01-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_DirectorsOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TARA:DirectorsOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_DirectorsOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TARA:DirectorsOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_DirectorsTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TARA:DirectorsTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_ConsultantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TARA:ConsultantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_EmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TARA:EmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_EmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TARA:EmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-12-31_custom_TwentySeventeenEquityIncentivePlanMember_srt_BoardOfDirectorsChairmanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">TARA:TwentySeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_TwentySeventeenEquityIncentivePlanMember_srt_BoardOfDirectorsChairmanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">TARA:TwentySeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_custom_TwentyFourteenEquityIncentivePlanMember_srt_BoardOfDirectorsChairmanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">TARA:TwentyFourteenEquityIncentivePlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_TwentyFourteenEquityIncentivePlanMember_srt_BoardOfDirectorsChairmanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">TARA:TwentyFourteenEquityIncentivePlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_TwentyFourteenEquityIncentivePlanMember_srt_BoardOfDirectorsChairmanMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">TARA:TwentyFourteenEquityIncentivePlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_TwentyFourteenEquityIncentivePlanMember_srt_BoardOfDirectorsChairmanMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">TARA:TwentyFourteenEquityIncentivePlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-01-09">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-01-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_custom_ComputerEquipmentAndSoftwareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">TARA:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-09-25to2019-10-02_custom_ClinicalServicesAgreementsMember_custom_DrBuchmanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">TARA:ClinicalServicesAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TARA:DrBuchmanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-09-25</xbrli:startDate>
        <xbrli:endDate>2019-10-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-09">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-09</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2020-12-31" unitRef="Shares" decimals="INF">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2019-12-31" unitRef="Shares" decimals="INF">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2014-10-03_custom_TwentyFourteenEmployeeStockPurchasePlanMember" unitRef="Shares" decimals="INF">3513</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2020-12-31_custom_TwentyFourteenEmployeeStockPurchasePlanMember" unitRef="Shares" decimals="INF">18012</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2021-01-01_custom_TwentyFourteenEmployeeStockPurchasePlanMember_us-gaap_SubsequentEventMember_srt_MinimumMember" unitRef="Shares" decimals="INF">7025</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2021-01-01_custom_TwentyFourteenEmployeeStockPurchasePlanMember_us-gaap_SubsequentEventMember_srt_MaximumMember" unitRef="Shares" decimals="INF">25037</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2021-01-01_custom_TwentyFourteenEquityIncentivePlanMember_us-gaap_SubsequentEventMember_srt_MinimumMember" unitRef="Shares" decimals="INF">812889</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2021-01-01_custom_TwentyFourteenEquityIncentivePlanMember_us-gaap_SubsequentEventMember_srt_MaximumMember" unitRef="Shares" decimals="INF">1861189</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2020-12-31" unitRef="Shares" decimals="INF">11211840</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2019-12-31" unitRef="Shares" decimals="INF">2627533</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2020-12-31_us-gaap_RestrictedStockUnitsRSUMember" unitRef="Shares" decimals="INF">20870</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2020-12-31_custom_TwentyFourteenEmployeeStockPurchasePlanMember" unitRef="Shares" decimals="INF">13340</us-gaap:CommonStockSharesIssued>
    <us-gaap:ShareBasedCompensation contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">9746000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2020-01-01to2020-12-31_us-gaap_RestrictedStockUnitsRSUMember" unitRef="USD" decimals="-3">6357000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2020-01-01to2020-12-31_us-gaap_EmployeeStockOptionMember" unitRef="USD" decimals="-3">3389000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2020-01-01to2020-12-31_us-gaap_RestrictedStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ShareBasedCompensation contextRef="From2019-01-01to2019-12-31_us-gaap_EmployeeStockOptionMember" unitRef="USD" decimals="-3">313000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2019-01-01to2019-12-31_us-gaap_RestrictedStockUnitsRSUMember" unitRef="USD" decimals="-3">36000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2019-01-01to2019-12-31_us-gaap_RestrictedStockMember" unitRef="USD" decimals="-3">75000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2020-01-01to2020-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="USD" decimals="-3">741000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2020-01-01to2020-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="USD" decimals="-3">9005000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2019-01-01to2019-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="USD" decimals="-3">200000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2019-01-01to2019-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="USD" decimals="-3">224000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="-3">424000</us-gaap:ShareBasedCompensation>
    <us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;For the Years Ended&lt;br /&gt; December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 76%; text-align: left"&gt;Stock options&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;674,039&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;219,592&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left"&gt;Restricted stock units&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;407,325&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,245&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -8.1pt; padding-left: 8.1pt"&gt;Conversion of Series 1 Convertible Preferred Stock&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;8,029,039&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: 10pt"&gt;Total potentially dilutive shares&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;9,110,403&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;224,837&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock>
    <us-gaap:ConversionOfStockSharesIssued1 contextRef="From2020-01-01to2020-12-31_us-gaap_PrivatePlacementMember" unitRef="Shares" decimals="INF">18954</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:ConversionOfStockSharesIssued1 contextRef="From2020-01-01to2020-12-31_custom_Series1PreferredStockMember" unitRef="Shares" decimals="INF">1000</us-gaap:ConversionOfStockSharesIssued1>
    <TARA:SharesAvailableForIssuance contextRef="AsOf2020-01-09" unitRef="Shares" decimals="INF">2627533</TARA:SharesAvailableForIssuance>
    <TARA:SharesAvailableForIssuance contextRef="AsOf2020-01-09_custom_EquityIncentivePlanMember" unitRef="Shares" decimals="INF">219699</TARA:SharesAvailableForIssuance>
    <TARA:SharesAvailableForIssuance contextRef="AsOf2020-01-02_custom_EquityIncentivePlanOneMember" unitRef="Shares" decimals="INF">1048300</TARA:SharesAvailableForIssuance>
    <TARA:SharesAvailableForIssuance contextRef="AsOf2020-12-31_custom_TwentyTwentyInducementPlanMember" unitRef="Shares" decimals="INF">460650</TARA:SharesAvailableForIssuance>
    <TARA:SharesAvailableForIssuance contextRef="AsOf2017-08-10_custom_TwentySeventeenEquityIncentivePlanMember" unitRef="Shares" decimals="INF">2000000</TARA:SharesAvailableForIssuance>
    <TARA:SharesAvailableForIssuance contextRef="AsOf2020-12-31_custom_TwentyFourteenEquityIncentivePlanMember" unitRef="Shares" decimals="INF">227850</TARA:SharesAvailableForIssuance>
    <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 11 &amp;#8211; EMPLOYEE BENEFIT PLAN &lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The Company maintains a defined contribution benefit plan under&#13;section 401(k) of the Internal Revenue Code covering substantially all qualified employees of the Company (the "401(k) Plan").&#13;Under the 401(k) Plan, the Company matches 100% up to a 4% contribution. The 401(k) Plan was implemented in June of 2020. For the&#13;year ended December 31, 2020, the Company recorded expense of $69 under the 401(k) Plan.&lt;/p&gt;</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
    <dei:EntityRegistrantName contextRef="From2020-01-01to2020-12-31">Protara Therapeutics, Inc.</dei:EntityRegistrantName>
    <dei:EntityCentralIndexKey contextRef="From2020-01-01to2020-12-31">0001359931</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2020-01-01to2020-12-31">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="From2020-01-01to2020-12-31">10-K</dei:DocumentType>
    <dei:DocumentFiscalPeriodFocus contextRef="From2020-01-01to2020-12-31">FY</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="From2020-01-01to2020-12-31">2020</dei:DocumentFiscalYearFocus>
    <dei:DocumentPeriodEndDate contextRef="From2020-01-01to2020-12-31">2020-12-31</dei:DocumentPeriodEndDate>
    <dei:EntityCurrentReportingStatus contextRef="From2020-01-01to2020-12-31">Yes</dei:EntityCurrentReportingStatus>
    <dei:CurrentFiscalYearEndDate contextRef="From2020-01-01to2020-12-31">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityFileNumber contextRef="From2020-01-01to2020-12-31">001-36694</dei:EntityFileNumber>
    <dei:EntityInteractiveDataCurrent contextRef="From2020-01-01to2020-12-31">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2020-01-01to2020-12-31">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2020-01-01to2020-12-31">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2020-01-01to2020-12-31">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="From2020-01-01to2020-12-31">false</dei:EntityShellCompany>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2020-01-01to2020-12-31_us-gaap_RestrictedStockUnitsRSUMember" unitRef="Shares" decimals="INF">479325</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2020-01-01to2020-12-31_us-gaap_EmployeeStockMember" unitRef="Shares" decimals="INF">565100</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2020-09-05to2020-09-24_custom_UnderwrittenPublicOfferingMember" unitRef="Shares" decimals="INF">690000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2020-10-03to2020-10-06_us-gaap_OverAllotmentOptionMember" unitRef="Shares" decimals="INF">690000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="AsOf2019-12-31_us-gaap_RestrictedStockUnitsRSUMember" unitRef="USDPShares" xsi:nil="true" />
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="AsOf2020-12-31_us-gaap_RestrictedStockUnitsRSUMember" unitRef="USDPShares" decimals="INF">29.95</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="AsOf2019-12-31_us-gaap_EmployeeStockMember" unitRef="USDPShares" decimals="INF">7.29</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="AsOf2020-12-31_us-gaap_EmployeeStockMember" unitRef="USDPShares" decimals="INF">20.60</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="AsOf2020-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_DirectorsOneMember" unitRef="USDPShares" decimals="INF">9480</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="AsOf2020-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_EmployeesMember" unitRef="USDPShares" decimals="INF">4887</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="AsOf2019-12-31_custom_TwentySeventeenEquityIncentivePlanMember_srt_BoardOfDirectorsChairmanMember" unitRef="USDPShares" decimals="INF">317</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="AsOf2020-12-31_custom_TwentyFourteenEquityIncentivePlanMember_srt_BoardOfDirectorsChairmanMember" unitRef="USDPShares" decimals="INF">10867</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2020-01-01to2020-12-31_us-gaap_RestrictedStockUnitsRSUMember" unitRef="USDPShares" decimals="INF">29.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2020-01-01to2020-12-31_us-gaap_EmployeeStockMember" unitRef="USDPShares" decimals="INF">22.61</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="From2020-01-01to2020-12-31_us-gaap_RestrictedStockUnitsRSUMember" unitRef="Shares" decimals="INF">56375</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="From2020-01-01to2020-12-31_us-gaap_EmployeeStockMember" unitRef="Shares" decimals="INF">52886</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue contextRef="From2020-01-01to2020-12-31_us-gaap_RestrictedStockUnitsRSUMember" unitRef="USDPShares" decimals="INF">30.00</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue contextRef="From2020-01-01to2020-12-31_us-gaap_EmployeeStockMember" unitRef="USDPShares" decimals="INF">14.08</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">11982000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="-3">3878000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2020-01-01to2020-12-31" unitRef="USDPShares" decimals="INF">-4.70</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2019-01-01to2019-12-31" unitRef="USDPShares" decimals="INF">-3.04</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2020-01-01to2020-12-31" unitRef="Shares" decimals="INF">7233913</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2019-01-01to2019-12-31" unitRef="Shares" decimals="INF">2577493</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2020-01-01to2020-12-31_custom_Series1ConvertiblePreferredStockMember" unitRef="Shares" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2020-01-01to2020-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">57767</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2020-01-01to2020-12-31_us-gaap_EmployeeStockMember" unitRef="Shares" decimals="INF">57767</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2020-01-01to2020-12-31" unitRef="Shares" decimals="INF">9110403</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2020-01-01to2020-12-31_us-gaap_RestrictedStockMember" unitRef="Shares" decimals="INF">407325</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2019-01-01to2019-12-31_us-gaap_RestrictedStockMember" unitRef="Shares" decimals="INF">5245</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2019-01-01to2019-12-31" unitRef="Shares" decimals="INF">224837</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2020-01-01to2020-12-31_us-gaap_StockCompensationPlanMember" unitRef="Shares" decimals="INF">674039</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2019-01-01to2019-12-31_us-gaap_StockCompensationPlanMember" unitRef="Shares" decimals="INF">219592</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2020-01-01to2020-12-31_us-gaap_ConvertibleDebtSecuritiesMember" unitRef="Shares" decimals="INF">8029039</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2019-01-01to2019-12-31_us-gaap_ConvertibleDebtSecuritiesMember" unitRef="Shares" xsi:nil="true" />
    <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 88%; text-indent: -10pt; padding-left: 10pt"&gt;Cash&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,669&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Restricted cash&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;50&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Prepaid expenses and other current assets&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,662&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;Goodwill&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;29,517&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Accrued expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(365&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"&gt;Total purchase price consideration&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;34,533&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock>
    <us-gaap:BusinessAcquisitionProFormaInformationTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;For the Years Ended &lt;br /&gt; December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 76%; text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"&gt;Net loss&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;(33,754&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;(22,821&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"&gt;Pro forma loss per common share, basic and diluted&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(4.62&lt;/td&gt;&lt;td style="padding-bottom: 2pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(3.94&lt;/td&gt;&lt;td style="padding-bottom: 2pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"&gt;Pro forma weighted average number of common shares outstanding, basic and diluted&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7,304,201&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,793,024&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:BusinessAcquisitionProFormaInformationTextBlock>
    <us-gaap:OtherResearchAndDevelopmentExpense contextRef="From2020-01-01to2020-12-31_us-gaap_RestrictedStockUnitsRSUMember" unitRef="USD" decimals="-3">152000</us-gaap:OtherResearchAndDevelopmentExpense>
    <TARA:Covid19DisclosureTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 12 &amp;#8211; COVID-19&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The ultimate impact of the current COVID-19 pandemic or a similar&#13;health epidemic is highly uncertain and subject to change. The Company has experienced minimal delays, but may experience future&#13;delays that impact its business, research and development activities, healthcare systems and the global economy as a whole. However,&#13;the Company will continue to monitor the COVID-19 situation closely should the effects have a material impact on its operations,&#13;liquidity and capital resources.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 18pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;In response to public health directives and orders, the Company&#13;has implemented work-from-home policies for its employees and temporarily modified its operations to comply with applicable social&#13;distancing recommendations. Similar health directives and orders are affecting third parties with whom the Company does business,&#13;including the third parties that the Company has contracted with to conduct studies for TARA-002. The effects of the orders and&#13;the Company's related adjustments in its business are likely to negatively impact productivity, disrupt the Company's&#13;business and delay its timelines, the magnitude of which will depend, in part, on the length and severity of the restrictions and&#13;other limitations on the Company's ability to conduct its business in the ordinary course.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 18pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Severe and/or long-term disruptions in the Company's operations&#13;will negatively impact its business, operating results and financial condition in other ways, as well. Specifically, the Company&#13;anticipates that the stress of COVID-19 on healthcare systems around the globe will negatively impact its ability to conduct clinical&#13;trials in the near term due primarily to the lack of resources at clinical trial sites and the resulting inability to enroll patients&#13;in the trials. The Company also anticipates that the global impact of COVID-19 will negatively impact its ability to conduct nonclinical&#13;studies due primarily to laboratory closures and limited availability of personnel. In addition, while the potential economic impact&#13;brought by, and the duration of, COVID-19 may be difficult to assess or predict, it has significantly disrupted global financial&#13;markets, and may limit the Company's ability to access capital, which could in the future negatively affect its liquidity.&#13;A recession or market correction resulting from the spread of COVID-19 could materially affect the Company's business and&#13;the value of its Common Stock.&lt;/p&gt;</TARA:Covid19DisclosureTextBlock>
    <TARA:BusinessLiquidityAndCapitalResourcesTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 1 &amp;#8211; BUSINESS, LIQUIDITY AND CAPITAL RESOURCES&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;Overview&lt;/p&gt;&#13;&#13;&lt;p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Protara Therapeutics, Inc. and its consolidated subsidiaries&#13;("Protara" or the "Company") is committed to identifying and advancing transformative therapies for the&#13;treatment of cancer and rare diseases with significant unmet needs. Protara's portfolio includes two development programs&#13;utilizing TARA-002, an investigational cell therapy in development for the treatment of lymphatic malformations (LMs) and non-muscle&#13;invasive bladder cancer (NMIBC). The third program in the portfolio is Intravenous (IV) Choline Chloride, an investigational phospholipid&#13;substrate replacement therapy initially in development for patients receiving parenteral nutrition (PN) who have intestinal failure&#13;associated liver disease (IFALD). The fourth program in the portfolio is Vonapanitase, a recombinant human elastase.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;On January 9, 2020, privately-held ArTara Subsidiary, Inc. ("Private&#13;ArTara") and Protara Therapeutics, Inc. (formerly ArTara Therapeutics, Inc., formerly Proteon Therapeutics, Inc.) completed&#13;the merger and reorganization (the "Merger"), in accordance with the terms of the Agreement and Plan of Merger and&#13;Reorganization, dated September 23, 2019, (the "Merger Agreement") by and among Protara Therapeutics, Inc., Private&#13;ArTara and REM 1 Acquisition, Inc., a wholly owned subsidiary of Protara Therapeutics, Inc ("Merger Sub"). Thereupon,&#13;Merger Sub merged with and into Private ArTara, with Private ArTara surviving as a wholly owned subsidiary of Protara Therapeutics,&#13;Inc. The Merger was structured as a reverse merger and Private ArTara was determined to be the accounting acquirer based on the&#13;terms of the Merger and other factors, and the post-merger company retained the name ArTara Therapeutics, Inc., which on May 11,&#13;2020 was changed to Protara Therapeutics, Inc.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;On January 9, 2020, in connection with and prior to the completion&#13;of the Merger, Protara Therapeutics, Inc. effected a 1-for-40 reverse stock split of its common stock (the "Protara Reverse&#13;Stock Split"), Private ArTara changed its name from "ArTara Therapeutics, Inc." to "ArTara Subsidiary,&#13;Inc.", and ArTara Therapeutics, Inc. changed its name from "Proteon Therapeutics, Inc." to "ArTara Therapeutics,&#13;Inc" then subsequently changed its name from "ArTara Therapeutics, Inc" to "Protara Therapeutics, Inc."&#13;All share and per share amounts presented in this annual report on Form 10-K have been adjusted to reflect the Protara Reverse&#13;Stock Split and the Exchange Ratio (defined below). In addition, immediately following the closing of the Private Placements (defined&#13;below), all of the outstanding shares of Protara Therapeutics, Inc.'s Series A Preferred Stock were converted into shares&#13;of Protara Therapeutics, Inc.'s Common Stock (defined below). Shares of the Company's Common Stock commenced trading&#13;on The Nasdaq Capital Market under the new name and ticker symbol "TARA" as of market open on January 10, 2020. See&#13;Note 3 for the full discussion regarding the Merger, Exchange Ratio and recapitalization.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;Liquidity, Capital Resources&#13;and Management Plans&lt;/p&gt;&#13;&#13;&lt;p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;As of December 31, 2020 and 2019, the Company's cash and&#13;cash equivalents was $168,598 and $564, respectively. The Company has not generated revenues since its inception and has incurred&#13;net losses of $33,978 and $7,830 for the years ended December 31, 2020 and 2019, respectively. As of December 31, 2020, the Company&#13;had working capital of $166,520 and stockholder's equity of $199,243. During the year ended December 31, 2020, cash flows&#13;used in operating activities were $23,407, consisting primarily of a net loss of $33,978, which includes non-cash stock-based compensation&#13;charges of $9,746. Since inception, the Company has met its liquidity requirements principally through the sale of its Common Stock&#13;and Series 1 Convertible Preferred Stock.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;In connection with the Merger, the Company consummated the Private&#13;Placements, raising gross proceeds of $42.5 million and proceeds, net of offering costs, of $39.6 million.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;On September 22, 2020, the Company entered into underwriting&#13;agreements with Cowen and Company, LLC and Guggenheim Securities, LLC, as representatives of several underwriters for separate,&#13;concurrent underwritten public offerings of the Company's Common Stock and Series 1 Convertible Preferred Stock. On September&#13;24, 2020, gross and net proceeds from this offering were $147.6 million and $139.9 million, respectively. On October 6, 2020, the&#13;underwriters exercised their overallotment option, resulting in the receipt of gross and net proceeds of $11.6 million and $11.1&#13;million, respectively (See Note 8).&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The Company is in the business of developing biopharmaceuticals&#13;and has no current or near term revenues. The Company has incurred substantial clinical and other costs in its drug development&#13;efforts. The Company will need to raise additional capital in order to fully realize management's plans.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The Company believes that its current financial resources are&#13;sufficient to satisfy the Company's estimated liquidity needs for at least twelve months from the date of issuance of these&#13;consolidated financial statements.&lt;/p&gt;</TARA:BusinessLiquidityAndCapitalResourcesTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;Basis of Presentation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5pt 0pt 0"&gt;The accompanying financial statements have been prepared&#13;in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") and pursuant&#13;to the rules and regulations of the Securities and Exchange Commission ("SEC").&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5pt 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5pt 0pt 0; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;Principles of Consolidation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5pt 0pt 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The consolidated financial statements include the accounts of&#13;the Company and its wholly-owned subsidiaries. All inter-company balances and transactions have been eliminated in the accompanying&#13;consolidated financial statements.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;Use of Estimates&lt;/p&gt;&#13;&#13;&lt;p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The preparation of financial statements in conformity with U.S.&#13;GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure&#13;of contingent assets and liabilities as of the date of the financial statements, and also that affect the amount of expenses reported&#13;for each period. Actual results could differ from those which result from using such estimates. Management also utilizes various&#13;other estimates, including but not limited to income taxes, the valuation of deferred tax assets, determining the fair value of&#13;business combination considerations, determining the fair value and evaluation for impairment of goodwill, determining the fair&#13;value of the Company's Common Stock, and the valuation of securities and assumptions underlying stock-based compensation.&#13;The results of any changes in accounting estimates are reflected in the financial statements of the period in which the change&#13;becomes evident. Estimates and assumptions are reviewed periodically and the effects of revisions are reflected in the period that&#13;they are determined to be necessary.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;Cash and cash equivalents&lt;/p&gt;&#13;&#13;&lt;p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The Company considers all highly liquid instruments with an&#13;original maturity of three months or less when acquired to be cash equivalents. Cash and cash equivalents are held in depository&#13;and money market accounts and are reported at fair value.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;Restricted Cash&lt;/p&gt;&#13;&#13;&lt;p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Restricted cash as of December 31, 2020 and 2019 was $795 and&#13;$0, respectively. As of December 31, 2020, restricted cash consists of cash deposits of $795 to collateralize letter of credit&#13;obligations.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;Property and Equipment&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Property and equipment is recorded at cost. Major property additions,&#13;replacements, and betterments are capitalized, while maintenance and repairs that do not extend the useful lives of an asset or&#13;add new functionality are expensed as incurred. Property and equipment not placed into service is not depreciated until such time&#13;that it is placed into service. Depreciation is recorded using the straight-line method over the respective estimated useful lives&#13;of the Company's assets.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;Goodwill&lt;/p&gt;&#13;&#13;&lt;p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Goodwill represents the excess of purchase price over the fair&#13;value of identifiable net assets acquired in a business combination. Goodwill and other intangible assets acquired in a business&#13;combination and determined to have an indefinite useful life are not amortized, but instead tested for impairment at least annually.&#13;An entity has the option to first assess qualitative factors to determine whether events or circumstances lead to a conclusion&#13;that is more likely than not that the fair value of a reporting unit is greater than its carrying amount. If an entity determines&#13;that qualitative factors indicate that it is more likely than not that the fair value of the entity exceeds the carrying amount,&#13;the quantitative evaluation is not necessary. Under the quantitative impairment test, the evaluation of impairment involves comparing&#13;the current fair value of each reporting unit to its carrying value, including goodwill.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;In the event the estimated fair value of the Company is less&#13;than the carrying value, the Company would recognize a goodwill impairment equal to the difference between the carrying value and&#13;its fair value, not to exceed the carrying value of goodwill.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;On January 9, 2020, in connection with the Merger, the Company&#13;separately valued the assets and liabilities acquired, and then determined goodwill as the residual of the purchase price less&#13;identified net assets. On December 31, 2020, in connection with the finalization of the purchase price allocation, the Company&#13;recorded an adjustment of $150 to goodwill related to prepaid expenses and accrued expenses (See Note 3).&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;Net Loss per Common Share&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Basic loss per common share is computed by dividing net loss&#13;by the weighted average number of common shares outstanding during the period. Diluted loss per common share is computed by dividing&#13;net loss by the weighted average number of common shares outstanding, plus the impact of common shares, if dilutive, resulting&#13;from the exercise of outstanding stock options.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The following securities are excluded from the calculation of&#13;weighted average dilutive common shares because their inclusion would have been anti-dilutive:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;For the Years Ended&lt;br /&gt; December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 76%; text-align: left"&gt;Stock options&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;674,039&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;219,592&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left"&gt;Restricted stock units&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;407,325&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,245&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -8.1pt; padding-left: 8.1pt"&gt;Conversion of Series 1 Convertible Preferred Stock&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;8,029,039&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: 10pt"&gt;Total potentially dilutive shares&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;9,110,403&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;224,837&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;Concentrations of Credit Risk&lt;/p&gt;&#13;&#13;&lt;p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Financial instruments which potentially subject the Company&#13;to concentrations of credit risk consists principally of cash amounts on deposit with financial institutions. At times, the Company's&#13;cash in banks is in excess of the Federal Deposit Insurance Corporation insurance limit. The Company has not experienced any loss&#13;as a result of these deposits.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;Stock-Based Compensation&lt;/p&gt;&#13;&#13;&lt;p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The Company accounts for stock-based compensation in accordance&#13;with the Financial Accounting Standards Board ("FASB") Accounting Standards Codification, or ("ASC"), Topic&#13;718, "Compensation - Stock Compensation" ("ASC 718"). ASC 718 establishes accounting for stock-based awards&#13;exchanged for employee and consultant services. Under the provisions of ASC 718, stock-based compensation cost is measured at the&#13;grant date, based on the fair value of the award, and is recognized as expense over the employee's requisite service period&#13;(generally the vesting period of the equity grant). The fair value of the Company's stock options are estimated using the&#13;Black Scholes option-pricing model with the following assumptions: fair value of the Company's Common Stock, expected volatility,&#13;dividend rate, risk free interest rate and the expected life. The Company calculates the expected volatility using the historical&#13;volatility for a pool of peer companies over the most recent period equal to the expected term and evaluates the extent to which&#13;available information indicate that future volatility may differ from historical volatility. The expected dividend rate is zero&#13;as the Company does not expect to pay or declare any cash dividends on its Common Stock. The risk-free rates for the expected terms&#13;of the stock options are based on the U.S. Treasury yield curve in effect at the time of the grant. The Company has not experienced&#13;significant exercise activity on stock options. Due to the lack of historical information, the Company determined the expected&#13;term of its stock option awards issued using the simplified method. The simplified method assumes each vesting tranche of the award&#13;has a term equal to the midpoint between when the award vests and when the award expires. Restricted stock awards generally vest&#13;over the requisite service periods (vesting on a straight&amp;#8211;line basis). The fair value of a stock award is equal to the fair&#13;market value of a share of the Company's Common Stock on the grant date. The Company accounts for the forfeiture of equity&#13;awards as they occur.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;Fair Value Measurements&lt;/p&gt;&#13;&#13;&lt;p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The carrying amounts of cash and cash equivalents, prepaid expenses&#13;and accounts payable approximate their fair values due to the short-term nature of these instruments.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;ASC Topic 820 "Fair Value Measurements and Disclosures" provides the framework for measuring fair value. That framework&#13;provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives&#13;the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurements) and&#13;the lowest priority to unobservable inputs (level 3 measurements).&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Fair value is defined as an exit price, representing the amount&#13;that would be received upon the sale of an asset or payment to transfer a liability in an orderly transaction between market participants.&#13;Fair value is a market-based measurement that is determined based on assumptions that market participants would use in pricing&#13;an asset or liability. A three-tier fair value hierarchy is used to prioritize the inputs in measuring fair value as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 22.5pt"&gt;&lt;/td&gt;&lt;td style="width: 13.5pt"&gt;&lt;font style="font-family: Wingdings"&gt;&amp;#216;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;Level 1 Quoted prices in active markets&#13;for identical assets or liabilities.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 22.5pt"&gt;&lt;/td&gt;&lt;td style="width: 13.5pt"&gt;&lt;font style="font-family: Wingdings"&gt;&amp;#216;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;Level 2 Quoted prices for similar assets or liabilities in active&#13;markets, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are&#13;observable, either directly or indirectly.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 22.5pt"&gt;&lt;/td&gt;&lt;td style="width: 13.5pt"&gt;&lt;font style="font-family: Wingdings"&gt;&amp;#216;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;Level 3 Significant unobservable inputs&#13;that cannot be corroborated by market data.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Deferred tax assets and liabilities are recognized for the estimated&#13;future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities&#13;and their respective tax basis, operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using&#13;enacted tax rates in effect for the year in which those temporary differences are expected to be recovered or settled. The measurement&#13;of net deferred tax assets is reduced by the amount of any tax benefit that, based on available evidence, is not expected to be&#13;realized, and a corresponding valuation allowance is established.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Tax benefits are recognized only for tax positions that are&#13;more likely than not to be sustained upon examination by tax authorities. The amount recognized is measured as the largest amount&#13;of benefit that is greater than 50 percent likely to be realized upon settlement. A liability for "unrecognized tax benefits"&#13;is recorded for any tax benefits claimed in the Company's tax returns that do not meet these recognition and measurement&#13;standards. As of December 31, 2020 and 2019, no liability for unrecognized tax benefits was required to be recorded. The guidance&#13;also discusses the classification of related interest and penalties on income taxes. The Company's policy is to record interest&#13;and penalties on uncertain tax positions as a component of income tax expense. No interest or penalties were recorded during the&#13;years ended December 31, 2020 and 2019.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;Research and Development Costs&lt;/p&gt;&#13;&#13;&lt;p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Research and development costs are expensed as incurred. These&#13;expenses include the costs of our proprietary research and development efforts, as well as costs incurred in connection with certain&#13;licensing arrangements. Before a compound receives regulatory approval, the Company records upfront and milestone payments made&#13;to third parties under licensing arrangements as expense. Upfront payments are recorded when incurred, and milestone payments are&#13;recorded when the specific milestone or progress has been achieved. Once a compound receives regulatory approval, the Company records&#13;any milestone payments in&amp;#160;identifiable intangible assets, less accumulated amortization&amp;#160;and, unless the asset is determined&#13;to have an indefinite life, the Company amortizes the payments on a straight-line basis over the remaining agreement term or the&#13;expected product life cycle, whichever is shorter.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Research and development expenses were $11,982 and $3,878 for&#13;the years ended December 31, 2020 and 2019, respectively.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&lt;b&gt;&lt;i&gt;Business Combinations&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;For a business combination, the assets acquired and the liabilities&#13;assumed are recognized at the acquisition date, measured at their fair values as of that date. In a business combination achieved&#13;in stages, the identifiable assets and liabilities are recognized at their fair values. In a bargain purchase in which the total&#13;acquisition-date fair value of the identifiable net assets acquired exceeds the fair value of the consideration transferred plus&#13;any non-controlling interest in the acquiree, that excess in fair value is recognized as a gain.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Deferred tax liabilities and assets are recognized for the deferred&#13;tax consequences of differences between the tax bases and the recognized values of assets acquired and liabilities assumed in a&#13;business combination in accordance with ASC Topic 740-10 "Income Taxes". See Note 3 for the Company's accounting&#13;for the reverse merger.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;Recent Accounting Pronouncements Adopted&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;In January 2017, the FASB issued Accounting Standards Update&#13;("ASU") 2017-04 ("ASU 2017-04"), Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill&#13;Impairment. ASU 2017-04 simplifies the subsequent measurement of goodwill by eliminating the second step of the goodwill impairment&#13;test. The second step measures a goodwill impairment loss by comparing the implied fair value of a reporting unit's goodwill&#13;with the carrying amount of that goodwill. Under ASU 2017-04, a company will record an impairment charge based on the excess of&#13;a reporting unit's carrying amount over its fair value. ASU 2017-04 will be applied prospectively and is effective for annual&#13;or interim goodwill impairment tests in fiscal years beginning after December 15, 2019. On January 1, 2020, the Company adopted&#13;ASU 2017-04. The adoption of this standard did not have a material effect on the Company's financial position, results of&#13;operations, or cash flows.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;In August 2018, the FASB issued ASU No. 2018-13, Fair Value&#13;Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement ("ASU 2018-13"),&#13;which removes, adds and modifies certain disclosure requirements for fair value measurements in Topic 820. The Company will no&#13;longer be required to disclose the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy&#13;as well as the valuation processes of Level 3 fair value measurements. The Company will be required to provide additional disclosure&#13;related to the changes in unrealized gains and losses included in other comprehensive loss for recurring Level 3 fair value measurements&#13;and the range and weighted average of assumptions used to develop significant unobservable inputs for Level 3 fair value measurements.&#13;On January 1, 2020, the Company adopted ASU 2018-13. The adoption of this standard did not have a material effect on the Company's&#13;financial position, results of operations, or cash flows.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;Subsequent Events &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The Company evaluated subsequent events and transactions that&#13;occurred after the balance sheet date up to the date that the financial statements were available to be issued. The Company did&#13;not identify any subsequent events that would have required adjustment or disclosure in the financial statements.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;Basis of Presentation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5pt 0pt 0"&gt;The accompanying financial statements have been prepared&#13;in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") and pursuant&#13;to the rules and regulations of the Securities and Exchange Commission ("SEC").&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5pt 0pt 0"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5pt 0pt 0; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;Principles of Consolidation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5pt 0pt 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The consolidated financial statements include the accounts of&#13;the Company and its wholly-owned subsidiaries. All inter-company balances and transactions have been eliminated in the accompanying&#13;consolidated financial statements.&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2020-01-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;Use of Estimates&lt;/p&gt;&#13;&#13;&lt;p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The preparation of financial statements in conformity with U.S.&#13;GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure&#13;of contingent assets and liabilities as of the date of the financial statements, and also that affect the amount of expenses reported&#13;for each period. Actual results could differ from those which result from using such estimates. Management also utilizes various&#13;other estimates, including but not limited to income taxes, the valuation of deferred tax assets, determining the fair value of&#13;business combination considerations, determining the fair value and evaluation for impairment of goodwill, determining the fair&#13;value of the Company's Common Stock, and the valuation of securities and assumptions underlying stock-based compensation.&#13;The results of any changes in accounting estimates are reflected in the financial statements of the period in which the change&#13;becomes evident. Estimates and assumptions are reviewed periodically and the effects of revisions are reflected in the period that&#13;they are determined to be necessary.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;Cash and cash equivalents&lt;/p&gt;&#13;&#13;&lt;p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The Company considers all highly liquid instruments with an&#13;original maturity of three months or less when acquired to be cash equivalents. Cash and cash equivalents are held in depository&#13;and money market accounts and are reported at fair value.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="From2020-01-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;Restricted Cash&lt;/p&gt;&#13;&#13;&lt;p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Restricted cash as of December 31, 2020 and 2019 was $795 and&#13;$0, respectively. As of December 31, 2020, restricted cash consists of cash deposits of $795 to collateralize letter of credit&#13;obligations.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;Property and Equipment&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Property and equipment is recorded at cost. Major property additions,&#13;replacements, and betterments are capitalized, while maintenance and repairs that do not extend the useful lives of an asset or&#13;add new functionality are expensed as incurred. Property and equipment not placed into service is not depreciated until such time&#13;that it is placed into service. Depreciation is recorded using the straight-line method over the respective estimated useful lives&#13;of the Company's assets.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;Goodwill&lt;/p&gt;&#13;&#13;&lt;p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Goodwill represents the excess of purchase price over the fair&#13;value of identifiable net assets acquired in a business combination. Goodwill and other intangible assets acquired in a business&#13;combination and determined to have an indefinite useful life are not amortized, but instead tested for impairment at least annually.&#13;An entity has the option to first assess qualitative factors to determine whether events or circumstances lead to a conclusion&#13;that is more likely than not that the fair value of a reporting unit is greater than its carrying amount. If an entity determines&#13;that qualitative factors indicate that it is more likely than not that the fair value of the entity exceeds the carrying amount,&#13;the quantitative evaluation is not necessary. Under the quantitative impairment test, the evaluation of impairment involves comparing&#13;the current fair value of each reporting unit to its carrying value, including goodwill.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;In the event the estimated fair value of the Company is less&#13;than the carrying value, the Company would recognize a goodwill impairment equal to the difference between the carrying value and&#13;its fair value, not to exceed the carrying value of goodwill.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;On January 9, 2020, in connection with the Merger, the Company&#13;separately valued the assets and liabilities acquired, and then determined goodwill as the residual of the purchase price less&#13;identified net assets. On December 31, 2020, in connection with the finalization of the purchase price allocation, the Company&#13;recorded an adjustment of $150 to goodwill related to prepaid expenses and accrued expenses (See Note 3).&lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;Net Loss per Common Share&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Basic loss per common share is computed by dividing net loss&#13;by the weighted average number of common shares outstanding during the period. Diluted loss per common share is computed by dividing&#13;net loss by the weighted average number of common shares outstanding, plus the impact of common shares, if dilutive, resulting&#13;from the exercise of outstanding stock options.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The following securities are excluded from the calculation of&#13;weighted average dilutive common shares because their inclusion would have been anti-dilutive:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;For the Years Ended&lt;br /&gt; December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 76%; text-align: left"&gt;Stock options&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;674,039&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;219,592&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left"&gt;Restricted stock units&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;407,325&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,245&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -8.1pt; padding-left: 8.1pt"&gt;Conversion of Series 1 Convertible Preferred Stock&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;8,029,039&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: 10pt"&gt;Total potentially dilutive shares&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;9,110,403&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;224,837&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="From2020-01-01to2020-12-31">&lt;p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;Concentrations of Credit Risk&lt;/p&gt;&#13;&#13;&lt;p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Financial instruments which potentially subject the Company&#13;to concentrations of credit risk consists principally of cash amounts on deposit with financial institutions. At times, the Company's&#13;cash in banks is in excess of the Federal Deposit Insurance Corporation insurance limit. The Company has not experienced any loss&#13;as a result of these deposits.&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="From2020-01-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;Stock-Based Compensation&lt;/p&gt;&#13;&#13;&lt;p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The Company accounts for stock-based compensation in accordance&#13;with the Financial Accounting Standards Board ("FASB") Accounting Standards Codification, or ("ASC"), Topic&#13;718, "Compensation - Stock Compensation" ("ASC 718"). ASC 718 establishes accounting for stock-based awards&#13;exchanged for employee and consultant services. Under the provisions of ASC 718, stock-based compensation cost is measured at the&#13;grant date, based on the fair value of the award, and is recognized as expense over the employee's requisite service period&#13;(generally the vesting period of the equity grant). The fair value of the Company's stock options are estimated using the&#13;Black Scholes option-pricing model with the following assumptions: fair value of the Company's Common Stock, expected volatility,&#13;dividend rate, risk free interest rate and the expected life. The Company calculates the expected volatility using the historical&#13;volatility for a pool of peer companies over the most recent period equal to the expected term and evaluates the extent to which&#13;available information indicate that future volatility may differ from historical volatility. The expected dividend rate is zero&#13;as the Company does not expect to pay or declare any cash dividends on its Common Stock. The risk-free rates for the expected terms&#13;of the stock options are based on the U.S. Treasury yield curve in effect at the time of the grant. The Company has not experienced&#13;significant exercise activity on stock options. Due to the lack of historical information, the Company determined the expected&#13;term of its stock option awards issued using the simplified method. The simplified method assumes each vesting tranche of the award&#13;has a term equal to the midpoint between when the award vests and when the award expires. Restricted stock awards generally vest&#13;over the requisite service periods (vesting on a straight&amp;#8211;line basis). The fair value of a stock award is equal to the fair&#13;market value of a share of the Company's Common Stock on the grant date. The Company accounts for the forfeiture of equity&#13;awards as they occur.&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;Fair Value Measurements&lt;/p&gt;&#13;&#13;&lt;p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The carrying amounts of cash and cash equivalents, prepaid expenses&#13;and accounts payable approximate their fair values due to the short-term nature of these instruments.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;ASC Topic 820 "Fair Value Measurements and Disclosures" provides the framework for measuring fair value. That framework&#13;provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives&#13;the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurements) and&#13;the lowest priority to unobservable inputs (level 3 measurements).&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Fair value is defined as an exit price, representing the amount&#13;that would be received upon the sale of an asset or payment to transfer a liability in an orderly transaction between market participants.&#13;Fair value is a market-based measurement that is determined based on assumptions that market participants would use in pricing&#13;an asset or liability. A three-tier fair value hierarchy is used to prioritize the inputs in measuring fair value as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 22.5pt"&gt;&lt;/td&gt;&lt;td style="width: 13.5pt"&gt;&lt;font style="font-family: Wingdings"&gt;&amp;#216;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;Level 1 Quoted prices in active markets&#13;for identical assets or liabilities.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 22.5pt"&gt;&lt;/td&gt;&lt;td style="width: 13.5pt"&gt;&lt;font style="font-family: Wingdings"&gt;&amp;#216;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;Level 2 Quoted prices for similar assets or liabilities in active&#13;markets, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are&#13;observable, either directly or indirectly.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 22.5pt"&gt;&lt;/td&gt;&lt;td style="width: 13.5pt"&gt;&lt;font style="font-family: Wingdings"&gt;&amp;#216;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;Level 3 Significant unobservable inputs&#13;that cannot be corroborated by market data.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Deferred tax assets and liabilities are recognized for the estimated&#13;future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities&#13;and their respective tax basis, operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using&#13;enacted tax rates in effect for the year in which those temporary differences are expected to be recovered or settled. The measurement&#13;of net deferred tax assets is reduced by the amount of any tax benefit that, based on available evidence, is not expected to be&#13;realized, and a corresponding valuation allowance is established.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Tax benefits are recognized only for tax positions that are&#13;more likely than not to be sustained upon examination by tax authorities. The amount recognized is measured as the largest amount&#13;of benefit that is greater than 50 percent likely to be realized upon settlement. A liability for "unrecognized tax benefits"&#13;is recorded for any tax benefits claimed in the Company's tax returns that do not meet these recognition and measurement&#13;standards. As of December 31, 2020 and 2019, no liability for unrecognized tax benefits was required to be recorded. The guidance&#13;also discusses the classification of related interest and penalties on income taxes. The Company's policy is to record interest&#13;and penalties on uncertain tax positions as a component of income tax expense. No interest or penalties were recorded during the&#13;years ended December 31, 2020 and 2019.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2020-01-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;Research and Development Costs&lt;/p&gt;&#13;&#13;&lt;p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Research and development costs are expensed as incurred. These&#13;expenses include the costs of our proprietary research and development efforts, as well as costs incurred in connection with certain&#13;licensing arrangements. Before a compound receives regulatory approval, the Company records upfront and milestone payments made&#13;to third parties under licensing arrangements as expense. Upfront payments are recorded when incurred, and milestone payments are&#13;recorded when the specific milestone or progress has been achieved. Once a compound receives regulatory approval, the Company records&#13;any milestone payments in&amp;#160;identifiable intangible assets, less accumulated amortization&amp;#160;and, unless the asset is determined&#13;to have an indefinite life, the Company amortizes the payments on a straight-line basis over the remaining agreement term or the&#13;expected product life cycle, whichever is shorter.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Research and development expenses were $11,982 and $3,878 for&#13;the years ended December 31, 2020 and 2019, respectively.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:BusinessCombinationsPolicy contextRef="From2020-01-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&lt;b&gt;&lt;i&gt;Business Combinations&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;For a business combination, the assets acquired and the liabilities&#13;assumed are recognized at the acquisition date, measured at their fair values as of that date. In a business combination achieved&#13;in stages, the identifiable assets and liabilities are recognized at their fair values. In a bargain purchase in which the total&#13;acquisition-date fair value of the identifiable net assets acquired exceeds the fair value of the consideration transferred plus&#13;any non-controlling interest in the acquiree, that excess in fair value is recognized as a gain.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Deferred tax liabilities and assets are recognized for the deferred&#13;tax consequences of differences between the tax bases and the recognized values of assets acquired and liabilities assumed in a&#13;business combination in accordance with ASC Topic 740-10 "Income Taxes". See Note 3 for the Company's accounting&#13;for the reverse merger.&lt;/p&gt;</us-gaap:BusinessCombinationsPolicy>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;Recent Accounting Pronouncements Adopted&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;In January 2017, the FASB issued Accounting Standards Update&#13;("ASU") 2017-04 ("ASU 2017-04"), Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill&#13;Impairment. ASU 2017-04 simplifies the subsequent measurement of goodwill by eliminating the second step of the goodwill impairment&#13;test. The second step measures a goodwill impairment loss by comparing the implied fair value of a reporting unit's goodwill&#13;with the carrying amount of that goodwill. Under ASU 2017-04, a company will record an impairment charge based on the excess of&#13;a reporting unit's carrying amount over its fair value. ASU 2017-04 will be applied prospectively and is effective for annual&#13;or interim goodwill impairment tests in fiscal years beginning after December 15, 2019. On January 1, 2020, the Company adopted&#13;ASU 2017-04. The adoption of this standard did not have a material effect on the Company's financial position, results of&#13;operations, or cash flows.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;In August 2018, the FASB issued ASU No. 2018-13, Fair Value&#13;Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement ("ASU 2018-13"),&#13;which removes, adds and modifies certain disclosure requirements for fair value measurements in Topic 820. The Company will no&#13;longer be required to disclose the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy&#13;as well as the valuation processes of Level 3 fair value measurements. The Company will be required to provide additional disclosure&#13;related to the changes in unrealized gains and losses included in other comprehensive loss for recurring Level 3 fair value measurements&#13;and the range and weighted average of assumptions used to develop significant unobservable inputs for Level 3 fair value measurements.&#13;On January 1, 2020, the Company adopted ASU 2018-13. The adoption of this standard did not have a material effect on the Company's&#13;financial position, results of operations, or cash flows.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:SubsequentEventsPolicyPolicyTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;Subsequent Events &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The Company evaluated subsequent events and transactions that&#13;occurred after the balance sheet date up to the date that the financial statements were available to be issued. The Company did&#13;not identify any subsequent events that would have required adjustment or disclosure in the financial statements.&lt;/p&gt;</us-gaap:SubsequentEventsPolicyPolicyTextBlock>
    <us-gaap:BusinessCombinationDisclosureTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 3 &amp;#8211; REVERSE MERGER WITH PROTARA AND RECAPITALIZATION&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;On January 9, 2020, in connection with, and prior to the completion&#13;of the Merger, Protara Therapeutics, Inc. effected the Protara Reverse Stock Split, which resulted in 557,631 pre-merger shares&#13;of Protara Therapeutics, Inc. outstanding.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Under the terms of the Merger Agreement, Protara Therapeutics,&#13;Inc. issued shares of its common stock ("Common Stock") to the Company's stockholders, at an exchange ratio of&#13;0.190756 (the "Exchange Ratio"), after taking into account the Protara Reverse Stock Split, for each share of Private&#13;ArTara common stock outstanding immediately prior to the Merger. Protara Therapeutics, Inc. assumed all of the unvested Private&#13;ArTara restricted stock awards, which were exchanged for a number of shares of Common Stock equal to 0.190756 multiplied by the&#13;number of shares of Private ArTara common stock previously represented by such Private ArTara restricted stock awards and unvested&#13;to the same extent as such Private ArTara restricted stock awards and subject to the same restrictions as such Private ArTara restricted&#13;stock awards. On account of the adjustment required pursuant to the Exchange Ratio, there were 2,627,533 shares of Private ArTara&#13;common stock outstanding immediately prior to the Merger.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Protara Therapeutics, Inc. assumed all of the outstanding and&#13;unexercised stock options of Private ArTara, with such stock options representing the right to purchase a number of shares of Common&#13;Stock equal to 0.190756 multiplied by the number of shares of Private ArTara common stock previously represented by such Private&#13;ArTara stock options. As a result, 219,699 shares were assumed under Private ArTara's 2017 Equity Incentive Plan. No additional&#13;awards will be made under the 2017 Equity Incentive Plan. On January 1, 2020, Protara Therapeutics, Inc. amended its Amended and&#13;Restated 2014 Equity Incentive Plan (the "2014 Equity Incentive Plan") to increase the number of shares of stock available&#13;for issuance under the 2014 Equity Incentive Plan to 1,048,300 shares and made conforming changes and updates pursuant to Section&#13;162(m) of the Code.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Concurrently with the execution of the Merger Agreement, certain&#13;institutional investors (together, the "Investors") entered into a subscription agreement (as amended on November 19,&#13;2019, the "Subscription Agreement") with Protara Therapeutics, Inc. and Private ArTara, pursuant to which (A) Protara&#13;Therapeutics, Inc. issued in a private placement immediately after the Merger (the "Proteon Private Placement") (i)&#13;3,879.356 of shares of Protara Therapeutics, Inc.'s Series 1 Convertible Non-Voting Preferred Stock at a purchase price of&#13;approximately $7,011.47 per share for gross proceeds of $27,200 and proceeds, net of issuance costs, of $25,319, (ii) 1,896,888&#13;shares of Protara Therapeutics, Inc.'s Common Stock at a purchase price of approximately $7.01 per share for gross proceeds&#13;of $13,300 and proceeds, net of issuance costs, of $12,413 and (B) Private ArTara issued in a private placement immediately prior&#13;to the Merger (the "ArTara Private Placement") 284,875 shares of Private ArTara common stock (post-Exchange Ratio basis)&#13;at a purchase price of approximately $7.01 per share (post-Exchange Ratio basis) (together with the Proteon Private Placement,&#13;the "Private Placements") for gross proceeds of $2,000 and proceeds, net of issuance costs, of $1,867. The shares issued&#13;in the Proteon Private Placement were registered for resale on a registration statement on Form S-3 filed and declared effective&#13;by the SEC on January 30, 2020.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Immediately following the closing of the Proteon Private Placement,&#13;18,954 shares of Protara Therapeutics, Inc.'s Series A Convertible Preferred Stock outstanding were converted into 476,276&#13;shares of Protara Therapeutics, Inc.'s Common Stock. These shares, combined with the 557,631 pre-merger shares of Protara&#13;Therapeutics, Inc. outstanding after the Protara Reverse Stock Split, resulted in an aggregate of 1,033,907 shares of Common Stock&#13;issued in connection with the Merger.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Immediately after the consummation of the Merger and prior to&#13;the consummation of the Proteon Private Placement, the former stockholders and option holders of Private ArTara owned, or held&#13;rights to acquire, approximately 75.2% of the fully-diluted Common Stock of Protara, with Protara Therapeutics, Inc.'s stockholders&#13;and option holders immediately prior to the Merger owning approximately 24.8% of the fully-diluted Common Stock of Protara.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Based&#13;on the terms of the Merger, the transaction was treated as a reverse merger of Protara Therapeutics, Inc. by Private ArTara.&lt;/font&gt;&#13;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The Merger was accounted for using acquisition accounting under ASC Topic&#13;805 "Business Combinations". Under acquisition accounting, the assets and liabilities (including executory contracts,&#13;commitments and other obligations) of Protara Therapeutics, Inc. as of the effective time of the Merger were recorded at their&#13;respective fair values and added to those of Private ArTara. Any excess of purchase price consideration over the fair values of&#13;the identifiable net assets is recorded as goodwill. During the year ended December 31, 2020, the Company recorded an adjustment&#13;of $150 to goodwill. This adjustment was comprised of a decrease of $78 in prepaid expenses and other current assets, and an increase&#13;of $77 in accrued expenses, resulting in a final purchase price allocation as follows: &lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 88%; text-indent: -10pt; padding-left: 10pt"&gt;Cash&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,669&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Restricted cash&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;50&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Prepaid expenses and other current assets&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,662&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;Goodwill&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;29,517&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Accrued expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(365&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"&gt;Total purchase price consideration&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;34,533&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The total fair value of the net assets of Protara Therapeutics&#13;Inc. was determined by the Company to be $34,533 based on the consideration transferred. The total consideration was based on the&#13;enterprise value of Protara Therapeutics Inc. as of January 9, 2020, based upon the number of common shares deemed outstanding,&#13;multiplied by the closing stock price on January 9, 2020.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Of the amount of goodwill acquired in the reverse merger, no&#13;portion is deductible for tax purposes.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The primary reasons for the reverse merger: the increased access&#13;to sources of capital and a broader range of investors to support the clinical development of Private ArTara's product candidates,&#13;the potential to provide current stockholders with greater liquidity by owning stock in a public company, the potential for a more&#13;cost-effective means to access capital and the registration of Protara Common Stock issued to Private ArTara's stockholders.&#13;In addition, Protara assumed the existing 2014 Equity Incentive Plan (the "2014 Plan"), and all outstanding stock options&#13;thereunder.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The following presents the unaudited pro forma combined financial&#13;information as if the reverse merger had occurred as of January 1, 2019.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;For the Years Ended &lt;br /&gt; December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 76%; text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"&gt;Net loss&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;(33,754&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;(22,821&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"&gt;Pro forma loss per common share, basic and diluted&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(4.62&lt;/td&gt;&lt;td style="padding-bottom: 2pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(3.94&lt;/td&gt;&lt;td style="padding-bottom: 2pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"&gt;Pro forma weighted average number of common shares outstanding, basic and diluted&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7,304,201&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,793,024&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The pro forma combined results of operations are not necessarily&#13;indicative of the results of operations that actually would have occurred had the reverse merger been completed as of January 1,&#13;2019, nor are they necessarily indicative of future consolidated results.&lt;/p&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: -1in"&gt;&lt;b&gt;NOTE 5 &amp;#8211;&#13;ACCRUED EXPENSES &lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: -1in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="background-color: white"&gt;Included in the Company's&#13;accrued expenses within the consolidated financial statements are:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;As of December 31,&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2019&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 76%; text-align: left"&gt;Employee bonus&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,530&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;-&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td&gt;Taxes&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;159&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;Legal fees&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;156&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,573&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left"&gt;Research and development costs&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;37&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,050&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Other expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;31&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;12&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,913&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,635&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;As of December 31,&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2019&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 76%; text-align: left"&gt;Employee bonus&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,530&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;-&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td&gt;Taxes&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;159&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;Legal fees&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;156&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,573&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left"&gt;Research and development costs&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;37&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,050&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Other expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;31&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;12&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,913&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,635&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:ShortTermDebtTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 6 &amp;#8211; SHORT-TERM DEBT&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;Financing Agreement&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;On February 19, 2020, the Company entered into a nine month&#13;financing agreement with AFCO Credit Corporation for its directors and officers ("D&amp;#38;O") liability insurance in the&#13;amount of $2,225. The Company made a down payment of $556, leaving a principal balance of $1,669. The financing bore interest at&#13;a rate of 4.25% per annum, and was repaid in monthly installments of $189, which included both principal and interest. As of December&#13;31, 2020, the balance under this debt was $0. The Company recorded interest expense of $34 for the year ended December 31, 2020&#13;under this financing agreement.&lt;/p&gt;</us-gaap:ShortTermDebtTextBlock>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 4 &amp;#8211; PROPERTY AND EQUIPMENT &lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: -1in"&gt;Property and&#13;equipment consists of the following:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: -1in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: -1in"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; padding-left: 10pt; text-indent: -10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;As of December 31,&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; padding-left: 10pt; text-indent: -10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Useful Life &lt;br /&gt; (in years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2019&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 64%; text-align: left; padding-left: 10pt; text-indent: -10pt"&gt;Computer equipment&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: center; padding-left: 5.4pt"&gt;5&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;34&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;-&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-left: 10pt; text-indent: -10pt"&gt;Furniture, fixtures and other&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;5&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;21&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;21&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-left: 10pt; text-indent: -10pt"&gt;Laboratory equipment&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;7&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;601&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;446&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-left: 10pt; text-indent: -10pt; vertical-align: top"&gt;Leasehold improvements&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;Over the shorter of the useful life or the lease term&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;200&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-left: 10pt; text-indent: -10pt; padding-bottom: 1.5pt"&gt;Property and equipment not yet placed into service&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; padding-left: 5.4pt; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;503&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;8&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-left: 0.25in; text-indent: -10pt"&gt;Total property and equipment, gross&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,359&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;475&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-left: 10pt; text-indent: -10pt; padding-bottom: 1.5pt"&gt;Less: Accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; padding-left: 5.4pt; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(119&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(16&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-left: 0.25in; text-indent: -10pt; padding-bottom: 4pt"&gt;Total property and equipment, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; padding-left: 5.4pt; padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,240&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;459&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: -1in"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Depreciation expense was $103 and $16 for the years ended December&#13;31, 2020 and 2019, respectively. During the year ended December 31, 2020, $99 and $4 was included in research and development expense&#13;and general and administrative expense, respectively, within the consolidated statements of operations. For the year ended December&#13;31, 2019, $16 was included in research and development expense within the consolidated statements of operations.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="From2020-01-01to2020-12-31">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td style="padding-bottom: 1.5pt; padding-left: 10pt; text-indent: -10pt"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;As of December 31,&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; padding-left: 10pt; text-indent: -10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Useful Life &lt;br /&gt; (in years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2019&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 64%; text-align: left; padding-left: 10pt; text-indent: -10pt"&gt;Computer equipment&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: center; padding-left: 5.4pt"&gt;5&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;34&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;-&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-left: 10pt; text-indent: -10pt"&gt;Furniture, fixtures and other&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;5&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;21&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;21&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-left: 10pt; text-indent: -10pt"&gt;Laboratory equipment&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;7&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;601&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;446&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-left: 10pt; text-indent: -10pt; vertical-align: top"&gt;Leasehold improvements&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;Over the shorter of the useful life or the lease term&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;200&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-left: 10pt; text-indent: -10pt; padding-bottom: 1.5pt"&gt;Property and equipment not yet placed into service&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; padding-left: 5.4pt; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;503&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;8&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-left: 0.25in; text-indent: -10pt"&gt;Total property and equipment, gross&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,359&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;475&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-left: 10pt; text-indent: -10pt; padding-bottom: 1.5pt"&gt;Less: Accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; padding-left: 5.4pt; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(119&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(16&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-left: 0.25in; text-indent: -10pt; padding-bottom: 4pt"&gt;Total property and equipment, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; padding-left: 5.4pt; padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,240&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;459&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 7 &amp;#8211; COMMITMENTS AND CONTINGENCIES&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;Lease Agreements&lt;/p&gt;&#13;&#13;&lt;p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The Company has entered into operating leases for office and&#13;laboratory space. On January 1, 2019 ("Effective Date"), the Company adopted ASC Topic 842, Leases ("ASC 842"),&#13;which increases transparency and comparability by recognizing a lessee's rights and obligations resulting from leases. ASC&#13;842 requires the recognition of the right-of-use ("ROU") assets and related operating lease liabilities on the balance&#13;sheet. The Company adopted the new guidance using the modified retrospective approach on January 1, 2019.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The adoption of ASC 842 on January 1, 2019 did not immediately&#13;result in the recognition of ROU assets as the Company did not have any leases at that time with a term of twelve months or more.&#13;However, on January 9, 2020, subsequent to the Merger and Private Placements, it became reasonably certain that the Company would&#13;maintain its quarter-to-quarter lease with its contract development and manufacturing organization for its manufacturing space&#13;for an expected term of approximately eight years, therefore resulting in the recognition of an ROU asset and related operating&#13;lease liability.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The Company elected the package of practical expedients permitted&#13;within the standard, which allow an entity to forgo reassessing (i) whether a contract contains a lease, (ii) classification of&#13;leases, and (iii) whether capitalized costs associated with a lease meet the definition of initial direct costs. Also, the Company&#13;elected the expedient to allow the Company to not have to separate lease and non-lease components. The Company has also elected&#13;the short-term lease accounting policy under which the Company would not recognize a lease liability or ROU asset for any lease&#13;that at the commencement date has a lease term of twelve months or less and does not include a purchase option that the Company&#13;is more than reasonably certain to exercise.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;On July 1, 2020 and December 1, 2020, the Company entered into&#13;additional quarter-to-quarter leases for additional contract development and manufacturing space for expected terms of approximately&#13;seven years, therefore resulting in the recognition of additional ROU assets and related operating lease liabilities.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;On December 1, 2020, the Company entered into a long-term lease&#13;for office space for a term of seven years. This lease was entered into with a related party of the Company, and its terms were&#13;determined by management to be on an arms-length basis. The lease will not commence until the second quarter of 2021 when the Company&#13;is granted access to the premises. Accordingly, as of December 31, 2020, the Company did not recognize an additional ROU asset&#13;and related operating lease liability for this lease.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;For contracts entered into on or after the Effective Date, at&#13;the inception of a contract, the Company will assess whether the contract is, or contains, a lease. The Company's assessment is&#13;based on: (i) whether the contract involves the use of a distinct identified asset, (ii) whether the Company obtained the right&#13;to substantially all the economic benefit from the use of the asset throughout the period, and (iii) whether the Company has the&#13;right to direct the use of the asset. Leases entered into prior to January 1, 2019, which were accounted for under ASC 840, Leases,&#13;were not reassessed for classification.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;For operating leases, the lease liability is initially and subsequently&#13;measured at the present value of the unpaid lease payments. The Company generally uses its incremental borrowing rate as the discount&#13;rate for leases, unless an interest rate is implicitly stated in the lease. The present value of the lease payments is calculated&#13;using the incremental borrowing rate for operating leases, which was determined using a rate of interest that the Company would&#13;have to pay to borrow an amount equal to the lease payments on a collateralized basis over a similar term. The lease term for the&#13;Company's lease includes the noncancellable period of the lease plus any additional periods covered by either a Company option&#13;to extend the lease that the Company is reasonably certain to exercise, or an option to extend the lease controlled by the lessor.&#13;ROU assets, once recorded, are reviewed for impairment.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Lease expense for operating leases consists of the lease payments&#13;plus any initial direct costs and is recognized on a straight-line basis over the lease term.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Balance sheet information related to our leases is presented&#13;below:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;As of&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; font-style: italic"&gt;Operating leases:&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Balance Sheet &lt;br /&gt;&#13;Location&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;December 31, &lt;br /&gt;&#13;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;January 9, 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;December 31, &lt;br /&gt;&#13;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 30%; padding-bottom: 4pt; padding-left: 0in"&gt;Right-of-use assets&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 30%; text-align: left; padding-bottom: 4pt"&gt;Other assets&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 10%; text-align: right"&gt;1,060&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 10%; text-align: right"&gt;403&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 10%; text-align: right"&gt;-&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 0in"&gt;Operating lease liability, current&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Operating lease liability, current&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;88&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;9&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 0in"&gt;Operating lease liability, long-term&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Operating lease liability, long-term&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;999&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;394&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The following provides details of the Company's lease&#13;expense:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;Lease cost&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;For the Year Ended&lt;br /&gt; December 31, 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 82%; text-align: left; padding-left: 0.125in"&gt;Operating lease cost&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;93&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in"&gt;Short-term lease cost&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;215&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;308&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.05pt; text-indent: -20.05pt"&gt;Other information related&#13;to leases is presented below:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.05pt; text-indent: -20.05pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;As of &lt;br /&gt; December 31, 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="font-weight: bold; text-align: left; padding-left: 0.125in"&gt;Other information&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="width: 82%; text-align: left; padding-left: 0.125in"&gt;Weighted-average discount rate &amp;#8211; operating lease&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;12.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-left: 0.125in"&gt;Weighted-average remaining lease term &amp;#8211; operating lease (in months)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;87&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;As of December 31, 2020, the expected annual minimum lease payments&#13;of our operating lease liabilities and other short-term leases were as follows (includes long-term lease entered into on December&#13;1, 2020 that does not commence until the second quarter of 2021):&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;For Years Ending December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Operating lease&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 82%; text-align: left"&gt;2021&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;1,111&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left"&gt;2022&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,333&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;2023&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,338&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left"&gt;2024&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,342&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;2025&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,423&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Thereafter&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,277&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;Total future minimum lease payments, undiscounted&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,824&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: Imputed interest for leases in excess of one year&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;8,676&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Present value of future minimum lease payments&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,148&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Present value of future minimum lease payments for our operating lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,087&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Present value of future minimum lease payments, short-term leases&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;61&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;Employment Agreements&lt;/p&gt;&#13;&#13;&lt;p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;u&gt;Executive Employment Agreements&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The Company's executive officers have entered into at-will&#13;employment agreements.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;u&gt;Temporary Employment Agreement&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;On December 6, 2018, the Company entered into a temporary employment&#13;agreement (the "Temporary Employment Agreement") with an individual who assisted with certain corporate development&#13;activities. Pursuant to the Temporary Employment Agreement, the individual was entitled to receive an annual base salary of $90.&#13;In addition, the individual would be entitled to a performance-based success fee which would be adjusted based on amounts of funding&#13;achieved and timing of when such funding was received. On January 9, 2020, the Company's capital raise triggered a performance-based&#13;compensation obligation and accordingly this individual was paid $462, which was included in general and administrative expenses&#13;within the Company's consolidated statements of operations for the year ended December 31, 2020.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&lt;b&gt;&lt;i&gt;Collaborations and License Agreements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;u&gt;Choline License Agreement&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;On September 27, 2017, the Company entered into a license agreement&#13;(the "Choline License Agreement") with Alan L. Buchman ("Dr. Buchman"). Pursuant to the Choline License&#13;Agreement, the Company received from Dr. Buchman the license rights in and to the "Licensed Orphan Designations", the&#13;"Licensed IND", "Existing Study Data" and the "Licensed Know-How" for one or more of the licensed&#13;indications. In consideration for the rights and licenses granted, Dr. Buchman received a payment of $50 on October 2, 2017, and&#13;license payments of $50 and $50 on December 12, 2018 and January 8, 2019, respectively, upon the Company meeting the criteria for&#13;certain meetings to be held with the Federal Drug Administration (the "FDA"). Pursuant to the Choline License Agreement,&#13;effective October 2017, the Company incurred a fixed obligation to Dr. Buchman of $400 (the "Choline License Fee").&#13;Upon the Company receiving $5,000 in cumulative funding (as defined), Dr. Buchman would be entitled to receive payment of the Choline&#13;License Fee as a lump sum if the funds are received by April 15, 2019 and the Choline License Fee shall be increased to a one-time&#13;payment of $600 if the funds are received by October 15, 2019. On October 2, 2019, the Company made a payment of $50 to Dr. Buchman.&#13;On January 22, 2020, in connection with the closing of the Merger and concurrent financing, Dr. Buchman was paid $550 which was&#13;included in accrued expenses as of December 31, 2019.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;During the years ended December 31, 2020 and 2019, the Company&#13;recorded research and development expense of $0 and $200 (representing the increase in the Choline License Fee obligation), respectively,&#13;for expenditures to Dr. Buchman in connection with obligations under the Choline License Agreement.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;u&gt;License Agreement&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;On December 22, 2017, the Company entered into an agreement&#13;(the "Feinstein Agreement") with The Feinstein Institute for Medical Research (the "Feinstein Institute"),&#13;a not-for-profit corporation with 50 research labs and 2,500 clinical research studies. Pursuant to the Feinstein Agreement, the&#13;Company acquired an exclusive license relating to treatment of fatty liver diseases in humans for which Choline may be an effective&#13;therapeutic. In consideration for the rights and license granted, the Feinstein Institute would receive a royalty of one percent&#13;(1%) of the first one hundred million dollars ($100,000) of net sales of IV Choline Chloride and a royalty of one and one-half&#13;percent (1.5%) of all net sales thereafter. In addition, the Company would pay the Feinstein Institute twelve and one-half percent&#13;(12.5%) of net proceeds resulting from agreements entered within 2 years from the effective date, and seven and one-half percent&#13;(7.5%) of net proceeds resulting from agreements entered into thereafter. Pursuant to the Feinstein Agreement additional payments&#13;would be due to the Feinstein Institute for license maintenance payments and for meeting milestone events. On January 9, 2020,&#13;the Company's raising of over $5,000 triggered a financing milestone obligation and accordingly the Feinstein Institute was&#13;paid $100. Pursuant to the Feinstein Agreement, upon the achievement of certain future new drug application milestones, the Company&#13;would be obligated to remit an aggregate of $275.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;During the years ended December 31, 2020 and 2019, the Company&#13;recorded research and development expense of $115 and $1, respectively, in connection with the Feinstein Agreement.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;u&gt;Sponsored Research and License Agreement&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;On November 28, 2018, the Company entered into a sponsored research&#13;and license agreement (the "Iowa Agreement") with the University of Iowa. Pursuant to the Iowa Agreement, the University&#13;of Iowa, which is engaged in clinical research to improve the diagnosis and treatment of lymphangioma using a pharmaceutical product&#13;(OK-432), would assist the Company in collecting case reports, forms, source data, and safety data available to the University&#13;of Iowa in support of the development of the Company's proprietary &lt;i&gt;Streptococcus Pyogenes&lt;/i&gt; investigational product,&#13;TARA-002 for the LMs indication. During the term of the services, the Company would pay the University of Iowa thirty thousand&#13;dollars ($30) per year to fund the project, plus additional amounts upon the realization of certain milestones. More specifically,&#13;upon forty-five (45) days of an approval of TARA-002 by the FDA, the Company would pay up to $1,750 to the University of Iowa for&#13;meeting these milestones. Furthermore, the Company would pay the University of Iowa royalties of up to 1.75% for net sales ranging&#13;from $0 - $25,000, 2.25% for net sales ranging from $25,000 to $50,000, and 2.50% for net sales in excess of $50,000. Pursuant&#13;to the Iowa Agreement, the University of Iowa would be entitled to additional payments for the Company achieving annual net sales&#13;of product according to the milestones. For annual net sales of product up to $25,000; $62; for annual net sales of product of&#13;up to $50,000; $62; and for annual net sales of product of up to $100,000; $125.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;During the years ended December 31, 2020 and 2019, the Company&#13;recorded research and development expense of $30 and $30 respectively, in connection with the Iowa Agreement.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;u&gt;Chugai Agreement&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;On June 17, 2019, the Company entered into an agreement (the&#13;"Chugai Pharmaceutical Agreement") with Chugai Pharmaceutical Co., LTD ("Chugai"), a drug manufacturing&#13;firm with offices and operations in Japan. Pursuant to the Chugai Pharmaceutical Agreement, Chugai would help the Company in its&#13;goals to develop and commercialize a therapeutic product (the "New Product") which is comparable to the Chugai existing&#13;therapeutic product (the "Existing Product"). In addition, the Company would be entitled to the use of Chugai materials&#13;and technical support as necessary. On July 14, 2020, the Company and Chugai entered into an amendment (the "Chugai Amendment")&#13;to the Chugai Pharmaceutical Agreement. The Chugai Amendment is effective as of June 30, 2020. The Chugai Amendment extended the&#13;date through which Chugai will exclusively provide the Existing Product and materials to the Company from June 30, 2020 to June&#13;30, 2021, extended the date through which Chugai will not provide materials or technical support to any third party for the purpose&#13;of development and commercialization in a given area from the fifth anniversary to the eleventh anniversary of the original effective&#13;date and provides that, in addition to the designated fee provided upon the initial indication approval in the Chugai Pharmaceutical&#13;Agreement, the Company will pay Chugai a designated fee for each additional indication approval. The Company is obligated to Chugai&#13;for certain payments upon the completion of agreed upon milestones. As of December 31, 2019, the Company recorded an obligation&#13;of $500 upon Chugai having completed an agreed upon milestone, which the Company paid on July 27, 2020.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;During the years ended December 31, 2020 and 2019, the Company&#13;recorded research and development expense of $0 and $500, respectively, respectively, in connection with the Chugai Agreement,&#13;as amended.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;u&gt;Johns Hopkins University&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;In February 2002, Proteon entered into an agreement to license&#13;certain intellectual property in connection with vonapanitase with Johns Hopkins University. The agreement calls for payments to&#13;be made by the Company upon the commencement of vonapanitase related product sales, in the form of a royalty of 2.5% on net sales&#13;of the product. As of December 31, 2020, the Company has not commenced vonapanitase product sales and therefore has recognized&#13;no royalties on product sales.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;Litigation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;From time to time, Protara may be subject to various legal proceedings&#13;and claims that arise in the ordinary course of its business activities. Management is of the opinion that the ultimate outcome&#13;of these matters would not have a material adverse impact on the financial position of the Company or the results of its operations.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;In the normal course of business, the Company enters into contracts&#13;in which it makes representations and warranties regarding the performance of its services and that its services will not infringe&#13;on third party intellectual rights. There have been no significant events related to such representations and warranties in which&#13;the Company believes the outcome could result in losses or penalties in the future.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:OperatingLeaseLeaseIncomeTableTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;As of&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; font-style: italic"&gt;Operating leases:&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Balance Sheet &lt;br /&gt;&#13;Location&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;December 31, &lt;br /&gt;&#13;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;January 9, 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;December 31, &lt;br /&gt;&#13;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 30%; padding-bottom: 4pt; padding-left: 0in"&gt;Right-of-use assets&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 30%; text-align: left; padding-bottom: 4pt"&gt;Other assets&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 10%; text-align: right"&gt;1,060&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 10%; text-align: right"&gt;403&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 10%; text-align: right"&gt;-&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 0in"&gt;Operating lease liability, current&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Operating lease liability, current&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;88&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;9&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 0in"&gt;Operating lease liability, long-term&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Operating lease liability, long-term&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;999&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;394&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The following provides details of the Company's lease&#13;expense:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;Lease cost&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;For the Year Ended&lt;br /&gt; December 31, 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 82%; text-align: left; padding-left: 0.125in"&gt;Operating lease cost&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;93&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in"&gt;Short-term lease cost&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;215&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;308&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.05pt; text-indent: -20.05pt"&gt;Other information related&#13;to leases is presented below:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.05pt; text-indent: -20.05pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;As of &lt;br /&gt; December 31, 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="font-weight: bold; text-align: left; padding-left: 0.125in"&gt;Other information&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="width: 82%; text-align: left; padding-left: 0.125in"&gt;Weighted-average discount rate &amp;#8211; operating lease&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;12.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-left: 0.125in"&gt;Weighted-average remaining lease term &amp;#8211; operating lease (in months)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;87&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:OperatingLeaseLeaseIncomeTableTextBlock>
    <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;For Years Ending December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Operating lease&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 82%; text-align: left"&gt;2021&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;1,111&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left"&gt;2022&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,333&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;2023&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,338&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left"&gt;2024&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,342&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;2025&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,423&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Thereafter&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,277&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;Total future minimum lease payments, undiscounted&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,824&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: Imputed interest for leases in excess of one year&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;8,676&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Present value of future minimum lease payments&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,148&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Present value of future minimum lease payments for our operating lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,087&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Present value of future minimum lease payments, short-term leases&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;61&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
    <us-gaap:SaleOfStockPricePerShare contextRef="AsOf2020-09-24_custom_UnderwrittenPublicOfferingMember" unitRef="USDPShares" decimals="INF">16.87</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockPricePerShare contextRef="AsOf2020-09-24_custom_UnderwrittenPublicOfferingMember_custom_Series1PreferredStockMember" unitRef="USDPShares" decimals="INF">16873.54</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockPricePerShare contextRef="AsOf2019-12-31_custom_TwentySeventeenEquityIncentivePlanMember_srt_BoardOfDirectorsChairmanMember" unitRef="USDPShares" decimals="INF">9.18</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockPricePerShare contextRef="AsOf2020-12-31_custom_TwentyFourteenEquityIncentivePlanMember_srt_BoardOfDirectorsChairmanMember_srt_MinimumMember" unitRef="USDPShares" decimals="INF">17.84</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockPricePerShare contextRef="AsOf2020-12-31_custom_TwentyFourteenEquityIncentivePlanMember_srt_BoardOfDirectorsChairmanMember_srt_MaximumMember" unitRef="USDPShares" decimals="INF">51.12</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 8 &amp;#8211; STOCKHOLDERS' EQUITY &lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;Authorized Common Stock &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;As of December 31, 2020, the Company has 100,000,000 shares&#13;of Common Stock authorized for issuance, $0.001 par value per share, of which 11,211,840 and 2,627,533 shares were issued and outstanding&#13;as of December 31, 2020 and 2019, respectively.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The holders of the Company's Common Stock are entitled&#13;to one vote per share.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;Authorized Series 1 Convertible Preferred&#13;Stock&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;In connection with the Preferred Offering (defined below) on&#13;September 22, 2020, the Company filed a Certificate of Amendment to the Certificate of Designation of Preferences, Rights and Limitations&#13;of Series 1 Convertible Preferred Stock of the Company (the "Amendment") with the State of Delaware to increase the&#13;authorized number of shares of the Company's Series 1 Convertible Preferred Stock that may be issued from 3,880 to 8,028.&#13;The Amendment was approved by a committee of the Company's Board of Directors and the requisite holders of outstanding shares&#13;of Series 1 Convertible Preferred Stock. No approval of the holders of the Company's Common Stock was required to effectuate&#13;the Amendment.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;As of December 31, 2020 and 2019, the Company has 10,000,000&#13;shares of preferred stock authorized for issuance, $0.001 par value per share of which 8,028 shares of Series 1 Convertible Preferred&#13;Stock are authorized for issuance and 8,027 and 0 shares were issued and outstanding, respectively.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;Description of Series 1 Convertible&#13;Preferred Stock&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Each share of Series 1 Convertible Preferred Stock is convertible&#13;into 1,000 shares of Common Stock, at a conversion price initially equal to approximately $7.01 per common share, subject to adjustment&#13;for any stock splits, stock dividends and similar events, at any time at the option of the holder, provided that any conversion&#13;of Series 1 Convertible Preferred Stock by a holder into shares of Common Stock would be prohibited if, as a result of such conversion,&#13;the holder, together with its affiliates and any other person or entity whose beneficial ownership of the Common Stock would be&#13;aggregated with such holder's for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, would beneficially&#13;own more than 9.99% of the total number of shares Common Stock issued and outstanding after giving effect to such conversion. Upon&#13;written notice to the Company, the holder may from time to time increase or decrease such limitation to any other percentage not&#13;in excess of 19.99% specified in such notice. Each share of Series 1 Convertible Preferred Stock is entitled to a preference of&#13;$10.00 per share upon liquidation of the Company, and thereafter will share ratably in any distributions or payments on an as-converted&#13;basis with the holders of Common Stock. In addition, upon the occurrence of certain transactions that involve the merger or consolidation&#13;of the Company, an exchange or tender offer, a sale of all or substantially all of the assets of the Company or a reclassification&#13;of its Common Stock, each share of Series 1 Convertible Preferred Stock will be convertible into the kind and amount of securities,&#13;cash and/or other property that the holder of a number of shares of Common Stock issuable upon conversion of one share of Series&#13;1 Convertible Preferred Stock would receive in connection with such transaction. The Company's Series 1 Convertible Preferred&#13;Stock are non-voting.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The terms of the Series 1 Convertible Preferred Stock provide&#13;that, in the event of a fundamental transaction (as such term is described in the certificate of designation of preferences, rights&#13;and limitations of series 1 convertible non-voting preferred stock), each share of Series 1 Convertible Preferred Stock outstanding&#13;shall thereafter be convertible into the kind and amount of securities, cash and/or other property which a holder of the number&#13;of shares of Common Stock of the Company issuable upon conversion of one share of Series 1 Convertible Preferred Stock immediately&#13;prior to such fundamental transaction would have been entitled to receive pursuant to such fundamental transaction, provided that,&#13;if the value of the aggregate of such securities, cash and/or other property the which the holder of one share of Series 1 Convertible&#13;Preferred Stock would be entitled to upon conversion thereof would be less than the stated value, then each outstanding share of&#13;Series 1 Convertible Preferred Stock shall instead be convertible into such kind of securities, cash and/or other property with&#13;an aggregate value equal to the stated value.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;Common Stock&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;On September 23, 2019, the Company completed a placement of&#13;69,114 shares of its common stock at a price of $7.23 per share for gross proceeds of $500.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;Underwritten Public Offering &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;On September 24, 2020, pursuant to an underwriting agreement&#13;dated September 22, 2020, the Company issued and sold in an underwritten public offering (the "Common Offering") an&#13;aggregate of 4,600,000 shares of its Common Stock at an offering price of $16.87 per share, for gross and net proceeds of approximately&#13;$77.6 million and $73.6 million, respectively. The underwriters were granted an option to purchase up to 690,000 additional shares&#13;of Common Stock at the public offering price, less the underwriting discount. On October 6, 2020, the underwriters exercised their&#13;overallotment option in full, purchasing an additional 690,000 shares, resulting in the receipt of gross and net proceeds of $11.6&#13;million and $11.1 million, respectively.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;On September 24, 2020, pursuant to an underwriting agreement&#13;(dated September 22, 2020), the Company issued and sold in an underwritten public offering (the "Preferred Offering")&#13;an aggregate of 4,148 shares of its Series 1 Convertible Preferred Stock at an offering price of $16,873.54 per share, for gross&#13;and net proceeds of approximately $70.0 million and $66.3 million, respectively.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The Common Offering and the Preferred Offering were made pursuant&#13;to the Company's registration statement on Form S-3, declared effective by the Securities and Exchange Commission on May&#13;26, 2020 (Registration No. 333-238273).&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;In December 2020, the Company filed a shelf registration statement&#13;on Form S-3, declared effective by the Securities and Exchange Commission on December 18, 2020 (Registration No. 333-251224) (the&#13;"Shelf Registration Statement"). The Shelf Registration Statement permits: (i) the offering, issuance and sale by the&#13;Company of up to a maximum aggregate offering price of $300 million of common stock, preferred stock, debt securities and warrants&#13;in one or more offerings and in any combination. No securities have been sold to date under the Shelf Registration Statement.&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 9 &amp;#8211; STOCK-BASED COMPENSATION&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;2020 Inducement Plan&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;On March 26, 2020, the Compensation Committee of the Board of&#13;Directors (the "Compensation Committee") approved the ArTara Therapeutics, Inc. Inducement Plan (the "2020 Inducement&#13;Plan") in order to award nonstatutory stock options, restricted stock awards, restricted stock unit awards and other stock-based&#13;awards to persons not previously an employee or director of the Company, or following a bona fide period of non-employment, as&#13;an inducement material to such persons entering into employment with the Company.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The 2020 Inducement Plan provides for a total of 600,000 shares&#13;for the issuance of the Company's Common Stock. The Compensation Committee also adopted a form of stock option grant notice&#13;and stock option agreement and forms of restricted stock unit grant notice and restricted stock unit agreement for use with the&#13;Inducement Plan.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;As of December 31, 2020, 460,650 shares remain available to&#13;be issued under the 2020 Inducement Plan.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;2017 Equity Incentive Plan &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;On August 10, 2017, Private ArTara, its Board of Directors and&#13;its shareholders approved the ArTara Therapeutics, Inc. 2017 Equity Incentive Plan (the "2017 Equity Incentive Plan")&#13;to enable Private ArTara and its affiliates to recruit and retain highly qualified personnel and to incentivize personnel for productivity&#13;and growth.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The 2017 Equity Incentive Plan provided for the grant of a total&#13;of 2,000,000 shares for the issuance of stock options, stock appreciation rights, restricted stock and restricted stock units to&#13;among others, members of the Board of Directors, employees, consultants and service providers to the Company and its affiliates.&#13;As of January 9, 2020, in connection with the Merger, no additional awards will be made under the 2017 Equity Incentive Plan.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&lt;b&gt;&lt;i&gt;2014 Equity Incentive Plan &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;On October 3, 2014, the stockholders approved&#13;the 2014 Plan. On June 20, 2017, the Company's Board of Directors amended the 2014 Plan (the "Amended 2014 Plan").&#13;On July 31, 2017, the stockholders approved this amendment.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 18pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The Amended 2014 Plan provides for the grant of incentive and&#13;non-statutory stock options, stock appreciation rights, restricted stock and stock unit awards, performance units, stock grants&#13;and qualified performance-based awards. The 2014 Plan provides that the number of shares reserved and available for issuance under&#13;the 2014 Plan will automatically increase each January 1, beginning January 1, 2015 by four percent of the outstanding shares of&#13;Common Stock on the immediately preceding December 31 or such lesser number of shares as determined by the Company's Board&#13;of Directors prior to each such January 1st. The Amended 2014 Plan clarifies that the number of shares for purposes of calculating&#13;the evergreen feature includes the number of shares of Common Stock issuable upon conversion of any security that the Company may&#13;issue that is convertible into or exchangeable for Common Stock, including, but not limited to, preferred stock or warrants. Pursuant&#13;to a special meeting of the Proteon stockholders held on January 9, 2020, the number of shares available for issuance under the&#13;Amended 2014 Plan increased by 900,002 shares from 148,298 shares to 1,048,300 shares on January 1, 2020. As of December 31, 2020,&#13;227,850 shares remain available to be issued under the Amended 2014 Plan. On January 1, 2021, pursuant to the Amended 2014 Plan's&#13;annual evergreen feature, the number of shares authorized under the Amended 2014 Plan was increased by 812,889 shares to 1,861,189&#13;shares.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 18pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Terms of the stock awards, including vesting requirements, are&#13;determined by the Board of Directors, subject to the provisions of the plans. Certain awards provide for accelerated vesting if&#13;there is a change in control as defined in the plans.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;2014 Employee Stock Purchase Plan&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;On October 3, 2014, the stockholders approved the 2014 Employee&#13;Stock Purchase Plan (the "2014 ESPP"). The 2014 ESPP initially authorized the issuance of up to 3,513 shares of Common&#13;Stock. The number of shares increases each January 1, commencing on January 1, 2015 and ending on (and including) January 1, 2024,&#13;by an amount equal to the lesser of one percent of the outstanding shares as of the end of the immediately preceding fiscal year,&#13;7,025 shares or any lower amount determined by the Company's Board of Directors prior to each such January 1st. As of December&#13;31, 2020, the authorized number of shares under the 2014 ESPP is 18,012 and the number of shares available for issuance is 13,340.&#13;During the years ended December 31, 2020 and 2019, no shares were issued under the 2014 ESPP. On January 1, 2021, pursuant to the&#13;increase per the 2014 ESPP, the number of share authorized under the 2014 ESPP was increased by 7,025 shares to 25,037 shares.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;Restricted Stock Units&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;u&gt;Awards to Directors&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The following restricted stock units ("RSUs") were&#13;granted pursuant to the Amended 2014 Plan. Settlement for the RSUs is deferred until the earliest to occur of (i) the director's&#13;termination of service, (ii) death, (iii) disability or (iv) a change in control of the Company. In the event of a change in control&#13;of the Company, the RSUs will vest in full.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;During the year ended December 31, 2020, the Board of Directors&#13;granted an aggregate of 316,000 RSUs to directors of the Company. Of these RSUs, 254,000 vest 12.5% on the date of grant and in&#13;twenty-one equal monthly installments thereafter and the remaining 62,000 RSUs vest 50% on the one year anniversary of the grant&#13;date and the remainder vest in 12 equal monthly installments thereafter. The grant date fair value of these RSUs was $9,480.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;u&gt;Awards to Others&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;During the year ended December 31, 2019, the Board of Directors&#13;granted of 5,245 RSUs to a consultant. The RSUs were granted under the Company's 2017 Equity Incentive Plan. The RSUs vested&#13;in five equal installments of 1,049 units on the 15th and 30th of each month, beginning on October 30, 2019. The grant date fair&#13;value of this RSU was $36.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;During the year December 31, 2020, Board of Directors granted&#13;an aggregate of 163,325 RSUs to employees of the Company. These RSUs will vest 25% on each of the first, second, third and fourth&#13;year anniversaries of the date of grant. The grant date fair value of these RSUs was $4,887.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Following is a summary of restricted stock unit activities for&#13;the year ended December 31, 2020:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" align="center" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Restricted Stock Units&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Weighted &lt;br /&gt;&#13;Average Grant &lt;br /&gt;&#13;Date Fair Value&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 64%; text-align: left; text-indent: -0.9pt"&gt;Non-vested 1/1/2020&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;-&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;-&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-indent: 8.1pt; text-align: left"&gt;Granted&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;479,325&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;29.97&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-indent: 8.1pt; text-align: left"&gt;Forfeited&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(56,375&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;30.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-indent: 8.1pt; text-align: left"&gt;Vested&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(148,334&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;30.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Non-vested 12/31/2020&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;274,616&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;29.95&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The fair&#13;value of restricted stock units is amortized on a straight line basis over the requisite service periods of the respective awards.&#13;As of December 31, 2020, the unamortized value of RSUs was $6,299. As of December 31, 2020, the weighted average remaining amortization&#13;period was 1.81 years.&lt;/font&gt; &lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;As of December 31, 2020 and 2019, 132,709&#13;and 5,245 RSUs, respectively, have vested that have not yet been settled into shares of the Company's Common Stock.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;During the year ended December 31, 2020, the Company issued&#13;20,870 shares of Common Stock from the settlement of RSUs.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;Restricted Stock Units Modification&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;On July 23, 2020, the Company agreed to accelerate the vesting&#13;of 5,687 RSUs of a former executive. The Company recorded a charge of $152 during the year ended December 31, 2020 to research&#13;and development expense within the Company's consolidated statements of operations in connection with the modification of&#13;this award. &lt;b&gt; &lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;Stock Option Grants&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;u&gt;Options to Directors&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;During the year ended December 31, 2019, the Board of Directors&#13;granted options for the purchase of 47,114 shares of the Company's common stock to members of the board of directors. These&#13;options were granted under the Company's 2017 Equity Incentive Plan, had an exercise price of $9.18 per share and a term&#13;of 10 years. These options vest ratably over approximately four years. The options had a grant date fair value of $317.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;During the year ended December 31, 2020, the Board of Directors&#13;granted options for the purchase of 80,250 shares of the Company's common stock to members of the board of directors. These&#13;options were granted under the Company's 2014 Equity Incentive Plan, had an exercise price ranging from $26.70 to $35.00&#13;per share and a term of 10 years. These options vest ratably over approximately one year. The options had a grant date fair value&#13;of $1,903.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;u&gt;Options to Employees&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;During the year ended December 31, 2019, the Board of Directors&#13;granted options for the purchase of 50,549 shares of the Company's common stock to employees of the Company. These options&#13;were granted under the Company's 2017 Equity Incentive Plan, had an exercise price of $9.18 per share and a term of 10 years.&#13;These options vest ratably over approximately four years. The options had a grant date fair value of $322.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;During the year ended December 31, 2020, the Board of Directors&#13;granted options for the purchase of 484,850 shares of the Company's common stock to employees of the Company. These options&#13;were granted under the Company's 2014 Equity Incentive Plan, had an exercise price ranging from $17.84 to $51.12 per share&#13;and a term of 10 years. These options vest ratably over approximately four years. The options had a grant date fair value of $10,867.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;Stock Option Modifications&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Effective July 20, 2020, a former director notified the Company&#13;of his resignation from the Company's Board of Directors. In connection with his resignation, the Compensation Committee&#13;approved the accelerated vesting of all stock options issued to him prior to the Merger, and to extend the post-termination exercise&#13;period of vested options to 12 months from the date of resignation. Due to the modification of his options, the Company recorded&#13;the incremental value of $501 during the year ended December 31, 2020 to general and administrative expense within the Company's&#13;consolidated statements of operations.&#13;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;Stock Options &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The Company determined the fair value of stock options granted&#13;based upon the assumptions as provided below.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" align="center" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;For the Years Ended &lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;December 31,&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; width: 40%; padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; width: 3%; padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 27%; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; width: 4%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: top; width: 26%; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2019&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Stock price&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$ 17.84 - $ 51.12&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$ 6.81 - $ 8.65&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top; background-color: White"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Exercise price&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$ 17.84 - $ 51.12&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$ 9.18&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Dividend yield&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.00%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.00%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top; background-color: White"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Expected volatility&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;95.00% - 101.00%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;97.00%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Risk-free interest rate&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.28% - 1.69%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1.71% - 2.37%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top; background-color: White"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Expected life (in years)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.27 - 6.08&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.58 - 6.02&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Following is a summary of stock option activities for the year&#13;ended December 31, 2020:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Options&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Weighted Average Grant Date Fair Value&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Weighted Average Exercise Price&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Weighted Average Remaining Contractual Term (years)&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Aggregate Intrinsic Value&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 35%; text-indent: -0.9pt"&gt;Outstanding 1/1/2020&lt;/td&gt;&lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;219,592&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7.29&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;9.18&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;9.72&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;-&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-indent: 8.1pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;565,100&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;22.61&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;29.23&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-indent: 8.1pt"&gt;Exercised&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(57,767&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6.72&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9.18&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-indent: 8.1pt"&gt;Forfeited&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(52,886&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;14.08&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;18.91&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;Outstanding 12/31/2020&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;674,039&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;20.60&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;25.23&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9.06&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2,311&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;Exercisable as of 12/31/2020&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;109,117&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;11.44&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;15.63&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8.25&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,201&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The weighted average grant date fair value of the options granted&#13;during the year ended December 31, 2019 was $6.55 per share. The fair value of stock options is amortized on a straight line basis&#13;over the requisite service periods of the respective awards. As of December 31, 2020, the unamortized value of stock options was&#13;$9,973. As of December 31, 2020, the weighted average remaining amortization period was 3.00 years.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;Summary of Stock-Based Compensation&#13;Expense&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The following tables summarize total stock-based compensation&#13;costs recognized:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -4.5pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;For the Years Ended &lt;br /&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 74%; text-align: left"&gt;Restricted stock&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;-&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;75&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td&gt;RSUs&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,357&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;36&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Stock options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,389&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;313&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td&gt;Total&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;9,746&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;424&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -4.5pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Stock-based compensation expense was reflected within the statements&#13;of operations as:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;For the Years Ended &lt;br /&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 74%; text-align: left"&gt;Research and development&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;741&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;200&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;General and administrative&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;9,005&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;224&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td&gt;Total&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;9,746&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;424&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock contextRef="From2020-01-01to2020-12-31">&lt;table cellpadding="0" cellspacing="0" align="center" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Restricted Stock Units&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Weighted &lt;br /&gt;&#13;Average Grant &lt;br /&gt;&#13;Date Fair Value&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 64%; text-align: left; text-indent: -0.9pt"&gt;Non-vested 1/1/2020&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;-&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;-&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-indent: 8.1pt; text-align: left"&gt;Granted&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;479,325&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;29.97&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-indent: 8.1pt; text-align: left"&gt;Forfeited&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(56,375&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;30.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-indent: 8.1pt; text-align: left"&gt;Vested&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(148,334&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;30.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Non-vested 12/31/2020&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;274,616&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;29.95&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2020-01-01to2020-12-31">&lt;table cellspacing="0" cellpadding="0" align="center" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&lt;tr&gt;&lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 1.5pt"&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;For the Years Ended &lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;December 31,&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; width: 40%; padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; width: 3%; padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 27%; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; width: 4%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: top; width: 26%; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2019&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Stock price&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$ 17.84 - $ 51.12&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$ 6.81 - $ 8.65&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top; background-color: White"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Exercise price&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$ 17.84 - $ 51.12&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$ 9.18&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Dividend yield&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.00%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.00%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top; background-color: White"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Expected volatility&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;95.00% - 101.00%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;97.00%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Risk-free interest rate&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.28% - 1.69%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1.71% - 2.37%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top; background-color: White"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Expected life (in years)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.27 - 6.08&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.58 - 6.02&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2020-01-01to2020-12-31">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Options&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Weighted Average Grant Date Fair Value&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Weighted Average Exercise Price&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Weighted Average Remaining Contractual Term (years)&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Aggregate Intrinsic Value&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 35%; text-indent: -0.9pt"&gt;Outstanding 1/1/2020&lt;/td&gt;&lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;219,592&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7.29&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;9.18&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;9.72&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;-&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-indent: 8.1pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;565,100&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;22.61&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;29.23&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-indent: 8.1pt"&gt;Exercised&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(57,767&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6.72&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9.18&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-indent: 8.1pt"&gt;Forfeited&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(52,886&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;14.08&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;18.91&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;Outstanding 12/31/2020&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;674,039&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;20.60&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;25.23&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9.06&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2,311&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;Exercisable as of 12/31/2020&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;109,117&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;11.44&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;15.63&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8.25&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,201&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <TARA:IssuanceOfStockOptionsAndRestrictedStockUnitsToEmployeesAndDirectorsTableTextBlock contextRef="From2020-01-01to2020-12-31">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;For the Years Ended &lt;br /&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 74%; text-align: left"&gt;Restricted stock&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;-&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;75&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td&gt;RSUs&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,357&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;36&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Stock options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,389&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;313&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td&gt;Total&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;9,746&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;424&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</TARA:IssuanceOfStockOptionsAndRestrictedStockUnitsToEmployeesAndDirectorsTableTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="From2020-01-01to2020-12-31">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;For the Years Ended &lt;br /&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 74%; text-align: left"&gt;Research and development&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;741&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;200&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;General and administrative&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;9,005&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;224&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td&gt;Total&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;9,746&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;424&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 10 &amp;#8211; INCOME TAXES &lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Federal and State income tax expense is as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;For the Years Ended &lt;br /&gt;December&amp;#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;Current&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-indent: -27.9pt; padding-left: 0.5in"&gt;Federal&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-indent: -27.9pt; padding-left: 0.5in"&gt;State&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -40.5pt; padding-left: 0.8in"&gt;Total current&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-left: 5.4pt"&gt;Deferred&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 74%; text-indent: -27.9pt; padding-left: 0.5in"&gt;Federal&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;(6,211&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;(1,614&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-indent: -27.9pt; padding-left: 0.5in"&gt;State&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(2,439&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(930&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -18.9pt; padding-left: 0.5in"&gt;Total deferred&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(8,650&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(2,544&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 5.4pt"&gt;Change in valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;8,650&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,544&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 5.4pt"&gt;Total income tax expense (benefit)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Deferred income taxes, if applicable, are provided for the differences&#13;between the basis of assets and liabilities for financial reporting and income tax purposes.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The tax effects of temporary differences that give rise to significant&#13;portions of the deferred tax assets are as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;As of &lt;br /&gt;December&amp;#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="font-weight: bold"&gt;Deferred tax assets:&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-left: 10pt; width: 74%; text-align: left"&gt;Net operating loss carry forwards&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;19,371&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;3,806&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-left: 10pt; text-align: left"&gt;Organization costs/legal fees&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-left: 10pt; text-align: left"&gt;Stock option expense&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;443&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;111&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-left: 10pt; text-align: left"&gt;Research and development credits&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;70&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-left: 10pt; text-align: left"&gt;Operating lease liability&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;330&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-left: 10pt; text-align: left"&gt;Restricted stock expense&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;238&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-left: 10pt; text-align: left"&gt;RSU expense&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,796&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;12&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-left: 10pt; text-align: left"&gt;Charitable contributions&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-left: 10pt; text-align: left"&gt;Total deferred tax assets&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;22,020&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,178&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-left: 10pt; text-align: left"&gt;Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(21,698&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(4,176&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-left: 10pt; text-align: left"&gt;Deferred tax assets, net of valuation allowance&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;322&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-weight: bold; text-align: left"&gt;Deferred tax liabilities:&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-left: 10pt; text-align: left"&gt;Operating right-of-use asset&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(322&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-weight: bold; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;-&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-left: 10pt"&gt;Depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-left: 10pt; text-align: left"&gt;Total deferred tax liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(322&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-left: 10pt; text-align: left"&gt;Deferred tax assets, net of valuation allowance and deferred tax liabilities&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;A reconciliation of the provision for income taxes with the&#13;amounts computed by applying the statutory Federal income tax to income before provision for income taxes is as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;For the Years Ended &lt;br /&gt;December&amp;#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 74%; text-align: left"&gt;U.S. federal statutory rate&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;(21.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)%&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;(21.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left"&gt;State taxes, net of federal benefit&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(9.4&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(12.1&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;Option expense&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.2&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.5&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td&gt;Other&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.9&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.1&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;True-up to prior years return&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.8&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left"&gt;Change in valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;25.5&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;32.5&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;Effective tax rate&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;As of December 31, 2020 for U.S. federal and state income tax&#13;reporting purposes, the Company has approximately $63.7 million of unused net operating losses ("NOLs") available for&#13;carry forward to future years. The 2018 - 2020 federal NOLs may be carried forward indefinitely. The Company does not have the&#13;ability to carry any of these losses back. The New York state and city NOLs may be carried forward through the year 2040 and may&#13;be applied against future taxable income. Because United States tax laws limit the time during which NOL carry forwards may be&#13;applied against future taxable income, the Company may be unable to take full advantage of its NOLs for federal and state income&#13;tax purposes when the Company does generate taxable income. Further, the benefit from utilization of NOL carry forwards could be&#13;subject to limitations due to material ownership changes that could occur as the Company continues to issue additional shares of&#13;common stock pursuant to its capital raising plans. Based on such limitations, the Company has significant NOLs for which realization&#13;of tax benefits is uncertain.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;On January 9, 2020, the Company completed the Merger. In connection&#13;with the Merger, the Company acquired NOL's from Proteon of $41.6 million. These NOLs were determined to be impaired by $12.4&#13;million, with an annual limitation of $0.5 million on the remaining $29.2 million of NOLs. The general business credits of $3.6&#13;million acquired in the merger were determined to be fully impaired.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;As a result of the Merger, the company performed a study to&#13;review the application of IRC &amp;#167;382 to the Company. It was determined there was an ownership change as of January 9, 2020 and&#13;the Company's NOLs generated prior to January 9, 2020 would be limited. The annual limitation of the Company's NOL's&#13;after application of the IRC &amp;#167;382 are $1.4 million.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The Company remains subject to examination by tax authorities&#13;for tax years 2018 through 2020. The Company has identified its federal tax return and its state tax return in New York state and&#13;New York City as its "major" tax jurisdictions.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Based on a history of cumulative losses at the Company and the&#13;results of operations for the years ended December 31, 2020 and 2019, the Company determined that it is more likely than not that&#13;it will not realize benefits from the net deferred tax assets. The Company will not record income tax benefits in the financial&#13;statements until it is determined that it is more likely than not that the Company will generate sufficient taxable income to realize&#13;the deferred income tax assets. As a result of the analysis, the Company determined that a full valuation allowance against the&#13;deferred tax assets was required. As of December 31, 2020 and 2019, the Company has recorded a valuation allowance of $21.7 million&#13;and $4.2 million, respectively.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;As of December 31, 2020 and 2019, management does not believe&#13;that the Company has any material uncertain tax positions that would require it to measure and reflect the potential lack of sustainability&#13;of a position on audit in its consolidated financial statements. The Company will continue to evaluate its uncertain tax positions&#13;in future periods to determine if measurement and recognition in its financial statements is necessary. The Company does not believe&#13;there will be any material changes in its unrecognized tax positions over the next year.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;For the Years Ended &lt;br /&gt;December&amp;#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;Current&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-indent: -27.9pt; padding-left: 0.5in"&gt;Federal&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-indent: -27.9pt; padding-left: 0.5in"&gt;State&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -40.5pt; padding-left: 0.8in"&gt;Total current&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-left: 5.4pt"&gt;Deferred&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 74%; text-indent: -27.9pt; padding-left: 0.5in"&gt;Federal&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;(6,211&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;(1,614&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-indent: -27.9pt; padding-left: 0.5in"&gt;State&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(2,439&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(930&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -18.9pt; padding-left: 0.5in"&gt;Total deferred&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(8,650&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(2,544&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 5.4pt"&gt;Change in valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;8,650&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,544&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 5.4pt"&gt;Total income tax expense (benefit)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;As of &lt;br /&gt;December&amp;#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="font-weight: bold"&gt;Deferred tax assets:&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-left: 10pt; width: 74%; text-align: left"&gt;Net operating loss carry forwards&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;19,371&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;3,806&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-left: 10pt; text-align: left"&gt;Organization costs/legal fees&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-left: 10pt; text-align: left"&gt;Stock option expense&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;443&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;111&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-left: 10pt; text-align: left"&gt;Research and development credits&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;70&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-left: 10pt; text-align: left"&gt;Operating lease liability&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;330&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-left: 10pt; text-align: left"&gt;Restricted stock expense&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;238&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-left: 10pt; text-align: left"&gt;RSU expense&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,796&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;12&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-left: 10pt; text-align: left"&gt;Charitable contributions&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-left: 10pt; text-align: left"&gt;Total deferred tax assets&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;22,020&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,178&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-left: 10pt; text-align: left"&gt;Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(21,698&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(4,176&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-left: 10pt; text-align: left"&gt;Deferred tax assets, net of valuation allowance&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;322&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-weight: bold; text-align: left"&gt;Deferred tax liabilities:&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-left: 10pt; text-align: left"&gt;Operating right-of-use asset&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(322&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-weight: bold; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;-&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-left: 10pt"&gt;Depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-left: 10pt; text-align: left"&gt;Total deferred tax liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(322&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-left: 10pt; text-align: left"&gt;Deferred tax assets, net of valuation allowance and deferred tax liabilities&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;For the Years Ended &lt;br /&gt;December&amp;#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 74%; text-align: left"&gt;U.S. federal statutory rate&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;(21.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)%&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;(21.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left"&gt;State taxes, net of federal benefit&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(9.4&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(12.1&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;Option expense&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.2&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.5&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td&gt;Other&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.9&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.1&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;True-up to prior years return&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.8&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left"&gt;Change in valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;25.5&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;32.5&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;Effective tax rate&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <dei:EntityVoluntaryFilers contextRef="From2020-01-01to2020-12-31">No</dei:EntityVoluntaryFilers>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2020-01-01to2020-12-31">No</dei:EntityWellKnownSeasonedIssuer>
    <us-gaap:DeferredOfferingCosts contextRef="AsOf2020-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:DeferredOfferingCosts contextRef="AsOf2019-12-31" unitRef="USD" decimals="-3">122000</us-gaap:DeferredOfferingCosts>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2020-12-31" unitRef="USD" decimals="-3">787000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2019-12-31" unitRef="USD" decimals="-3">78000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2020-12-31" unitRef="USD" decimals="-3">169435000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2019-12-31" unitRef="USD" decimals="-3">764000</us-gaap:AssetsCurrent>
    <us-gaap:Goodwill contextRef="AsOf2020-12-31" unitRef="USD" decimals="-3">29517000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="AsOf2019-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:OtherAssetsNoncurrent contextRef="AsOf2020-12-31" unitRef="USD" decimals="-3">2220000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="AsOf2019-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:Assets contextRef="AsOf2020-12-31" unitRef="USD" decimals="-3">203157000</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2019-12-31" unitRef="USD" decimals="-3">1223000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2020-12-31" unitRef="USD" decimals="-3">914000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2019-12-31" unitRef="USD" decimals="-3">716000</us-gaap:AccountsPayableCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2020-12-31" unitRef="USD" decimals="-3">88000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2019-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2020-12-31" unitRef="USD" decimals="-3">2915000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2019-12-31" unitRef="USD" decimals="-3">3351000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2020-12-31" unitRef="USD" decimals="-3">999000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2019-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:Liabilities contextRef="AsOf2020-12-31" unitRef="USD" decimals="-3">3914000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="AsOf2019-12-31" unitRef="USD" decimals="-3">3351000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies contextRef="AsOf2020-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:CommitmentsAndContingencies contextRef="AsOf2019-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:PreferredStockValue contextRef="AsOf2020-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:PreferredStockValue contextRef="AsOf2019-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:CommonStockValue contextRef="AsOf2020-12-31" unitRef="USD" decimals="-3">11000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2019-12-31" unitRef="USD" decimals="-3">3000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2020-12-31" unitRef="USD" decimals="-3">245992000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2019-12-31" unitRef="USD" decimals="-3">10651000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2020-12-31" unitRef="USD" decimals="-3">-46760000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2019-12-31" unitRef="USD" decimals="-3">-12782000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2020-12-31" unitRef="USD" decimals="-3">203157000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2019-12-31" unitRef="USD" decimals="-3">1223000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:OperatingExpenses contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">34444000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="-3">7830000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">-34444000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="-3">-7830000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNet contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">466000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet contextRef="From2019-01-01to2019-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:NonoperatingIncomeExpense contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">466000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="From2019-01-01to2019-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockholdersEquity contextRef="AsOf2020-12-31" unitRef="USD" decimals="-3">199243000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-12-31" unitRef="USD" decimals="-3">-2128000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-12-31_custom_Series1ConvertiblePreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockholdersEquity contextRef="AsOf2020-12-31_custom_Series1ConvertiblePreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockholdersEquity contextRef="AsOf2018-12-31_custom_Series1ConvertiblePreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockholdersEquity contextRef="AsOf2019-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="-3">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="-3">11000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2018-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="-3">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">10651000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">245992000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2018-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">9727000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="-3">-12782000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="-3">-46760000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2018-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="-3">-4952000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2018-12-31" unitRef="USD" decimals="-3">4778000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding contextRef="AsOf2019-12-31_custom_Series1ConvertiblePreferredStockMember" unitRef="Shares" xsi:nil="true" />
    <us-gaap:SharesOutstanding contextRef="AsOf2020-12-31_custom_Series1ConvertiblePreferredStockMember" unitRef="Shares" decimals="INF">8027</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2018-12-31_custom_Series1ConvertiblePreferredStockMember" unitRef="Shares" xsi:nil="true" />
    <us-gaap:SharesOutstanding contextRef="AsOf2019-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">2627533</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">11211840</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2018-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">2558419</us-gaap:SharesOutstanding>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="From2020-01-01to2020-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="From2019-01-01to2019-12-31_custom_Series1ConvertiblePreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="From2019-01-01to2019-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">75000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="From2019-01-01to2019-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="From2019-01-01to2019-12-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="-3">75000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">6357000</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther contextRef="From2019-01-01to2019-12-31_custom_Series1ConvertiblePreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther contextRef="From2020-01-01to2020-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">6357000</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther contextRef="From2019-01-01to2019-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">36000</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther contextRef="From2020-01-01to2020-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther contextRef="From2019-01-01to2019-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther contextRef="From2019-01-01to2019-12-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="-3">36000</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">3389000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2020-01-01to2020-12-31_custom_Series1ConvertiblePreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2019-01-01to2019-12-31_custom_Series1ConvertiblePreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2020-01-01to2020-12-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2020-01-01to2020-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">3389000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2019-01-01to2019-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">313000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2020-01-01to2020-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2019-01-01to2019-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2019-01-01to2019-12-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="-3">313000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <TARA:StockIssueDuringPeriodvalueIssuedForCapitalRaise contextRef="From2019-01-01to2019-12-31_custom_Series1ConvertiblePreferredStockMember" unitRef="USD" xsi:nil="true" />
    <TARA:StockIssueDuringPeriodvalueIssuedForCapitalRaise contextRef="From2019-01-01to2019-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">500000</TARA:StockIssueDuringPeriodvalueIssuedForCapitalRaise>
    <TARA:StockIssueDuringPeriodvalueIssuedForCapitalRaise contextRef="From2019-01-01to2019-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <TARA:StockIssueDuringPeriodvalueIssuedForCapitalRaise contextRef="From2019-01-01to2019-12-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <TARA:StockIssueDuringPeriodvalueIssuedForCapitalRaise contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="-3">500000</TARA:StockIssueDuringPeriodvalueIssuedForCapitalRaise>
    <TARA:Issuanceofcommonstockinseptembercapitalraiseshares contextRef="From2019-01-01to2019-12-31_custom_Series1ConvertiblePreferredStockMember" unitRef="USD" xsi:nil="true" />
    <TARA:Issuanceofcommonstockinseptembercapitalraiseshares contextRef="From2019-01-01to2019-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="-3">69114000</TARA:Issuanceofcommonstockinseptembercapitalraiseshares>
    <us-gaap:ProfitLoss contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">-33978000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="From2020-01-01to2020-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProfitLoss contextRef="From2019-01-01to2019-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProfitLoss contextRef="From2020-01-01to2020-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="-3">-33978000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="From2019-01-01to2019-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="-3">-7830000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="-3">-7830000</us-gaap:ProfitLoss>
    <TARA:IssuanceOfCommonStockInArtaraPrivatePlacementNetOfOfferingCosts contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">1867000</TARA:IssuanceOfCommonStockInArtaraPrivatePlacementNetOfOfferingCosts>
    <TARA:IssuanceOfCommonStockInArtaraPrivatePlacementNetOfOfferingCosts contextRef="From2020-01-01to2020-12-31_custom_Series1ConvertiblePreferredStockMember" unitRef="USD" xsi:nil="true" />
    <TARA:IssuanceOfCommonStockInArtaraPrivatePlacementNetOfOfferingCosts contextRef="From2020-01-01to2020-12-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <TARA:IssuanceOfCommonStockInArtaraPrivatePlacementNetOfOfferingCosts contextRef="From2020-01-01to2020-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">1867000</TARA:IssuanceOfCommonStockInArtaraPrivatePlacementNetOfOfferingCosts>
    <TARA:IssuanceOfCommonStockInArtaraPrivatePlacementNetOfOfferingCosts contextRef="From2020-01-01to2020-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <TARA:IssuanceOfCommonStockInArtaraPrivatePlacementNetOfOfferingCostsShares contextRef="From2020-01-01to2020-12-31_custom_Series1ConvertiblePreferredStockMember" unitRef="Shares" xsi:nil="true" />
    <TARA:IssuanceOfCommonStockInArtaraPrivatePlacementNetOfOfferingCostsShares contextRef="From2020-01-01to2020-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">284875</TARA:IssuanceOfCommonStockInArtaraPrivatePlacementNetOfOfferingCostsShares>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">12413000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2020-01-01to2020-12-31_custom_Series1ConvertiblePreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2020-01-01to2020-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="-3">2000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2020-01-01to2020-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">12411000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2020-01-01to2020-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodSharesOther contextRef="From2020-01-01to2020-12-31_custom_Series1ConvertiblePreferredStockMember" unitRef="Shares" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodSharesOther contextRef="From2020-01-01to2020-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">1896888</us-gaap:StockIssuedDuringPeriodSharesOther>
    <TARA:IssuanceOfSeries1ConvertiblePreferredStockInProteonPrivatePlacementNetOfOfferingCosts contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">25319000</TARA:IssuanceOfSeries1ConvertiblePreferredStockInProteonPrivatePlacementNetOfOfferingCosts>
    <TARA:IssuanceOfSeries1ConvertiblePreferredStockInProteonPrivatePlacementNetOfOfferingCosts contextRef="From2020-01-01to2020-12-31_custom_Series1ConvertiblePreferredStockMember" unitRef="USD" xsi:nil="true" />
    <TARA:IssuanceOfSeries1ConvertiblePreferredStockInProteonPrivatePlacementNetOfOfferingCosts contextRef="From2020-01-01to2020-12-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <TARA:IssuanceOfSeries1ConvertiblePreferredStockInProteonPrivatePlacementNetOfOfferingCosts contextRef="From2020-01-01to2020-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">25319000</TARA:IssuanceOfSeries1ConvertiblePreferredStockInProteonPrivatePlacementNetOfOfferingCosts>
    <TARA:IssuanceOfSeries1ConvertiblePreferredStockInProteonPrivatePlacementNetOfOfferingCosts contextRef="From2020-01-01to2020-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <TARA:IssuanceOfSeries1ConvertiblePreferredStockInProteonPrivatePlacementNetOfOfferingCostsShares contextRef="From2020-01-01to2020-12-31_custom_Series1ConvertiblePreferredStockMember" unitRef="Shares" decimals="INF">3879</TARA:IssuanceOfSeries1ConvertiblePreferredStockInProteonPrivatePlacementNetOfOfferingCostsShares>
    <TARA:IssuanceOfSeries1ConvertiblePreferredStockInProteonPrivatePlacementNetOfOfferingCostsShares contextRef="From2020-01-01to2020-12-31_us-gaap_CommonStockMember" unitRef="Shares" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">34533000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="From2020-01-01to2020-12-31_custom_Series1ConvertiblePreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="From2020-01-01to2020-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="-3">1000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="From2020-01-01to2020-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">34532000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="From2020-01-01to2020-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions contextRef="From2020-01-01to2020-12-31_custom_Series1ConvertiblePreferredStockMember" unitRef="Shares" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions contextRef="From2020-01-01to2020-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">1033907</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">73570000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2020-01-01to2020-12-31_custom_Series1ConvertiblePreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2020-01-01to2020-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="-3">4000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2020-01-01to2020-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">73566000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2020-01-01to2020-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="From2020-01-01to2020-12-31_custom_Series1ConvertiblePreferredStockMember" unitRef="Shares" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="From2020-01-01to2020-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">4600000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <TARA:StockIssuedDuringPeriodValueIssuanceOfSeries1ConvertiblePreferredStockNetOfOfferingCosts contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">66284000</TARA:StockIssuedDuringPeriodValueIssuanceOfSeries1ConvertiblePreferredStockNetOfOfferingCosts>
    <TARA:StockIssuedDuringPeriodValueIssuanceOfSeries1ConvertiblePreferredStockNetOfOfferingCosts contextRef="From2020-01-01to2020-12-31_custom_Series1ConvertiblePreferredStockMember" unitRef="USD" xsi:nil="true" />
    <TARA:StockIssuedDuringPeriodValueIssuanceOfSeries1ConvertiblePreferredStockNetOfOfferingCosts contextRef="From2020-01-01to2020-12-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <TARA:StockIssuedDuringPeriodValueIssuanceOfSeries1ConvertiblePreferredStockNetOfOfferingCosts contextRef="From2020-01-01to2020-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">66284000</TARA:StockIssuedDuringPeriodValueIssuanceOfSeries1ConvertiblePreferredStockNetOfOfferingCosts>
    <TARA:StockIssuedDuringPeriodValueIssuanceOfSeries1ConvertiblePreferredStockNetOfOfferingCosts contextRef="From2020-01-01to2020-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <TARA:StockIssuedDuringPeriodSharesIssuanceOfSeries1ConvertiblePreferredStockNetOfOfferingCosts contextRef="From2020-01-01to2020-12-31_custom_Series1ConvertiblePreferredStockMember" unitRef="Shares" decimals="INF">4148</TARA:StockIssuedDuringPeriodSharesIssuanceOfSeries1ConvertiblePreferredStockNetOfOfferingCosts>
    <TARA:StockIssuedDuringPeriodSharesIssuanceOfSeries1ConvertiblePreferredStockNetOfOfferingCosts contextRef="From2020-01-01to2020-12-31_us-gaap_CommonStockMember" unitRef="Shares" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">11087000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2020-01-01to2020-12-31_custom_Series1ConvertiblePreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2020-01-01to2020-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="-3">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2020-01-01to2020-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">11086000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2020-01-01to2020-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2020-01-01to2020-12-31_custom_Series1ConvertiblePreferredStockMember" unitRef="Shares" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2020-01-01to2020-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">690000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <TARA:StockIssuedDuringPeriodValueIssuedForSettlementOfRestrictedStockUnits contextRef="From2020-01-01to2020-12-31" unitRef="USD" xsi:nil="true" />
    <TARA:StockIssuedDuringPeriodValueIssuedForSettlementOfRestrictedStockUnits contextRef="From2020-01-01to2020-12-31_custom_Series1ConvertiblePreferredStockMember" unitRef="USD" xsi:nil="true" />
    <TARA:StockIssuedDuringPeriodValueIssuedForSettlementOfRestrictedStockUnits contextRef="From2020-01-01to2020-12-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <TARA:StockIssuedDuringPeriodValueIssuedForSettlementOfRestrictedStockUnits contextRef="From2020-01-01to2020-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <TARA:StockIssuedDuringPeriodValueIssuedForSettlementOfRestrictedStockUnits contextRef="From2020-01-01to2020-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <TARA:StockIssuedDuringPeriodSharesIssuedForSettlementOfRestrictedStockUnits contextRef="From2020-01-01to2020-12-31_custom_Series1ConvertiblePreferredStockMember" unitRef="Shares" xsi:nil="true" />
    <TARA:StockIssuedDuringPeriodSharesIssuedForSettlementOfRestrictedStockUnits contextRef="From2020-01-01to2020-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">20870</TARA:StockIssuedDuringPeriodSharesIssuedForSettlementOfRestrictedStockUnits>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">530000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2020-01-01to2020-12-31_custom_Series1ConvertiblePreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2020-01-01to2020-12-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2020-01-01to2020-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">530000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2020-01-01to2020-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <TARA:CashAndRestrictedCashAcquiredInConnectionWithReverseMergerWithArtaraTherapeuticsInc. contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">3719000</TARA:CashAndRestrictedCashAcquiredInConnectionWithReverseMergerWithArtaraTherapeuticsInc.>
    <TARA:CashAndRestrictedCashAcquiredInConnectionWithReverseMergerWithArtaraTherapeuticsInc. contextRef="From2019-01-01to2019-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">884000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="-3">475000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">2835000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="-3">-475000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">1867000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="From2019-01-01to2019-12-31" unitRef="USD" xsi:nil="true" />
    <TARA:ProceedsFromProteonPrivatePlacementNetOfOfferingCosts contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">12413000</TARA:ProceedsFromProteonPrivatePlacementNetOfOfferingCosts>
    <TARA:ProceedsFromProteonPrivatePlacementNetOfOfferingCosts contextRef="From2019-01-01to2019-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">25319000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock contextRef="From2019-01-01to2019-12-31" unitRef="USD" xsi:nil="true" />
    <TARA:ProceedsFromIssuancesOfConvertiblePreferredStock contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">73570000</TARA:ProceedsFromIssuancesOfConvertiblePreferredStock>
    <TARA:ProceedsFromIssuancesOfConvertiblePreferredStock contextRef="From2019-01-01to2019-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">66284000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2019-01-01to2019-12-31" unitRef="USD" xsi:nil="true" />
    <TARA:ProceedsFromUnderwritersOverallotmentOption contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">11087000</TARA:ProceedsFromUnderwritersOverallotmentOption>
    <TARA:ProceedsFromUnderwritersOverallotmentOption contextRef="From2019-01-01to2019-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:RepaymentsOfShortTermDebt contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">1669000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt contextRef="From2019-01-01to2019-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">530000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="From2019-01-01to2019-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="From2020-01-01to2020-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="-3">500000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">189401000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="-3">500000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">168829000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="-3">-4986000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2020-12-31" unitRef="USD" decimals="-3">169393000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2019-12-31" unitRef="USD" decimals="-3">564000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2018-12-31" unitRef="USD" decimals="-3">5550000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <TARA:ReconciliationOfRestrictedCashAndCashEquivalents contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">169393000</TARA:ReconciliationOfRestrictedCashAndCashEquivalents>
    <TARA:ReconciliationOfRestrictedCashAndCashEquivalents contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="-3">564000</TARA:ReconciliationOfRestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashNoncurrent contextRef="AsOf2020-12-31" unitRef="USD" decimals="-3">745000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashCurrent contextRef="AsOf2020-12-31" unitRef="USD" decimals="-3">50000</us-gaap:RestrictedCashCurrent>
    <us-gaap:InterestPaidNet contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">34000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="From2019-01-01to2019-12-31" unitRef="USD" xsi:nil="true" />
    <TARA:CommonStockIssuedInConnectionWithReverseMerger contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">34533000</TARA:CommonStockIssuedInConnectionWithReverseMerger>
    <TARA:CommonStockIssuedInConnectionWithReverseMerger contextRef="From2019-01-01to2019-12-31" unitRef="USD" xsi:nil="true" />
    <TARA:PurchaseOfInsuranceAgreementWithNotesPayable contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">1669000</TARA:PurchaseOfInsuranceAgreementWithNotesPayable>
    <TARA:PurchaseOfInsuranceAgreementWithNotesPayable contextRef="From2019-01-01to2019-12-31" unitRef="USD" xsi:nil="true" />
    <TARA:DeferredOfferingCostsRecognizedThatWerePreviouslyRecordedInAccruedExpenses contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">122000</TARA:DeferredOfferingCostsRecognizedThatWerePreviouslyRecordedInAccruedExpenses>
    <TARA:DeferredOfferingCostsRecognizedThatWerePreviouslyRecordedInAccruedExpenses contextRef="From2019-01-01to2019-12-31" unitRef="USD" xsi:nil="true" />
    <TARA:DeferredOfferingCostsRecordedInAccruedExpenses contextRef="From2020-01-01to2020-12-31" unitRef="USD" xsi:nil="true" />
    <TARA:DeferredOfferingCostsRecordedInAccruedExpenses contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="-3">122000</TARA:DeferredOfferingCostsRecordedInAccruedExpenses>
    <TARA:IncreaseDecreaseRightofuseLiability contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">66000</TARA:IncreaseDecreaseRightofuseLiability>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">-966000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="-3">2050000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">198000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="-3">366000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">-58000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">-1405000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="-3">37000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <TARA:AmortizationOfOperatingLeaseRightsofuseAsset contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">93000</TARA:AmortizationOfOperatingLeaseRightsofuseAsset>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2020-12-31" unitRef="USD" decimals="-3">168598000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2019-12-31" unitRef="USD" decimals="-3">564000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:NetIncomeLoss contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">-33978000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="-3">-7830000</us-gaap:NetIncomeLoss>
    <TARA:WorkingCapital contextRef="AsOf2020-12-31" unitRef="USD" decimals="-3">166520000</TARA:WorkingCapital>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">-23407000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="-3">-5011000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <TARA:NetOfOfferingCosts contextRef="AsOf2020-12-31" unitRef="USD" decimals="-3">39600000000</TARA:NetOfOfferingCosts>
    <TARA:ProceedsFrompublicOfferingGross contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">42500000000</TARA:ProceedsFrompublicOfferingGross>
    <TARA:ProceedsFrompublicOfferingGross contextRef="From2020-09-01to2020-09-24" unitRef="USD" decimals="-3">147600000000</TARA:ProceedsFrompublicOfferingGross>
    <TARA:ProceedsFrompublicOfferingGross contextRef="From2020-10-03to2020-10-06_us-gaap_SubsequentEventMember" unitRef="USD" decimals="-3">11600000000</TARA:ProceedsFrompublicOfferingGross>
    <TARA:PublicOfferingProceedsNet contextRef="From2020-09-01to2020-09-24" unitRef="USD" decimals="-3">139900000000</TARA:PublicOfferingProceedsNet>
    <TARA:PublicOfferingProceedsNet contextRef="From2020-10-03to2020-10-06_us-gaap_SubsequentEventMember" unitRef="USD" decimals="-3">11100000000</TARA:PublicOfferingProceedsNet>
    <TARA:RestrictCash contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">795000</TARA:RestrictCash>
    <TARA:RestrictCash contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="-3">0</TARA:RestrictCash>
    <us-gaap:CashCollateralForBorrowedSecurities contextRef="AsOf2020-12-31" unitRef="USD" decimals="-3">795000</us-gaap:CashCollateralForBorrowedSecurities>
    <TARA:AssetsAcquiredAndLiabilitiesAssumedCash contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">3669000</TARA:AssetsAcquiredAndLiabilitiesAssumedCash>
    <TARA:AssetsAcquiredAndLiabilitiesAssumedRestrictedCash contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">50000</TARA:AssetsAcquiredAndLiabilitiesAssumedRestrictedCash>
    <TARA:AssetsAcquiredAndLiabilitiesAssumedPrepaidExpensesAndOtherAssets contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">1662000</TARA:AssetsAcquiredAndLiabilitiesAssumedPrepaidExpensesAndOtherAssets>
    <TARA:AssetsAcquiredAndLiabilitiesAssumedGoodwill contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">29517000</TARA:AssetsAcquiredAndLiabilitiesAssumedGoodwill>
    <TARA:AssetsAcquiredAndLiabilitiesAssumedAccruedExpenses contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">365000</TARA:AssetsAcquiredAndLiabilitiesAssumedAccruedExpenses>
    <TARA:AssetsAcquiredAndLiabilitiesAssumedTotalPurchasePrice contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">34533000</TARA:AssetsAcquiredAndLiabilitiesAssumedTotalPurchasePrice>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">-33754000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="-3">-22821000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <TARA:ProFormaLossPerCommonShareBasicAndDiluted contextRef="From2020-01-01to2020-12-31" unitRef="USDPShares" decimals="INF">-4.62</TARA:ProFormaLossPerCommonShareBasicAndDiluted>
    <TARA:ProFormaLossPerCommonShareBasicAndDiluted contextRef="From2019-01-01to2019-12-31" unitRef="USDPShares" decimals="INF">-3.94</TARA:ProFormaLossPerCommonShareBasicAndDiluted>
    <TARA:ProFormaWeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted contextRef="From2020-01-01to2020-12-31" unitRef="Shares" decimals="INF">7304201</TARA:ProFormaWeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted>
    <TARA:ProFormaWeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted contextRef="From2019-01-01to2019-12-31" unitRef="Shares" decimals="INF">5793024</TARA:ProFormaWeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="From2020-01-01to2020-12-31">On January 9, 2020, in connection with, and prior to the completion of the Merger, Protara Therapeutics, Inc. effected the Protara Reverse Stock Split, which resulted in 557,631 pre-merger shares of Protara Therapeutics, Inc. outstanding.</us-gaap:StockholdersEquityReverseStockSplit>
    <TARA:OutstandingReverseStock contextRef="AsOf2020-01-09" unitRef="Shares" decimals="INF">557631</TARA:OutstandingReverseStock>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1 contextRef="From2020-01-03to2020-01-09" unitRef="Pure" decimals="INF">0.190756</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1 contextRef="From2020-01-03to2020-01-09_custom_EquityIncentivePlanMember" unitRef="Pure" decimals="INF">0.190756</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1 contextRef="From2020-01-03to2020-01-09_custom_MergerAgreementMember" unitRef="Pure" decimals="INF">0.190756</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <TARA:SubscriptionAgreementDescription contextRef="From2020-01-01to2020-12-31_us-gaap_PrivatePlacementMember">(i) 3,879.356 of shares of Protara Therapeutics, Inc.'s Series 1 Convertible Non-Voting Preferred Stock at a purchase price of approximately $7,011.47 per share for gross proceeds of $27,200 and proceeds, net of issuance costs, of $25,319, (ii) 1,896,888 shares of Protara Therapeutics, Inc.'s Common Stock at a purchase price of approximately $7.01 per share for gross proceeds of $13,300 and proceeds, net of issuance costs, of $12,413 and (B) Private ArTara issued in a private placement immediately prior to the Merger (the "ArTara Private Placement") 284,875 shares of Private ArTara common stock (post-Exchange Ratio basis) at a purchase price of approximately $7.01 per share (post-Exchange Ratio basis) (together with the Proteon Private Placement, the "Private Placements") for gross proceeds of $2,000 and proceeds, net of issuance costs, of $1,867. The shares issued in the Proteon Private Placement were registered for resale on a registration statement on Form S-3 filed and declared effective by the SEC on January 30, 2020.</TARA:SubscriptionAgreementDescription>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion contextRef="AsOf2020-12-31_custom_SeriesAConvertiblePreferredStockMember" unitRef="Shares" decimals="INF">476276</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <TARA:FairValueOfNetAssets contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">34533000</TARA:FairValueOfNetAssets>
    <TARA:DescriptionOfOwnershipRights contextRef="From2020-01-01to2020-12-31">Immediately after the consummation of the Merger and prior to the consummation of the Proteon Private Placement, the former stockholders and option holders of Private ArTara owned, or held rights to acquire, approximately 75.2% of the fully-diluted Common Stock of Protara, with Protara Therapeutics, Inc.'s stockholders and option holders immediately prior to the Merger owning approximately 24.8% of the fully-diluted Common Stock of Protara.</TARA:DescriptionOfOwnershipRights>
    <TARA:PreMergerShares contextRef="From2020-01-01to2020-12-31" unitRef="Shares" decimals="INF">557631</TARA:PreMergerShares>
    <TARA:ReverseBusinessCombination contextRef="From2020-01-01to2020-12-31" unitRef="Shares" decimals="INF">1033907</TARA:ReverseBusinessCombination>
    <us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">150000000</us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit>
    <us-gaap:DeferredTaxLiabilitiesPrepaidExpenses contextRef="AsOf2020-12-31" unitRef="USD" decimals="-3">78000</us-gaap:DeferredTaxLiabilitiesPrepaidExpenses>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">77000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2020-12-31" unitRef="USD" decimals="-3">1359000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2019-12-31" unitRef="USD" decimals="-3">475000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2020-12-31_custom_ComputerEquipmentAndSoftwareMember" unitRef="USD" decimals="-3">34000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2019-12-31_custom_ComputerEquipmentAndSoftwareMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2020-12-31_us-gaap_FurnitureAndFixturesMember" unitRef="USD" decimals="-3">21000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2019-12-31_us-gaap_FurnitureAndFixturesMember" unitRef="USD" decimals="-3">21000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2020-12-31_custom_LaboratoryEquipmentMember" unitRef="USD" decimals="-3">601000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2019-12-31_custom_LaboratoryEquipmentMember" unitRef="USD" decimals="-3">446000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2020-12-31_us-gaap_LeaseholdImprovementsMember" unitRef="USD" decimals="-3">200000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2019-12-31_us-gaap_LeaseholdImprovementsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2020-12-31" unitRef="USD" decimals="-3">119000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2019-12-31" unitRef="USD" decimals="-3">16000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2020-12-31" unitRef="USD" decimals="-3">1240000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2019-12-31" unitRef="USD" decimals="-3">459000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2020-01-01to2020-12-31_us-gaap_FurnitureAndFixturesMember">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2020-01-01to2020-12-31_custom_LaboratoryEquipmentMember">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2020-01-01to2020-12-31_custom_ComputerEquipmentAndSoftwareMember">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentOther contextRef="AsOf2020-12-31" unitRef="USD" decimals="-3">503000</us-gaap:PropertyPlantAndEquipmentOther>
    <us-gaap:PropertyPlantAndEquipmentOther contextRef="AsOf2019-12-31" unitRef="USD" decimals="-3">8000</us-gaap:PropertyPlantAndEquipmentOther>
    <us-gaap:AccruedEmployeeBenefitsCurrent contextRef="AsOf2020-12-31" unitRef="USD" decimals="-3">1530000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent contextRef="AsOf2019-12-31" unitRef="USD" xsi:nil="true" />
    <TARA:LegalFeesOfAccruedExpenses contextRef="AsOf2020-12-31" unitRef="USD" decimals="-3">156000</TARA:LegalFeesOfAccruedExpenses>
    <TARA:LegalFeesOfAccruedExpenses contextRef="AsOf2019-12-31" unitRef="USD" decimals="-3">1573000</TARA:LegalFeesOfAccruedExpenses>
    <us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts contextRef="AsOf2020-12-31" unitRef="USD" decimals="-3">37000</us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts>
    <us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts contextRef="AsOf2019-12-31" unitRef="USD" decimals="-3">1050000</us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="AsOf2020-12-31" unitRef="USD" decimals="-3">31000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="AsOf2019-12-31" unitRef="USD" decimals="-3">12000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2020-12-31" unitRef="USD" decimals="-3">1913000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2019-12-31" unitRef="USD" decimals="-3">2635000</us-gaap:AccruedLiabilitiesCurrent>
    <TARA:DescriptionOfFinancingAgreement contextRef="From2020-02-02to2020-02-19">The Company entered into a nine month financing agreement with AFCO Credit Corporation for its directors and officers ("D&amp;O") liability insurance in the amount of $2,225. The Company made a down payment of $556, leaving a principal balance of $1,669. The financing bore interest at a rate of 4.25% per annum, and was repaid in monthly installments of $189, which included both principal and interest.</TARA:DescriptionOfFinancingAgreement>
    <us-gaap:DebtCurrent contextRef="AsOf2020-12-31" unitRef="USD" decimals="-3">0</us-gaap:DebtCurrent>
    <us-gaap:InterestExpense contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">34000</us-gaap:InterestExpense>
    <us-gaap:Depreciation contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">103000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="From2020-01-01to2020-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="USD" decimals="-3">99000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="From2020-01-01to2020-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="USD" decimals="-3">4000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="From2019-01-01to2019-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="USD" decimals="-3">16000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="From2019-01-01to2019-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="USD" decimals="-3">0</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="-3">16000</us-gaap:Depreciation>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2020-12-31_custom_RightOffUseAssetsMember" unitRef="USD" decimals="-3">1060000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2020-12-31_custom_RightOfUseLiabilityMember" unitRef="USD" decimals="-3">88000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2020-12-31_custom_RightOfUseLeaseLiabilityLongTermMember" unitRef="USD" decimals="-3">999000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2020-01-09_custom_RightOffUseAssetsMember" unitRef="USD" decimals="-3">403000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2020-01-09_custom_RightOfUseLiabilityMember" unitRef="USD" decimals="-3">9000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2020-01-09_custom_RightOfUseLeaseLiabilityLongTermMember" unitRef="USD" decimals="-3">394000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2019-12-31_custom_RightOffUseAssetsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2019-12-31_custom_RightOfUseLiabilityMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2019-12-31_custom_RightOfUseLeaseLiabilityLongTermMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:OperatingLeaseCost contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">93000</us-gaap:OperatingLeaseCost>
    <us-gaap:ShortTermLeaseCost contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">215000</us-gaap:ShortTermLeaseCost>
    <us-gaap:LeaseCost contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">308000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="AsOf2020-12-31" unitRef="Pure" decimals="INF">0.1200</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2020-12-31">P87M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear contextRef="AsOf2020-12-31" unitRef="USD" decimals="-3">1111000</us-gaap:OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears contextRef="AsOf2020-12-31" unitRef="USD" decimals="-3">1333000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears contextRef="AsOf2020-12-31" unitRef="USD" decimals="-3">1338000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears contextRef="AsOf2020-12-31" unitRef="USD" decimals="-3">1342000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears contextRef="AsOf2020-12-31" unitRef="USD" decimals="-3">1423000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter contextRef="AsOf2020-12-31" unitRef="USD" decimals="-3">3277000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="AsOf2020-12-31" unitRef="USD" decimals="-3">9824000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="AsOf2020-12-31" unitRef="USD" decimals="-3">8676000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="AsOf2020-12-31" unitRef="USD" decimals="-3">1148000</us-gaap:OperatingLeaseLiability>
    <TARA:PresentValueOfFutureMinimumLeasePaymentsForOurOperatingLeaseLiabilities contextRef="AsOf2020-12-31" unitRef="USD" decimals="-3">1087000</TARA:PresentValueOfFutureMinimumLeasePaymentsForOurOperatingLeaseLiabilities>
    <TARA:PresentValueOfFutureMinimumLeasePaymentsShorttermLeases contextRef="AsOf2020-12-31" unitRef="USD" decimals="-3">61000</TARA:PresentValueOfFutureMinimumLeasePaymentsShorttermLeases>
    <TARA:DescriptionOfAgreements contextRef="From2018-11-03to2018-11-28_custom_IowaAgreementMember">The Company entered into a sponsored research and license agreement (the "Iowa Agreement") with the University of Iowa. Pursuant to the Iowa Agreement, the University of Iowa, which is engaged in clinical research to improve the diagnosis and treatment of lymphangioma using a pharmaceutical product (OK-432), would assist the Company in collecting case reports, forms, source data, and safety data available to the University of Iowa in support of the development of the Company's proprietary Streptococcus Pyogenes investigational product, TARA-002 for the LMs indication. During the term of the services, the Company would pay the University of Iowa thirty thousand dollars ($30) per year to fund the project, plus additional amounts upon the realization of certain milestones. More specifically, upon forty-five (45) days of an approval of TARA-002 by the FDA, the Company would pay up to $1,750 to the University of Iowa for meeting these milestones. Furthermore, the Company would pay the University of Iowa royalties of up to 1.75% for net sales ranging from $0 - $25,000, 2.25% for net sales ranging from $25,000 to $50,000, and 2.50% for net sales in excess of $50,000. Pursuant to the Iowa Agreement, the University of Iowa would be entitled to additional payments for the Company achieving annual net sales of product according to the milestones. For annual net sales of product up to $25,000; $62; for annual net sales of product of up to $50,000; $62; and for annual net sales of product of up to $100,000; $125.</TARA:DescriptionOfAgreements>
    <TARA:AnnualBaseSalary contextRef="From2018-12-02to2018-12-06_custom_TemporaryEmploymentAgreementMember" unitRef="USD" decimals="-3">90000</TARA:AnnualBaseSalary>
    <us-gaap:ContractualObligation contextRef="AsOf2019-12-31_custom_ChugaiPharmaceuticalAgreementMember" unitRef="USD" decimals="-3">500000</us-gaap:ContractualObligation>
    <us-gaap:ContractualObligation contextRef="AsOf2020-01-09_custom_TemporaryEmploymentAgreementMember" unitRef="USD" decimals="-3">462000</us-gaap:ContractualObligation>
    <us-gaap:BroadcastersLicenseAgreementCommitmentsDescription contextRef="From2017-09-03to2017-09-27_custom_ClinicalServicesAgreementsMember">The Company entered into a license agreement (the "Choline License Agreement") with Alan L. Buchman ("Dr. Buchman"). Pursuant to the Choline License Agreement, the Company received from Dr. Buchman the license rights in and to the "Licensed Orphan Designations", the "Licensed IND", "Existing Study Data" and the "Licensed Know-How" for one or more of the licensed indications. In consideration for the rights and licenses granted, Dr. Buchman received a payment of $50 on October 2, 2017, and license payments of $50 and $50 on December 12, 2018 and January 8, 2019, respectively, upon the Company meeting the criteria for certain meetings to be held with the Federal Drug Administration (the "FDA"). Pursuant to the Choline License Agreement, effective October 2017, the Company incurred a fixed obligation to Dr. Buchman of $400 (the "Choline License Fee"). Upon the Company receiving $5,000 in cumulative funding (as defined), Dr. Buchman would be entitled to receive payment of the Choline License Fee as a lump sum if the funds are received by April 15, 2019 and the Choline License Fee shall be increased to a one-time payment of $600 if the funds are received by October 15, 2019.</us-gaap:BroadcastersLicenseAgreementCommitmentsDescription>
    <TARA:RoyaltyPaymentPercentageOfNetSales contextRef="AsOf2002-02-28" unitRef="Pure" decimals="INF">0.025</TARA:RoyaltyPaymentPercentageOfNetSales>
    <us-gaap:ArtistAdvancesAndRoyaltyGuaranteesCommitments contextRef="From2017-12-02to2017-12-22">The Company entered into an agreement (the "Feinstein Agreement") with The Feinstein Institute for Medical Research (the "Feinstein Institute"), a not-for-profit corporation with 50 research labs and 2,500 clinical research studies. Pursuant to the Feinstein Agreement, the Company acquired an exclusive license relating to treatment of fatty liver diseases in humans for which Choline may be an effective therapeutic. In consideration for the rights and license granted, the Feinstein Institute would receive a royalty of one percent (1%) of the first one hundred million dollars ($100,000) of net sales of IV Choline Chloride and a royalty of one and one-half percent (1.5%) of all net sales thereafter. In addition, the Company would pay the Feinstein Institute twelve and one-half percent (12.5%) of net proceeds resulting from agreements entered within 2 years from the effective date, and seven and one-half percent (7.5%) of net proceeds resulting from agreements entered into thereafter. Pursuant to the Feinstein Agreement additional payments would be due to the Feinstein Institute for license maintenance payments and for meeting milestone events. On January 9, 2020, the Company's raising of over $5,000 triggered a financing milestone obligation and accordingly the Feinstein Institute was paid $100. Pursuant to the Feinstein Agreement, upon the achievement of certain future new drug application milestones, the Company would be obligated to remit an aggregate of $275.</us-gaap:ArtistAdvancesAndRoyaltyGuaranteesCommitments>
    <TARA:ResearchAndDevelopmentExpenses contextRef="From2020-01-01to2020-12-31_custom_FeinsteinAgreementMember" unitRef="USD" decimals="-3">115000</TARA:ResearchAndDevelopmentExpenses>
    <TARA:ResearchAndDevelopmentExpenses contextRef="From2019-01-01to2019-12-31_custom_FeinsteinAgreementMember" unitRef="USD" decimals="-3">1000</TARA:ResearchAndDevelopmentExpenses>
    <TARA:ResearchAndDevelopmentExpenses contextRef="From2020-01-01to2020-12-31_custom_IowaAgreementMember" unitRef="USD" decimals="-3">30000</TARA:ResearchAndDevelopmentExpenses>
    <TARA:ResearchAndDevelopmentExpenses contextRef="From2019-01-01to2019-12-31_custom_IowaAgreementMember" unitRef="USD" decimals="-3">30000</TARA:ResearchAndDevelopmentExpenses>
    <TARA:ResearchAndDevelopmentExpenses contextRef="From2020-01-01to2020-12-31_custom_ChugaiPharmaceuticalAgreementMember" unitRef="USD" decimals="-3">0</TARA:ResearchAndDevelopmentExpenses>
    <TARA:ResearchAndDevelopmentExpenses contextRef="From2019-01-01to2019-12-31_custom_ChugaiPharmaceuticalAgreementMember" unitRef="USD" decimals="-3">500000</TARA:ResearchAndDevelopmentExpenses>
    <TARA:ResearchAndDevelopmentExpenses contextRef="From2020-01-01to2020-12-31_custom_ClinicalServicesAgreementsMember" unitRef="USD" decimals="-3">0</TARA:ResearchAndDevelopmentExpenses>
    <TARA:ResearchAndDevelopmentExpenses contextRef="From2019-01-01to2019-12-31_custom_ClinicalServicesAgreementsMember" unitRef="USD" decimals="-3">200000</TARA:ResearchAndDevelopmentExpenses>
    <TARA:CholineLicenseFee contextRef="From2020-09-25to2020-10-02_custom_ClinicalServicesAgreementsMember_custom_DrBuchmanMember" unitRef="USD" decimals="-3">50000</TARA:CholineLicenseFee>
    <TARA:CholineLicenseFee contextRef="From2019-09-25to2019-10-02_custom_ClinicalServicesAgreementsMember_custom_DrBuchmanMember" unitRef="USD" decimals="-3">50000</TARA:CholineLicenseFee>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent contextRef="AsOf2019-12-31_custom_ClinicalServicesAgreementsMember_custom_DrBuchmanMember" unitRef="USD" decimals="-3">550000</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2020-12-31" unitRef="USDPShares" decimals="INF">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2019-12-31" unitRef="USDPShares" decimals="INF">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2020-12-31" unitRef="Shares" decimals="INF">11211840</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2019-12-31" unitRef="Shares" decimals="INF">2627533</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2020-12-31" unitRef="USDPShares" decimals="INF">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2019-12-31" unitRef="USDPShares" decimals="INF">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2020-12-31" unitRef="Shares" decimals="INF">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2019-12-31" unitRef="Shares" decimals="INF">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2020-12-31_custom_Series1PreferredStockMember" unitRef="Shares" decimals="INF">8028</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2019-12-31_custom_Series1PreferredStockMember" unitRef="Shares" decimals="INF">0</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2020-12-31_custom_Series1PreferredStockMember" unitRef="Shares" decimals="INF">8027</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2019-12-31_custom_Series1PreferredStockMember" unitRef="Shares" decimals="INF">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2020-09-22_custom_Series1PreferredStockMember_srt_MinimumMember" unitRef="Shares" decimals="INF">3880</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2020-09-22_custom_Series1PreferredStockMember_srt_MaximumMember" unitRef="Shares" decimals="INF">8028</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2020-12-31_custom_Series1PreferredStockMember" unitRef="Shares" decimals="INF">8027</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2019-12-31_custom_Series1PreferredStockMember" unitRef="Shares" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:SharesIssuedPricePerShare contextRef="AsOf2020-12-31_custom_Series1PreferredStockMember" unitRef="USDPShares" decimals="INF">10.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssuedPricePerShare contextRef="AsOf2019-09-23" unitRef="USDPShares" decimals="INF">7.23</us-gaap:SharesIssuedPricePerShare>
    <TARA:IncreaseOrDecreaseEquityPercentage contextRef="AsOf2020-12-31_custom_Series1PreferredStockMember" unitRef="Pure" decimals="INF">0.1999</TARA:IncreaseOrDecreaseEquityPercentage>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="AsOf2020-12-31_custom_Series1PreferredStockMember" unitRef="USDPShares" decimals="INF">7.01</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <TARA:AggregateOfSharesOfCommonStock contextRef="AsOf2020-09-24_custom_UnderwrittenPublicOfferingMember" unitRef="Shares" decimals="INF">4600000</TARA:AggregateOfSharesOfCommonStock>
    <TARA:AggregateOfSharesOfCommonStock contextRef="AsOf2020-09-24_custom_UnderwrittenPublicOfferingMember_custom_Series1PreferredStockMember" unitRef="Shares" decimals="INF">4148</TARA:AggregateOfSharesOfCommonStock>
    <us-gaap:ProceedsFromConvertibleDebt contextRef="From2020-09-05to2020-09-24_custom_UnderwrittenPublicOfferingMember" unitRef="USD" decimals="-3">77600000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromConvertibleDebt contextRef="From2020-10-03to2020-10-06_us-gaap_OverAllotmentOptionMember" unitRef="USD" decimals="-3">11600000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromConvertibleDebt contextRef="From2020-09-05to2020-09-24_custom_UnderwrittenPublicOfferingMember_custom_Series1PreferredStockMember" unitRef="USD" decimals="-3">70000000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromConvertibleDebt contextRef="From2019-09-01to2019-09-23" unitRef="USD" decimals="-3">500000</us-gaap:ProceedsFromConvertibleDebt>
    <TARA:NetProceeds contextRef="From2020-09-05to2020-09-24_custom_UnderwrittenPublicOfferingMember" unitRef="USD" decimals="-3">73600000</TARA:NetProceeds>
    <TARA:NetProceeds contextRef="From2020-10-03to2020-10-06_us-gaap_OverAllotmentOptionMember" unitRef="USD" decimals="-3">11100000</TARA:NetProceeds>
    <TARA:NetProceeds contextRef="From2020-09-05to2020-09-24_custom_UnderwrittenPublicOfferingMember_custom_Series1PreferredStockMember" unitRef="USD" decimals="-3">66300000</TARA:NetProceeds>
    <TARA:CommonStockIssuanceAndOutstandingPercentage contextRef="AsOf2020-12-31" unitRef="Pure" decimals="INF">0.0999</TARA:CommonStockIssuanceAndOutstandingPercentage>
    <TARA:MaximumAggregateOfferingPrice contextRef="AsOf2019-09-23" unitRef="USD" decimals="-3">300000000</TARA:MaximumAggregateOfferingPrice>
    <us-gaap:SharesIssued contextRef="AsOf2019-09-23" unitRef="Shares" decimals="INF">69114</us-gaap:SharesIssued>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares contextRef="AsOf2019-12-31_us-gaap_RestrictedStockUnitsRSUMember" unitRef="Shares" xsi:nil="true" />
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares contextRef="AsOf2020-12-31_us-gaap_RestrictedStockUnitsRSUMember" unitRef="Shares" decimals="INF">274616</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares contextRef="From2020-01-01to2020-12-31_us-gaap_RestrictedStockUnitsRSUMember" unitRef="Shares" decimals="INF">148334</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue contextRef="From2020-01-01to2020-12-31_us-gaap_RestrictedStockUnitsRSUMember" unitRef="USDPShares" decimals="INF">30.00</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <TARA:StockOptionExercisePrice contextRef="From2020-01-01to2020-12-31_srt_MaximumMember" unitRef="USDPShares" decimals="INF">51.12</TARA:StockOptionExercisePrice>
    <TARA:StockOptionExercisePrice contextRef="From2020-01-01to2020-12-31_srt_MinimumMember" unitRef="USDPShares" decimals="INF">17.84</TARA:StockOptionExercisePrice>
    <TARA:StockOptionExercisePrice contextRef="From2019-01-01to2019-12-31_srt_MaximumMember" unitRef="USDPShares" decimals="INF">8.65</TARA:StockOptionExercisePrice>
    <TARA:StockOptionExercisePrice contextRef="From2019-01-01to2019-12-31_srt_MinimumMember" unitRef="USDPShares" decimals="INF">6.81</TARA:StockOptionExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice contextRef="AsOf2019-12-31" unitRef="USDPShares" decimals="INF">9.18</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice contextRef="AsOf2020-12-31_srt_MaximumMember" unitRef="USDPShares" decimals="INF">51.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice contextRef="AsOf2020-12-31_srt_MinimumMember" unitRef="USDPShares" decimals="INF">17.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice contextRef="AsOf2019-12-31_srt_MinimumMember" unitRef="USDPShares" decimals="INF">6.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice contextRef="AsOf2019-12-31_srt_MaximumMember" unitRef="USDPShares" decimals="INF">8.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2020-01-01to2020-12-31" unitRef="Pure" decimals="INF">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2019-01-01to2019-12-31" unitRef="Pure" decimals="INF">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2020-01-01to2020-12-31_srt_MaximumMember" unitRef="Pure" decimals="INF">1.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2020-01-01to2020-12-31_srt_MinimumMember" unitRef="Pure" decimals="INF">0.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2019-01-01to2019-12-31_srt_MaximumMember" unitRef="Pure" decimals="INF">0.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2019-01-01to2019-12-31_srt_MinimumMember" unitRef="Pure" decimals="INF">0.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2020-01-01to2020-12-31_srt_MaximumMember" unitRef="Pure" decimals="INF">0.0169</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2020-01-01to2020-12-31_srt_MinimumMember" unitRef="Pure" decimals="INF">0.0028</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2019-01-01to2019-12-31_srt_MaximumMember" unitRef="Pure" decimals="INF">0.0237</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2019-01-01to2019-12-31_srt_MinimumMember" unitRef="Pure" decimals="INF">0.0171</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2020-01-01to2020-12-31_srt_MaximumMember">P6Y0M29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2020-01-01to2020-12-31_srt_MinimumMember">P5Y3M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2019-01-01to2019-12-31_srt_MaximumMember">P6Y0M7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2019-01-01to2019-12-31_srt_MinimumMember">P5Y6M29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2019-12-31_us-gaap_EmployeeStockMember" unitRef="Shares" decimals="INF">219592</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2020-12-31_us-gaap_EmployeeStockMember" unitRef="Shares" decimals="INF">674039</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <TARA:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberExercisable contextRef="AsOf2020-12-31_us-gaap_EmployeeStockMember" unitRef="Shares" decimals="INF">109117</TARA:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberExercisable>
    <TARA:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageGrantDateFairValue contextRef="From2020-01-01to2020-12-31_us-gaap_EmployeeStockMember" unitRef="USDPShares" decimals="INF">6.72</TARA:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageGrantDateFairValue>
    <TARA:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercisable contextRef="AsOf2020-12-31_us-gaap_EmployeeStockMember" unitRef="USDPShares" decimals="INF">11.44</TARA:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercisable>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2019-12-31_us-gaap_EmployeeStockMember" unitRef="USDPShares" decimals="INF">9.18</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2020-12-31_us-gaap_EmployeeStockMember" unitRef="USDPShares" decimals="INF">25.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2020-01-01to2020-12-31_us-gaap_EmployeeStockMember" unitRef="USDPShares" decimals="INF">29.23</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="From2020-01-01to2020-12-31_us-gaap_EmployeeStockMember" unitRef="USDPShares" decimals="INF">9.18</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="From2020-01-01to2020-12-31_us-gaap_EmployeeStockMember" unitRef="USDPShares" decimals="INF">18.91</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <TARA:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceExercisable contextRef="AsOf2020-12-31_us-gaap_EmployeeStockMember" unitRef="USDPShares" decimals="INF">15.63</TARA:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceExercisable>
    <TARA:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTerm1 contextRef="From2020-01-01to2020-12-31_us-gaap_EmployeeStockMember">P9Y8M19D</TARA:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTerm1>
    <TARA:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTerm2 contextRef="From2020-01-01to2020-12-31_us-gaap_EmployeeStockMember">P9Y0M22D</TARA:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTerm2>
    <TARA:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTermExercisable contextRef="From2020-01-01to2020-12-31_us-gaap_EmployeeStockMember">P8Y2M30D</TARA:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTermExercisable>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding contextRef="AsOf2019-12-31_us-gaap_EmployeeStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding contextRef="AsOf2020-12-31_us-gaap_EmployeeStockMember" unitRef="USD" decimals="-3">2311000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <TARA:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted contextRef="From2020-01-01to2020-12-31_us-gaap_EmployeeStockMember" unitRef="USD" xsi:nil="true" />
    <TARA:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisable contextRef="AsOf2020-12-31_us-gaap_EmployeeStockMember" unitRef="USD" decimals="-3">1201000</TARA:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisable>
    <TARA:VestPeriod contextRef="From2019-01-01to2019-12-31_custom_TwentySeventeenEquityIncentivePlanMember_srt_BoardOfDirectorsChairmanMember">P10Y0M0D</TARA:VestPeriod>
    <TARA:VestPeriod contextRef="From2020-01-01to2020-12-31_custom_TwentyFourteenEquityIncentivePlanMember_srt_BoardOfDirectorsChairmanMember">P10Y0M0D</TARA:VestPeriod>
    <TARA:IncrementalValue contextRef="From2020-01-01to2020-12-31_us-gaap_EmployeeStockMember" unitRef="USD" decimals="-3">501000</TARA:IncrementalValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="AsOf2020-07-23_us-gaap_RestrictedStockUnitsRSUMember" unitRef="Shares" decimals="INF">5687</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="AsOf2020-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_DirectorsOneMember" unitRef="Shares" decimals="INF">254000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="AsOf2020-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_DirectorsTwoMember" unitRef="Shares" decimals="INF">62000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <TARA:UnamortizedValueOfStock contextRef="From2020-01-01to2020-12-31_us-gaap_EmployeeStockMember" unitRef="USD" decimals="-3">9973000</TARA:UnamortizedValueOfStock>
    <TARA:WeightedAverageRemainingAmortizationPeriod contextRef="From2020-01-01to2020-12-31_us-gaap_RestrictedStockUnitsRSUMember">P1Y9M22D</TARA:WeightedAverageRemainingAmortizationPeriod>
    <TARA:WeightedAverageRemainingAmortizationPeriod contextRef="From2020-01-01to2020-12-31_us-gaap_EmployeeStockMember">P3Y0M0D</TARA:WeightedAverageRemainingAmortizationPeriod>
    <TARA:NumberOfSharesRestrictedStock contextRef="From2020-01-01to2020-12-31_us-gaap_RestrictedStockUnitsRSUMember" unitRef="Shares" decimals="INF">132709</TARA:NumberOfSharesRestrictedStock>
    <TARA:NumberOfSharesRestrictedStock contextRef="From2019-01-01to2019-12-31_us-gaap_RestrictedStockUnitsRSUMember" unitRef="Shares" decimals="INF">5245</TARA:NumberOfSharesRestrictedStock>
    <TARA:UnamortizedValueOfRsus contextRef="From2020-01-01to2020-12-31_us-gaap_RestrictedStockUnitsRSUMember" unitRef="USD" decimals="-3">6299000</TARA:UnamortizedValueOfRsus>
    <TARA:VestedOptionsPercentage contextRef="AsOf2020-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_DirectorsOneMember" unitRef="Pure" decimals="INF">0.125</TARA:VestedOptionsPercentage>
    <TARA:VestedOptionsPercentage contextRef="AsOf2020-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_DirectorsTwoMember" unitRef="Pure" decimals="INF">0.50</TARA:VestedOptionsPercentage>
    <TARA:VestedOptionsPercentage contextRef="AsOf2020-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_EmployeesMember" unitRef="Pure" decimals="INF">0.25</TARA:VestedOptionsPercentage>
    <us-gaap:SaleOfStockDescriptionOfTransaction contextRef="From2014-10-01to2014-10-03_custom_TwentyFourteenEmployeeStockPurchasePlanMember">The number of shares increases each January 1, commencing on January 1, 2015 and ending on (and including) January 1, 2024, by an amount equal to the lesser of one percent of the outstanding shares as of the end of the immediately preceding fiscal year, 7,025 shares or any lower amount determined by the Company&#8217;s Board of Directors prior to each such January 1st.</us-gaap:SaleOfStockDescriptionOfTransaction>
    <us-gaap:SaleOfStockDescriptionOfTransaction contextRef="From2020-01-01to2020-01-09_custom_TwentyFourteenEquityIncentivePlanMember">The number of shares available for issuance under the Amended 2014 Plan increased by 900,002 shares from 148,298 shares to 1,048,300 shares on January 1, 2020.</us-gaap:SaleOfStockDescriptionOfTransaction>
    <us-gaap:SaleOfStockDescriptionOfTransaction contextRef="From2019-01-01to2019-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_ConsultantMember">The Board of Directors granted of 5,245 RSUs to a consultant. The RSUs were granted under the Company's 2017 Equity Incentive Plan. The RSUs vested in five equal installments of 1,049 units on the 15th and 30th of each month, beginning on October 30, 2019. The grant date fair value of this RSU was $36.</us-gaap:SaleOfStockDescriptionOfTransaction>
    <TARA:StocksIssuedDuringPeriodValueNewIssues contextRef="From2020-01-01to2020-12-31_custom_TwentyTwentyInducementPlanMember" unitRef="USD" decimals="-3">600000000</TARA:StocksIssuedDuringPeriodValueNewIssues>
    <TARA:StocksIssuedDuringPeriodValueNewIssues contextRef="From2020-01-01to2020-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_DirectorsOneMember" unitRef="USD" decimals="-3">316000000</TARA:StocksIssuedDuringPeriodValueNewIssues>
    <TARA:StocksIssuedDuringPeriodValueNewIssues contextRef="From2020-01-01to2020-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_EmployeesMember" unitRef="USD" decimals="-3">163325000</TARA:StocksIssuedDuringPeriodValueNewIssues>
    <TARA:StocksIssuedDuringPeriodValueNewIssues contextRef="From2019-01-01to2019-12-31_custom_TwentySeventeenEquityIncentivePlanMember_srt_BoardOfDirectorsChairmanMember" unitRef="USD" decimals="-3">47114000</TARA:StocksIssuedDuringPeriodValueNewIssues>
    <TARA:StocksIssuedDuringPeriodValueNewIssues contextRef="From2020-01-01to2020-12-31_custom_TwentyFourteenEquityIncentivePlanMember_srt_BoardOfDirectorsChairmanMember" unitRef="USD" decimals="-3">484850000</TARA:StocksIssuedDuringPeriodValueNewIssues>
    <TARA:WeightedAverageGrantDateFairValue contextRef="AsOf2019-12-31_us-gaap_EmployeeStockMember" unitRef="USDPShares" decimals="INF">6.55</TARA:WeightedAverageGrantDateFairValue>
    <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="From2020-01-01to2020-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="From2019-01-01to2019-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="From2020-01-01to2020-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="From2019-01-01to2019-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="From2020-01-01to2020-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="From2019-01-01to2019-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">-6211000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="-3">-1614000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">-2439000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="-3">-930000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredOtherTaxExpenseBenefit contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">-8650000</us-gaap:DeferredOtherTaxExpenseBenefit>
    <us-gaap:DeferredOtherTaxExpenseBenefit contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="-3">-2544000</us-gaap:DeferredOtherTaxExpenseBenefit>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">8650000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="-3">2544000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="From2020-01-01to2020-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:IncomeTaxExpenseBenefit contextRef="From2019-01-01to2019-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:DeferredTaxAssetsOtherLossCarryforwards contextRef="AsOf2020-12-31" unitRef="USD" decimals="-3">19371000</us-gaap:DeferredTaxAssetsOtherLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOtherLossCarryforwards contextRef="AsOf2019-12-31" unitRef="USD" decimals="-3">3806000</us-gaap:DeferredTaxAssetsOtherLossCarryforwards>
    <TARA:DeferredTaxAssetsOrganizationCostslegalFees contextRef="AsOf2020-12-31" unitRef="USD" decimals="-3">8000</TARA:DeferredTaxAssetsOrganizationCostslegalFees>
    <TARA:DeferredTaxAssetsOrganizationCostslegalFees contextRef="AsOf2019-12-31" unitRef="USD" decimals="-3">9000</TARA:DeferredTaxAssetsOrganizationCostslegalFees>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits contextRef="AsOf2020-12-31" unitRef="USD" decimals="-3">443000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits contextRef="AsOf2019-12-31" unitRef="USD" decimals="-3">111000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <TARA:DeferredTaxAssetsRestrictedStockExpense contextRef="AsOf2020-12-31" unitRef="USD" xsi:nil="true" />
    <TARA:DeferredTaxAssetsRestrictedStockExpense contextRef="AsOf2019-12-31" unitRef="USD" decimals="-3">238000</TARA:DeferredTaxAssetsRestrictedStockExpense>
    <TARA:RestrictedStockUnitsExpense contextRef="AsOf2020-12-31" unitRef="USD" decimals="-3">1796000</TARA:RestrictedStockUnitsExpense>
    <TARA:RestrictedStockUnitsExpense contextRef="AsOf2019-12-31" unitRef="USD" decimals="-3">12000</TARA:RestrictedStockUnitsExpense>
    <TARA:DeferredTaxAssetsCharitableContributions contextRef="AsOf2020-12-31" unitRef="USD" decimals="-3">2000</TARA:DeferredTaxAssetsCharitableContributions>
    <TARA:DeferredTaxAssetsCharitableContributions contextRef="AsOf2019-12-31" unitRef="USD" decimals="-3">2000</TARA:DeferredTaxAssetsCharitableContributions>
    <us-gaap:DeferredTaxAssetsGross contextRef="AsOf2020-12-31" unitRef="USD" decimals="-3">22020000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="AsOf2019-12-31" unitRef="USD" decimals="-3">4178000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2020-12-31" unitRef="USD" decimals="-3">21698000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2019-12-31" unitRef="USD" decimals="-3">4176000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet contextRef="AsOf2020-12-31" unitRef="USD" decimals="-3">322000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet contextRef="AsOf2019-12-31" unitRef="USD" decimals="-3">2000</us-gaap:DeferredTaxAssetsNet>
    <TARA:DeferredTaxLiabilitiesDepreciation contextRef="AsOf2020-12-31" unitRef="USD" xsi:nil="true" />
    <TARA:DeferredTaxLiabilitiesDepreciation contextRef="AsOf2019-12-31" unitRef="USD" decimals="-3">-2000</TARA:DeferredTaxLiabilitiesDepreciation>
    <us-gaap:DeferredTaxLiabilitiesTaxDeferredIncome contextRef="AsOf2020-12-31" unitRef="USD" decimals="-3">322000</us-gaap:DeferredTaxLiabilitiesTaxDeferredIncome>
    <us-gaap:DeferredTaxLiabilitiesTaxDeferredIncome contextRef="AsOf2019-12-31" unitRef="USD" decimals="-3">2000</us-gaap:DeferredTaxLiabilitiesTaxDeferredIncome>
    <us-gaap:DeferredTaxLiabilities contextRef="AsOf2020-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:DeferredTaxLiabilities contextRef="AsOf2019-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="From2020-01-01to2020-12-31" unitRef="Pure" decimals="INF">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="From2019-01-01to2019-12-31" unitRef="Pure" decimals="INF">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="From2020-01-01to2020-12-31" unitRef="Pure" decimals="INF">0.094</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="From2019-01-01to2019-12-31" unitRef="Pure" decimals="INF">0.121</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="From2020-01-01to2020-12-31" unitRef="Pure" decimals="INF">0.012</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="From2019-01-01to2019-12-31" unitRef="Pure" decimals="INF">0.005</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther contextRef="From2020-01-01to2020-12-31" unitRef="Pure" decimals="INF">0.019</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther contextRef="From2019-01-01to2019-12-31" unitRef="Pure" decimals="INF">0.001</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="From2020-01-01to2020-12-31" unitRef="Pure" decimals="INF">0.255</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="From2019-01-01to2019-12-31" unitRef="Pure" decimals="INF">0.325</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="From2020-01-01to2020-12-31" unitRef="Pure" xsi:nil="true" />
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="From2019-01-01to2019-12-31" unitRef="Pure" xsi:nil="true" />
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="AsOf2020-12-31" unitRef="USD" decimals="-3">63700000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">21700000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="-3">4200000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <TARA:NetOperatingLossAfterApplication contextRef="AsOf2020-12-31" unitRef="USD" decimals="-3">1400000</TARA:NetOperatingLossAfterApplication>
    <TARA:MergerDescription contextRef="From2020-01-01to2020-01-09">The Company acquired NOL's from Proteon of $41.6 million. These NOLs were determined to be impaired by $12.4 million, with an annual limitation of $0.5 million on the remaining $29.2 million of NOLs. The general business credits of $3.6 million acquired in the merger were determined to be fully impaired.</TARA:MergerDescription>
    <us-gaap:DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans contextRef="From2020-01-01to2020-12-31">The Company maintains a defined contribution benefit plan under section 401(k) of the Internal Revenue Code covering substantially all qualified employees of the Company (the "401(k) Plan"). Under the 401(k) Plan, the Company matches 100% up to a 4% contribution.</us-gaap:DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans>
    <us-gaap:OtherExpenses contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">69000</us-gaap:OtherExpenses>
    <us-gaap:RestrictedCashAndInvestments contextRef="AsOf2020-12-31" unitRef="USD" decimals="-3">745000</us-gaap:RestrictedCashAndInvestments>
    <us-gaap:RestrictedCashAndInvestments contextRef="AsOf2019-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:IncomeTaxesPaid contextRef="From2020-01-01to2020-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:IncomeTaxesPaid contextRef="From2019-01-01to2019-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:AccruedPayrollTaxesCurrent contextRef="AsOf2020-12-31" unitRef="USD" decimals="-3">159000</us-gaap:AccruedPayrollTaxesCurrent>
    <us-gaap:AccruedPayrollTaxesCurrent contextRef="AsOf2019-12-31" unitRef="USD" xsi:nil="true" />
    <dei:EntityIncorporationStateCountryCode contextRef="From2020-01-01to2020-12-31">DE</dei:EntityIncorporationStateCountryCode>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">22462000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="-3">3952000</us-gaap:GeneralAndAdministrativeExpense>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2021-03-09" unitRef="Shares" decimals="INF">11228606</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="AsOf2020-12-31" unitRef="USD" decimals="-3">70000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="AsOf2019-12-31" unitRef="USD" xsi:nil="true" />
    <TARA:DeferredTaxAssetsOperatingLeaseLiability contextRef="AsOf2020-12-31" unitRef="USD" decimals="-3">330000</TARA:DeferredTaxAssetsOperatingLeaseLiability>
    <TARA:DeferredTaxAssetsOperatingLeaseLiability contextRef="AsOf2019-12-31" unitRef="USD" xsi:nil="true" />
    <TARA:DeferredTaxLiabilitiesOperatingRightofuseAsset contextRef="AsOf2020-12-31" unitRef="USD" decimals="-3">-322000</TARA:DeferredTaxLiabilitiesOperatingRightofuseAsset>
    <TARA:DeferredTaxLiabilitiesOperatingRightofuseAsset contextRef="AsOf2019-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes contextRef="From2020-01-01to2020-12-31" unitRef="Pure" decimals="INF">0.018</us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes contextRef="From2019-01-01to2019-12-31" unitRef="Pure" xsi:nil="true" />
    <dei:EntityPublicFloat contextRef="AsOf2020-06-30" unitRef="USD" decimals="-3">76900000</dei:EntityPublicFloat>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>15
<FILENAME>tara-20201231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoXBRL; Version: 5.6b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Source; Value: tara%2D20201231.xfr; Date: 2021%2D03%2D10T22:42:15Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Ipo7xRiXgen8uHa3gsOaeMycPtyJRyKYkxsWh5bTl6LyIi9+n/MC7NqM8W8fAD -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:us-roles="http://fasb.org/us-roles/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:TARA="http://artaratx.com/20201231" elementFormDefault="qualified" targetNamespace="http://artaratx.com/20201231">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://artaratx.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
	  <link:definition>00000001 - Document - Document and Entity Information</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://artaratx.com/role/BalanceSheets" id="BalanceSheets">
	  <link:definition>00000002 - Statement - Consolidated Balance Sheets</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://artaratx.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
	  <link:definition>00000003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://artaratx.com/role/StatementsOfOperations" id="StatementsOfOperations">
	  <link:definition>00000004 - Statement - Consolidated Statements of Operations</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://artaratx.com/role/StatementsOfChangesInStockholdersEquityDeficit" id="StatementsOfChangesInStockholdersEquityDeficit">
	  <link:definition>00000005 - Statement - Consolidated Statements of Changes In Stockholders' Equity (Deficit)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://artaratx.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
	  <link:definition>00000006 - Statement - Consolidated Statements Of Cash Flows</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://artaratx.com/role/BusinessLiquidityAndCapitalResources" id="BusinessLiquidityAndCapitalResources">
	  <link:definition>00000007 - Disclosure - Business, Liquidity and Capital Resources</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://artaratx.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
	  <link:definition>00000008 - Disclosure - Summary of Significant Accounting Policies</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://artaratx.com/role/ReverseMergerWithProtaraAndRecapitalization" id="ReverseMergerWithProtaraAndRecapitalization">
	  <link:definition>00000009 - Disclosure - Reverse Merger with Protara and Recapitalization</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://artaratx.com/role/PropertyAndEquipment" id="PropertyAndEquipment">
	  <link:definition>00000010 - Disclosure - Property and Equipment</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://artaratx.com/role/AccruedExpenses" id="AccruedExpenses">
	  <link:definition>00000011 - Disclosure - Accrued Expenses</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://artaratx.com/role/Short-termDebt" id="Short-termDebt">
	  <link:definition>00000012 - Disclosure - Short-Term Debt</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://artaratx.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
	  <link:definition>00000013 - Disclosure - Commitments and Contingencies</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://artaratx.com/role/StockholdersEquity" id="StockholdersEquity">
	  <link:definition>00000014 - Disclosure - Stockholders' Equity</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://artaratx.com/role/Stock-basedCompensation" id="Stock-basedCompensation">
	  <link:definition>00000015 - Disclosure -  Stock-Based Compensation</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://artaratx.com/role/IncomeTaxes" id="IncomeTaxes">
	  <link:definition>00000016 - Disclosure -  Income Taxes</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://artaratx.com/role/EmployeeBenefitPlan" id="EmployeeBenefitPlan">
	  <link:definition>00000017 - Disclosure - Employee Benefit Plan</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://artaratx.com/role/Covid-19" id="Covid-19">
	  <link:definition>00000018 - Disclosure - COVID-19</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://artaratx.com/role/SubsequentEvents" id="SubsequentEvents">
	  <link:definition>00000019 - Disclosure - Subsequent Events</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://artaratx.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
	  <link:definition>00000020 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://artaratx.com/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
	  <link:definition>00000021 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://artaratx.com/role/ReverseMergerWithProtaraAndRecapitalizationTables" id="ReverseMergerWithProtaraAndRecapitalizationTables">
	  <link:definition>00000022 - Disclosure - Reverse Merger with Protara and Recapitalization (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://artaratx.com/role/PropertyAndEquipmentTables" id="PropertyAndEquipmentTables">
	  <link:definition>00000023 - Disclosure - Property and Equipment (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://artaratx.com/role/AccruedExpensesTables" id="AccruedExpensesTables">
	  <link:definition>00000024 - Disclosure - Accrued Expenses (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://artaratx.com/role/CommitmentsAndContingenciesTables" id="CommitmentsAndContingenciesTables">
	  <link:definition>00000025 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://artaratx.com/role/Stock-basedCompensationTables" id="Stock-basedCompensationTables">
	  <link:definition>00000026 - Disclosure -  Stock-Based Compensation (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://artaratx.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
	  <link:definition>00000027 - Disclosure -  Income Taxes (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://artaratx.com/role/BusinessLiquidityAndCapitalResourcesDetails" id="BusinessLiquidityAndCapitalResourcesDetails">
	  <link:definition>00000028 - Disclosure - Business, Liquidity and Capital Resources (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://artaratx.com/role/SummaryOfSignificantAccountingPoliciesDetails" id="SummaryOfSignificantAccountingPoliciesDetails">
	  <link:definition>00000029 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://artaratx.com/role/SummaryOfSignificantAccountingPoliciesDetailsTextual" id="SummaryOfSignificantAccountingPoliciesDetailsTextual">
	  <link:definition>00000030 - Disclosure -  Summary of Significant Accounting Policies (Details Textual)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://artaratx.com/role/ReverseMergerWithProtaraAndRecapitalizationDetails" id="ReverseMergerWithProtaraAndRecapitalizationDetails">
	  <link:definition>00000031 - Disclosure - Reverse Merger with Protara and Recapitalization (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://artaratx.com/role/ReverseMergerWithProtaraAndRecapitalizationDetails1" id="ReverseMergerWithProtaraAndRecapitalizationDetails1">
	  <link:definition>00000032 - Disclosure - Reverse Merger with Protara and Recapitalization (Details 1)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://artaratx.com/role/ReverseMergerWithProtaraAndRecapitalizationDetailsTextual" id="ReverseMergerWithProtaraAndRecapitalizationDetailsTextual">
	  <link:definition>00000033 - Disclosure - Reverse Merger with Protara and Recapitalization (Details Textual)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://artaratx.com/role/PropertyAndEquipmentDetails" id="PropertyAndEquipmentDetails">
	  <link:definition>00000034 - Disclosure - Property and Equipment (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://artaratx.com/role/PropertyAndEquipmentDetailsTextual" id="PropertyAndEquipmentDetailsTextual">
	  <link:definition>00000035 - Disclosure - Property and Equipment (Details Textual)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://artaratx.com/role/AccruedExpensesDetails" id="AccruedExpensesDetails">
	  <link:definition>00000036 - Disclosure - Accrued Expenses (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://artaratx.com/role/Short-termDebtDetails" id="Short-termDebtDetails">
	  <link:definition>00000037 - Disclosure - Short-Term Debt (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://artaratx.com/role/CommitmentsAndContingenciesDetails" id="CommitmentsAndContingenciesDetails">
	  <link:definition>00000038 - Disclosure - Commitments and Contingencies (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://artaratx.com/role/CommitmentsAndContingenciesDetails1" id="CommitmentsAndContingenciesDetails1">
	  <link:definition>00000039 - Disclosure - Commitments and Contingencies (Details 1)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://artaratx.com/role/CommitmentsAndContingenciesDetailsTextual" id="CommitmentsAndContingenciesDetailsTextual">
	  <link:definition>00000040 - Disclosure - Commitments and Contingencies (Details Textual)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://artaratx.com/role/StockholdersEquityDetails" id="StockholdersEquityDetails">
	  <link:definition>00000041 - Disclosure - Stockholders' Equity (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://artaratx.com/role/Stock-basedCompensationDetails" id="Stock-basedCompensationDetails">
	  <link:definition>00000042 - Disclosure -  Stock-Based Compensation (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://artaratx.com/role/Stock-basedCompensationDetails1" id="Stock-basedCompensationDetails1">
	  <link:definition>00000043 - Disclosure -  Stock-Based Compensation (Details 1)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://artaratx.com/role/Stock-basedCompensationDetails2" id="Stock-basedCompensationDetails2">
	  <link:definition>00000044 - Disclosure -  Stock-Based Compensation (Details 2)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://artaratx.com/role/Stock-basedCompensationDetails3" id="Stock-basedCompensationDetails3">
	  <link:definition>00000045 - Disclosure -  Stock-Based Compensation (Details 3)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://artaratx.com/role/Stock-basedCompensationDetails4" id="Stock-basedCompensationDetails4">
	  <link:definition>00000046 - Disclosure -  Stock-Based Compensation (Details 4)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://artaratx.com/role/Stock-basedCompensationDetailsTextual" id="Stock-basedCompensationDetailsTextual">
	  <link:definition>00000047 - Disclosure -  Stock-Based Compensation (Details Textual)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://artaratx.com/role/IncomeTaxesDetails" id="IncomeTaxesDetails">
	  <link:definition>00000048 - Disclosure -  Income Taxes (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://artaratx.com/role/IncomeTaxesDetails1" id="IncomeTaxesDetails1">
	  <link:definition>00000049 - Disclosure -  Income Taxes (Details 1)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://artaratx.com/role/IncomeTaxesDetails2" id="IncomeTaxesDetails2">
	  <link:definition>00000050 - Disclosure -  Income Taxes (Details 2)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://artaratx.com/role/IncomeTaxesDetailsTextual" id="IncomeTaxesDetailsTextual">
	  <link:definition>00000051 - Disclosure -  Income Taxes (Details Textual)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://artaratx.com/role/EmployeeBenefitPlanDetails" id="EmployeeBenefitPlanDetails">
	  <link:definition>00000052 - Disclosure - Employee Benefit Plan (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="tara-20201231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="tara-20201231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="tara-20201231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="tara-20201231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" />
    <import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2020-01-31" schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd" />
    <import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd" />
    <import namespace="http://fasb.org/srt-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd" />
    <element id="TARA_SharesAvailableForIssuance" name="SharesAvailableForIssuance" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_Covid19DisclosureTextBlock" name="Covid19DisclosureTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_BusinessLiquidityAndCapitalResourcesTextBlock" name="BusinessLiquidityAndCapitalResourcesTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_IssuanceOfStockOptionsAndRestrictedStockUnitsToEmployeesAndDirectorsTableTextBlock" name="IssuanceOfStockOptionsAndRestrictedStockUnitsToEmployeesAndDirectorsTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_StockIssueDuringPeriodvalueIssuedForCapitalRaise" name="StockIssueDuringPeriodvalueIssuedForCapitalRaise" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_Issuanceofcommonstockinseptembercapitalraiseshares" name="Issuanceofcommonstockinseptembercapitalraiseshares" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_IssuanceOfCommonStockInArtaraPrivatePlacementNetOfOfferingCosts" name="IssuanceOfCommonStockInArtaraPrivatePlacementNetOfOfferingCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_IssuanceOfCommonStockInArtaraPrivatePlacementNetOfOfferingCostsShares" name="IssuanceOfCommonStockInArtaraPrivatePlacementNetOfOfferingCostsShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_IssuanceOfSeries1ConvertiblePreferredStockInProteonPrivatePlacementNetOfOfferingCosts" name="IssuanceOfSeries1ConvertiblePreferredStockInProteonPrivatePlacementNetOfOfferingCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_IssuanceOfSeries1ConvertiblePreferredStockInProteonPrivatePlacementNetOfOfferingCostsShares" name="IssuanceOfSeries1ConvertiblePreferredStockInProteonPrivatePlacementNetOfOfferingCostsShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_StockIssuedDuringPeriodValueIssuanceOfSeries1ConvertiblePreferredStockNetOfOfferingCosts" name="StockIssuedDuringPeriodValueIssuanceOfSeries1ConvertiblePreferredStockNetOfOfferingCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_StockIssuedDuringPeriodSharesIssuanceOfSeries1ConvertiblePreferredStockNetOfOfferingCosts" name="StockIssuedDuringPeriodSharesIssuanceOfSeries1ConvertiblePreferredStockNetOfOfferingCosts" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_StockIssuedDuringPeriodValueIssuedForSettlementOfRestrictedStockUnits" name="StockIssuedDuringPeriodValueIssuedForSettlementOfRestrictedStockUnits" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_StockIssuedDuringPeriodSharesIssuedForSettlementOfRestrictedStockUnits" name="StockIssuedDuringPeriodSharesIssuedForSettlementOfRestrictedStockUnits" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_CashAndRestrictedCashAcquiredInConnectionWithReverseMergerWithArtaraTherapeuticsInc." name="CashAndRestrictedCashAcquiredInConnectionWithReverseMergerWithArtaraTherapeuticsInc." nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_ProceedsFromProteonPrivatePlacementNetOfOfferingCosts" name="ProceedsFromProteonPrivatePlacementNetOfOfferingCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_ProceedsFromIssuancesOfConvertiblePreferredStock" name="ProceedsFromIssuancesOfConvertiblePreferredStock" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_ProceedsFromUnderwritersOverallotmentOption" name="ProceedsFromUnderwritersOverallotmentOption" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_ReconciliationOfRestrictedCashAndCashEquivalents" name="ReconciliationOfRestrictedCashAndCashEquivalents" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_CommonStockIssuedInConnectionWithReverseMerger" name="CommonStockIssuedInConnectionWithReverseMerger" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_PurchaseOfInsuranceAgreementWithNotesPayable" name="PurchaseOfInsuranceAgreementWithNotesPayable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_DeferredOfferingCostsRecognizedThatWerePreviouslyRecordedInAccruedExpenses" name="DeferredOfferingCostsRecognizedThatWerePreviouslyRecordedInAccruedExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_DeferredOfferingCostsRecordedInAccruedExpenses" name="DeferredOfferingCostsRecordedInAccruedExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_IncreaseDecreaseRightofuseLiability" name="IncreaseDecreaseRightofuseLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_AmortizationOfOperatingLeaseRightsofuseAsset" name="AmortizationOfOperatingLeaseRightsofuseAsset" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_WorkingCapital" name="WorkingCapital" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_NetOfOfferingCosts" name="NetOfOfferingCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_ProceedsFrompublicOfferingGross" name="ProceedsFrompublicOfferingGross" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_PublicOfferingProceedsNet" name="PublicOfferingProceedsNet" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_RestrictCash" name="RestrictCash" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_AssetsAcquiredAndLiabilitiesAssumedCash" name="AssetsAcquiredAndLiabilitiesAssumedCash" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_AssetsAcquiredAndLiabilitiesAssumedRestrictedCash" name="AssetsAcquiredAndLiabilitiesAssumedRestrictedCash" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_AssetsAcquiredAndLiabilitiesAssumedPrepaidExpensesAndOtherAssets" name="AssetsAcquiredAndLiabilitiesAssumedPrepaidExpensesAndOtherAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_AssetsAcquiredAndLiabilitiesAssumedGoodwill" name="AssetsAcquiredAndLiabilitiesAssumedGoodwill" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_AssetsAcquiredAndLiabilitiesAssumedAccruedExpenses" name="AssetsAcquiredAndLiabilitiesAssumedAccruedExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_AssetsAcquiredAndLiabilitiesAssumedTotalPurchasePrice" name="AssetsAcquiredAndLiabilitiesAssumedTotalPurchasePrice" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_ProFormaLossPerCommonShareBasicAndDiluted" name="ProFormaLossPerCommonShareBasicAndDiluted" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_ProFormaWeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted" name="ProFormaWeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_OutstandingReverseStock" name="OutstandingReverseStock" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_SubscriptionAgreementDescription" name="SubscriptionAgreementDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_FairValueOfNetAssets" name="FairValueOfNetAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_DescriptionOfOwnershipRights" name="DescriptionOfOwnershipRights" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_PreMergerShares" name="PreMergerShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_ReverseBusinessCombination" name="ReverseBusinessCombination" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_LegalFeesOfAccruedExpenses" name="LegalFeesOfAccruedExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_DescriptionOfFinancingAgreement" name="DescriptionOfFinancingAgreement" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_PresentValueOfFutureMinimumLeasePaymentsForOurOperatingLeaseLiabilities" name="PresentValueOfFutureMinimumLeasePaymentsForOurOperatingLeaseLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_PresentValueOfFutureMinimumLeasePaymentsShorttermLeases" name="PresentValueOfFutureMinimumLeasePaymentsShorttermLeases" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_DescriptionOfAgreements" name="DescriptionOfAgreements" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_AnnualBaseSalary" name="AnnualBaseSalary" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_RoyaltyPaymentPercentageOfNetSales" name="RoyaltyPaymentPercentageOfNetSales" nillable="true" xbrli:periodType="instant" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_ResearchAndDevelopmentExpenses" name="ResearchAndDevelopmentExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_CholineLicenseFee" name="CholineLicenseFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_IncreaseOrDecreaseEquityPercentage" name="IncreaseOrDecreaseEquityPercentage" nillable="true" xbrli:periodType="instant" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_AggregateOfSharesOfCommonStock" name="AggregateOfSharesOfCommonStock" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_NetProceeds" name="NetProceeds" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_CommonStockIssuanceAndOutstandingPercentage" name="CommonStockIssuanceAndOutstandingPercentage" nillable="true" xbrli:periodType="instant" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_MaximumAggregateOfferingPrice" name="MaximumAggregateOfferingPrice" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_StockOptionExercisePrice" name="StockOptionExercisePrice" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberExercisable" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberExercisable" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercisable" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercisable" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceExercisable" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceExercisable" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTerm1" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTerm1" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTerm2" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTerm2" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTermExercisable" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTermExercisable" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted" name="SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisable" name="SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_VestPeriod" name="VestPeriod" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_IncrementalValue" name="IncrementalValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_UnamortizedValueOfStock" name="UnamortizedValueOfStock" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_WeightedAverageRemainingAmortizationPeriod" name="WeightedAverageRemainingAmortizationPeriod" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_NumberOfSharesRestrictedStock" name="NumberOfSharesRestrictedStock" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_UnamortizedValueOfRsus" name="UnamortizedValueOfRsus" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_VestedOptionsPercentage" name="VestedOptionsPercentage" nillable="true" xbrli:periodType="instant" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_StocksIssuedDuringPeriodValueNewIssues" name="StocksIssuedDuringPeriodValueNewIssues" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_WeightedAverageGrantDateFairValue" name="WeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_DeferredTaxAssetsOrganizationCostslegalFees" name="DeferredTaxAssetsOrganizationCostslegalFees" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_DeferredTaxAssetsRestrictedStockExpense" name="DeferredTaxAssetsRestrictedStockExpense" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_RestrictedStockUnitsExpense" name="RestrictedStockUnitsExpense" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_DeferredTaxAssetsCharitableContributions" name="DeferredTaxAssetsCharitableContributions" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_DeferredTaxLiabilitiesDepreciation" name="DeferredTaxLiabilitiesDepreciation" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_NetOperatingLossAfterApplication" name="NetOperatingLossAfterApplication" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_MergerDescription" name="MergerDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_DeferredTaxAssetsOperatingLeaseLiability" name="DeferredTaxAssetsOperatingLeaseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_DeferredTaxLiabilitiesOperatingRightofuseAsset" name="DeferredTaxLiabilitiesOperatingRightofuseAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_Series1ConvertiblePreferredStockMember" name="Series1ConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_MergerAgreementMember" name="MergerAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_EquityIncentivePlanMember" name="EquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_EquityIncentivePlanOneMember" name="EquityIncentivePlanOneMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_SeriesAConvertiblePreferredStockMember" name="SeriesAConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_BalanceSheetLocationMember" name="BalanceSheetLocationMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_RightOffUseAssetsMember" name="RightOffUseAssetsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_RightOfUseLiabilityMember" name="RightOfUseLiabilityMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_RightOfUseLeaseLiabilityLongTermMember" name="RightOfUseLeaseLiabilityLongTermMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_ClinicalServicesAgreementsMember" name="ClinicalServicesAgreementsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_FeinsteinAgreementMember" name="FeinsteinAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_IowaAgreementMember" name="IowaAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_ChugaiPharmaceuticalAgreementMember" name="ChugaiPharmaceuticalAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_SettlementAgreementMember" name="SettlementAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_TwentyTwentyInducementPlanMember" name="TwentyTwentyInducementPlanMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_TwentySeventeenEquityIncentivePlanMember" name="TwentySeventeenEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_TwentyFourteenEquityIncentivePlanMember" name="TwentyFourteenEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_TwentyFourteenEmployeeStockPurchasePlanMember" name="TwentyFourteenEmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_DirectorsOneMember" name="DirectorsOneMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_DirectorsTwoMember" name="DirectorsTwoMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_OfficersMember" name="OfficersMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_EmployeesMember" name="EmployeesMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_DrZummoMember" name="DrZummoMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_DrCasoyMember" name="DrCasoyMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_DrBuchmanMember" name="DrBuchmanMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_Series1PreferredStockMember" name="Series1PreferredStockMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_TemporaryEmploymentAgreementMember" name="TemporaryEmploymentAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_UnderwrittenPublicOfferingMember" name="UnderwrittenPublicOfferingMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_DrFlannellyMember" name="DrFlannellyMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_DrBraunsteinMember" name="DrBraunsteinMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_ComputerEquipmentAndSoftwareMember" name="ComputerEquipmentAndSoftwareMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_LaboratoryEquipmentMember" name="LaboratoryEquipmentMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_ConsultantMember" name="ConsultantMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_DocumentAndEntityInformationAbstract" name="DocumentAndEntityInformationAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_CashPaidForAbstract" name="CashPaidForAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_BusinessLiquidityAndCapitalResourcesAbstract" name="BusinessLiquidityAndCapitalResourcesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_Covid19Abstract" name="Covid19Abstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_BusinessLiquidityAndCapitalResourcesTextualAbstract" name="BusinessLiquidityAndCapitalResourcesTextualAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_SummaryOfSignificantAccountingPoliciesDetailsTextualAbstract" name="SummaryOfSignificantAccountingPoliciesDetailsTextualAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_SummaryOfSignificantAccountingPoliciesTextualAbstract" name="SummaryOfSignificantAccountingPoliciesTextualAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_BusinessCombinationsTextualAbstract" name="BusinessCombinationsTextualAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_PropertyAndEquipmentDetailsTextualAbstract" name="PropertyAndEquipmentDetailsTextualAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_PropertyAndEquipmentTextualAbstract" name="PropertyAndEquipmentTextualAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_ShorttermDebtTextualAbstract" name="ShorttermDebtTextualAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_RightofuseLiability" name="RightofuseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_RightofuseLeaseLiabilityLongterm" name="RightofuseLeaseLiabilityLongterm" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_CommitmentsTextualAbstract" name="CommitmentsTextualAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_PaymentOfAttorneysFees" name="PaymentOfAttorneysFees" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_GeneralAndAdministrativeExpenses" name="GeneralAndAdministrativeExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_StockholdersEquityTextualAbstract" name="StockholdersEquityTextualAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_RestrictedStockUnitsAbstract" name="RestrictedStockUnitsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_WeightedAverageGrantDateFairValueOneAbstract" name="WeightedAverageGrantDateFairValueOneAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_OptionsAbstract" name="OptionsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_WeightedAverageGrantDateFairValueAbstract" name="WeightedAverageGrantDateFairValueAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_WeightedAverageExercisePriceAbstract" name="WeightedAverageExercisePriceAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_WeightedAverageRemainingContractualTermYearsAbstract" name="WeightedAverageRemainingContractualTermYearsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTermGranted" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTermGranted" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_AggregateIntrinsicValueAbstract" name="AggregateIntrinsicValueAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeited" name="SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeited" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_StockBasedCompensationTextualAbstract" name="StockBasedCompensationTextualAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_OptionsDescription" name="OptionsDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_ShareBasedCompensationGrantDateFairValue" name="ShareBasedCompensationGrantDateFairValue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_DeferredTaxAssetsAbstract" name="DeferredTaxAssetsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_IncomeTaxesTextualAbstract" name="IncomeTaxesTextualAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_PercentageOfAnnualDeductionLimitation" name="PercentageOfAnnualDeductionLimitation" nillable="true" xbrli:periodType="instant" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_EmployeeBenefitPlanDetailsAbstract" name="EmployeeBenefitPlanDetailsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="TARA_EmployeeBenefitPlanTextualAbstract" name="EmployeeBenefitPlanTextualAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>16
<FILENAME>tara-20201231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoXBRL; Version: 5.6b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Source; Value: tara%2D20201231.xfr; Date: 2021%2D03%2D10T22:42:15Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://artaratx.com/role/DocumentAndEntityInformation" xlink:href="tara-20201231.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/BalanceSheets" xlink:href="tara-20201231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/BalanceSheetsParenthetical" xlink:href="tara-20201231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/StatementsOfOperations" xlink:href="tara-20201231.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/StatementsOfChangesInStockholdersEquityDeficit" xlink:href="tara-20201231.xsd#StatementsOfChangesInStockholdersEquityDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/StatementsOfCashFlows" xlink:href="tara-20201231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/BusinessLiquidityAndCapitalResources" xlink:href="tara-20201231.xsd#BusinessLiquidityAndCapitalResources" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="tara-20201231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/ReverseMergerWithProtaraAndRecapitalization" xlink:href="tara-20201231.xsd#ReverseMergerWithProtaraAndRecapitalization" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/PropertyAndEquipment" xlink:href="tara-20201231.xsd#PropertyAndEquipment" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/AccruedExpenses" xlink:href="tara-20201231.xsd#AccruedExpenses" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/Short-termDebt" xlink:href="tara-20201231.xsd#Short-termDebt" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/CommitmentsAndContingencies" xlink:href="tara-20201231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/StockholdersEquity" xlink:href="tara-20201231.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/Stock-basedCompensation" xlink:href="tara-20201231.xsd#Stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/IncomeTaxes" xlink:href="tara-20201231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/EmployeeBenefitPlan" xlink:href="tara-20201231.xsd#EmployeeBenefitPlan" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/Covid-19" xlink:href="tara-20201231.xsd#Covid-19" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/SubsequentEvents" xlink:href="tara-20201231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="tara-20201231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="tara-20201231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/ReverseMergerWithProtaraAndRecapitalizationTables" xlink:href="tara-20201231.xsd#ReverseMergerWithProtaraAndRecapitalizationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/PropertyAndEquipmentTables" xlink:href="tara-20201231.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/AccruedExpensesTables" xlink:href="tara-20201231.xsd#AccruedExpensesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/CommitmentsAndContingenciesTables" xlink:href="tara-20201231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/Stock-basedCompensationTables" xlink:href="tara-20201231.xsd#Stock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/IncomeTaxesTables" xlink:href="tara-20201231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/BusinessLiquidityAndCapitalResourcesDetails" xlink:href="tara-20201231.xsd#BusinessLiquidityAndCapitalResourcesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:href="tara-20201231.xsd#SummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/SummaryOfSignificantAccountingPoliciesDetailsTextual" xlink:href="tara-20201231.xsd#SummaryOfSignificantAccountingPoliciesDetailsTextual" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/ReverseMergerWithProtaraAndRecapitalizationDetails" xlink:href="tara-20201231.xsd#ReverseMergerWithProtaraAndRecapitalizationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/ReverseMergerWithProtaraAndRecapitalizationDetails1" xlink:href="tara-20201231.xsd#ReverseMergerWithProtaraAndRecapitalizationDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/ReverseMergerWithProtaraAndRecapitalizationDetailsTextual" xlink:href="tara-20201231.xsd#ReverseMergerWithProtaraAndRecapitalizationDetailsTextual" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/PropertyAndEquipmentDetails" xlink:href="tara-20201231.xsd#PropertyAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/PropertyAndEquipmentDetailsTextual" xlink:href="tara-20201231.xsd#PropertyAndEquipmentDetailsTextual" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/AccruedExpensesDetails" xlink:href="tara-20201231.xsd#AccruedExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/Short-termDebtDetails" xlink:href="tara-20201231.xsd#Short-termDebtDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/CommitmentsAndContingenciesDetails" xlink:href="tara-20201231.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/CommitmentsAndContingenciesDetails1" xlink:href="tara-20201231.xsd#CommitmentsAndContingenciesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/CommitmentsAndContingenciesDetailsTextual" xlink:href="tara-20201231.xsd#CommitmentsAndContingenciesDetailsTextual" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/StockholdersEquityDetails" xlink:href="tara-20201231.xsd#StockholdersEquityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/Stock-basedCompensationDetails" xlink:href="tara-20201231.xsd#Stock-basedCompensationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/Stock-basedCompensationDetails1" xlink:href="tara-20201231.xsd#Stock-basedCompensationDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/Stock-basedCompensationDetails2" xlink:href="tara-20201231.xsd#Stock-basedCompensationDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/Stock-basedCompensationDetails3" xlink:href="tara-20201231.xsd#Stock-basedCompensationDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/Stock-basedCompensationDetails4" xlink:href="tara-20201231.xsd#Stock-basedCompensationDetails4" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/Stock-basedCompensationDetailsTextual" xlink:href="tara-20201231.xsd#Stock-basedCompensationDetailsTextual" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/IncomeTaxesDetails" xlink:href="tara-20201231.xsd#IncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/IncomeTaxesDetails1" xlink:href="tara-20201231.xsd#IncomeTaxesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/IncomeTaxesDetails2" xlink:href="tara-20201231.xsd#IncomeTaxesDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/IncomeTaxesDetailsTextual" xlink:href="tara-20201231.xsd#IncomeTaxesDetailsTextual" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/EmployeeBenefitPlanDetails" xlink:href="tara-20201231.xsd#EmployeeBenefitPlanDetails" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://artaratx.com/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information" />
    <link:calculationLink xlink:type="extended" xlink:role="http://artaratx.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaapRestrictedCashCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapRestrictedCashCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaapDeferredOfferingCosts" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapDeferredOfferingCosts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaapGoodwill" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapGoodwill" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndInvestments" xlink:label="loc_us-gaapRestrictedCashAndInvestments" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapRestrictedCashAndInvestments" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://artaratx.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://artaratx.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Consolidated Statements of Operations">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaapInterestIncomeExpenseNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestIncomeExpenseNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://artaratx.com/role/StatementsOfChangesInStockholdersEquityDeficit" xlink:title="00000005 - Statement - Consolidated Statements of Changes In Stockholders&apos; Equity (Deficit)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://artaratx.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Consolidated Statements Of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_AmortizationOfOperatingLeaseRightsofuseAsset" xlink:label="loc_TARAAmortizationOfOperatingLeaseRightsofuseAsset" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_TARAAmortizationOfOperatingLeaseRightsofuseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_IncreaseDecreaseRightofuseLiability" xlink:label="loc_TARAIncreaseDecreaseRightofuseLiability" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_TARAIncreaseDecreaseRightofuseLiability" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherNoncurrentAssets" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherNoncurrentAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_CashAndRestrictedCashAcquiredInConnectionWithReverseMergerWithArtaraTherapeuticsInc." xlink:label="loc_TARACashAndRestrictedCashAcquiredInConnectionWithReverseMergerWithArtaraTherapeuticsInc." />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_TARACashAndRestrictedCashAcquiredInConnectionWithReverseMergerWithArtaraTherapeuticsInc." xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_ProceedsFromProteonPrivatePlacementNetOfOfferingCosts" xlink:label="loc_TARAProceedsFromProteonPrivatePlacementNetOfOfferingCosts" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_TARAProceedsFromProteonPrivatePlacementNetOfOfferingCosts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfConvertiblePreferredStock" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_ProceedsFromIssuancesOfConvertiblePreferredStock" xlink:label="loc_TARAProceedsFromIssuancesOfConvertiblePreferredStock" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_TARAProceedsFromIssuancesOfConvertiblePreferredStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_ProceedsFromUnderwritersOverallotmentOption" xlink:label="loc_TARAProceedsFromUnderwritersOverallotmentOption" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_TARAProceedsFromUnderwritersOverallotmentOption" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfShortTermDebt" xlink:label="loc_us-gaapRepaymentsOfShortTermDebt" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapRepaymentsOfShortTermDebt" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://artaratx.com/role/BusinessLiquidityAndCapitalResources" xlink:title="00000007 - Disclosure - Business, Liquidity and Capital Resources" />
    <link:calculationLink xlink:type="extended" xlink:role="http://artaratx.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000008 - Disclosure - Summary of Significant Accounting Policies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://artaratx.com/role/ReverseMergerWithProtaraAndRecapitalization" xlink:title="00000009 - Disclosure - Reverse Merger with Protara and Recapitalization" />
    <link:calculationLink xlink:type="extended" xlink:role="http://artaratx.com/role/PropertyAndEquipment" xlink:title="00000010 - Disclosure - Property and Equipment" />
    <link:calculationLink xlink:type="extended" xlink:role="http://artaratx.com/role/AccruedExpenses" xlink:title="00000011 - Disclosure - Accrued Expenses" />
    <link:calculationLink xlink:type="extended" xlink:role="http://artaratx.com/role/Short-termDebt" xlink:title="00000012 - Disclosure - Short-Term Debt" />
    <link:calculationLink xlink:type="extended" xlink:role="http://artaratx.com/role/CommitmentsAndContingencies" xlink:title="00000013 - Disclosure - Commitments and Contingencies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://artaratx.com/role/StockholdersEquity" xlink:title="00000014 - Disclosure - Stockholders&apos; Equity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://artaratx.com/role/Stock-basedCompensation" xlink:title="00000015 - Disclosure -  Stock-Based Compensation" />
    <link:calculationLink xlink:type="extended" xlink:role="http://artaratx.com/role/IncomeTaxes" xlink:title="00000016 - Disclosure -  Income Taxes" />
    <link:calculationLink xlink:type="extended" xlink:role="http://artaratx.com/role/EmployeeBenefitPlan" xlink:title="00000017 - Disclosure - Employee Benefit Plan" />
    <link:calculationLink xlink:type="extended" xlink:role="http://artaratx.com/role/Covid-19" xlink:title="00000018 - Disclosure - COVID-19" />
    <link:calculationLink xlink:type="extended" xlink:role="http://artaratx.com/role/SubsequentEvents" xlink:title="00000019 - Disclosure - Subsequent Events" />
    <link:calculationLink xlink:type="extended" xlink:role="http://artaratx.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000020 - Disclosure - Summary of Significant Accounting Policies (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://artaratx.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000021 - Disclosure - Summary of Significant Accounting Policies (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://artaratx.com/role/ReverseMergerWithProtaraAndRecapitalizationTables" xlink:title="00000022 - Disclosure - Reverse Merger with Protara and Recapitalization (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://artaratx.com/role/PropertyAndEquipmentTables" xlink:title="00000023 - Disclosure - Property and Equipment (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://artaratx.com/role/AccruedExpensesTables" xlink:title="00000024 - Disclosure - Accrued Expenses (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://artaratx.com/role/CommitmentsAndContingenciesTables" xlink:title="00000025 - Disclosure - Commitments and Contingencies (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://artaratx.com/role/Stock-basedCompensationTables" xlink:title="00000026 - Disclosure -  Stock-Based Compensation (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://artaratx.com/role/IncomeTaxesTables" xlink:title="00000027 - Disclosure -  Income Taxes (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://artaratx.com/role/BusinessLiquidityAndCapitalResourcesDetails" xlink:title="00000028 - Disclosure - Business, Liquidity and Capital Resources (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://artaratx.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:title="00000029 - Disclosure - Summary of Significant Accounting Policies (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://artaratx.com/role/SummaryOfSignificantAccountingPoliciesDetailsTextual" xlink:title="00000030 - Disclosure -  Summary of Significant Accounting Policies (Details Textual)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://artaratx.com/role/ReverseMergerWithProtaraAndRecapitalizationDetails" xlink:title="00000031 - Disclosure - Reverse Merger with Protara and Recapitalization (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://artaratx.com/role/ReverseMergerWithProtaraAndRecapitalizationDetails1" xlink:title="00000032 - Disclosure - Reverse Merger with Protara and Recapitalization (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://artaratx.com/role/ReverseMergerWithProtaraAndRecapitalizationDetailsTextual" xlink:title="00000033 - Disclosure - Reverse Merger with Protara and Recapitalization (Details Textual)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://artaratx.com/role/PropertyAndEquipmentDetails" xlink:title="00000034 - Disclosure - Property and Equipment (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://artaratx.com/role/PropertyAndEquipmentDetailsTextual" xlink:title="00000035 - Disclosure - Property and Equipment (Details Textual)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://artaratx.com/role/AccruedExpensesDetails" xlink:title="00000036 - Disclosure - Accrued Expenses (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="loc_us-gaapAccruedEmployeeBenefitsCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedEmployeeBenefitsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_LegalFeesOfAccruedExpenses" xlink:label="loc_TARALegalFeesOfAccruedExpenses" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_TARALegalFeesOfAccruedExpenses" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:label="loc_us-gaapDeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapDeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedPayrollTaxesCurrent" xlink:label="loc_us-gaapAccruedPayrollTaxesCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedPayrollTaxesCurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://artaratx.com/role/Short-termDebtDetails" xlink:title="00000037 - Disclosure - Short-Term Debt (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://artaratx.com/role/CommitmentsAndContingenciesDetails" xlink:title="00000038 - Disclosure - Commitments and Contingencies (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://artaratx.com/role/CommitmentsAndContingenciesDetails1" xlink:title="00000039 - Disclosure - Commitments and Contingencies (Details 1)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInTwoYears" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInThreeYears" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInFourYears" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInFiveYears" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueThereafter" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://artaratx.com/role/CommitmentsAndContingenciesDetailsTextual" xlink:title="00000040 - Disclosure - Commitments and Contingencies (Details Textual)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://artaratx.com/role/StockholdersEquityDetails" xlink:title="00000041 - Disclosure - Stockholders&apos; Equity (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://artaratx.com/role/Stock-basedCompensationDetails" xlink:title="00000042 - Disclosure -  Stock-Based Compensation (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://artaratx.com/role/Stock-basedCompensationDetails1" xlink:title="00000043 - Disclosure -  Stock-Based Compensation (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://artaratx.com/role/Stock-basedCompensationDetails2" xlink:title="00000044 - Disclosure -  Stock-Based Compensation (Details 2)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://artaratx.com/role/Stock-basedCompensationDetails3" xlink:title="00000045 - Disclosure -  Stock-Based Compensation (Details 3)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://artaratx.com/role/Stock-basedCompensationDetails4" xlink:title="00000046 - Disclosure -  Stock-Based Compensation (Details 4)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://artaratx.com/role/Stock-basedCompensationDetailsTextual" xlink:title="00000047 - Disclosure -  Stock-Based Compensation (Details Textual)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://artaratx.com/role/IncomeTaxesDetails" xlink:title="00000048 - Disclosure -  Income Taxes (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://artaratx.com/role/IncomeTaxesDetails1" xlink:title="00000049 - Disclosure -  Income Taxes (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://artaratx.com/role/IncomeTaxesDetails2" xlink:title="00000050 - Disclosure -  Income Taxes (Details 2)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://artaratx.com/role/IncomeTaxesDetailsTextual" xlink:title="00000051 - Disclosure -  Income Taxes (Details Textual)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://artaratx.com/role/EmployeeBenefitPlanDetails" xlink:title="00000052 - Disclosure - Employee Benefit Plan (Details)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>17
<FILENAME>tara-20201231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoXBRL; Version: 5.6b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Source; Value: tara%2D20201231.xfr; Date: 2021%2D03%2D10T22:42:15Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://artaratx.com/role/DocumentAndEntityInformation" xlink:href="tara-20201231.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/BalanceSheets" xlink:href="tara-20201231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/BalanceSheetsParenthetical" xlink:href="tara-20201231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/StatementsOfOperations" xlink:href="tara-20201231.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/StatementsOfChangesInStockholdersEquityDeficit" xlink:href="tara-20201231.xsd#StatementsOfChangesInStockholdersEquityDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/StatementsOfCashFlows" xlink:href="tara-20201231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/BusinessLiquidityAndCapitalResources" xlink:href="tara-20201231.xsd#BusinessLiquidityAndCapitalResources" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="tara-20201231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/ReverseMergerWithProtaraAndRecapitalization" xlink:href="tara-20201231.xsd#ReverseMergerWithProtaraAndRecapitalization" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/PropertyAndEquipment" xlink:href="tara-20201231.xsd#PropertyAndEquipment" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/AccruedExpenses" xlink:href="tara-20201231.xsd#AccruedExpenses" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/Short-termDebt" xlink:href="tara-20201231.xsd#Short-termDebt" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/CommitmentsAndContingencies" xlink:href="tara-20201231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/StockholdersEquity" xlink:href="tara-20201231.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/Stock-basedCompensation" xlink:href="tara-20201231.xsd#Stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/IncomeTaxes" xlink:href="tara-20201231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/EmployeeBenefitPlan" xlink:href="tara-20201231.xsd#EmployeeBenefitPlan" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/Covid-19" xlink:href="tara-20201231.xsd#Covid-19" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/SubsequentEvents" xlink:href="tara-20201231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="tara-20201231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="tara-20201231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/ReverseMergerWithProtaraAndRecapitalizationTables" xlink:href="tara-20201231.xsd#ReverseMergerWithProtaraAndRecapitalizationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/PropertyAndEquipmentTables" xlink:href="tara-20201231.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/AccruedExpensesTables" xlink:href="tara-20201231.xsd#AccruedExpensesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/CommitmentsAndContingenciesTables" xlink:href="tara-20201231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/Stock-basedCompensationTables" xlink:href="tara-20201231.xsd#Stock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/IncomeTaxesTables" xlink:href="tara-20201231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/BusinessLiquidityAndCapitalResourcesDetails" xlink:href="tara-20201231.xsd#BusinessLiquidityAndCapitalResourcesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:href="tara-20201231.xsd#SummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/SummaryOfSignificantAccountingPoliciesDetailsTextual" xlink:href="tara-20201231.xsd#SummaryOfSignificantAccountingPoliciesDetailsTextual" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/ReverseMergerWithProtaraAndRecapitalizationDetails" xlink:href="tara-20201231.xsd#ReverseMergerWithProtaraAndRecapitalizationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/ReverseMergerWithProtaraAndRecapitalizationDetails1" xlink:href="tara-20201231.xsd#ReverseMergerWithProtaraAndRecapitalizationDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/ReverseMergerWithProtaraAndRecapitalizationDetailsTextual" xlink:href="tara-20201231.xsd#ReverseMergerWithProtaraAndRecapitalizationDetailsTextual" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/PropertyAndEquipmentDetails" xlink:href="tara-20201231.xsd#PropertyAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/PropertyAndEquipmentDetailsTextual" xlink:href="tara-20201231.xsd#PropertyAndEquipmentDetailsTextual" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/AccruedExpensesDetails" xlink:href="tara-20201231.xsd#AccruedExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/Short-termDebtDetails" xlink:href="tara-20201231.xsd#Short-termDebtDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/CommitmentsAndContingenciesDetails" xlink:href="tara-20201231.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/CommitmentsAndContingenciesDetails1" xlink:href="tara-20201231.xsd#CommitmentsAndContingenciesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/CommitmentsAndContingenciesDetailsTextual" xlink:href="tara-20201231.xsd#CommitmentsAndContingenciesDetailsTextual" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/StockholdersEquityDetails" xlink:href="tara-20201231.xsd#StockholdersEquityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/Stock-basedCompensationDetails" xlink:href="tara-20201231.xsd#Stock-basedCompensationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/Stock-basedCompensationDetails1" xlink:href="tara-20201231.xsd#Stock-basedCompensationDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/Stock-basedCompensationDetails2" xlink:href="tara-20201231.xsd#Stock-basedCompensationDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/Stock-basedCompensationDetails3" xlink:href="tara-20201231.xsd#Stock-basedCompensationDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/Stock-basedCompensationDetails4" xlink:href="tara-20201231.xsd#Stock-basedCompensationDetails4" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/Stock-basedCompensationDetailsTextual" xlink:href="tara-20201231.xsd#Stock-basedCompensationDetailsTextual" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/IncomeTaxesDetails" xlink:href="tara-20201231.xsd#IncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/IncomeTaxesDetails1" xlink:href="tara-20201231.xsd#IncomeTaxesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/IncomeTaxesDetails2" xlink:href="tara-20201231.xsd#IncomeTaxesDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/IncomeTaxesDetailsTextual" xlink:href="tara-20201231.xsd#IncomeTaxesDetailsTextual" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/EmployeeBenefitPlanDetails" xlink:href="tara-20201231.xsd#EmployeeBenefitPlanDetails" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://artaratx.com/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information" />
    <link:definitionLink xlink:type="extended" xlink:role="http://artaratx.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets" />
    <link:definitionLink xlink:type="extended" xlink:role="http://artaratx.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_Series1PreferredStockMember" xlink:label="loc_TARASeries1PreferredStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_TARASeries1PreferredStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_50" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://artaratx.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Consolidated Statements of Operations" />
    <link:definitionLink xlink:type="extended" xlink:role="http://artaratx.com/role/StatementsOfChangesInStockholdersEquityDeficit" xlink:title="00000005 - Statement - Consolidated Statements of Changes In Stockholders&apos; Equity (Deficit)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_Series1ConvertiblePreferredStockMember" xlink:label="loc_TARASeries1ConvertiblePreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_TARASeries1ConvertiblePreferredStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_IssuanceOfCommonStockInArtaraPrivatePlacementNetOfOfferingCosts" xlink:label="loc_TARAIssuanceOfCommonStockInArtaraPrivatePlacementNetOfOfferingCosts_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TARAIssuanceOfCommonStockInArtaraPrivatePlacementNetOfOfferingCosts_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_IssuanceOfCommonStockInArtaraPrivatePlacementNetOfOfferingCostsShares" xlink:label="loc_TARAIssuanceOfCommonStockInArtaraPrivatePlacementNetOfOfferingCostsShares_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TARAIssuanceOfCommonStockInArtaraPrivatePlacementNetOfOfferingCostsShares_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_IssuanceOfSeries1ConvertiblePreferredStockInProteonPrivatePlacementNetOfOfferingCosts" xlink:label="loc_TARAIssuanceOfSeries1ConvertiblePreferredStockInProteonPrivatePlacementNetOfOfferingCosts_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TARAIssuanceOfSeries1ConvertiblePreferredStockInProteonPrivatePlacementNetOfOfferingCosts_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_IssuanceOfSeries1ConvertiblePreferredStockInProteonPrivatePlacementNetOfOfferingCostsShares" xlink:label="loc_TARAIssuanceOfSeries1ConvertiblePreferredStockInProteonPrivatePlacementNetOfOfferingCostsShares_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TARAIssuanceOfSeries1ConvertiblePreferredStockInProteonPrivatePlacementNetOfOfferingCostsShares_60" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions_60" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions_60" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_60" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_60" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_StockIssuedDuringPeriodValueIssuanceOfSeries1ConvertiblePreferredStockNetOfOfferingCosts" xlink:label="loc_TARAStockIssuedDuringPeriodValueIssuanceOfSeries1ConvertiblePreferredStockNetOfOfferingCosts_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TARAStockIssuedDuringPeriodValueIssuanceOfSeries1ConvertiblePreferredStockNetOfOfferingCosts_60" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_StockIssuedDuringPeriodSharesIssuanceOfSeries1ConvertiblePreferredStockNetOfOfferingCosts" xlink:label="loc_TARAStockIssuedDuringPeriodSharesIssuanceOfSeries1ConvertiblePreferredStockNetOfOfferingCosts_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TARAStockIssuedDuringPeriodSharesIssuanceOfSeries1ConvertiblePreferredStockNetOfOfferingCosts_60" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_60" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_60" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_StockIssuedDuringPeriodValueIssuedForSettlementOfRestrictedStockUnits" xlink:label="loc_TARAStockIssuedDuringPeriodValueIssuedForSettlementOfRestrictedStockUnits_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TARAStockIssuedDuringPeriodValueIssuedForSettlementOfRestrictedStockUnits_60" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_StockIssuedDuringPeriodSharesIssuedForSettlementOfRestrictedStockUnits" xlink:label="loc_TARAStockIssuedDuringPeriodSharesIssuedForSettlementOfRestrictedStockUnits_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TARAStockIssuedDuringPeriodSharesIssuedForSettlementOfRestrictedStockUnits_60" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_60" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_60" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross_60" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalOther_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalOther_60" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_60" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_StockIssueDuringPeriodvalueIssuedForCapitalRaise" xlink:label="loc_TARAStockIssueDuringPeriodvalueIssuedForCapitalRaise_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TARAStockIssueDuringPeriodvalueIssuedForCapitalRaise_60" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_Issuanceofcommonstockinseptembercapitalraiseshares" xlink:label="loc_TARAIssuanceofcommonstockinseptembercapitalraiseshares_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TARAIssuanceofcommonstockinseptembercapitalraiseshares_60" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProfitLoss_60" xlink:type="arc" order="26" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://artaratx.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Consolidated Statements Of Cash Flows" />
    <link:definitionLink xlink:type="extended" xlink:role="http://artaratx.com/role/BusinessLiquidityAndCapitalResources" xlink:title="00000007 - Disclosure - Business, Liquidity and Capital Resources" />
    <link:definitionLink xlink:type="extended" xlink:role="http://artaratx.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000008 - Disclosure - Summary of Significant Accounting Policies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://artaratx.com/role/ReverseMergerWithProtaraAndRecapitalization" xlink:title="00000009 - Disclosure - Reverse Merger with Protara and Recapitalization" />
    <link:definitionLink xlink:type="extended" xlink:role="http://artaratx.com/role/PropertyAndEquipment" xlink:title="00000010 - Disclosure - Property and Equipment" />
    <link:definitionLink xlink:type="extended" xlink:role="http://artaratx.com/role/AccruedExpenses" xlink:title="00000011 - Disclosure - Accrued Expenses" />
    <link:definitionLink xlink:type="extended" xlink:role="http://artaratx.com/role/Short-termDebt" xlink:title="00000012 - Disclosure - Short-Term Debt" />
    <link:definitionLink xlink:type="extended" xlink:role="http://artaratx.com/role/CommitmentsAndContingencies" xlink:title="00000013 - Disclosure - Commitments and Contingencies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://artaratx.com/role/StockholdersEquity" xlink:title="00000014 - Disclosure - Stockholders&apos; Equity" />
    <link:definitionLink xlink:type="extended" xlink:role="http://artaratx.com/role/Stock-basedCompensation" xlink:title="00000015 - Disclosure -  Stock-Based Compensation" />
    <link:definitionLink xlink:type="extended" xlink:role="http://artaratx.com/role/IncomeTaxes" xlink:title="00000016 - Disclosure -  Income Taxes" />
    <link:definitionLink xlink:type="extended" xlink:role="http://artaratx.com/role/EmployeeBenefitPlan" xlink:title="00000017 - Disclosure - Employee Benefit Plan" />
    <link:definitionLink xlink:type="extended" xlink:role="http://artaratx.com/role/Covid-19" xlink:title="00000018 - Disclosure - COVID-19" />
    <link:definitionLink xlink:type="extended" xlink:role="http://artaratx.com/role/SubsequentEvents" xlink:title="00000019 - Disclosure - Subsequent Events" />
    <link:definitionLink xlink:type="extended" xlink:role="http://artaratx.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000020 - Disclosure - Summary of Significant Accounting Policies (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://artaratx.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000021 - Disclosure - Summary of Significant Accounting Policies (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://artaratx.com/role/ReverseMergerWithProtaraAndRecapitalizationTables" xlink:title="00000022 - Disclosure - Reverse Merger with Protara and Recapitalization (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://artaratx.com/role/PropertyAndEquipmentTables" xlink:title="00000023 - Disclosure - Property and Equipment (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://artaratx.com/role/AccruedExpensesTables" xlink:title="00000024 - Disclosure - Accrued Expenses (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://artaratx.com/role/CommitmentsAndContingenciesTables" xlink:title="00000025 - Disclosure - Commitments and Contingencies (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://artaratx.com/role/Stock-basedCompensationTables" xlink:title="00000026 - Disclosure -  Stock-Based Compensation (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://artaratx.com/role/IncomeTaxesTables" xlink:title="00000027 - Disclosure -  Income Taxes (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://artaratx.com/role/BusinessLiquidityAndCapitalResourcesDetails" xlink:title="00000028 - Disclosure - Business, Liquidity and Capital Resources (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://artaratx.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:title="00000029 - Disclosure - Summary of Significant Accounting Policies (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockCompensationPlanMember" xlink:label="loc_us-gaapStockCompensationPlanMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapStockCompensationPlanMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="loc_us-gaapConvertibleDebtSecuritiesMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapConvertibleDebtSecuritiesMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_90" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://artaratx.com/role/SummaryOfSignificantAccountingPoliciesDetailsTextual" xlink:title="00000030 - Disclosure -  Summary of Significant Accounting Policies (Details Textual)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://artaratx.com/role/ReverseMergerWithProtaraAndRecapitalizationDetails" xlink:title="00000031 - Disclosure - Reverse Merger with Protara and Recapitalization (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://artaratx.com/role/ReverseMergerWithProtaraAndRecapitalizationDetails1" xlink:title="00000032 - Disclosure - Reverse Merger with Protara and Recapitalization (Details 1)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://artaratx.com/role/ReverseMergerWithProtaraAndRecapitalizationDetailsTextual" xlink:title="00000033 - Disclosure - Reverse Merger with Protara and Recapitalization (Details Textual)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_EquityIncentivePlanMember" xlink:label="loc_TARAEquityIncentivePlanMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_TARAEquityIncentivePlanMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_EquityIncentivePlanOneMember" xlink:label="loc_TARAEquityIncentivePlanOneMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_TARAEquityIncentivePlanOneMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapPrivatePlacementMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_SeriesAConvertiblePreferredStockMember" xlink:label="loc_TARASeriesAConvertiblePreferredStockMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_TARASeriesAConvertiblePreferredStockMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_MergerAgreementMember" xlink:label="loc_TARAMergerAgreementMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_TARAMergerAgreementMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_BusinessCombinationsTextualAbstract" xlink:label="loc_TARABusinessCombinationsTextualAbstract_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TARABusinessCombinationsTextualAbstract_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_TARABusinessCombinationsTextualAbstract_110" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_OutstandingReverseStock" xlink:label="loc_TARAOutstandingReverseStock_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_TARABusinessCombinationsTextualAbstract_110" xlink:to="loc_TARAOutstandingReverseStock_110" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionRatio1_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_TARABusinessCombinationsTextualAbstract_110" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionRatio1_110" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_SharesAvailableForIssuance" xlink:label="loc_TARASharesAvailableForIssuance_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_TARABusinessCombinationsTextualAbstract_110" xlink:to="loc_TARASharesAvailableForIssuance_110" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_SubscriptionAgreementDescription" xlink:label="loc_TARASubscriptionAgreementDescription_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_TARABusinessCombinationsTextualAbstract_110" xlink:to="loc_TARASubscriptionAgreementDescription_110" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaapConversionOfStockSharesIssued1_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_TARABusinessCombinationsTextualAbstract_110" xlink:to="loc_us-gaapConversionOfStockSharesIssued1_110" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaapConvertiblePreferredStockSharesIssuedUponConversion_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_TARABusinessCombinationsTextualAbstract_110" xlink:to="loc_us-gaapConvertiblePreferredStockSharesIssuedUponConversion_110" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_FairValueOfNetAssets" xlink:label="loc_TARAFairValueOfNetAssets_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_TARABusinessCombinationsTextualAbstract_110" xlink:to="loc_TARAFairValueOfNetAssets_110" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_DescriptionOfOwnershipRights" xlink:label="loc_TARADescriptionOfOwnershipRights_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_TARABusinessCombinationsTextualAbstract_110" xlink:to="loc_TARADescriptionOfOwnershipRights_110" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_PreMergerShares" xlink:label="loc_TARAPreMergerShares_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_TARABusinessCombinationsTextualAbstract_110" xlink:to="loc_TARAPreMergerShares_110" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_ReverseBusinessCombination" xlink:label="loc_TARAReverseBusinessCombination_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_TARABusinessCombinationsTextualAbstract_110" xlink:to="loc_TARAReverseBusinessCombination_110" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:label="loc_us-gaapGoodwillWrittenOffRelatedToSaleOfBusinessUnit_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_TARABusinessCombinationsTextualAbstract_110" xlink:to="loc_us-gaapGoodwillWrittenOffRelatedToSaleOfBusinessUnit_110" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:label="loc_us-gaapDeferredTaxLiabilitiesPrepaidExpenses_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_TARABusinessCombinationsTextualAbstract_110" xlink:to="loc_us-gaapDeferredTaxLiabilitiesPrepaidExpenses_110" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_TARABusinessCombinationsTextualAbstract_110" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_110" xlink:type="arc" order="14" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://artaratx.com/role/PropertyAndEquipmentDetails" xlink:title="00000034 - Disclosure - Property and Equipment (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_ComputerEquipmentAndSoftwareMember" xlink:label="loc_TARAComputerEquipmentAndSoftwareMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_TARAComputerEquipmentAndSoftwareMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_LaboratoryEquipmentMember" xlink:label="loc_TARALaboratoryEquipmentMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_TARALaboratoryEquipmentMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember_110" xlink:type="arc" order="111" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentOther" xlink:label="loc_us-gaapPropertyPlantAndEquipmentOther_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentOther_140" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross_140" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_140" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_140" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_140" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://artaratx.com/role/PropertyAndEquipmentDetailsTextual" xlink:title="00000035 - Disclosure - Property and Equipment (Details Textual)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_PropertyAndEquipmentTextualAbstract" xlink:label="loc_TARAPropertyAndEquipmentTextualAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TARAPropertyAndEquipmentTextualAbstract_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_TARAPropertyAndEquipmentTextualAbstract_70" xlink:to="loc_us-gaapDepreciation_70" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://artaratx.com/role/AccruedExpensesDetails" xlink:title="00000036 - Disclosure - Accrued Expenses (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://artaratx.com/role/Short-termDebtDetails" xlink:title="00000037 - Disclosure - Short-Term Debt (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://artaratx.com/role/CommitmentsAndContingenciesDetails" xlink:title="00000038 - Disclosure - Commitments and Contingencies (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaapBalanceSheetLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapBalanceSheetLocationAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaapBalanceSheetLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapBalanceSheetLocationAxis" xlink:to="loc_us-gaapBalanceSheetLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaapBalanceSheetLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBalanceSheetLocationAxis" xlink:to="loc_us-gaapBalanceSheetLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_RightOffUseAssetsMember" xlink:label="loc_TARARightOffUseAssetsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBalanceSheetLocationDomain" xlink:to="loc_TARARightOffUseAssetsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_RightOfUseLiabilityMember" xlink:label="loc_TARARightOfUseLiabilityMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBalanceSheetLocationDomain" xlink:to="loc_TARARightOfUseLiabilityMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_RightOfUseLeaseLiabilityLongTermMember" xlink:label="loc_TARARightOfUseLeaseLiabilityLongTermMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBalanceSheetLocationDomain" xlink:to="loc_TARARightOfUseLeaseLiabilityLongTermMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset_130" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_RightofuseLiability" xlink:label="loc_TARARightofuseLiability_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TARARightofuseLiability_130" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_RightofuseLeaseLiabilityLongterm" xlink:label="loc_TARARightofuseLeaseLiabilityLongterm_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TARARightofuseLeaseLiabilityLongterm_130" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaapOperatingLeaseCost_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseCost_130" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermLeaseCost" xlink:label="loc_us-gaapShortTermLeaseCost_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShortTermLeaseCost_130" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaapLeaseCost_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLeaseCost_130" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent_130" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1_130" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://artaratx.com/role/CommitmentsAndContingenciesDetails1" xlink:title="00000039 - Disclosure - Commitments and Contingencies (Details 1)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://artaratx.com/role/CommitmentsAndContingenciesDetailsTextual" xlink:title="00000040 - Disclosure - Commitments and Contingencies (Details Textual)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_TemporaryEmploymentAgreementMember" xlink:label="loc_TARATemporaryEmploymentAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_TARATemporaryEmploymentAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_ClinicalServicesAgreementsMember" xlink:label="loc_TARAClinicalServicesAgreementsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_TARAClinicalServicesAgreementsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_FeinsteinAgreementMember" xlink:label="loc_TARAFeinsteinAgreementMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_TARAFeinsteinAgreementMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_IowaAgreementMember" xlink:label="loc_TARAIowaAgreementMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_TARAIowaAgreementMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_ChugaiPharmaceuticalAgreementMember" xlink:label="loc_TARAChugaiPharmaceuticalAgreementMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_TARAChugaiPharmaceuticalAgreementMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_DrBuchmanMember" xlink:label="loc_TARADrBuchmanMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_TARADrBuchmanMember_150" xlink:type="arc" order="152" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_CommitmentsTextualAbstract" xlink:label="loc_TARACommitmentsTextualAbstract_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TARACommitmentsTextualAbstract_200" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_DescriptionOfAgreements" xlink:label="loc_TARADescriptionOfAgreements_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_TARACommitmentsTextualAbstract_200" xlink:to="loc_TARADescriptionOfAgreements_200" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_AnnualBaseSalary" xlink:label="loc_TARAAnnualBaseSalary_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_TARACommitmentsTextualAbstract_200" xlink:to="loc_TARAAnnualBaseSalary_200" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractualObligation" xlink:label="loc_us-gaapContractualObligation_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_TARACommitmentsTextualAbstract_200" xlink:to="loc_us-gaapContractualObligation_200" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BroadcastersLicenseAgreementCommitmentsDescription" xlink:label="loc_us-gaapBroadcastersLicenseAgreementCommitmentsDescription_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_TARACommitmentsTextualAbstract_200" xlink:to="loc_us-gaapBroadcastersLicenseAgreementCommitmentsDescription_200" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_RoyaltyPaymentPercentageOfNetSales" xlink:label="loc_TARARoyaltyPaymentPercentageOfNetSales_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_TARACommitmentsTextualAbstract_200" xlink:to="loc_TARARoyaltyPaymentPercentageOfNetSales_200" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArtistAdvancesAndRoyaltyGuaranteesCommitments" xlink:label="loc_us-gaapArtistAdvancesAndRoyaltyGuaranteesCommitments_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_TARACommitmentsTextualAbstract_200" xlink:to="loc_us-gaapArtistAdvancesAndRoyaltyGuaranteesCommitments_200" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_ResearchAndDevelopmentExpenses" xlink:label="loc_TARAResearchAndDevelopmentExpenses_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_TARACommitmentsTextualAbstract_200" xlink:to="loc_TARAResearchAndDevelopmentExpenses_200" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_PaymentOfAttorneysFees" xlink:label="loc_TARAPaymentOfAttorneysFees_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_TARACommitmentsTextualAbstract_200" xlink:to="loc_TARAPaymentOfAttorneysFees_200" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_GeneralAndAdministrativeExpenses" xlink:label="loc_TARAGeneralAndAdministrativeExpenses_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_TARACommitmentsTextualAbstract_200" xlink:to="loc_TARAGeneralAndAdministrativeExpenses_200" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToEmployees" xlink:label="loc_us-gaapPaymentsToEmployees_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_TARACommitmentsTextualAbstract_200" xlink:to="loc_us-gaapPaymentsToEmployees_200" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleLeasebackTransactionMonthlyRentalPayments" xlink:label="loc_us-gaapSaleLeasebackTransactionMonthlyRentalPayments_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_TARACommitmentsTextualAbstract_200" xlink:to="loc_us-gaapSaleLeasebackTransactionMonthlyRentalPayments_200" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaapProfessionalFees_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_TARACommitmentsTextualAbstract_200" xlink:to="loc_us-gaapProfessionalFees_200" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_CholineLicenseFee" xlink:label="loc_TARACholineLicenseFee_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_TARACommitmentsTextualAbstract_200" xlink:to="loc_TARACholineLicenseFee_200" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrentAndNoncurrent_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_TARACommitmentsTextualAbstract_200" xlink:to="loc_us-gaapAccruedLiabilitiesCurrentAndNoncurrent_200" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_TARACommitmentsTextualAbstract_200" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1_200" xlink:type="arc" order="15" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://artaratx.com/role/StockholdersEquityDetails" xlink:title="00000041 - Disclosure - Stockholders&apos; Equity (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_Series1PreferredStockMember" xlink:label="loc_TARASeries1PreferredStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_TARASeries1PreferredStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_UnderwrittenPublicOfferingMember" xlink:label="loc_TARAUnderwrittenPublicOfferingMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_TARAUnderwrittenPublicOfferingMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaapOverAllotmentOptionMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapOverAllotmentOptionMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_StockholdersEquityTextualAbstract" xlink:label="loc_TARAStockholdersEquityTextualAbstract_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TARAStockholdersEquityTextualAbstract_150" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_TARAStockholdersEquityTextualAbstract_150" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_150" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_TARAStockholdersEquityTextualAbstract_150" xlink:to="loc_us-gaapCommonStockSharesAuthorized_150" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_TARAStockholdersEquityTextualAbstract_150" xlink:to="loc_us-gaapCommonStockSharesIssued_150" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_TARAStockholdersEquityTextualAbstract_150" xlink:to="loc_us-gaapCommonStockSharesOutstanding_150" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_TARAStockholdersEquityTextualAbstract_150" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_150" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_TARAStockholdersEquityTextualAbstract_150" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_150" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_TARAStockholdersEquityTextualAbstract_150" xlink:to="loc_us-gaapPreferredStockSharesIssued_150" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_TARAStockholdersEquityTextualAbstract_150" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_150" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaapConversionOfStockSharesIssued1_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_TARAStockholdersEquityTextualAbstract_150" xlink:to="loc_us-gaapConversionOfStockSharesIssued1_150" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_TARAStockholdersEquityTextualAbstract_150" xlink:to="loc_us-gaapSharesIssuedPricePerShare_150" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_IncreaseOrDecreaseEquityPercentage" xlink:label="loc_TARAIncreaseOrDecreaseEquityPercentage_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_TARAStockholdersEquityTextualAbstract_150" xlink:to="loc_TARAIncreaseOrDecreaseEquityPercentage_150" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionPrice1_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_TARAStockholdersEquityTextualAbstract_150" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionPrice1_150" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_AggregateOfSharesOfCommonStock" xlink:label="loc_TARAAggregateOfSharesOfCommonStock_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_TARAStockholdersEquityTextualAbstract_150" xlink:to="loc_TARAAggregateOfSharesOfCommonStock_150" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_TARAStockholdersEquityTextualAbstract_150" xlink:to="loc_us-gaapSaleOfStockPricePerShare_150" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaapProceedsFromConvertibleDebt_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_TARAStockholdersEquityTextualAbstract_150" xlink:to="loc_us-gaapProceedsFromConvertibleDebt_150" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_NetProceeds" xlink:label="loc_TARANetProceeds_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_TARAStockholdersEquityTextualAbstract_150" xlink:to="loc_TARANetProceeds_150" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_TARAStockholdersEquityTextualAbstract_150" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_150" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_CommonStockIssuanceAndOutstandingPercentage" xlink:label="loc_TARACommonStockIssuanceAndOutstandingPercentage_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_TARAStockholdersEquityTextualAbstract_150" xlink:to="loc_TARACommonStockIssuanceAndOutstandingPercentage_150" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_MaximumAggregateOfferingPrice" xlink:label="loc_TARAMaximumAggregateOfferingPrice_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_TARAStockholdersEquityTextualAbstract_150" xlink:to="loc_TARAMaximumAggregateOfferingPrice_150" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_TARAStockholdersEquityTextualAbstract_150" xlink:to="loc_us-gaapSharesIssued_150" xlink:type="arc" order="20" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://artaratx.com/role/Stock-basedCompensationDetails" xlink:title="00000042 - Disclosure -  Stock-Based Compensation (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_RestrictedStockUnitsAbstract" xlink:label="loc_TARARestrictedStockUnitsAbstract_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TARARestrictedStockUnitsAbstract_20" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_TARARestrictedStockUnitsAbstract_20" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_20" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_TARARestrictedStockUnitsAbstract_20" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_20" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_TARARestrictedStockUnitsAbstract_20" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_20" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_TARARestrictedStockUnitsAbstract_20" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_20" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_WeightedAverageGrantDateFairValueOneAbstract" xlink:label="loc_TARAWeightedAverageGrantDateFairValueOneAbstract_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TARAWeightedAverageGrantDateFairValueOneAbstract_20" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_TARAWeightedAverageGrantDateFairValueOneAbstract_20" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_20" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_TARAWeightedAverageGrantDateFairValueOneAbstract_20" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_20" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_TARAWeightedAverageGrantDateFairValueOneAbstract_20" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_20" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_TARAWeightedAverageGrantDateFairValueOneAbstract_20" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_20" xlink:type="arc" order="10" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://artaratx.com/role/Stock-basedCompensationDetails1" xlink:title="00000043 - Disclosure -  Stock-Based Compensation (Details 1)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_StockOptionExercisePrice" xlink:label="loc_TARAStockOptionExercisePrice_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TARAStockOptionExercisePrice_120" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_120" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_120" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_120" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_120" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_120" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://artaratx.com/role/Stock-basedCompensationDetails2" xlink:title="00000044 - Disclosure -  Stock-Based Compensation (Details 2)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaapEmployeeStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapEmployeeStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_OptionsAbstract" xlink:label="loc_TARAOptionsAbstract_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TARAOptionsAbstract_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_TARAOptionsAbstract_30" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_TARAOptionsAbstract_30" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_30" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_TARAOptionsAbstract_30" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_30" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_TARAOptionsAbstract_30" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_30" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberExercisable" xlink:label="loc_TARAShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberExercisable_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_TARAOptionsAbstract_30" xlink:to="loc_TARAShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberExercisable_30" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_WeightedAverageGrantDateFairValueAbstract" xlink:label="loc_TARAWeightedAverageGrantDateFairValueAbstract_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TARAWeightedAverageGrantDateFairValueAbstract_30" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_TARAWeightedAverageGrantDateFairValueAbstract_30" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_30" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_TARAWeightedAverageGrantDateFairValueAbstract_30" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_30" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_TARAShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageGrantDateFairValue_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_TARAWeightedAverageGrantDateFairValueAbstract_30" xlink:to="loc_TARAShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageGrantDateFairValue_30" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_TARAWeightedAverageGrantDateFairValueAbstract_30" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_30" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercisable" xlink:label="loc_TARASharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercisable_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_TARAWeightedAverageGrantDateFairValueAbstract_30" xlink:to="loc_TARASharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercisable_30" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_WeightedAverageExercisePriceAbstract" xlink:label="loc_TARAWeightedAverageExercisePriceAbstract_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TARAWeightedAverageExercisePriceAbstract_30" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_TARAWeightedAverageExercisePriceAbstract_30" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_30" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_TARAWeightedAverageExercisePriceAbstract_30" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_30" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_TARAWeightedAverageExercisePriceAbstract_30" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_30" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_TARAWeightedAverageExercisePriceAbstract_30" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_30" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceExercisable" xlink:label="loc_TARAShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceExercisable_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_TARAWeightedAverageExercisePriceAbstract_30" xlink:to="loc_TARAShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceExercisable_30" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_WeightedAverageRemainingContractualTermYearsAbstract" xlink:label="loc_TARAWeightedAverageRemainingContractualTermYearsAbstract_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TARAWeightedAverageRemainingContractualTermYearsAbstract_30" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTerm1" xlink:label="loc_TARAShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTerm1_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_TARAWeightedAverageRemainingContractualTermYearsAbstract_30" xlink:to="loc_TARAShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTerm1_30" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTermGranted" xlink:label="loc_TARAShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTermGranted_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_TARAWeightedAverageRemainingContractualTermYearsAbstract_30" xlink:to="loc_TARAShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTermGranted_30" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTerm2" xlink:label="loc_TARAShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTerm2_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_TARAWeightedAverageRemainingContractualTermYearsAbstract_30" xlink:to="loc_TARAShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTerm2_30" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTermExercisable" xlink:label="loc_TARAShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTermExercisable_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_TARAWeightedAverageRemainingContractualTermYearsAbstract_30" xlink:to="loc_TARAShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTermExercisable_30" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_AggregateIntrinsicValueAbstract" xlink:label="loc_TARAAggregateIntrinsicValueAbstract_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TARAAggregateIntrinsicValueAbstract_30" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_TARAAggregateIntrinsicValueAbstract_30" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_30" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted" xlink:label="loc_TARASharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_TARAAggregateIntrinsicValueAbstract_30" xlink:to="loc_TARASharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted_30" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeited" xlink:label="loc_TARASharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeited_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_TARAAggregateIntrinsicValueAbstract_30" xlink:to="loc_TARASharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeited_30" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisable" xlink:label="loc_TARASharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisable_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_TARAAggregateIntrinsicValueAbstract_30" xlink:to="loc_TARASharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisable_30" xlink:type="arc" order="31" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://artaratx.com/role/Stock-basedCompensationDetails3" xlink:title="00000045 - Disclosure -  Stock-Based Compensation (Details 3)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensation_90" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://artaratx.com/role/Stock-basedCompensationDetails4" xlink:title="00000046 - Disclosure -  Stock-Based Compensation (Details 4)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensation_70" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://artaratx.com/role/Stock-basedCompensationDetailsTextual" xlink:title="00000047 - Disclosure -  Stock-Based Compensation (Details Textual)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_TwentyFourteenEmployeeStockPurchasePlanMember" xlink:label="loc_TARATwentyFourteenEmployeeStockPurchasePlanMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_TARATwentyFourteenEmployeeStockPurchasePlanMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_TwentyFourteenEquityIncentivePlanMember" xlink:label="loc_TARATwentyFourteenEquityIncentivePlanMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_TARATwentyFourteenEquityIncentivePlanMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_TwentyTwentyInducementPlanMember" xlink:label="loc_TARATwentyTwentyInducementPlanMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_TARATwentyTwentyInducementPlanMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_TwentySeventeenEquityIncentivePlanMember" xlink:label="loc_TARATwentySeventeenEquityIncentivePlanMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_TARATwentySeventeenEquityIncentivePlanMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_0" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_10" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_110" xlink:type="arc" order="111" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_DirectorsOneMember" xlink:label="loc_TARADirectorsOneMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_TARADirectorsOneMember_110" xlink:type="arc" order="112" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_DirectorsTwoMember" xlink:label="loc_TARADirectorsTwoMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_TARADirectorsTwoMember_130" xlink:type="arc" order="132" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_ConsultantMember" xlink:label="loc_TARAConsultantMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_TARAConsultantMember_140" xlink:type="arc" order="142" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_EmployeesMember" xlink:label="loc_TARAEmployeesMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_TARAEmployeesMember_150" xlink:type="arc" order="152" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_BoardOfDirectorsChairmanMember" xlink:label="loc_srtBoardOfDirectorsChairmanMember_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtBoardOfDirectorsChairmanMember_200" xlink:type="arc" order="202" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaapEmployeeStockMember_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapEmployeeStockMember_280" xlink:type="arc" order="281" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_StockBasedCompensationTextualAbstract" xlink:label="loc_TARAStockBasedCompensationTextualAbstract_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TARAStockBasedCompensationTextualAbstract_320" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_StocksIssuedDuringPeriodValueNewIssues" xlink:label="loc_TARAStocksIssuedDuringPeriodValueNewIssues_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_TARAStockBasedCompensationTextualAbstract_320" xlink:to="loc_TARAStocksIssuedDuringPeriodValueNewIssues_320" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_SharesAvailableForIssuance" xlink:label="loc_TARASharesAvailableForIssuance_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_TARAStockBasedCompensationTextualAbstract_320" xlink:to="loc_TARASharesAvailableForIssuance_320" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockDescriptionOfTransaction" xlink:label="loc_us-gaapSaleOfStockDescriptionOfTransaction_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_TARAStockBasedCompensationTextualAbstract_320" xlink:to="loc_us-gaapSaleOfStockDescriptionOfTransaction_320" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_TARAStockBasedCompensationTextualAbstract_320" xlink:to="loc_us-gaapCommonStockSharesAuthorized_320" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_TARAStockBasedCompensationTextualAbstract_320" xlink:to="loc_us-gaapCommonStockSharesIssued_320" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_VestedOptionsPercentage" xlink:label="loc_TARAVestedOptionsPercentage_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_TARAStockBasedCompensationTextualAbstract_320" xlink:to="loc_TARAVestedOptionsPercentage_320" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_TARAStockBasedCompensationTextualAbstract_320" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_320" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_UnamortizedValueOfRsus" xlink:label="loc_TARAUnamortizedValueOfRsus_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_TARAStockBasedCompensationTextualAbstract_320" xlink:to="loc_TARAUnamortizedValueOfRsus_320" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_NumberOfSharesRestrictedStock" xlink:label="loc_TARANumberOfSharesRestrictedStock_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_TARAStockBasedCompensationTextualAbstract_320" xlink:to="loc_TARANumberOfSharesRestrictedStock_320" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_WeightedAverageGrantDateFairValue" xlink:label="loc_TARAWeightedAverageGrantDateFairValue_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_TARAStockBasedCompensationTextualAbstract_320" xlink:to="loc_TARAWeightedAverageGrantDateFairValue_320" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_WeightedAverageRemainingAmortizationPeriod" xlink:label="loc_TARAWeightedAverageRemainingAmortizationPeriod_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_TARAStockBasedCompensationTextualAbstract_320" xlink:to="loc_TARAWeightedAverageRemainingAmortizationPeriod_320" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_OptionsDescription" xlink:label="loc_TARAOptionsDescription_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_TARAStockBasedCompensationTextualAbstract_320" xlink:to="loc_TARAOptionsDescription_320" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_UnamortizedValueOfStock" xlink:label="loc_TARAUnamortizedValueOfStock_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_TARAStockBasedCompensationTextualAbstract_320" xlink:to="loc_TARAUnamortizedValueOfStock_320" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_ShareBasedCompensationGrantDateFairValue" xlink:label="loc_TARAShareBasedCompensationGrantDateFairValue_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_TARAStockBasedCompensationTextualAbstract_320" xlink:to="loc_TARAShareBasedCompensationGrantDateFairValue_320" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_TARAStockBasedCompensationTextualAbstract_320" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_320" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="loc_us-gaapOtherResearchAndDevelopmentExpense_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_TARAStockBasedCompensationTextualAbstract_320" xlink:to="loc_us-gaapOtherResearchAndDevelopmentExpense_320" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_IncrementalValue" xlink:label="loc_TARAIncrementalValue_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_TARAStockBasedCompensationTextualAbstract_320" xlink:to="loc_TARAIncrementalValue_320" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_TARAStockBasedCompensationTextualAbstract_320" xlink:to="loc_us-gaapSaleOfStockPricePerShare_320" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_VestPeriod" xlink:label="loc_TARAVestPeriod_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_TARAStockBasedCompensationTextualAbstract_320" xlink:to="loc_TARAVestPeriod_320" xlink:type="arc" order="19" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://artaratx.com/role/IncomeTaxesDetails" xlink:title="00000048 - Disclosure -  Income Taxes (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://artaratx.com/role/IncomeTaxesDetails1" xlink:title="00000049 - Disclosure -  Income Taxes (Details 1)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://artaratx.com/role/IncomeTaxesDetails2" xlink:title="00000050 - Disclosure -  Income Taxes (Details 2)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://artaratx.com/role/IncomeTaxesDetailsTextual" xlink:title="00000051 - Disclosure -  Income Taxes (Details Textual)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://artaratx.com/role/EmployeeBenefitPlanDetails" xlink:title="00000052 - Disclosure - Employee Benefit Plan (Details)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>18
<FILENAME>tara-20201231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoXBRL; Version: 5.6b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Source; Value: tara%2D20201231.xfr; Date: 2021%2D03%2D10T22:42:15Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_Series1ConvertiblePreferredStockMember" xlink:label="TARA_Series1ConvertiblePreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_Series1ConvertiblePreferredStockMember" xlink:to="TARA_Series1ConvertiblePreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_Series1ConvertiblePreferredStockMember_lbl" xml:lang="en-US">Series 1 Convertible Preferred Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_EquityIncentivePlanMember" xlink:label="TARA_EquityIncentivePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_EquityIncentivePlanMember" xlink:to="TARA_EquityIncentivePlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_EquityIncentivePlanMember_lbl" xml:lang="en-US">2017 Equity Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US">Private Placement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_SeriesAConvertiblePreferredStockMember" xlink:label="TARA_SeriesAConvertiblePreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_SeriesAConvertiblePreferredStockMember" xlink:to="TARA_SeriesAConvertiblePreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_SeriesAConvertiblePreferredStockMember_lbl" xml:lang="en-US">Series A Convertible Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_RightOffUseAssetsMember" xlink:label="TARA_RightOffUseAssetsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_RightOffUseAssetsMember" xlink:to="TARA_RightOffUseAssetsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_RightOffUseAssetsMember_lbl" xml:lang="en-US">Right-of-use assets [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_RightOfUseLiabilityMember" xlink:label="TARA_RightOfUseLiabilityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_RightOfUseLiabilityMember" xlink:to="TARA_RightOfUseLiabilityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_RightOfUseLiabilityMember_lbl" xml:lang="en-US">Right-of-use liability [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_RightOfUseLeaseLiabilityLongTermMember" xlink:label="TARA_RightOfUseLeaseLiabilityLongTermMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_RightOfUseLeaseLiabilityLongTermMember" xlink:to="TARA_RightOfUseLeaseLiabilityLongTermMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_RightOfUseLeaseLiabilityLongTermMember_lbl" xml:lang="en-US">Right-of-use lease liability, long-term [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_ClinicalServicesAgreementsMember" xlink:label="TARA_ClinicalServicesAgreementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_ClinicalServicesAgreementsMember" xlink:to="TARA_ClinicalServicesAgreementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_ClinicalServicesAgreementsMember_lbl" xml:lang="en-US">Clinical Services Agreements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_FeinsteinAgreementMember" xlink:label="TARA_FeinsteinAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_FeinsteinAgreementMember" xlink:to="TARA_FeinsteinAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_FeinsteinAgreementMember_lbl" xml:lang="en-US">Feinstein Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_IowaAgreementMember" xlink:label="TARA_IowaAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_IowaAgreementMember" xlink:to="TARA_IowaAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_IowaAgreementMember_lbl" xml:lang="en-US">Iowa Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_ChugaiPharmaceuticalAgreementMember" xlink:label="TARA_ChugaiPharmaceuticalAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_ChugaiPharmaceuticalAgreementMember" xlink:to="TARA_ChugaiPharmaceuticalAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_ChugaiPharmaceuticalAgreementMember_lbl" xml:lang="en-US">Chugai Pharmaceutical Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockMember" xlink:to="us-gaap_EmployeeStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockMember_lbl" xml:lang="en-US">Employee Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US">Restricted Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_TwentyTwentyInducementPlanMember" xlink:label="TARA_TwentyTwentyInducementPlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_TwentyTwentyInducementPlanMember" xlink:to="TARA_TwentyTwentyInducementPlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_TwentyTwentyInducementPlanMember_lbl" xml:lang="en-US">2020 Inducement Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_TwentyFourteenEmployeeStockPurchasePlanMember" xlink:label="TARA_TwentyFourteenEmployeeStockPurchasePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_TwentyFourteenEmployeeStockPurchasePlanMember" xlink:to="TARA_TwentyFourteenEmployeeStockPurchasePlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_TwentyFourteenEmployeeStockPurchasePlanMember_lbl" xml:lang="en-US">2014 Employee Stock Purchase Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_MergerAgreementMember" xlink:label="TARA_MergerAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_MergerAgreementMember" xlink:to="TARA_MergerAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_MergerAgreementMember_lbl" xml:lang="en-US">Merger Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_EquityIncentivePlanOneMember" xlink:label="TARA_EquityIncentivePlanOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_EquityIncentivePlanOneMember" xlink:to="TARA_EquityIncentivePlanOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_EquityIncentivePlanOneMember_lbl" xml:lang="en-US">2014 Equity Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_TwentySeventeenEquityIncentivePlanMember" xlink:label="TARA_TwentySeventeenEquityIncentivePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_TwentySeventeenEquityIncentivePlanMember" xlink:to="TARA_TwentySeventeenEquityIncentivePlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="TARA_TwentySeventeenEquityIncentivePlanMember_lbl" xml:lang="en-US">2017 Equity Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_TwentyFourteenEquityIncentivePlanMember" xlink:label="TARA_TwentyFourteenEquityIncentivePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_TwentyFourteenEquityIncentivePlanMember" xlink:to="TARA_TwentyFourteenEquityIncentivePlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="TARA_TwentyFourteenEquityIncentivePlanMember_lbl" xml:lang="en-US">2014 Equity Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title of Individual [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_DrBuchmanMember" xlink:label="TARA_DrBuchmanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_DrBuchmanMember" xlink:to="TARA_DrBuchmanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_DrBuchmanMember_lbl" xml:lang="en-US">Dr. Buchman [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_Series1PreferredStockMember" xlink:label="TARA_Series1PreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_Series1PreferredStockMember" xlink:to="TARA_Series1PreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="TARA_Series1PreferredStockMember_lbl" xml:lang="en-US">Series 1 Convertible Preferred Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_TemporaryEmploymentAgreementMember" xlink:label="TARA_TemporaryEmploymentAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_TemporaryEmploymentAgreementMember" xlink:to="TARA_TemporaryEmploymentAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_TemporaryEmploymentAgreementMember_lbl" xml:lang="en-US">Temporary Employment Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockCompensationPlanMember" xlink:label="us-gaap_StockCompensationPlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockCompensationPlanMember" xlink:to="us-gaap_StockCompensationPlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockCompensationPlanMember_lbl" xml:lang="en-US">Share-based Payment Arrangement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtSecuritiesMember" xlink:to="us-gaap_ConvertibleDebtSecuritiesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember_lbl" xml:lang="en-US">Convertible Debt Securities [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_UnderwrittenPublicOfferingMember" xlink:label="TARA_UnderwrittenPublicOfferingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_UnderwrittenPublicOfferingMember" xlink:to="TARA_UnderwrittenPublicOfferingMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_UnderwrittenPublicOfferingMember_lbl" xml:lang="en-US">Underwritten Public Offering [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_ComputerEquipmentAndSoftwareMember" xlink:label="TARA_ComputerEquipmentAndSoftwareMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_ComputerEquipmentAndSoftwareMember" xlink:to="TARA_ComputerEquipmentAndSoftwareMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_ComputerEquipmentAndSoftwareMember_lbl" xml:lang="en-US">Computer Equipment and Software [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US">Furniture, fixtures and other [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_LaboratoryEquipmentMember" xlink:label="TARA_LaboratoryEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_LaboratoryEquipmentMember" xlink:to="TARA_LaboratoryEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_LaboratoryEquipmentMember_lbl" xml:lang="en-US">Laboratory equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold improvements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_DirectorsOneMember" xlink:label="TARA_DirectorsOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_DirectorsOneMember" xlink:to="TARA_DirectorsOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_DirectorsOneMember_lbl" xml:lang="en-US">Directors One Member</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_DirectorsTwoMember" xlink:label="TARA_DirectorsTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_DirectorsTwoMember" xlink:to="TARA_DirectorsTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_DirectorsTwoMember_lbl" xml:lang="en-US">Directors OneMember</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_ConsultantMember" xlink:label="TARA_ConsultantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_ConsultantMember" xlink:to="TARA_ConsultantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_ConsultantMember_lbl" xml:lang="en-US">Consultant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_EmployeesMember" xlink:label="TARA_EmployeesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_EmployeesMember" xlink:to="TARA_EmployeesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_EmployeesMember_lbl" xml:lang="en-US">Employees [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_BoardOfDirectorsChairmanMember" xlink:label="srt_BoardOfDirectorsChairmanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_BoardOfDirectorsChairmanMember" xlink:to="srt_BoardOfDirectorsChairmanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_BoardOfDirectorsChairmanMember_lbl" xml:lang="en-US">Board Of Directors [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_DocumentAndEntityInformationAbstract" xlink:label="TARA_DocumentAndEntityInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_DocumentAndEntityInformationAbstract" xlink:to="TARA_DocumentAndEntityInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US">Document and Entity Information [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashCurrent" xlink:to="us-gaap_RestrictedCashCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashCurrent_lbl" xml:lang="en-US">Restricted cash</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOfferingCosts" xlink:to="us-gaap_DeferredOfferingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredOfferingCosts_lbl" xml:lang="en-US">Deferred offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xml:lang="en-US">Non-current assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndInvestments" xlink:label="us-gaap_RestrictedCashAndInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndInvestments" xlink:to="us-gaap_RestrictedCashAndInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndInvestments_lbl" xml:lang="en-US">Restricted cash, long-term</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Goodwill_lbl" xml:lang="en-US">Goodwill</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Stockholders' Equity (Deficit)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating lease liability, current</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">Non-current liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating lease liability, long-term</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and Contingencies (Note 7)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders' Equity (Deficit)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred Stock, $0.001 par value, authorized 10,000,000 shares: Series 1 Convertible Preferred Stock, 8,028 and 0 shares authorized at December 31, 2020 and 2019, respectively, 8,027 and 0 shares issued and outstanding as of December 31, 2020 and 2019, respectively.</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common Stock, $0.001 par value, authorized 100,000,000 shares: Common Stock, 11,211,840 and 2,627,533 shares issued and outstanding as of December 31, 2020 and 2019, respectively.</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional Paid in Capital</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated Deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total Stockholders' Equity (Deficit)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total Liabilities and Stockholders' Equity (Deficit)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expense:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research &amp; development</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General &amp; administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating loss</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other income, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl" xml:lang="en-US">Interest income, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other income, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net Loss</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US">Weighted Average Shares Outstanding, basic and diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">Net loss per share, basic and diluted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_IssuanceOfCommonStockInArtaraPrivatePlacementNetOfOfferingCosts" xlink:label="TARA_IssuanceOfCommonStockInArtaraPrivatePlacementNetOfOfferingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_IssuanceOfCommonStockInArtaraPrivatePlacementNetOfOfferingCosts" xlink:to="TARA_IssuanceOfCommonStockInArtaraPrivatePlacementNetOfOfferingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_IssuanceOfCommonStockInArtaraPrivatePlacementNetOfOfferingCosts_lbl" xml:lang="en-US">Issuance of Common Stock in ArTara Private Placement, net of offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_IssuanceOfCommonStockInArtaraPrivatePlacementNetOfOfferingCostsShares" xlink:label="TARA_IssuanceOfCommonStockInArtaraPrivatePlacementNetOfOfferingCostsShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_IssuanceOfCommonStockInArtaraPrivatePlacementNetOfOfferingCostsShares" xlink:to="TARA_IssuanceOfCommonStockInArtaraPrivatePlacementNetOfOfferingCostsShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_IssuanceOfCommonStockInArtaraPrivatePlacementNetOfOfferingCostsShares_lbl" xml:lang="en-US">Issuance of Common Stock in ArTara Private Placement, net of offering costs, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Issuance of Common Stock in Proteon Private Placement, net of offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Issuance of Common Stock in Proteon Private Placement, net of offering costs, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_IssuanceOfSeries1ConvertiblePreferredStockInProteonPrivatePlacementNetOfOfferingCosts" xlink:label="TARA_IssuanceOfSeries1ConvertiblePreferredStockInProteonPrivatePlacementNetOfOfferingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_IssuanceOfSeries1ConvertiblePreferredStockInProteonPrivatePlacementNetOfOfferingCosts" xlink:to="TARA_IssuanceOfSeries1ConvertiblePreferredStockInProteonPrivatePlacementNetOfOfferingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_IssuanceOfSeries1ConvertiblePreferredStockInProteonPrivatePlacementNetOfOfferingCosts_lbl" xml:lang="en-US">Issuance of Series 1 Convertible Preferred Stock in Proteon Private Placement, net of offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_IssuanceOfSeries1ConvertiblePreferredStockInProteonPrivatePlacementNetOfOfferingCostsShares" xlink:label="TARA_IssuanceOfSeries1ConvertiblePreferredStockInProteonPrivatePlacementNetOfOfferingCostsShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_IssuanceOfSeries1ConvertiblePreferredStockInProteonPrivatePlacementNetOfOfferingCostsShares" xlink:to="TARA_IssuanceOfSeries1ConvertiblePreferredStockInProteonPrivatePlacementNetOfOfferingCostsShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_IssuanceOfSeries1ConvertiblePreferredStockInProteonPrivatePlacementNetOfOfferingCostsShares_lbl" xml:lang="en-US">Issuance of Series 1 Convertible Preferred Stock in Proteon Private Placement, net of offering costs, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" xml:lang="en-US">Reverse business combination</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xml:lang="en-US">Reverse business combination, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xml:lang="en-US">Issuance of Common Stock in Common Offering, net of offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US">Issuance of Common Stock in Common Offering, net of offering costs, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_StockIssuedDuringPeriodValueIssuanceOfSeries1ConvertiblePreferredStockNetOfOfferingCosts" xlink:label="TARA_StockIssuedDuringPeriodValueIssuanceOfSeries1ConvertiblePreferredStockNetOfOfferingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_StockIssuedDuringPeriodValueIssuanceOfSeries1ConvertiblePreferredStockNetOfOfferingCosts" xlink:to="TARA_StockIssuedDuringPeriodValueIssuanceOfSeries1ConvertiblePreferredStockNetOfOfferingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_StockIssuedDuringPeriodValueIssuanceOfSeries1ConvertiblePreferredStockNetOfOfferingCosts_lbl" xml:lang="en-US">Issuance of Series 1 Convertible Preferred Stock in Preferred Offering, net of offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_StockIssuedDuringPeriodSharesIssuanceOfSeries1ConvertiblePreferredStockNetOfOfferingCosts" xlink:label="TARA_StockIssuedDuringPeriodSharesIssuanceOfSeries1ConvertiblePreferredStockNetOfOfferingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_StockIssuedDuringPeriodSharesIssuanceOfSeries1ConvertiblePreferredStockNetOfOfferingCosts" xlink:to="TARA_StockIssuedDuringPeriodSharesIssuanceOfSeries1ConvertiblePreferredStockNetOfOfferingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_StockIssuedDuringPeriodSharesIssuanceOfSeries1ConvertiblePreferredStockNetOfOfferingCosts_lbl" xml:lang="en-US">Issuance of Series 1 Convertible Preferred Stock in Preferred Offering, net of offering costs, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Issuance of Common Stock in Common Offering (Underwriters Overallotment Option), net of offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance of Common Stock in Common Offering (Underwriters Overallotment Option), net of offering costs, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_StockIssuedDuringPeriodValueIssuedForSettlementOfRestrictedStockUnits" xlink:label="TARA_StockIssuedDuringPeriodValueIssuedForSettlementOfRestrictedStockUnits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_StockIssuedDuringPeriodValueIssuedForSettlementOfRestrictedStockUnits" xlink:to="TARA_StockIssuedDuringPeriodValueIssuedForSettlementOfRestrictedStockUnits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_StockIssuedDuringPeriodValueIssuedForSettlementOfRestrictedStockUnits_lbl" xml:lang="en-US">Settlement of restricted stock units</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_StockIssuedDuringPeriodSharesIssuedForSettlementOfRestrictedStockUnits" xlink:label="TARA_StockIssuedDuringPeriodSharesIssuedForSettlementOfRestrictedStockUnits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_StockIssuedDuringPeriodSharesIssuedForSettlementOfRestrictedStockUnits" xlink:to="TARA_StockIssuedDuringPeriodSharesIssuedForSettlementOfRestrictedStockUnits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_StockIssuedDuringPeriodSharesIssuedForSettlementOfRestrictedStockUnits_lbl" xml:lang="en-US">Settlement of restricted stock units, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Exercise of stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Exercise of stock options, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xml:lang="en-US">Stock-based compensation - restricted stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_lbl" xml:lang="en-US">Stock-based compensation - restricted stock units</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Stock-based compensation - stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_StockIssueDuringPeriodvalueIssuedForCapitalRaise" xlink:label="TARA_StockIssueDuringPeriodvalueIssuedForCapitalRaise" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_StockIssueDuringPeriodvalueIssuedForCapitalRaise" xlink:to="TARA_StockIssueDuringPeriodvalueIssuedForCapitalRaise_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_StockIssueDuringPeriodvalueIssuedForCapitalRaise_lbl" xml:lang="en-US">Issuance of common stock in September capital raise</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_Issuanceofcommonstockinseptembercapitalraiseshares" xlink:label="TARA_Issuanceofcommonstockinseptembercapitalraiseshares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_Issuanceofcommonstockinseptembercapitalraiseshares" xlink:to="TARA_Issuanceofcommonstockinseptembercapitalraiseshares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_Issuanceofcommonstockinseptembercapitalraiseshares_lbl" xml:lang="en-US">Issuance of common stock in September capital raise,shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities:</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_AmortizationOfOperatingLeaseRightsofuseAsset" xlink:label="TARA_AmortizationOfOperatingLeaseRightsofuseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_AmortizationOfOperatingLeaseRightsofuseAsset" xlink:to="TARA_AmortizationOfOperatingLeaseRightsofuseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_AmortizationOfOperatingLeaseRightsofuseAsset_lbl" xml:lang="en-US">Amortization of operating lease right-of-use asset</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xml:lang="en-US">Other Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US">Accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_IncreaseDecreaseRightofuseLiability" xlink:label="TARA_IncreaseDecreaseRightofuseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_IncreaseDecreaseRightofuseLiability" xlink:to="TARA_IncreaseDecreaseRightofuseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="TARA_IncreaseDecreaseRightofuseLiability_lbl" xml:lang="en-US">Right-of-use liability</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from investing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_CashAndRestrictedCashAcquiredInConnectionWithReverseMergerWithArtaraTherapeuticsInc." xlink:label="TARA_CashAndRestrictedCashAcquiredInConnectionWithReverseMergerWithArtaraTherapeuticsInc." />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_CashAndRestrictedCashAcquiredInConnectionWithReverseMergerWithArtaraTherapeuticsInc." xlink:to="TARA_CashAndRestrictedCashAcquiredInConnectionWithReverseMergerWithArtaraTherapeuticsInc._lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_CashAndRestrictedCashAcquiredInConnectionWithReverseMergerWithArtaraTherapeuticsInc._lbl" xml:lang="en-US">Cash and restricted cash acquired in connection with the reverse merger with ArTara Therapeutics, Inc.</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash provided by/(used in) investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US">Proceeds from - ArTara Private Placement, net of offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_ProceedsFromProteonPrivatePlacementNetOfOfferingCosts" xlink:label="TARA_ProceedsFromProteonPrivatePlacementNetOfOfferingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_ProceedsFromProteonPrivatePlacementNetOfOfferingCosts" xlink:to="TARA_ProceedsFromProteonPrivatePlacementNetOfOfferingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_ProceedsFromProteonPrivatePlacementNetOfOfferingCosts_lbl" xml:lang="en-US">Proceeds from - Common Stock in Proteon Private Placement, net of offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xml:lang="en-US">Proceeds from - Series&#160;1&#160;Convertible Preferred Stock in Proteon Private Placement, net of offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_ProceedsFromIssuancesOfConvertiblePreferredStock" xlink:label="TARA_ProceedsFromIssuancesOfConvertiblePreferredStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_ProceedsFromIssuancesOfConvertiblePreferredStock" xlink:to="TARA_ProceedsFromIssuancesOfConvertiblePreferredStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_ProceedsFromIssuancesOfConvertiblePreferredStock_lbl" xml:lang="en-US">Proceeds from Common Offering, net of offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from Preferred Offering, net of offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_ProceedsFromUnderwritersOverallotmentOption" xlink:label="TARA_ProceedsFromUnderwritersOverallotmentOption" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_ProceedsFromUnderwritersOverallotmentOption" xlink:to="TARA_ProceedsFromUnderwritersOverallotmentOption_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_ProceedsFromUnderwritersOverallotmentOption_lbl" xml:lang="en-US">Proceeds from Underwriters Overallotment Option</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfShortTermDebt" xlink:label="us-gaap_RepaymentsOfShortTermDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfShortTermDebt" xlink:to="us-gaap_RepaymentsOfShortTermDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfShortTermDebt_lbl" xml:lang="en-US">Repayments under short-term debt</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from the exercise of stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xml:lang="en-US">Proceeds from private placements</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US">Net increase/(decrease) in cash and cash equivalents and restricted cash</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash and cash equivalents and restricted cash - beginning of year</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xml:lang="en-US">Cash and cash equivalents and restricted cash - end of year</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract_lbl" xml:lang="en-US">Reconciliation of cash and cash equivalents and restricted cash to the consolidated balance sheets:</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_2_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashCurrent" xlink:to="us-gaap_RestrictedCashCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_RestrictedCashCurrent_2_lbl" xml:lang="en-US">Restricted cash</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xml:lang="en-US">Restricted cash, long-term</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_ReconciliationOfRestrictedCashAndCashEquivalents" xlink:label="TARA_ReconciliationOfRestrictedCashAndCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_ReconciliationOfRestrictedCashAndCashEquivalents" xlink:to="TARA_ReconciliationOfRestrictedCashAndCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_ReconciliationOfRestrictedCashAndCashEquivalents_lbl" xml:lang="en-US">Cash and cash equivalents and restricted cash</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental cash flow information</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_CashPaidForAbstract" xlink:label="TARA_CashPaidForAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_CashPaidForAbstract" xlink:to="TARA_CashPaidForAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_CashPaidForAbstract_lbl" xml:lang="en-US">Cash paid for:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="us-gaap_IncomeTaxesPaid" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaid" xlink:to="us-gaap_IncomeTaxesPaid_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaid_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">Non-cash investing and financing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_DeferredOfferingCostsRecordedInAccruedExpenses" xlink:label="TARA_DeferredOfferingCostsRecordedInAccruedExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_DeferredOfferingCostsRecordedInAccruedExpenses" xlink:to="TARA_DeferredOfferingCostsRecordedInAccruedExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_DeferredOfferingCostsRecordedInAccruedExpenses_lbl" xml:lang="en-US">Deferred offering costs recorded in accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_DeferredOfferingCostsRecognizedThatWerePreviouslyRecordedInAccruedExpenses" xlink:label="TARA_DeferredOfferingCostsRecognizedThatWerePreviouslyRecordedInAccruedExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_DeferredOfferingCostsRecognizedThatWerePreviouslyRecordedInAccruedExpenses" xlink:to="TARA_DeferredOfferingCostsRecognizedThatWerePreviouslyRecordedInAccruedExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_DeferredOfferingCostsRecognizedThatWerePreviouslyRecordedInAccruedExpenses_lbl" xml:lang="en-US">Deferred offering costs recognized that were previously recorded in accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_PurchaseOfInsuranceAgreementWithNotesPayable" xlink:label="TARA_PurchaseOfInsuranceAgreementWithNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_PurchaseOfInsuranceAgreementWithNotesPayable" xlink:to="TARA_PurchaseOfInsuranceAgreementWithNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_PurchaseOfInsuranceAgreementWithNotesPayable_lbl" xml:lang="en-US">Purchase of insurance agreement with notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_CommonStockIssuedInConnectionWithReverseMerger" xlink:label="TARA_CommonStockIssuedInConnectionWithReverseMerger" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_CommonStockIssuedInConnectionWithReverseMerger" xlink:to="TARA_CommonStockIssuedInConnectionWithReverseMerger_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_CommonStockIssuedInConnectionWithReverseMerger_lbl" xml:lang="en-US">Common stock issued in connection with the reverse merger with ArTara Therapeutics, Inc.</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_BusinessLiquidityAndCapitalResourcesAbstract" xlink:label="TARA_BusinessLiquidityAndCapitalResourcesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_BusinessLiquidityAndCapitalResourcesAbstract" xlink:to="TARA_BusinessLiquidityAndCapitalResourcesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_BusinessLiquidityAndCapitalResourcesAbstract_lbl" xml:lang="en-US">Business, Liquidity and Capital Resources [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_BusinessLiquidityAndCapitalResourcesTextBlock" xlink:label="TARA_BusinessLiquidityAndCapitalResourcesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_BusinessLiquidityAndCapitalResourcesTextBlock" xlink:to="TARA_BusinessLiquidityAndCapitalResourcesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_BusinessLiquidityAndCapitalResourcesTextBlock_lbl" xml:lang="en-US">BUSINESS, LIQUIDITY AND CAPITAL RESOURCES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessCombinationsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationsAbstract_lbl" xml:lang="en-US">Business Combinations [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xml:lang="en-US">REVERSE MERGER WITH PROTARA AND RECAPITALIZATION</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">PROPERTY AND EQUIPMENT</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US">ACCRUED EXPENSES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTextBlock" xlink:label="us-gaap_ShortTermDebtTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTextBlock" xlink:to="us-gaap_ShortTermDebtTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTextBlock_lbl" xml:lang="en-US">SHORT-TERM DEBT</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">STOCKHOLDERS' EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">STOCK-BASED COMPENSATION</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">INCOME TAXES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xml:lang="en-US">EMPLOYEE BENEFIT PLAN</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_Covid19Abstract" xlink:label="TARA_Covid19Abstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_Covid19Abstract" xlink:to="TARA_Covid19Abstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_Covid19Abstract_lbl" xml:lang="en-US">Covid19 [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_Covid19DisclosureTextBlock" xlink:label="TARA_Covid19DisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_Covid19DisclosureTextBlock" xlink:to="TARA_Covid19DisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_Covid19DisclosureTextBlock_lbl" xml:lang="en-US">COVID-19</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Presentation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Principles of Consolidation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xml:lang="en-US">Restricted Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property and Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl" xml:lang="en-US">Goodwill</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Net Loss per Common Share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentrations of Credit Risk</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Stock-Based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair Value Measurements</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="us-gaap_BusinessCombinationsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationsPolicy" xlink:to="us-gaap_BusinessCombinationsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationsPolicy_lbl" xml:lang="en-US">Business Combinations</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recent Accounting Pronouncements Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:label="us-gaap_SubsequentEventsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:to="us-gaap_SubsequentEventsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Subsequent Events</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:label="us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:to="us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_lbl" xml:lang="en-US">Schedule of weighted average dilutive common shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_lbl" xml:lang="en-US">Schedule of preliminary allocation of the purchase price consideration</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:label="us-gaap_BusinessAcquisitionProFormaInformationTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:to="us-gaap_BusinessAcquisitionProFormaInformationTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionProFormaInformationTextBlock_lbl" xml:lang="en-US">Schedule of unaudited pro forma combined financial information</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Schedule of property and equipment consists</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLeaseIncomeTableTextBlock" xlink:label="us-gaap_OperatingLeaseLeaseIncomeTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLeaseIncomeTableTextBlock" xlink:to="us-gaap_OperatingLeaseLeaseIncomeTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLeaseIncomeTableTextBlock_lbl" xml:lang="en-US">Schedule of operating leases</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xml:lang="en-US">Schedule of minimum lease payments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of restricted stock unit activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of the fair value of stock options granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of stock option activities</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_IssuanceOfStockOptionsAndRestrictedStockUnitsToEmployeesAndDirectorsTableTextBlock" xlink:label="TARA_IssuanceOfStockOptionsAndRestrictedStockUnitsToEmployeesAndDirectorsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_IssuanceOfStockOptionsAndRestrictedStockUnitsToEmployeesAndDirectorsTableTextBlock" xlink:to="TARA_IssuanceOfStockOptionsAndRestrictedStockUnitsToEmployeesAndDirectorsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_IssuanceOfStockOptionsAndRestrictedStockUnitsToEmployeesAndDirectorsTableTextBlock_lbl" xml:lang="en-US">Schedule of total stock-based compensation costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US">Schedule of stock based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of federal and state income tax expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of deferred tax assets and liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US">Schedule of federal income tax to income before provision for income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_BusinessLiquidityAndCapitalResourcesTextualAbstract" xlink:label="TARA_BusinessLiquidityAndCapitalResourcesTextualAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_BusinessLiquidityAndCapitalResourcesTextualAbstract" xlink:to="TARA_BusinessLiquidityAndCapitalResourcesTextualAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_BusinessLiquidityAndCapitalResourcesTextualAbstract_lbl" xml:lang="en-US">Business, Liquidity and Capital Resources (Textual)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_3_lbl" xml:lang="en-US">Net losses</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_WorkingCapital" xlink:label="TARA_WorkingCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_WorkingCapital" xlink:to="TARA_WorkingCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_WorkingCapital_lbl" xml:lang="en-US">Working capital</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Stockholders' equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_2_lbl" xml:lang="en-US">Non stock based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_NetOfOfferingCosts" xlink:label="TARA_NetOfOfferingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_NetOfOfferingCosts" xlink:to="TARA_NetOfOfferingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_NetOfOfferingCosts_lbl" xml:lang="en-US">Net of offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_ProceedsFrompublicOfferingGross" xlink:label="TARA_ProceedsFrompublicOfferingGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_ProceedsFrompublicOfferingGross" xlink:to="TARA_ProceedsFrompublicOfferingGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_ProceedsFrompublicOfferingGross_lbl" xml:lang="en-US">Gross proceeds</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_PublicOfferingProceedsNet" xlink:label="TARA_PublicOfferingProceedsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_PublicOfferingProceedsNet" xlink:to="TARA_PublicOfferingProceedsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_PublicOfferingProceedsNet_lbl" xml:lang="en-US">Net proceeds</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockCompensationPlanMember" xlink:to="us-gaap_StockCompensationPlanMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockCompensationPlanMember_2_lbl" xml:lang="en-US">Stock options [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtSecuritiesMember" xlink:to="us-gaap_ConvertibleDebtSecuritiesMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember_2_lbl" xml:lang="en-US">Conversion of series 1 convertible preferred stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RestrictedStockMember_2_lbl" xml:lang="en-US">Restricted stock units [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Total potentially dilutive shares</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_SummaryOfSignificantAccountingPoliciesDetailsTextualAbstract" xlink:label="TARA_SummaryOfSignificantAccountingPoliciesDetailsTextualAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_SummaryOfSignificantAccountingPoliciesDetailsTextualAbstract" xlink:to="TARA_SummaryOfSignificantAccountingPoliciesDetailsTextualAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_SummaryOfSignificantAccountingPoliciesDetailsTextualAbstract_lbl" xml:lang="en-US">Summary Of Significant Accounting Policies</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_SummaryOfSignificantAccountingPoliciesTextualAbstract" xlink:label="TARA_SummaryOfSignificantAccountingPoliciesTextualAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_SummaryOfSignificantAccountingPoliciesTextualAbstract" xlink:to="TARA_SummaryOfSignificantAccountingPoliciesTextualAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_SummaryOfSignificantAccountingPoliciesTextualAbstract_lbl" xml:lang="en-US">Summary of Significant Accounting Policies (Textual)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCollateralForBorrowedSecurities" xlink:label="us-gaap_CashCollateralForBorrowedSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCollateralForBorrowedSecurities" xlink:to="us-gaap_CashCollateralForBorrowedSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCollateralForBorrowedSecurities_lbl" xml:lang="en-US">Cash deposit to collateralize</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTransfersAndChanges" xlink:label="us-gaap_PropertyPlantAndEquipmentTransfersAndChanges" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTransfersAndChanges" xlink:to="us-gaap_PropertyPlantAndEquipmentTransfersAndChanges_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTransfersAndChanges_lbl" xml:lang="en-US">Depreciable lives of its property and equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xml:lang="en-US">Research and development expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:label="us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:to="us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_lbl" xml:lang="en-US">Goodwill related</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_RestrictCash" xlink:label="TARA_RestrictCash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_RestrictCash" xlink:to="TARA_RestrictCash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="TARA_RestrictCash_lbl" xml:lang="en-US">Restricted cash</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_AssetsAcquiredAndLiabilitiesAssumedCash" xlink:label="TARA_AssetsAcquiredAndLiabilitiesAssumedCash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_AssetsAcquiredAndLiabilitiesAssumedCash" xlink:to="TARA_AssetsAcquiredAndLiabilitiesAssumedCash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_AssetsAcquiredAndLiabilitiesAssumedCash_lbl" xml:lang="en-US">Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_AssetsAcquiredAndLiabilitiesAssumedRestrictedCash" xlink:label="TARA_AssetsAcquiredAndLiabilitiesAssumedRestrictedCash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_AssetsAcquiredAndLiabilitiesAssumedRestrictedCash" xlink:to="TARA_AssetsAcquiredAndLiabilitiesAssumedRestrictedCash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="TARA_AssetsAcquiredAndLiabilitiesAssumedRestrictedCash_lbl" xml:lang="en-US">Restricted cash</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_AssetsAcquiredAndLiabilitiesAssumedPrepaidExpensesAndOtherAssets" xlink:label="TARA_AssetsAcquiredAndLiabilitiesAssumedPrepaidExpensesAndOtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_AssetsAcquiredAndLiabilitiesAssumedPrepaidExpensesAndOtherAssets" xlink:to="TARA_AssetsAcquiredAndLiabilitiesAssumedPrepaidExpensesAndOtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="TARA_AssetsAcquiredAndLiabilitiesAssumedPrepaidExpensesAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_AssetsAcquiredAndLiabilitiesAssumedGoodwill" xlink:label="TARA_AssetsAcquiredAndLiabilitiesAssumedGoodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_AssetsAcquiredAndLiabilitiesAssumedGoodwill" xlink:to="TARA_AssetsAcquiredAndLiabilitiesAssumedGoodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="TARA_AssetsAcquiredAndLiabilitiesAssumedGoodwill_lbl" xml:lang="en-US">Goodwill</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_AssetsAcquiredAndLiabilitiesAssumedAccruedExpenses" xlink:label="TARA_AssetsAcquiredAndLiabilitiesAssumedAccruedExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_AssetsAcquiredAndLiabilitiesAssumedAccruedExpenses" xlink:to="TARA_AssetsAcquiredAndLiabilitiesAssumedAccruedExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="TARA_AssetsAcquiredAndLiabilitiesAssumedAccruedExpenses_lbl" xml:lang="en-US">Accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_AssetsAcquiredAndLiabilitiesAssumedTotalPurchasePrice" xlink:label="TARA_AssetsAcquiredAndLiabilitiesAssumedTotalPurchasePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_AssetsAcquiredAndLiabilitiesAssumedTotalPurchasePrice" xlink:to="TARA_AssetsAcquiredAndLiabilitiesAssumedTotalPurchasePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_AssetsAcquiredAndLiabilitiesAssumedTotalPurchasePrice_lbl" xml:lang="en-US">Total purchase price consideration</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:label="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:to="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_ProFormaLossPerCommonShareBasicAndDiluted" xlink:label="TARA_ProFormaLossPerCommonShareBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_ProFormaLossPerCommonShareBasicAndDiluted" xlink:to="TARA_ProFormaLossPerCommonShareBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_ProFormaLossPerCommonShareBasicAndDiluted_lbl" xml:lang="en-US">Pro forma loss per common share, basic and diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_ProFormaWeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted" xlink:label="TARA_ProFormaWeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_ProFormaWeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted" xlink:to="TARA_ProFormaWeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_ProFormaWeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted_lbl" xml:lang="en-US">Pro forma weighted average number of common shares outstanding, basic and diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_BusinessCombinationsTextualAbstract" xlink:label="TARA_BusinessCombinationsTextualAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_BusinessCombinationsTextualAbstract" xlink:to="TARA_BusinessCombinationsTextualAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_BusinessCombinationsTextualAbstract_lbl" xml:lang="en-US">Reverse Merger with Artara and Recapitalization (Textual)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xml:lang="en-US">Reverse stock split</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_OutstandingReverseStock" xlink:label="TARA_OutstandingReverseStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_OutstandingReverseStock" xlink:to="TARA_OutstandingReverseStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_OutstandingReverseStock_lbl" xml:lang="en-US">Outstanding reverse stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionRatio1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionRatio1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleConversionRatio1_lbl" xml:lang="en-US">Common shares exchange ratio</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_SharesAvailableForIssuance" xlink:label="TARA_SharesAvailableForIssuance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_SharesAvailableForIssuance" xlink:to="TARA_SharesAvailableForIssuance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_SharesAvailableForIssuance_lbl" xml:lang="en-US">Shares available for issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_SubscriptionAgreementDescription" xlink:label="TARA_SubscriptionAgreementDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_SubscriptionAgreementDescription" xlink:to="TARA_SubscriptionAgreementDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_SubscriptionAgreementDescription_lbl" xml:lang="en-US">Subscription agreement, description</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesIssued1" xlink:to="us-gaap_ConversionOfStockSharesIssued1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl" xml:lang="en-US">Converted shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xml:lang="en-US">Convertible preferred stock</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_FairValueOfNetAssets" xlink:label="TARA_FairValueOfNetAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_FairValueOfNetAssets" xlink:to="TARA_FairValueOfNetAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_FairValueOfNetAssets_lbl" xml:lang="en-US">Fair value of net assets</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_DescriptionOfOwnershipRights" xlink:label="TARA_DescriptionOfOwnershipRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_DescriptionOfOwnershipRights" xlink:to="TARA_DescriptionOfOwnershipRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_DescriptionOfOwnershipRights_lbl" xml:lang="en-US">Description of ownership rights</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_PreMergerShares" xlink:label="TARA_PreMergerShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_PreMergerShares" xlink:to="TARA_PreMergerShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_PreMergerShares_lbl" xml:lang="en-US">Pre merger shares</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_ReverseBusinessCombination" xlink:label="TARA_ReverseBusinessCombination" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_ReverseBusinessCombination" xlink:to="TARA_ReverseBusinessCombination_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="TARA_ReverseBusinessCombination_lbl" xml:lang="en-US">Reverse business combination</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:label="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:to="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_lbl" xml:lang="en-US">Prepaid expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xml:lang="en-US">Accrued expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_ComputerEquipmentAndSoftwareMember" xlink:to="TARA_ComputerEquipmentAndSoftwareMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="TARA_ComputerEquipmentAndSoftwareMember_2_lbl" xml:lang="en-US">Computer equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentOther" xlink:label="us-gaap_PropertyPlantAndEquipmentOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentOther" xlink:to="us-gaap_PropertyPlantAndEquipmentOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentOther_lbl" xml:lang="en-US">Property and equipment not yet placed into service</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Total property and equipment, gross</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Less: Accumulated depreciation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xml:lang="en-US">Total property and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Property, plant and equipment, useful life</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_PropertyAndEquipmentTextualAbstract" xlink:label="TARA_PropertyAndEquipmentTextualAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_PropertyAndEquipmentTextualAbstract" xlink:to="TARA_PropertyAndEquipmentTextualAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_PropertyAndEquipmentTextualAbstract_lbl" xml:lang="en-US">Property and Equipment (Textual)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Depreciation_2_lbl" xml:lang="en-US">Depreciation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedEmployeeBenefitsCurrent" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" xml:lang="en-US">Employee bonus</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedPayrollTaxesCurrent" xlink:label="us-gaap_AccruedPayrollTaxesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedPayrollTaxesCurrent" xlink:to="us-gaap_AccruedPayrollTaxesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedPayrollTaxesCurrent_lbl" xml:lang="en-US">Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_LegalFeesOfAccruedExpenses" xlink:label="TARA_LegalFeesOfAccruedExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_LegalFeesOfAccruedExpenses" xlink:to="TARA_LegalFeesOfAccruedExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_LegalFeesOfAccruedExpenses_lbl" xml:lang="en-US">Legal fees</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:to="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_lbl" xml:lang="en-US">Research and development costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Other expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_2_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_ShorttermDebtTextualAbstract" xlink:label="TARA_ShorttermDebtTextualAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_ShorttermDebtTextualAbstract" xlink:to="TARA_ShorttermDebtTextualAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_ShorttermDebtTextualAbstract_lbl" xml:lang="en-US">Short-term Debt (Textual)</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_DescriptionOfFinancingAgreement" xlink:label="TARA_DescriptionOfFinancingAgreement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_DescriptionOfFinancingAgreement" xlink:to="TARA_DescriptionOfFinancingAgreement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_DescriptionOfFinancingAgreement_lbl" xml:lang="en-US">Description of financing agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtCurrent" xlink:label="us-gaap_DebtCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtCurrent" xlink:to="us-gaap_DebtCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtCurrent_lbl" xml:lang="en-US">Debt amount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_RightOfUseLiabilityMember" xlink:to="TARA_RightOfUseLiabilityMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="TARA_RightOfUseLiabilityMember_2_lbl" xml:lang="en-US">Right of use liability, current [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Right-of-use assets</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_RightofuseLiability" xlink:label="TARA_RightofuseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_RightofuseLiability" xlink:to="TARA_RightofuseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_RightofuseLiability_lbl" xml:lang="en-US">Right-of-use liability, current</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_RightofuseLeaseLiabilityLongterm" xlink:label="TARA_RightofuseLeaseLiabilityLongterm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_RightofuseLeaseLiabilityLongterm" xlink:to="TARA_RightofuseLeaseLiabilityLongterm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_RightofuseLeaseLiabilityLongterm_lbl" xml:lang="en-US">Right-of-use lease liability, long-term</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US">Operating lease cost</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermLeaseCost" xlink:to="us-gaap_ShortTermLeaseCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xml:lang="en-US">Short-term lease cost</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Weighted-average discount rate - operating leases</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Weighted-average remaining lease term - operating lease (in months)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_lbl" xml:lang="en-US">2021</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xml:lang="en-US">2022</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xml:lang="en-US">2023</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xml:lang="en-US">2024</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl" xml:lang="en-US">2025</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_lbl" xml:lang="en-US">Thereafter</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xml:lang="en-US">Total future minimum lease payments, undiscounted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less: Imputed interest for leases in excess of one year</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Present value of future minimum lease payments</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_PresentValueOfFutureMinimumLeasePaymentsForOurOperatingLeaseLiabilities" xlink:label="TARA_PresentValueOfFutureMinimumLeasePaymentsForOurOperatingLeaseLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_PresentValueOfFutureMinimumLeasePaymentsForOurOperatingLeaseLiabilities" xlink:to="TARA_PresentValueOfFutureMinimumLeasePaymentsForOurOperatingLeaseLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_PresentValueOfFutureMinimumLeasePaymentsForOurOperatingLeaseLiabilities_lbl" xml:lang="en-US">Present value of future minimum lease payments for our operating lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_PresentValueOfFutureMinimumLeasePaymentsShorttermLeases" xlink:label="TARA_PresentValueOfFutureMinimumLeasePaymentsShorttermLeases" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_PresentValueOfFutureMinimumLeasePaymentsShorttermLeases" xlink:to="TARA_PresentValueOfFutureMinimumLeasePaymentsShorttermLeases_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_PresentValueOfFutureMinimumLeasePaymentsShorttermLeases_lbl" xml:lang="en-US">Present value of future minimum lease payments, short-term leases</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_CommitmentsTextualAbstract" xlink:label="TARA_CommitmentsTextualAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_CommitmentsTextualAbstract" xlink:to="TARA_CommitmentsTextualAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_CommitmentsTextualAbstract_lbl" xml:lang="en-US">Commitments (Textual)</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_DescriptionOfAgreements" xlink:label="TARA_DescriptionOfAgreements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_DescriptionOfAgreements" xlink:to="TARA_DescriptionOfAgreements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_DescriptionOfAgreements_lbl" xml:lang="en-US">Description of agreements</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_AnnualBaseSalary" xlink:label="TARA_AnnualBaseSalary" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_AnnualBaseSalary" xlink:to="TARA_AnnualBaseSalary_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_AnnualBaseSalary_lbl" xml:lang="en-US">Annual base salary</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractualObligation" xlink:label="us-gaap_ContractualObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligation" xlink:to="us-gaap_ContractualObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractualObligation_lbl" xml:lang="en-US">Compensation obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BroadcastersLicenseAgreementCommitmentsDescription" xlink:label="us-gaap_BroadcastersLicenseAgreementCommitmentsDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BroadcastersLicenseAgreementCommitmentsDescription" xlink:to="us-gaap_BroadcastersLicenseAgreementCommitmentsDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BroadcastersLicenseAgreementCommitmentsDescription_lbl" xml:lang="en-US">Description of license agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_RoyaltyPaymentPercentageOfNetSales" xlink:label="TARA_RoyaltyPaymentPercentageOfNetSales" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_RoyaltyPaymentPercentageOfNetSales" xlink:to="TARA_RoyaltyPaymentPercentageOfNetSales_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_RoyaltyPaymentPercentageOfNetSales_lbl" xml:lang="en-US">Royalty percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArtistAdvancesAndRoyaltyGuaranteesCommitments" xlink:label="us-gaap_ArtistAdvancesAndRoyaltyGuaranteesCommitments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArtistAdvancesAndRoyaltyGuaranteesCommitments" xlink:to="us-gaap_ArtistAdvancesAndRoyaltyGuaranteesCommitments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArtistAdvancesAndRoyaltyGuaranteesCommitments_lbl" xml:lang="en-US">Description of royalty</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_ResearchAndDevelopmentExpenses" xlink:label="TARA_ResearchAndDevelopmentExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_ResearchAndDevelopmentExpenses" xlink:to="TARA_ResearchAndDevelopmentExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_ResearchAndDevelopmentExpenses_lbl" xml:lang="en-US">Research and development expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_PaymentOfAttorneysFees" xlink:label="TARA_PaymentOfAttorneysFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_PaymentOfAttorneysFees" xlink:to="TARA_PaymentOfAttorneysFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_PaymentOfAttorneysFees_lbl" xml:lang="en-US">Payment of attorney's fees</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_GeneralAndAdministrativeExpenses" xlink:label="TARA_GeneralAndAdministrativeExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_GeneralAndAdministrativeExpenses" xlink:to="TARA_GeneralAndAdministrativeExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_GeneralAndAdministrativeExpenses_lbl" xml:lang="en-US">General and administrative expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToEmployees" xlink:label="us-gaap_PaymentsToEmployees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToEmployees" xlink:to="us-gaap_PaymentsToEmployees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToEmployees_lbl" xml:lang="en-US">Bonus payments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleLeasebackTransactionMonthlyRentalPayments" xlink:label="us-gaap_SaleLeasebackTransactionMonthlyRentalPayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleLeasebackTransactionMonthlyRentalPayments" xlink:to="us-gaap_SaleLeasebackTransactionMonthlyRentalPayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleLeasebackTransactionMonthlyRentalPayments_lbl" xml:lang="en-US">Monthly rent</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfessionalFees" xlink:label="us-gaap_ProfessionalFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfessionalFees" xlink:to="us-gaap_ProfessionalFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfessionalFees_lbl" xml:lang="en-US">Aggregate amount</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_CholineLicenseFee" xlink:label="TARA_CholineLicenseFee" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_CholineLicenseFee" xlink:to="TARA_CholineLicenseFee_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_CholineLicenseFee_lbl" xml:lang="en-US">Choline License Fee</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_lbl" xml:lang="en-US">Accrued expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_2_lbl" xml:lang="en-US">Lease term</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_Series1PreferredStockMember" xlink:to="TARA_Series1PreferredStockMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_Series1PreferredStockMember_2_lbl" xml:lang="en-US">Series 1 Convertible Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_StockholdersEquityTextualAbstract" xlink:label="TARA_StockholdersEquityTextualAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_StockholdersEquityTextualAbstract" xlink:to="TARA_StockholdersEquityTextualAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_StockholdersEquityTextualAbstract_lbl" xml:lang="en-US">Stockholders' Equity (Textual)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_2_lbl" xml:lang="en-US">Common shares of par value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/disclosureGuidance" xlink:label="us-gaap_CommonStockSharesIssued_2_lbl" xml:lang="en-US">Common stock shares issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_2_lbl" xml:lang="en-US">Preferred shares of par value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesIssued1" xlink:to="us-gaap_ConversionOfStockSharesIssued1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConversionOfStockSharesIssued1_2_lbl" xml:lang="en-US">Conversion of stock shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Shares issued, price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_IncreaseOrDecreaseEquityPercentage" xlink:label="TARA_IncreaseOrDecreaseEquityPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_IncreaseOrDecreaseEquityPercentage" xlink:to="TARA_IncreaseOrDecreaseEquityPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_IncreaseOrDecreaseEquityPercentage_lbl" xml:lang="en-US">Convertible preferred stock, percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xml:lang="en-US">Conversion price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_AggregateOfSharesOfCommonStock" xlink:label="TARA_AggregateOfSharesOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_AggregateOfSharesOfCommonStock" xlink:to="TARA_AggregateOfSharesOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_AggregateOfSharesOfCommonStock_lbl" xml:lang="en-US">Aggregate of shares of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US">Offering price, per share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xml:lang="en-US">Gross proceeds</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_NetProceeds" xlink:label="TARA_NetProceeds" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_NetProceeds" xlink:to="TARA_NetProceeds_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="TARA_NetProceeds_lbl" xml:lang="en-US">Net proceeds</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Granted option to purchase</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_CommonStockIssuanceAndOutstandingPercentage" xlink:label="TARA_CommonStockIssuanceAndOutstandingPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_CommonStockIssuanceAndOutstandingPercentage" xlink:to="TARA_CommonStockIssuanceAndOutstandingPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_CommonStockIssuanceAndOutstandingPercentage_lbl" xml:lang="en-US">Common stock issuance and outstanding, percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_MaximumAggregateOfferingPrice" xlink:label="TARA_MaximumAggregateOfferingPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_MaximumAggregateOfferingPrice" xlink:to="TARA_MaximumAggregateOfferingPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_MaximumAggregateOfferingPrice_lbl" xml:lang="en-US">Maximum aggregate offering price</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US">Issuance of common stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_2_lbl" xml:lang="en-US">Restricted stock unit [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_RestrictedStockUnitsAbstract" xlink:label="TARA_RestrictedStockUnitsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_RestrictedStockUnitsAbstract" xlink:to="TARA_RestrictedStockUnitsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_RestrictedStockUnitsAbstract_lbl" xml:lang="en-US">Restricted Stock Units</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xml:lang="en-US">Balance at beginning</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_lbl" xml:lang="en-US">Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xml:lang="en-US">Vested</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_2_lbl" xml:lang="en-US">Balance at ending</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_WeightedAverageGrantDateFairValueOneAbstract" xlink:label="TARA_WeightedAverageGrantDateFairValueOneAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_WeightedAverageGrantDateFairValueOneAbstract" xlink:to="TARA_WeightedAverageGrantDateFairValueOneAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_WeightedAverageGrantDateFairValueOneAbstract_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Balance at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">vested</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xml:lang="en-US">Balance at ending</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_StockOptionExercisePrice" xlink:label="TARA_StockOptionExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_StockOptionExercisePrice" xlink:to="TARA_StockOptionExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_StockOptionExercisePrice_lbl" xml:lang="en-US">Stock price</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xml:lang="en-US">Exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend yield</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Expected volatility</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected life (in years)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockMember" xlink:to="us-gaap_EmployeeStockMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EmployeeStockMember_2_lbl" xml:lang="en-US">Options [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_OptionsAbstract" xlink:label="TARA_OptionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_OptionsAbstract" xlink:to="TARA_OptionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_OptionsAbstract_lbl" xml:lang="en-US">Options</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Balance at beginning</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xml:lang="en-US">Exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Balance at ending</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberExercisable" xlink:label="TARA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberExercisable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberExercisable" xlink:to="TARA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberExercisable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberExercisable_lbl" xml:lang="en-US">Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_WeightedAverageGrantDateFairValueAbstract" xlink:label="TARA_WeightedAverageGrantDateFairValueAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_WeightedAverageGrantDateFairValueAbstract" xlink:to="TARA_WeightedAverageGrantDateFairValueAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="TARA_WeightedAverageGrantDateFairValueAbstract_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" xlink:label="TARA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" xlink:to="TARA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercisable" xlink:label="TARA_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercisable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercisable" xlink:to="TARA_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercisable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="TARA_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercisable_lbl" xml:lang="en-US">Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_WeightedAverageExercisePriceAbstract" xlink:label="TARA_WeightedAverageExercisePriceAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_WeightedAverageExercisePriceAbstract" xlink:to="TARA_WeightedAverageExercisePriceAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_WeightedAverageExercisePriceAbstract_lbl" xml:lang="en-US">Weighted Average Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Balance at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Balance at ending</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceExercisable" xlink:label="TARA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceExercisable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceExercisable" xlink:to="TARA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceExercisable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="TARA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceExercisable_lbl" xml:lang="en-US">Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_WeightedAverageRemainingContractualTermYearsAbstract" xlink:label="TARA_WeightedAverageRemainingContractualTermYearsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_WeightedAverageRemainingContractualTermYearsAbstract" xlink:to="TARA_WeightedAverageRemainingContractualTermYearsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_WeightedAverageRemainingContractualTermYearsAbstract_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term (years)</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTerm1" xlink:label="TARA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTerm1" xlink:to="TARA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTerm1_lbl" xml:lang="en-US">Balance at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTermGranted" xlink:label="TARA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTermGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTermGranted" xlink:to="TARA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTermGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="TARA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTermGranted_lbl" xml:lang="en-US">Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTerm2" xlink:label="TARA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTerm2" xlink:to="TARA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTerm2_lbl" xml:lang="en-US">Balance at ending</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTermExercisable" xlink:label="TARA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTermExercisable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTermExercisable" xlink:to="TARA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTermExercisable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="TARA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTermExercisable_lbl" xml:lang="en-US">Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_AggregateIntrinsicValueAbstract" xlink:label="TARA_AggregateIntrinsicValueAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_AggregateIntrinsicValueAbstract" xlink:to="TARA_AggregateIntrinsicValueAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_AggregateIntrinsicValueAbstract_lbl" xml:lang="en-US">Aggregate Intrinsic Value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl" xml:lang="en-US">Balance at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted" xlink:label="TARA_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted" xlink:to="TARA_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="TARA_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted_lbl" xml:lang="en-US">Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeited" xlink:label="TARA_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeited" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeited" xlink:to="TARA_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeited_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="TARA_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeited_lbl" xml:lang="en-US">Forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_2_lbl" xml:lang="en-US">Balance at ending</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisable" xlink:label="TARA_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisable" xlink:to="TARA_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="TARA_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisable_lbl" xml:lang="en-US">Exercisable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockMember_3_lbl" xml:lang="en-US">Restricted stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_3_lbl" xml:lang="en-US">RSUs [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EmployeeStockOptionMember_2_lbl" xml:lang="en-US">Stock options [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_3_lbl" xml:lang="en-US">Total stock-based compensation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_2_lbl" xml:lang="en-US">Research and development [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_2_lbl" xml:lang="en-US">General and administrative [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_DirectorsOneMember" xlink:to="TARA_DirectorsOneMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="TARA_DirectorsOneMember_2_lbl" xml:lang="en-US">Directors One [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_DirectorsTwoMember" xlink:to="TARA_DirectorsTwoMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="TARA_DirectorsTwoMember_2_lbl" xml:lang="en-US">Directors Two [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockMember" xlink:to="us-gaap_EmployeeStockMember_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeStockMember_3_lbl" xml:lang="en-US">Stock Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_StockBasedCompensationTextualAbstract" xlink:label="TARA_StockBasedCompensationTextualAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_StockBasedCompensationTextualAbstract" xlink:to="TARA_StockBasedCompensationTextualAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_StockBasedCompensationTextualAbstract_lbl" xml:lang="en-US">Stock Based Compensation (Textual)</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_StocksIssuedDuringPeriodValueNewIssues" xlink:label="TARA_StocksIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_StocksIssuedDuringPeriodValueNewIssues" xlink:to="TARA_StocksIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="TARA_StocksIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Issuance of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockDescriptionOfTransaction" xlink:label="us-gaap_SaleOfStockDescriptionOfTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockDescriptionOfTransaction" xlink:to="us-gaap_SaleOfStockDescriptionOfTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockDescriptionOfTransaction_lbl" xml:lang="en-US">Sale of stock, description</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesIssued_3_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_VestedOptionsPercentage" xlink:label="TARA_VestedOptionsPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_VestedOptionsPercentage" xlink:to="TARA_VestedOptionsPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_VestedOptionsPercentage_lbl" xml:lang="en-US">Vested options, percentage</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_3_lbl" xml:lang="en-US">Grant date fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_UnamortizedValueOfRsus" xlink:label="TARA_UnamortizedValueOfRsus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_UnamortizedValueOfRsus" xlink:to="TARA_UnamortizedValueOfRsus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_UnamortizedValueOfRsus_lbl" xml:lang="en-US">Unamortized value of RSUs</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_NumberOfSharesRestrictedStock" xlink:label="TARA_NumberOfSharesRestrictedStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_NumberOfSharesRestrictedStock" xlink:to="TARA_NumberOfSharesRestrictedStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_NumberOfSharesRestrictedStock_lbl" xml:lang="en-US">Number of RSUs</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_WeightedAverageGrantDateFairValue" xlink:label="TARA_WeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_WeightedAverageGrantDateFairValue" xlink:to="TARA_WeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_WeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average grant date fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_WeightedAverageRemainingAmortizationPeriod" xlink:label="TARA_WeightedAverageRemainingAmortizationPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_WeightedAverageRemainingAmortizationPeriod" xlink:to="TARA_WeightedAverageRemainingAmortizationPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_WeightedAverageRemainingAmortizationPeriod_lbl" xml:lang="en-US">Weighted average remaining amortization period</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_OptionsDescription" xlink:label="TARA_OptionsDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_OptionsDescription" xlink:to="TARA_OptionsDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_OptionsDescription_lbl" xml:lang="en-US">Options description</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_UnamortizedValueOfStock" xlink:label="TARA_UnamortizedValueOfStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_UnamortizedValueOfStock" xlink:to="TARA_UnamortizedValueOfStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_UnamortizedValueOfStock_lbl" xml:lang="en-US">Unamortized value of stock</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_ShareBasedCompensationGrantDateFairValue" xlink:label="TARA_ShareBasedCompensationGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_ShareBasedCompensationGrantDateFairValue" xlink:to="TARA_ShareBasedCompensationGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="TARA_ShareBasedCompensationGrantDateFairValue_lbl" xml:lang="en-US">Grant date fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US">Vested shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Amount of charges</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_IncrementalValue" xlink:label="TARA_IncrementalValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_IncrementalValue" xlink:to="TARA_IncrementalValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_IncrementalValue_lbl" xml:lang="en-US">Incremental value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SaleOfStockPricePerShare_2_lbl" xml:lang="en-US">Exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_VestPeriod" xlink:label="TARA_VestPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_VestPeriod" xlink:to="TARA_VestPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_VestPeriod_lbl" xml:lang="en-US">Vest period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xml:lang="en-US">Current</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xml:lang="en-US">Federal</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xml:lang="en-US">State</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Total current</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xml:lang="en-US">Deferred</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Federal</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">State</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredOtherTaxExpenseBenefit" xlink:label="us-gaap_DeferredOtherTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOtherTaxExpenseBenefit" xlink:to="us-gaap_DeferredOtherTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredOtherTaxExpenseBenefit_lbl" xml:lang="en-US">Total deferred</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Total income tax expense (benefit)</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_DeferredTaxAssetsAbstract" xlink:label="TARA_DeferredTaxAssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_DeferredTaxAssetsAbstract" xlink:to="TARA_DeferredTaxAssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_DeferredTaxAssetsAbstract_lbl" xml:lang="en-US">Deferred tax assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOtherLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOtherLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOtherLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOtherLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOtherLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carry forwards</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_DeferredTaxAssetsOrganizationCostslegalFees" xlink:label="TARA_DeferredTaxAssetsOrganizationCostslegalFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_DeferredTaxAssetsOrganizationCostslegalFees" xlink:to="TARA_DeferredTaxAssetsOrganizationCostslegalFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_DeferredTaxAssetsOrganizationCostslegalFees_lbl" xml:lang="en-US">Organization costs/legal fees</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_lbl" xml:lang="en-US">Stock option expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US">Research and development credits</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_DeferredTaxAssetsOperatingLeaseLiability" xlink:label="TARA_DeferredTaxAssetsOperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_DeferredTaxAssetsOperatingLeaseLiability" xlink:to="TARA_DeferredTaxAssetsOperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_DeferredTaxAssetsOperatingLeaseLiability_lbl" xml:lang="en-US">Operating lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_DeferredTaxAssetsRestrictedStockExpense" xlink:label="TARA_DeferredTaxAssetsRestrictedStockExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_DeferredTaxAssetsRestrictedStockExpense" xlink:to="TARA_DeferredTaxAssetsRestrictedStockExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_DeferredTaxAssetsRestrictedStockExpense_lbl" xml:lang="en-US">Restricted stock expense</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_RestrictedStockUnitsExpense" xlink:label="TARA_RestrictedStockUnitsExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_RestrictedStockUnitsExpense" xlink:to="TARA_RestrictedStockUnitsExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_RestrictedStockUnitsExpense_lbl" xml:lang="en-US">RSU expense</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_DeferredTaxAssetsCharitableContributions" xlink:label="TARA_DeferredTaxAssetsCharitableContributions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_DeferredTaxAssetsCharitableContributions" xlink:to="TARA_DeferredTaxAssetsCharitableContributions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_DeferredTaxAssetsCharitableContributions_lbl" xml:lang="en-US">Charitable contributions</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Total deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Deferred tax assets, net of valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xml:lang="en-US">Deferred tax liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_DeferredTaxLiabilitiesOperatingRightofuseAsset" xlink:label="TARA_DeferredTaxLiabilitiesOperatingRightofuseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_DeferredTaxLiabilitiesOperatingRightofuseAsset" xlink:to="TARA_DeferredTaxLiabilitiesOperatingRightofuseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_DeferredTaxLiabilitiesOperatingRightofuseAsset_lbl" xml:lang="en-US">Operating right-of-use asset</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_DeferredTaxLiabilitiesDepreciation" xlink:label="TARA_DeferredTaxLiabilitiesDepreciation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_DeferredTaxLiabilitiesDepreciation" xlink:to="TARA_DeferredTaxLiabilitiesDepreciation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="TARA_DeferredTaxLiabilitiesDepreciation_lbl" xml:lang="en-US">Depreciation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome" xlink:label="us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome" xlink:to="us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome_lbl" xml:lang="en-US">Total deferred tax liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xml:lang="en-US">Deferred tax assets, net of valuation allowance and deferred tax liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">U.S. federal statutory rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State taxes, net of federal benefit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xml:lang="en-US">Option expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_lbl" xml:lang="en-US">Other</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_lbl" xml:lang="en-US">True-up to prior years return</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Effective tax rate</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_IncomeTaxesTextualAbstract" xlink:label="TARA_IncomeTaxesTextualAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_IncomeTaxesTextualAbstract" xlink:to="TARA_IncomeTaxesTextualAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_IncomeTaxesTextualAbstract_lbl" xml:lang="en-US">Income Taxes (Textual)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss and credit carryovers</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_PercentageOfAnnualDeductionLimitation" xlink:label="TARA_PercentageOfAnnualDeductionLimitation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_PercentageOfAnnualDeductionLimitation" xlink:to="TARA_PercentageOfAnnualDeductionLimitation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_PercentageOfAnnualDeductionLimitation_lbl" xml:lang="en-US">Percentage of annual deduction limitation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US">Valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_NetOperatingLossAfterApplication" xlink:label="TARA_NetOperatingLossAfterApplication" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_NetOperatingLossAfterApplication" xlink:to="TARA_NetOperatingLossAfterApplication_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_NetOperatingLossAfterApplication_lbl" xml:lang="en-US">Net operating loss after application</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_MergerDescription" xlink:label="TARA_MergerDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_MergerDescription" xlink:to="TARA_MergerDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_MergerDescription_lbl" xml:lang="en-US">Merger, description</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_EmployeeBenefitPlanDetailsAbstract" xlink:label="TARA_EmployeeBenefitPlanDetailsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_EmployeeBenefitPlanDetailsAbstract" xlink:to="TARA_EmployeeBenefitPlanDetailsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_EmployeeBenefitPlanDetailsAbstract_lbl" xml:lang="en-US">Employee Benefit Plan</link:label>
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_EmployeeBenefitPlanTextualAbstract" xlink:label="TARA_EmployeeBenefitPlanTextualAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_EmployeeBenefitPlanTextualAbstract" xlink:to="TARA_EmployeeBenefitPlanTextualAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_EmployeeBenefitPlanTextualAbstract_lbl" xml:lang="en-US">Employee Benefit Plan (Textual)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans" xlink:label="us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans" xlink:to="us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans_lbl" xml:lang="en-US">Defined contribution benefit plant, description</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherExpenses" xlink:label="us-gaap_OtherExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherExpenses" xlink:to="us-gaap_OtherExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherExpenses_lbl" xml:lang="en-US">Recorded expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_AmortizationOfOperatingLeaseRightsofuseAsset" xlink:to="TARA_AmortizationOfOperatingLeaseRightsofuseAsset_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TARA_AmortizationOfOperatingLeaseRightsofuseAsset_doc" xml:lang="en-US">Amortization of operating lease right-of-use asset.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_CashAndRestrictedCashAcquiredInConnectionWithReverseMergerWithArtaraTherapeuticsInc." xlink:to="TARA_CashAndRestrictedCashAcquiredInConnectionWithReverseMergerWithArtaraTherapeuticsInc._doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TARA_CashAndRestrictedCashAcquiredInConnectionWithReverseMergerWithArtaraTherapeuticsInc._doc" xml:lang="en-US">Cash and restricted cash acquired in connection with the reverse merger with ArTara Therapeutics, Inc.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_Covid19DisclosureTextBlock" xlink:to="TARA_Covid19DisclosureTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TARA_Covid19DisclosureTextBlock_doc" xml:lang="en-US">The entire disclosure of covid 19.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_DeferredOfferingCostsRecognizedThatWerePreviouslyRecordedInAccruedExpenses" xlink:to="TARA_DeferredOfferingCostsRecognizedThatWerePreviouslyRecordedInAccruedExpenses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TARA_DeferredOfferingCostsRecognizedThatWerePreviouslyRecordedInAccruedExpenses_doc" xml:lang="en-US">Deferred offering costs recognized that were previously recorded in accrued expenses.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_DescriptionOfAgreements" xlink:to="TARA_DescriptionOfAgreements_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TARA_DescriptionOfAgreements_doc" xml:lang="en-US">Description of agreements.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_GeneralAndAdministrativeExpenses" xlink:to="TARA_GeneralAndAdministrativeExpenses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TARA_GeneralAndAdministrativeExpenses_doc" xml:lang="en-US">The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_IssuanceOfStockOptionsAndRestrictedStockUnitsToEmployeesAndDirectorsTableTextBlock" xlink:to="TARA_IssuanceOfStockOptionsAndRestrictedStockUnitsToEmployeesAndDirectorsTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TARA_IssuanceOfStockOptionsAndRestrictedStockUnitsToEmployeesAndDirectorsTableTextBlock_doc" xml:lang="en-US">Tabular disclosure of issuance of stock options and restricted stock units to employees and directors.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_NetOfOfferingCosts" xlink:to="TARA_NetOfOfferingCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TARA_NetOfOfferingCosts_doc" xml:lang="en-US">Net of offering costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_NumberOfSharesRestrictedStock" xlink:to="TARA_NumberOfSharesRestrictedStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TARA_NumberOfSharesRestrictedStock_doc" xml:lang="en-US">Number of RSUs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_OutstandingReverseStock" xlink:to="TARA_OutstandingReverseStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TARA_OutstandingReverseStock_doc" xml:lang="en-US">Outstanding reverse stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_PreMergerShares" xlink:to="TARA_PreMergerShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TARA_PreMergerShares_doc" xml:lang="en-US">Pre merger shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_ProceedsFromProteonPrivatePlacementNetOfOfferingCosts" xlink:to="TARA_ProceedsFromProteonPrivatePlacementNetOfOfferingCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TARA_ProceedsFromProteonPrivatePlacementNetOfOfferingCosts_doc" xml:lang="en-US">Proceeds from - Proteon Private Placement, net of offering costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_PurchaseOfInsuranceAgreementWithNotesPayable" xlink:to="TARA_PurchaseOfInsuranceAgreementWithNotesPayable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TARA_PurchaseOfInsuranceAgreementWithNotesPayable_doc" xml:lang="en-US">Purchase of insurance agreement with notes payable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_ResearchAndDevelopmentExpenses" xlink:to="TARA_ResearchAndDevelopmentExpenses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TARA_ResearchAndDevelopmentExpenses_doc" xml:lang="en-US">The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_ReverseBusinessCombination" xlink:to="TARA_ReverseBusinessCombination_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TARA_ReverseBusinessCombination_doc" xml:lang="en-US">Reverse business combination.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberExercisable" xlink:to="TARA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberExercisable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TARA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberExercisable_doc" xml:lang="en-US">Number of options exercisable, including both vested and non-vested options.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceExercisable" xlink:to="TARA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceExercisable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TARA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceExercisable_doc" xml:lang="en-US">Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan exercisable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisable" xlink:to="TARA_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TARA_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisable_doc" xml:lang="en-US">Intrinsic value exercisable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercisable" xlink:to="TARA_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercisable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TARA_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercisable_doc" xml:lang="en-US">Weighted average grant-date fair value of non-vested options exercisable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_SharesAvailableForIssuance" xlink:to="TARA_SharesAvailableForIssuance_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TARA_SharesAvailableForIssuance_doc" xml:lang="en-US">Shares available for issuance.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_StockIssuedDuringPeriodSharesIssuanceOfSeries1ConvertiblePreferredStockNetOfOfferingCosts" xlink:to="TARA_StockIssuedDuringPeriodSharesIssuanceOfSeries1ConvertiblePreferredStockNetOfOfferingCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TARA_StockIssuedDuringPeriodSharesIssuanceOfSeries1ConvertiblePreferredStockNetOfOfferingCosts_doc" xml:lang="en-US">Numbr of shares issuance of Series 1 Convertible Preferred Stock, net of offering costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_StockIssuedDuringPeriodValueIssuanceOfSeries1ConvertiblePreferredStockNetOfOfferingCosts" xlink:to="TARA_StockIssuedDuringPeriodValueIssuanceOfSeries1ConvertiblePreferredStockNetOfOfferingCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TARA_StockIssuedDuringPeriodValueIssuanceOfSeries1ConvertiblePreferredStockNetOfOfferingCosts_doc" xml:lang="en-US">Value issuance of Series 1 Convertible Preferred Stock, net of offering costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_StockOptionExercisePrice" xlink:to="TARA_StockOptionExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TARA_StockOptionExercisePrice_doc" xml:lang="en-US">Stock price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_StocksIssuedDuringPeriodValueNewIssues" xlink:to="TARA_StocksIssuedDuringPeriodValueNewIssues_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TARA_StocksIssuedDuringPeriodValueNewIssues_doc" xml:lang="en-US">Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_SubscriptionAgreementDescription" xlink:to="TARA_SubscriptionAgreementDescription_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TARA_SubscriptionAgreementDescription_doc" xml:lang="en-US">Description of subscription agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_UnamortizedValueOfRsus" xlink:to="TARA_UnamortizedValueOfRsus_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TARA_UnamortizedValueOfRsus_doc" xml:lang="en-US">Unamortized value of RSUs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_UnamortizedValueOfStock" xlink:to="TARA_UnamortizedValueOfStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TARA_UnamortizedValueOfStock_doc" xml:lang="en-US">Unamortized value of stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_VestedOptionsPercentage" xlink:to="TARA_VestedOptionsPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TARA_VestedOptionsPercentage_doc" xml:lang="en-US">Vested options, percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_WeightedAverageGrantDateFairValue" xlink:to="TARA_WeightedAverageGrantDateFairValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TARA_WeightedAverageGrantDateFairValue_doc" xml:lang="en-US">Weighted average grant date fair value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_StockIssuedDuringPeriodValueIssuedForSettlementOfRestrictedStockUnits" xlink:to="TARA_StockIssuedDuringPeriodValueIssuedForSettlementOfRestrictedStockUnits_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TARA_StockIssuedDuringPeriodValueIssuedForSettlementOfRestrictedStockUnits_doc" xml:lang="en-US">Rhe value of restricted stock units issued for settlement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_StockIssuedDuringPeriodSharesIssuedForSettlementOfRestrictedStockUnits" xlink:to="TARA_StockIssuedDuringPeriodSharesIssuedForSettlementOfRestrictedStockUnits_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TARA_StockIssuedDuringPeriodSharesIssuedForSettlementOfRestrictedStockUnits_doc" xml:lang="en-US">Number of shares issued for restricted stock units settlement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_StockIssueDuringPeriodvalueIssuedForCapitalRaise" xlink:to="TARA_StockIssueDuringPeriodvalueIssuedForCapitalRaise_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TARA_StockIssueDuringPeriodvalueIssuedForCapitalRaise_doc" xml:lang="en-US">Value of stock issued for raise of common stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_ProceedsFrompublicOfferingGross" xlink:to="TARA_ProceedsFrompublicOfferingGross_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TARA_ProceedsFrompublicOfferingGross_doc" xml:lang="en-US">Cash inflow from gross proceeds of offering.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_AggregateOfSharesOfCommonStock" xlink:to="TARA_AggregateOfSharesOfCommonStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TARA_AggregateOfSharesOfCommonStock_doc" xml:lang="en-US">Aggregate of shares of common stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_NetProceeds" xlink:to="TARA_NetProceeds_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TARA_NetProceeds_doc" xml:lang="en-US">Amount of net proceeds.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" xlink:to="TARA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageGrantDateFairValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TARA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageGrantDateFairValue_doc" xml:lang="en-US">The weighted average exercised fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_IncrementalValue" xlink:to="TARA_IncrementalValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TARA_IncrementalValue_doc" xml:lang="en-US">Amount of incremental value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeited" xlink:to="TARA_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeited_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TARA_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeited_doc" xml:lang="en-US">Intrinsic value of Forfeited under share-based payment arrangement. Excludes share and unit options.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_PresentValueOfFutureMinimumLeasePaymentsForOurOperatingLeaseLiabilities" xlink:to="TARA_PresentValueOfFutureMinimumLeasePaymentsForOurOperatingLeaseLiabilities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TARA_PresentValueOfFutureMinimumLeasePaymentsForOurOperatingLeaseLiabilities_doc" xml:lang="en-US">Present value of future minimum lease payments for our operating lease liabilities.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_CommonStockIssuanceAndOutstandingPercentage" xlink:to="TARA_CommonStockIssuanceAndOutstandingPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TARA_CommonStockIssuanceAndOutstandingPercentage_doc" xml:lang="en-US">Common stock issuance and outstanding percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_DeferredTaxLiabilitiesDepreciation" xlink:to="TARA_DeferredTaxLiabilitiesDepreciation_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TARA_DeferredTaxLiabilitiesDepreciation_doc" xml:lang="en-US">Amount of depreciation deferred tax liabilities.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_DeferredTaxAssetsOrganizationCostslegalFees" xlink:to="TARA_DeferredTaxAssetsOrganizationCostslegalFees_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TARA_DeferredTaxAssetsOrganizationCostslegalFees_doc" xml:lang="en-US">Amount of organization costs deferred tax assets.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_DeferredTaxAssetsRestrictedStockExpense" xlink:to="TARA_DeferredTaxAssetsRestrictedStockExpense_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TARA_DeferredTaxAssetsRestrictedStockExpense_doc" xml:lang="en-US">Amount of restricted stock expense deferred tax assets.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_RestrictedStockUnitsExpense" xlink:to="TARA_RestrictedStockUnitsExpense_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TARA_RestrictedStockUnitsExpense_doc" xml:lang="en-US">Amount of restricted stock unit deferred tax assets.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_DeferredTaxAssetsCharitableContributions" xlink:to="TARA_DeferredTaxAssetsCharitableContributions_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TARA_DeferredTaxAssetsCharitableContributions_doc" xml:lang="en-US">Amount of charitable contribution deferred tax assets.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_PercentageOfAnnualDeductionLimitation" xlink:to="TARA_PercentageOfAnnualDeductionLimitation_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TARA_PercentageOfAnnualDeductionLimitation_doc" xml:lang="en-US">Percentage of annual deduction limitation on taxable income.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_NetOperatingLossAfterApplication" xlink:to="TARA_NetOperatingLossAfterApplication_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TARA_NetOperatingLossAfterApplication_doc" xml:lang="en-US">Amount of net operating loss after application.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_DeferredTaxAssetsOperatingLeaseLiability" xlink:to="TARA_DeferredTaxAssetsOperatingLeaseLiability_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TARA_DeferredTaxAssetsOperatingLeaseLiability_doc" xml:lang="en-US">Operating lease liability.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_DeferredTaxLiabilitiesOperatingRightofuseAsset" xlink:to="TARA_DeferredTaxLiabilitiesOperatingRightofuseAsset_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TARA_DeferredTaxLiabilitiesOperatingRightofuseAsset_doc" xml:lang="en-US">Operating right-of-use asset.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_TwentySeventeenEquityIncentivePlanMember" xlink:to="TARA_TwentySeventeenEquityIncentivePlanMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_TwentySeventeenEquityIncentivePlanMember_2_lbl" xml:lang="en-US">TwentySeventeenEquityIncentivePlanMember</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_TwentyFourteenEquityIncentivePlanMember" xlink:to="TARA_TwentyFourteenEquityIncentivePlanMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_TwentyFourteenEquityIncentivePlanMember_2_lbl" xml:lang="en-US">TwentyFourteenEquityIncentivePlanMember</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_2_lbl" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeExpenseNet_2_lbl" xml:lang="en-US">Interest Income (Expense), Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_2_lbl" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_IncreaseDecreaseRightofuseLiability" xlink:to="TARA_IncreaseDecreaseRightofuseLiability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_IncreaseDecreaseRightofuseLiability_2_lbl" xml:lang="en-US">IncreaseDecreaseRightofuseLiability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfShortTermDebt" xlink:to="us-gaap_RepaymentsOfShortTermDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfShortTermDebt_2_lbl" xml:lang="en-US">Repayments of Short-term Debt</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashNoncurrent_2_lbl" xml:lang="en-US">Restricted Cash, Noncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_2_lbl" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_2_lbl" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_2_lbl" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_RestrictCash" xlink:to="TARA_RestrictCash_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_RestrictCash_2_lbl" xml:lang="en-US">RestrictCash</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_AssetsAcquiredAndLiabilitiesAssumedRestrictedCash" xlink:to="TARA_AssetsAcquiredAndLiabilitiesAssumedRestrictedCash_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_AssetsAcquiredAndLiabilitiesAssumedRestrictedCash_2_lbl" xml:lang="en-US">AssetsAcquiredAndLiabilitiesAssumedRestrictedCash</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_AssetsAcquiredAndLiabilitiesAssumedPrepaidExpensesAndOtherAssets" xlink:to="TARA_AssetsAcquiredAndLiabilitiesAssumedPrepaidExpensesAndOtherAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_AssetsAcquiredAndLiabilitiesAssumedPrepaidExpensesAndOtherAssets_2_lbl" xml:lang="en-US">AssetsAcquiredAndLiabilitiesAssumedPrepaidExpensesAndOtherAssets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_AssetsAcquiredAndLiabilitiesAssumedGoodwill" xlink:to="TARA_AssetsAcquiredAndLiabilitiesAssumedGoodwill_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_AssetsAcquiredAndLiabilitiesAssumedGoodwill_2_lbl" xml:lang="en-US">AssetsAcquiredAndLiabilitiesAssumedGoodwill</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_AssetsAcquiredAndLiabilitiesAssumedAccruedExpenses" xlink:to="TARA_AssetsAcquiredAndLiabilitiesAssumedAccruedExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_AssetsAcquiredAndLiabilitiesAssumedAccruedExpenses_2_lbl" xml:lang="en-US">AssetsAcquiredAndLiabilitiesAssumedAccruedExpenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:to="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_2_lbl" xml:lang="en-US">Business Acquisition, Pro Forma Net Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_ReverseBusinessCombination" xlink:to="TARA_ReverseBusinessCombination_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_ReverseBusinessCombination_3_lbl" xml:lang="en-US">ReverseBusinessCombination</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_2_lbl" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_2_lbl" xml:lang="en-US">Operating Leases, Future Minimum Payments Due</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_2_lbl" xml:lang="en-US">Accrued Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromConvertibleDebt_2_lbl" xml:lang="en-US">Proceeds from Convertible Debt</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_NetProceeds" xlink:to="TARA_NetProceeds_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_NetProceeds_3_lbl" xml:lang="en-US">NetProceeds</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercisable" xlink:to="TARA_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercisable_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercisable_3_lbl" xml:lang="en-US">SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercisable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceExercisable" xlink:to="TARA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceExercisable_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceExercisable_3_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceExercisable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTermGranted" xlink:to="TARA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTermGranted_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTermGranted_2_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTermGranted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTermExercisable" xlink:to="TARA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTermExercisable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTermExercisable_2_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTermExercisable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted" xlink:to="TARA_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted_2_lbl" xml:lang="en-US">SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeited" xlink:to="TARA_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeited_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeited_3_lbl" xml:lang="en-US">SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisable" xlink:to="TARA_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisable_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisable_3_lbl" xml:lang="en-US">SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_StocksIssuedDuringPeriodValueNewIssues" xlink:to="TARA_StocksIssuedDuringPeriodValueNewIssues_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_StocksIssuedDuringPeriodValueNewIssues_3_lbl" xml:lang="en-US">StocksIssuedDuringPeriodValueNewIssues</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_ShareBasedCompensationGrantDateFairValue" xlink:to="TARA_ShareBasedCompensationGrantDateFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_ShareBasedCompensationGrantDateFairValue_2_lbl" xml:lang="en-US">ShareBasedCompensationGrantDateFairValue</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TARA_DeferredTaxLiabilitiesDepreciation" xlink:to="TARA_DeferredTaxLiabilitiesDepreciation_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TARA_DeferredTaxLiabilitiesDepreciation_3_lbl" xml:lang="en-US">DeferredTaxLiabilitiesDepreciation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome" xlink:to="us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome_2_lbl" xml:lang="en-US">Deferred Tax Liabilities, Tax Deferred Income</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>19
<FILENAME>tara-20201231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoXBRL; Version: 5.6b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Source; Value: tara%2D20201231.xfr; Date: 2021%2D03%2D10T22:42:15Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://artaratx.com/role/DocumentAndEntityInformation" xlink:href="tara-20201231.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/BalanceSheets" xlink:href="tara-20201231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/BalanceSheetsParenthetical" xlink:href="tara-20201231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/StatementsOfOperations" xlink:href="tara-20201231.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/StatementsOfChangesInStockholdersEquityDeficit" xlink:href="tara-20201231.xsd#StatementsOfChangesInStockholdersEquityDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/StatementsOfCashFlows" xlink:href="tara-20201231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/BusinessLiquidityAndCapitalResources" xlink:href="tara-20201231.xsd#BusinessLiquidityAndCapitalResources" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="tara-20201231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/ReverseMergerWithProtaraAndRecapitalization" xlink:href="tara-20201231.xsd#ReverseMergerWithProtaraAndRecapitalization" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/PropertyAndEquipment" xlink:href="tara-20201231.xsd#PropertyAndEquipment" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/AccruedExpenses" xlink:href="tara-20201231.xsd#AccruedExpenses" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/Short-termDebt" xlink:href="tara-20201231.xsd#Short-termDebt" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/CommitmentsAndContingencies" xlink:href="tara-20201231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/StockholdersEquity" xlink:href="tara-20201231.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/Stock-basedCompensation" xlink:href="tara-20201231.xsd#Stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/IncomeTaxes" xlink:href="tara-20201231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/EmployeeBenefitPlan" xlink:href="tara-20201231.xsd#EmployeeBenefitPlan" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/Covid-19" xlink:href="tara-20201231.xsd#Covid-19" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/SubsequentEvents" xlink:href="tara-20201231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="tara-20201231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="tara-20201231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/ReverseMergerWithProtaraAndRecapitalizationTables" xlink:href="tara-20201231.xsd#ReverseMergerWithProtaraAndRecapitalizationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/PropertyAndEquipmentTables" xlink:href="tara-20201231.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/AccruedExpensesTables" xlink:href="tara-20201231.xsd#AccruedExpensesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/CommitmentsAndContingenciesTables" xlink:href="tara-20201231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/Stock-basedCompensationTables" xlink:href="tara-20201231.xsd#Stock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/IncomeTaxesTables" xlink:href="tara-20201231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/BusinessLiquidityAndCapitalResourcesDetails" xlink:href="tara-20201231.xsd#BusinessLiquidityAndCapitalResourcesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:href="tara-20201231.xsd#SummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/SummaryOfSignificantAccountingPoliciesDetailsTextual" xlink:href="tara-20201231.xsd#SummaryOfSignificantAccountingPoliciesDetailsTextual" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/ReverseMergerWithProtaraAndRecapitalizationDetails" xlink:href="tara-20201231.xsd#ReverseMergerWithProtaraAndRecapitalizationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/ReverseMergerWithProtaraAndRecapitalizationDetails1" xlink:href="tara-20201231.xsd#ReverseMergerWithProtaraAndRecapitalizationDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/ReverseMergerWithProtaraAndRecapitalizationDetailsTextual" xlink:href="tara-20201231.xsd#ReverseMergerWithProtaraAndRecapitalizationDetailsTextual" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/PropertyAndEquipmentDetails" xlink:href="tara-20201231.xsd#PropertyAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/PropertyAndEquipmentDetailsTextual" xlink:href="tara-20201231.xsd#PropertyAndEquipmentDetailsTextual" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/AccruedExpensesDetails" xlink:href="tara-20201231.xsd#AccruedExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/Short-termDebtDetails" xlink:href="tara-20201231.xsd#Short-termDebtDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/CommitmentsAndContingenciesDetails" xlink:href="tara-20201231.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/CommitmentsAndContingenciesDetails1" xlink:href="tara-20201231.xsd#CommitmentsAndContingenciesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/CommitmentsAndContingenciesDetailsTextual" xlink:href="tara-20201231.xsd#CommitmentsAndContingenciesDetailsTextual" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/StockholdersEquityDetails" xlink:href="tara-20201231.xsd#StockholdersEquityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/Stock-basedCompensationDetails" xlink:href="tara-20201231.xsd#Stock-basedCompensationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/Stock-basedCompensationDetails1" xlink:href="tara-20201231.xsd#Stock-basedCompensationDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/Stock-basedCompensationDetails2" xlink:href="tara-20201231.xsd#Stock-basedCompensationDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/Stock-basedCompensationDetails3" xlink:href="tara-20201231.xsd#Stock-basedCompensationDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/Stock-basedCompensationDetails4" xlink:href="tara-20201231.xsd#Stock-basedCompensationDetails4" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/Stock-basedCompensationDetailsTextual" xlink:href="tara-20201231.xsd#Stock-basedCompensationDetailsTextual" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/IncomeTaxesDetails" xlink:href="tara-20201231.xsd#IncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/IncomeTaxesDetails1" xlink:href="tara-20201231.xsd#IncomeTaxesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/IncomeTaxesDetails2" xlink:href="tara-20201231.xsd#IncomeTaxesDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/IncomeTaxesDetailsTextual" xlink:href="tara-20201231.xsd#IncomeTaxesDetailsTextual" xlink:type="simple" />
    <link:roleRef roleURI="http://artaratx.com/role/EmployeeBenefitPlanDetails" xlink:href="tara-20201231.xsd#EmployeeBenefitPlanDetails" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://artaratx.com/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information">
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_DocumentAndEntityInformationAbstract" xlink:label="loc_TARADocumentAndEntityInformationAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARADocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARADocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARADocumentAndEntityInformationAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARADocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARADocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARADocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARADocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARADocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARADocumentAndEntityInformationAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARADocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARADocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARADocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARADocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARADocumentAndEntityInformationAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARADocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARADocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARADocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARADocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARADocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARADocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://artaratx.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaapRestrictedCashCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapRestrictedCashCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaapDeferredOfferingCosts" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapDeferredOfferingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="loc_us-gaapAssetsNoncurrentAbstract" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsNoncurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndInvestments" xlink:label="loc_us-gaapRestrictedCashAndInvestments" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapRestrictedCashAndInvestments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaapGoodwill" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaapLiabilitiesNoncurrentAbstract" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://artaratx.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_Series1PreferredStockMember" xlink:label="loc_TARASeries1PreferredStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_TARASeries1PreferredStockMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://artaratx.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Consolidated Statements of Operations">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaapInterestIncomeExpenseNet" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInterestIncomeExpenseNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaapEarningsPerShareBasicAndDiluted" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasicAndDiluted" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://artaratx.com/role/StatementsOfChangesInStockholdersEquityDeficit" xlink:title="00000005 - Statement - Consolidated Statements of Changes In Stockholders&apos; Equity (Deficit)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="50" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_Series1ConvertiblePreferredStockMember" xlink:label="loc_TARASeries1ConvertiblePreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_TARASeries1ConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_IssuanceOfCommonStockInArtaraPrivatePlacementNetOfOfferingCosts" xlink:label="loc_TARAIssuanceOfCommonStockInArtaraPrivatePlacementNetOfOfferingCosts" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TARAIssuanceOfCommonStockInArtaraPrivatePlacementNetOfOfferingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_IssuanceOfCommonStockInArtaraPrivatePlacementNetOfOfferingCostsShares" xlink:label="loc_TARAIssuanceOfCommonStockInArtaraPrivatePlacementNetOfOfferingCostsShares" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TARAIssuanceOfCommonStockInArtaraPrivatePlacementNetOfOfferingCostsShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_IssuanceOfSeries1ConvertiblePreferredStockInProteonPrivatePlacementNetOfOfferingCosts" xlink:label="loc_TARAIssuanceOfSeries1ConvertiblePreferredStockInProteonPrivatePlacementNetOfOfferingCosts" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TARAIssuanceOfSeries1ConvertiblePreferredStockInProteonPrivatePlacementNetOfOfferingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_IssuanceOfSeries1ConvertiblePreferredStockInProteonPrivatePlacementNetOfOfferingCostsShares" xlink:label="loc_TARAIssuanceOfSeries1ConvertiblePreferredStockInProteonPrivatePlacementNetOfOfferingCostsShares" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TARAIssuanceOfSeries1ConvertiblePreferredStockInProteonPrivatePlacementNetOfOfferingCostsShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_StockIssuedDuringPeriodValueIssuanceOfSeries1ConvertiblePreferredStockNetOfOfferingCosts" xlink:label="loc_TARAStockIssuedDuringPeriodValueIssuanceOfSeries1ConvertiblePreferredStockNetOfOfferingCosts" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TARAStockIssuedDuringPeriodValueIssuanceOfSeries1ConvertiblePreferredStockNetOfOfferingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_StockIssuedDuringPeriodSharesIssuanceOfSeries1ConvertiblePreferredStockNetOfOfferingCosts" xlink:label="loc_TARAStockIssuedDuringPeriodSharesIssuanceOfSeries1ConvertiblePreferredStockNetOfOfferingCosts" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TARAStockIssuedDuringPeriodSharesIssuanceOfSeries1ConvertiblePreferredStockNetOfOfferingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_StockIssuedDuringPeriodValueIssuedForSettlementOfRestrictedStockUnits" xlink:label="loc_TARAStockIssuedDuringPeriodValueIssuedForSettlementOfRestrictedStockUnits" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TARAStockIssuedDuringPeriodValueIssuedForSettlementOfRestrictedStockUnits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_StockIssuedDuringPeriodSharesIssuedForSettlementOfRestrictedStockUnits" xlink:label="loc_TARAStockIssuedDuringPeriodSharesIssuedForSettlementOfRestrictedStockUnits" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TARAStockIssuedDuringPeriodSharesIssuedForSettlementOfRestrictedStockUnits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalOther" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_StockIssueDuringPeriodvalueIssuedForCapitalRaise" xlink:label="loc_TARAStockIssueDuringPeriodvalueIssuedForCapitalRaise" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TARAStockIssueDuringPeriodvalueIssuedForCapitalRaise" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_Issuanceofcommonstockinseptembercapitalraiseshares" xlink:label="loc_TARAIssuanceofcommonstockinseptembercapitalraiseshares" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TARAIssuanceofcommonstockinseptembercapitalraiseshares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://artaratx.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Consolidated Statements Of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_AmortizationOfOperatingLeaseRightsofuseAsset" xlink:label="loc_TARAAmortizationOfOperatingLeaseRightsofuseAsset" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_TARAAmortizationOfOperatingLeaseRightsofuseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherNoncurrentAssets" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherNoncurrentAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_IncreaseDecreaseRightofuseLiability" xlink:label="loc_TARAIncreaseDecreaseRightofuseLiability" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_TARAIncreaseDecreaseRightofuseLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_CashAndRestrictedCashAcquiredInConnectionWithReverseMergerWithArtaraTherapeuticsInc." xlink:label="loc_TARACashAndRestrictedCashAcquiredInConnectionWithReverseMergerWithArtaraTherapeuticsInc." />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_TARACashAndRestrictedCashAcquiredInConnectionWithReverseMergerWithArtaraTherapeuticsInc." xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_ProceedsFromProteonPrivatePlacementNetOfOfferingCosts" xlink:label="loc_TARAProceedsFromProteonPrivatePlacementNetOfOfferingCosts" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_TARAProceedsFromProteonPrivatePlacementNetOfOfferingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfConvertiblePreferredStock" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_ProceedsFromIssuancesOfConvertiblePreferredStock" xlink:label="loc_TARAProceedsFromIssuancesOfConvertiblePreferredStock" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_TARAProceedsFromIssuancesOfConvertiblePreferredStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_ProceedsFromUnderwritersOverallotmentOption" xlink:label="loc_TARAProceedsFromUnderwritersOverallotmentOption" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_TARAProceedsFromUnderwritersOverallotmentOption" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfShortTermDebt" xlink:label="loc_us-gaapRepaymentsOfShortTermDebt" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapRepaymentsOfShortTermDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaapRestrictedCashCurrent" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract" xlink:to="loc_us-gaapRestrictedCashCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaapRestrictedCashNoncurrent" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract" xlink:to="loc_us-gaapRestrictedCashNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_ReconciliationOfRestrictedCashAndCashEquivalents" xlink:label="loc_TARAReconciliationOfRestrictedCashAndCashEquivalents" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract" xlink:to="loc_TARAReconciliationOfRestrictedCashAndCashEquivalents" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_CashPaidForAbstract" xlink:label="loc_TARACashPaidForAbstract" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_TARACashPaidForAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaapInterestPaidNet" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARACashPaidForAbstract" xlink:to="loc_us-gaapInterestPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaapIncomeTaxesPaid" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARACashPaidForAbstract" xlink:to="loc_us-gaapIncomeTaxesPaid" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_DeferredOfferingCostsRecordedInAccruedExpenses" xlink:label="loc_TARADeferredOfferingCostsRecordedInAccruedExpenses" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_TARADeferredOfferingCostsRecordedInAccruedExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_DeferredOfferingCostsRecognizedThatWerePreviouslyRecordedInAccruedExpenses" xlink:label="loc_TARADeferredOfferingCostsRecognizedThatWerePreviouslyRecordedInAccruedExpenses" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_TARADeferredOfferingCostsRecognizedThatWerePreviouslyRecordedInAccruedExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_PurchaseOfInsuranceAgreementWithNotesPayable" xlink:label="loc_TARAPurchaseOfInsuranceAgreementWithNotesPayable" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_TARAPurchaseOfInsuranceAgreementWithNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_CommonStockIssuedInConnectionWithReverseMerger" xlink:label="loc_TARACommonStockIssuedInConnectionWithReverseMerger" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_TARACommonStockIssuedInConnectionWithReverseMerger" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://artaratx.com/role/BusinessLiquidityAndCapitalResources" xlink:title="00000007 - Disclosure - Business, Liquidity and Capital Resources">
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_BusinessLiquidityAndCapitalResourcesAbstract" xlink:label="loc_TARABusinessLiquidityAndCapitalResourcesAbstract" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_BusinessLiquidityAndCapitalResourcesTextBlock" xlink:label="loc_TARABusinessLiquidityAndCapitalResourcesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARABusinessLiquidityAndCapitalResourcesAbstract" xlink:to="loc_TARABusinessLiquidityAndCapitalResourcesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://artaratx.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000008 - Disclosure - Summary of Significant Accounting Policies">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://artaratx.com/role/ReverseMergerWithProtaraAndRecapitalization" xlink:title="00000009 - Disclosure - Reverse Merger with Protara and Recapitalization">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaapBusinessCombinationsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="loc_us-gaapBusinessCombinationDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationsAbstract" xlink:to="loc_us-gaapBusinessCombinationDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://artaratx.com/role/PropertyAndEquipment" xlink:title="00000010 - Disclosure - Property and Equipment">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://artaratx.com/role/AccruedExpenses" xlink:title="00000011 - Disclosure - Accrued Expenses">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://artaratx.com/role/Short-termDebt" xlink:title="00000012 - Disclosure - Short-Term Debt">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTextBlock" xlink:label="loc_us-gaapShortTermDebtTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapShortTermDebtTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://artaratx.com/role/CommitmentsAndContingencies" xlink:title="00000013 - Disclosure - Commitments and Contingencies">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://artaratx.com/role/StockholdersEquity" xlink:title="00000014 - Disclosure - Stockholders&apos; Equity">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://artaratx.com/role/Stock-basedCompensation" xlink:title="00000015 - Disclosure -  Stock-Based Compensation">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://artaratx.com/role/IncomeTaxes" xlink:title="00000016 - Disclosure -  Income Taxes">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://artaratx.com/role/EmployeeBenefitPlan" xlink:title="00000017 - Disclosure - Employee Benefit Plan">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaapCompensationAndRetirementDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="loc_us-gaapCompensationAndEmployeeBenefitPlansTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCompensationAndRetirementDisclosureAbstract" xlink:to="loc_us-gaapCompensationAndEmployeeBenefitPlansTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://artaratx.com/role/Covid-19" xlink:title="00000018 - Disclosure - COVID-19">
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_Covid19Abstract" xlink:label="loc_TARACovid19Abstract" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_Covid19DisclosureTextBlock" xlink:label="loc_TARACovid19DisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARACovid19Abstract" xlink:to="loc_TARACovid19DisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://artaratx.com/role/SubsequentEvents" xlink:title="00000019 - Disclosure - Subsequent Events">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://artaratx.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000020 - Disclosure - Summary of Significant Accounting Policies (Policies)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaapConsolidationPolicyTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConsolidationPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaapCashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsPolicyTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapGoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaapConcentrationRiskCreditRisk" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConcentrationRiskCreditRisk" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="loc_us-gaapBusinessCombinationsPolicy" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBusinessCombinationsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:label="loc_us-gaapSubsequentEventsPolicyPolicyTextBlock" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSubsequentEventsPolicyPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://artaratx.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000021 - Disclosure - Summary of Significant Accounting Policies (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:label="loc_us-gaapScheduleOfWeightedAverageNumberOfSharesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://artaratx.com/role/ReverseMergerWithProtaraAndRecapitalizationTables" xlink:title="00000022 - Disclosure - Reverse Merger with Protara and Recapitalization (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaapBusinessCombinationsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:label="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationsAbstract" xlink:to="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:label="loc_us-gaapBusinessAcquisitionProFormaInformationTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationsAbstract" xlink:to="loc_us-gaapBusinessAcquisitionProFormaInformationTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://artaratx.com/role/PropertyAndEquipmentTables" xlink:title="00000023 - Disclosure - Property and Equipment (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://artaratx.com/role/AccruedExpensesTables" xlink:title="00000024 - Disclosure - Accrued Expenses (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfAccruedLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://artaratx.com/role/CommitmentsAndContingenciesTables" xlink:title="00000025 - Disclosure - Commitments and Contingencies (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLeaseIncomeTableTextBlock" xlink:label="loc_us-gaapOperatingLeaseLeaseIncomeTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeaseLeaseIncomeTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_us-gaapScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://artaratx.com/role/Stock-basedCompensationTables" xlink:title="00000026 - Disclosure -  Stock-Based Compensation (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_IssuanceOfStockOptionsAndRestrictedStockUnitsToEmployeesAndDirectorsTableTextBlock" xlink:label="loc_TARAIssuanceOfStockOptionsAndRestrictedStockUnitsToEmployeesAndDirectorsTableTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_TARAIssuanceOfStockOptionsAndRestrictedStockUnitsToEmployeesAndDirectorsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://artaratx.com/role/IncomeTaxesTables" xlink:title="00000027 - Disclosure -  Income Taxes (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaapScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://artaratx.com/role/BusinessLiquidityAndCapitalResourcesDetails" xlink:title="00000028 - Disclosure - Business, Liquidity and Capital Resources (Details)">
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_BusinessLiquidityAndCapitalResourcesAbstract" xlink:label="loc_TARABusinessLiquidityAndCapitalResourcesAbstract" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_BusinessLiquidityAndCapitalResourcesTextualAbstract" xlink:label="loc_TARABusinessLiquidityAndCapitalResourcesTextualAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARABusinessLiquidityAndCapitalResourcesAbstract" xlink:to="loc_TARABusinessLiquidityAndCapitalResourcesTextualAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARABusinessLiquidityAndCapitalResourcesTextualAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARABusinessLiquidityAndCapitalResourcesTextualAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_WorkingCapital" xlink:label="loc_TARAWorkingCapital" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARABusinessLiquidityAndCapitalResourcesTextualAbstract" xlink:to="loc_TARAWorkingCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARABusinessLiquidityAndCapitalResourcesTextualAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARABusinessLiquidityAndCapitalResourcesTextualAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARABusinessLiquidityAndCapitalResourcesTextualAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_NetOfOfferingCosts" xlink:label="loc_TARANetOfOfferingCosts" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARABusinessLiquidityAndCapitalResourcesTextualAbstract" xlink:to="loc_TARANetOfOfferingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_ProceedsFrompublicOfferingGross" xlink:label="loc_TARAProceedsFrompublicOfferingGross" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARABusinessLiquidityAndCapitalResourcesTextualAbstract" xlink:to="loc_TARAProceedsFrompublicOfferingGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_PublicOfferingProceedsNet" xlink:label="loc_TARAPublicOfferingProceedsNet" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARABusinessLiquidityAndCapitalResourcesTextualAbstract" xlink:to="loc_TARAPublicOfferingProceedsNet" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://artaratx.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:title="00000029 - Disclosure - Summary of Significant Accounting Policies (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockCompensationPlanMember" xlink:label="loc_us-gaapStockCompensationPlanMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapStockCompensationPlanMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="loc_us-gaapConvertibleDebtSecuritiesMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapConvertibleDebtSecuritiesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://artaratx.com/role/SummaryOfSignificantAccountingPoliciesDetailsTextual" xlink:title="00000030 - Disclosure -  Summary of Significant Accounting Policies (Details Textual)">
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_SummaryOfSignificantAccountingPoliciesDetailsTextualAbstract" xlink:label="loc_TARASummaryOfSignificantAccountingPoliciesDetailsTextualAbstract" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_SummaryOfSignificantAccountingPoliciesTextualAbstract" xlink:label="loc_TARASummaryOfSignificantAccountingPoliciesTextualAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARASummaryOfSignificantAccountingPoliciesDetailsTextualAbstract" xlink:to="loc_TARASummaryOfSignificantAccountingPoliciesTextualAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCollateralForBorrowedSecurities" xlink:label="loc_us-gaapCashCollateralForBorrowedSecurities" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARASummaryOfSignificantAccountingPoliciesTextualAbstract" xlink:to="loc_us-gaapCashCollateralForBorrowedSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTransfersAndChanges" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTransfersAndChanges" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARASummaryOfSignificantAccountingPoliciesTextualAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTransfersAndChanges" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARASummaryOfSignificantAccountingPoliciesTextualAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:label="loc_us-gaapGoodwillWrittenOffRelatedToSaleOfBusinessUnit" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARASummaryOfSignificantAccountingPoliciesTextualAbstract" xlink:to="loc_us-gaapGoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_RestrictCash" xlink:label="loc_TARARestrictCash" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARASummaryOfSignificantAccountingPoliciesTextualAbstract" xlink:to="loc_TARARestrictCash" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://artaratx.com/role/ReverseMergerWithProtaraAndRecapitalizationDetails" xlink:title="00000031 - Disclosure - Reverse Merger with Protara and Recapitalization (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaapBusinessCombinationsAbstract" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_AssetsAcquiredAndLiabilitiesAssumedCash" xlink:label="loc_TARAAssetsAcquiredAndLiabilitiesAssumedCash" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationsAbstract" xlink:to="loc_TARAAssetsAcquiredAndLiabilitiesAssumedCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_AssetsAcquiredAndLiabilitiesAssumedRestrictedCash" xlink:label="loc_TARAAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationsAbstract" xlink:to="loc_TARAAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_AssetsAcquiredAndLiabilitiesAssumedPrepaidExpensesAndOtherAssets" xlink:label="loc_TARAAssetsAcquiredAndLiabilitiesAssumedPrepaidExpensesAndOtherAssets" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationsAbstract" xlink:to="loc_TARAAssetsAcquiredAndLiabilitiesAssumedPrepaidExpensesAndOtherAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_AssetsAcquiredAndLiabilitiesAssumedGoodwill" xlink:label="loc_TARAAssetsAcquiredAndLiabilitiesAssumedGoodwill" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationsAbstract" xlink:to="loc_TARAAssetsAcquiredAndLiabilitiesAssumedGoodwill" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_AssetsAcquiredAndLiabilitiesAssumedAccruedExpenses" xlink:label="loc_TARAAssetsAcquiredAndLiabilitiesAssumedAccruedExpenses" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationsAbstract" xlink:to="loc_TARAAssetsAcquiredAndLiabilitiesAssumedAccruedExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_AssetsAcquiredAndLiabilitiesAssumedTotalPurchasePrice" xlink:label="loc_TARAAssetsAcquiredAndLiabilitiesAssumedTotalPurchasePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationsAbstract" xlink:to="loc_TARAAssetsAcquiredAndLiabilitiesAssumedTotalPurchasePrice" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://artaratx.com/role/ReverseMergerWithProtaraAndRecapitalizationDetails1" xlink:title="00000032 - Disclosure - Reverse Merger with Protara and Recapitalization (Details 1)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaapBusinessCombinationsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:label="loc_us-gaapBusinessAcquisitionsProFormaNetIncomeLoss" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationsAbstract" xlink:to="loc_us-gaapBusinessAcquisitionsProFormaNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_ProFormaLossPerCommonShareBasicAndDiluted" xlink:label="loc_TARAProFormaLossPerCommonShareBasicAndDiluted" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationsAbstract" xlink:to="loc_TARAProFormaLossPerCommonShareBasicAndDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_ProFormaWeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted" xlink:label="loc_TARAProFormaWeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationsAbstract" xlink:to="loc_TARAProFormaWeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://artaratx.com/role/ReverseMergerWithProtaraAndRecapitalizationDetailsTextual" xlink:title="00000033 - Disclosure - Reverse Merger with Protara and Recapitalization (Details Textual)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaapBusinessCombinationsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_EquityIncentivePlanMember" xlink:label="loc_TARAEquityIncentivePlanMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_TARAEquityIncentivePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_EquityIncentivePlanOneMember" xlink:label="loc_TARAEquityIncentivePlanOneMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_TARAEquityIncentivePlanOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapPrivatePlacementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_SeriesAConvertiblePreferredStockMember" xlink:label="loc_TARASeriesAConvertiblePreferredStockMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_TARASeriesAConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_MergerAgreementMember" xlink:label="loc_TARAMergerAgreementMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_TARAMergerAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_BusinessCombinationsTextualAbstract" xlink:label="loc_TARABusinessCombinationsTextualAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TARABusinessCombinationsTextualAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARABusinessCombinationsTextualAbstract" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_OutstandingReverseStock" xlink:label="loc_TARAOutstandingReverseStock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARABusinessCombinationsTextualAbstract" xlink:to="loc_TARAOutstandingReverseStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionRatio1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARABusinessCombinationsTextualAbstract" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionRatio1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_SharesAvailableForIssuance" xlink:label="loc_TARASharesAvailableForIssuance" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARABusinessCombinationsTextualAbstract" xlink:to="loc_TARASharesAvailableForIssuance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_SubscriptionAgreementDescription" xlink:label="loc_TARASubscriptionAgreementDescription" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARABusinessCombinationsTextualAbstract" xlink:to="loc_TARASubscriptionAgreementDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaapConversionOfStockSharesIssued1" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARABusinessCombinationsTextualAbstract" xlink:to="loc_us-gaapConversionOfStockSharesIssued1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaapConvertiblePreferredStockSharesIssuedUponConversion" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARABusinessCombinationsTextualAbstract" xlink:to="loc_us-gaapConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_FairValueOfNetAssets" xlink:label="loc_TARAFairValueOfNetAssets" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARABusinessCombinationsTextualAbstract" xlink:to="loc_TARAFairValueOfNetAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_DescriptionOfOwnershipRights" xlink:label="loc_TARADescriptionOfOwnershipRights" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARABusinessCombinationsTextualAbstract" xlink:to="loc_TARADescriptionOfOwnershipRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_PreMergerShares" xlink:label="loc_TARAPreMergerShares" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARABusinessCombinationsTextualAbstract" xlink:to="loc_TARAPreMergerShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_ReverseBusinessCombination" xlink:label="loc_TARAReverseBusinessCombination" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARABusinessCombinationsTextualAbstract" xlink:to="loc_TARAReverseBusinessCombination" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:label="loc_us-gaapGoodwillWrittenOffRelatedToSaleOfBusinessUnit" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARABusinessCombinationsTextualAbstract" xlink:to="loc_us-gaapGoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:label="loc_us-gaapDeferredTaxLiabilitiesPrepaidExpenses" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARABusinessCombinationsTextualAbstract" xlink:to="loc_us-gaapDeferredTaxLiabilitiesPrepaidExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARABusinessCombinationsTextualAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://artaratx.com/role/PropertyAndEquipmentDetails" xlink:title="00000034 - Disclosure - Property and Equipment (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_ComputerEquipmentAndSoftwareMember" xlink:label="loc_TARAComputerEquipmentAndSoftwareMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_TARAComputerEquipmentAndSoftwareMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_LaboratoryEquipmentMember" xlink:label="loc_TARALaboratoryEquipmentMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_TARALaboratoryEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentOther" xlink:label="loc_us-gaapPropertyPlantAndEquipmentOther" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://artaratx.com/role/PropertyAndEquipmentDetailsTextual" xlink:title="00000035 - Disclosure - Property and Equipment (Details Textual)">
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_PropertyAndEquipmentDetailsTextualAbstract" xlink:label="loc_TARAPropertyAndEquipmentDetailsTextualAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARAPropertyAndEquipmentDetailsTextualAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_PropertyAndEquipmentTextualAbstract" xlink:label="loc_TARAPropertyAndEquipmentTextualAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TARAPropertyAndEquipmentTextualAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARAPropertyAndEquipmentTextualAbstract" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://artaratx.com/role/AccruedExpensesDetails" xlink:title="00000036 - Disclosure - Accrued Expenses (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="loc_us-gaapAccruedEmployeeBenefitsCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedEmployeeBenefitsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedPayrollTaxesCurrent" xlink:label="loc_us-gaapAccruedPayrollTaxesCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedPayrollTaxesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_LegalFeesOfAccruedExpenses" xlink:label="loc_TARALegalFeesOfAccruedExpenses" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_TARALegalFeesOfAccruedExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:label="loc_us-gaapDeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapDeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://artaratx.com/role/Short-termDebtDetails" xlink:title="00000037 - Disclosure - Short-Term Debt (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_ShorttermDebtTextualAbstract" xlink:label="loc_TARAShorttermDebtTextualAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_TARAShorttermDebtTextualAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_DescriptionOfFinancingAgreement" xlink:label="loc_TARADescriptionOfFinancingAgreement" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARAShorttermDebtTextualAbstract" xlink:to="loc_TARADescriptionOfFinancingAgreement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtCurrent" xlink:label="loc_us-gaapDebtCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARAShorttermDebtTextualAbstract" xlink:to="loc_us-gaapDebtCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARAShorttermDebtTextualAbstract" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://artaratx.com/role/CommitmentsAndContingenciesDetails" xlink:title="00000038 - Disclosure - Commitments and Contingencies (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaapBalanceSheetLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapBalanceSheetLocationAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaapBalanceSheetLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBalanceSheetLocationAxis" xlink:to="loc_us-gaapBalanceSheetLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_RightOffUseAssetsMember" xlink:label="loc_TARARightOffUseAssetsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBalanceSheetLocationDomain" xlink:to="loc_TARARightOffUseAssetsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_RightOfUseLiabilityMember" xlink:label="loc_TARARightOfUseLiabilityMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBalanceSheetLocationDomain" xlink:to="loc_TARARightOfUseLiabilityMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_RightOfUseLeaseLiabilityLongTermMember" xlink:label="loc_TARARightOfUseLeaseLiabilityLongTermMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBalanceSheetLocationDomain" xlink:to="loc_TARARightOfUseLeaseLiabilityLongTermMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_RightofuseLiability" xlink:label="loc_TARARightofuseLiability" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TARARightofuseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_RightofuseLeaseLiabilityLongterm" xlink:label="loc_TARARightofuseLeaseLiabilityLongterm" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TARARightofuseLeaseLiabilityLongterm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaapOperatingLeaseCost" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermLeaseCost" xlink:label="loc_us-gaapShortTermLeaseCost" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShortTermLeaseCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaapLeaseCost" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLeaseCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://artaratx.com/role/CommitmentsAndContingenciesDetails1" xlink:title="00000039 - Disclosure - Commitments and Contingencies (Details 1)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInTwoYears" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInThreeYears" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInFourYears" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInFiveYears" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueThereafter" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_PresentValueOfFutureMinimumLeasePaymentsForOurOperatingLeaseLiabilities" xlink:label="loc_TARAPresentValueOfFutureMinimumLeasePaymentsForOurOperatingLeaseLiabilities" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_TARAPresentValueOfFutureMinimumLeasePaymentsForOurOperatingLeaseLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_PresentValueOfFutureMinimumLeasePaymentsShorttermLeases" xlink:label="loc_TARAPresentValueOfFutureMinimumLeasePaymentsShorttermLeases" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_TARAPresentValueOfFutureMinimumLeasePaymentsShorttermLeases" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://artaratx.com/role/CommitmentsAndContingenciesDetailsTextual" xlink:title="00000040 - Disclosure - Commitments and Contingencies (Details Textual)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_TemporaryEmploymentAgreementMember" xlink:label="loc_TARATemporaryEmploymentAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_TARATemporaryEmploymentAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_ClinicalServicesAgreementsMember" xlink:label="loc_TARAClinicalServicesAgreementsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_TARAClinicalServicesAgreementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_FeinsteinAgreementMember" xlink:label="loc_TARAFeinsteinAgreementMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_TARAFeinsteinAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_IowaAgreementMember" xlink:label="loc_TARAIowaAgreementMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_TARAIowaAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_ChugaiPharmaceuticalAgreementMember" xlink:label="loc_TARAChugaiPharmaceuticalAgreementMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_TARAChugaiPharmaceuticalAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtTitleOfIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_DrBuchmanMember" xlink:label="loc_TARADrBuchmanMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_TARADrBuchmanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_CommitmentsTextualAbstract" xlink:label="loc_TARACommitmentsTextualAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TARACommitmentsTextualAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_DescriptionOfAgreements" xlink:label="loc_TARADescriptionOfAgreements" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARACommitmentsTextualAbstract" xlink:to="loc_TARADescriptionOfAgreements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_AnnualBaseSalary" xlink:label="loc_TARAAnnualBaseSalary" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARACommitmentsTextualAbstract" xlink:to="loc_TARAAnnualBaseSalary" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractualObligation" xlink:label="loc_us-gaapContractualObligation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARACommitmentsTextualAbstract" xlink:to="loc_us-gaapContractualObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BroadcastersLicenseAgreementCommitmentsDescription" xlink:label="loc_us-gaapBroadcastersLicenseAgreementCommitmentsDescription" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARACommitmentsTextualAbstract" xlink:to="loc_us-gaapBroadcastersLicenseAgreementCommitmentsDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_RoyaltyPaymentPercentageOfNetSales" xlink:label="loc_TARARoyaltyPaymentPercentageOfNetSales" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARACommitmentsTextualAbstract" xlink:to="loc_TARARoyaltyPaymentPercentageOfNetSales" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArtistAdvancesAndRoyaltyGuaranteesCommitments" xlink:label="loc_us-gaapArtistAdvancesAndRoyaltyGuaranteesCommitments" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARACommitmentsTextualAbstract" xlink:to="loc_us-gaapArtistAdvancesAndRoyaltyGuaranteesCommitments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_ResearchAndDevelopmentExpenses" xlink:label="loc_TARAResearchAndDevelopmentExpenses" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARACommitmentsTextualAbstract" xlink:to="loc_TARAResearchAndDevelopmentExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_PaymentOfAttorneysFees" xlink:label="loc_TARAPaymentOfAttorneysFees" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARACommitmentsTextualAbstract" xlink:to="loc_TARAPaymentOfAttorneysFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_GeneralAndAdministrativeExpenses" xlink:label="loc_TARAGeneralAndAdministrativeExpenses" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARACommitmentsTextualAbstract" xlink:to="loc_TARAGeneralAndAdministrativeExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToEmployees" xlink:label="loc_us-gaapPaymentsToEmployees" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARACommitmentsTextualAbstract" xlink:to="loc_us-gaapPaymentsToEmployees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleLeasebackTransactionMonthlyRentalPayments" xlink:label="loc_us-gaapSaleLeasebackTransactionMonthlyRentalPayments" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARACommitmentsTextualAbstract" xlink:to="loc_us-gaapSaleLeasebackTransactionMonthlyRentalPayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaapProfessionalFees" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARACommitmentsTextualAbstract" xlink:to="loc_us-gaapProfessionalFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_CholineLicenseFee" xlink:label="loc_TARACholineLicenseFee" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARACommitmentsTextualAbstract" xlink:to="loc_TARACholineLicenseFee" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrentAndNoncurrent" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARACommitmentsTextualAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrentAndNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARACommitmentsTextualAbstract" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://artaratx.com/role/StockholdersEquityDetails" xlink:title="00000041 - Disclosure - Stockholders&apos; Equity (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_Series1PreferredStockMember" xlink:label="loc_TARASeries1PreferredStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_TARASeries1PreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_UnderwrittenPublicOfferingMember" xlink:label="loc_TARAUnderwrittenPublicOfferingMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_TARAUnderwrittenPublicOfferingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaapOverAllotmentOptionMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapOverAllotmentOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_StockholdersEquityTextualAbstract" xlink:label="loc_TARAStockholdersEquityTextualAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TARAStockholdersEquityTextualAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARAStockholdersEquityTextualAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARAStockholdersEquityTextualAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARAStockholdersEquityTextualAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/disclosureGuidance" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARAStockholdersEquityTextualAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARAStockholdersEquityTextualAbstract" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARAStockholdersEquityTextualAbstract" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARAStockholdersEquityTextualAbstract" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARAStockholdersEquityTextualAbstract" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaapConversionOfStockSharesIssued1" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARAStockholdersEquityTextualAbstract" xlink:to="loc_us-gaapConversionOfStockSharesIssued1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARAStockholdersEquityTextualAbstract" xlink:to="loc_us-gaapSharesIssuedPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_IncreaseOrDecreaseEquityPercentage" xlink:label="loc_TARAIncreaseOrDecreaseEquityPercentage" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARAStockholdersEquityTextualAbstract" xlink:to="loc_TARAIncreaseOrDecreaseEquityPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionPrice1" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARAStockholdersEquityTextualAbstract" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionPrice1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_AggregateOfSharesOfCommonStock" xlink:label="loc_TARAAggregateOfSharesOfCommonStock" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARAStockholdersEquityTextualAbstract" xlink:to="loc_TARAAggregateOfSharesOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARAStockholdersEquityTextualAbstract" xlink:to="loc_us-gaapSaleOfStockPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaapProceedsFromConvertibleDebt" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARAStockholdersEquityTextualAbstract" xlink:to="loc_us-gaapProceedsFromConvertibleDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_NetProceeds" xlink:label="loc_TARANetProceeds" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARAStockholdersEquityTextualAbstract" xlink:to="loc_TARANetProceeds" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARAStockholdersEquityTextualAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_CommonStockIssuanceAndOutstandingPercentage" xlink:label="loc_TARACommonStockIssuanceAndOutstandingPercentage" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARAStockholdersEquityTextualAbstract" xlink:to="loc_TARACommonStockIssuanceAndOutstandingPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_MaximumAggregateOfferingPrice" xlink:label="loc_TARAMaximumAggregateOfferingPrice" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARAStockholdersEquityTextualAbstract" xlink:to="loc_TARAMaximumAggregateOfferingPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARAStockholdersEquityTextualAbstract" xlink:to="loc_us-gaapSharesIssued" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://artaratx.com/role/Stock-basedCompensationDetails" xlink:title="00000042 - Disclosure -  Stock-Based Compensation (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_RestrictedStockUnitsAbstract" xlink:label="loc_TARARestrictedStockUnitsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TARARestrictedStockUnitsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARARestrictedStockUnitsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARARestrictedStockUnitsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARARestrictedStockUnitsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARARestrictedStockUnitsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_2" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARARestrictedStockUnitsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_WeightedAverageGrantDateFairValueOneAbstract" xlink:label="loc_TARAWeightedAverageGrantDateFairValueOneAbstract" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TARAWeightedAverageGrantDateFairValueOneAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARAWeightedAverageGrantDateFairValueOneAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARAWeightedAverageGrantDateFairValueOneAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARAWeightedAverageGrantDateFairValueOneAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARAWeightedAverageGrantDateFairValueOneAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_2" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARAWeightedAverageGrantDateFairValueOneAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://artaratx.com/role/Stock-basedCompensationDetails1" xlink:title="00000043 - Disclosure -  Stock-Based Compensation (Details 1)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_StockOptionExercisePrice" xlink:label="loc_TARAStockOptionExercisePrice" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TARAStockOptionExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://artaratx.com/role/Stock-basedCompensationDetails2" xlink:title="00000044 - Disclosure -  Stock-Based Compensation (Details 2)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaapEmployeeStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapEmployeeStockMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_OptionsAbstract" xlink:label="loc_TARAOptionsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TARAOptionsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARAOptionsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARAOptionsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARAOptionsAbstract" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARAOptionsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARAOptionsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberExercisable" xlink:label="loc_TARAShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberExercisable" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARAOptionsAbstract" xlink:to="loc_TARAShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberExercisable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_WeightedAverageGrantDateFairValueAbstract" xlink:label="loc_TARAWeightedAverageGrantDateFairValueAbstract" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TARAWeightedAverageGrantDateFairValueAbstract" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARAWeightedAverageGrantDateFairValueAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARAWeightedAverageGrantDateFairValueAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_TARAShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARAWeightedAverageGrantDateFairValueAbstract" xlink:to="loc_TARAShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARAWeightedAverageGrantDateFairValueAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_2" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARAWeightedAverageGrantDateFairValueAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercisable" xlink:label="loc_TARASharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercisable" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARAWeightedAverageGrantDateFairValueAbstract" xlink:to="loc_TARASharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercisable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_WeightedAverageExercisePriceAbstract" xlink:label="loc_TARAWeightedAverageExercisePriceAbstract" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TARAWeightedAverageExercisePriceAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARAWeightedAverageExercisePriceAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARAWeightedAverageExercisePriceAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARAWeightedAverageExercisePriceAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARAWeightedAverageExercisePriceAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARAWeightedAverageExercisePriceAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceExercisable" xlink:label="loc_TARAShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceExercisable" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARAWeightedAverageExercisePriceAbstract" xlink:to="loc_TARAShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceExercisable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_WeightedAverageRemainingContractualTermYearsAbstract" xlink:label="loc_TARAWeightedAverageRemainingContractualTermYearsAbstract" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TARAWeightedAverageRemainingContractualTermYearsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTerm1" xlink:label="loc_TARAShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTerm1" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARAWeightedAverageRemainingContractualTermYearsAbstract" xlink:to="loc_TARAShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTermGranted" xlink:label="loc_TARAShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTermGranted" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARAWeightedAverageRemainingContractualTermYearsAbstract" xlink:to="loc_TARAShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTermGranted" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTerm2" xlink:label="loc_TARAShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTerm2" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARAWeightedAverageRemainingContractualTermYearsAbstract" xlink:to="loc_TARAShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTermExercisable" xlink:label="loc_TARAShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTermExercisable" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARAWeightedAverageRemainingContractualTermYearsAbstract" xlink:to="loc_TARAShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTermExercisable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_AggregateIntrinsicValueAbstract" xlink:label="loc_TARAAggregateIntrinsicValueAbstract" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TARAAggregateIntrinsicValueAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARAAggregateIntrinsicValueAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted" xlink:label="loc_TARASharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARAAggregateIntrinsicValueAbstract" xlink:to="loc_TARASharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeited" xlink:label="loc_TARASharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeited" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARAAggregateIntrinsicValueAbstract" xlink:to="loc_TARASharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeited" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_2" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARAAggregateIntrinsicValueAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisable" xlink:label="loc_TARASharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisable" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARAAggregateIntrinsicValueAbstract" xlink:to="loc_TARASharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://artaratx.com/role/Stock-basedCompensationDetails3" xlink:title="00000045 - Disclosure -  Stock-Based Compensation (Details 3)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://artaratx.com/role/Stock-basedCompensationDetails4" xlink:title="00000046 - Disclosure -  Stock-Based Compensation (Details 4)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://artaratx.com/role/Stock-basedCompensationDetailsTextual" xlink:title="00000047 - Disclosure -  Stock-Based Compensation (Details Textual)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_TwentyFourteenEmployeeStockPurchasePlanMember" xlink:label="loc_TARATwentyFourteenEmployeeStockPurchasePlanMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_TARATwentyFourteenEmployeeStockPurchasePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_TwentyFourteenEquityIncentivePlanMember" xlink:label="loc_TARATwentyFourteenEquityIncentivePlanMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_TARATwentyFourteenEquityIncentivePlanMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_TwentyTwentyInducementPlanMember" xlink:label="loc_TARATwentyTwentyInducementPlanMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_TARATwentyTwentyInducementPlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_TwentySeventeenEquityIncentivePlanMember" xlink:label="loc_TARATwentySeventeenEquityIncentivePlanMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_TARATwentySeventeenEquityIncentivePlanMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtTitleOfIndividualAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_DirectorsOneMember" xlink:label="loc_TARADirectorsOneMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_TARADirectorsOneMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_DirectorsTwoMember" xlink:label="loc_TARADirectorsTwoMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_TARADirectorsTwoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_ConsultantMember" xlink:label="loc_TARAConsultantMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_TARAConsultantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_EmployeesMember" xlink:label="loc_TARAEmployeesMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_TARAEmployeesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_BoardOfDirectorsChairmanMember" xlink:label="loc_srtBoardOfDirectorsChairmanMember" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtBoardOfDirectorsChairmanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaapEmployeeStockMember" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapEmployeeStockMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_StockBasedCompensationTextualAbstract" xlink:label="loc_TARAStockBasedCompensationTextualAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TARAStockBasedCompensationTextualAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_StocksIssuedDuringPeriodValueNewIssues" xlink:label="loc_TARAStocksIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARAStockBasedCompensationTextualAbstract" xlink:to="loc_TARAStocksIssuedDuringPeriodValueNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_SharesAvailableForIssuance" xlink:label="loc_TARASharesAvailableForIssuance" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARAStockBasedCompensationTextualAbstract" xlink:to="loc_TARASharesAvailableForIssuance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockDescriptionOfTransaction" xlink:label="loc_us-gaapSaleOfStockDescriptionOfTransaction" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARAStockBasedCompensationTextualAbstract" xlink:to="loc_us-gaapSaleOfStockDescriptionOfTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARAStockBasedCompensationTextualAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARAStockBasedCompensationTextualAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_VestedOptionsPercentage" xlink:label="loc_TARAVestedOptionsPercentage" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARAStockBasedCompensationTextualAbstract" xlink:to="loc_TARAVestedOptionsPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARAStockBasedCompensationTextualAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_UnamortizedValueOfRsus" xlink:label="loc_TARAUnamortizedValueOfRsus" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARAStockBasedCompensationTextualAbstract" xlink:to="loc_TARAUnamortizedValueOfRsus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_NumberOfSharesRestrictedStock" xlink:label="loc_TARANumberOfSharesRestrictedStock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARAStockBasedCompensationTextualAbstract" xlink:to="loc_TARANumberOfSharesRestrictedStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_WeightedAverageGrantDateFairValue" xlink:label="loc_TARAWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARAStockBasedCompensationTextualAbstract" xlink:to="loc_TARAWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_WeightedAverageRemainingAmortizationPeriod" xlink:label="loc_TARAWeightedAverageRemainingAmortizationPeriod" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARAStockBasedCompensationTextualAbstract" xlink:to="loc_TARAWeightedAverageRemainingAmortizationPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_OptionsDescription" xlink:label="loc_TARAOptionsDescription" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARAStockBasedCompensationTextualAbstract" xlink:to="loc_TARAOptionsDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_UnamortizedValueOfStock" xlink:label="loc_TARAUnamortizedValueOfStock" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARAStockBasedCompensationTextualAbstract" xlink:to="loc_TARAUnamortizedValueOfStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_ShareBasedCompensationGrantDateFairValue" xlink:label="loc_TARAShareBasedCompensationGrantDateFairValue" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARAStockBasedCompensationTextualAbstract" xlink:to="loc_TARAShareBasedCompensationGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARAStockBasedCompensationTextualAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="loc_us-gaapOtherResearchAndDevelopmentExpense" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARAStockBasedCompensationTextualAbstract" xlink:to="loc_us-gaapOtherResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_IncrementalValue" xlink:label="loc_TARAIncrementalValue" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARAStockBasedCompensationTextualAbstract" xlink:to="loc_TARAIncrementalValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARAStockBasedCompensationTextualAbstract" xlink:to="loc_us-gaapSaleOfStockPricePerShare" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_VestPeriod" xlink:label="loc_TARAVestPeriod" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARAStockBasedCompensationTextualAbstract" xlink:to="loc_TARAVestPeriod" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://artaratx.com/role/IncomeTaxesDetails" xlink:title="00000048 - Disclosure -  Income Taxes (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaapCurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapCurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentFederalTaxExpenseBenefit" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="loc_us-gaapCurrentFederalTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentStateAndLocalTaxExpenseBenefit" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="loc_us-gaapCurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentIncomeTaxExpenseBenefit" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="loc_us-gaapCurrentIncomeTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaapDeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredFederalIncomeTaxExpenseBenefit" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="loc_us-gaapDeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredStateAndLocalIncomeTaxExpenseBenefit" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="loc_us-gaapDeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredOtherTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredOtherTaxExpenseBenefit" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="loc_us-gaapDeferredOtherTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://artaratx.com/role/IncomeTaxesDetails1" xlink:title="00000049 - Disclosure -  Income Taxes (Details 1)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_DeferredTaxAssetsAbstract" xlink:label="loc_TARADeferredTaxAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_TARADeferredTaxAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOtherLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOtherLossCarryforwards" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARADeferredTaxAssetsAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOtherLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_DeferredTaxAssetsOrganizationCostslegalFees" xlink:label="loc_TARADeferredTaxAssetsOrganizationCostslegalFees" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARADeferredTaxAssetsAbstract" xlink:to="loc_TARADeferredTaxAssetsOrganizationCostslegalFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARADeferredTaxAssetsAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARADeferredTaxAssetsAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_DeferredTaxAssetsOperatingLeaseLiability" xlink:label="loc_TARADeferredTaxAssetsOperatingLeaseLiability" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARADeferredTaxAssetsAbstract" xlink:to="loc_TARADeferredTaxAssetsOperatingLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_DeferredTaxAssetsRestrictedStockExpense" xlink:label="loc_TARADeferredTaxAssetsRestrictedStockExpense" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARADeferredTaxAssetsAbstract" xlink:to="loc_TARADeferredTaxAssetsRestrictedStockExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_RestrictedStockUnitsExpense" xlink:label="loc_TARARestrictedStockUnitsExpense" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARADeferredTaxAssetsAbstract" xlink:to="loc_TARARestrictedStockUnitsExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_DeferredTaxAssetsCharitableContributions" xlink:label="loc_TARADeferredTaxAssetsCharitableContributions" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARADeferredTaxAssetsAbstract" xlink:to="loc_TARADeferredTaxAssetsCharitableContributions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARADeferredTaxAssetsAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARADeferredTaxAssetsAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARADeferredTaxAssetsAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="loc_us-gaapDeferredTaxLiabilitiesAbstract" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARADeferredTaxAssetsAbstract" xlink:to="loc_us-gaapDeferredTaxLiabilitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_DeferredTaxLiabilitiesOperatingRightofuseAsset" xlink:label="loc_TARADeferredTaxLiabilitiesOperatingRightofuseAsset" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxLiabilitiesAbstract" xlink:to="loc_TARADeferredTaxLiabilitiesOperatingRightofuseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_DeferredTaxLiabilitiesDepreciation" xlink:label="loc_TARADeferredTaxLiabilitiesDepreciation" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxLiabilitiesAbstract" xlink:to="loc_TARADeferredTaxLiabilitiesDepreciation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome" xlink:label="loc_us-gaapDeferredTaxLiabilitiesTaxDeferredIncome" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxLiabilitiesAbstract" xlink:to="loc_us-gaapDeferredTaxLiabilitiesTaxDeferredIncome" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaapDeferredTaxLiabilities" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxLiabilitiesAbstract" xlink:to="loc_us-gaapDeferredTaxLiabilities" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://artaratx.com/role/IncomeTaxesDetails2" xlink:title="00000050 - Disclosure -  Income Taxes (Details 2)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://artaratx.com/role/IncomeTaxesDetailsTextual" xlink:title="00000051 - Disclosure -  Income Taxes (Details Textual)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_IncomeTaxesTextualAbstract" xlink:label="loc_TARAIncomeTaxesTextualAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_TARAIncomeTaxesTextualAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARAIncomeTaxesTextualAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_PercentageOfAnnualDeductionLimitation" xlink:label="loc_TARAPercentageOfAnnualDeductionLimitation" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARAIncomeTaxesTextualAbstract" xlink:to="loc_TARAPercentageOfAnnualDeductionLimitation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARAIncomeTaxesTextualAbstract" xlink:to="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_NetOperatingLossAfterApplication" xlink:label="loc_TARANetOperatingLossAfterApplication" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARAIncomeTaxesTextualAbstract" xlink:to="loc_TARANetOperatingLossAfterApplication" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_MergerDescription" xlink:label="loc_TARAMergerDescription" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARAIncomeTaxesTextualAbstract" xlink:to="loc_TARAMergerDescription" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://artaratx.com/role/EmployeeBenefitPlanDetails" xlink:title="00000052 - Disclosure - Employee Benefit Plan (Details)">
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_EmployeeBenefitPlanDetailsAbstract" xlink:label="loc_TARAEmployeeBenefitPlanDetailsAbstract" />
      <link:loc xlink:type="locator" xlink:href="tara-20201231.xsd#TARA_EmployeeBenefitPlanTextualAbstract" xlink:label="loc_TARAEmployeeBenefitPlanTextualAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARAEmployeeBenefitPlanDetailsAbstract" xlink:to="loc_TARAEmployeeBenefitPlanTextualAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans" xlink:label="loc_us-gaapDescriptionOfDefinedContributionPensionAndOtherPostretirementPlans" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARAEmployeeBenefitPlanTextualAbstract" xlink:to="loc_us-gaapDescriptionOfDefinedContributionPensionAndOtherPostretirementPlans" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherExpenses" xlink:label="loc_us-gaapOtherExpenses" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TARAEmployeeBenefitPlanTextualAbstract" xlink:to="loc_us-gaapOtherExpenses" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140712343956488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Mar. 09, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Protara Therapeutics, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001359931<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36694<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,228,606<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 76,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TARA_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TARA_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TARA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140712350544824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 168,598<span></span>
</td>
<td class="nump">$ 564<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Deferred offering costs</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">122<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">787<span></span>
</td>
<td class="nump">78<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">169,435<span></span>
</td>
<td class="nump">764<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Non-current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndInvestments', window );">Restricted cash, long-term</a></td>
<td class="nump">745<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">1,240<span></span>
</td>
<td class="nump">459<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">29,517<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">2,220<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">203,157<span></span>
</td>
<td class="nump">1,223<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">914<span></span>
</td>
<td class="nump">716<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">1,913<span></span>
</td>
<td class="nump">2,635<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability, current</a></td>
<td class="nump">88<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">2,915<span></span>
</td>
<td class="nump">3,351<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Non-current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, long-term</a></td>
<td class="nump">999<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">3,914<span></span>
</td>
<td class="nump">3,351<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies (Note 7)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Equity (Deficit)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred Stock, $0.001 par value, authorized 10,000,000 shares: Series 1 Convertible Preferred Stock, 8,028 and 0 shares authorized at December 31, 2020 and 2019, respectively, 8,027 and 0 shares issued and outstanding as of December 31, 2020 and 2019, respectively.</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Stock, $0.001 par value, authorized 100,000,000 shares: Common Stock, 11,211,840 and 2,627,533 shares issued and outstanding as of December 31, 2020 and 2019, respectively.</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional Paid in Capital</a></td>
<td class="nump">245,992<span></span>
</td>
<td class="nump">10,651<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated Deficit</a></td>
<td class="num">(46,760)<span></span>
</td>
<td class="num">(12,782)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders' Equity (Deficit)</a></td>
<td class="nump">199,243<span></span>
</td>
<td class="num">(2,128)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Stockholders' Equity (Deficit)</a></td>
<td class="nump">$ 203,157<span></span>
</td>
<td class="nump">$ 1,223<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011391&amp;loc=d3e105025-122735<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash and investments whose use in whole or in part is restricted for the long-term, generally by contractual agreements or regulatory requirements. For use in an unclassified balance sheet.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140712341912264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">11,211,840<span></span>
</td>
<td class="nump">2,627,533<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">11,211,840<span></span>
</td>
<td class="nump">2,627,533<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=TARA_Series1PreferredStockMember', window );">Series 1 Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">8,028<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">8,027<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">8,027<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=TARA_Series1PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=TARA_Series1PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140712341917704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expense:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research &amp; development</a></td>
<td class="nump">$ 11,982<span></span>
</td>
<td class="nump">$ 3,878<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General &amp; administrative</a></td>
<td class="nump">22,462<span></span>
</td>
<td class="nump">3,952<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">34,444<span></span>
</td>
<td class="nump">7,830<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(34,444)<span></span>
</td>
<td class="num">(7,830)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest income, net</a></td>
<td class="num">(466)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income, net</a></td>
<td class="num">(466)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">$ (33,978)<span></span>
</td>
<td class="num">$ (7,830)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted Average Shares Outstanding, basic and diluted</a></td>
<td class="nump">7,233,913<span></span>
</td>
<td class="nump">2,577,493<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share, basic and diluted</a></td>
<td class="num">$ (4.70)<span></span>
</td>
<td class="num">$ (3.04)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140712341040360">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes In Stockholders' Equity (Deficit) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Series 1 Convertible Preferred Stock</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2018</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 9,727<span></span>
</td>
<td class="num">$ (4,952)<span></span>
</td>
<td class="nump">$ 4,778<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2018</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,558,419<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Stock-based compensation - restricted stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">75<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther', window );">Stock-based compensation - restricted stock units</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">36<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation - stock options</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">313<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">313<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_StockIssueDuringPeriodvalueIssuedForCapitalRaise', window );">Issuance of common stock in September capital raise</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_Issuanceofcommonstockinseptembercapitalraiseshares', window );">Issuance of common stock in September capital raise,shares</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">69,114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(7,830)<span></span>
</td>
<td class="num">(7,830)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2019</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">10,651<span></span>
</td>
<td class="num">(12,782)<span></span>
</td>
<td class="num">(2,128)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2019</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,627,533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_IssuanceOfCommonStockInArtaraPrivatePlacementNetOfOfferingCosts', window );">Issuance of Common Stock in ArTara Private Placement, net of offering costs</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,867<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,867<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_IssuanceOfCommonStockInArtaraPrivatePlacementNetOfOfferingCostsShares', window );">Issuance of Common Stock in ArTara Private Placement, net of offering costs, shares</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">284,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Issuance of Common Stock in Proteon Private Placement, net of offering costs</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">12,411<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">12,413<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Issuance of Common Stock in Proteon Private Placement, net of offering costs, shares</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,896,888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_IssuanceOfSeries1ConvertiblePreferredStockInProteonPrivatePlacementNetOfOfferingCosts', window );">Issuance of Series 1 Convertible Preferred Stock in Proteon Private Placement, net of offering costs</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">25,319<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">25,319<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_IssuanceOfSeries1ConvertiblePreferredStockInProteonPrivatePlacementNetOfOfferingCostsShares', window );">Issuance of Series 1 Convertible Preferred Stock in Proteon Private Placement, net of offering costs, shares</a></td>
<td class="nump">3,879<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Reverse business combination</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">34,532<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">34,533<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Reverse business combination, shares</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,033,907<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of Common Stock in Common Offering, net of offering costs</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">73,566<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">73,570<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of Common Stock in Common Offering, net of offering costs, shares</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">4,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_StockIssuedDuringPeriodValueIssuanceOfSeries1ConvertiblePreferredStockNetOfOfferingCosts', window );">Issuance of Series 1 Convertible Preferred Stock in Preferred Offering, net of offering costs</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">66,284<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">66,284<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_StockIssuedDuringPeriodSharesIssuanceOfSeries1ConvertiblePreferredStockNetOfOfferingCosts', window );">Issuance of Series 1 Convertible Preferred Stock in Preferred Offering, net of offering costs, shares</a></td>
<td class="nump">4,148<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of Common Stock in Common Offering (Underwriters Overallotment Option), net of offering costs</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">11,086<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">11,087<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Common Stock in Common Offering (Underwriters Overallotment Option), net of offering costs, shares</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">690,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_StockIssuedDuringPeriodValueIssuedForSettlementOfRestrictedStockUnits', window );">Settlement of restricted stock units</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_StockIssuedDuringPeriodSharesIssuedForSettlementOfRestrictedStockUnits', window );">Settlement of restricted stock units, shares</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">20,870<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">530<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">530<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, shares</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">57,767<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Stock-based compensation - restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther', window );">Stock-based compensation - restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,357<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6,357<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation - stock options</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,389<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,389<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(33,978)<span></span>
</td>
<td class="num">(33,978)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">$ 245,992<span></span>
</td>
<td class="num">$ (46,760)<span></span>
</td>
<td class="nump">$ 199,243<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2020</a></td>
<td class="nump">8,027<span></span>
</td>
<td class="nump">11,211,840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TARA_IssuanceOfCommonStockInArtaraPrivatePlacementNetOfOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TARA_IssuanceOfCommonStockInArtaraPrivatePlacementNetOfOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TARA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TARA_IssuanceOfCommonStockInArtaraPrivatePlacementNetOfOfferingCostsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TARA_IssuanceOfCommonStockInArtaraPrivatePlacementNetOfOfferingCostsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TARA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TARA_IssuanceOfSeries1ConvertiblePreferredStockInProteonPrivatePlacementNetOfOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TARA_IssuanceOfSeries1ConvertiblePreferredStockInProteonPrivatePlacementNetOfOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TARA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TARA_IssuanceOfSeries1ConvertiblePreferredStockInProteonPrivatePlacementNetOfOfferingCostsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TARA_IssuanceOfSeries1ConvertiblePreferredStockInProteonPrivatePlacementNetOfOfferingCostsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TARA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TARA_Issuanceofcommonstockinseptembercapitalraiseshares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TARA_Issuanceofcommonstockinseptembercapitalraiseshares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TARA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TARA_StockIssueDuringPeriodvalueIssuedForCapitalRaise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued for raise of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TARA_StockIssueDuringPeriodvalueIssuedForCapitalRaise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TARA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TARA_StockIssuedDuringPeriodSharesIssuanceOfSeries1ConvertiblePreferredStockNetOfOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Numbr of shares issuance of Series 1 Convertible Preferred Stock, net of offering costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TARA_StockIssuedDuringPeriodSharesIssuanceOfSeries1ConvertiblePreferredStockNetOfOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TARA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TARA_StockIssuedDuringPeriodSharesIssuedForSettlementOfRestrictedStockUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for restricted stock units settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TARA_StockIssuedDuringPeriodSharesIssuedForSettlementOfRestrictedStockUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TARA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TARA_StockIssuedDuringPeriodValueIssuanceOfSeries1ConvertiblePreferredStockNetOfOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value issuance of Series 1 Convertible Preferred Stock, net of offering costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TARA_StockIssuedDuringPeriodValueIssuanceOfSeries1ConvertiblePreferredStockNetOfOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TARA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TARA_StockIssuedDuringPeriodValueIssuedForSettlementOfRestrictedStockUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rhe value of restricted stock units issued for settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TARA_StockIssuedDuringPeriodValueIssuedForSettlementOfRestrictedStockUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TARA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other increase (decrease) in additional paid in capital (APIC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140712341060968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements Of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (33,978)<span></span>
</td>
<td class="num">$ (7,830)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="nump">9,746<span></span>
</td>
<td class="nump">424<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_AmortizationOfOperatingLeaseRightsofuseAsset', window );">Amortization of operating lease right-of-use asset</a></td>
<td class="nump">93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">103<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,405<span></span>
</td>
<td class="num">(37)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other Assets</a></td>
<td class="nump">58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">198<span></span>
</td>
<td class="nump">366<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="num">(966)<span></span>
</td>
<td class="nump">2,050<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_IncreaseDecreaseRightofuseLiability', window );">Right-of-use liability</a></td>
<td class="num">(66)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(23,407)<span></span>
</td>
<td class="num">(5,011)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_CashAndRestrictedCashAcquiredInConnectionWithReverseMergerWithArtaraTherapeuticsInc.', window );">Cash and restricted cash acquired in connection with the reverse merger with ArTara Therapeutics, Inc.</a></td>
<td class="nump">3,719<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(884)<span></span>
</td>
<td class="num">(475)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by/(used in) investing activities</a></td>
<td class="nump">2,835<span></span>
</td>
<td class="num">(475)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from - ArTara Private Placement, net of offering costs</a></td>
<td class="nump">1,867<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_ProceedsFromProteonPrivatePlacementNetOfOfferingCosts', window );">Proceeds from - Common Stock in Proteon Private Placement, net of offering costs</a></td>
<td class="nump">12,413<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from - Series&#160;1&#160;Convertible Preferred Stock in Proteon Private Placement, net of offering costs</a></td>
<td class="nump">25,319<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_ProceedsFromIssuancesOfConvertiblePreferredStock', window );">Proceeds from Common Offering, net of offering costs</a></td>
<td class="nump">73,570<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Preferred Offering, net of offering costs</a></td>
<td class="nump">66,284<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_ProceedsFromUnderwritersOverallotmentOption', window );">Proceeds from Underwriters Overallotment Option</a></td>
<td class="nump">11,087<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfShortTermDebt', window );">Repayments under short-term debt</a></td>
<td class="num">(1,669)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from the exercise of stock options</a></td>
<td class="nump">530<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from private placements</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">189,401<span></span>
</td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net increase/(decrease) in cash and cash equivalents and restricted cash</a></td>
<td class="nump">168,829<span></span>
</td>
<td class="num">(4,986)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents and restricted cash - beginning of year</a></td>
<td class="nump">564<span></span>
</td>
<td class="nump">5,550<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents and restricted cash - end of year</a></td>
<td class="nump">169,393<span></span>
</td>
<td class="nump">564<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract', window );"><strong>Reconciliation of cash and cash equivalents and restricted cash to the consolidated balance sheets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">168,598<span></span>
</td>
<td class="nump">564<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash, long-term</a></td>
<td class="nump">745<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_ReconciliationOfRestrictedCashAndCashEquivalents', window );">Cash and cash equivalents and restricted cash</a></td>
<td class="nump">169,393<span></span>
</td>
<td class="nump">564<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_CashPaidForAbstract', window );"><strong>Cash paid for:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest</a></td>
<td class="nump">34<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Income Taxes</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_DeferredOfferingCostsRecordedInAccruedExpenses', window );">Deferred offering costs recorded in accrued expenses</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">122<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_DeferredOfferingCostsRecognizedThatWerePreviouslyRecordedInAccruedExpenses', window );">Deferred offering costs recognized that were previously recorded in accrued expenses</a></td>
<td class="nump">122<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_PurchaseOfInsuranceAgreementWithNotesPayable', window );">Purchase of insurance agreement with notes payable</a></td>
<td class="nump">1,669<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_CommonStockIssuedInConnectionWithReverseMerger', window );">Common stock issued in connection with the reverse merger with ArTara Therapeutics, Inc.</a></td>
<td class="nump">$ 34,533<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TARA_AmortizationOfOperatingLeaseRightsofuseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortization of operating lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TARA_AmortizationOfOperatingLeaseRightsofuseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TARA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TARA_CashAndRestrictedCashAcquiredInConnectionWithReverseMergerWithArtaraTherapeuticsInc.">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash and restricted cash acquired in connection with the reverse merger with ArTara Therapeutics, Inc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TARA_CashAndRestrictedCashAcquiredInConnectionWithReverseMergerWithArtaraTherapeuticsInc.</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TARA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TARA_CashPaidForAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TARA_CashPaidForAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TARA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TARA_CommonStockIssuedInConnectionWithReverseMerger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TARA_CommonStockIssuedInConnectionWithReverseMerger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TARA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TARA_DeferredOfferingCostsRecognizedThatWerePreviouslyRecordedInAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred offering costs recognized that were previously recorded in accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TARA_DeferredOfferingCostsRecognizedThatWerePreviouslyRecordedInAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TARA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TARA_DeferredOfferingCostsRecordedInAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TARA_DeferredOfferingCostsRecordedInAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TARA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TARA_IncreaseDecreaseRightofuseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TARA_IncreaseDecreaseRightofuseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TARA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TARA_ProceedsFromIssuancesOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TARA_ProceedsFromIssuancesOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TARA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TARA_ProceedsFromProteonPrivatePlacementNetOfOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from - Proteon Private Placement, net of offering costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TARA_ProceedsFromProteonPrivatePlacementNetOfOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TARA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TARA_ProceedsFromUnderwritersOverallotmentOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TARA_ProceedsFromUnderwritersOverallotmentOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TARA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TARA_PurchaseOfInsuranceAgreementWithNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase of insurance agreement with notes payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TARA_PurchaseOfInsuranceAgreementWithNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TARA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TARA_ReconciliationOfRestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TARA_ReconciliationOfRestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TARA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140712348125224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business, Liquidity and Capital Resources<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_BusinessLiquidityAndCapitalResourcesAbstract', window );"><strong>Business, Liquidity and Capital Resources [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_BusinessLiquidityAndCapitalResourcesTextBlock', window );">BUSINESS, LIQUIDITY AND CAPITAL RESOURCES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 1 &#8211; BUSINESS, LIQUIDITY AND CAPITAL RESOURCES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Overview</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Protara Therapeutics, Inc. and its consolidated subsidiaries
("Protara" or the "Company") is committed to identifying and advancing transformative therapies for the
treatment of cancer and rare diseases with significant unmet needs. Protara's portfolio includes two development programs
utilizing TARA-002, an investigational cell therapy in development for the treatment of lymphatic malformations (LMs) and non-muscle
invasive bladder cancer (NMIBC). The third program in the portfolio is Intravenous (IV) Choline Chloride, an investigational phospholipid
substrate replacement therapy initially in development for patients receiving parenteral nutrition (PN) who have intestinal failure
associated liver disease (IFALD). The fourth program in the portfolio is Vonapanitase, a recombinant human elastase.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On January 9, 2020, privately-held ArTara Subsidiary, Inc. ("Private
ArTara") and Protara Therapeutics, Inc. (formerly ArTara Therapeutics, Inc., formerly Proteon Therapeutics, Inc.) completed
the merger and reorganization (the "Merger"), in accordance with the terms of the Agreement and Plan of Merger and
Reorganization, dated September 23, 2019, (the "Merger Agreement") by and among Protara Therapeutics, Inc., Private
ArTara and REM 1 Acquisition, Inc., a wholly owned subsidiary of Protara Therapeutics, Inc ("Merger Sub"). Thereupon,
Merger Sub merged with and into Private ArTara, with Private ArTara surviving as a wholly owned subsidiary of Protara Therapeutics,
Inc. The Merger was structured as a reverse merger and Private ArTara was determined to be the accounting acquirer based on the
terms of the Merger and other factors, and the post-merger company retained the name ArTara Therapeutics, Inc., which on May 11,
2020 was changed to Protara Therapeutics, Inc.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On January 9, 2020, in connection with and prior to the completion
of the Merger, Protara Therapeutics, Inc. effected a 1-for-40 reverse stock split of its common stock (the "Protara Reverse
Stock Split"), Private ArTara changed its name from "ArTara Therapeutics, Inc." to "ArTara Subsidiary,
Inc.", and ArTara Therapeutics, Inc. changed its name from "Proteon Therapeutics, Inc." to "ArTara Therapeutics,
Inc" then subsequently changed its name from "ArTara Therapeutics, Inc" to "Protara Therapeutics, Inc."
All share and per share amounts presented in this annual report on Form 10-K have been adjusted to reflect the Protara Reverse
Stock Split and the Exchange Ratio (defined below). In addition, immediately following the closing of the Private Placements (defined
below), all of the outstanding shares of Protara Therapeutics, Inc.'s Series A Preferred Stock were converted into shares
of Protara Therapeutics, Inc.'s Common Stock (defined below). Shares of the Company's Common Stock commenced trading
on The Nasdaq Capital Market under the new name and ticker symbol "TARA" as of market open on January 10, 2020. See
Note 3 for the full discussion regarding the Merger, Exchange Ratio and recapitalization.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Liquidity, Capital Resources
and Management Plans</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of December 31, 2020 and 2019, the Company's cash and
cash equivalents was $168,598 and $564, respectively. The Company has not generated revenues since its inception and has incurred
net losses of $33,978 and $7,830 for the years ended December 31, 2020 and 2019, respectively. As of December 31, 2020, the Company
had working capital of $166,520 and stockholder's equity of $199,243. During the year ended December 31, 2020, cash flows
used in operating activities were $23,407, consisting primarily of a net loss of $33,978, which includes non-cash stock-based compensation
charges of $9,746. Since inception, the Company has met its liquidity requirements principally through the sale of its Common Stock
and Series 1 Convertible Preferred Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In connection with the Merger, the Company consummated the Private
Placements, raising gross proceeds of $42.5 million and proceeds, net of offering costs, of $39.6 million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On September 22, 2020, the Company entered into underwriting
agreements with Cowen and Company, LLC and Guggenheim Securities, LLC, as representatives of several underwriters for separate,
concurrent underwritten public offerings of the Company's Common Stock and Series 1 Convertible Preferred Stock. On September
24, 2020, gross and net proceeds from this offering were $147.6 million and $139.9 million, respectively. On October 6, 2020, the
underwriters exercised their overallotment option, resulting in the receipt of gross and net proceeds of $11.6 million and $11.1
million, respectively (See Note 8).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company is in the business of developing biopharmaceuticals
and has no current or near term revenues. The Company has incurred substantial clinical and other costs in its drug development
efforts. The Company will need to raise additional capital in order to fully realize management's plans.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company believes that its current financial resources are
sufficient to satisfy the Company's estimated liquidity needs for at least twelve months from the date of issuance of these
consolidated financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TARA_BusinessLiquidityAndCapitalResourcesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TARA_BusinessLiquidityAndCapitalResourcesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TARA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TARA_BusinessLiquidityAndCapitalResourcesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TARA_BusinessLiquidityAndCapitalResourcesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TARA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140712345341064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b><i>Basis of Presentation</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5pt 0pt 0">The accompanying financial statements have been prepared
in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") and pursuant
to the rules and regulations of the Securities and Exchange Commission ("SEC").</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5pt 0pt 0; text-indent: 0.5in"><b><i>Principles of Consolidation</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5pt 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The consolidated financial statements include the accounts of
the Company and its wholly-owned subsidiaries. All inter-company balances and transactions have been eliminated in the accompanying
consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Use of Estimates</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The preparation of financial statements in conformity with U.S.
GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure
of contingent assets and liabilities as of the date of the financial statements, and also that affect the amount of expenses reported
for each period. Actual results could differ from those which result from using such estimates. Management also utilizes various
other estimates, including but not limited to income taxes, the valuation of deferred tax assets, determining the fair value of
business combination considerations, determining the fair value and evaluation for impairment of goodwill, determining the fair
value of the Company's Common Stock, and the valuation of securities and assumptions underlying stock-based compensation.
The results of any changes in accounting estimates are reflected in the financial statements of the period in which the change
becomes evident. Estimates and assumptions are reviewed periodically and the effects of revisions are reflected in the period that
they are determined to be necessary.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Cash and cash equivalents</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company considers all highly liquid instruments with an
original maturity of three months or less when acquired to be cash equivalents. Cash and cash equivalents are held in depository
and money market accounts and are reported at fair value.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Restricted Cash</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Restricted cash as of December 31, 2020 and 2019 was $795 and
$0, respectively. As of December 31, 2020, restricted cash consists of cash deposits of $795 to collateralize letter of credit
obligations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b><i>Property and Equipment</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Property and equipment is recorded at cost. Major property additions,
replacements, and betterments are capitalized, while maintenance and repairs that do not extend the useful lives of an asset or
add new functionality are expensed as incurred. Property and equipment not placed into service is not depreciated until such time
that it is placed into service. Depreciation is recorded using the straight-line method over the respective estimated useful lives
of the Company's assets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Goodwill</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Goodwill represents the excess of purchase price over the fair
value of identifiable net assets acquired in a business combination. Goodwill and other intangible assets acquired in a business
combination and determined to have an indefinite useful life are not amortized, but instead tested for impairment at least annually.
An entity has the option to first assess qualitative factors to determine whether events or circumstances lead to a conclusion
that is more likely than not that the fair value of a reporting unit is greater than its carrying amount. If an entity determines
that qualitative factors indicate that it is more likely than not that the fair value of the entity exceeds the carrying amount,
the quantitative evaluation is not necessary. Under the quantitative impairment test, the evaluation of impairment involves comparing
the current fair value of each reporting unit to its carrying value, including goodwill.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In the event the estimated fair value of the Company is less
than the carrying value, the Company would recognize a goodwill impairment equal to the difference between the carrying value and
its fair value, not to exceed the carrying value of goodwill.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On January 9, 2020, in connection with the Merger, the Company
separately valued the assets and liabilities acquired, and then determined goodwill as the residual of the purchase price less
identified net assets. On December 31, 2020, in connection with the finalization of the purchase price allocation, the Company
recorded an adjustment of $150 to goodwill related to prepaid expenses and accrued expenses (See Note 3).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b><i>Net Loss per Common Share</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Basic loss per common share is computed by dividing net loss
by the weighted average number of common shares outstanding during the period. Diluted loss per common share is computed by dividing
net loss by the weighted average number of common shares outstanding, plus the impact of common shares, if dilutive, resulting
from the exercise of outstanding stock options.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following securities are excluded from the calculation of
weighted average dilutive common shares because their inclusion would have been anti-dilutive:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">For the Years Ended<br /> December 31,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2019</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Stock options</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">674,039</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">219,592</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Restricted stock units</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">407,325</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,245</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -8.1pt; padding-left: 8.1pt">Conversion of Series 1 Convertible Preferred Stock</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,029,039</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: 10pt">Total potentially dilutive shares</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">9,110,403</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">224,837</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Concentrations of Credit Risk</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Financial instruments which potentially subject the Company
to concentrations of credit risk consists principally of cash amounts on deposit with financial institutions. At times, the Company's
cash in banks is in excess of the Federal Deposit Insurance Corporation insurance limit. The Company has not experienced any loss
as a result of these deposits.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Stock-Based Compensation</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company accounts for stock-based compensation in accordance
with the Financial Accounting Standards Board ("FASB") Accounting Standards Codification, or ("ASC"), Topic
718, "Compensation - Stock Compensation" ("ASC 718"). ASC 718 establishes accounting for stock-based awards
exchanged for employee and consultant services. Under the provisions of ASC 718, stock-based compensation cost is measured at the
grant date, based on the fair value of the award, and is recognized as expense over the employee's requisite service period
(generally the vesting period of the equity grant). The fair value of the Company's stock options are estimated using the
Black Scholes option-pricing model with the following assumptions: fair value of the Company's Common Stock, expected volatility,
dividend rate, risk free interest rate and the expected life. The Company calculates the expected volatility using the historical
volatility for a pool of peer companies over the most recent period equal to the expected term and evaluates the extent to which
available information indicate that future volatility may differ from historical volatility. The expected dividend rate is zero
as the Company does not expect to pay or declare any cash dividends on its Common Stock. The risk-free rates for the expected terms
of the stock options are based on the U.S. Treasury yield curve in effect at the time of the grant. The Company has not experienced
significant exercise activity on stock options. Due to the lack of historical information, the Company determined the expected
term of its stock option awards issued using the simplified method. The simplified method assumes each vesting tranche of the award
has a term equal to the midpoint between when the award vests and when the award expires. Restricted stock awards generally vest
over the requisite service periods (vesting on a straight&#8211;line basis). The fair value of a stock award is equal to the fair
market value of a share of the Company's Common Stock on the grant date. The Company accounts for the forfeiture of equity
awards as they occur.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Fair Value Measurements</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The carrying amounts of cash and cash equivalents, prepaid expenses
and accounts payable approximate their fair values due to the short-term nature of these instruments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ASC Topic 820 "Fair Value Measurements and Disclosures" provides the framework for measuring fair value. That framework
provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives
the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurements) and
the lowest priority to unobservable inputs (level 3 measurements).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Fair value is defined as an exit price, representing the amount
that would be received upon the sale of an asset or payment to transfer a liability in an orderly transaction between market participants.
Fair value is a market-based measurement that is determined based on assumptions that market participants would use in pricing
an asset or liability. A three-tier fair value hierarchy is used to prioritize the inputs in measuring fair value as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 22.5pt"></td><td style="width: 13.5pt"><font style="font-family: Wingdings">&#216;</font></td><td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">Level 1 Quoted prices in active markets
for identical assets or liabilities.</font></td></tr>
<tr style="vertical-align: top">
<td style="width: 22.5pt"></td><td style="width: 13.5pt"><font style="font-family: Wingdings">&#216;</font></td><td><font style="font-family: Times New Roman, Times, Serif">Level 2 Quoted prices for similar assets or liabilities in active
markets, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are
observable, either directly or indirectly.</font></td></tr>
<tr style="vertical-align: top">
<td style="width: 22.5pt"></td><td style="width: 13.5pt"><font style="font-family: Wingdings">&#216;</font></td><td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">Level 3 Significant unobservable inputs
that cannot be corroborated by market data.</font></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b><i>Income Taxes</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Deferred tax assets and liabilities are recognized for the estimated
future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities
and their respective tax basis, operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using
enacted tax rates in effect for the year in which those temporary differences are expected to be recovered or settled. The measurement
of net deferred tax assets is reduced by the amount of any tax benefit that, based on available evidence, is not expected to be
realized, and a corresponding valuation allowance is established.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Tax benefits are recognized only for tax positions that are
more likely than not to be sustained upon examination by tax authorities. The amount recognized is measured as the largest amount
of benefit that is greater than 50 percent likely to be realized upon settlement. A liability for "unrecognized tax benefits"
is recorded for any tax benefits claimed in the Company's tax returns that do not meet these recognition and measurement
standards. As of December 31, 2020 and 2019, no liability for unrecognized tax benefits was required to be recorded. The guidance
also discusses the classification of related interest and penalties on income taxes. The Company's policy is to record interest
and penalties on uncertain tax positions as a component of income tax expense. No interest or penalties were recorded during the
years ended December 31, 2020 and 2019.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Research and Development Costs</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Research and development costs are expensed as incurred. These
expenses include the costs of our proprietary research and development efforts, as well as costs incurred in connection with certain
licensing arrangements. Before a compound receives regulatory approval, the Company records upfront and milestone payments made
to third parties under licensing arrangements as expense. Upfront payments are recorded when incurred, and milestone payments are
recorded when the specific milestone or progress has been achieved. Once a compound receives regulatory approval, the Company records
any milestone payments in&#160;identifiable intangible assets, less accumulated amortization&#160;and, unless the asset is determined
to have an indefinite life, the Company amortizes the payments on a straight-line basis over the remaining agreement term or the
expected product life cycle, whichever is shorter.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Research and development expenses were $11,982 and $3,878 for
the years ended December 31, 2020 and 2019, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><b><i>Business Combinations</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For a business combination, the assets acquired and the liabilities
assumed are recognized at the acquisition date, measured at their fair values as of that date. In a business combination achieved
in stages, the identifiable assets and liabilities are recognized at their fair values. In a bargain purchase in which the total
acquisition-date fair value of the identifiable net assets acquired exceeds the fair value of the consideration transferred plus
any non-controlling interest in the acquiree, that excess in fair value is recognized as a gain.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Deferred tax liabilities and assets are recognized for the deferred
tax consequences of differences between the tax bases and the recognized values of assets acquired and liabilities assumed in a
business combination in accordance with ASC Topic 740-10 "Income Taxes". See Note 3 for the Company's accounting
for the reverse merger.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b><i>Recent Accounting Pronouncements Adopted</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In January 2017, the FASB issued Accounting Standards Update
("ASU") 2017-04 ("ASU 2017-04"), Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill
Impairment. ASU 2017-04 simplifies the subsequent measurement of goodwill by eliminating the second step of the goodwill impairment
test. The second step measures a goodwill impairment loss by comparing the implied fair value of a reporting unit's goodwill
with the carrying amount of that goodwill. Under ASU 2017-04, a company will record an impairment charge based on the excess of
a reporting unit's carrying amount over its fair value. ASU 2017-04 will be applied prospectively and is effective for annual
or interim goodwill impairment tests in fiscal years beginning after December 15, 2019. On January 1, 2020, the Company adopted
ASU 2017-04. The adoption of this standard did not have a material effect on the Company's financial position, results of
operations, or cash flows.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In August 2018, the FASB issued ASU No. 2018-13, Fair Value
Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement ("ASU 2018-13"),
which removes, adds and modifies certain disclosure requirements for fair value measurements in Topic 820. The Company will no
longer be required to disclose the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy
as well as the valuation processes of Level 3 fair value measurements. The Company will be required to provide additional disclosure
related to the changes in unrealized gains and losses included in other comprehensive loss for recurring Level 3 fair value measurements
and the range and weighted average of assumptions used to develop significant unobservable inputs for Level 3 fair value measurements.
On January 1, 2020, the Company adopted ASU 2018-13. The adoption of this standard did not have a material effect on the Company's
financial position, results of operations, or cash flows.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b><i>Subsequent Events </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company evaluated subsequent events and transactions that
occurred after the balance sheet date up to the date that the financial statements were available to be issued. The Company did
not identify any subsequent events that would have required adjustment or disclosure in the financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140712509855960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reverse Merger with Protara and Recapitalization<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">REVERSE MERGER WITH PROTARA AND RECAPITALIZATION</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 3 &#8211; REVERSE MERGER WITH PROTARA AND RECAPITALIZATION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On January 9, 2020, in connection with, and prior to the completion
of the Merger, Protara Therapeutics, Inc. effected the Protara Reverse Stock Split, which resulted in 557,631 pre-merger shares
of Protara Therapeutics, Inc. outstanding.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Under the terms of the Merger Agreement, Protara Therapeutics,
Inc. issued shares of its common stock ("Common Stock") to the Company's stockholders, at an exchange ratio of
0.190756 (the "Exchange Ratio"), after taking into account the Protara Reverse Stock Split, for each share of Private
ArTara common stock outstanding immediately prior to the Merger. Protara Therapeutics, Inc. assumed all of the unvested Private
ArTara restricted stock awards, which were exchanged for a number of shares of Common Stock equal to 0.190756 multiplied by the
number of shares of Private ArTara common stock previously represented by such Private ArTara restricted stock awards and unvested
to the same extent as such Private ArTara restricted stock awards and subject to the same restrictions as such Private ArTara restricted
stock awards. On account of the adjustment required pursuant to the Exchange Ratio, there were 2,627,533 shares of Private ArTara
common stock outstanding immediately prior to the Merger.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Protara Therapeutics, Inc. assumed all of the outstanding and
unexercised stock options of Private ArTara, with such stock options representing the right to purchase a number of shares of Common
Stock equal to 0.190756 multiplied by the number of shares of Private ArTara common stock previously represented by such Private
ArTara stock options. As a result, 219,699 shares were assumed under Private ArTara's 2017 Equity Incentive Plan. No additional
awards will be made under the 2017 Equity Incentive Plan. On January 1, 2020, Protara Therapeutics, Inc. amended its Amended and
Restated 2014 Equity Incentive Plan (the "2014 Equity Incentive Plan") to increase the number of shares of stock available
for issuance under the 2014 Equity Incentive Plan to 1,048,300 shares and made conforming changes and updates pursuant to Section
162(m) of the Code.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Concurrently with the execution of the Merger Agreement, certain
institutional investors (together, the "Investors") entered into a subscription agreement (as amended on November 19,
2019, the "Subscription Agreement") with Protara Therapeutics, Inc. and Private ArTara, pursuant to which (A) Protara
Therapeutics, Inc. issued in a private placement immediately after the Merger (the "Proteon Private Placement") (i)
3,879.356 of shares of Protara Therapeutics, Inc.'s Series 1 Convertible Non-Voting Preferred Stock at a purchase price of
approximately $7,011.47 per share for gross proceeds of $27,200 and proceeds, net of issuance costs, of $25,319, (ii) 1,896,888
shares of Protara Therapeutics, Inc.'s Common Stock at a purchase price of approximately $7.01 per share for gross proceeds
of $13,300 and proceeds, net of issuance costs, of $12,413 and (B) Private ArTara issued in a private placement immediately prior
to the Merger (the "ArTara Private Placement") 284,875 shares of Private ArTara common stock (post-Exchange Ratio basis)
at a purchase price of approximately $7.01 per share (post-Exchange Ratio basis) (together with the Proteon Private Placement,
the "Private Placements") for gross proceeds of $2,000 and proceeds, net of issuance costs, of $1,867. The shares issued
in the Proteon Private Placement were registered for resale on a registration statement on Form S-3 filed and declared effective
by the SEC on January 30, 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Immediately following the closing of the Proteon Private Placement,
18,954 shares of Protara Therapeutics, Inc.'s Series A Convertible Preferred Stock outstanding were converted into 476,276
shares of Protara Therapeutics, Inc.'s Common Stock. These shares, combined with the 557,631 pre-merger shares of Protara
Therapeutics, Inc. outstanding after the Protara Reverse Stock Split, resulted in an aggregate of 1,033,907 shares of Common Stock
issued in connection with the Merger.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Immediately after the consummation of the Merger and prior to
the consummation of the Proteon Private Placement, the former stockholders and option holders of Private ArTara owned, or held
rights to acquire, approximately 75.2% of the fully-diluted Common Stock of Protara, with Protara Therapeutics, Inc.'s stockholders
and option holders immediately prior to the Merger owning approximately 24.8% of the fully-diluted Common Stock of Protara.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font: 10pt Times New Roman, Times, Serif">Based
on the terms of the Merger, the transaction was treated as a reverse merger of Protara Therapeutics, Inc. by Private ArTara.</font>
<font style="font: 10pt Times New Roman, Times, Serif">The Merger was accounted for using acquisition accounting under ASC Topic
805 "Business Combinations". Under acquisition accounting, the assets and liabilities (including executory contracts,
commitments and other obligations) of Protara Therapeutics, Inc. as of the effective time of the Merger were recorded at their
respective fair values and added to those of Private ArTara. Any excess of purchase price consideration over the fair values of
the identifiable net assets is recorded as goodwill. During the year ended December 31, 2020, the Company recorded an adjustment
of $150 to goodwill. This adjustment was comprised of a decrease of $78 in prepaid expenses and other current assets, and an increase
of $77 in accrued expenses, resulting in a final purchase price allocation as follows: </font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-indent: -10pt; padding-left: 10pt">Cash</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,669</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Restricted cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">50</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Prepaid expenses and other current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,662</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt">Goodwill</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">29,517</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Accrued expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(365</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Total purchase price consideration</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">34,533</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The total fair value of the net assets of Protara Therapeutics
Inc. was determined by the Company to be $34,533 based on the consideration transferred. The total consideration was based on the
enterprise value of Protara Therapeutics Inc. as of January 9, 2020, based upon the number of common shares deemed outstanding,
multiplied by the closing stock price on January 9, 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Of the amount of goodwill acquired in the reverse merger, no
portion is deductible for tax purposes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The primary reasons for the reverse merger: the increased access
to sources of capital and a broader range of investors to support the clinical development of Private ArTara's product candidates,
the potential to provide current stockholders with greater liquidity by owning stock in a public company, the potential for a more
cost-effective means to access capital and the registration of Protara Common Stock issued to Private ArTara's stockholders.
In addition, Protara assumed the existing 2014 Equity Incentive Plan (the "2014 Plan"), and all outstanding stock options
thereunder.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following presents the unaudited pro forma combined financial
information as if the reverse merger had occurred as of January 1, 2019.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">For the Years Ended <br /> December 31,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2019</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Net loss</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">(33,754</td><td style="width: 1%; padding-bottom: 2pt; text-align: left">)</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">(22,821</td><td style="width: 1%; padding-bottom: 2pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Pro forma loss per common share, basic and diluted</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(4.62</td><td style="padding-bottom: 2pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(3.94</td><td style="padding-bottom: 2pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Pro forma weighted average number of common shares outstanding, basic and diluted</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">7,304,201</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">5,793,024</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The pro forma combined results of operations are not necessarily
indicative of the results of operations that actually would have occurred had the reverse merger been completed as of January 1,
2019, nor are they necessarily indicative of future consolidated results.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140712348187944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY AND EQUIPMENT</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 4 &#8211; PROPERTY AND EQUIPMENT </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: -1in">Property and
equipment consists of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: -1in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: -1in"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt; text-indent: -10pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">As of December 31,</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt; text-indent: -10pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center">Useful Life <br /> (in years)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2019</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-left: 10pt; text-indent: -10pt">Computer equipment</td><td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: center; padding-left: 5.4pt">5</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">34</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">Furniture, fixtures and other</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">5</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">21</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">21</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">Laboratory equipment</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">7</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">601</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">446</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt; text-indent: -10pt; vertical-align: top">Leasehold improvements</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">Over the shorter of the useful life or the lease term</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">200</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt; text-indent: -10pt; padding-bottom: 1.5pt">Property and equipment not yet placed into service</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">503</td><td style="text-align: left; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8</td><td style="text-align: left; padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.25in; text-indent: -10pt">Total property and equipment, gross</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,359</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">475</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt; text-indent: -10pt; padding-bottom: 1.5pt">Less: Accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: right; padding-left: 5.4pt; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(119</td><td style="text-align: left; padding-bottom: 1.5pt">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(16</td><td style="text-align: left; padding-bottom: 1.5pt">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.25in; text-indent: -10pt; padding-bottom: 4pt">Total property and equipment, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="text-align: right; padding-left: 5.4pt; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,240</td><td style="text-align: left; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">459</td><td style="text-align: left; padding-bottom: 4pt">&#160;</td></tr>
</table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: -1in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Depreciation expense was $103 and $16 for the years ended December
31, 2020 and 2019, respectively. During the year ended December 31, 2020, $99 and $4 was included in research and development expense
and general and administrative expense, respectively, within the consolidated statements of operations. For the year ended December
31, 2019, $16 was included in research and development expense within the consolidated statements of operations.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140712348138616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">ACCRUED EXPENSES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: -1in"><b>NOTE 5 &#8211;
ACCRUED EXPENSES </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: -1in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="background-color: white">Included in the Company's
accrued expenses within the consolidated financial statements are:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">As of December 31,</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2019</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Employee bonus</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,530</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">159</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Legal fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">156</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,573</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Research and development costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">37</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,050</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">31</td><td style="text-align: left; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">12</td><td style="text-align: left; padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,913</td><td style="text-align: left; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,635</td><td style="text-align: left; padding-bottom: 4pt">&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140712344154216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-Term Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTextBlock', window );">SHORT-TERM DEBT</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 6 &#8211; SHORT-TERM DEBT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b><i>Financing Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On February 19, 2020, the Company entered into a nine month
financing agreement with AFCO Credit Corporation for its directors and officers ("D&#38;O") liability insurance in the
amount of $2,225. The Company made a down payment of $556, leaving a principal balance of $1,669. The financing bore interest at
a rate of 4.25% per annum, and was repaid in monthly installments of $189, which included both principal and interest. As of December
31, 2020, the balance under this debt was $0. The Company recorded interest expense of $34 for the year ended December 31, 2020
under this financing agreement.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for short-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140712348095720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 7 &#8211; COMMITMENTS AND CONTINGENCIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Lease Agreements</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company has entered into operating leases for office and
laboratory space. On January 1, 2019 ("Effective Date"), the Company adopted ASC Topic 842, Leases ("ASC 842"),
which increases transparency and comparability by recognizing a lessee's rights and obligations resulting from leases. ASC
842 requires the recognition of the right-of-use ("ROU") assets and related operating lease liabilities on the balance
sheet. The Company adopted the new guidance using the modified retrospective approach on January 1, 2019.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The adoption of ASC 842 on January 1, 2019 did not immediately
result in the recognition of ROU assets as the Company did not have any leases at that time with a term of twelve months or more.
However, on January 9, 2020, subsequent to the Merger and Private Placements, it became reasonably certain that the Company would
maintain its quarter-to-quarter lease with its contract development and manufacturing organization for its manufacturing space
for an expected term of approximately eight years, therefore resulting in the recognition of an ROU asset and related operating
lease liability.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company elected the package of practical expedients permitted
within the standard, which allow an entity to forgo reassessing (i) whether a contract contains a lease, (ii) classification of
leases, and (iii) whether capitalized costs associated with a lease meet the definition of initial direct costs. Also, the Company
elected the expedient to allow the Company to not have to separate lease and non-lease components. The Company has also elected
the short-term lease accounting policy under which the Company would not recognize a lease liability or ROU asset for any lease
that at the commencement date has a lease term of twelve months or less and does not include a purchase option that the Company
is more than reasonably certain to exercise.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On July 1, 2020 and December 1, 2020, the Company entered into
additional quarter-to-quarter leases for additional contract development and manufacturing space for expected terms of approximately
seven years, therefore resulting in the recognition of additional ROU assets and related operating lease liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On December 1, 2020, the Company entered into a long-term lease
for office space for a term of seven years. This lease was entered into with a related party of the Company, and its terms were
determined by management to be on an arms-length basis. The lease will not commence until the second quarter of 2021 when the Company
is granted access to the premises. Accordingly, as of December 31, 2020, the Company did not recognize an additional ROU asset
and related operating lease liability for this lease.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For contracts entered into on or after the Effective Date, at
the inception of a contract, the Company will assess whether the contract is, or contains, a lease. The Company's assessment is
based on: (i) whether the contract involves the use of a distinct identified asset, (ii) whether the Company obtained the right
to substantially all the economic benefit from the use of the asset throughout the period, and (iii) whether the Company has the
right to direct the use of the asset. Leases entered into prior to January 1, 2019, which were accounted for under ASC 840, Leases,
were not reassessed for classification.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For operating leases, the lease liability is initially and subsequently
measured at the present value of the unpaid lease payments. The Company generally uses its incremental borrowing rate as the discount
rate for leases, unless an interest rate is implicitly stated in the lease. The present value of the lease payments is calculated
using the incremental borrowing rate for operating leases, which was determined using a rate of interest that the Company would
have to pay to borrow an amount equal to the lease payments on a collateralized basis over a similar term. The lease term for the
Company's lease includes the noncancellable period of the lease plus any additional periods covered by either a Company option
to extend the lease that the Company is reasonably certain to exercise, or an option to extend the lease controlled by the lessor.
ROU assets, once recorded, are reviewed for impairment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Lease expense for operating leases consists of the lease payments
plus any initial direct costs and is recognized on a straight-line basis over the lease term.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Balance sheet information related to our leases is presented
below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center">As of</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-style: italic">Operating leases:</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center">Balance Sheet <br />
Location</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, <br />
2020</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">January 9, 2020</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, <br />
2019</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 30%; padding-bottom: 4pt; padding-left: 0in">Right-of-use assets</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 30%; text-align: left; padding-bottom: 4pt">Other assets</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 10%; text-align: right">1,060</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 10%; text-align: right">403</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 10%; text-align: right">-</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 0in">Operating lease liability, current</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 4pt">Operating lease liability, current</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">88</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">9</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 0in">Operating lease liability, long-term</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 4pt">Operating lease liability, long-term</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">999</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">394</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following provides details of the Company's lease
expense:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">Lease cost</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">For the Year Ended<br /> December 31, 2020</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 82%; text-align: left; padding-left: 0.125in">Operating lease cost</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">93</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in">Short-term lease cost</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">215</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">308</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.05pt; text-indent: -20.05pt">Other information related
to leases is presented below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.05pt; text-indent: -20.05pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">As of <br /> December 31, 2020</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-left: 0.125in">Other information</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 82%; text-align: left; padding-left: 0.125in">Weighted-average discount rate &#8211; operating lease</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 15%; text-align: right">12.00</td><td style="width: 1%; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in">Weighted-average remaining lease term &#8211; operating lease (in months)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">87</td><td style="text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of December 31, 2020, the expected annual minimum lease payments
of our operating lease liabilities and other short-term leases were as follows (includes long-term lease entered into on December
1, 2020 that does not commence until the second quarter of 2021):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left">For Years Ending December 31,</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Operating lease</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 82%; text-align: left">2021</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">1,111</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,333</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,338</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,342</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,423</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">Thereafter</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,277</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total future minimum lease payments, undiscounted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,824</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: Imputed interest for leases in excess of one year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,676</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Present value of future minimum lease payments</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,148</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt">Present value of future minimum lease payments for our operating lease liabilities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,087</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Present value of future minimum lease payments, short-term leases</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">61</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Employment Agreements</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><u>Executive Employment Agreements</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company's executive officers have entered into at-will
employment agreements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><u>Temporary Employment Agreement</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On December 6, 2018, the Company entered into a temporary employment
agreement (the "Temporary Employment Agreement") with an individual who assisted with certain corporate development
activities. Pursuant to the Temporary Employment Agreement, the individual was entitled to receive an annual base salary of $90.
In addition, the individual would be entitled to a performance-based success fee which would be adjusted based on amounts of funding
achieved and timing of when such funding was received. On January 9, 2020, the Company's capital raise triggered a performance-based
compensation obligation and accordingly this individual was paid $462, which was included in general and administrative expenses
within the Company's consolidated statements of operations for the year ended December 31, 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><b><i>Collaborations and License Agreements</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><u>Choline License Agreement</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On September 27, 2017, the Company entered into a license agreement
(the "Choline License Agreement") with Alan L. Buchman ("Dr. Buchman"). Pursuant to the Choline License
Agreement, the Company received from Dr. Buchman the license rights in and to the "Licensed Orphan Designations", the
"Licensed IND", "Existing Study Data" and the "Licensed Know-How" for one or more of the licensed
indications. In consideration for the rights and licenses granted, Dr. Buchman received a payment of $50 on October 2, 2017, and
license payments of $50 and $50 on December 12, 2018 and January 8, 2019, respectively, upon the Company meeting the criteria for
certain meetings to be held with the Federal Drug Administration (the "FDA"). Pursuant to the Choline License Agreement,
effective October 2017, the Company incurred a fixed obligation to Dr. Buchman of $400 (the "Choline License Fee").
Upon the Company receiving $5,000 in cumulative funding (as defined), Dr. Buchman would be entitled to receive payment of the Choline
License Fee as a lump sum if the funds are received by April 15, 2019 and the Choline License Fee shall be increased to a one-time
payment of $600 if the funds are received by October 15, 2019. On October 2, 2019, the Company made a payment of $50 to Dr. Buchman.
On January 22, 2020, in connection with the closing of the Merger and concurrent financing, Dr. Buchman was paid $550 which was
included in accrued expenses as of December 31, 2019.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the years ended December 31, 2020 and 2019, the Company
recorded research and development expense of $0 and $200 (representing the increase in the Choline License Fee obligation), respectively,
for expenditures to Dr. Buchman in connection with obligations under the Choline License Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><u>License Agreement</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On December 22, 2017, the Company entered into an agreement
(the "Feinstein Agreement") with The Feinstein Institute for Medical Research (the "Feinstein Institute"),
a not-for-profit corporation with 50 research labs and 2,500 clinical research studies. Pursuant to the Feinstein Agreement, the
Company acquired an exclusive license relating to treatment of fatty liver diseases in humans for which Choline may be an effective
therapeutic. In consideration for the rights and license granted, the Feinstein Institute would receive a royalty of one percent
(1%) of the first one hundred million dollars ($100,000) of net sales of IV Choline Chloride and a royalty of one and one-half
percent (1.5%) of all net sales thereafter. In addition, the Company would pay the Feinstein Institute twelve and one-half percent
(12.5%) of net proceeds resulting from agreements entered within 2 years from the effective date, and seven and one-half percent
(7.5%) of net proceeds resulting from agreements entered into thereafter. Pursuant to the Feinstein Agreement additional payments
would be due to the Feinstein Institute for license maintenance payments and for meeting milestone events. On January 9, 2020,
the Company's raising of over $5,000 triggered a financing milestone obligation and accordingly the Feinstein Institute was
paid $100. Pursuant to the Feinstein Agreement, upon the achievement of certain future new drug application milestones, the Company
would be obligated to remit an aggregate of $275.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the years ended December 31, 2020 and 2019, the Company
recorded research and development expense of $115 and $1, respectively, in connection with the Feinstein Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><u>Sponsored Research and License Agreement</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On November 28, 2018, the Company entered into a sponsored research
and license agreement (the "Iowa Agreement") with the University of Iowa. Pursuant to the Iowa Agreement, the University
of Iowa, which is engaged in clinical research to improve the diagnosis and treatment of lymphangioma using a pharmaceutical product
(OK-432), would assist the Company in collecting case reports, forms, source data, and safety data available to the University
of Iowa in support of the development of the Company's proprietary <i>Streptococcus Pyogenes</i> investigational product,
TARA-002 for the LMs indication. During the term of the services, the Company would pay the University of Iowa thirty thousand
dollars ($30) per year to fund the project, plus additional amounts upon the realization of certain milestones. More specifically,
upon forty-five (45) days of an approval of TARA-002 by the FDA, the Company would pay up to $1,750 to the University of Iowa for
meeting these milestones. Furthermore, the Company would pay the University of Iowa royalties of up to 1.75% for net sales ranging
from $0 - $25,000, 2.25% for net sales ranging from $25,000 to $50,000, and 2.50% for net sales in excess of $50,000. Pursuant
to the Iowa Agreement, the University of Iowa would be entitled to additional payments for the Company achieving annual net sales
of product according to the milestones. For annual net sales of product up to $25,000; $62; for annual net sales of product of
up to $50,000; $62; and for annual net sales of product of up to $100,000; $125.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the years ended December 31, 2020 and 2019, the Company
recorded research and development expense of $30 and $30 respectively, in connection with the Iowa Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><u>Chugai Agreement</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On June 17, 2019, the Company entered into an agreement (the
"Chugai Pharmaceutical Agreement") with Chugai Pharmaceutical Co., LTD ("Chugai"), a drug manufacturing
firm with offices and operations in Japan. Pursuant to the Chugai Pharmaceutical Agreement, Chugai would help the Company in its
goals to develop and commercialize a therapeutic product (the "New Product") which is comparable to the Chugai existing
therapeutic product (the "Existing Product"). In addition, the Company would be entitled to the use of Chugai materials
and technical support as necessary. On July 14, 2020, the Company and Chugai entered into an amendment (the "Chugai Amendment")
to the Chugai Pharmaceutical Agreement. The Chugai Amendment is effective as of June 30, 2020. The Chugai Amendment extended the
date through which Chugai will exclusively provide the Existing Product and materials to the Company from June 30, 2020 to June
30, 2021, extended the date through which Chugai will not provide materials or technical support to any third party for the purpose
of development and commercialization in a given area from the fifth anniversary to the eleventh anniversary of the original effective
date and provides that, in addition to the designated fee provided upon the initial indication approval in the Chugai Pharmaceutical
Agreement, the Company will pay Chugai a designated fee for each additional indication approval. The Company is obligated to Chugai
for certain payments upon the completion of agreed upon milestones. As of December 31, 2019, the Company recorded an obligation
of $500 upon Chugai having completed an agreed upon milestone, which the Company paid on July 27, 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the years ended December 31, 2020 and 2019, the Company
recorded research and development expense of $0 and $500, respectively, respectively, in connection with the Chugai Agreement,
as amended.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><u>Johns Hopkins University</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In February 2002, Proteon entered into an agreement to license
certain intellectual property in connection with vonapanitase with Johns Hopkins University. The agreement calls for payments to
be made by the Company upon the commencement of vonapanitase related product sales, in the form of a royalty of 2.5% on net sales
of the product. As of December 31, 2020, the Company has not commenced vonapanitase product sales and therefore has recognized
no royalties on product sales.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b><i>Litigation</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">From time to time, Protara may be subject to various legal proceedings
and claims that arise in the ordinary course of its business activities. Management is of the opinion that the ultimate outcome
of these matters would not have a material adverse impact on the financial position of the Company or the results of its operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In the normal course of business, the Company enters into contracts
in which it makes representations and warranties regarding the performance of its services and that its services will not infringe
on third party intellectual rights. There have been no significant events related to such representations and warranties in which
the Company believes the outcome could result in losses or penalties in the future.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140712345397944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS' EQUITY</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 8 &#8211; STOCKHOLDERS' EQUITY </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b><i>Authorized Common Stock </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of December 31, 2020, the Company has 100,000,000 shares
of Common Stock authorized for issuance, $0.001 par value per share, of which 11,211,840 and 2,627,533 shares were issued and outstanding
as of December 31, 2020 and 2019, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The holders of the Company's Common Stock are entitled
to one vote per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b><i>Authorized Series 1 Convertible Preferred
Stock</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In connection with the Preferred Offering (defined below) on
September 22, 2020, the Company filed a Certificate of Amendment to the Certificate of Designation of Preferences, Rights and Limitations
of Series 1 Convertible Preferred Stock of the Company (the "Amendment") with the State of Delaware to increase the
authorized number of shares of the Company's Series 1 Convertible Preferred Stock that may be issued from 3,880 to 8,028.
The Amendment was approved by a committee of the Company's Board of Directors and the requisite holders of outstanding shares
of Series 1 Convertible Preferred Stock. No approval of the holders of the Company's Common Stock was required to effectuate
the Amendment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of December 31, 2020 and 2019, the Company has 10,000,000
shares of preferred stock authorized for issuance, $0.001 par value per share of which 8,028 shares of Series 1 Convertible Preferred
Stock are authorized for issuance and 8,027 and 0 shares were issued and outstanding, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b><i>Description of Series 1 Convertible
Preferred Stock</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Each share of Series 1 Convertible Preferred Stock is convertible
into 1,000 shares of Common Stock, at a conversion price initially equal to approximately $7.01 per common share, subject to adjustment
for any stock splits, stock dividends and similar events, at any time at the option of the holder, provided that any conversion
of Series 1 Convertible Preferred Stock by a holder into shares of Common Stock would be prohibited if, as a result of such conversion,
the holder, together with its affiliates and any other person or entity whose beneficial ownership of the Common Stock would be
aggregated with such holder's for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, would beneficially
own more than 9.99% of the total number of shares Common Stock issued and outstanding after giving effect to such conversion. Upon
written notice to the Company, the holder may from time to time increase or decrease such limitation to any other percentage not
in excess of 19.99% specified in such notice. Each share of Series 1 Convertible Preferred Stock is entitled to a preference of
$10.00 per share upon liquidation of the Company, and thereafter will share ratably in any distributions or payments on an as-converted
basis with the holders of Common Stock. In addition, upon the occurrence of certain transactions that involve the merger or consolidation
of the Company, an exchange or tender offer, a sale of all or substantially all of the assets of the Company or a reclassification
of its Common Stock, each share of Series 1 Convertible Preferred Stock will be convertible into the kind and amount of securities,
cash and/or other property that the holder of a number of shares of Common Stock issuable upon conversion of one share of Series
1 Convertible Preferred Stock would receive in connection with such transaction. The Company's Series 1 Convertible Preferred
Stock are non-voting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The terms of the Series 1 Convertible Preferred Stock provide
that, in the event of a fundamental transaction (as such term is described in the certificate of designation of preferences, rights
and limitations of series 1 convertible non-voting preferred stock), each share of Series 1 Convertible Preferred Stock outstanding
shall thereafter be convertible into the kind and amount of securities, cash and/or other property which a holder of the number
of shares of Common Stock of the Company issuable upon conversion of one share of Series 1 Convertible Preferred Stock immediately
prior to such fundamental transaction would have been entitled to receive pursuant to such fundamental transaction, provided that,
if the value of the aggregate of such securities, cash and/or other property the which the holder of one share of Series 1 Convertible
Preferred Stock would be entitled to upon conversion thereof would be less than the stated value, then each outstanding share of
Series 1 Convertible Preferred Stock shall instead be convertible into such kind of securities, cash and/or other property with
an aggregate value equal to the stated value.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b><i>Common Stock</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On September 23, 2019, the Company completed a placement of
69,114 shares of its common stock at a price of $7.23 per share for gross proceeds of $500.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b><i>Underwritten Public Offering </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On September 24, 2020, pursuant to an underwriting agreement
dated September 22, 2020, the Company issued and sold in an underwritten public offering (the "Common Offering") an
aggregate of 4,600,000 shares of its Common Stock at an offering price of $16.87 per share, for gross and net proceeds of approximately
$77.6 million and $73.6 million, respectively. The underwriters were granted an option to purchase up to 690,000 additional shares
of Common Stock at the public offering price, less the underwriting discount. On October 6, 2020, the underwriters exercised their
overallotment option in full, purchasing an additional 690,000 shares, resulting in the receipt of gross and net proceeds of $11.6
million and $11.1 million, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On September 24, 2020, pursuant to an underwriting agreement
(dated September 22, 2020), the Company issued and sold in an underwritten public offering (the "Preferred Offering")
an aggregate of 4,148 shares of its Series 1 Convertible Preferred Stock at an offering price of $16,873.54 per share, for gross
and net proceeds of approximately $70.0 million and $66.3 million, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Common Offering and the Preferred Offering were made pursuant
to the Company's registration statement on Form S-3, declared effective by the Securities and Exchange Commission on May
26, 2020 (Registration No. 333-238273).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In December 2020, the Company filed a shelf registration statement
on Form S-3, declared effective by the Securities and Exchange Commission on December 18, 2020 (Registration No. 333-251224) (the
"Shelf Registration Statement"). The Shelf Registration Statement permits: (i) the offering, issuance and sale by the
Company of up to a maximum aggregate offering price of $300 million of common stock, preferred stock, debt securities and warrants
in one or more offerings and in any combination. No securities have been sold to date under the Shelf Registration Statement.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140712348167976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">STOCK-BASED COMPENSATION</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 9 &#8211; STOCK-BASED COMPENSATION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b><i>2020 Inducement Plan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On March 26, 2020, the Compensation Committee of the Board of
Directors (the "Compensation Committee") approved the ArTara Therapeutics, Inc. Inducement Plan (the "2020 Inducement
Plan") in order to award nonstatutory stock options, restricted stock awards, restricted stock unit awards and other stock-based
awards to persons not previously an employee or director of the Company, or following a bona fide period of non-employment, as
an inducement material to such persons entering into employment with the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The 2020 Inducement Plan provides for a total of 600,000 shares
for the issuance of the Company's Common Stock. The Compensation Committee also adopted a form of stock option grant notice
and stock option agreement and forms of restricted stock unit grant notice and restricted stock unit agreement for use with the
Inducement Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of December 31, 2020, 460,650 shares remain available to
be issued under the 2020 Inducement Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b><i>2017 Equity Incentive Plan </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On August 10, 2017, Private ArTara, its Board of Directors and
its shareholders approved the ArTara Therapeutics, Inc. 2017 Equity Incentive Plan (the "2017 Equity Incentive Plan")
to enable Private ArTara and its affiliates to recruit and retain highly qualified personnel and to incentivize personnel for productivity
and growth.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The 2017 Equity Incentive Plan provided for the grant of a total
of 2,000,000 shares for the issuance of stock options, stock appreciation rights, restricted stock and restricted stock units to
among others, members of the Board of Directors, employees, consultants and service providers to the Company and its affiliates.
As of January 9, 2020, in connection with the Merger, no additional awards will be made under the 2017 Equity Incentive Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><b><i>2014 Equity Incentive Plan </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">On October 3, 2014, the stockholders approved
the 2014 Plan. On June 20, 2017, the Company's Board of Directors amended the 2014 Plan (the "Amended 2014 Plan").
On July 31, 2017, the stockholders approved this amendment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 18pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Amended 2014 Plan provides for the grant of incentive and
non-statutory stock options, stock appreciation rights, restricted stock and stock unit awards, performance units, stock grants
and qualified performance-based awards. The 2014 Plan provides that the number of shares reserved and available for issuance under
the 2014 Plan will automatically increase each January 1, beginning January 1, 2015 by four percent of the outstanding shares of
Common Stock on the immediately preceding December 31 or such lesser number of shares as determined by the Company's Board
of Directors prior to each such January 1st. The Amended 2014 Plan clarifies that the number of shares for purposes of calculating
the evergreen feature includes the number of shares of Common Stock issuable upon conversion of any security that the Company may
issue that is convertible into or exchangeable for Common Stock, including, but not limited to, preferred stock or warrants. Pursuant
to a special meeting of the Proteon stockholders held on January 9, 2020, the number of shares available for issuance under the
Amended 2014 Plan increased by 900,002 shares from 148,298 shares to 1,048,300 shares on January 1, 2020. As of December 31, 2020,
227,850 shares remain available to be issued under the Amended 2014 Plan. On January 1, 2021, pursuant to the Amended 2014 Plan's
annual evergreen feature, the number of shares authorized under the Amended 2014 Plan was increased by 812,889 shares to 1,861,189
shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 18pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Terms of the stock awards, including vesting requirements, are
determined by the Board of Directors, subject to the provisions of the plans. Certain awards provide for accelerated vesting if
there is a change in control as defined in the plans.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b><i>2014 Employee Stock Purchase Plan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On October 3, 2014, the stockholders approved the 2014 Employee
Stock Purchase Plan (the "2014 ESPP"). The 2014 ESPP initially authorized the issuance of up to 3,513 shares of Common
Stock. The number of shares increases each January 1, commencing on January 1, 2015 and ending on (and including) January 1, 2024,
by an amount equal to the lesser of one percent of the outstanding shares as of the end of the immediately preceding fiscal year,
7,025 shares or any lower amount determined by the Company's Board of Directors prior to each such January 1st. As of December
31, 2020, the authorized number of shares under the 2014 ESPP is 18,012 and the number of shares available for issuance is 13,340.
During the years ended December 31, 2020 and 2019, no shares were issued under the 2014 ESPP. On January 1, 2021, pursuant to the
increase per the 2014 ESPP, the number of share authorized under the 2014 ESPP was increased by 7,025 shares to 25,037 shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b><i>Restricted Stock Units</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><u>Awards to Directors</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following restricted stock units ("RSUs") were
granted pursuant to the Amended 2014 Plan. Settlement for the RSUs is deferred until the earliest to occur of (i) the director's
termination of service, (ii) death, (iii) disability or (iv) a change in control of the Company. In the event of a change in control
of the Company, the RSUs will vest in full.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the year ended December 31, 2020, the Board of Directors
granted an aggregate of 316,000 RSUs to directors of the Company. Of these RSUs, 254,000 vest 12.5% on the date of grant and in
twenty-one equal monthly installments thereafter and the remaining 62,000 RSUs vest 50% on the one year anniversary of the grant
date and the remainder vest in 12 equal monthly installments thereafter. The grant date fair value of these RSUs was $9,480.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><u>Awards to Others</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the year ended December 31, 2019, the Board of Directors
granted of 5,245 RSUs to a consultant. The RSUs were granted under the Company's 2017 Equity Incentive Plan. The RSUs vested
in five equal installments of 1,049 units on the 15th and 30th of each month, beginning on October 30, 2019. The grant date fair
value of this RSU was $36.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the year December 31, 2020, Board of Directors granted
an aggregate of 163,325 RSUs to employees of the Company. These RSUs will vest 25% on each of the first, second, third and fourth
year anniversaries of the date of grant. The grant date fair value of these RSUs was $4,887.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Following is a summary of restricted stock unit activities for
the year ended December 31, 2020:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" align="center" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Restricted Stock Units</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted <br />
Average Grant <br />
Date Fair Value</td>
    <td style="text-align: center">&#160;</td>
    </tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -0.9pt">Non-vested 1/1/2020</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 15%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td>
    </tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 8.1pt; text-align: left">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">479,325</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">29.97</td><td style="text-align: left">&#160;</td>
    </tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 8.1pt; text-align: left">Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(56,375</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30.00</td><td style="text-align: left">&#160;</td>
    </tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 8.1pt; text-align: left">Vested</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(148,334</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">30.00</td><td style="text-align: left">&#160;</td>
    </tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Non-vested 12/31/2020</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">274,616</td><td style="text-align: left; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">29.95</td><td style="text-align: left; padding-bottom: 4pt">&#160;</td>
    </tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font: 10pt Times New Roman, Times, Serif">The fair
value of restricted stock units is amortized on a straight line basis over the requisite service periods of the respective awards.
As of December 31, 2020, the unamortized value of RSUs was $6,299. As of December 31, 2020, the weighted average remaining amortization
period was 1.81 years.</font> <font style="font: 10pt Times New Roman, Times, Serif">As of December 31, 2020 and 2019, 132,709
and 5,245 RSUs, respectively, have vested that have not yet been settled into shares of the Company's Common Stock.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the year ended December 31, 2020, the Company issued
20,870 shares of Common Stock from the settlement of RSUs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b><i>Restricted Stock Units Modification</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On July 23, 2020, the Company agreed to accelerate the vesting
of 5,687 RSUs of a former executive. The Company recorded a charge of $152 during the year ended December 31, 2020 to research
and development expense within the Company's consolidated statements of operations in connection with the modification of
this award. <b> </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b><i>Stock Option Grants</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><u>Options to Directors</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the year ended December 31, 2019, the Board of Directors
granted options for the purchase of 47,114 shares of the Company's common stock to members of the board of directors. These
options were granted under the Company's 2017 Equity Incentive Plan, had an exercise price of $9.18 per share and a term
of 10 years. These options vest ratably over approximately four years. The options had a grant date fair value of $317.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the year ended December 31, 2020, the Board of Directors
granted options for the purchase of 80,250 shares of the Company's common stock to members of the board of directors. These
options were granted under the Company's 2014 Equity Incentive Plan, had an exercise price ranging from $26.70 to $35.00
per share and a term of 10 years. These options vest ratably over approximately one year. The options had a grant date fair value
of $1,903.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><u>Options to Employees</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the year ended December 31, 2019, the Board of Directors
granted options for the purchase of 50,549 shares of the Company's common stock to employees of the Company. These options
were granted under the Company's 2017 Equity Incentive Plan, had an exercise price of $9.18 per share and a term of 10 years.
These options vest ratably over approximately four years. The options had a grant date fair value of $322.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the year ended December 31, 2020, the Board of Directors
granted options for the purchase of 484,850 shares of the Company's common stock to employees of the Company. These options
were granted under the Company's 2014 Equity Incentive Plan, had an exercise price ranging from $17.84 to $51.12 per share
and a term of 10 years. These options vest ratably over approximately four years. The options had a grant date fair value of $10,867.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b><i>Stock Option Modifications</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Effective July 20, 2020, a former director notified the Company
of his resignation from the Company's Board of Directors. In connection with his resignation, the Compensation Committee
approved the accelerated vesting of all stock options issued to him prior to the Merger, and to extend the post-termination exercise
period of vested options to 12 months from the date of resignation. Due to the modification of his options, the Company recorded
the incremental value of $501 during the year ended December 31, 2020 to general and administrative expense within the Company's
consolidated statements of operations.
</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b><i>Stock Options </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company determined the fair value of stock options granted
based upon the assumptions as provided below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" align="center" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">For the Years Ended </font><br />
<font style="font: 10pt Times New Roman, Times, Serif">December 31,</font></td></tr>
<tr>
    <td style="vertical-align: top; width: 40%; padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="vertical-align: top; width: 3%; padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 27%; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">2020</font></td>
    <td style="vertical-align: top; width: 4%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: top; width: 26%; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">2019</font></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">Stock price</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">$ 17.84 - $ 51.12</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">$ 6.81 - $ 8.65</font></td></tr>
<tr style="vertical-align: top; background-color: White">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">Exercise price</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">$ 17.84 - $ 51.12</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">$ 9.18</font></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">Dividend yield</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.00%</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.00%</font></td></tr>
<tr style="vertical-align: top; background-color: White">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">Expected volatility</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">95.00% - 101.00%</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">97.00%</font></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">Risk-free interest rate</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.28% - 1.69%</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1.71% - 2.37%</font></td></tr>
<tr style="vertical-align: top; background-color: White">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">Expected life (in years)</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5.27 - 6.08</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5.58 - 6.02</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Following is a summary of stock option activities for the year
ended December 31, 2020:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Options</td><td style="border-bottom: Black 1.5pt solid">&#160;</td><td style="border-bottom: Black 1.5pt solid">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted Average Grant Date Fair Value</td><td style="border-bottom: Black 1.5pt solid">&#160;</td><td style="border-bottom: Black 1.5pt solid">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted Average Exercise Price</td><td style="border-bottom: Black 1.5pt solid">&#160;</td><td style="border-bottom: Black 1.5pt solid">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted Average Remaining Contractual Term (years)</td><td style="border-bottom: Black 1.5pt solid">&#160;</td><td style="border-bottom: Black 1.5pt solid">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Aggregate Intrinsic Value</td><td style="border-bottom: Black 1.5pt solid">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 35%; text-indent: -0.9pt">Outstanding 1/1/2020</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">219,592</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">7.29</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">9.18</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">9.72</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 8.1pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">565,100</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">22.61</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">29.23</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 8.1pt">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(57,767</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.72</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9.18</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 8.1pt">Forfeited</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(52,886</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14.08</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18.91</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Outstanding 12/31/2020</td><td>&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">674,039</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">20.60</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">25.23</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9.06</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2,311</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Exercisable as of 12/31/2020</td><td>&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">109,117</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">11.44</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">15.63</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8.25</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,201</td><td style="text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The weighted average grant date fair value of the options granted
during the year ended December 31, 2019 was $6.55 per share. The fair value of stock options is amortized on a straight line basis
over the requisite service periods of the respective awards. As of December 31, 2020, the unamortized value of stock options was
$9,973. As of December 31, 2020, the weighted average remaining amortization period was 3.00 years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b><i>Summary of Stock-Based Compensation
Expense</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following tables summarize total stock-based compensation
costs recognized:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -4.5pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">For the Years Ended <br />December 31,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2019</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 74%; text-align: left">Restricted stock</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">75</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>RSUs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,357</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">36</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Stock options</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,389</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">313</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Total</td><td>&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">9,746</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">424</td><td style="text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Stock-based compensation expense was reflected within the statements
of operations as:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">For the Years Ended <br />December 31,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2019</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 74%; text-align: left">Research and development</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">741</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">200</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">General and administrative</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,005</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">224</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Total</td><td>&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">9,746</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">424</td><td style="text-align: left">&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140712348127448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 10 &#8211; INCOME TAXES </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Federal and State income tax expense is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">For the Years Ended <br />December&#160;31,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2019</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>Current</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -27.9pt; padding-left: 0.5in">Federal</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-indent: -27.9pt; padding-left: 0.5in">State</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -40.5pt; padding-left: 0.8in">Total current</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 5.4pt">Deferred</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 74%; text-indent: -27.9pt; padding-left: 0.5in">Federal</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">(6,211</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">(1,614</td><td style="width: 1%; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-indent: -27.9pt; padding-left: 0.5in">State</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,439</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(930</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -18.9pt; padding-left: 0.5in">Total deferred</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(8,650</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,544</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 5.4pt">Change in valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,650</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,544</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 5.4pt">Total income tax expense (benefit)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Deferred income taxes, if applicable, are provided for the differences
between the basis of assets and liabilities for financial reporting and income tax purposes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The tax effects of temporary differences that give rise to significant
portions of the deferred tax assets are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">As of <br />December&#160;31,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2019</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-weight: bold">Deferred tax assets:</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 74%; text-align: left">Net operating loss carry forwards</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">19,371</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">3,806</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Organization costs/legal fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Stock option expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">443</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">111</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Research and development credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">70</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Operating lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">330</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Restricted stock expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">238</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">RSU expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,796</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Charitable contributions</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Total deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">22,020</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,178</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(21,698</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,176</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Deferred tax assets, net of valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">322</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Deferred tax liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Operating right-of-use asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(322</td><td style="text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">-</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Total deferred tax liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(322</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Deferred tax assets, net of valuation allowance and deferred tax liabilities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A reconciliation of the provision for income taxes with the
amounts computed by applying the statutory Federal income tax to income before provision for income taxes is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">For the Years Ended <br />December&#160;31,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2019</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 74%; text-align: left">U.S. federal statutory rate</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">(21.0</td><td style="width: 1%; text-align: left">)%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">(21.0</td><td style="width: 1%; text-align: left">)%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">State taxes, net of federal benefit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(9.4</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(12.1</td><td style="text-align: left">)%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Option expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.2</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.5</td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.9</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.1</td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">True-up to prior years return</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.8</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Change in valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">25.5</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">32.5</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Effective tax rate</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">%</td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of December 31, 2020 for U.S. federal and state income tax
reporting purposes, the Company has approximately $63.7 million of unused net operating losses ("NOLs") available for
carry forward to future years. The 2018 - 2020 federal NOLs may be carried forward indefinitely. The Company does not have the
ability to carry any of these losses back. The New York state and city NOLs may be carried forward through the year 2040 and may
be applied against future taxable income. Because United States tax laws limit the time during which NOL carry forwards may be
applied against future taxable income, the Company may be unable to take full advantage of its NOLs for federal and state income
tax purposes when the Company does generate taxable income. Further, the benefit from utilization of NOL carry forwards could be
subject to limitations due to material ownership changes that could occur as the Company continues to issue additional shares of
common stock pursuant to its capital raising plans. Based on such limitations, the Company has significant NOLs for which realization
of tax benefits is uncertain.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On January 9, 2020, the Company completed the Merger. In connection
with the Merger, the Company acquired NOL's from Proteon of $41.6 million. These NOLs were determined to be impaired by $12.4
million, with an annual limitation of $0.5 million on the remaining $29.2 million of NOLs. The general business credits of $3.6
million acquired in the merger were determined to be fully impaired.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As a result of the Merger, the company performed a study to
review the application of IRC &#167;382 to the Company. It was determined there was an ownership change as of January 9, 2020 and
the Company's NOLs generated prior to January 9, 2020 would be limited. The annual limitation of the Company's NOL's
after application of the IRC &#167;382 are $1.4 million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company remains subject to examination by tax authorities
for tax years 2018 through 2020. The Company has identified its federal tax return and its state tax return in New York state and
New York City as its "major" tax jurisdictions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Based on a history of cumulative losses at the Company and the
results of operations for the years ended December 31, 2020 and 2019, the Company determined that it is more likely than not that
it will not realize benefits from the net deferred tax assets. The Company will not record income tax benefits in the financial
statements until it is determined that it is more likely than not that the Company will generate sufficient taxable income to realize
the deferred income tax assets. As a result of the analysis, the Company determined that a full valuation allowance against the
deferred tax assets was required. As of December 31, 2020 and 2019, the Company has recorded a valuation allowance of $21.7 million
and $4.2 million, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of December 31, 2020 and 2019, management does not believe
that the Company has any material uncertain tax positions that would require it to measure and reflect the potential lack of sustainability
of a position on audit in its consolidated financial statements. The Company will continue to evaluate its uncertain tax positions
in future periods to determine if measurement and recognition in its financial statements is necessary. The Company does not believe
there will be any material changes in its unrecognized tax positions over the next year.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140712348217848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">EMPLOYEE BENEFIT PLAN</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 11 &#8211; EMPLOYEE BENEFIT PLAN </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company maintains a defined contribution benefit plan under
section 401(k) of the Internal Revenue Code covering substantially all qualified employees of the Company (the "401(k) Plan").
Under the 401(k) Plan, the Company matches 100% up to a 4% contribution. The 401(k) Plan was implemented in June of 2020. For the
year ended December 31, 2020, the Company recorded expense of $69 under the 401(k) Plan.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -URI http://asc.fasb.org/topic&amp;trid=2197446<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -URI http://asc.fasb.org/topic&amp;trid=2127225<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140712345652168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COVID-19<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_Covid19Abstract', window );"><strong>Covid19 [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_Covid19DisclosureTextBlock', window );">COVID-19</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 12 &#8211; COVID-19</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The ultimate impact of the current COVID-19 pandemic or a similar
health epidemic is highly uncertain and subject to change. The Company has experienced minimal delays, but may experience future
delays that impact its business, research and development activities, healthcare systems and the global economy as a whole. However,
the Company will continue to monitor the COVID-19 situation closely should the effects have a material impact on its operations,
liquidity and capital resources.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 18pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In response to public health directives and orders, the Company
has implemented work-from-home policies for its employees and temporarily modified its operations to comply with applicable social
distancing recommendations. Similar health directives and orders are affecting third parties with whom the Company does business,
including the third parties that the Company has contracted with to conduct studies for TARA-002. The effects of the orders and
the Company's related adjustments in its business are likely to negatively impact productivity, disrupt the Company's
business and delay its timelines, the magnitude of which will depend, in part, on the length and severity of the restrictions and
other limitations on the Company's ability to conduct its business in the ordinary course.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 18pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Severe and/or long-term disruptions in the Company's operations
will negatively impact its business, operating results and financial condition in other ways, as well. Specifically, the Company
anticipates that the stress of COVID-19 on healthcare systems around the globe will negatively impact its ability to conduct clinical
trials in the near term due primarily to the lack of resources at clinical trial sites and the resulting inability to enroll patients
in the trials. The Company also anticipates that the global impact of COVID-19 will negatively impact its ability to conduct nonclinical
studies due primarily to laboratory closures and limited availability of personnel. In addition, while the potential economic impact
brought by, and the duration of, COVID-19 may be difficult to assess or predict, it has significantly disrupted global financial
markets, and may limit the Company's ability to access capital, which could in the future negatively affect its liquidity.
A recession or market correction resulting from the spread of COVID-19 could materially affect the Company's business and
the value of its Common Stock.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TARA_Covid19Abstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TARA_Covid19Abstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TARA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TARA_Covid19DisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of covid 19.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TARA_Covid19DisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TARA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140712340807912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b><i>Basis of Presentation</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5pt 0pt 0">The accompanying financial statements have been prepared
in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") and pursuant
to the rules and regulations of the Securities and Exchange Commission ("SEC").</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5pt 0pt 0; text-indent: 0.5in"><b><i>Principles of Consolidation</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5pt 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The consolidated financial statements include the accounts of
the Company and its wholly-owned subsidiaries. All inter-company balances and transactions have been eliminated in the accompanying
consolidated financial statements.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Use of Estimates</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The preparation of financial statements in conformity with U.S.
GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure
of contingent assets and liabilities as of the date of the financial statements, and also that affect the amount of expenses reported
for each period. Actual results could differ from those which result from using such estimates. Management also utilizes various
other estimates, including but not limited to income taxes, the valuation of deferred tax assets, determining the fair value of
business combination considerations, determining the fair value and evaluation for impairment of goodwill, determining the fair
value of the Company's Common Stock, and the valuation of securities and assumptions underlying stock-based compensation.
The results of any changes in accounting estimates are reflected in the financial statements of the period in which the change
becomes evident. Estimates and assumptions are reviewed periodically and the effects of revisions are reflected in the period that
they are determined to be necessary.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and cash equivalents</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Cash and cash equivalents</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company considers all highly liquid instruments with an
original maturity of three months or less when acquired to be cash equivalents. Cash and cash equivalents are held in depository
and money market accounts and are reported at fair value.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Restricted Cash</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Restricted cash as of December 31, 2020 and 2019 was $795 and
$0, respectively. As of December 31, 2020, restricted cash consists of cash deposits of $795 to collateralize letter of credit
obligations.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b><i>Property and Equipment</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Property and equipment is recorded at cost. Major property additions,
replacements, and betterments are capitalized, while maintenance and repairs that do not extend the useful lives of an asset or
add new functionality are expensed as incurred. Property and equipment not placed into service is not depreciated until such time
that it is placed into service. Depreciation is recorded using the straight-line method over the respective estimated useful lives
of the Company's assets.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Goodwill</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Goodwill</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Goodwill represents the excess of purchase price over the fair
value of identifiable net assets acquired in a business combination. Goodwill and other intangible assets acquired in a business
combination and determined to have an indefinite useful life are not amortized, but instead tested for impairment at least annually.
An entity has the option to first assess qualitative factors to determine whether events or circumstances lead to a conclusion
that is more likely than not that the fair value of a reporting unit is greater than its carrying amount. If an entity determines
that qualitative factors indicate that it is more likely than not that the fair value of the entity exceeds the carrying amount,
the quantitative evaluation is not necessary. Under the quantitative impairment test, the evaluation of impairment involves comparing
the current fair value of each reporting unit to its carrying value, including goodwill.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In the event the estimated fair value of the Company is less
than the carrying value, the Company would recognize a goodwill impairment equal to the difference between the carrying value and
its fair value, not to exceed the carrying value of goodwill.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On January 9, 2020, in connection with the Merger, the Company
separately valued the assets and liabilities acquired, and then determined goodwill as the residual of the purchase price less
identified net assets. On December 31, 2020, in connection with the finalization of the purchase price allocation, the Company
recorded an adjustment of $150 to goodwill related to prepaid expenses and accrued expenses (See Note 3).</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Common Share</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b><i>Net Loss per Common Share</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Basic loss per common share is computed by dividing net loss
by the weighted average number of common shares outstanding during the period. Diluted loss per common share is computed by dividing
net loss by the weighted average number of common shares outstanding, plus the impact of common shares, if dilutive, resulting
from the exercise of outstanding stock options.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following securities are excluded from the calculation of
weighted average dilutive common shares because their inclusion would have been anti-dilutive:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">For the Years Ended<br /> December 31,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2019</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Stock options</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">674,039</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">219,592</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Restricted stock units</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">407,325</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,245</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -8.1pt; padding-left: 8.1pt">Conversion of Series 1 Convertible Preferred Stock</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,029,039</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: 10pt">Total potentially dilutive shares</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">9,110,403</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">224,837</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk</a></td>
<td class="text"><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Concentrations of Credit Risk</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Financial instruments which potentially subject the Company
to concentrations of credit risk consists principally of cash amounts on deposit with financial institutions. At times, the Company's
cash in banks is in excess of the Federal Deposit Insurance Corporation insurance limit. The Company has not experienced any loss
as a result of these deposits.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Stock-Based Compensation</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company accounts for stock-based compensation in accordance
with the Financial Accounting Standards Board ("FASB") Accounting Standards Codification, or ("ASC"), Topic
718, "Compensation - Stock Compensation" ("ASC 718"). ASC 718 establishes accounting for stock-based awards
exchanged for employee and consultant services. Under the provisions of ASC 718, stock-based compensation cost is measured at the
grant date, based on the fair value of the award, and is recognized as expense over the employee's requisite service period
(generally the vesting period of the equity grant). The fair value of the Company's stock options are estimated using the
Black Scholes option-pricing model with the following assumptions: fair value of the Company's Common Stock, expected volatility,
dividend rate, risk free interest rate and the expected life. The Company calculates the expected volatility using the historical
volatility for a pool of peer companies over the most recent period equal to the expected term and evaluates the extent to which
available information indicate that future volatility may differ from historical volatility. The expected dividend rate is zero
as the Company does not expect to pay or declare any cash dividends on its Common Stock. The risk-free rates for the expected terms
of the stock options are based on the U.S. Treasury yield curve in effect at the time of the grant. The Company has not experienced
significant exercise activity on stock options. Due to the lack of historical information, the Company determined the expected
term of its stock option awards issued using the simplified method. The simplified method assumes each vesting tranche of the award
has a term equal to the midpoint between when the award vests and when the award expires. Restricted stock awards generally vest
over the requisite service periods (vesting on a straight&#8211;line basis). The fair value of a stock award is equal to the fair
market value of a share of the Company's Common Stock on the grant date. The Company accounts for the forfeiture of equity
awards as they occur.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Fair Value Measurements</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The carrying amounts of cash and cash equivalents, prepaid expenses
and accounts payable approximate their fair values due to the short-term nature of these instruments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ASC Topic 820 "Fair Value Measurements and Disclosures" provides the framework for measuring fair value. That framework
provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives
the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurements) and
the lowest priority to unobservable inputs (level 3 measurements).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Fair value is defined as an exit price, representing the amount
that would be received upon the sale of an asset or payment to transfer a liability in an orderly transaction between market participants.
Fair value is a market-based measurement that is determined based on assumptions that market participants would use in pricing
an asset or liability. A three-tier fair value hierarchy is used to prioritize the inputs in measuring fair value as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 22.5pt"></td><td style="width: 13.5pt"><font style="font-family: Wingdings">&#216;</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">Level 1 Quoted prices in active markets
for identical assets or liabilities.</font></td></tr>
<tr style="vertical-align: top">
<td style="width: 22.5pt"></td><td style="width: 13.5pt"><font style="font-family: Wingdings">&#216;</font></td><td><font style="font-family: Times New Roman, Times, Serif">Level 2 Quoted prices for similar assets or liabilities in active
markets, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are
observable, either directly or indirectly.</font></td></tr>
<tr style="vertical-align: top">
<td style="width: 22.5pt"></td><td style="width: 13.5pt"><font style="font-family: Wingdings">&#216;</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">Level 3 Significant unobservable inputs
that cannot be corroborated by market data.</font></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b><i>Income Taxes</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Deferred tax assets and liabilities are recognized for the estimated
future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities
and their respective tax basis, operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using
enacted tax rates in effect for the year in which those temporary differences are expected to be recovered or settled. The measurement
of net deferred tax assets is reduced by the amount of any tax benefit that, based on available evidence, is not expected to be
realized, and a corresponding valuation allowance is established.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Tax benefits are recognized only for tax positions that are
more likely than not to be sustained upon examination by tax authorities. The amount recognized is measured as the largest amount
of benefit that is greater than 50 percent likely to be realized upon settlement. A liability for "unrecognized tax benefits"
is recorded for any tax benefits claimed in the Company's tax returns that do not meet these recognition and measurement
standards. As of December 31, 2020 and 2019, no liability for unrecognized tax benefits was required to be recorded. The guidance
also discusses the classification of related interest and penalties on income taxes. The Company's policy is to record interest
and penalties on uncertain tax positions as a component of income tax expense. No interest or penalties were recorded during the
years ended December 31, 2020 and 2019.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Research and Development Costs</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Research and development costs are expensed as incurred. These
expenses include the costs of our proprietary research and development efforts, as well as costs incurred in connection with certain
licensing arrangements. Before a compound receives regulatory approval, the Company records upfront and milestone payments made
to third parties under licensing arrangements as expense. Upfront payments are recorded when incurred, and milestone payments are
recorded when the specific milestone or progress has been achieved. Once a compound receives regulatory approval, the Company records
any milestone payments in&#160;identifiable intangible assets, less accumulated amortization&#160;and, unless the asset is determined
to have an indefinite life, the Company amortizes the payments on a straight-line basis over the remaining agreement term or the
expected product life cycle, whichever is shorter.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Research and development expenses were $11,982 and $3,878 for
the years ended December 31, 2020 and 2019, respectively.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Business Combinations</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><b><i>Business Combinations</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For a business combination, the assets acquired and the liabilities
assumed are recognized at the acquisition date, measured at their fair values as of that date. In a business combination achieved
in stages, the identifiable assets and liabilities are recognized at their fair values. In a bargain purchase in which the total
acquisition-date fair value of the identifiable net assets acquired exceeds the fair value of the consideration transferred plus
any non-controlling interest in the acquiree, that excess in fair value is recognized as a gain.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Deferred tax liabilities and assets are recognized for the deferred
tax consequences of differences between the tax bases and the recognized values of assets acquired and liabilities assumed in a
business combination in accordance with ASC Topic 740-10 "Income Taxes". See Note 3 for the Company's accounting
for the reverse merger.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements Adopted</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b><i>Recent Accounting Pronouncements Adopted</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In January 2017, the FASB issued Accounting Standards Update
("ASU") 2017-04 ("ASU 2017-04"), Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill
Impairment. ASU 2017-04 simplifies the subsequent measurement of goodwill by eliminating the second step of the goodwill impairment
test. The second step measures a goodwill impairment loss by comparing the implied fair value of a reporting unit's goodwill
with the carrying amount of that goodwill. Under ASU 2017-04, a company will record an impairment charge based on the excess of
a reporting unit's carrying amount over its fair value. ASU 2017-04 will be applied prospectively and is effective for annual
or interim goodwill impairment tests in fiscal years beginning after December 15, 2019. On January 1, 2020, the Company adopted
ASU 2017-04. The adoption of this standard did not have a material effect on the Company's financial position, results of
operations, or cash flows.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In August 2018, the FASB issued ASU No. 2018-13, Fair Value
Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement ("ASU 2018-13"),
which removes, adds and modifies certain disclosure requirements for fair value measurements in Topic 820. The Company will no
longer be required to disclose the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy
as well as the valuation processes of Level 3 fair value measurements. The Company will be required to provide additional disclosure
related to the changes in unrealized gains and losses included in other comprehensive loss for recurring Level 3 fair value measurements
and the range and weighted average of assumptions used to develop significant unobservable inputs for Level 3 fair value measurements.
On January 1, 2020, the Company adopted ASU 2018-13. The adoption of this standard did not have a material effect on the Company's
financial position, results of operations, or cash flows.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsPolicyPolicyTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b><i>Subsequent Events </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company evaluated subsequent events and transactions that
occurred after the balance sheet date up to the date that the financial statements were available to be issued. The Company did
not identify any subsequent events that would have required adjustment or disclosure in the financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32280-109318<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reporting subsequent events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140712345412360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock', window );">Schedule of weighted average dilutive common shares</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">For the Years Ended<br /> December 31,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2019</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Stock options</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">674,039</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">219,592</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Restricted stock units</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">407,325</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,245</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -8.1pt; padding-left: 8.1pt">Conversion of Series 1 Convertible Preferred Stock</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,029,039</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: 10pt">Total potentially dilutive shares</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">9,110,403</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">224,837</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140712442310216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reverse Merger with Protara and Recapitalization (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock', window );">Schedule of preliminary allocation of the purchase price consideration</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-indent: -10pt; padding-left: 10pt">Cash</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,669</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Restricted cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">50</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Prepaid expenses and other current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,662</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt">Goodwill</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">29,517</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Accrued expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(365</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Total purchase price consideration</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">34,533</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock', window );">Schedule of unaudited pro forma combined financial information</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">For the Years Ended <br /> December 31,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2019</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Net loss</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">(33,754</td><td style="width: 1%; padding-bottom: 2pt; text-align: left">)</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">(22,821</td><td style="width: 1%; padding-bottom: 2pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Pro forma loss per common share, basic and diluted</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(4.62</td><td style="padding-bottom: 2pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(3.94</td><td style="padding-bottom: 2pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Pro forma weighted average number of common shares outstanding, basic and diluted</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">7,304,201</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">5,793,024</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140712345431768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of property and equipment consists</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"><tr style="vertical-align: bottom"><td style="padding-bottom: 1.5pt; padding-left: 10pt; text-indent: -10pt"></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">As of December 31,</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt; text-indent: -10pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center">Useful Life <br /> (in years)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2019</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-left: 10pt; text-indent: -10pt">Computer equipment</td><td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: center; padding-left: 5.4pt">5</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">34</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">Furniture, fixtures and other</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">5</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">21</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">21</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">Laboratory equipment</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">7</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">601</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">446</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt; text-indent: -10pt; vertical-align: top">Leasehold improvements</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">Over the shorter of the useful life or the lease term</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">200</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt; text-indent: -10pt; padding-bottom: 1.5pt">Property and equipment not yet placed into service</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">503</td><td style="text-align: left; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8</td><td style="text-align: left; padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.25in; text-indent: -10pt">Total property and equipment, gross</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,359</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">475</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt; text-indent: -10pt; padding-bottom: 1.5pt">Less: Accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: right; padding-left: 5.4pt; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(119</td><td style="text-align: left; padding-bottom: 1.5pt">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(16</td><td style="text-align: left; padding-bottom: 1.5pt">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.25in; text-indent: -10pt; padding-bottom: 4pt">Total property and equipment, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="text-align: right; padding-left: 5.4pt; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,240</td><td style="text-align: left; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">459</td><td style="text-align: left; padding-bottom: 4pt">&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140712345377160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of accrued expenses</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">As of December 31,</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2019</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Employee bonus</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,530</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">159</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Legal fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">156</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,573</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Research and development costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">37</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,050</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">31</td><td style="text-align: left; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">12</td><td style="text-align: left; padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,913</td><td style="text-align: left; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,635</td><td style="text-align: left; padding-bottom: 4pt">&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140712345676808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLeaseIncomeTableTextBlock', window );">Schedule of operating leases</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center">As of</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-style: italic">Operating leases:</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center">Balance Sheet <br />
Location</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, <br />
2020</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">January 9, 2020</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, <br />
2019</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 30%; padding-bottom: 4pt; padding-left: 0in">Right-of-use assets</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 30%; text-align: left; padding-bottom: 4pt">Other assets</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 10%; text-align: right">1,060</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 10%; text-align: right">403</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 10%; text-align: right">-</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 0in">Operating lease liability, current</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 4pt">Operating lease liability, current</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">88</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">9</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 0in">Operating lease liability, long-term</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 4pt">Operating lease liability, long-term</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">999</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">394</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following provides details of the Company's lease
expense:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">Lease cost</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">For the Year Ended<br /> December 31, 2020</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 82%; text-align: left; padding-left: 0.125in">Operating lease cost</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">93</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in">Short-term lease cost</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">215</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">308</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.05pt; text-indent: -20.05pt">Other information related
to leases is presented below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.05pt; text-indent: -20.05pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">As of <br /> December 31, 2020</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-left: 0.125in">Other information</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 82%; text-align: left; padding-left: 0.125in">Weighted-average discount rate &#8211; operating lease</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 15%; text-align: right">12.00</td><td style="width: 1%; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in">Weighted-average remaining lease term &#8211; operating lease (in months)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">87</td><td style="text-align: left">&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Schedule of minimum lease payments</a></td>
<td class="text"><p style="margin: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left">For Years Ending December 31,</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Operating lease</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 82%; text-align: left">2021</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">1,111</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,333</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,338</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,342</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,423</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">Thereafter</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,277</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total future minimum lease payments, undiscounted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,824</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: Imputed interest for leases in excess of one year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,676</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Present value of future minimum lease payments</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,148</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt">Present value of future minimum lease payments for our operating lease liabilities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,087</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Present value of future minimum lease payments, short-term leases</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">61</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
</table>
<p style="margin: 0pt"></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLeaseIncomeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of components of income from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121576215&amp;loc=SL77919372-209981<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6A<br> -URI http://asc.fasb.org/extlink&amp;oid=121640914&amp;loc=SL77927221-108306<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLeaseIncomeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140712349699080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of restricted stock unit activities</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" align="center" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"><tr style="vertical-align: bottom"><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Restricted Stock Units</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted <br />
Average Grant <br />
Date Fair Value</td>
    <td style="text-align: center">&#160;</td>
    </tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -0.9pt">Non-vested 1/1/2020</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 15%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td>
    </tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 8.1pt; text-align: left">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">479,325</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">29.97</td><td style="text-align: left">&#160;</td>
    </tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 8.1pt; text-align: left">Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(56,375</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30.00</td><td style="text-align: left">&#160;</td>
    </tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 8.1pt; text-align: left">Vested</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(148,334</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">30.00</td><td style="text-align: left">&#160;</td>
    </tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Non-vested 12/31/2020</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">274,616</td><td style="text-align: left; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">29.95</td><td style="text-align: left; padding-bottom: 4pt">&#160;</td>
    </tr>
</table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of the fair value of stock options granted</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" align="center" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr><td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 1.5pt"></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">For the Years Ended </font><br />
<font style="font: 10pt Times New Roman, Times, Serif">December 31,</font></td></tr>
<tr>
    <td style="vertical-align: top; width: 40%; padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="vertical-align: top; width: 3%; padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 27%; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">2020</font></td>
    <td style="vertical-align: top; width: 4%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: top; width: 26%; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">2019</font></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">Stock price</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">$ 17.84 - $ 51.12</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">$ 6.81 - $ 8.65</font></td></tr>
<tr style="vertical-align: top; background-color: White">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">Exercise price</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">$ 17.84 - $ 51.12</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">$ 9.18</font></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">Dividend yield</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.00%</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.00%</font></td></tr>
<tr style="vertical-align: top; background-color: White">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">Expected volatility</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">95.00% - 101.00%</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">97.00%</font></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">Risk-free interest rate</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.28% - 1.69%</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1.71% - 2.37%</font></td></tr>
<tr style="vertical-align: top; background-color: White">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif">Expected life (in years)</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5.27 - 6.08</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5.58 - 6.02</font></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of stock option activities</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"><tr style="vertical-align: bottom"><td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Options</td><td style="border-bottom: Black 1.5pt solid">&#160;</td><td style="border-bottom: Black 1.5pt solid">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted Average Grant Date Fair Value</td><td style="border-bottom: Black 1.5pt solid">&#160;</td><td style="border-bottom: Black 1.5pt solid">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted Average Exercise Price</td><td style="border-bottom: Black 1.5pt solid">&#160;</td><td style="border-bottom: Black 1.5pt solid">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted Average Remaining Contractual Term (years)</td><td style="border-bottom: Black 1.5pt solid">&#160;</td><td style="border-bottom: Black 1.5pt solid">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Aggregate Intrinsic Value</td><td style="border-bottom: Black 1.5pt solid">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 35%; text-indent: -0.9pt">Outstanding 1/1/2020</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">219,592</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">7.29</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">9.18</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">9.72</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 8.1pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">565,100</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">22.61</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">29.23</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 8.1pt">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(57,767</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.72</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9.18</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 8.1pt">Forfeited</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(52,886</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14.08</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18.91</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Outstanding 12/31/2020</td><td>&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">674,039</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">20.60</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">25.23</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9.06</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2,311</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Exercisable as of 12/31/2020</td><td>&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">109,117</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">11.44</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">15.63</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8.25</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,201</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_IssuanceOfStockOptionsAndRestrictedStockUnitsToEmployeesAndDirectorsTableTextBlock', window );">Schedule of total stock-based compensation costs</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"><tr style="vertical-align: bottom"><td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">For the Years Ended <br />December 31,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2019</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 74%; text-align: left">Restricted stock</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">75</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>RSUs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,357</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">36</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Stock options</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,389</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">313</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Total</td><td>&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">9,746</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">424</td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of stock based compensation expense</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"><tr style="vertical-align: bottom"><td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">For the Years Ended <br />December 31,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2019</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 74%; text-align: left">Research and development</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">741</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">200</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">General and administrative</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,005</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">224</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Total</td><td>&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">9,746</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">424</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TARA_IssuanceOfStockOptionsAndRestrictedStockUnitsToEmployeesAndDirectorsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of issuance of stock options and restricted stock units to employees and directors.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TARA_IssuanceOfStockOptionsAndRestrictedStockUnitsToEmployeesAndDirectorsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TARA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140712344145336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of federal and state income tax expense</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">For the Years Ended <br />December&#160;31,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2019</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>Current</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -27.9pt; padding-left: 0.5in">Federal</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-indent: -27.9pt; padding-left: 0.5in">State</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -40.5pt; padding-left: 0.8in">Total current</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 5.4pt">Deferred</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 74%; text-indent: -27.9pt; padding-left: 0.5in">Federal</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">(6,211</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">(1,614</td><td style="width: 1%; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-indent: -27.9pt; padding-left: 0.5in">State</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,439</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(930</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -18.9pt; padding-left: 0.5in">Total deferred</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(8,650</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,544</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 5.4pt">Change in valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,650</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,544</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 5.4pt">Total income tax expense (benefit)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of deferred tax assets and liabilities</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">As of <br />December&#160;31,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2019</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-weight: bold">Deferred tax assets:</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 74%; text-align: left">Net operating loss carry forwards</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">19,371</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">3,806</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Organization costs/legal fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Stock option expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">443</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">111</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Research and development credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">70</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Operating lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">330</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Restricted stock expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">238</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">RSU expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,796</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Charitable contributions</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Total deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">22,020</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,178</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(21,698</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,176</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Deferred tax assets, net of valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">322</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Deferred tax liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Operating right-of-use asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(322</td><td style="text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">-</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Total deferred tax liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(322</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Deferred tax assets, net of valuation allowance and deferred tax liabilities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of federal income tax to income before provision for income taxes</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">For the Years Ended <br />December&#160;31,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2019</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 74%; text-align: left">U.S. federal statutory rate</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">(21.0</td><td style="width: 1%; text-align: left">)%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">(21.0</td><td style="width: 1%; text-align: left">)%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">State taxes, net of federal benefit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(9.4</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(12.1</td><td style="text-align: left">)%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Option expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.2</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.5</td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.9</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.1</td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">True-up to prior years return</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.8</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Change in valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">25.5</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">32.5</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Effective tax rate</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">%</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140712343851208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business, Liquidity and Capital Resources (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 06, 2020</div></th>
<th class="th"><div>Sep. 24, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_BusinessLiquidityAndCapitalResourcesTextualAbstract', window );"><strong>Business, Liquidity and Capital Resources (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 168,598<span></span>
</td>
<td class="nump">$ 564<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(33,978)<span></span>
</td>
<td class="num">(7,830)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_WorkingCapital', window );">Working capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">166,520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">199,243<span></span>
</td>
<td class="num">(2,128)<span></span>
</td>
<td class="nump">$ 4,778<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23,407)<span></span>
</td>
<td class="num">(5,011)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Non stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,746<span></span>
</td>
<td class="nump">$ 424<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_NetOfOfferingCosts', window );">Net of offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_ProceedsFrompublicOfferingGross', window );">Gross proceeds</a></td>
<td class="nump">$ 11,600,000<span></span>
</td>
<td class="nump">$ 147,600,000<span></span>
</td>
<td class="nump">$ 42,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_PublicOfferingProceedsNet', window );">Net proceeds</a></td>
<td class="nump">$ 11,100,000<span></span>
</td>
<td class="nump">$ 139,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TARA_BusinessLiquidityAndCapitalResourcesTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TARA_BusinessLiquidityAndCapitalResourcesTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TARA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TARA_NetOfOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net of offering costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TARA_NetOfOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TARA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TARA_ProceedsFrompublicOfferingGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash inflow from gross proceeds of offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TARA_ProceedsFrompublicOfferingGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TARA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TARA_PublicOfferingProceedsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TARA_PublicOfferingProceedsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TARA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TARA_WorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TARA_WorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TARA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140712341135432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total potentially dilutive shares</a></td>
<td class="nump">9,110,403<span></span>
</td>
<td class="nump">224,837<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted stock units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total potentially dilutive shares</a></td>
<td class="nump">407,325<span></span>
</td>
<td class="nump">5,245<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember', window );">Stock options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total potentially dilutive shares</a></td>
<td class="nump">674,039<span></span>
</td>
<td class="nump">219,592<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember', window );">Conversion of series 1 convertible preferred stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total potentially dilutive shares</a></td>
<td class="nump">8,029,039<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140712424258424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details Textual) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_SummaryOfSignificantAccountingPoliciesTextualAbstract', window );"><strong>Summary of Significant Accounting Policies (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCollateralForBorrowedSecurities', window );">Cash deposit to collateralize</a></td>
<td class="nump">$ 795<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">11,982<span></span>
</td>
<td class="nump">$ 3,878<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit', window );">Goodwill related</a></td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_RestrictCash', window );">Restricted cash</a></td>
<td class="nump">$ 795<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TARA_RestrictCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TARA_RestrictCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TARA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TARA_SummaryOfSignificantAccountingPoliciesTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TARA_SummaryOfSignificantAccountingPoliciesTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TARA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCollateralForBorrowedSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of cash collateral held for borrowed securities, for which the cash is restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCollateralForBorrowedSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of divestiture of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140712422114520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reverse Merger with Protara and Recapitalization (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_AssetsAcquiredAndLiabilitiesAssumedCash', window );">Cash</a></td>
<td class="nump">$ 3,669<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_AssetsAcquiredAndLiabilitiesAssumedRestrictedCash', window );">Restricted cash</a></td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_AssetsAcquiredAndLiabilitiesAssumedPrepaidExpensesAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,662<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_AssetsAcquiredAndLiabilitiesAssumedGoodwill', window );">Goodwill</a></td>
<td class="nump">29,517<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_AssetsAcquiredAndLiabilitiesAssumedAccruedExpenses', window );">Accrued expenses</a></td>
<td class="num">(365)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_AssetsAcquiredAndLiabilitiesAssumedTotalPurchasePrice', window );">Total purchase price consideration</a></td>
<td class="nump">$ 34,533<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TARA_AssetsAcquiredAndLiabilitiesAssumedAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TARA_AssetsAcquiredAndLiabilitiesAssumedAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TARA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TARA_AssetsAcquiredAndLiabilitiesAssumedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TARA_AssetsAcquiredAndLiabilitiesAssumedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TARA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TARA_AssetsAcquiredAndLiabilitiesAssumedGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TARA_AssetsAcquiredAndLiabilitiesAssumedGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TARA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TARA_AssetsAcquiredAndLiabilitiesAssumedPrepaidExpensesAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TARA_AssetsAcquiredAndLiabilitiesAssumedPrepaidExpensesAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TARA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TARA_AssetsAcquiredAndLiabilitiesAssumedRestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TARA_AssetsAcquiredAndLiabilitiesAssumedRestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TARA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TARA_AssetsAcquiredAndLiabilitiesAssumedTotalPurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TARA_AssetsAcquiredAndLiabilitiesAssumedTotalPurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TARA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140712350398696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reverse Merger with Protara and Recapitalization (Details 1) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (33,754)<span></span>
</td>
<td class="num">$ (22,821)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_ProFormaLossPerCommonShareBasicAndDiluted', window );">Pro forma loss per common share, basic and diluted</a></td>
<td class="num">$ (4.62)<span></span>
</td>
<td class="num">$ (3.94)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_ProFormaWeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted', window );">Pro forma weighted average number of common shares outstanding, basic and diluted</a></td>
<td class="nump">7,304,201<span></span>
</td>
<td class="nump">5,793,024<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TARA_ProFormaLossPerCommonShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TARA_ProFormaLossPerCommonShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TARA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TARA_ProFormaWeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TARA_ProFormaWeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TARA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140712342727640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reverse Merger with Protara and Recapitalization (Details Textual)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 09, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 02, 2020 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_BusinessCombinationsTextualAbstract', window );"><strong>Reverse Merger with Artara and Recapitalization (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">On January 9, 2020, in connection with, and prior to the completion of the Merger, Protara Therapeutics, Inc. effected the Protara Reverse Stock Split, which resulted in 557,631 pre-merger shares of Protara Therapeutics, Inc. outstanding.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_OutstandingReverseStock', window );">Outstanding reverse stock</a></td>
<td class="nump">557,631<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Common shares exchange ratio</a></td>
<td class="nump">0.190756<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_SharesAvailableForIssuance', window );">Shares available for issuance</a></td>
<td class="nump">2,627,533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_FairValueOfNetAssets', window );">Fair value of net assets | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_DescriptionOfOwnershipRights', window );">Description of ownership rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Immediately after the consummation of the Merger and prior to the consummation of the Proteon Private Placement, the former stockholders and option holders of Private ArTara owned, or held rights to acquire, approximately 75.2% of the fully-diluted Common Stock of Protara, with Protara Therapeutics, Inc.'s stockholders and option holders immediately prior to the Merger owning approximately 24.8% of the fully-diluted Common Stock of Protara.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_PreMergerShares', window );">Pre merger shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">557,631<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_ReverseBusinessCombination', window );">Reverse business combination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,033,907<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit', window );">Goodwill related | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses', window );">Prepaid expenses | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=TARA_MergerAgreementMember', window );">Merger Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_BusinessCombinationsTextualAbstract', window );"><strong>Reverse Merger with Artara and Recapitalization (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Common shares exchange ratio</a></td>
<td class="nump">0.190756<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=TARA_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_BusinessCombinationsTextualAbstract', window );"><strong>Reverse Merger with Artara and Recapitalization (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">476,276<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_BusinessCombinationsTextualAbstract', window );"><strong>Reverse Merger with Artara and Recapitalization (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_SubscriptionAgreementDescription', window );">Subscription agreement, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">(i) 3,879.356 of shares of Protara Therapeutics, Inc.'s Series 1 Convertible Non-Voting Preferred Stock at a purchase price of approximately $7,011.47 per share for gross proceeds of $27,200 and proceeds, net of issuance costs, of $25,319, (ii) 1,896,888 shares of Protara Therapeutics, Inc.'s Common Stock at a purchase price of approximately $7.01 per share for gross proceeds of $13,300 and proceeds, net of issuance costs, of $12,413 and (B) Private ArTara issued in a private placement immediately prior to the Merger (the "ArTara Private Placement") 284,875 shares of Private ArTara common stock (post-Exchange Ratio basis) at a purchase price of approximately $7.01 per share (post-Exchange Ratio basis) (together with the Proteon Private Placement, the "Private Placements") for gross proceeds of $2,000 and proceeds, net of issuance costs, of $1,867. The shares issued in the Proteon Private Placement were registered for resale on a registration statement on Form S-3 filed and declared effective by the SEC on January 30, 2020.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Converted shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,954<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=TARA_EquityIncentivePlanMember', window );">2017 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_BusinessCombinationsTextualAbstract', window );"><strong>Reverse Merger with Artara and Recapitalization (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Common shares exchange ratio</a></td>
<td class="nump">0.190756<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_SharesAvailableForIssuance', window );">Shares available for issuance</a></td>
<td class="nump">219,699<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=TARA_EquityIncentivePlanOneMember', window );">2014 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_BusinessCombinationsTextualAbstract', window );"><strong>Reverse Merger with Artara and Recapitalization (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_SharesAvailableForIssuance', window );">Shares available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,048,300<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TARA_BusinessCombinationsTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TARA_BusinessCombinationsTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TARA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TARA_DescriptionOfOwnershipRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TARA_DescriptionOfOwnershipRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TARA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TARA_FairValueOfNetAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TARA_FairValueOfNetAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TARA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TARA_OutstandingReverseStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Outstanding reverse stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TARA_OutstandingReverseStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TARA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TARA_PreMergerShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Pre merger shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TARA_PreMergerShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TARA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TARA_ReverseBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reverse business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TARA_ReverseBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TARA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TARA_SharesAvailableForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares available for issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TARA_SharesAvailableForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TARA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TARA_SubscriptionAgreementDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of subscription agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TARA_SubscriptionAgreementDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TARA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21521-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of divestiture of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=TARA_MergerAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=TARA_MergerAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=TARA_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=TARA_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=TARA_EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=TARA_EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=TARA_EquityIncentivePlanOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=TARA_EquityIncentivePlanOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140712343836584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentOther', window );">Property and equipment not yet placed into service</a></td>
<td class="nump">$ 503<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, gross</a></td>
<td class="nump">1,359<span></span>
</td>
<td class="nump">475<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: Accumulated depreciation</a></td>
<td class="num">(119)<span></span>
</td>
<td class="num">(16)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property and equipment, net</a></td>
<td class="nump">1,240<span></span>
</td>
<td class="nump">459<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=TARA_ComputerEquipmentAndSoftwareMember', window );">Computer equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, gross</a></td>
<td class="nump">$ 34<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=TARA_LaboratoryEquipmentMember', window );">Laboratory equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, gross</a></td>
<td class="nump">$ 601<span></span>
</td>
<td class="nump">446<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture, fixtures and other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, gross</a></td>
<td class="nump">$ 21<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, gross</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of other physical assets used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=TARA_ComputerEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=TARA_ComputerEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=TARA_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=TARA_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140712340811944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Details Textual) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_PropertyAndEquipmentTextualAbstract', window );"><strong>Property and Equipment (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 103<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_PropertyAndEquipmentTextualAbstract', window );"><strong>Property and Equipment (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_PropertyAndEquipmentTextualAbstract', window );"><strong>Property and Equipment (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 99<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TARA_PropertyAndEquipmentTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TARA_PropertyAndEquipmentTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TARA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140712343801752">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Employee bonus</a></td>
<td class="nump">$ 1,530<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedPayrollTaxesCurrent', window );">Taxes</a></td>
<td class="nump">159<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_LegalFeesOfAccruedExpenses', window );">Legal fees</a></td>
<td class="nump">156<span></span>
</td>
<td class="nump">1,573<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts', window );">Research and development costs</a></td>
<td class="nump">37<span></span>
</td>
<td class="nump">1,050<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other expenses</a></td>
<td class="nump">31<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 1,913<span></span>
</td>
<td class="nump">$ 2,635<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TARA_LegalFeesOfAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TARA_LegalFeesOfAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TARA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedPayrollTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory payroll taxes incurred through that date and withheld from employees pertaining to services received from them, including entity's matching share of the employees FICA taxes and contributions to the state and federal unemployment insurance programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedPayrollTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from research and development costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140712350431960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-Term Debt (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 19, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_ShorttermDebtTextualAbstract', window );"><strong>Short-term Debt (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_DescriptionOfFinancingAgreement', window );">Description of financing agreement</a></td>
<td class="text">The Company entered into a nine month financing agreement with AFCO Credit Corporation for its directors and officers ("D&O") liability insurance in the amount of $2,225. The Company made a down payment of $556, leaving a principal balance of $1,669. The financing bore interest at a rate of 4.25% per annum, and was repaid in monthly installments of $189, which included both principal and interest.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Debt amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TARA_DescriptionOfFinancingAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TARA_DescriptionOfFinancingAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TARA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TARA_ShorttermDebtTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TARA_ShorttermDebtTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TARA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term debt and current maturity of long-term debt and capital lease obligations due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140712344030168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jan. 09, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease cost</a></td>
<td class="nump">215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total</a></td>
<td class="nump">$ 308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate - operating leases</a></td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term - operating lease (in months)</a></td>
<td class="text">87 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=TARA_RightOffUseAssetsMember', window );">Right-of-use assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">$ 1,060<span></span>
</td>
<td class="nump">$ 403<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=TARA_RightOfUseLiabilityMember', window );">Right of use liability, current [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">88<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=TARA_RightOfUseLeaseLiabilityLongTermMember', window );">Right-of-use lease liability, long-term [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">$ 999<span></span>
</td>
<td class="nump">$ 394<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=TARA_RightOffUseAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=TARA_RightOffUseAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=TARA_RightOfUseLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=TARA_RightOfUseLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=TARA_RightOfUseLeaseLiabilityLongTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=TARA_RightOfUseLeaseLiabilityLongTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140712343834296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Details 1)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear', window );">2021</a></td>
<td class="nump">$ 1,111<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2022</a></td>
<td class="nump">1,333<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">2023</a></td>
<td class="nump">1,338<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">2024</a></td>
<td class="nump">1,342<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears', window );">2025</a></td>
<td class="nump">1,423<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter', window );">Thereafter</a></td>
<td class="nump">3,277<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Total future minimum lease payments, undiscounted</a></td>
<td class="nump">9,824<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Imputed interest for leases in excess of one year</a></td>
<td class="nump">8,676<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of future minimum lease payments</a></td>
<td class="nump">1,148<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_PresentValueOfFutureMinimumLeasePaymentsForOurOperatingLeaseLiabilities', window );">Present value of future minimum lease payments for our operating lease liabilities</a></td>
<td class="nump">1,087<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_PresentValueOfFutureMinimumLeasePaymentsShorttermLeases', window );">Present value of future minimum lease payments, short-term leases</a></td>
<td class="nump">$ 61<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TARA_PresentValueOfFutureMinimumLeasePaymentsForOurOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of future minimum lease payments for our operating lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TARA_PresentValueOfFutureMinimumLeasePaymentsForOurOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TARA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TARA_PresentValueOfFutureMinimumLeasePaymentsShorttermLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TARA_PresentValueOfFutureMinimumLeasePaymentsShorttermLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TARA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140712340174536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details Textual) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 02, 2020</div></th>
<th class="th"><div>Oct. 02, 2019</div></th>
<th class="th"><div>Dec. 06, 2018</div></th>
<th class="th"><div>Nov. 28, 2018</div></th>
<th class="th"><div>Dec. 22, 2017</div></th>
<th class="th"><div>Sep. 27, 2017</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jan. 09, 2020</div></th>
<th class="th"><div>Feb. 28, 2002</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_CommitmentsTextualAbstract', window );"><strong>Commitments (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_RoyaltyPaymentPercentageOfNetSales', window );">Royalty percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ArtistAdvancesAndRoyaltyGuaranteesCommitments', window );">Description of royalty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company entered into an agreement (the "Feinstein Agreement") with The Feinstein Institute for Medical Research (the "Feinstein Institute"), a not-for-profit corporation with 50 research labs and 2,500 clinical research studies. Pursuant to the Feinstein Agreement, the Company acquired an exclusive license relating to treatment of fatty liver diseases in humans for which Choline may be an effective therapeutic. In consideration for the rights and license granted, the Feinstein Institute would receive a royalty of one percent (1%) of the first one hundred million dollars ($100,000) of net sales of IV Choline Chloride and a royalty of one and one-half percent (1.5%) of all net sales thereafter. In addition, the Company would pay the Feinstein Institute twelve and one-half percent (12.5%) of net proceeds resulting from agreements entered within 2 years from the effective date, and seven and one-half percent (7.5%) of net proceeds resulting from agreements entered into thereafter. Pursuant to the Feinstein Agreement additional payments would be due to the Feinstein Institute for license maintenance payments and for meeting milestone events. On January 9, 2020, the Company's raising of over $5,000 triggered a financing milestone obligation and accordingly the Feinstein Institute was paid $100. Pursuant to the Feinstein Agreement, upon the achievement of certain future new drug application milestones, the Company would be obligated to remit an aggregate of $275.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">87 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=TARA_TemporaryEmploymentAgreementMember', window );">Temporary Employment Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_CommitmentsTextualAbstract', window );"><strong>Commitments (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_AnnualBaseSalary', window );">Annual base salary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Compensation obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 462<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=TARA_ClinicalServicesAgreementsMember', window );">Clinical Services Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_CommitmentsTextualAbstract', window );"><strong>Commitments (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BroadcastersLicenseAgreementCommitmentsDescription', window );">Description of license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company entered into a license agreement (the "Choline License Agreement") with Alan L. Buchman ("Dr. Buchman"). Pursuant to the Choline License Agreement, the Company received from Dr. Buchman the license rights in and to the "Licensed Orphan Designations", the "Licensed IND", "Existing Study Data" and the "Licensed Know-How" for one or more of the licensed indications. In consideration for the rights and licenses granted, Dr. Buchman received a payment of $50 on October 2, 2017, and license payments of $50 and $50 on December 12, 2018 and January 8, 2019, respectively, upon the Company meeting the criteria for certain meetings to be held with the Federal Drug Administration (the "FDA"). Pursuant to the Choline License Agreement, effective October 2017, the Company incurred a fixed obligation to Dr. Buchman of $400 (the "Choline License Fee"). Upon the Company receiving $5,000 in cumulative funding (as defined), Dr. Buchman would be entitled to receive payment of the Choline License Fee as a lump sum if the funds are received by April 15, 2019 and the Choline License Fee shall be increased to a one-time payment of $600 if the funds are received by October 15, 2019.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_ResearchAndDevelopmentExpenses', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=TARA_ClinicalServicesAgreementsMember', window );">Clinical Services Agreements [Member] | Dr. Buchman [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_CommitmentsTextualAbstract', window );"><strong>Commitments (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_CholineLicenseFee', window );">Choline License Fee</a></td>
<td class="nump">$ 50<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent', window );">Accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=TARA_FeinsteinAgreementMember', window );">Feinstein Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_CommitmentsTextualAbstract', window );"><strong>Commitments (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_ResearchAndDevelopmentExpenses', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=TARA_IowaAgreementMember', window );">Iowa Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_CommitmentsTextualAbstract', window );"><strong>Commitments (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_DescriptionOfAgreements', window );">Description of agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company entered into a sponsored research and license agreement (the "Iowa Agreement") with the University of Iowa. Pursuant to the Iowa Agreement, the University of Iowa, which is engaged in clinical research to improve the diagnosis and treatment of lymphangioma using a pharmaceutical product (OK-432), would assist the Company in collecting case reports, forms, source data, and safety data available to the University of Iowa in support of the development of the Company's proprietary Streptococcus Pyogenes investigational product, TARA-002 for the LMs indication. During the term of the services, the Company would pay the University of Iowa thirty thousand dollars ($30) per year to fund the project, plus additional amounts upon the realization of certain milestones. More specifically, upon forty-five (45) days of an approval of TARA-002 by the FDA, the Company would pay up to $1,750 to the University of Iowa for meeting these milestones. Furthermore, the Company would pay the University of Iowa royalties of up to 1.75% for net sales ranging from $0 - $25,000, 2.25% for net sales ranging from $25,000 to $50,000, and 2.50% for net sales in excess of $50,000. Pursuant to the Iowa Agreement, the University of Iowa would be entitled to additional payments for the Company achieving annual net sales of product according to the milestones. For annual net sales of product up to $25,000; $62; for annual net sales of product of up to $50,000; $62; and for annual net sales of product of up to $100,000; $125.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_ResearchAndDevelopmentExpenses', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=TARA_ChugaiPharmaceuticalAgreementMember', window );">Chugai Pharmaceutical Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_CommitmentsTextualAbstract', window );"><strong>Commitments (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Compensation obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_ResearchAndDevelopmentExpenses', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TARA_AnnualBaseSalary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TARA_AnnualBaseSalary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TARA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TARA_CholineLicenseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TARA_CholineLicenseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TARA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TARA_CommitmentsTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TARA_CommitmentsTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TARA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TARA_DescriptionOfAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TARA_DescriptionOfAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TARA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TARA_ResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TARA_ResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TARA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TARA_RoyaltyPaymentPercentageOfNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TARA_RoyaltyPaymentPercentageOfNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TARA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ArtistAdvancesAndRoyaltyGuaranteesCommitments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the commitments made for future artist advances payable and royalty guarantees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473578&amp;loc=d3e63223-108013<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ArtistAdvancesAndRoyaltyGuaranteesCommitments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BroadcastersLicenseAgreementCommitmentsDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A description of the commitments for license agreements that have been executed but were not reported because they do not meet the conditions for recording a liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472701&amp;loc=d3e49107-107924<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BroadcastersLicenseAgreementCommitmentsDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=TARA_TemporaryEmploymentAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=TARA_TemporaryEmploymentAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=TARA_ClinicalServicesAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=TARA_ClinicalServicesAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=TARA_DrBuchmanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=TARA_DrBuchmanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=TARA_FeinsteinAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=TARA_FeinsteinAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=TARA_IowaAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=TARA_IowaAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=TARA_ChugaiPharmaceuticalAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=TARA_ChugaiPharmaceuticalAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140712339737624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 06, 2020</div></th>
<th class="th"><div>Sep. 24, 2020</div></th>
<th class="th"><div>Sep. 23, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 22, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_StockholdersEquityTextualAbstract', window );"><strong>Stockholders' Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common shares of par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,211,840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,627,533<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,211,840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,627,533<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred shares of par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_CommonStockIssuanceAndOutstandingPercentage', window );">Common stock issuance and outstanding, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_MaximumAggregateOfferingPrice', window );">Maximum aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=TARA_UnderwrittenPublicOfferingMember', window );">Underwritten Public Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_StockholdersEquityTextualAbstract', window );"><strong>Stockholders' Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_AggregateOfSharesOfCommonStock', window );">Aggregate of shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Offering price, per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 77,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_NetProceeds', window );">Net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 73,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted option to purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">690,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_StockholdersEquityTextualAbstract', window );"><strong>Stockholders' Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Gross proceeds</a></td>
<td class="nump">$ 11,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_NetProceeds', window );">Net proceeds</a></td>
<td class="nump">$ 11,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted option to purchase</a></td>
<td class="nump">690,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=TARA_Series1PreferredStockMember', window );">Series 1 Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_StockholdersEquityTextualAbstract', window );"><strong>Stockholders' Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Conversion of stock shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_IncreaseOrDecreaseEquityPercentage', window );">Convertible preferred stock, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=TARA_Series1PreferredStockMember', window );">Series 1 Convertible Preferred Stock [Member] | Underwritten Public Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_StockholdersEquityTextualAbstract', window );"><strong>Stockholders' Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_AggregateOfSharesOfCommonStock', window );">Aggregate of shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,148<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Offering price, per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,873.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_NetProceeds', window );">Net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 66,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=TARA_Series1PreferredStockMember', window );">Series 1 Convertible Preferred Stock [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_StockholdersEquityTextualAbstract', window );"><strong>Stockholders' Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,880<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=TARA_Series1PreferredStockMember', window );">Series 1 Convertible Preferred Stock [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_StockholdersEquityTextualAbstract', window );"><strong>Stockholders' Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TARA_AggregateOfSharesOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate of shares of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TARA_AggregateOfSharesOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TARA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TARA_CommonStockIssuanceAndOutstandingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock issuance and outstanding percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TARA_CommonStockIssuanceAndOutstandingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TARA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TARA_IncreaseOrDecreaseEquityPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TARA_IncreaseOrDecreaseEquityPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TARA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TARA_MaximumAggregateOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TARA_MaximumAggregateOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TARA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TARA_NetProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of net proceeds.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TARA_NetProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TARA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TARA_StockholdersEquityTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TARA_StockholdersEquityTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TARA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=TARA_UnderwrittenPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=TARA_UnderwrittenPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=TARA_Series1PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=TARA_Series1PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140712343839864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details) - Restricted stock unit [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_RestrictedStockUnitsAbstract', window );"><strong>Restricted Stock Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Balance at beginning | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted | shares</a></td>
<td class="nump">479,325<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited | shares</a></td>
<td class="num">(56,375)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Vested | shares</a></td>
<td class="num">(148,334)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Balance at ending | shares</a></td>
<td class="nump">274,616<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_WeightedAverageGrantDateFairValueOneAbstract', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Balance at beginning | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted | $ / shares</a></td>
<td class="nump">29.97<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue', window );">Forfeited | $ / shares</a></td>
<td class="nump">30.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">vested | $ / shares</a></td>
<td class="nump">30.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Balance at ending | $ / shares</a></td>
<td class="nump">$ 29.95<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TARA_RestrictedStockUnitsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TARA_RestrictedStockUnitsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TARA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TARA_WeightedAverageGrantDateFairValueOneAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TARA_WeightedAverageGrantDateFairValueOneAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TARA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140712339715768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details 1) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_StockOptionExercisePrice', window );">Stock price</a></td>
<td class="nump">$ 17.84<span></span>
</td>
<td class="nump">$ 6.81<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 17.84<span></span>
</td>
<td class="nump">$ 6.81<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">95.00%<span></span>
</td>
<td class="nump">97.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.28%<span></span>
</td>
<td class="nump">1.71%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (in years)</a></td>
<td class="text">5 years 3 months 8 days<span></span>
</td>
<td class="text">5 years 6 months 29 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_StockOptionExercisePrice', window );">Stock price</a></td>
<td class="nump">$ 51.12<span></span>
</td>
<td class="nump">$ 8.65<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 51.12<span></span>
</td>
<td class="nump">$ 8.65<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="nump">97.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.69%<span></span>
</td>
<td class="nump">2.37%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (in years)</a></td>
<td class="text">6 years 29 days<span></span>
</td>
<td class="text">6 years 7 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TARA_StockOptionExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TARA_StockOptionExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TARA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140712350612824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details 2) - Options [Member]<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_OptionsAbstract', window );"><strong>Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance at beginning | shares</a></td>
<td class="nump">219,592<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted | shares</a></td>
<td class="nump">565,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised | shares</a></td>
<td class="num">(57,767)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited | shares</a></td>
<td class="num">(52,886)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance at ending | shares</a></td>
<td class="nump">674,039<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberExercisable', window );">Exercisable | shares</a></td>
<td class="nump">109,117<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_WeightedAverageGrantDateFairValueAbstract', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Balance at beginning</a></td>
<td class="nump">$ 7.29<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted</a></td>
<td class="nump">22.61<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageGrantDateFairValue', window );">Exercised</a></td>
<td class="nump">6.72<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue', window );">Forfeited</a></td>
<td class="nump">14.08<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Balance at ending</a></td>
<td class="nump">20.60<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercisable', window );">Exercisable</a></td>
<td class="nump">11.44<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_WeightedAverageExercisePriceAbstract', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance at beginning</a></td>
<td class="nump">9.18<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted</a></td>
<td class="nump">29.23<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised</a></td>
<td class="nump">9.18<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited</a></td>
<td class="nump">18.91<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance at ending</a></td>
<td class="nump">25.23<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceExercisable', window );">Exercisable</a></td>
<td class="nump">$ 15.63<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_WeightedAverageRemainingContractualTermYearsAbstract', window );"><strong>Weighted Average Remaining Contractual Term (years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTerm1', window );">Balance at beginning</a></td>
<td class="text">9 years 8 months 19 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTerm2', window );">Balance at ending</a></td>
<td class="text">9 years 22 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTermExercisable', window );">Exercisable</a></td>
<td class="text">8 years 2 months 30 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_AggregateIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Balance at beginning | $</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted', window );">Granted | $</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Balance at ending | $</a></td>
<td class="nump">2,311<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisable', window );">Exercisable | $</a></td>
<td class="nump">$ 1,201<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TARA_AggregateIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TARA_AggregateIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TARA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TARA_OptionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TARA_OptionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TARA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TARA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercised fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TARA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TARA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TARA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options exercisable, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TARA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TARA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TARA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TARA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TARA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TARA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TARA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TARA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TARA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TARA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TARA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TARA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTermExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TARA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTermExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TARA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TARA_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TARA_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TARA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TARA_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TARA_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TARA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TARA_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TARA_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TARA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TARA_WeightedAverageExercisePriceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TARA_WeightedAverageExercisePriceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TARA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TARA_WeightedAverageGrantDateFairValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TARA_WeightedAverageGrantDateFairValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TARA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TARA_WeightedAverageRemainingContractualTermYearsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TARA_WeightedAverageRemainingContractualTermYearsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TARA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140712341990072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details 3) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total stock-based compensation</a></td>
<td class="nump">$ 9,746<span></span>
</td>
<td class="nump">$ 424<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total stock-based compensation</a></td>
<td class="nump">6,357<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total stock-based compensation</a></td>
<td class="nump">$ 3,389<span></span>
</td>
<td class="nump">$ 313<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140712341915960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details 4) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total stock-based compensation</a></td>
<td class="nump">$ 9,746<span></span>
</td>
<td class="nump">$ 424<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total stock-based compensation</a></td>
<td class="nump">741<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total stock-based compensation</a></td>
<td class="nump">$ 9,005<span></span>
</td>
<td class="nump">$ 224<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140712335891768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details Textual) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 09, 2020</div></th>
<th class="th"><div>Oct. 03, 2014</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Jul. 23, 2020</div></th>
<th class="th"><div>Aug. 10, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_StockBasedCompensationTextualAbstract', window );"><strong>Stock Based Compensation (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_SharesAvailableForIssuance', window );">Shares available for issuance</a></td>
<td class="nump">2,627,533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,211,840<span></span>
</td>
<td class="nump">2,627,533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember', window );">Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_StockBasedCompensationTextualAbstract', window );"><strong>Stock Based Compensation (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Grant date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.60<span></span>
</td>
<td class="nump">$ 7.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_WeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_WeightedAverageRemainingAmortizationPeriod', window );">Weighted average remaining amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_UnamortizedValueOfStock', window );">Unamortized value of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,973<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_IncrementalValue', window );">Incremental value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_StockBasedCompensationTextualAbstract', window );"><strong>Stock Based Compensation (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,870<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Grant date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29.95<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_UnamortizedValueOfRsus', window );">Unamortized value of RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_NumberOfSharesRestrictedStock', window );">Number of RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">132,709<span></span>
</td>
<td class="nump">5,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_WeightedAverageRemainingAmortizationPeriod', window );">Weighted average remaining amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 9 months 22 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,687<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Amount of charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 152<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member] | Directors One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_StockBasedCompensationTextualAbstract', window );"><strong>Stock Based Compensation (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_StocksIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 316,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_VestedOptionsPercentage', window );">Vested options, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Grant date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,480<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">254,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member] | Directors Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_StockBasedCompensationTextualAbstract', window );"><strong>Stock Based Compensation (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_VestedOptionsPercentage', window );">Vested options, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member] | Consultant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_StockBasedCompensationTextualAbstract', window );"><strong>Stock Based Compensation (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockDescriptionOfTransaction', window );">Sale of stock, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Board of Directors granted of 5,245 RSUs to a consultant. The RSUs were granted under the Company's 2017 Equity Incentive Plan. The RSUs vested in five equal installments of 1,049 units on the 15th and 30th of each month, beginning on October 30, 2019. The grant date fair value of this RSU was $36.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member] | Employees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_StockBasedCompensationTextualAbstract', window );"><strong>Stock Based Compensation (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_StocksIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 163,325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_VestedOptionsPercentage', window );">Vested options, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Grant date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,887<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=TARA_TwentyFourteenEmployeeStockPurchasePlanMember', window );">2014 Employee Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_StockBasedCompensationTextualAbstract', window );"><strong>Stock Based Compensation (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockDescriptionOfTransaction', window );">Sale of stock, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The number of shares increases each January 1, commencing on January 1, 2015 and ending on (and including) January 1, 2024, by an amount equal to the lesser of one percent of the outstanding shares as of the end of the immediately preceding fiscal year, 7,025 shares or any lower amount determined by the Company&#8217;s Board of Directors prior to each such January 1st.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,513<span></span>
</td>
<td class="nump">18,012<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=TARA_TwentyFourteenEmployeeStockPurchasePlanMember', window );">2014 Employee Stock Purchase Plan [Member] | Subsequent Event [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_StockBasedCompensationTextualAbstract', window );"><strong>Stock Based Compensation (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=TARA_TwentyFourteenEmployeeStockPurchasePlanMember', window );">2014 Employee Stock Purchase Plan [Member] | Subsequent Event [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_StockBasedCompensationTextualAbstract', window );"><strong>Stock Based Compensation (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=TARA_TwentyFourteenEquityIncentivePlanMember', window );">2014 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_StockBasedCompensationTextualAbstract', window );"><strong>Stock Based Compensation (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_SharesAvailableForIssuance', window );">Shares available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">227,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockDescriptionOfTransaction', window );">Sale of stock, description</a></td>
<td class="text">The number of shares available for issuance under the Amended 2014 Plan increased by 900,002 shares from 148,298 shares to 1,048,300 shares on January 1, 2020.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=TARA_TwentyFourteenEquityIncentivePlanMember', window );">2014 Equity Incentive Plan [Member] | Board Of Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_StockBasedCompensationTextualAbstract', window );"><strong>Stock Based Compensation (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_StocksIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 484,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Grant date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,867<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_VestPeriod', window );">Vest period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=TARA_TwentyFourteenEquityIncentivePlanMember', window );">2014 Equity Incentive Plan [Member] | Minimum [Member] | Board Of Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_StockBasedCompensationTextualAbstract', window );"><strong>Stock Based Compensation (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=TARA_TwentyFourteenEquityIncentivePlanMember', window );">2014 Equity Incentive Plan [Member] | Maximum [Member] | Board Of Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_StockBasedCompensationTextualAbstract', window );"><strong>Stock Based Compensation (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=TARA_TwentyFourteenEquityIncentivePlanMember', window );">2014 Equity Incentive Plan [Member] | Subsequent Event [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_StockBasedCompensationTextualAbstract', window );"><strong>Stock Based Compensation (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">812,889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=TARA_TwentyFourteenEquityIncentivePlanMember', window );">2014 Equity Incentive Plan [Member] | Subsequent Event [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_StockBasedCompensationTextualAbstract', window );"><strong>Stock Based Compensation (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,861,189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=TARA_TwentyTwentyInducementPlanMember', window );">2020 Inducement Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_StockBasedCompensationTextualAbstract', window );"><strong>Stock Based Compensation (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_StocksIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_SharesAvailableForIssuance', window );">Shares available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">460,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=TARA_TwentySeventeenEquityIncentivePlanMember', window );">2017 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_StockBasedCompensationTextualAbstract', window );"><strong>Stock Based Compensation (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_SharesAvailableForIssuance', window );">Shares available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=TARA_TwentySeventeenEquityIncentivePlanMember', window );">2017 Equity Incentive Plan [Member] | Board Of Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_StockBasedCompensationTextualAbstract', window );"><strong>Stock Based Compensation (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_StocksIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47,114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Grant date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 317<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_VestPeriod', window );">Vest period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TARA_IncrementalValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of incremental value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TARA_IncrementalValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TARA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TARA_NumberOfSharesRestrictedStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of RSUs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TARA_NumberOfSharesRestrictedStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TARA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TARA_SharesAvailableForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares available for issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TARA_SharesAvailableForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TARA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TARA_StockBasedCompensationTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TARA_StockBasedCompensationTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TARA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TARA_StocksIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TARA_StocksIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TARA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TARA_UnamortizedValueOfRsus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unamortized value of RSUs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TARA_UnamortizedValueOfRsus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TARA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TARA_UnamortizedValueOfStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unamortized value of stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TARA_UnamortizedValueOfStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TARA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TARA_VestPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TARA_VestPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TARA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TARA_VestedOptionsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Vested options, percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TARA_VestedOptionsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TARA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TARA_WeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TARA_WeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TARA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TARA_WeightedAverageRemainingAmortizationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TARA_WeightedAverageRemainingAmortizationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TARA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other research and development expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockDescriptionOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of stock transaction which may include details of the offering (IPO, private placement), a description of the stock sold, percentage of subsidiary's or equity investee's stock sold, a description of the investors and whether the stock was issued in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4582445-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569655-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockDescriptionOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=TARA_DirectorsOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=TARA_DirectorsOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=TARA_DirectorsTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=TARA_DirectorsTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=TARA_ConsultantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=TARA_ConsultantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=TARA_EmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=TARA_EmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=TARA_TwentyFourteenEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=TARA_TwentyFourteenEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=TARA_TwentyFourteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=TARA_TwentyFourteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=TARA_TwentyTwentyInducementPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=TARA_TwentyTwentyInducementPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=TARA_TwentySeventeenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=TARA_TwentySeventeenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140712340141288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="num">(6,211)<span></span>
</td>
<td class="num">(1,614)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="num">(2,439)<span></span>
</td>
<td class="num">(930)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredOtherTaxExpenseBenefit', window );">Total deferred</a></td>
<td class="num">(8,650)<span></span>
</td>
<td class="num">(2,544)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">8,650<span></span>
</td>
<td class="nump">2,544<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total income tax expense (benefit)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOtherTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other deferred income tax expense (benefit) pertaining to income (loss) from continuing operations. For example, but not limited to, acquisition-date income tax benefits or expenses recognized from changes in the acquirer's valuation allowance for its previously existing deferred tax assets resulting from a business combination and adjustments to beginning-of-year balance of a valuation allowance because of a change in circumstance causing a change in judgment about the realizability of the related deferred tax asset in future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOtherTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140712344035912">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Details 1) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_DeferredTaxAssetsAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOtherLossCarryforwards', window );">Net operating loss carry forwards</a></td>
<td class="nump">$ 19,371<span></span>
</td>
<td class="nump">$ 3,806<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_DeferredTaxAssetsOrganizationCostslegalFees', window );">Organization costs/legal fees</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits', window );">Stock option expense</a></td>
<td class="nump">443<span></span>
</td>
<td class="nump">111<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Research and development credits</a></td>
<td class="nump">70<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_DeferredTaxAssetsOperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="nump">330<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_DeferredTaxAssetsRestrictedStockExpense', window );">Restricted stock expense</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">238<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_RestrictedStockUnitsExpense', window );">RSU expense</a></td>
<td class="nump">1,796<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_DeferredTaxAssetsCharitableContributions', window );">Charitable contributions</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">22,020<span></span>
</td>
<td class="nump">4,178<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(21,698)<span></span>
</td>
<td class="num">(4,176)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred tax assets, net of valuation allowance</a></td>
<td class="nump">322<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_DeferredTaxLiabilitiesOperatingRightofuseAsset', window );">Operating right-of-use asset</a></td>
<td class="num">(322)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_DeferredTaxLiabilitiesDepreciation', window );">Depreciation</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome', window );">Total deferred tax liabilities</a></td>
<td class="num">(322)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Deferred tax assets, net of valuation allowance and deferred tax liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TARA_DeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TARA_DeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TARA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TARA_DeferredTaxAssetsCharitableContributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of charitable contribution deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TARA_DeferredTaxAssetsCharitableContributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TARA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TARA_DeferredTaxAssetsOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TARA_DeferredTaxAssetsOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TARA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TARA_DeferredTaxAssetsOrganizationCostslegalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of organization costs deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TARA_DeferredTaxAssetsOrganizationCostslegalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TARA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TARA_DeferredTaxAssetsRestrictedStockExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of restricted stock expense deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TARA_DeferredTaxAssetsRestrictedStockExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TARA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TARA_DeferredTaxLiabilitiesDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of depreciation deferred tax liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TARA_DeferredTaxLiabilitiesDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TARA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TARA_DeferredTaxLiabilitiesOperatingRightofuseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TARA_DeferredTaxLiabilitiesOperatingRightofuseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TARA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TARA_RestrictedStockUnitsExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of restricted stock unit deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TARA_RestrictedStockUnitsExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TARA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOtherLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible loss carryforwards, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOtherLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from tax deferred revenue or income classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140712350507448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details 2)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">U.S. federal statutory rate</a></td>
<td class="num">(21.00%)<span></span>
</td>
<td class="num">(21.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes, net of federal benefit</a></td>
<td class="num">(9.40%)<span></span>
</td>
<td class="num">(12.10%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Option expense</a></td>
<td class="nump">1.20%<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther', window );">Other</a></td>
<td class="nump">1.90%<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes', window );">True-up to prior years return</a></td>
<td class="nump">1.80%<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">25.50%<span></span>
</td>
<td class="nump">32.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140712429990216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details Textual) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 09, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_IncomeTaxesTextualAbstract', window );"><strong>Income Taxes (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss and credit carryovers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 63,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,700<span></span>
</td>
<td class="nump">$ 4,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_NetOperatingLossAfterApplication', window );">Net operating loss after application</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_MergerDescription', window );">Merger, description</a></td>
<td class="text">The Company acquired NOL's from Proteon of $41.6 million. These NOLs were determined to be impaired by $12.4 million, with an annual limitation of $0.5 million on the remaining $29.2 million of NOLs. The general business credits of $3.6 million acquired in the merger were determined to be fully impaired.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TARA_IncomeTaxesTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TARA_IncomeTaxesTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TARA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TARA_MergerDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TARA_MergerDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TARA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TARA_NetOperatingLossAfterApplication">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of net operating loss after application.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TARA_NetOperatingLossAfterApplication</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TARA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140712345709624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TARA_EmployeeBenefitPlanTextualAbstract', window );"><strong>Employee Benefit Plan (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans', window );">Defined contribution benefit plant, description</a></td>
<td class="text">The Company maintains a defined contribution benefit plan under section 401(k) of the Internal Revenue Code covering substantially all qualified employees of the Company (the "401(k) Plan"). Under the 401(k) Plan, the Company matches 100% up to a 4% contribution.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherExpenses', window );">Recorded expense</a></td>
<td class="nump">$ 69<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TARA_EmployeeBenefitPlanTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TARA_EmployeeBenefitPlanTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TARA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of defined contribution pension and other postretirement plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4,6)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>71
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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MD,8 OV^%T,\#LT#;\Z[^ U!+ P04    "  ;.&M2BY-?;C('   Y+P  &
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M?[Y$2!PI)6%2^EKEHF3H&WWR4V:X^QERX"<,=&JBXZ8$!]?[#U$-;:0>'=1
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MX/^E@ AJ?I@)#N_P7/\74$L#!!0    ( !LX:U)HJ0]]/ H  +T8   8
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MJ?U,B33K$F3=IA$E"2^,PHHXQ/>5Q-LC0"@+/[8RGZ])1+^&!"DX[OFB?4K
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MDHB2DO5/<UDM@_*O)-E+&0W8H]A5;0?9QQ")3AQN6*\VI; @VC(V>>TPM5A
M*(5!C Z0N0>381\,]'SI-^'J0G-E"!6W!.+;+R$Y.N'W85<TXV\SVD4)^R2,
MG0M(&#MR84TIXIWNC,FZ^#F#,:KB$+6=FW>=MIN8MHY[!N.8O%HQZ-7W!D2
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MBZ*#;_<U8<=CB4$/P*%/T?K@-8?A;'#2[>*69*,['K^ 0<'S4L>E3%DKFIM
M;K)KF]M!^-*L5-"DW9N(CQ\O^<6?FB7R,%>ZQ'E(,,81?TZ(VE#A0O'C<9S-
M<U2V /?^1!0Q3CFG,,3!34D$_W&N5OYQE8<&=3,O,.9VUO\::__VV&YZ*QI/
M.F^%V/ $K?QCC+A?X#K>QR$DSFCR]C$&@5%&",M9]^HI5>#83^AE*40G&Q&*
MMERC?BB;:A>@I*TP[+["M/-_FR<0W!2<JNUXRJ-QS6C98093R>B9PJ/!*'I1
M7[&'(B2X")WN;U.R=MVQ\_9>C*2W8SLI-=>F1K:7P#\59UF$LA*H7'3!!@@J
MXC'J_WM2?T[^'9-S6X<&@RX*T*KHB@1O# J<'*0897UFF^7F14*$/AK-UQ/Q
M*QC.MSS<="%%5=\GT1DM4Q-]6B[QAJLPD1!54TQ#?9VDRR&JE-ORT75H18G@
M<QF(K+-]09<%J>:NL+LZ1&<2N6:QT*GFNQ&T/,@CMU@_03U=:Y3M+49'BU6
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MG[Q4]QCQTXN7S^E)]M/QF+1PK1D$UQ#XQ?[Y/&RP$<O<R:GS \\>/^ -("W
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MBDJER1X2I4JKQ'5*B+J6/Z'OH3T6QMD11, W9PR#';=*=.H%V;?T+.1$BJD
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M&H%IIV:[<;H*DXHDI;D7EB5]:-!X [HOM';GC0_0?;J6_P%02P,$%     @
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MQ/SX<A\^?GDKSL1__L?Y<K'X+_'HZN)7!:L5EYM**<?VEZT"V\5.EO=B*ZW
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MFX(_;A4PJJ(!IW0D"(#U7VB#^'OBU_\'4$L#!!0    ( !LX:U(OC3NH4@H
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MA_]I<RL7=ATLCNFFU^C3.]EXX,XUVJ1R1:Z'LCJ/42NLHA%!"V+YDKV T15
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M%?0*@0$H2L6R+""[2AM?DZ+1<7)2"\;#90EP8,C-0[R0^1QT$+.YT>5H['U
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M[0O!_P7UXWU8/_F#P/[X6+%WTF4CQGLTGFQA_2#&?"('P@EP>S;>F0?!LWD
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M*K/Y7C3LYQJEN%FM3%JI<PZWT6.;-;2OO-"K%7R)UQ,>89O"+O2EUJ8MTB9
MIUI[W.C8C^I[E$Z]P&0-.L#'6M24^:">&MQX-LTUJ&JCMEU[D6@TU]7F#0/Y
MI9*FZ-_E9779;_PTQF!U+_>8!#7O_!OL8*M?G6L%TE1BO3,2LF3#PEY&P_)H
M[VK[26"3LG%EQ=TYRIM04W>Z#UWO6_*WM<P@/_U^193@I(KJ%3:,4QF<]:(,
MSK'Z%E@.LL]>1[C:[%OP4'E-L:TOCODFD)4/G6[-E*CL7N1XH)=3'2H%>=I_
M<3OVYD $EB[T$& ,EQKA9T*CFJI,C>HS,:/RAAXLG%EHW0Q=PK$%Y,>M#XKX
M@5R?%5WH4;7Y@_X+$E3HD-'F=%G*S<)ER!,NX2T\_K2<\]Q/JOSM<H7DG\H<
M61B7(4')7_!T9[;\ 7_G'GWSG6#>HY^JE13GT!Y[D0L1.OX<LV:.N\#G<*$_
M^R<*_>&+68/ZOC4P:[2^;S3?%/3BVM24G)N+#W20'TGUO[+J#Z:ULKYC61^,
M?VI+T_?4(P5_U&&B&S9Q;HY\W?9G?L(,E94JUKM9M[T+D+:[X"/A")>DQ+GC
M+XTN\6?N#]H.X2RT/1?3?6?F49/ #R#+R]8XJ $QM^>SN;B A+&8R=",?HN"
M+@MGF.%-22'>PEEZ/&? 6=>5F,VGMAL04[[KS%SZ']+&2\?E5H4=>%[# =]6
MZ/N<'@7/7:(FF9/1>LYT2O]#9Q; L/V0OMC  \/TH EPJG5T@-07.2!O:7H2
M3AAVH=-I>RUC[N!%+1;KC[183O='CK98ABSB7-;9TE[.@S^GUR)ZO98 7J%)
M"NX[G(Z]^\V^@-SX\-:%<@Z@6 .=WJ;3+X;VWI&EM*NC$B,6EAQ_UAF=_-4Q
M_]ISJ9_VVV-G["#GH<7MB9D=A',1S(SK;>06V,%B"1$%UF=F!^BSYU.R[:D_
M-4<\9*Z+5!&QN$JU[^O%K2Y 6<,60U2^X"#<X!#[#0X<9NHQ%%WKK^-1=&F[
M;@@W,3UZI&/OIE_U?@"PI>2$?N9 67"=5?JW .W3]I<4U_H'!-UT_3.,CU&!
M=+44J5QAJ>O,PXE^T:OY4N4[_CG!0UY5^98_;F2$3)DF8'R5YU7SA39H?U_R
M]O\!4$L#!!0    ( !LX:U)4^M)FV@D  %48   9    >&PO=V]R:W-H965T
M<R]S:&5E=#$V+GAM;)59;6_;.!+^KE]!^++7%' <2W82IYL&2-(6V\.U*9IT
M[Q:'^T!+M,V-)'I)*D[VU]\S0\J64R=[_=!6ICC#>7GFF:%ZMC+VSBV4\N*A
M*FOWMK?P?OGF\-#E"U5)-S!+5>/-S-A*>ORT\T.WM$H6+%25A]EP>'Q825WW
MSL]X[8L]/S.-+W6MOECAFJJ2]O%2E6;UMI?VVH6O>K[PM'!X?K:4<W6C_+?E
M%XM?AVLMA:Y4[;2IA56SM[V+],WEF/;SAE^U6KG.LR!/IL;<T8^/Q=O>D Q2
MI<H]:9#XYUY=J;(D13#CCZBSMSZ2!+O/K?8/[#M\F4JGKDSY+UWXQ=O>I"<*
M-9--Z;^:U2\J^G-$^G)3.OY;K,+>T:@G\L9Y4T5A6%#I.OPK'V(<.@*3X3,"
M613(V.YP$%OY3GIY?F;-2EC:#6WTP*ZR-(S3-27EQEN\U9#SYQ_KW%1*W,H'
MY<X./332^F$>I2^#=/:,=)J)3Z;V"R?>UX4JMA4<PI2U/5EKSV7VHL9W*A^(
M4=H7V3 ;OJ!OM/9OQ/I&?^F?>*==7AK76"7^<S%UW@(1_WWAB/'ZB#$?,7[N
MB,]7UY_>B]N+?[^_V17"EZ4_7]^^%^E0_/UODRQ-?Q9=;>*#*I25I9!U(6Z\
M]$KHX(^'/^H!E>FPY(1T8F9*%)A[DP"LPB^4^$U)&_.24# 1T?0TN6JL5;5/
M6LU[XH#^)$'[ 9YNC<=Z'O;QRCLU4_A5K(7VC_NP5;P6^VG_.!V+UU%\/^N/
M1Z>T?CH:8C6H*J*XV)_TCX^&]#KK'XU)[&HAZSDY)>YEV<A0I^2'K',EPG;>
M&U7M\'Y_JFHUT_YUZXIHS>WL5JXO]$S(Y;+4N9R6JB\D8+"TYEXC/@A>B%FA
M9Y!5.-PE4^572M6\CKI'E TT.*>\XWR46DYUJ;U6CN5GNH;5&E9:M336ZWK.
M^SHV+QN[-$ZY@;A=1"]P7NY9M5<5Q$",72MPNO1B#N(25L-;;X33\UK/X :R
MR.>8.LB3_:WKI+NU%8YV\7%!NSN(>/>]S)OD,]H!B-]*=@-5XT0N+6R#IRMI
M"X=(IZ?]T4F*AU%_,CQ.KNU<UOK/D,3<..\.2S5'.&8*?DS$*4!B\CNHY1UM
M_L;CD4C3-/FJ' ";+SAFA;I'NUA6A, <MFGX<3($%*\W-BEP\3H)CV(THO?0
MXJW./=QQ?%I[S('(1I/DZ\VW]4K:/SD]%FE&(+3:$RI@=@WQ:1."FHGL*80[
M<<VR/L5PW$]/)LFO.^"[GZ$Z3B>$=]IT#+SOB'5?U!3KV<X*&&5DPY94!W9O
M.N&PU'T.S.R@<2IH%OLD_9KK%_T:R&3E![#K^])\HKF5Y:T_:G1(X#.*VR*]
M0)4@VCG6@WQ$,)<D=WRJJ6X%HS'Z!>U)9&6:&AG NV5#J9X^<FD_4B!(B0,;
M-=X KBUC=8H0)11_317.>/'('Z+6;X.; < >#MR88 ,SI@,PWT_KA\B8D9MB
M-%OA2&F@T<&8A=)LD)+0]7;MI(-,_"2&@R.!5S#,8N645U*LW-I&'31+<GAI
M-4Q_9+.M\HVML7."G0?8]S()9T>D'DCD4]XS7Q$=42AMZ!FL1C"O@'QS54UA
M2=O#.:A;H2%\N"?-+-EP9DN2?0[U%7(LZT>Q0!Z08VL>-$8Q53Z*O>/1X 0C
M45E&^#0UL%^$6&Y1%^&Y]_GZGZ[W6LA[J4NN==B5;'$:!6K6>)H/.%*!I9':
M";$'NQ(](%T8PAZ1**9%'5H(*]% !5J!)AN#AM:%PL"0VGCX0O$C($?NPL'!
M$MH6"H&X+9@^E?E=4/09,^YOF'%C]"B..8F_9(Y?6-/,N6[8*S@R'K(H!-#C
M0D^$@)QC@G>^C0!RPE$**1J(2Y5+HI9OY%D<1ERH;KER*/$*>*5#/$9V4326
M@K]::! ZS'O:/(*QR?]U]C8.HIM-S3L0."_OD,NF!*Z*>_1$W"0HA-0Q."[<
MFI]!7M)MRK V=ONMA,U1BS:6ZE9$/C262BZ8UU;LS)I*H'V4;2.$*3O\STU3
M%A0!UTQ_1T&1(QQ"&3I/T;!OA'1+$X59P0BWT$N1<['&N2"H,3F&->*IKNW4
MR73=T$[PG7-0* OT4:@G=D++4SP'P)<*9H9FB5"X!C%D&2)8N=34)JP$/U)I
MEK)&65Q*JC.2:I#>CMW?EVQG6-FD(\ "5\@V2@EA'JF(463>;4 ^U@,7 W%=
MBW_(NJ'1Z#202O^)K]6R5 1+6OVD[%S9@?A(4TA=A]M?TC:/^'I;@<S_:#1U
M*YCXRH4D?K'&JY# O7$Z.&Z9ADL1A<#>K#"FH=<A2[B:*680@%-#*ZM#7]H#
M=8^3*-L//4R"7VOX4W9BQ^<0DZ\)+6#1*KI94_#WLE/0?8?OR() # &CZ!L-
MTJ1H5HLS$RD=#8[;\S>.ZJ"]XF \XP85U>/:F0$1O(0]#O?=MEMW@YG'8()Z
MZ5L!E35@U11$;Z#W>[JAT[XXA+=.?_QZA;M/>GSR\VB2<4%O$H,D>K$"C+JV
M+<A86D08G]8%50%T/D$+U7W24?LJ4D-;VD7LCSC\J>0J%FK(%$6!XKTS>]\=
M\,HE<@:[GWI,&[>]IA%]+T6O[V)LC<X  =32ABO4@T0T@D: C >SQB^,Y2$K
MX>L,UD+#YP[6]@'R:EL]E2DN0:"+&7$QP:;E2^[Q85S@FPQ>N79L:5\ 2=_W
MI62]=$4-BDZ ;*^2OQO;8^G?T2%<H;DXNY0BQ4([GIL0J;RIFE+RN!&;H?3;
MA5LS()* 2LY];/W$HNVM+H1!T;BV8SXA'32_;5/"%N)P*K@=I%31O%CJ.YH_
ML%QS.Z?W"=ZOD#Q>",RF-G3&A$+::3;9<9?83DA'3V[LU@5R0Y"A?M=WSH1#
M3_<E8D[TGVCP#[JQ%0*V8]W^7#,#CVNZD6UW0L)C]#C9NH-V[&[=W$$A$OWH
M$;?KE\,O0XO?>=V(PP/A8-<]C:C"JL![@V>GU-TH6+ L98'I;-?Q1+&8Z=>3
M:$*:]L8;JNZ3P\LP-=-(^-<65(C)G).YF1FG"I/2/47X299X,.;!*,X*Z\89
M/CD8IT,UL&3@LQ@.0@--&;A)T]A%!E@U*YECZ"J&!@@H$=%)NK?/@ %'BN/8
M2EU;K@_@XFT* E@=A@<<:DI=,,%N/HYL@+H#]>W4PAP7HJU8V3-.)5B(0R/*
M7IN"QYTU>.B;3_2.HQD\S UF$C8Y6KK+."H3S YHIF@'S\SQFYQP2R(':*#N
M)J,=U^))31V/_S-B=),><Z]LY(@'SY0UV/5M\K#SJ9>[-WW0YH&R]N&K[WIU
M_<W\(GPJWFP/']P_23NGOE*J&42'@Y.C7OB,T/[P9LD?CJ?&>U/QXT))M ;:
M@/<S X3$'W3 ^G\2SO\'4$L#!!0    ( !LX:U+>F">XU0(   D&   9
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M6;FT9@,K&KB3Q[6&23R*?V\<&AO7P,^1A1/Y4\M@HJVIX6B_ P4/(-RF<<(
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M>B;G\_/QU=FE'-+0>:NA\^%0'6 '[&G;?/@=A5CR5^T^]VKIGUA/OHM)F$Z
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M%;&>^T&BU0; S9J&%.!(\[HD)(;@D+_M'?FLTV7:HU4L_? 4R< . 6.M66"
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M5GI_OU K73$466+X&SW_[&+,H4C:R1E;'CLPB%5%)*?PD7GA"WK$?D0K7D'
M)!84MS+,PE=]@&R@R6=BS'[<VZ:@0H06>MB([SYS1*_'8?,U5EZ6F',E_W;3
MK!I0%2#MJD=]@>B?S82>GLS.QK(MCXBD/!)4\6J.JMB62>2[4.XXN?/OJ_GJ
M3#+F5PZ-V;#@A?678%KS@)2 >1#AQ<8-2 T&-$7!OF)#G2S8Q.QCU_95SA"'
MMYLEZI/6%5 2XIFZQ3N2G,J(TL"!+$?S;7#O]U('N2F$^9E#R$5.P?OOUN>%
MO#>.#/GJ\!)I3\Y=)/$;=8G$K!2H!&H<N\>0!CYRS)Z3[9W'EZGB2S@@9,F;
ML4E[+1F6]J5$3(?X;!#B!X^_C$LB6'+*G.]&TV+5&H.X!\4&#[EDL8&2+-Y7
MSB$B1J!7UJGRO-],R6"A??'2%RQ\-"#=<**<Z/D:-\4W&@.92/*_V1B(86,@
MCQN#(5#2OD0V&W[[Z[[UGF\?CM:4_^ :'2$-S3-%ZJG]JR4'[]C3NZ-4."=L
MN*Q]B.G?RI?\EU@(L#?;^ Y ;+,YDM_WT6*;4.:D'MO,KDK![0F\/0_^=Y3-
M/"0\J4'2/4<-3-O;;6K(!M[H[;W)T^1OEA *Q;_,0B^-5S7_^9+X:_SK+S?\
M-T_:X?RG8WX")X\:7:HE3)U.+B]&TO)?8^$OM=G27T!9F+HV&_JX5AD@"AP
MSY<&H+/_@AO$OXGS^O\!4$L#!!0    ( !LX:U(+PUXEI (  &\%   9
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M5-:![@LIS4&Q!,-CF/P%4$L#!!0    ( !LX:U(N:G9\Z0,  )P)   9
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M=U92-=S@5*T#O57 *W>HJ0,6AFG0<-%.YZ=N[4K-3^7.U**%*T7TKFFX>KB
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M8)W$WK.#00Q1%'7NB1]7R=J].L4M=>Y-87,C(6Z"O'$>4I+<?N>$U!9;][Q
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M3 RWK,Q,!VD#S/M2& ^[C2W0_TO(G@%02P,$%     @ &SAK4LS5/ 2G @
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MZP$U2U>66DVL*KTK/2M+'N>'.7V%4+L VE\I90\3EZ#YKDU^ 5!+ P04
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M/<APR>K"S.7F$V[U=&V]5!;:_<)FFQMXD-;:R'(+)@8E%\V3O6[/80\0]DX
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MT;6]G#QU,YCQHC:'_W\CH>EQN\\MZ?2B P5'LN+.77)<0*\5T'NG@(WS"LR
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M.(9;',-&'.^Y4&3%XQRL*Z185[G68#3YFUP<BXA"VV '1M"K!3':@A@U@IB
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MH\P!%-H4E,F1DRM57KJN3',HL.SQ$IC^LN"BP$I/Q=*5I0"<65!!W<#S(K?
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MF[9)U:IU'P_3'DQR(=82F]D&NG^_:R<-%()'I[U G-QSSKW'SLT=;87\J7(
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MV<L<YUJ0)@"?+X30CPLCT$S*DS]02P,$%     @ &SAK4OPJ#6H& P  / D
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M7 TP4M4<U4W'R+(^'I?2X&%;-W/\O %E)^!X)J5YZ]@3M_M@FOX"4$L#!!0
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MP:Y::X] D&>"Q96P1!"'R?Z7O%2.: A 1R. *@$T5 !7 GBH@%,).$,%II7
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M*9%/7BR0]Q\9$Z\GQ6>E^E/HXC]02P,$%     @ &SAK4J7T H0( P  L0D
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M3+T@GR\H%?L;!= =*4W_!U!+ P04    "  ;.&M2#T2S^*@"  #=!P  &0
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MXP%I G!_*83>34R![E>6_@-02P,$%     @ &SAK4F:C>%F@"0  +S,  !D
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M .=OTS3??- _']C^1N;L_U!+ P04    "  ;.&M277#)MOX"  ":"@  &0
M 'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6RM5EUOVC 4_2M6M(=66IO$"2E4
M$*G JO6A4E7:[=DD%Q+5L9GM /OWLYV0 @U1/_9";.>><\^YV/$=;KAXD1F
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M?MW>">W$JMIWR;6RU'/]L*1K%+7;0.N%(M>[B6N\_<6\^ U02P,$%     @
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M+C>ET5(NDK3?<0O&B?)5\29 WO"M[4H<WW[E'F21S*>^PITPUG5'=/5SS_@
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M&^IM!'K;8+.$0&]#O8U ;T.]C4!O0[V-0&]#O8U ;T.]C4!O0[V-0&]'O9U
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MM7^@IY]02P$"% ,4    "  ;.&M2!T%-8H$   "Q    $
M@ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( !LX:U(?H+]V[0
M "L"   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4
M Q0    ( !LX:U*97)PC$ 8  )PG   3              "  <L!  !X;"]T
M:&5M92]T:&5M93$N>&UL4$L! A0#%     @ &SAK4OW @P)=!   AA   !@
M             ("!# @  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4
M Q0    ( !LX:U+[FL39B 4  !07   8              " @9\,  !X;"]W
M;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4    "  ;.&M2"G:H2\0"  #U
M"0  &               @(%=$@  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL
M4$L! A0#%     @ &SAK4N\LN_9Y P  _PH  !@              ("!5Q4
M 'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( !LX:U*+DU]N
M,@<  #DO   8              " @089  !X;"]W;W)K<VAE971S+W-H965T
M-2YX;6Q02P$"% ,4    "  ;.&M23E%^9-D'  #/(P  &
M@(%N(   >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ &SAK
M4FBI#WT\"@  O1@  !@              ("!?2@  'AL+W=O<FMS:&5E=',O
M<VAE970W+GAM;%!+ 0(4 Q0    ( !LX:U*MCQC"818   X_   8
M      " @>\R  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4
M"  ;.&M21,PT;LL+   N(0  &               @(&&20  >&PO=V]R:W-H
M965T<R]S:&5E=#DN>&UL4$L! A0#%     @ &SAK4BH_^0F9 P  #0@  !D
M             ("!AU4  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"
M% ,4    "  ;.&M2IVIH=[H"  " !0  &0              @(%760  >&PO
M=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( !LX:U*5*0N 1 ,
M ,8&   9              " @4A<  !X;"]W;W)K<VAE971S+W-H965T,3(N
M>&UL4$L! A0#%     @ &SAK4DMK@+)\%   6SP  !D              ("!
MPU\  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    "  ;.&M2
M+XT[J%(*  !>'@  &0              @(%V=   >&PO=V]R:W-H965T<R]S
M:&5E=#$T+GAM;%!+ 0(4 Q0    ( !LX:U)+4)- $!   &LR   9
M      " @?]^  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%
M  @ &SAK4E3ZTF;:"0  51@  !D              ("!1H\  'AL+W=O<FMS
M:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    "  ;.&M2WI@GN-4"   )!@
M&0              @(%7F0  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+
M 0(4 Q0    ( !LX:U(K.WW&\P4  *X-   9              " @6.<  !X
M;"]W;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @ &SAK4JD>6$!%
M%P  'T<  !D              ("!C:(  'AL+W=O<FMS:&5E=',O<VAE970Q
M.2YX;6Q02P$"% ,4    "  ;.&M2"\->):0"  !O!0  &0
M@($)N@  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( !LX
M:U(;8T=Z/@,   X'   9              " @>2\  !X;"]W;W)K<VAE971S
M+W-H965T,C$N>&UL4$L! A0#%     @ &SAK4C8U5C7I @  + 8  !D
M         ("!6<   'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4
M    "  ;.&M2WMP7W'H"   8!0  &0              @(%YPP  >&PO=V]R
M:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( !LX:U(N:G9\Z0,  )P)
M   9              " @2K&  !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL
M4$L! A0#%     @ &SAK4HM?%R/#!   X0L  !D              ("!2LH
M 'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4    "  ;.&M2E/D^
M958$  "7"@  &0              @(%$SP  >&PO=V]R:W-H965T<R]S:&5E
M=#(V+GAM;%!+ 0(4 Q0    ( !LX:U(X'S<X5P,  !D+   9
M  " @='3  !X;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @
M&SAK4OOG/M_3 @  ,0@  !D              ("!7]<  'AL+W=O<FMS:&5E
M=',O<VAE970R."YX;6Q02P$"% ,4    "  ;.&M2S-4\!*<"  #C!@  &0
M            @(%IV@  >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4
M Q0    ( !LX:U+Q419+O0(  .,&   9              " @4?=  !X;"]W
M;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%     @ &SAK4NX@A;C. @
MW08  !D              ("!.^   'AL+W=O<FMS:&5E=',O<VAE970S,2YX
M;6Q02P$"% ,4    "  ;.&M2*0M7@JH&   V&0  &0              @(%
MXP  >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( !LX:U*%
M@A@HCP,  $4-   9              " @2'J  !X;"]W;W)K<VAE971S+W-H
M965T,S,N>&UL4$L! A0#%     @ &SAK4J"3%T^E @  \0<  !D
M     ("!Y^T  'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( !LX:U)E3W292PH  &$D   9              "
M@<[]  !X;"]W;W)K<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @ &SAK
M4CY[?QVZ!0  %AT  !D              ("!4 @! 'AL+W=O<FMS:&5E=',O
M<VAE970T,"YX;6Q02P$"% ,4    "  ;.&M2I?0"A @#  "Q"0  &0
M        @(%!#@$ >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0
M   ( !LX:U)BB)$S;0,  $H-   9              " @8 1 0!X;"]W;W)K
M<VAE971S+W-H965T-#(N>&UL4$L! A0#%     @ &SAK4OL?MJM\!   7A(
M !D              ("!)!4! 'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q0
M2P$"% ,4    "  ;.&M2#T2S^*@"  #=!P  &0              @('7&0$
M>&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    ( !LX:U+LX^UU
MBP(  -8&   9              " @;8< 0!X;"]W;W)K<VAE971S+W-H965T
M-#4N>&UL4$L! A0#%     @ &SAK4F:C>%F@"0  +S,  !D
M ("!>!\! 'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6Q02P$"% ,4    "  ;
M.&M277#)MOX"  ":"@  &0              @(%/*0$ >&PO=V]R:W-H965T
M<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    ( !LX:U)(LG$QYP,   @/   9
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M;',O+G)E;'-02P$"% ,4    "  ;.&M2E';FU2$$   B(@  #P
M    @ %./0$ >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ &SAK4J&7ZI3)
M 0  H!X  !H              ( !G$$! 'AL+U]R96QS+W=O<FMB;V]K+GAM
M;"YR96QS4$L! A0#%     @ &SAK4BBT:!/# 0  B1X  !,
M ( !G4,! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     #L .P 4$   D44!
#

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>141</ContextCount>
  <ElementCount>394</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>45</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="tara-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://artaratx.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="tara-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://artaratx.com/role/BalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="tara-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://artaratx.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="tara-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://artaratx.com/role/StatementsOfOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="tara-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Consolidated Statements of Changes In Stockholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://artaratx.com/role/StatementsOfChangesInStockholdersEquityDeficit</Role>
      <ShortName>Consolidated Statements of Changes In Stockholders' Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="tara-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - Consolidated Statements Of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://artaratx.com/role/StatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements Of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="tara-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Disclosure - Business, Liquidity and Capital Resources</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://artaratx.com/role/BusinessLiquidityAndCapitalResources</Role>
      <ShortName>Business, Liquidity and Capital Resources</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="tara-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://artaratx.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="tara-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - Reverse Merger with Protara and Recapitalization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://artaratx.com/role/ReverseMergerWithProtaraAndRecapitalization</Role>
      <ShortName>Reverse Merger with Protara and Recapitalization</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="tara-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://artaratx.com/role/PropertyAndEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="tara-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://artaratx.com/role/AccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="tara-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - Short-Term Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://artaratx.com/role/Short-termDebt</Role>
      <ShortName>Short-Term Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="tara-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://artaratx.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="tara-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://artaratx.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="tara-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure -  Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://artaratx.com/role/Stock-basedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="tara-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure -  Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://artaratx.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="tara-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - Employee Benefit Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://artaratx.com/role/EmployeeBenefitPlan</Role>
      <ShortName>Employee Benefit Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="tara-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - COVID-19</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://artaratx.com/role/Covid-19</Role>
      <ShortName>COVID-19</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="tara-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://artaratx.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://artaratx.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="tara-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://artaratx.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://artaratx.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="tara-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - Reverse Merger with Protara and Recapitalization (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://artaratx.com/role/ReverseMergerWithProtaraAndRecapitalizationTables</Role>
      <ShortName>Reverse Merger with Protara and Recapitalization (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://artaratx.com/role/ReverseMergerWithProtaraAndRecapitalization</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="tara-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://artaratx.com/role/PropertyAndEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://artaratx.com/role/PropertyAndEquipment</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="tara-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://artaratx.com/role/AccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://artaratx.com/role/AccruedExpenses</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="tara-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000025 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://artaratx.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://artaratx.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="tara-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00000026 - Disclosure -  Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://artaratx.com/role/Stock-basedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://artaratx.com/role/Stock-basedCompensation</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="tara-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>00000027 - Disclosure -  Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://artaratx.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://artaratx.com/role/IncomeTaxes</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="tara-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>00000028 - Disclosure - Business, Liquidity and Capital Resources (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://artaratx.com/role/BusinessLiquidityAndCapitalResourcesDetails</Role>
      <ShortName>Business, Liquidity and Capital Resources (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://artaratx.com/role/BusinessLiquidityAndCapitalResources</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="tara-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>00000029 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://artaratx.com/role/SummaryOfSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://artaratx.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="tara-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>00000030 - Disclosure -  Summary of Significant Accounting Policies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://artaratx.com/role/SummaryOfSignificantAccountingPoliciesDetailsTextual</Role>
      <ShortName>Summary of Significant Accounting Policies (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://artaratx.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="tara-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>00000031 - Disclosure - Reverse Merger with Protara and Recapitalization (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://artaratx.com/role/ReverseMergerWithProtaraAndRecapitalizationDetails</Role>
      <ShortName>Reverse Merger with Protara and Recapitalization (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://artaratx.com/role/ReverseMergerWithProtaraAndRecapitalizationTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="tara-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>00000032 - Disclosure - Reverse Merger with Protara and Recapitalization (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://artaratx.com/role/ReverseMergerWithProtaraAndRecapitalizationDetails1</Role>
      <ShortName>Reverse Merger with Protara and Recapitalization (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://artaratx.com/role/ReverseMergerWithProtaraAndRecapitalizationTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="tara-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>00000033 - Disclosure - Reverse Merger with Protara and Recapitalization (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://artaratx.com/role/ReverseMergerWithProtaraAndRecapitalizationDetailsTextual</Role>
      <ShortName>Reverse Merger with Protara and Recapitalization (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://artaratx.com/role/ReverseMergerWithProtaraAndRecapitalizationTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="tara-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>00000034 - Disclosure - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://artaratx.com/role/PropertyAndEquipmentDetails</Role>
      <ShortName>Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://artaratx.com/role/PropertyAndEquipmentTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="tara-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>00000035 - Disclosure - Property and Equipment (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://artaratx.com/role/PropertyAndEquipmentDetailsTextual</Role>
      <ShortName>Property and Equipment (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://artaratx.com/role/PropertyAndEquipmentTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="tara-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>00000036 - Disclosure - Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://artaratx.com/role/AccruedExpensesDetails</Role>
      <ShortName>Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://artaratx.com/role/AccruedExpensesTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="tara-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>00000037 - Disclosure - Short-Term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://artaratx.com/role/Short-termDebtDetails</Role>
      <ShortName>Short-Term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://artaratx.com/role/Short-termDebt</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="tara-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>00000038 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://artaratx.com/role/CommitmentsAndContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://artaratx.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="tara-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>00000039 - Disclosure - Commitments and Contingencies (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://artaratx.com/role/CommitmentsAndContingenciesDetails1</Role>
      <ShortName>Commitments and Contingencies (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://artaratx.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="tara-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>00000040 - Disclosure - Commitments and Contingencies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://artaratx.com/role/CommitmentsAndContingenciesDetailsTextual</Role>
      <ShortName>Commitments and Contingencies (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://artaratx.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="tara-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>00000041 - Disclosure - Stockholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://artaratx.com/role/StockholdersEquityDetails</Role>
      <ShortName>Stockholders' Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://artaratx.com/role/StockholdersEquity</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="tara-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>00000042 - Disclosure -  Stock-Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://artaratx.com/role/Stock-basedCompensationDetails</Role>
      <ShortName>Stock-Based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://artaratx.com/role/Stock-basedCompensationTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="tara-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>00000043 - Disclosure -  Stock-Based Compensation (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://artaratx.com/role/Stock-basedCompensationDetails1</Role>
      <ShortName>Stock-Based Compensation (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://artaratx.com/role/Stock-basedCompensationTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="tara-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>00000044 - Disclosure -  Stock-Based Compensation (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://artaratx.com/role/Stock-basedCompensationDetails2</Role>
      <ShortName>Stock-Based Compensation (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://artaratx.com/role/Stock-basedCompensationTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="tara-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>00000045 - Disclosure -  Stock-Based Compensation (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://artaratx.com/role/Stock-basedCompensationDetails3</Role>
      <ShortName>Stock-Based Compensation (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://artaratx.com/role/Stock-basedCompensationTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="tara-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>00000046 - Disclosure -  Stock-Based Compensation (Details 4)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://artaratx.com/role/Stock-basedCompensationDetails4</Role>
      <ShortName>Stock-Based Compensation (Details 4)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://artaratx.com/role/Stock-basedCompensationTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="tara-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>00000047 - Disclosure -  Stock-Based Compensation (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://artaratx.com/role/Stock-basedCompensationDetailsTextual</Role>
      <ShortName>Stock-Based Compensation (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://artaratx.com/role/Stock-basedCompensationTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="tara-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>00000048 - Disclosure -  Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://artaratx.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://artaratx.com/role/IncomeTaxesTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="tara-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>00000049 - Disclosure -  Income Taxes (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://artaratx.com/role/IncomeTaxesDetails1</Role>
      <ShortName>Income Taxes (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://artaratx.com/role/IncomeTaxesTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="tara-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>00000050 - Disclosure -  Income Taxes (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://artaratx.com/role/IncomeTaxesDetails2</Role>
      <ShortName>Income Taxes (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://artaratx.com/role/IncomeTaxesTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="tara-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>00000051 - Disclosure -  Income Taxes (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://artaratx.com/role/IncomeTaxesDetailsTextual</Role>
      <ShortName>Income Taxes (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://artaratx.com/role/IncomeTaxesTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="tara-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>00000052 - Disclosure - Employee Benefit Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://artaratx.com/role/EmployeeBenefitPlanDetails</Role>
      <ShortName>Employee Benefit Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://artaratx.com/role/EmployeeBenefitPlan</ParentRole>
      <Position>51</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>tara-20201231.xml</File>
    <File>tara-20201231.xsd</File>
    <File>tara-20201231_cal.xml</File>
    <File>tara-20201231_def.xml</File>
    <File>tara-20201231_lab.xml</File>
    <File>tara-20201231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>76
<FILENAME>0001213900-21-014709-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-21-014709-xbrl.zip
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MMX0!("Q^Q.@UKDZO]--C2AF<<O<D+M9*&Z]^&Z6AC<V@C;5T[#M+0F";22@
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M\HD4#<NNLVTNLFRT^76>N9ZTEY8X3;WVX.!@N&>N,!UG?@YBZ/8(]08 PI;
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M/TA@KO._O[=.P%0&5@;_]8(0MJIP>;.[()KA@S.7N2J5;L>ZNL"\9ZI'BH$
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M+LV<_LCXEGX$DA<^<'D)I=S>%O^:_1)  1%+)UY[Z98!D^ @:L)#+0'"[@S
MBL *2+"[( T<HJ$990@C!PF^Y0C<=VIQ ?#?LCJ/Y)%0>A]\!-2&\#[5V9#&
M/1.=22\I94A3<FQ3N;!4X9\%4=R6L(QT]P=TOPI^P,<&# O.!2O@ ,!74-Y[
M/48$'EI:!_ML:1'E9+2M3,NEQNN^M"0T20(O0ZG+=J_D&)A)2WX;<]]:BY@6
M^[^0JJQ>&YA3>Z^K:8N[K48S,)J49:&BJ/0+GWLU^!6_1?-S*^%K?!-Y4HXR
MU6[B@$079!/ME%+'#JYR9YY9Z\.RPX18.D#9C.4\.#-EX0G=00S[=*;%'XD@
M(W7)A?$DY9NSP_P0U"Z*6O.NPP&3?]']P@CMYDBHKBV@':%="!2$+G<4_WBF
M, IH85\.5C1NA?"E$Y//5"C&GK(SG]A.?>)/?_!JK2N4#]:N:J5S"YK0P_N<
M+\&=3L&X)\D+$M"#)Y1?%TU0_"PI5E&*;DH7Z9'9V4"CMZB3CG+9IJ%\'=U?
M( 0ZH"'+]JW'^9:MU@,Z[T9\!5-(KL]CJF.U<%S3[I['R+4&+FO/9]YB=SO&
MH$#WQ#7QQ$2CUC<[<NP_+&F% ZLD-T/:3<<'1D-T1YODCGY'8GF<@@5G[:!N
MOX.R ^:7_HE@!G00I!RGUVW)=C_7@C?^&YP/:Z#5^W&"OF4W&B7LZ@C%Q ZU
MBUYQFQQEL,XB/2U2FZ@9KUZ-I:L=)RV]8]IQ(GVL#NRA;W/%*]+#HK=@FQ\3
M$<[UCB)*88TR>T#P4J162^D/X+C )SSB#Z@?O.L='+7VAT<TQ+O]@SV*N<XX
M-.4]S@=[_2"V)L*7?5-"[MV%/D=4FEV*ZXP$^>MI2 K,^1279BA\F5/+Y_G=
M8- :'LK9#UM'@ZX^,H^4YE[2+<M8<1;<$@P510PY2HAG4(5:$:#>P4%K7TY
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MP().^826ME+;3W<M55B,O4%N!,=,:@!Y,T(R5X5ZX&_(.,8F.,RP4?0S,3S
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M*K;>9L4;;LQ.S'C][-[%R)XC8MOUHEP^CXH <C(DAX*:4,.*0PU?9%PRJJZ
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MD6QTF$4I!P0')BG;,Y'$[F@IE2W5V.*2S6'1K=T35A@\VAYWX$ ]$JS8D2:
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MH9)GTK(+)&TVF!>:M4J62;L#/3O($E.KR>O9S-?^(D26C;%H.SR:1^ H&ZT
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MAW9$G9W#.K'>,*\V&8STF=+R&=T]@?XM,@V9*/J.=E\WI/@.L"G*'0C $)B
M7N&$UZ[A9J<3!R\@?"%T4T3WP3D.V;<GWZZ_>U@1A7#E383?[E7*AS"U[UO1
MS1\^A:.Q[#%N9('(-2TFRPW7,K%X-%IQF!Z*FUZ$)8E+;:[I,Q$=)I=Q'^\
M'H?G5Z#UW]//^(?IL9JQ-&WSK?GP+E/C2]Z[TJS55&+<SCO"-$_<L8<X4D\%
MZIPBHO>YRQHZ3>K,R#LR!CE*?8*!T@&MNCJEEPZ4?!B*%9ZQZ<6YI'][C-(P
MXV1,7Z345K7AY"?AHUGQH9FKC2DIC']H/<)35#>8)D+[>U%O$B@;EL4RG_TH
M&S"JBB.:ATVU"%HZ\V04SBO*G,-KMHD>#CP&.184%F8&(73)@?% $TP#)WPI
MV)AFQU"D0ZX-TTVDS7F")^%P?+,8C.<'2(_ILD"GS1=?F#0OM3-%<M:>G0D_
M3 ;:>!)N12-VJ\;8C?%3/!TCTL8B?;G@@BL:!?F=7VJ@J,0G&-\G^!V++@Q&
MXP4_E_A&4R<^S5E4]!%\@&>H%DXW3-P![,0,.'9!LLC<-12(V,Z!@PI 9/M&
MG[Y("9XANS.L'+[((A@L(;?5*1@56L0LX5WLCMR^B8FB\'C4F+AFN:_LA;7I
M>OX ?<&.O4*.-=T5CT<*7)Z)FA*O9C1=0NA7%([CP7P^>Q'K_"G4[*B/RPLV
M&WX(Y01IL< (D]T#A/[^HE.^M:;0)>E4KG<CO1?\[Q/>-+ Z9(=NY5BU,TG^
MSZGQ9?9=++ FR\%V/-!%/]A$;VIVE\(;Q/Y&I<7.S^<H/CZA^/@=Q4<!N!DK
M&0-@/\9':CTY'6>V34XV91\-%_R^X2M6Y*!GMZ+^K/Y<V-"[X]V03_<#WGSZ
M;K7FE(VR;/XMUWQ&L.5\J.8VN/B-ZRZUI4\K7<'&LP5J3:7>DGH,M(*-MA@N
MI/2B/J88+,U1GQQW3<SN\=3;R72@SRKR5-=ZFNNCHL[T+T(B_<XLWJ9T[UZ7
MN[<86Z+K%;L=-N? [E&BLUS<3KNNN"ZH_:SOT0:/UX*K[HKO[\6ES<:#J9K?
MXK$\+4O ^()ZF*'F4/[$JDJUHMV3[F?6D@L\"==A_-WX?M6QHCO!'4=HSMT@
MC>YV0/#@93SF#BJ8)(\KJUBF3116(1:KW/ ;#M%0($S)H'FGH>,NJ@PB@HN9
M65[4OB:P(Q!">"-_WG2@+1;YL8NL+*!P"!C<_H_N>/C81EC?E6?*XMCJ<*ZR
MP GF+T0Z(PF51@NPO^R_JFN#V6@1QFA'GOID;94!JV[ I3*-EZ5?8+SK$_%Y
MV0-Z0[M*U](N2$%-X-HN(W?HXB2[3!<+?1T-YK.\,NZ\&#7&BD5WX9Q#G[N;
MN7'PB?+%647EDZT^$F4GZI"FVK"ZBFD.I$G5K%!X&.3*ZJ6R.%<1G3 93.<S
M)A%9?5_'W1",D2?+  5%HJHR9ESB,;YB\0[N'2\,-=&45;EMPM(V/8(5'T(1
MM2(@D)PM97[R Y/760HXCZV-)$U4UYL>-;S0"NL\P[J"8OAO3@;>)L9-(G&#
MI2#A83)4PL4]6".\8^@ %7B;;<5+EOC_&\O\Z7=A7O@ H]-+#@B3&D+ J27B
MOL+ZC%BY;I:J^IH6 K'ZKT#M5/KOK9@XC _B%\M,XO%Y&X0FH.*T8@T$6,W&
M6/DJ;!8;JS]+,]AH170A;M41UPGY9;> AUYUBY8+5"5.ELVC^6C1F^%[%)3\
M^^LWNOHRKJME!I85\=Y\-- FH^/S7D[R<Q[OP6!W-)P=U<DWVG0XHR?M&WTR
MY.V^LIA2:<"0(H2M-#N*'?!&'2Q&^HM@RBS9+Y(Z>ME?:_]-1H/)>%%Z_^V+
M)>)3T>D/+?(3NXM"<""1KVDO8G<=2N2/Y^-X;NK!>:Z1J*>MVJFHIPW,(T8,
MC:OFHKXN(ZJCP7SZ[-6/N@93W'G1$;OI0!T0PR*WS#TQ$OLT="Z$%0BQ-!PM
M'Q';%$)/0,O<C?4("CUE1>EV-#$C;?RG1BJJ+\EV33Q3,RM%V&&-P1)U-T2R
M&VS%>W,3I?WA&*+V#Z] !:M#>%3_UO'\TWBRBMCL<6\R3,>]M$ZD9\!>IV',
M7D08$=@:PW6HG =A0[R4 X32):P:$O<="2]/&.5),^9X6YYH?T]&:A6WSQVQ
ML9X].R%7@#&OF8OQW 5.'PI$*<?/,+JZ>77BQGM51>[B+LE8/JY_GSZ#DELT
M'J7.BM2$_08-V+T;_ICA1;70:#?S8Q]A42!S/' Y'=C<-) Y%JU<$-6<#F0N
MN$%.!QWXSC:ZGZ4WO+\HD^%X&[NUQ3O<G2_%52X-JZA\CWUD*,+09+U":')>
MN$8%L/."BYM</G[BVO,?-!W\(Q7U._=]B9CH1M/%3Y'=:\4H'& W[*4J.W#6
M'R/G=X-!.43Z,0"JSY\<:FWV4SL,&$8-97%"C?6N1MU=C(Y'\3@:VK0U<JN+
M:ANOD.K-@LU*+U1SO$4W5*R"78W;*@)9,X@VBHYJA.8;A7D/3I4W"O4>M(5L
M7FS7T?&?8HP.HC\?3B>M<OK>X. #LO?'A$.IY_"7S.'HG7Z-(OS<1/O-7BE/
M)K%6+YG',9#\IU?&U\4XOSQYC4&;Z']TL-HJUJIYR0R]P#OKGT!FJR/U%?+V
M8M8Z<W=49G\SO7^=KEU"*_42E]]*O6@%9334YI35A]/%:V-T=3A3$7=MJ,]>
MH3"WS#51WIHVNUE]]Y*Y?#+49K#0T^$H7Q=]F3P^&4[F#/-\TR.#P].I1]9S
MCCCFKN.\<C/)]F*)*C/AM2*%Y5E7F:D,RC'+RNPM1F(=K3H+O^W< :;LP/N0
MDC!.B]B'M6F2I6@**L^\9N*$?JZKT,_54T7Y%F8O?L ZI2!QL98>5NU7WL94
MD=='J;.P:-T%T,6T/7/9ZGXZ4A4G/:SYDU&SZ3)63+ULT2;MF$6;%KD%C#1U
M,9@LM'T#2("A!0+LK=R4C_=LJ"U>'=*AF_O9(2V#U1?#V>OC\Q9JLAVI"A!]
MNIM5R";3R4"54ZBF ]AHVG"JOA1<%D--?R&XY&_EUXG'\0O;)>($NB:4WDYF
M@]FT8CG!KI6QFQ:=V<^+[0N5K^>%2B^)NJ,1R:NBV;WR?V\GV"*R?#6X3HHP
M=2PN=)[_AE'GP\5+40U[(79<=2JO!&'"N99?!5.*=#MBI<OI;#P8Z?D^J*,P
M8;ZC(<>\&@VG'3-[*Z,P>3D6XF(XJGA8=FXU!KHJZX!I52OK-!]4?+'[C-TC
MU"/TW!'JBG[%_54T'H>U@'[!6I8Z6@Q454I/C>,=BJHZ'%=L!M Y%";#Z4O1
MLN;#KC6<J;P: VW4EI;5;CWXO7&&T@IG[-0S+^I^F%D[HU31%W7!2ZP/)Y.H
M+!6K(%54I*-4U7@*1I/*\<4EWS.KQB?!!-PH$&\6@\5,EU-"7HF5C]>'HU&\
M?/SKJ&@3A073'.S3][1*2[Q6$P7K(ZL71"%^125OHF[L5!1Y/(P:V%3Q':S-
M1%GTE)6V6::)MG0\WZ.UG>YLY.S6 J?3X67CO)H(+R^:NN3Q*ZNFS+1YU&->
M31=1QF6G"(L,?&H8#1V@MH08TTIMCTI0L:-(JOG>WP.PBJ1 V5E6NU/ZWK=4
MOYM<9(_9VG/T^KJ9YJ-<T/2PF]&"E,VNOU=IF7R0J)6!/NF8SZ$V+KJL&X7N
MM=V+A.IUW&AIZ_#H;)B%/M#G%8^B^D"^6"*J^?XM*21L79#>H''46/ITI"'B
M8C ;'^\NM"-$&&NRW,:'\O(U,8JE.!"N<WP#4?%E [T#:XN5)XB58H[J+3.W
M6Z+9EN'U"=C/R8CM70;/SIKN708OPF5 >QXJJ7Z'S\V.'N??KKU8YX%6D #7
M3>]!'4OQM]SV#*_.XED,1J-\AU%O-I8BHE:@HG?&;"PCXWL+LK<@R_!APGC\
MV\^!=WIG&-M?SDUO:3E>X)++=?PB^QNQL)O-![R5O<;0"'K7?64\44OK!D!X
M;X'%]NM__@?2\&]BN.OE/5D%%@Q&7Z+V7')8<3=!#;XS>Y7ZAK;6/F-UMIYN
M$-YP+NR<A+A_(^O_/OGD.AO4/4]'*OSC._2SJIWJZLFOY<TN2L4&34FJ6&&E
M38+#\+M,_3B[07H%V(X'>EB *&XBT@F31:QV?BZH:K5?V]E;PBP^Q)&LA6F6
MM9!?F^>K8Y_R/F!E2_.TH$A7T.(GK^\&\G HR^;?&EFZ.?!VLY+)>+88Z%T+
M;ZV-C;88+J3<PQY3#);F*'F9X')7X>UD.M +0@LR9^M:%K>.Q?2[R$KR)-+O
M]-1LQW(Y;AD!=3P?Z'I%2Z8Y!W:/$IWE8KF!'>,,73 _QRG/W5*G+'C7\I^T
MV7@P5<N[,?)I6<-'=S@"2O=[H.90_L2J2K6BW9/E'&G3F[''<Q)WMYQA4@@=
MC]>71HN3 G 6]865XBOI2@-7*LUVU[_%9JE[-TC?J+5OU+J/'?I&K=64I;Y1
M:]^HM9(B^[PZ1O6-6N4BV]$N.GVCUI[#7SJ']XU:^T:M+X^O^T:M+YBA^T:M
M?:/6OE'KRV?TOE%KWZCUI?-XQ4:M5JGKC(97#&4N,.*7)?'1#Q;@V?&(SKZ5
M:4>[+?:M3/M6IGTKTY8HU;<R[5N9OH 6CWTKTV>%M Q6[UN9RL&X;V6:)G+?
MRK2SN/2M3%\L'L?/*4G<I'=-*/6M3+N%2M_*],7BT;<R;2D'J6]EVC%<^E:F
M+Q:/KK3:ZEN9'H\)^U:F74"A@8K9MS(]D%;6:3ZH^&+W&;M'J$?HN2/4%?VJ
M;V5Z;)[L6YEV 87:DN%EMC*M$7Y8+4!0A!S>G'T[^^7"\P+#7N)P\1>S:S#<
M.!\W6\MY(@2?.#==LO0=5T[1A&<2?UB28?M*_I6/V1K*O6QJ]Y7\^TK^]+V^
M^5\^'W83Y;[YGZ1[WK[YW_'E4QJZOOE?W_RO32+VS?\:^$SZU@UM$&&W=4..
M7=R2%9N?ER=>!E/SP5R2;"O\S()!Z*?+]3>R=.YL\T^RN@+KU&'=('ISN3>7
M>W.Y-Y=?BKG<-[Y[IH9SW_CNE6G[?>,["43L&]]UU7#HK:<JUE/KYDW:CKJP
ME\Z&W!@_HI9Y]4PA.8W'4;''#U\O;S["& I;Z[FFJG]5+KY^N/SR4;DY^W\?
MKUEE[=N0A*UU0A< I9BN_9D_D55X0EYC,WC%I$NE^,:/L'V\B;W@E358A\YC
MWQ/^61EK!S2-(\!Z&[FWD9^'C9S'*A\"U\VR9)L0*8<$M=20K@%SU%S@4VV&
MI6'2->E&PXEIQP^YQFJ>E."OCN4]'0O\@_@*BFRRTMQ#U:)79^KFKW/O*^@"
M 3L:G)#>7.,1^S:]N>9\<U$GA++,.6Y['NDWV7/?9*4/J73!X'.R)K MNE;7
MI,\TZIIHWKFH:ZP8MW]W5>'B+/\2Z^UTH!6DJ^Z#(;^$:-?Q5@=3-?\FHBK>
MO2K>[4/NK388%U0JJ'+2Y;/\BR7>0J_H1CO@KCF  HXE8XJV%%/ 5WFZQHMG
MC_E@.FF'05X!\;3!I" S]MB[2U8H27Y/CP_WAGV'5V;*@VCYH!AX2X91J:^.
M'>1MI5=LT<K;4IVQ3_9OL\+&.>R$RKB6?GM+;+(V_?*"MTXOGH[$=I3W=.QT
MXFFRK7J*E=M#473-BPH/$3ZHV/;#Y\VU8FRW%H@*0'J@&"[VL76PV^=*6?-P
M@96YAG<)'(0>A>F6^(^$V/2W6\,S:>D3P_.([]'H$\LT;K&OHDD\.L;:M.$4
M-6'KNV3K@%RR[^AS,4&P#=RMXQ%OV"H-]H>D2)GFYIY+-R#;TJ?4\<D&,#?<
MIS@Q@8"&K]R9#P1X':2@[R@>,*VYAM6P?0H3)9=CLS%P*<0JXOB"Y"[I@WI>
M;U#/&64.*ECZ,)X^C.<%AO'$I<7I(V'-"V\=:Y4\V"*1^,L.!DUHV4?[R#,@
MDI8!"OY0?N=G)WTEON)L":9[@.9@.9ZG+ T7SE)0+K!A8W[6?#<S=M3%0)^]
MPDPE?3 OJ*K:[5RE+,;-!//2O3-L\T_F05IB*/W/%KD#W7=-2-=JA;R48NJR
M:C]W01IF0ARO$2*<)AU;@_'XI50E5)]'W>3*3)27Y*LL07LR_:X)IUG'RJ'7
M1J1+<;:M2*?+2#<CAD="_\]3QQ9"+[@_[EFJ$P(J4;2OHR==Q\+^:^,!,J!#
M;-2*9/IV_;VC3*0.9HN.=9BHCXNLQG+=$D<?[@W7Y.YL[%QNW@:OLT9?_O+V
MD0!=(&!GQ6\R(BWFH.V8 -.T09%O_WE)X_% G77I8)<GD'_O([/^^E93!]-%
M_OKV88Z%U,/-D:]V'3O,L14AG'$_-E!LO%)9EXIU/++-KKV4KL7/2DG>N6HM
MPURQN)\&-["M$+]/=7NV2F3D7:38GSKKT\ C3))U;%'>5I96^4=P=K!#%=S*
M[N$2Z.X9JHQOK#$T1])%N9C;NF1ITJ/RU2E-?6I[8YW]=6F<&69_3#5X?<M?
M="KT]MHSW3GRW!H5#31^?=]P<_79('W^C!R*E<J?>2%)-&<*J(&.O83=QG8E
M3\N@*3,>?H'Y+O$,&^71]._Q&0J(L0$1XGL*_+X-\)[[]HFFWSRA>8,#>;[A
M![[C/BFBG&LL2<9WQ%^W!.8IG+8O]/J:<T+Z0J_5R=YGB#R/#)'6FZ%\'UX/
ME347OY% =HL*UG2]S)"F#NMW"7GW4X_WX>R&G !P+.C.<W:Y;2!8E.?.[Z!9
M=44D^T(7P_SB!V79[,@HJ-JP8BAX*RS3I$(#=Z%W.'% '5;TF7>-34;#_&X\
MI1!HO;OF)>B";L>HI@XK9NUT;]DKRH9.BH8;-R"GP19MRZUK@MGP1$T&E_B!
MNWO5<6R6J1C7U#66J1@YWAWUHZ^.E8CDF!1(_"I^Z7R]^J623M=:(ETGA.E'
M6O %Z[F@NZ[08#R>=[GNZA[&S5Q^2_04*[<3#N"/W^L EN-\IX5NXNV;%72X
M4=]WPF>#%V1>J@,:!24J/R7J30VHFQ0[XQGVDW)O>.B.=YT?Y@9>MYZ4-U-]
M.%,VIF5Q;W]@!QY9,1,\49("<'E[\O7RLW?R3C$>#-.B/F^ C<Z<J%>!RM8Z
M  6+,&UKJ&#%*&VDSI53CA+'!,<#2CR!C4]+7IBL*A<=!.O"KDW;1#C9" *-
ME0/ V(X/^* H$G</+"<3)V?0X*/L_@)S-AD**!398+@P?SCNOS@ED:9+?+T(
M)/\>Y.D=O>Z@F $RXQ%]%5Z@0,!+M-P8O&3<&:;M^8(2L$:48FS)ALI[LC0P
MS@L[OA/>T<YCUYW&HZ=8YL;TZ40^L(VR"EQ<B,=[<WF/(*8*A'" &1W*S)_D
M"XYN8-,G@("^\2]8V\ "7EL]&+9O@'($I#1]C]&'5CW+X48*1+SF&4#-BZDE
M%O".=KSU=RGS*7#1GF,@<N>/LG:=C1+XL,1_AC=3&718.H&U$I3P@MM_PGF%
M"%%R&JS4V"J@..(.<+%HF_,(@'CWYE994C60URUC0SG+9>#B55,<?DR7,NT
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M>25*L7X7WSXH HG97_6Y1D5OQ&O F[[R")L\3N9[I#M^"5R1EEPHIV#<U"9
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M99+PHHY?J,N1FS,6'EV2P7=@. 0"QY.@M2&N*4;''5\(&;D_^B15R:*[:!Y
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M1VC;&#PRPR.. #0[F SHSR<[WWN 8AZW#4:55FDPG\Z&R$J"5M'*%(*F/!)
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M=<,JG6*I6CNR #H@HB7S-*8'P3/WP72(4*5%TL8E.3XC ; B1"75C+*Z3Q6
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MB@R(.SMC@^F?_#90TR;L>D^ NS%6\(BR<AYMA5?1HX].)M.!8A'C@<*+EP$
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M8)N7?=9S[(.XS 28E_=PJ$96 NN:8C,5P5EC<QN7-OE@]:,\A1C+^["?@3H
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M5TPBLQ7&/@\5GFW2:_@$U"KF<ARI>.11[KG$@1;'B@A9(:4?ZKU!#.1:89\
MMP6ZSO;K%7]:7_'63QG"?^JD(1)=\>EBNA$!&#PM<OB2/KT!7NL,L*-H>0MK
M1[/SJA^M$%UB/J$SW[._K3S7@9CWPV\!3,6P1A&;^*I):N#H3?6FOJFB9\&R
M8*6?]D<K?)[U4_3$'X-HA/CJTO4>"L;0KDMOE[<U[3(%NP!)2]+LI.(O DXH
MYOR*@!LZX(@0#(W0AOC(O<5<YFSQXET'4F^6GT6H! F6Z_& 8?@CIOD7*Z$J
M0ZB(KI40[J1M9L%ZC=AVNIB1)878VD80J]JV%T" 29<WX- VB:U3$U9OGU_R
M]HFHBODK1=?:$;9BRITTT"T6A1O\"4.^P[X2?W7#/ $#(^,6VZ$/D]]3&4<3
M!+VISO*FBDA;(6WK 8A;$74YI/+T.VDP4 A$3'+J$LON1JP"H64*>[0F&!SG
M31#3"+/ F$HG%0TS! NP\^%Q@RF/YZA\HUZ]@[QZ(W0KQN^D8F<K3Y26L*B\
MS..0-MNF5^N),L=+[#O M@1Z)[4Z\M9KXLN84$0UGES;,-TMKSH O;Y/\_I.
MD0ICG32Q3FI?S;[BR%]IU^OZM>+;!9E6=U7<$R\!P'G78OY,125EG7IEO\DK
M.]1V[T+0L=*$.JGQ"85?\1UZC*>0=(->LV\5S8:XED3NI#8_K#>NM\7X E-X
MF'_CHLAWBSKTVE62T)B$%=&P!)%.:GGDW1.G-SB+U[SH+[T^E:1Q-/TR&0->
M)U4X"^8<_Q: .!_NQ1(?9^>Y5KU*E>1NAV^%!#JJVSHUCGWJ(O7J(R=*QE>_
M/F+]%/_6T0)O+3O<H;G;S'(1AMYN2BK9Q&[A$[IIM0;UJK3IFJ/I[:?DK$V+
M7=VV8E%M*VTN3;_>+DIN6UP!Z[;V<U6OM.*+N_0Z5W+<?%FLV]K6%&K2FJ\&
MTUM!27ZU59UNFZ2DO)!9Z[4@>E.HV7)9':+;9DC5']*J5YOUZE;2YTQQHMLJ
MKO.*?(Q]1-P&[]1C!+U9E"R\]JMUL?-$/J&;-JN79F2LU@Q%;[>"5+]^:O+#
M<'6M<(<?_2#>&KD7IM:,ITIE8!\[6M&SNFG/!DEC9C3N@:>WI5(M:)YM=GI@
M-C?(8%]+#BI,>8#"03PV!S^,6<\FF:EV?W2]897*P_Z&[?2D6U3ZR<RN.@"]
MB91"15EQJ-.3I4:_F8%4 TYO#J5B46&.;H^+7&4N,R1*^O3J5ZH4:MFNT^,@
MNX<MFVX5=NG5K50I<KO<.JYM3?DSH_H:<'H[J)L#]'72'U;1:GM0URQ5@;%2
M=JAGEZY&P=4*SRS6]<&U5GJM5!5J6JG32W?16;[T:E+:K;>%NH>@Y!1?AR>P
MDM<XJO[+8?1&4/)YS;N>'Y8HU?*@CBDJEI#72@I>;8NN+A]Z19_4L<9)A364
M;+N&-4Y^6$-5]&D=:YQ66*/^WOB=-4Y_6$-5].LZUGA=88TF.P1B:[S^80U5
MT=FW:+5 ]991-Q-46Z;3P6UJMT8FJBIHUVM>2<QSVS@Z'3VIVAR4J;DJ2E(2
M[6(]=S4R4A5Z4J;IB@CHC?H*OEC3'8UZ5(5F9O/R;KW6E;2X1.N=GK4+#JEE
M9F]-OU[[2CY<>);MWW$V%S]$['&+%Y:\"_-<7&CX_H@3T("XN5*VK1A>O#\2
MYNC%]PW^"T1[];AV8Q!!6G,7IK1?7AO1@V,2B-D*%>6N3B BW[<1S/LQ\S$!
MG_@"_2;U&$L\!]RC?PB1731O*C*@8/<99;T2] \J)'A?4R%S#OM,HHYV3SFH
MP#!TF@J<'6W/).\X>4A:W.A&S_[N2L_H[_RUG^] <(_Y%E7N#]7=5!O>L7OE
MV9*4!D7\U8OQ>J*I-SCIB1N(N;/CM D3.S4T8R+&VX,)[7VY15SP,B3Q2V^'
M79<![>V[)6J0SR]$[&/7YW'+$[E1[[7=GQU):P]^:ESI6\=5TIC7(:+PE3/A
M*X.W3V1F/T;VYB+C?'(++-LV]]HT8OS'4_PE?Z]S+5>)D4(W$3<]/XV#?5U6
MY:/"7Z-KFV7(*:YY_M=LA2#D&-Y#;"A.;5QZ;,)Y$$ZH@F>Q]T(#05S9".L2
M"\0B(*X5/X?%@7C.G5S#PFG6/[+")2T$X)+DQ,=K 02R!G,.*T<@)/W(O& 3
M Q( T7$O[R<8G.WB7Y%C7+B>_2WF7@M1R;T3L.B2E)#]\-[N<S^F<0 1ZIS_
M4*1JBF2"H+'73!>RP#?=" I<[@+E/LPH/G9DQV<('/B=%Z<Q F),&+9]CX7'
MDQ1M/ ME$U0FN1;2X7' Q+D$^?A[\64"V>K 8(S-C@C?#=GF> W$#?OFX370
M[X]LAAV2&^!KCT*ZR;8'=!MO ;DTT.5"-IA5\ 80YYA%>WJ9D".<5_)NT0C3
M>#U,%R,I36AC.I25AAM&[I&/(=.W)=HU]J>+Z6*!A?5''O<5I>Q/YM]50[-"
MYWDJL<;3R(%7R-3<" _%?##RZ+U(WH"I&\@H,6/1[#BA8K,\]N@^SG18XB_
MQ0XH<)GC/<<CVG;'W<KDI)>F+_'25$_R<H]\1OK&.F6)S*'-GU&I!WF Z0XI
M8Z49]OT0<;HHBBGK>E]=8B_7U0ZAKN;4VG8B\0&!3+HA&VS(S< <$PHC@D*6
M 53%\3?E/%P84]RM,$,;# ^W^83:KY($]GEH[^]B#IX_HX?!DF9C[/!+YJT;
MQR/[(K\$9<3SK/@$1MD,6Z2'FG@O006?J8/9 P,4QJ<@"7)=3^Z$#S/^(NFK
M44P5_!;;'K6)2^3#TU-?-".(_\26<TCKPULF0^GWP#-5!>G,2ZX&VNEN5_%K
MB&6J^#<!LU>(0V0UH1Q8@$<.EPQ+*"''-4QP_ 9M!?.)[S?#,3;0&$?34V:F
M%JZ]I.1W[-RMD/\5,S&-W1,OX.Y6]#%'&%OY[D"HF8-2?'EZVT\W+TY^B&X8
M!O\?X_#_6[)<^=XBX/B*H#G,BN)B^2C1K@5JK*3#M0=+^>_1+!]]!8XNKQ)1
MN)1ER#GV8Y$;XI@Z,7[UV#?AI6']-A9.::W_;NK[6JX\?MTO."T3X_L%9IM@
M[A([9AS(\,*0O!C,5"^[R7 ;RW&]&TTZ %.%BJ-!$03N(L9,FZFLRUF)QYDO
M!++Q-$TPA[Y@'4:XR5Q7&_P%"YP-[AN(KB"^8"5 R+9!) E/ &;JKS +,1OH
MI(K."U;11\]S'H#_!MI(H;Q@P4L"WKTPS0T%JZ6Y\R FBI/#&QCYN($J"I%-
M=0I8A\5'Z=$51!<WF$75 %'IO4"<V'+/AQOXXB/U2812&Z'YII!@+?HEN0,*
M]Q6+:!W,)4I:2WP=B/T,R:MJ6=:>!KX("QT(32H$?RJQMJOO*>:BTDZF&%K>
MW?+F-?%%%YL168A,BC1CG+0EKTFJX?8U@2\BUP.(<HD(DV^YI@N(?[,K;TF?
MJ?-'2K&0BSU0<)@5V839\:Y>HH5IVQH0R(3%S>S. K6Y[9$;C<=X-R/,.'-"
M4=KWM1!MLW^%E\B]Q.+52DF<H84PM3Z1\>Y+4#>UP2^3F:=P$!2"&3 .Q&&J
M:/*Y#/P 1@"A9!VL9<GK!FWE/4JP"DX#EBV'I:*@U/@Y$#E3+5]70GF3GKB-
M3[8V5I"*;JI",CZ>N';Q.I#I;MOUAY0&R!5W*,Q 52PI>A>TF[H0WWI;Y/K;
MR&D@,K?%P<AE&$8 ]SN_JP79--B+(G=!ZC!U-XP@@1*!,RQIKB=O6LTO%Y50
MIMIJM/)<6*"O(#4$3F'!2U[&%G28*D3\0FC*XE="X8UN.X?*OSK20K;K<,,E
M3$=+Y(M]>6$*E][(G$P'55 MIT@P?N.Z>NH=2:K)5%_*;4*0[^&IDTI%5:=J
MAM*N=WU"CV)53[E/_!(D55FJ C+TQ5;J#-&'1] 8R17,-/UMEX?BJE7V.J8A
M8X@N)>C%=@<2+9?#!\2<Z,A4RMG"*E D8'J'R3,_H^V:S!.EBSW"F=!P,VNN
MN/81"/EC& Q)5>10>MWKR48XK')_F"KTO$3H:[&CD8.0E<*6>7(+#]]SZC9P
MDL@)GID.GW?JJ/_D%Z[MG*"W>(T(I<E>>7&;_>!0^JWYK#USV[CU92CUY#LJ
M]:0K2GV&.:'Q4PU1]#[K3IAD3F"^8H$L-,G]"7<K1.,C[W&H/:&BD,2)+9<?
MN2#MWONU^'Q3T[7OKI)#AB.'X<'0;.P+1%CA4([UE&EI?S3+6I!H0FXFGB]H
M-]7[/P/'<F,P=J+:?:9(5-YMJD"%BX)X.97:_YQUJD88[3M=O$<C+-KE3D4F
ME;(*H+9?GZI^=<L#7NYU4:^I3O=%YH+1E*N6]\J[VRWE26_@)8>6K_&#[,D>
MV:T#;>QFN=H%F8/43YXWN8S/[=RAQW!?S90M$8VF*WE^P(TW(.2/^M1#,30H
M4(3(36[1&[-2F4O!#96WZ-A[3D8]B*%R*889P< @OF!5?-:*D;FD6>Z\Y?#F
M2YS:$C+&&X9MDMGY5 O2U'T3XB!3LO_%XWRX\#$;;C8NL3-"UH SU)#A3KJ"
MW9I%'6WO!E$G_<+-2=OR1:(4WE#S%(^>1(S=6<_,^<C&6*:.OZJK>#[)"_"2
MH*XN]+YW(CJ>2*<.-NJ2G599,<HZ6^<Z+M"(B)W<B[M(:)9S'8")W$\IKA0@
M#=.Z#*&'#QN-AQK0K<MU$<XGLQ7&?GQ5<%86+43K_,L9=;I8?(ZF5)YEOKS;
M%,X_IU;#0MX+ 4SB/K.@7WET*5Z9E(JBAVY=KI%+*(2.+HS@>V+#&$[VY&8E
MJ@'7NBR76 0/\*-DN=/TM\[[Q'M )6P7=[7.\6@5+!&Y@7QRC6QY4QIR2R2H
M!]JZ1+M[\TKDT &TSOW= _RY#7].J!.$M[>IH5,-.$-DF>%[^ ]C6AD.-H W
M1+9++V -1*L#;IIDT:7Q,@!,SD)7R5>)U+J4R07X2DQ?V&,.OW</7@F_Z9[6
M^87H%0(,EHL_E-;6^4P^BI!+[)3FUCD=LW\&ZW7>^+E& [@<(>YM\UQF&PW@
M\B*P5^O\+*8VM\YI5*.J4<8R-5>_P^)+0(AMPS&E"<QJ0;8N3W*UJH]I]BJL
MK#0UX%J79<PN856FV'65$:MV&,#M!4-!F/PI U?M:9U?L9\M\#$3X9X\T3BD
MSLQ;^ ^(Y6*.6I"MRW.%YC \(=38)GQFQ= !M,[]R*,\<,5;B;SNE?;6>1U[
M=A"YP0=($42NL!!7ULB=D4"3(7OW\J86+(I^BV5J_=V<N'_M!A%QTWU>HL(N
MXP2H\RVRO&3-<(P3.?JHG&*O?+-QC-?];ER W'U,IJ :IX 99 D06$T7,[*D
M!)(PF.Z&MOR,I-C+YD%T0O*?/\]KXFDT7JA*GJ0+\Y50<,%0U4#0@AHGX$WX
MS68Q:I.81._F33!>A+@-Y#1?P.0.G3&>ETFFAS%.),U=[7O>S=[2;LT=L\KK
M4F&- J'*X R54%Q50>1G5,HF#QV$<8X7':::+H8^Y&P4;WEZQW1IKZ'&^8BI
M^,X-3&=#9TTH$<H6;U?REPW5@#/UJ(6L[*T\U\&,A^^0RF; :D#CO+%H)W=>
M+CV,<2)5'J684IP7L1F.<2+'1R]S4BG-QC%>J??&AGHYPF:ND:B0LP36=!&3
MDXWRP 0P"I.AV,/U#XR8XJW[X1JG@N]PQT#1$?OO]<3VCZ.6'##/NU,EF)F>
M\SW/Y%]Z;(%)FY<UI#DP.OY3AI<N!JP&-L[W(C,5'#$J[&F;W>(IK^E]9T\\
M99OSPN_TL;WDF)3R2JH<P#AWFU#;6V/@M+36JX,P3IR;U"W X:7'8^P$\AN@
M5V1-_,PQQ+K [9[4C_=B74#BOB!RCVM4C\U;J@ZD<18K8+K$$>M MBC>NSZW
M5Q"QP:__#U!+ P04    "  ;.&M2O:6M;,P.  #=OP  %0   '1A<F$M,C R
M,#$R,S%?8V%L+GAM;.U=ZV_CN!'_7J#_@YI##U>@CF,[V;MD=WO(YG$PD%L'
M3G9[[9<#(]$Q<;+H%>4\^M>7E"5'$I^R)9$NF@]Y.)S1_#C#F2$YI#[\_+((
MO2<8$X2CCP>#PZ,##T8^#E#T^/'@RUWO_.YB/#[P2 *B (0X@A\/(GSP\S_^
M_">/?GWX2Z_G72,8!F?>)?9[XVB&WWN?P0*>>;_ ",8@P?%[[RL(5^P3_-NG
MZ0W]<_VX,^_D\-V#U^L9,/L*HP#'7Z;C#;-YDBS/^OWGY^?#"#^!9QS_00Y]
MO##C=X=7L0\WS!(0@[\.+X='PZ/!<#0X?)E1J2]!0O]%/QO0?QV-Z+?!T?UP
M>'8\/!N<_-OP.0E(5F3SG*.7H^QK3?XA1-$?9^S; R#0H[J(R-D+01\/"O">
M1X<X?NP/CXX&_=]^O;GSYW !>BAB.O'A04[%N(CH!J>GI_WTOWE3KN7+0QSF
MSQCU<W$VG.E_D:)]01*"SD@JW@WV09*:E/8QGK0%^ZN7-^NQCWJ#88^IAP0'
M>>>G/1CC$$[AS&,_J9%LG@IBIMGDA1E&G_VS3Q6T6L H.8^"JRA!R2O35KQ(
MA:4 4F[S&,X^'C#*WIM%D. [$]KD=4F'"$&+94@[I+^EE)] R'KT;@YA0G1B
M"1NW(,<MB"GX.4R0#\):0@DIFY&0#3#(E$(FL\F2.1RJ#&V7J:F:E^QB#J)'
M2,;178+]/^8X#*@+O/JVHC9T"6?(1TD=B<VYM8 $D/EUB)]K=3%'U)!UK@B*
M("$WB&(/*'HZ,"_ $B4@G$*2>GC]X*G!HZ'>7"T6('Z=S.[08X2HN@#U*+Z/
M5]2E1(^W.*0*U,M=CTLSDD\A2Q3@KS!^A/$_43*_C3%K0[ML"OUUIZ'_&+G2
M+5@U@X$^AX[W5,ULQ"R9A>J$5=$T(Q757+R"P=7+$D9$KWQ)\X;L<X[CI)?
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M3$]#JWI2(G5.+Y=P!JF$P61&?U(KNL#DS</Q>I$T-]/+R*I>E$B=T\MM#)<
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M<<D\:?!^R']K]92?$<C*&\)+$+F85@?BFG&; &LD2"J47&2LFR9U@564+ZE
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MF<5W:,_UJ%,1)H<NV8?R6ECWX@71/FVZG[79YW;0/M_KC^VY>.EX-9FN4G?
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MM,8&(FL^*$\W>!X].41\/4U.:*JV8)U!A6L+!(Y&S3D&GYT[3%CKES5#0CS
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M80FT;)D\?=DTR4I,C)X<XJ:)*^$G5H,J' =T['O8_41P*,H)T?^Q'IE%VTH
M+4QSP:G<TLQV+JPLV2AP<Q$#Z;:A1@\]PK>19"!HFNM692GO.4\KS15,%FX
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M2NT!]"^DZ2$,"O) :&A^F:G)Q,EY@K3WDUT-F<#MN.; "?3*ZR@=P8ED:=!
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M54*7V(>6"64 GMF>0X*$EYHP>9(KG+<Y (@==]FF? FH*S),=F>I N>F_%C
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MM7TMSVR3F6!@6%<%2J3Q.+CBF+87@3QI=D[4>/35J(%=HNU_&E6:9)Y/!57
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M/!9]C"3-=+/QHN?+U0U?!US Y8D59;$(4[&D!.NKT!< FL=MU\LX([]F\J#
M/K%HS:)?>')_%86RC1#9-5OD0N-_@);2'EV-PX/XCICO&<QRQCQ(#34-5D<S
MSJ@$<E'*EN^_/K @-H.O:#Z2?MZ'47*4L&ASQN[,ZU)GZW%&<AIN-CS)UA Y
M*\-,M<7I%# ] *1CK8W-)=B\,*HH1AS1D3PR";XW4D- ,]) -L[8+L358L-N
MO:]F!#N:CC.&]X(\?&;LG;B?K'AR)<XIIK%H2,;2]$>^/#I^:U;K>KNQ=J2[
MF/V>BLGR_E'.&//>T]U^G_OCN/NDF_T2]NU;[\X?BX]Z7WO?]6&L].[0W0D
M-G SI9/3 &QP6B+G^S%LC. .G.Z$P D'(1Y]5X2-34FPOWO5&4L\[H]RO6IT
MM<^U%\A%K\X0^+AE7Y/4;)L9TN?>]Q0@1/U[Q.+H>'R6CK%Y BK@X([=G02
MZ@8@=3Y&H+#A/3@YO0 %JJ=R8=F KOTZ(N?G*N @X3WL:\3&U<VBBWV-&3BA
MK#MR96F":K")T.EIVV:01NI]C-2HN4#R?8SU9-A83_8YUM?#QOIZGV-],VRL
M;_8Y5NBAWZ:3T>^UP%5 3>%J1,;9KB%Q-2;CK-:0N!H34,N,A,YL^$ -,U/J
M1O@0L5CL^]G,^2A^4",1C+)@R99E1W*D SU1Q(]E'X7/T/'L:%925?_J!<M9
MWL6LVD<Q\G+L?KBH#=>7+CIA9!+8[?QZ_JMNK/.[.(F\Q?;MS_?NF)]U_ZND
MA9&^ZC-8*=I8R#;S&HK9XOMU^/AJR?@KR8#\2\;)T0_'A<_0OXD?_9H/XIJM
MN?QVD$@_K8ZABZ;=+9LCK:K$/%K,PDB<LP1D99]>M*@I0MO-J6CQZB'SDCE:
MW'-_JT.K*-S8RK*06VA@I"I>,83]8W J.(D\_T+,F:__R9YU(+2: E$XI@>#
M@FL4'.:"BZ7DY-SWUMWR;S0!ROV$DMP[N421=\G K>BW6]SU%D!IOZ8D[2X>
M485]SN.%YU^QB(?+<_&S6"_YCN9 &-Y0A$')/0%,_L6\"(Q(I3$0CQ_IXM'B
M'!6-7#O>!TOI\:['HM$4B,1?*"+1R37F<2B-),?7["&,I$4Q#QW0GHH4%$!4
M_DH)%8@,4, IAK2;M]IYHFX-!.5OE$ Q\8XX6\ZYSSZGFSL6Z69(M140@+>4
M %#QBBAX:>&)Q/3,AIXY^9]*QX'H^31<:B_2!D+PC8X>/B"1H$*6,,D ?V1B
M]GK%K-9CU4T!!8G@O5LO!.25+#H52K,.(ZT1I-$0B@6IN[B&940(;C:>[Y>N
M:CH(&@VA$)"ZH&M81H3@_89%:W'B^Q"%3\F]?*'R NUL4!! (2%U60>( '-V
MW#/?!R!2;P<%@M0M7<TPYL4PW&S"/-;SYEYP'E^F21:/+W1%>SW4TD'Q(75W
MAPL$$:^K],[GBW,_]+1GK%HS*!H$[^P=["(*_^?0%T=O+\K/&-K-O-44"@*I
M.[J6;40@?A%KZ'\&X5-PP[PX#-CR(HY3_6U=20(%AN#=W2"&#H#^\:K%XT?Q
M V=^"-WI(VJ.!R>SH]DVGE_\_30,XM#G2_&3Y:R@GQ4=]%6S4LM67GR7H93&
M1VO/>\A5C?E)7/ZDJ7/%CW_=CO!R=<X#,2;N^5=AS U."@4YC+KW+!K.WCR.
MA7S-C#3;83DL6,FU/GL4G(RWIHV%1F%%@(+2:H[FQJ"7<!<,"E9IH"$3C&21
M9?&]]'!^]'PFO;.34R^*GL6I,$N_I$8'2([F_  "(NS#$B40KYG@B"_$GB)'
MK;92%NT5S=%\)GJ I.68!BAG;,7$L):7*_%?H3>G89QTG:J+]HKF:!X4/4#1
M<DP#E*N(/7B\#)82T_PRN6=1C4DU1"!B-!>+'H!92(,&?$"@^D$ROKVF!R0F
MX8NQYY/L8\ZU<H39\)(P\?RL)0'8/H?!PN[4UT6!YJ)A?_!3,TQC-M4W43']
M+X)'\:,L/@]Z>FA2H3EK0"6O.T=TBX &6&4PLHR[2*H1R9^9=LO24:$Y=O0#
M"R("&F!]",/E$_=]-3"[%GCN&_U0:/)&0^*5D\N.$[7X%<WQO#3Z8:'EF@8P
M^>A,.SVF4X;]QOY2SF4?N7?'?9YP)N/QV]'NYG,:O <\CX_AYE1;.=&8>951
M@ZVM.AH\!Y&^,"A1)&V2+1)*Q5?>LTQ19K[M*MKC^9' !1Z"."&&CDRWT^9-
M"Y"*!,^79 !&>OYIP%3DI@_6'YD7LW*TST:L3'1X[B9] 8-)@@9J-K-JR'1R
M9GZP1@<TCZ9^N+2Q_!G(\!Q:1C^$4#</*A8.T/7:3 I^$MX#D/#[-E0D-!"L
ML B:<'!4G!E ^J#2P>;4%T] %88.9PP=$1199_:5@0LGN"X%]J3K8T89P7!R
MXLQP,A"XJ9A+KLIU(ANPP>^ILS$4*6<&$FML-#S3 *42L&#R1&NUA,+AS/[1
M:XWKXI8&%O/E,C.6>OZ5QY<709&-7F/W4!% D7%F];!&QL [#8"N93J^@"W?
M>U$@-L=XOEBDF]27ON:-ZG9=K_IF6BALSFP?UK#!)=+[P/C(HKM0W 70CXSJ
MZEB0\P8<76>VDQ%.%B_E^&\Z<O5_D(/C[,R",L1FHI7&J*BC!A-UEWVM11:]
MAD<6S?Y<Z^_?#Y%&SMG+B@L!&"G:F>9D2[^IO9 W&:HZ+5' 0\Q.=B'^JK&>
M=+4EADM-JU0(5(9?M:%20.'4]^+X<I6MX/.O' )&FV2*F+2YJ,2G85ZO*^,Z
M"S?BK*RY8'>T)8:%2K^:U^P.3G:QG+W@4&3_OF&1.+0<U\TLGY@B^9HDT5)@
M1VBIU:64L)&%EW+;JG,GSE>74::&R\QP<\6B++\&U("HIJ<2@]S:0+661),\
M:-A+ZF/.$Z+,T^0^C/@?NW.[";LV'79L<D_05 *@"U:6$<(2J)(&.R1Y$$AU
MQND"I,^WI&&P3\(E]Y[#?:!RE&%IU*<5^^T+1(P=NPS&S4(4Y+"#;UM:(NRP
MY3Y8T=ZP6@,U[59* NSXY?[84-RG+),"JECKLT,Y?!CKBQ!L>]JW,7S+C[AM
M%CYW8:!(L?5&9PC?=30+5[-*5WCZEQ=ZVP[,;/56$E#P#2W+#IO9T) @7W(-
MB*A\0%6LTUCFKH4(Q1AD3/L9>V1^F$5*%V/6^0%HR;"OMF;AM^+[S5*@ =@'
M%@C>?#'2^7+#@ZSBG,RY;H3,2(A]U;4%#2@)&K"UF+-8 ?&OMK;0*+F=NL?%
MEK%\,_@8=J:S;TJAVAC[MML;RC;'4P?S<QB$=>[*%%?&4PJ %/NJ;'=< <N"
MQG*:%1MA<5(;JC;%C9H"^]X,%WT(Y*CO]'R;3\^ K>6MB/ $[3$Q\6_??7$V
M2F$HT+=$EF.60';51C/L3&*6RVP7CU/?1W]A?'TO]&C^*+1T7512NUQEEJ.*
MX>B=%_.%O&%Q/TUT%LZ^_6'G*;-3A6%2H[$-EP[SY?,'&&(C(7JZ,SLP@8(@
M9C,]O?>"-8LO@K:S=#/NH69+_1%N2RT^,;L(9M6/_,E[".._S_)OS?Y<?(V(
MRW&_T$P0.07WRJD['?<( #EX'1/Q</U(U^LX5R59E2P,LO!QF.=Q-]D4L>GF
MA(8'<F-L)B=D17-BJ.@TKGF^Z&:H8D-RX(\LMG5Q-DVXT!U[UV0C,?8;D14,
M-HQ1.J!7'O*5H+7?_"TA<N_\:#%3E!S3 $01(6X"QT"&_3[4!RB0)&B UHP/
M-Z&E:H_]]M,')CWO-/#94TP[OB>^@Z#F![&KA6(#\Z($WY)HX6G7W[T.WU<?
MXE.'@J+B/"C],V6@^.6JLKM>")G*]E<1?Q1\7_G>@A55%BY7IFI6LMO!O9+9
M]91XC\+F."NM&VAS378#<-DWF5W3)<QU01+:5G/?[+-4CO0J6V6R@(>LI(1A
ME]638OM'V&VZ$#&01JW8<WK!5J/%=I<8BEN'()ROK2;3P45P%84)"X,1-M-1
MOX7M,V&[]CH0])24 [@=._@BMAL&HJ),;>N>+\3-,4_7HWW@@/: [78QRD;>
M)1324!91C4.P[.H"W>]BG.U]<G!F2IC_^#R,Q.KTR!>Z( '+;M KUHTR297R
M(0UM-<9U"+;*?M!KXHTS9YVAJWKE-&@:[*  /J&[^QR=FGG:PY=K>>]7378Z
MNQ\]&>-[Z*7Y!BG*>!(GO5UD\^$S>\I^T_,$4"%'+^\WRL[?D@=I"'--[8]A
MBQZ]_M\X._SH*/;<V8M31I+XA4OIKKY[1OHEX+VW<6#?Z 4"Q]FSK22)M4$[
M@-NZ<_22@R-MO7L%W/T^F_WN\B&S$[S_RJ(%CW5A*SVZ0J]$.,K^JY43:9AS
MU1T'9VU?Z)4*Q]FCIXMTIJB-Y6C^Y$7+#Y$VH+1G=^@U$$>9V$9YT8!\OOSO
M-,[+^MV&"L]1P]NV11?H11#!T%K+93IP9LO1G2=6'^FGRH(X$_\URPW[K# 2
MYJI\S1;A.LAZ,=1_<_]E]$*,HRK/&"@X/_=75[7'VM6DX.+:XYU)(^I'7F@W
M! HXVIWE[>3CV.$A7"TR![E8#H\',7M(,I?R13Z42 XEAO@QV'1$H,BCC7^"
MO8QHK.M74;CBB3Y_1[4-@0J/X)S=3<YH2'Q8Z,.O)R3*-?:.?I#C;Z'1QW/^
M?4 @W=&0Z <;)!%M3+KA.P(2-<&&%]^?^^&3(B?Q7X!Y-"Y7,]G3+.^*0*Q\
MA3.KU!@=5+@)I^2 Q-+^R 6^[YZ_B&/N1;#->#A?)/PQKR=I3@C8HR\J17LT
M:+;35_64&(W=TFF*,6>&G@%2=YE]C$R1K=H]5EY"@P7W68W9VW"TF>[F:V1B
M%^&+@4NQTU@NRE1>=>.'X536T1X[4-$I4ATG.Z7(')D6YILP2O@?V:>VE2""
M]4<FQG$ML^S%X2J-V3R..S/$RC[LNL .2=P'H/92H31USYC 9,$-$[;>"CLB
M<8_3M$L\-( 3O$92O<Y8_M\*=X6Q$E0*!=P'=CCC'D&W%RU5E;B*V(/'EV?%
M<;7,HQPLL[>N;#G2'._[]H<=#-D#/Y,"V AR^OG$.P0HV?PLYEP:20#L-4?1
M 78XI -5T8KJ)>K&?+$(4[$L7WG/^HRI %+L&$D'^J 0S_3-"9VL1JE@@WMW
MW,]V6DME:%&CAUFZ40B%E#!U0O4:W1A^=IO)+C/E^+L>TK(W6@@E>KQE?WS!
M/+Z4E1]N7AW#_$\@7'./5PY[V4Z]&(:"XXO@D<4C/2II^Z(3##KX60D@,T<&
M13D:<0G:.<=F/Y Y!2(YL-,P"-A"2O07GMQ?,[%-Q>P3B]8LDC_(<W[=BN.R
M]\#2A"]B,;&^5VPG;CZ%'NDY -+0M7 HV3;$Z;ETP,S9$A(3BV/R?.5[XI(5
M+*6C2U:-5.-19=$'>CCH<,7HP?4+/ZIT"&^,385 W.EHVF(ON1=Z$#GG@2?.
M>Z,<1+1]T8EP'7P0 <B,R&X2A0O&EO&YD$7I2WPA/?(]_RJ]\_FB3(>@V4S@
M7:#'M Z J^7=:R<W1^?.ZCB&9H3LV1=ZO.IP4 =P3WTRR^S"BG0G=E-:VQ%Z
M**O3B0V0X1ZF=SF:V [2IF[#ND&/51U_4MO(C_9\WF8+MY_!%5+TF%7G<[8E
MISW,TB^!D-I3Q!,6Q9>R4*OOAYGE-(^0!TQ08P_H\:+CSTV@U&A,RVOV4%@2
M9/'=,$IN6;0Y8W>:ZY"&!#TV=+1I:)3+],TI59VUS! "($6/.76R(D\@/TCW
M!M(\_MONMFUZ].A5QUNN2F(T4(8S/X9=BT"<[&AHVTMNZK90R:[\OWP2>/1\
MN:DUWI2:CTR5EGG>A*9+Q/NO"S^5H:OB+UF-\VLQ5=ZO5DQG1]WW.- C@D?3
M61P$OVF]=Z3&<*TD;&(<1Q #E8Q4Z4:*JF:1%.$U?5OF8%&,HFXD,F4,$H78
M!_)U_XS'#V'L^1^B,'T0%.+?BS!(>)"R9>&A)BXYYM=1G-% %=M]_D'X^RHF
M;C1N+063#=;F8HF(HF?!FR%]'9 <JAO.C,&H0+=U#BSQE[ XUN5ZFH?KZ(R9
MG<VA*N3,+$U(A;02?7DJLPOR@FI-E0*J.,XLX&05IRU77-U1O'^5$0&\"/MO
M"<]\>)?]V'<#U1QG!G,*FM-/=)2..#?IPT->'<#SRX/A1; *HTV.I#EA&+0#
MJ,*X3Q\)/P);2L=A@(/,\WL>1AH\2A?\5DNHX-WY=EI*,30P1&G^7 0)$_),
MY" _=R:L*5JV&D)A&=_<:Q)L,W:TDT,JXI=!<+?>5Q;+\>G$WV@(%?_X=DU;
M\7=R2$/\\I D.-DYY@?+K:DL2RD*\%:'=P%.Y$1H![&6D*,]I$P:4G.AE4<7
M(;/E-AR\2"FB.B7:=@(%S)TGH[7TP_[<XN"W#O@?;'E[[R6_,!E6Q1YYF,;^
M\VC8]O@ %'=W[HU.<.\M:E>^CVFTN/=B=KFZ".(TDGX@\W7$LA5*AE1^#A.F
M28B2.0):=0'%U9WWXQ!<^XC+U8E^YQ^;5W?0AL>J#ON6G4#1<^?M. 2]?B+K
MP&_?*<;?I3$/6!Q_Y+^G?,F3Y\PDD%?R8'$HE+*R4-0RCO]U=C23]@@_%.K*
MQ#_*KO[/;-O9S N6LZ*[V:Z_$745,G[#M=2NBS$G&N3+MP+0=[XZ@L.R#ZQ$
MX?:";D^R7N(B,,=NTLW&BYXO5S=<;-(KOI!!Y7G**UE+)_3Y@JMFV=^:LZSH
M;!:N9I7N9KO^9ML.$=-HM[@#),/6T&":('68Z29G>2L#TF-GAC=#UK0^6@F&
MP#1L)?60P9RB36:)+\HA%0F*N^?BV^9<+'J<Y5W.GD2?LZ+3;.=K=8NGQN7:
M*0XJ=^)4 W1'T5,ASLJ.@>V0 <Q**#UR70T(:HUI:2<9 M.RS+72F6:E.O^.
M?VC.OY(TFVP[8M1PD>Z\,>:I!B#%C8/I'IW5K+/K!7GN@;%L!\!8BXK -%09
MAVHS\+@Y PNJV98,-?V5M(W$0N39J#P?L,%IB3#KT-0SXI;#JZ5$M9IZO3O$
MGH5F5)NU9(:)CL!4S$)DCY)FC&QM)IZT[H49D0RLG654F/4R[BIKG7D.JMJC
M5NNI!"E#+GF*]LB31X]$J]R.CF<"TT+:6'F>:U8:?C(_J#4+E+:3X]?-.5+I
M(;=,UOI ].16<V8SD2R[P71=AXP4,.]L^T&>C[UP;OJ@]Q(=@>FK+B]<G[5O
M6CM;A?!/WD,8_WU6T.,I<#X \Y1LMB-5WED^*5I--XLND&=:-S[&(M &B5"9
M14=WRJIXM:GT8W,JY7/I*"NJ-ZO1(QX7MP/,,C-MAW3-?)G:)?-OR$H!9DR7
MJ7H!Q\J!_6)6G(,._5UUZ( )/+AC[ /M*+K2+& WCK0)+ X5;\SN!>$OK04A
M)YGE- 0\96W.NUHB"FZ_5INKG@IYX@'P47D&T]Y/WV\>_/"9L7<L8"N>2*-M
M]]1IN;N4E+."=);1HMZIMDM7]J29\(C5[<Z@*R2\$]P+9'6<'2A"MD.[7O O
MC[;XMJ^.UD(C,$5/9;:+H^.WW?.RY2!S>OGSQ9EL/JI'I!C"\5M3?%.SU;A.
MF5GGL"VE,AI2NTFGE.JZ:AHZ&;6\2>]B]GLJNGO_6(N<K*EGRV=D1S8KZ###
M*^LL0.(I512H4:+U04$L&6H2Y&7>A$DK!M3 .XF9 O%_U/I!GK1\/^!^D+,_
MEW_[]X-+Y"C.5U[,X\M58W3/^9\0YRL@/?),M/:(M),+C1C)TS"(Q?B6F5#!
M".JI)N?*"A$"#;B^R "A]W'"-UZBRT;;; <NPT$%DFY&:8#0G3D#/GE@Y.!L
M@U0@LQ)+[W0U9&I[=[-KRJ^2B\-6.:"]@F/0:>N,G1!I+ I*MT_PN@#O 0BS
ML^1&UC#;"H<&I!_"</G$?5\,^$)(-UC+LD#S.&86B[U-'T!8G:4@LH;57D#3
M7_;?>U$@)"03@6>/@F!-,!("X7>6",D:?J H:$QF<<9?"!GD*=.N>?S;J5 ]
MGLB_:>\Y:B(@7LX2XO>YYIA$0 .KW6M[]<DBKQ23K362#?[(LB<+TXFJ5V=
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MB8VMR^P!%$Q77]COG0[P5XN,P+N3_;7IN/O>-$(QJO+MZ?AP<W)94B@NR^0
M ](MNIC0?<N>.;(;=CE>.<PK%LF,Y&%0.F7P19;!T$^3W9K0#DZ#TD_M@F8M
M&G=1@]DX%/4**^.*+],D3L0"R8.U'7P#^Y[:-6M4D4YR)]:Z@;2*AO7?CP?Y
M@AQVY1<7*=>G9.,A5NX0*Z=TIBB\0_5^[O56$Y)\?> TPL>@_NDT/<N[%$8A
M])%<PA7'NCR#C[@DB#'S1Z8-Q)($FO;8A@^]B[9A\$[/SAW?O0R8K9PK)'CI
M'8;(NL4S#9>HF_0NYDON1<^Y\T9>-4:[DFM(:*POL U5S0612*;=L*2R7:XR
M]SIQ1I,W"%-<$H"6"%8F_6O"!N",1/S05<0?A1J*J;_(=-$40*1JCY9AS4+@
MW5NX5@!$5K]RI3CUO3B&K7YJ$B(SRNHZT>:B\BJ+Z7U?&9=IM>MJ2PP+E7XU
M'>D[.'%S]+UAD7SBJD1C7Y7F<'V\8^;(""3&#E%7*U$M5L5*%&,L7'$Y/V*V
M^'X=/KY:,IY/#?&7YHP0/_KU(UM[_GMQEDR>%:N3:-5J1&P.=*Y'7>.N. GL
M3\3Y )1+C6A2;X$LW"ZYM21;'[&;A22W1\_7$=,?<V1C15NT1)8M$;47!RU[
MCF[,709:N[(!6DKR,<)@3F@=)9N9H8L7F^P7-P^^+I8$1$RBO ,$#U/*;*5@
M',VGROMA]=.*.:1L3:+T@H7\M<Q0FCHR#]!%()A(LZ/R[AR6_S66A?LDQ\?J
M"631!8F*#/;3R%I(CB93_B0_?_2X+\]SYV%4EN94718T!"2J-EA.*;, 7$D^
MO8L7$<\JGVX/)&=L^S.5_(UD)&HSV*( % :-%6XW1XO;:*Y$4G'84K.LF>A(
ME%^P7\M@XJ $78=9H#KF+P]AL&/*A*=E9R2*,_0%N9?@'"V@YQZ/LL)2EZO/
M+-&&/74W)5%QP7*AU#'M2,Z59?AR=?D4"'#O^<.U]/-3R5M/0J*Z@J7<(4)P
MYJU:N"'F,TTA\E8K&F43+,6LX-59OH'L#M4Q5H60=010>9.YT)L8:HG^D"!D
M_ 0AQV3L"YCY0,8R/&Q+0%?BOAK1O3JC X@<"BP]BX.%=&@ >A$L(N;%[(SE
M_[T(BNC-:EA?$:V]+>Y6^9T:Z^$]0]6 C+%C-,Z=[ O[CN\HLYY5$YYI,]&\
M:49PE#UDX1K;/DCDFU&F=#,':0!(*3CX3#)2 PS+(5R#BC_#!,(U5$KU[ME<
MK0!$/"&<0/P0B?E0IMT47S8&@D"(:>!FH9_@Q*05)MUXP>39REFT6Z&#Y4VX
M2IZ\2!_J "'$SJ-CH7E54P%<)@2#\D67821;/V^'K\51TQX]-*@??$8)T+CR
MG:=1P!-QPA:<G?.O\F_&VDHZ&FR?U1YH ;BBA-A'>8N4#D$7FX<H?,S+D)@@
MTQ+AF<X&@P80!@W4E"QF%_\>)X^"CKPW(I"/26"EJG%NXM&NRKFS]#'#P1JU
MDOE(A846BW239A;S,R8DNN!%DI 'GV6"#9;S31@E15X/)6MJ6,?[ G:2&7A]
MH9&%BIGMS_&:4"DI;[$B9%38%Y/AZT&%^>F_6RJY_!*S5>I_Y"N-!11$C)W>
M<SC@;5$0R!VE>5O0)HGZT?*)P4E9,//@#4$K-AU0L%Y/ZRG!5L*'!P62AFK"
M#PIYDLW= .67I "U#PE:H@GAHN6#QL.!8HBF)P,#&0V, +H' XQ4[I /+)"%
M].0E9;GA 9=KL\PC5#C=F&QE0'+LVSQ(+YO.9C:2H7&_UU95 Y25-A-C7\/Z
M &DA%7<Y?5N'HOX'UFE&65O(@,9DJAISU+.FW@HU;MI&PDWWRS:K$_>A:Y32
MT+K/_:5YMRV(9R4U#<<Y[UD>#J4#9#8^SP?D-=82X5JB,W@V#W[XS-@[L=>N
M>!*?IE%DLB]KZ9"70@!&;>LQ0! T5L1BK())(1'_UOO*P(!UTF"?"GNCI9&
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M2Q$Z)3@U!1!?9:.I0*4S;(/ ?I6@)<6)J<%YF$9C:4&E+VP+Q%Z5H"7#J>D
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M0TT(%QZ/AYH0+ZLFQ/AGO4--"&<>*#@U(71YA/.#]?NO+%KPF.EBTM3-)^&
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M8[L  '1A<F$M,C R,#$R,S$N>'-D4$L! A0#%     @ &SAK4KVEK6S,#@
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I<F$M,C R,#$R,S%?<')E+GAM;%!+!08     !@ & (H!  "]J@$    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
